
<html lang="en"     class="pb-page"  data-request-id="da531846-82fc-4186-bd20-8ce1c6a7f4e5"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2019.62.issue-13;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.8b01651"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Allosteric Modalities for Membrane-Bound Receptors: Insights from Drug Hunting for Brain Diseases" /></meta><meta name="dc.Creator" content="Quinn  Coughlin" /></meta><meta name="dc.Creator" content="Allen T.  Hopper" /></meta><meta name="dc.Creator" content="Maria-Jesus  Blanco" /></meta><meta name="dc.Creator" content="Vijaya  Tirunagaru" /></meta><meta name="dc.Creator" content="Albert J.  Robichaud" /></meta><meta name="dc.Creator" content="Dario  Doller" /></meta><meta name="dc.Description" content="Medicinal chemists are accountable for embedding the appropriate drug target profile into the molecular architecture of a clinical candidate. An accurate characterization of the functional effects ..." /></meta><meta name="Description" content="Medicinal chemists are accountable for embedding the appropriate drug target profile into the molecular architecture of a clinical candidate. An accurate characterization of the functional effects ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 5, 2019" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b01651" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright Â© 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01651" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b01651" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01651" /></link>
        
    
    

<title>Allosteric Modalities for Membrane-Bound Receptors: Insights from Drug Hunting for Brain Diseases | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b01651" /></meta><meta property="og:title" content="Allosteric Modalities for Membrane-Bound Receptors: Insights from Drug Hunting for Brain Diseases" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/large/jm-2018-01651e_0034.jpeg" /></meta><meta property="og:description" content="Medicinal chemists are accountable for embedding the appropriate drug target profile into the molecular architecture of a clinical candidate. An accurate characterization of the functional effects following binding of a drug to its biological target is a fundamental step in the discovery of new medicines, informing the translation of preclinical efficacy and safety observations into human trials. Membrane-bound proteins, particularly ion channels and G protein-coupled receptors (GPCRs), are biological targets prone to allosteric modulation. Investigations using allosteric drug candidates and chemical tools suggest that their functional effects may be tailored with a high degree of translational alignment, making them molecular tools to correct pathophysiological functional tone and enable personalized medicine when a causative target-to-disease link is known. We present select examples of functional molecular fine-tuning of allosterism and discuss consequences relevant to drug design." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b01651"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b01651">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b01651&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b01651&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b01651&amp;href=/doi/10.1021/acs.jmedchem.8b01651" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 13</span><span class="cit-fg-pageRange">, 5979-6002</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/13" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b01520" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.9b00654" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Allosteric Modalities for Membrane-Bound Receptors: Insights from Drug Hunting for Brain Diseases</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Quinn Coughlin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Quinn Coughlin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Exploratory Research; ; . Sage Therapeutics, Inc. 215 First Street Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Quinn++Coughlin">Quinn Coughlin</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Allen T. Hopper</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Allen T. Hopper</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Exploratory Research; ; . Sage Therapeutics, Inc. 215 First Street Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Allen+T.++Hopper">Allen T. Hopper</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Maria-Jesus Blanco</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Maria-Jesus Blanco</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry; ; . Sage Therapeutics, Inc. 215 First Street Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Maria-Jesus++Blanco">Maria-Jesus Blanco</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4333-365X" title="Orcid link">http://orcid.org/0000-0003-4333-365X</a></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Vijaya Tirunagaru</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Vijaya Tirunagaru</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Exploratory Research; ; . Sage Therapeutics, Inc. 215 First Street Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Vijaya++Tirunagaru">Vijaya Tirunagaru</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Albert J. Robichaud</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Albert J. Robichaud</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery & Nonclinical Development; ; . Sage Therapeutics, Inc. 215 First Street Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Albert+J.++Robichaud">Albert J. Robichaud</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div></div></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor">Dario Doller</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dario Doller</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Exploratory Research; ; . Sage Therapeutics, Inc. 215 First Street Cambridge, Massachusetts 02142, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: (617)949-4262. E-mail: <a href="/cdn-cgi/l/email-protection#036762716a6c2d676c6f6f66714370626466717b2d606c6e"><span class="__cf_email__" data-cfemail="71151003181e5f151e1d1d1403310210161403095f121e1c">[emailÂ protected]</span></a>. Address: Sage Therapeutics, Inc., 215 First Street, Cambridge Massachusetts 02142, United States.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dario++Doller">Dario Doller</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath6">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5944-383X" title="Orcid link">http://orcid.org/0000-0002-5944-383X</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01651&amp;href=/doi/10.1021%2Facs.jmedchem.8b01651" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 13</span><span class="cit-pageRange">, 5979â6002</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 5, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>23 October 2018</li><li><span class="item_label"><b>Published</b> online</span>5 February 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 11 July 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b01651" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01651</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D5979%26pageCount%3D24%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DQuinn%2BCoughlin%252C%2BAllen%2BT.%2BHopper%252C%2BMaria-Jesus%2BBlanco%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D13%26contentID%3Dacs.jmedchem.8b01651%26title%3DAllosteric%2BModalities%2Bfor%2BMembrane-Bound%2BReceptors%253A%2BInsights%2Bfrom%2BDrug%2BHunting%2Bfor%2BBrain%2BDiseases%26numPages%3D24%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6002%26publicationDate%3DJuly%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b01651"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2666</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">7</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b01651" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Allosteric Modalities for Membrane-Bound Receptors: Insights from Drug Hunting for Brain Diseases&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Quinn&quot;,&quot;last_name&quot;:&quot;Coughlin&quot;},{&quot;first_name&quot;:&quot;Allen&quot;,&quot;last_name&quot;:&quot;T. Hopper&quot;},{&quot;first_name&quot;:&quot;Maria-Jesus&quot;,&quot;last_name&quot;:&quot;Blanco&quot;},{&quot;first_name&quot;:&quot;Vijaya&quot;,&quot;last_name&quot;:&quot;Tirunagaru&quot;},{&quot;first_name&quot;:&quot;Albert&quot;,&quot;last_name&quot;:&quot;J. Robichaud&quot;},{&quot;first_name&quot;:&quot;Dario&quot;,&quot;last_name&quot;:&quot;Doller&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;05&quot;,&quot;issue&quot;:&quot;13&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;5979-6002&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b01651&quot;},&quot;abstract&quot;:&quot;Medicinal chemists are accountable for embedding the appropriate drug target profile into the molecular architecture of a clinical candidate. An accurate characterization of the functional effects following binding of a drug to its biological target is a fundamental step in the discovery of new medicines, informing the translation of preclinical efficacy and safety observations into human trials. Membrane-bound proteins, particularly ion channels and G protein-coupled receptors (GPCRs), are biological targets prone to allosteric modulation. Investigations using allosteric drug candidates and chemical tools suggest that their functional effects may be tailored with a high degree of translational alignment, making them molecular tools to correct pathophysiological functional tone and enable personalized medicine when a causative target-to-disease link is known. We present select examples of functional molecular fine-tuning of allosterism and discuss consequences relevant to drug design.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01651&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01651" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01651&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01651" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01651&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01651" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01651&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01651&amp;href=/doi/10.1021/acs.jmedchem.8b01651" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b01651" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b01651" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b01651%26sid%3Dliteratum%253Aachs%26pmid%3D30721063%26genre%3Darticle%26aulast%3DCoughlin%26date%3D2019%26atitle%3DAllosteric%2BModalities%2Bfor%2BMembrane-Bound%2BReceptors%253A%2BInsights%2Bfrom%2BDrug%2BHunting%2Bfor%2BBrain%2BDiseases%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D13%26spage%3D5979%26epage%3D6002%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291713" title="Polyacrylamide">Polyacrylamide</a>,</li><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a>,</li><li><a href="/action/doSearch?ConceptID=292366" title="Ligands">Ligands</a>,</li><li><a href="/action/doSearch?ConceptID=291071" title="Nicotinamide">Nicotinamide</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/13" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/jmcmar.2019.62.issue-13/20190711/jmcmar.2019.62.issue-13.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0034.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/large/jm-2018-01651e_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01651&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Medicinal chemists are accountable for embedding the appropriate drug target profile into the molecular architecture of a clinical candidate. An accurate characterization of the functional effects following binding of a drug to its biological target is a fundamental step in the discovery of new medicines, informing the translation of preclinical efficacy and safety observations into human trials. Membrane-bound proteins, particularly ion channels and G protein-coupled receptors (GPCRs), are biological targets prone to allosteric modulation. Investigations using allosteric drug candidates and chemical tools suggest that their functional effects may be tailored with a high degree of translational alignment, making them molecular tools to correct pathophysiological functional tone and enable personalized medicine when a causative target-to-disease link is known. We present select examples of functional molecular fine-tuning of allosterism and discuss consequences relevant to drug design.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction and Scope</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60278" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60278" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Despite the incessant progress in scientific understanding within the life sciences, there remains a large body of unknowns, and the task of finding new drug treatments to deal with human disease remains a major undertaking. The promise from the late 20th century that genomics would deliver a significant number of novel drug targets causally linked to a disease is yet to be fulfilled in many therapeutic areas, in particular, for central nervous system (CNS) diseases, where the complexity of brain physiology presents daunting challenges. Fundamental mechanisms linked to higher-order processes (e.g., mood, sleep/wake, chronic pain, feeding, cognition) remain insufficiently understood. Designing potential treatments based on biological hypotheses grounded on brain circuitry often show preclinical-to-clinical translational gaps. These last two factors, added to the multifactorial nature of CNS misfunction (same apparent disease phenotypes caused by different dysregulation mechanisms), portend major challenges for neurobiology.</div><div class="NLM_p">Arguably, discovery of novel disease treatments would benefit from breakthroughs in our current scientific understanding, excursions into new experimental systems, and computational models developed to enable the analysis of polygenic causal influences among brain cells.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Less than 2% of the human genome encodes protein, often considered as a biological target of new drug action.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Indeed, it has been suggested that viable new drug targets may be a finite resource rapidly running out and near exhaustion.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> These challenges are negatively impacting the identification of new and novel treatments for patients in need, and an infusion of productivity is immediately required to realize the potential promises of the genomics revolution. How can medicinal chemists help?</div><div class="NLM_p">Major progress at the interface between medicinal chemistry and molecular biology achieved during the past few years is disrupting the current drug discovery paradigm and offering feasible solutions. A decade ago, one of the first questions asked when proposing a novel biological target for a drug discovery project was âis the target <i>druggable</i>?â The question aimed to estimate the likelihood of identifying a small molecule that could be a good ligand to the target under examination, and incorporating the right pharmaceutical properties to achieve the desired target drug profile.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Efforts to answer that question led to the development of a number of new chemistry modalities aimed at biologically relevant targets which are not only proteins, but increasingly, also DNA and RNA.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> While not fully validated by regulatory approvals, these novel modalities rely on using stabilized cyclopeptides,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> nonpeptidic macrocycles, protein degradation by proteolysis-targeting chimeras or PROTACs,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> allosteric enzyme inhibitors and enhancers,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> antibody-based modalities (including brain target enabled bifunctional monoclonal antibodies<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> and antibodyâdrug conjugates,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> nucleic acids, proteinâprotein interaction inhibitors, small molecules binding to nucleic acids, and the scope of this review: <i>allosteric small molecule modulators of membrane bound targets, mainly GPCRs and ion channels</i>.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Today, that early question (âis the target druggable?â) has mostly been replaced by âwhat is the right chemistry modality to achieve the desired functional target modulation?â</div><div class="NLM_p">This understanding of allosteric drug modalities has the potential to provide medicinal chemists with a unique dexterity to create compounds acting at their biological targets with finely tuned precision compared with classical modalities based on competitive mode of action.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a> Furthermore, the functional consequences derived by a number of endogenous biomolecules are dependent on interactions between molecules in their physically accessible surroundings. For example, disruption of chaperone proteins<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> or proteinâprotein interactions by small molecules, which shift the equilibria between conformations of disordered proteins,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> can also be considered a particular type of allosteric interaction. Receptor activity-modifying proteins (RAMPs) are widely expressed in human tissues and, in some cases, have been shown to affect surface expression, ligand specificity, trafficking, and posttranslational modification of some GPCRs by acting as allosteric modulators via proteinâprotein interactions.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> However, allosteric modulation of these proteins is beyond the scope of this discussion. Given the importance, volume, and depth of work done with some biological targets prone to allosteric modulation and relevant to CNS diseases (e.g., GABA<sub>A</sub>, NMDAR, mGluRs, mAChRs), it should not be surprising that most of the key examples arise from research in these areas and are the focus of this work. Some examples from additional receptors are provided (e.g., D<sub>1</sub>R, P2X7, Î´-OR). Of note, a number of excellent reviews were recently published covering diverse aspects of allosteric drug discovery,<a onclick="showRef(event, 'ref17 ref18 ref19 ref20 ref21 ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19 ref20 ref21 ref22 ref23 ref24">(17â24)</a> including a thematic issue of the <i>Journal of Medicinal Chemistry</i>.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div><div id="sec1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Allostery in Drug Action: Sixty Years Young</h3><div class="NLM_p">The allostery concept introduced in 1961 by Monod and Jacob was based on conformational change in a two-state model for select oligomeric proteins. Allosterism was initially conceived as a concept closely linked to enzyme function, and most work focused on these types of biomolecules (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Notably, while benzodiazepines were recognized as allosteric modulators of GABA<sub>A</sub> ion channels some 40 years ago, work using allosteric modulators of GPCRs only reached meaningful levels after the year 2000.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/large/jm-2018-01651e_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. PubMed hits from searches related to allosterism in drug discovery (accessed on March 8, 2018).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/large/jm-2018-01651e_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01651&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Since then, allostery has evolved significantly, and it is now explained by advanced models based on a dynamic process linked to multiple conformational states defined by an ensemble of relevant ligands interacting with a monomeric or oligomeric biological target and which is relevant to most, if not all, proteins.<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26,27)</a></div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">2.  What? Allosteric Drug Modalities</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70266" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70266" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Progress in understanding drug action at the molecular level achieved during the past decade constitutes a remarkable example of the interdependence and synergism potentially attainable by combining concepts from diverse scientific disciplines within the âLife Scienceâ ecosystem, arguably leading to âa second molecular biology revolutionâ.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> On one end of the spectrum, some of these disciplines are highly virtual (e.g., computational biology, molecular dynamics, mathematical modeling). On the other end, some are heavily empirical, such as developing new biochemical systems and chemical probes to explore the nature of the functional response of a receptor, or most relevant to the medicinal chemist, the development of structureâfunctional activity relationships. Naturally, given their broad scope, a number of these areas may not always be familiar to industrial teams working in drug discovery or to academic scientists lacking the perspective obtained from testing large numbers of closely related analogues. By necessity, both of these groups take a pragmatic approach, focus on well-known strategies, and may be reluctant to invest resources in new findings, with uncertain short-term impact.</div><div class="NLM_p">Our experience is that allosteric drug discovery efforts benefit from a combination of mathematical, empirical, and mechanistic approaches to enable deeper understanding of receptor function. In turn, these provide a common language for sharper communication between pharmacologists, pharmacokineticists, and medicinal chemists, a necessity in the quest to deliver drug candidates. A working knowledge of the basic nomenclature of allosteric modulators is assumed.<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29,30)</a></div><div class="NLM_p">A number of complex mathematical models have been built for GPCRs and ion channels.<a onclick="showRef(event, 'ref31 ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref31 ref32 ref33">(31â33)</a> A relatively simple model, although at first glance may not appear to be so, used to facilitate the mechanistic interpretation of GPCR functional effects resulting from the interaction of agonists and allosteric modulators on receptors is represented by eq 1, sometimes referred to as the Leach equation (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(34,35)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Definition of Parameters Used in eq 1 (Leach Equation)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0037.gif" alt="" id="_i6" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center">definition</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>E</i><sub>m</sub></td><td class="colsep0 rowsep0" align="left">maximum functional effect in the system</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>E</i></td><td class="colsep0 rowsep0" align="left">functional effect caused by the allosteric modulator</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>E</i><sub>m</sub></td><td class="colsep0 rowsep0" align="left">maximum functional effect in the system</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[A]Â andÂ [B]</td><td class="colsep0 rowsep0" align="left">concentrations of agonist and allosteric ligand, respectively</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>K</i><sub>A</sub>Â andÂ <i>K</i><sub>B</sub></td><td class="colsep0 rowsep0" align="left">equilibrium dissociation constants for the agonistâ and modulatorâreceptor complexes (each alone), respectively</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ï<sub>A</sub>Â andÂ Ï<sub>B</sub></td><td class="colsep0 rowsep0" align="left">efficacies of the agonist and modulator (each alone), respectively</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Î±</td><td class="colsep0 rowsep0" align="left">binding affinity cooperativity (the same for both the agonist and the modulator)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Î²</td><td class="colsep0 rowsep0" align="left">efficacy cooperativity produced by the modulator on the agonist</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>n</i></td><td class="colsep0 rowsep0" align="left">Hill slope parameter in the system under study</td></tr></tbody></table></div></div><div class="NLM_p">According to this model, allosteric drugs impact the functional response of the target protein through four parameters: <i>K</i><sub>B</sub>, Î±, Î², or Ï<sub>B</sub>. As these parameters are <i><b>independent</b></i> of each other, their combination almost certainly provides diverse modalities of allosterism for noncovalent small molecule allosteric drugs.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Clearly, this affords a major opportunity to medicinal chemists who understand how to create drug candidates with the appropriate allosteric attributes (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) as required to chemically modulate disease pathophysiology.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/large/jm-2018-01651e_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Examples of simulated concentration response curves for an agonist in the presence of saturating concentration of functionally distinct allosteric modulators.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/large/jm-2018-01651e_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01651&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">While combinations of these allosteric parameters are generally seen in a given compound, chemical probes have been described occasionally where one of these effects is preponderant over the others in defining the allosteric nature of the compound. For example, PAMs characterized by Ï<sub>B</sub> = 0 are often called âpureâ PAMs, to differentiate them from âAgo-PAMsâ (Ï<sub>B</sub> > 0), which enhance the receptor functional response even in the absence of orthosteric agonist. These compounds may become important tools to define optimal allosteric drug target profile (ADTP) and align them according to the appropriate disease pathophysiology. For example, in a disease state characterized by an excess of endogenous agonist acting at an autoreceptor (e.g., hyperglutamatergic states for presynaptic mGluR2 or mGluR4), the ADPT would theoretically be that producing enhancement of functional efficacy above the <i>E</i><sub>max</sub> of the orthosteric agonist (<i>c</i>, <i>d</i>, or <i>e</i> on <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), whose binding site is already saturated by excess agonist.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> On the other hand, a disease state characterized by insufficient agonist tone, functional enhancement at low agonist concentrations by an Î± PAM (such as <i>b</i> in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) would be more relevant (vide infra, section on muscarinic PAMs).</div><div class="NLM_p"><a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> shows the concentrationâresponse curves obtained by titrating the allosteric ligand, either in PAM mode (agonist concentration [A] = EC<sub>20</sub>) or NAM mode (agonist concentration [A] = EC<sub>80</sub>). Examples of some of these modalities are presented below.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/large/jm-2018-01651e_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Modeling of concentrationâresponse curves (CRCs) for different combinations of Î± and Î² parameters tested under conditions to detect enhancers ((A), [Agonist] = EC<sub>20</sub>) or inhibitors ((B), [Agonist] = EC<sub>80</sub>) of functional response. Additional parameters used are p<i>K</i><sub>A</sub> = 7, p<i>K</i><sub>B</sub> = 7, Ï<sub>A</sub> = 1, Ï<sub>B</sub> = 0, and <i>n</i> = 1.5.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/large/jm-2018-01651e_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01651&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Equation 1 or similar may be used in a number of ways to support decision making in allosteric drug discovery projects, besides conducting simulations of different allosteric modalities as shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> and <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>. Popular software packages use it for the global fitting of experimental functional data sets obtained by varying both the concentrations of orthosteric agonist and allosteric modulator.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> A number of reports in the literature support an agreement between this model and experimental data, although this is not always the case (vide infra).</div><div class="NLM_p">Early work of medicinal chemists establishing allosteric SAR relied on classical parameters based on different agonist concentrations, for example, using EC<sub>20</sub> of agonist to determine EC<sub>50</sub> and <i>E</i><sub>max</sub> of a PAM (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A) or several agonist concentrations to measure fold-shift (FS, the maximal change in agonist activity in the presence of a PAM). Following a recent trend, compounds are qualified using p<i>K</i><sub>B</sub>, Î±, Î², and Ï<sub>B</sub> values (obtained using the Leach equation), or combinations thereof (e.g., log Î±Î²; <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). The increased complexity due to more parameters required for SAR optimization, from three (EC<sub>50</sub>, <i>E</i><sub>max</sub>, and FS) to four (p<i>K</i><sub>B</sub>, Î±, Î², and Ï<sub>B</sub>), is more than offset by the ability to identify compounds with unique functional properties and avoid nontractable SAR by deconstructing the individual contributions of these parameters to the global functional activity.<a onclick="showRef(event, 'ref22 ref33 ref40'); return false;" href="javascript:void(0);" class="ref ref22 ref33 ref40">(22,33,40)</a></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/large/jm-2018-01651e_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Example of an SAR table for developing SAR for a putative set of PAMs using classical parameters versus those in eq 1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/large/jm-2018-01651e_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01651&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A number of recent disclosures have followed this methodology in their investigations of allosteric ligands. Selective enhancers of dopamine D<sub>1</sub> receptors (D<sub>1</sub>R) have attracted interest as potential therapies in cognition, schizophrenia, Huntingtonâs disease, and Alzheimerâs disease, and the D<sub>1</sub>R PAMs ASP4345 (Astellas, structure not disclosed) and LY3154207 (<b>1</b>) have reached clinical studies.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> A practical liability discovered with some early D<sub>1</sub>R PAM tool compounds is their species selectivity, as they are active at human and nonhuman primate D<sub>1</sub>R but lack efficacy at the rat and mouse D<sub>1</sub>R, presumably due to a single amino acid difference (R130Q point mutation).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> One successful strategy followed to circumvent this issue was the development of mice with a humanized <i>knock-in</i> hD<sub>1</sub>R to enable in vivo readouts of behavioral efficacy.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43,44)</a> Another productive strategy included hit identification using a primary high-throughput screen (Ca<sup>2+</sup> mobilization in D<sub>1</sub>R-G<sub>15</sub> expressed in HEK293 cells) of the Molecular Libraries Screening Center Network,<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> followed by hits characterization through a combination of functional, bias (Î²-arrestin recruitment and cAMP accumulation), and binding affinity (vs [<sup>3</sup>H]-SCH-23390) assays using eq 1. This led to the discovery of two structurally distinct D<sub>1</sub>R PAM tool compounds, MLS6585 (<b>2</b>) and MLS1082 (<b>3</b>). <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> shows the allosteric attributes obtained for these two compounds. Of note, the binding affinities of <b>2</b> and <b>3</b> to the D<sub>1</sub>R obtained using either a binding or a Î²-arrestin recruitment assay show good agreement. Overall, these compounds seem to bind at two distinct allosteric sites and may operate different potentiation mechanisms.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0010.gif" alt="" id="fx1" /></img></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Characterization of D<sub>1</sub>R PAMs Using a Combination of Binding and Functional Assays and the Leach Equation</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="center" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">binding assay<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="5" align="center" char=".">dopamine-induced Î²-arrestin recruitment assay<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">dopamine-induced cAMP accumulation assay</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char="."><i>K</i><sub>B</sub> (Î¼M)</th><th class="colsep0 rowsep0" align="center" char=".">Î±</th><th class="colsep0 rowsep0" align="center" char=".">fold shift<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">efficacy ratio<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">Î²</th><th class="colsep0 rowsep0" align="center">Ago-PAM</th><th class="colsep0 rowsep0" align="center" char="."><i>K</i><sub>B</sub> (Î¼M)</th><th class="colsep0 rowsep0" align="center" char=".">fold shift<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">efficacy ratio<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">Ago-PAM</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="char" char=".">0.54</td><td class="colsep0 rowsep0" align="char" char=".">3.1</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td><td class="colsep0 rowsep0" align="char" char=".">0.41</td><td class="colsep0 rowsep0" align="center">no</td><td class="colsep0 rowsep0" align="char" char=".">0.46</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="center">no</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="char" char=".">5.4</td><td class="colsep0 rowsep0" align="char" char=".">6.6</td><td class="colsep0 rowsep0" align="char" char=".">6</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td><td class="colsep0 rowsep0" align="char" char=".">0.32</td><td class="colsep0 rowsep0" align="center">no</td><td class="colsep0 rowsep0" align="char" char=".">5.4</td><td class="colsep0 rowsep0" align="char" char=".">6</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="center">no</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">[<sup>3</sup>H]-SCH-23390 binding assays.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">DiscoverX Î²-arrestin-D<sub>1</sub>R complementation assay.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">Versus dopamine alone. Data obtained from ref <a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a>.</p></div></div></div><div class="NLM_p">The allosteric properties of compound <b>4</b> as a prototype Î´-opioid receptor-selective PAM tool compound were studied using a combination of receptor binding, G protein activation, Î²-arrestin recruitment, adenylyl cyclase inhibition, and extracellular signal-regulated kinases (ERK) activation and applying the Leach equation (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). Probe dependency was also studied using both peptidic and nonpeptidic orthosteric agonists SNC-80 (<b>5</b>) and leu-enkephalin (<b>6</b>).<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Analysis of the data on <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> indicates some consistent trends as well as significant variability in the parameters obtained (e.g., <i>K</i><sub>B</sub> values across assay types). A possible explanation for this discrepancy may likely be related to the use of different cell lines for each functional readout; thus, it is recommended that this type of analysis be made using cells with similar backgrounds as much as it is feasible.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0011.gif" alt="" id="fx2" /></img></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/large/jm-2018-01651e_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Comparison of allosteric parameters obtained from the Leach equation on functional readouts from screens using PAM <b>4</b> and either orthosteric agonist <b>5</b> or <b>6</b>. <i>K</i><sub>A</sub> and <i>K</i><sub>B</sub> values are in nM. Graphics obtained using data from ref <a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/large/jm-2018-01651e_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01651&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In a clinical application of this model, eq 1 was used to conduct the pharmacokinetic and pharmacodynamic profiling of an orally bioavailable P2X7 receptor NAM GSK1482160 (<b>7</b>) in healthy human subjects. In this case, with ATP as the agonist and GSK1482160 as the allosteric modulator, the model provided support for the hypothesis that <b>7</b> reduces the efficacy of ATP at the P2X7 receptor without affecting its affinity.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0012.gif" alt="" id="fx3" /></img></div><div class="NLM_p">However, sometimes disparities are observed between experimental data and this model. There are multiple possible explanations that can account for such findings, including intricacies due to multiple, nonequivalent orthosteric, or allosteric binding sites, receptor desensitization, state dependency, or the formation of homo- or hetero-oligomeric receptors. Nonetheless, this information is useful because it enlightens medicinal chemists of the complexities impacting the interpretation of functional and binding structureâactivity relationships (SAR).</div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Positive Binding Cooperativity (Î±-PAMs)</h3><div class="NLM_p">This may be the simplest mode of allosteric modulation: when the allosteric drug enhances only the affinity of the orthosteric ligand (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, trace <i>b</i>). There are no major observed changes to the maximum efficacy of the system compared with that of the agonist (generally considered as <i>E</i><sub>max</sub> = 100%). An important example of major efforts by many organizations seeking a drug with such an ADPT is in the area of muscarinic M<sub>1</sub> PAMs (vide infra). BQCA (<b>8</b>) is an early tool compound characterized by a large Î± = 400, <i>K</i><sub>B</sub> = 19 Î¼M (based on a radioligand binding assay), and Ï<sub>B</sub> = 28 (Ca<sup>2+</sup> mobilization assay).<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> PF-06827443 (<b>9</b>), a related advanced preclinical compound, also showed a large left-shift of agonist potency with values of Î± = 200, <i>K</i><sub>B</sub> = 3 Î¼M, and Ï<sub>B</sub> = 0.35.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> M<sub>1</sub> PAM clinical development compounds include MK-7622 (<b>10</b>), with ago-PAM properties characterized by approximate values of Î± = 338, <i>K</i><sub>B</sub> = 0.95 Î¼M, and Ï<sub>B</sub> = 1.07,<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> and PF-06764427 (<b>11</b>), also showing triple-digit acetylcholine FS values when tested in Ca<sup>2+</sup> mobilization assays.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Thus, these advanced compounds (<b>8</b>â<b>11</b>) share large binding cooperativity as a common feature.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0013.gif" alt="" id="fx4" /></img></div><div class="NLM_p">Compounds that enhance binding cooperativity (measured by Î± or FS) to a very small extent may have a desirable ADPT under some circumstances where excessive activation must be avoided. One such examples is a low FS M<sub>1</sub> PAM, which may produce use-dependent attenuation of transmitter-signaling and avoid agonist-like behavior, a limitation of previously reported high FS PAMs. It was hypothesized that compounds with very small, yet detectable functional effects could derive from a new allosteric site.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> To identify such putative binding site, the team at Roche utilized a high throughput screening of the compound collection using a cell line expressing the wild-type hM<sub>1</sub> receptor (WT hM<sub>1</sub>), followed by the use of a double Y179A-W400A mutant, corresponding to the known âgallamine/brucine siteâ. Thus, PAMs retaining activity at this double mutant would bind to a different allosteric site, with potential to lead to lower FS than those already known and explored (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). These efforts in conjunction with optimization of drug-like properties, led to <b>12</b> with an EC<sub>50</sub> = 71 nM, <i>E</i><sub>max</sub> = 72%; its FS = 8.6 at human receptors was 20â40-fold lower than the above referenced tools and earlier clinical compounds.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/large/jm-2018-01651e_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Strategy used to uncover low FS M<sub>1</sub> mAChR PAMs binding to a novel binding site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/large/jm-2018-01651e_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01651&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">It remains to be seen whether low FS M<sub>1</sub> PAMs, obtained via a more informed screening and design process, will identify ligands with better profiles in an area where earlier M<sub>1</sub> PAM clinical compounds with high FS values failed to provide improved profiles compared with agonists.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Supraphysiological Efficacy Cooperativity (Î²-PAMs)</h3><div class="NLM_p">Have membrane receptors evolved to deliver the highest possible functional efficacy for their endogenous agonists? It appears that is not always the case, as for some notable cases (e.g., GABA<sub>A</sub> and mGluRs) allosteric modulators have been reported that enhance the systemâs maximal efficacy above the nominal value of 100%, typically attributed to the endogenous agonists.</div><div class="NLM_p">In GABA<sub>A</sub> ion channels containing the Î´ subunit, the synthetic agonist gaboxadol, also known as 4,5,6,7-tetrahydroisoxazolo(5,4-<i>c</i>)pyridin-3-ol or THIP (<b>13</b>) acts as a superagonist (not a PAM as it functions in absence of native ligand). In addition, various neuroactive steroid (NAS) PAMs also potentiate GABA responses above its <i>E</i><sub>max</sub> in vitro. In a recent study, the functional effects at Î±4Î²2Î´ and Î±4Î²2Î³2 receptor subtypes were evaluated using recombinant receptors expressed in <i>Xenopus</i> oocytes for a chemically diverse group of agonists, including THIP (<b>13</b>) and muscimol (<b>14</b>), and PAMs, such as (<i>R</i>)-etomidate (<b>15</b>), pentobarbital (<b>16</b>), and DS2 (<b>17</b>), and the neuroactive steroids alfaxalone (<b>18</b>), allopregnanolone (<b>19</b>), and tetrahydrodeoxycorticosterone (3Î±,21-dihydroxy-5Î±-pregnan-20-one or THDOC, <b>20</b>). Maximal modulatory efficacies, relative to saturating concentrations of GABA (100 Î¼M), evoked currents at the two subtypes investigated are shown in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>. While etomidate and pentobarbital both have efficacies moderately larger than GABA <i>E</i><sub>max</sub>, at Î±4Î²2Î³2, all PAMs tested have significantly larger efficacies than GABA <i>I</i><sub>max</sub> at the Î±4Î²2Î´ subtype. In addition, this systematic work showed that the two subtypes studied present divergent intrinsic activation properties under the conditions of this study, showcasing the challenges associated with establishing physiologically relevant measures of subtype selectivity for some allosteric modulators.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a></div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/large/jm-2018-01651e_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Modulation of efficacy for GABA-evoked Î±4Î²2Î´ and Î±4Î²2Î³2 currents in <i>Xenopus laevis</i> oocytes. Values are relative to efficacies at saturating GABA concentrations. Graphic made with data reported in ref <a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/large/jm-2018-01651e_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01651&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0014.gif" alt="" id="fx5" /></img><div class="NLM_p">For GPCRs, support for the concept of supraphysiological efficacy has become better understood recently.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> For example, the potent and selective mGluR4 PAM ADX88178 (<b>21</b>) was shown to enhance the systemâs maximal functional response well above that for the endogenous agonist glutamate or the mGluR4-preferring synthetic agonist LSP1-2111 (<b>22</b>), in a number of in vitro systems, including Ca<sup>2+</sup> mobilization, [<sup>35</sup>S]-GTPÎ³S, phenotypic âlabel free.â and electrophysiology field excitatory postsynaptic potentials (fEPSP) measurements. Furthermore, this molecular feature (indicated by values of Î² > 1 using the operational model) was proposed as necessary to obtain efficacy in in vivo preclinical models of pharmacological response in a system exposed to saturating concentrations of the endogenous orthosteric ligand glutamate.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Supraphysiological efficacy was also reported for the clinical mGluR2 PAMs JNJ-40411813/ADX71149 (<b>23</b>; <i>E</i><sub>max</sub> ca. 200%), AZD8529 (<b>24</b>; <i>E</i><sub>max</sub> = 110%), and the tool compound JNJ-46281222 (<b>25</b>; <i>E</i><sub>max</sub> ca. 200%), all based on functional in vitro assays<a onclick="showRef(event, 'ref57 ref58 ref59'); return false;" href="javascript:void(0);" class="ref ref57 ref58 ref59">(57â59)</a> and, to a lower extent, for the mGluR5 PAM clinical candidate VU0409551/JNJ-46778212 (<b>26</b>; <i>E</i><sub>max</sub> = 120%).<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0015.gif" alt="" id="fx6" /></img><div class="NLM_p last">These observations underscore that unique perspectives on drug action may be obtained by characterizing compounds made in drug discovery projects by parameters derived from operational measures of agonist functional efficacy, such as Î±, Î², Ï<sub>B</sub>, and <i>K</i><sub>B</sub> using eq 1.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Neutral Allosteric Ligands (NALs)</h3><div class="NLM_p">Neutral allosteric ligands (NALs), also known as silent modulators, are compounds that bind at an allosteric site but do not perceptibly impact the functional activity of the orthosteric ligand. Identification of compounds with such properties are generally rare, as they are significantly more difficult to identify, particularly if one is not looking for them. First, it takes a number of functional and binding assays to sufficiently characterize a NAL. Second, functionally inactive compounds are often not followed up with binding assays to explore their potential NAL properties. NALs may be encountered during in vitro screening in SAR studies where a potent binder is subsequently found to have no functional activity. The pharmacological properties for a handful of GPCR and ion channel NALs have been thoroughly studied. As the examples discussed below show, the lack of a functional effect upon binding of a NAL to an allosteric site does not imply lack of pharmacological effects. NALs may act competitively at the allosteric site and block PAM or NAM activity of endogenous or exogenous ligands.</div><div class="NLM_p">SAR studies on a group of oxazolidinones demonstrated tractable features as allosteric modulators of mGluR5 with a range of functional activities (compounds <b>27</b>â<b>31</b>; <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) and led to the discovery of the potent NAL BMS-984923 (<b>30</b>) that enabled studies to clarify the mechanism-based neurotoxicity liabilities associated with mGluR5 activation.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Furthermore, recent studies with <b>30</b> suggest it has potential for the treatment of Alzheimerâs disease.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> It was shown that this compound does not change agonist glutamate signaling as determined by measuring Ca<sup>2+</sup> responses but blocks the effects of the well characterized mGluR5 NAM MTEP and prevents mGluR5 PAM induced seizures in vivo. mGluR5 PAMs have previously been associated with toxicities and side effects such as induction of seizures, leading many to conclude the target may not be viable. However, this work demonstrated that the ADPT of the close analogues tested (in this case, the magnitude of the FS PAM effect) was key in driving convulsions in mice: compounds with FS â¤ 3.4 did not produce convulsions in mice at saturating concentrations of compound. BMS-984923âs interaction with mGluR5, while silent in terms of agonist signaling, imparts inhibitory effects on other mGluR5 functions. It inhibits the interaction between mGluR5 and cellular prion protein (PrPc) bound to amyloid-beta oligomer (AÎ²o) and thereby antagonizes AÎ²o signal transduction and associated detrimental effects of synaptic depletion in transgenic AD mice. Mechanistic support for this hypothesis was obtained through subchronic dosing of <b>30</b> for 5 weeks in APP/PS1 mice, which resulted in restoration of synapses and improved memory performance but did not affect gliosis or AÎ² plaques.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Thus, while mGluR5 PAMs may lead to neurotoxicity and some mGluR5 NAMs have shown detrimental psychotomimetic effects in the clinic, an mGluR5 NAL may provide unique functional modulations and optimal therapeutic index (TI).</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/large/jm-2018-01651e_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Structure activity relationship of a set of oxazolidinones as allosteric modulators of mGluR5 with a range of functional activities. Data from ref <a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/large/jm-2018-01651e_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01651&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Allopregnanolone (<b>19</b>), an endogenous neuroactive steroid, acts as a PAM at the GABA<sub>A</sub> receptor, enhancing GABA-mediated Cl<sup>â</sup> currents by acting at an allosteric site distinct from the binding sites for GABA, benzodiazepines, barbiturates, and picrotoxin.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Structureâactivity relationships for this neuroactive steroid binding site are defined by a 3Î±-hydroxy group and a 20-ketone functionality in the pregnane molecule. Interestingly, the 3Î²-OH diastereoisomer of <b>19</b>, called isoallopreganolone (<b>32</b>), can inhibit noncompetitively allopregnanolone-enhanced GABA-mediated Cl<sup>â</sup> flux, even as isoallopregnanolone alone does not affect baseline Cl<sup>â</sup> uptake nor inhibits the functional effects of up to 10 Î¼M GABA in the Cl<sup>â</sup> uptake assay. Isoallopregnanolone does not affect flunitrazepam and pentobarbital-induced increase in Cl<sup>â</sup> uptake, either. Thus, isoallopregnanolone appears to be acting as a NAL at the GABA<sub>A</sub> receptor. These in vitro antagonistic effects on GABA<sub>A</sub> PAMs driven by the inversion of configuration at C-3 seem to be tractable across several analogues made and translate to the in vivo setting, as isoallopregnanolone antagonizes allopregnanolone-induced anesthesia in rats, and in humans it antagonizes allopregnanolone-induced sedation and reductions in saccadic eye velocity.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> The therapeutic potential of both diastereomeric series is being further tested in clinical studies. Among the 3Î±-OH GABA<sub>A</sub> PAMs,<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> allopregnanolone (<b>19</b>, brexanolone) has completed phase 3 clinical development for postpartum depression (PPD), and a New Drug Application is currently under review with the U.S. Food and Drug Administration, ganaxolone (<b>33</b>) is in phase 2 stage PPD and orphan epilepsies,<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> and SAGE-217 (<b>34</b>) is in phase 3 clinical development for PPD and major depressive disorders.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> In addition, alfaxolone (<b>18</b>) is already approved as an animal intravenous anesthetic in some countries. Among the 3Î²-OH GABA<sub>A</sub> NALs, isoallopregnanolone (<b>32</b>, sepranolone, or UC1010) is under clinical studies for premenstrual dysphoric disorder,<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> and GR3027 (<b>35</b>) is in phase 2 for the treatment of idiopathic hypersomnia and hepatic encephalopathy.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0016.gif" alt="" id="fx7" /></img><div class="NLM_p">Another interesting example of NAL activity by an endogenous metabolite is the case of the neuroactive oxysterol 25-hydroxycholesterol (25-HC, <b>36</b>). On its own, 25-HC shows a mild potentiation of the NMDA receptor (maximum 1.2-fold potentiation of recombinant GluN1a/GluN2A NMDA receptors expressed in <i>Xenopus</i> oocytes).<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> On the other hand, its regioisomer 24(<i>S</i>)-hydroxycholesterol (24(<i>S</i>)-HC, <b>37</b>) is one of the major brain metabolites of cholesterol and has potent NMDAR PAM activity (2-fold potentiation).<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> When 25-HC is coapplied with either 24(<i>S</i>)-HC or its congener, SGE-201 (<b>38</b>), it noncompetitively antagonizes the NMDAR effect of both PAMs, <b>37</b> or <b>38</b>.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> It is interesting that these two brain-derived endogenous cholesterol metabolites have opposing actions at the NMDAR, where they seem to act through distinct binding sites, suggesting a role in neuropsychiatric and neurological disorders for oxysterols.</div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0017.gif" alt="" id="fx8" /></img><div class="NLM_p">From this growing body of work, it is evident that NALs may have biological effects distinct from PAMs, NAMs, or compounds not binding at the respective receptor. Thus, it is important to differentiate drugs that are functionally selective (comparable binding affinities at different targets but different efficacies) from those that provide selectivity through large differences in their binding affinities. For example, the clinical drug PF-06372865 (<b>39</b>) is considered a functionally selective Î±2/3 GABA<sub>A</sub> PAM even though the compound has 10-fold higher affinity for Î±1-subtype receptor.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0018.gif" alt="" id="fx9" /></img><div class="NLM_p">Thus, because <b>39</b> is an Î±1 GABA<sub>A</sub> NAL, it confers functional PAM selectivity for the Î±2/3 GABA<sub>A</sub> receptor. While functionally selective, <b>39</b> may have different pharmacological properties than a compound that has functional activity at the Î±2/3 GABA<sub>A</sub> subtype and no significant affinity for its Î±1-counterpart, again highlighting the importance of the defining properties of allosteric modulators.</div><div class="NLM_p last">While largely unexplored, compounds with NAL functionality may have additional unique therapeutic potential, as well as major mechanistic utility as chemical probes in allosteric drug research.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Partial Negative Allosteric Modulators (Partial NAMs)</h3><div class="NLM_p">Occasionally, excessive functional response by a biological receptor may lead to a pathophysiology, yet complete functional inhibition can be associated with undesired side effects and toxicity. The goal would be to have a drug that affords partial inhibition of the target to impart the desired efficacy without the undesired effects observed with high levels of target inhibition. While difficult in practice, competitive compounds may theoretically present a solution to this problem by avoiding doses leading to high levels of receptor occupancy (RO). This approach is typically dependent upon having optimal pharmacokinetic properties and usually associated with a narrow TI. An alternative improved approach to avoid such effects is to use partial NAM compounds, where full occupancy at the allosteric site provides only partial inhibition of functional response regardless of the concentration of the ligand.</div><div class="NLM_p">For example, mGluR5 functional inhibition by negative allosteric modulation is a promising approach for the treatment of a variety of neuropsychiatric indications including addictions, depression, and anxiety and has been the subject of significant effort with a number of mGluR5 NAMs having reached advanced clinical testing.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> However, it has been shown that high levels of functional inhibition with NAMs such as 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP, <b>40</b>) or basimglurant (<b>41</b>) are associated with psychotomimetic effects both preclinically and clinically, leading to the discontinuation of several clinical development programs based on this approach.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> MTEP and analogues also act as an inverse agonist at the mGluR5 receptor, which may contribute to both the efficacy and side effects, therefore complicating the data interpretation for these analogues.</div><div class="NLM_p">VU0477573 (<b>42</b>), 2-(2-(3-methoxyphenyl)ethynyl)-5-methylpyridine (M-5MPEP, <b>43</b>) and 2-(2-(5-bromopyridin-3-yl)ethynyl)-5-methylpyridine (Br-5MPEPÎ³, <b>44</b>) are examples of compounds reportedly having mGluR5 partial NAM activity. The tool compound <b>42</b> was qualified through extensive in vitro and in vivo studies, demonstrating a partial mGluR5 NAM profile. When compared with a full mGluR5 NAM across a number of biological systems, it was shown that partial functional inhibition may be sufficient for efficacy. In vitro, at full RO, VU0477573 (<b>42</b>) produces a maximum 80% inhibition of Ca<sup>2+</sup> release in mGluR5-expressing HEK293A cells stimulated with a concentration of glutamate that yields maximal receptor activation. In contrast, full NAMs 2-methyl-6-(phenylethynyl)-pyridine (MPEP, <b>45</b>) and MTEP (<b>40</b>) show 100% inhibition of Ca<sup>2+</sup> release when tested under the same conditions. All three compounds show complete binding to the MPEP site, measured in membranes from the same mGluR5 expressing HEK293A cells.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0019.gif" alt="" id="fx10" /></img><div class="NLM_p last">While it has been demonstrated that partial NAM activity with <b>42</b> is sufficient for efficacy preclinically, the question of whether partial NAM activity would be devoid of the undesired side effects was not initially evaluated. In a follow up paper, NAM activity at 80% RO was not associated with psychotomimetic-like effects. At full RO, where strong efficacy is observed, partial mGluR5 NAMs <b>43</b> and <b>44</b> did not potentiate PCP-induced increases in locomotor activity in preclinical models, nor did they impact PCP discrimination, suggestive of a broader TI relative to fully functional NAMs.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> However, inverse agonist activity of MTEP and MPEP on [<sup>3</sup>H]-inositol phosphate accumulation is not observed with these partial NAMs, making it unclear if the reduced potential for side effects with these compounds is due to their partial NAM activity or lack of inverse agonist activity. Nonetheless, the concept of partial NAMs remains a viable avenue for potentially safer therapeutics.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Î±-PAM/Î²-NAMs (or PAM-NAMs)</h3><div class="NLM_p">Historically, the functional profile of a given compound (antagonist, agonist, PAM, NAM, etc.) has been linked to a core chemical structure. However, that clearly is not the case for all allosteric modulators. For example, probe dependence shows that the actual functional response is a property of the specific combination of ligands bound to a target subject to allosteric regulation; in other words, the combination of orthosteric/allosteric ligands determine the system functional response.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> Furthermore, the same agonist/allosteric ligand pair may display seemingly opposite functionalities at closely related receptor subtypes. For example, PNU-107484A (<b>46</b>) was shown to act as a PAM enhancing GABA-induced Cl<sup>â</sup> currents in the Î±1Î²2Î³2 subtype of GABA<sub>A</sub> ion channels but a NAM causing inhibition of the currents in the Î±3Î²2Î³2 and Î±6Î²2Î³2 subtypes.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0020.gif" alt="" id="fx11" /></img><div class="NLM_p">Furthermore, the phenomenon known as âuse dependencyâ indicates that a compound may have mixed effects depending on its concentration, such as enhancing the affinity for the orthosteric ligand as well as inhibiting its efficacy (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, curve <i>f</i>). Such compounds have been called Î±-PAMs/Î²-NAMs (or sometimes PAM-antagonists).<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> Compared with âclassicalâ orthosteric antagonists or NAMs, these PAM-NAMs have the unique characteristic of binding more tightly to the receptor at higher agonist concentrations, thus providing a favorable target coverage in vivo versus competitive inhibitors.</div><div class="NLM_p">While there is a paucity of such compounds that have been characterized in the literature to date, these are particularly important tool compounds often used in mechanistic studies. This select group includes ifenprodil (<b>47</b>), an antagonist of NMDA responses that in whole-cell voltage-clamp recordings from cultured cortical rat neurons <i><b>antagonized</b></i> functional effects of high NMDA concentrations (10 and 100 Î¼M). On the other hand, at lower NMDA concentrations (0.3 Î¼M and 1 Î¼M), ifenprodil <i><b>potentiated</b></i> approximately 200% of control. Thus, with increasing concentrations of NMDA, the effect of ifenprodil NMDA-evoked changed from potentiation to inhibition.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a></div><div class="NLM_p last">Therefore, the inherently uncorrelated structural links for allosteric parameters for binding cooperativity (Î±) and efficacy (Î²) cooperativity may lead to therapeutically useful drugs with truly unique pharmacological properties and impossible to emulate using ligands working through competitive mechanisms with orthosteric agonists. In addition, during the characterization of new compounds, measuring allosteric drug properties at a single concentration of the orthosteric ligand may be an oversimplification and fail to provide enough information to accurately conclude on a drugâs ADTP. Indeed, the challenging tasks required to characterize allosteric ligands are also associated with delivering uniquely differentiated and potentially more valuable drugs.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Mutant Protein or Autoantibody-Linked Functional Rescue</h3><div class="NLM_p">The versatility of allosteric ligands to fine-tune biological function is not limited to naturally occurring protein sequences. It has been used to restore functional output away from pathophysiological limits in diseases where amino acid mutations lead to loss or gain of function receptor systems.</div><div class="NLM_p">The gene <i>GRIN2B</i> encodes the GluN2B subunit of the NMDA receptor, and missense mutations have been linked to autism, intellectual disability, LennoxâGastaut and West Syndromes, and a number of epileptic encephalopathies. Functionally, these mutations lead to changes in glutamate potency, increased receptor desensitization, and ablation of Mg<sup>2+</sup> block, resulting in NMDA receptor dysfunction and concomitant neurological disorders.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a></div><div class="NLM_p">NMDARs containing GluN2B gain of function single-nucleotide polymorphisms (SNPs) in GRIN2 were reported to be sensitive to the NAM radiprodil (<b>48</b>).<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> Specifically, three gain of function mutations (R540H, N615I, and V618G) of the GluN2B subunit were studied. The R540H mutation, located in the ligand binding domain, resulted in a 2.5-fold decrease in the glutamate EC<sub>50</sub> (with coapplication of 1 Î¼M glycine) relative to wild-type receptor at pH 7.6, while the N615I and V618G forms had no impact on glutamate EC<sub>50</sub>. In the WT and R540H forms of the receptor, addition of Mg<sup>2+</sup> gave near complete blockade of glutamate-induced current. Remarkably, the transmembrane N615I and V618G mutants had a dramatic impact on the effect of Mg<sup>2+</sup>, which rather than block, potentiated glutamate-induced current. The nonselective NMDAR channel blockers MK-801 and memantine were equally potent against the WT and R540H mutant forms of the receptors. However, relative to the WT NMDAR, MK-801 was about 30-fold less potent against both the N615I and V618G mutants. Memantine, on the other hand, had similar activity against the WT and N615I mutant but was 30-fold less potent against the V618G form. These observations may be due to the proximity of the amino acid changes relative to the channel where MK-801 and memantine bind. Radiprodil (<b>48</b>), a selective GluN2B NAM which binds in the extracellular amino terminal region, far from the three sites of mutation, blocks glutamate-induced currents similarly across the WT and three mutant forms of the enzyme and importantly with similar potency both in the presence and absence of Mg<sup>2+</sup>.</div><div class="NLM_p">Yet another example is the calcium-sensing receptor (CaSR), which has many functionally disease relevant loss and gain of function SNPs leading to impaired cell surface expression and or altered functional Ca<sup>2+</sup> and ERK signaling.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> It is therefore important to understand the impact of these SNPs on drug efficacy, as it has meaningful consequences in how patients are treated. The CaSR PAM cinacalcet (<b>49</b>) and NAM NPS-2143 (<b>50</b>) were able to reverse SNP-induced impairments in cell-surface CaSR expression, purportedly through protein stabilization, enabling more of the protein to reach the cell surface. It is interesting to note that this effect was independent of the functional activity of the ligand, occurring with both a PAM and NAM. In addition, cinacalcet was shown to enhance Ca<sup>2+</sup> mobilization in some of the loss of function CaSR mutants, whereas NPS-2143 was able to reduce Ca<sup>2+</sup> mobilization in the gain of function CaSR mutants. Several of the SNPs modified the binding affinity of these ligands, whereas others modified the level of cooperativity with Ca<sup>2+</sup>. This data demonstrates feasibility for PAMs and NAMs to maintain effectiveness in altering functional effects of CaSR mutations and points to the highly dependent nature of both the specific SNP and allosteric modulator in question.</div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0021.gif" alt="" id="fx12" /></img><div class="NLM_p">Allosteric strategies may lead to effective treatments for diseases mechanistically linked to functional changes caused by the generation of autoantibodies under pathophysiological conditions. For example, anti-<i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate receptor encephalitis (NMDARE) is an autoimmune disease associated with GluN1 antibody-mediated NMDAR internalization and loss of function.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> It is increasingly recognized as an important cause of sudden-onset psychosis and other neuropsychiatric symptoms and comorbidities. Evidence recently obtained from in vitro studies on rat hippocampal neurons of both sexes using cerebrospinal fluid samples obtained from female human NMDARE patients or healthy controls is consistent with a loss of NMDA surface receptors caused by these antibodies. Following CSF exposure, the remaining functional NMDAR population was indistinguishable from baseline in terms of parameters such as channel open probability and synaptic or extrasynaptic NMDAR localization. Treatment with the NMDAR PAM tool compound SGE-301 (<b>51</b>) restored NMDAR function in samples incubated with patient CSF. This suggests that NMDAR PAMs may be a potential therapeutic strategy for NMDARE, and allosteric modulators in general, for autoimmune diseases modifying functional effects at other receptors.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0022.gif" alt="" id="fx13" /></img></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Covalent Allosteric Modulators</h3><div class="NLM_p">Drugs that bind covalently to their targets represent a drug design opportunity,<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> which is beginning to gain interest within the field of allosteric modulation.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> The principal advantage of this approach is long-lasting target engagement and duration of action, beyond that expected by their plasma half-life. The first example of covalent allosteric modulators was discovered by serendipity for the glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) PAM scaffold.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> GLP-1R is a class B GPCR involved in the potentiation of glucose-dependent insulin secretion for the treatment of type 2 diabetes, where only a few low molecular weight agonists have been disclosed.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> The discovery of PAMs of GLP-1R avoids the difficulty in mimicking with an agonist the complex two-step process by which the endogenous polypeptide ligands of GLP-1R activate the receptor.</div><div class="NLM_p">Some key examples of GLP-1R PAMs are 4-(3-benzyloxyphenyl)-2-ethylsulfinyl-6-(trifluoromethyl) pyrimidine<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> (BETP, <b>52</b>), 6,7-dichloro-2-methylsulfonyl-3-<i>tert</i>-butylaminoquinoxaline<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> (<b>53</b>), quercetin<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> (<b>54</b>), VU0453379<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> (<b>55</b>), and HIT-465 (undisclosed structure). Several of these PAMs have been shown to increase insulin secretion in islet preparations and glucose-dependent insulin secretion in animal models of diabetes. During the process to identify the GLP-1R binding sites of <b>52</b> and <b>53</b>, an unexpected mechanism of action was unveiled. These compounds potentiated the activities of several agonist peptides at GLP-1R by a covalent, irreversible mechanism, as opposed to the reversible fashion by which all other GPCR PAMs evoked their pharmacological effects. As mentioned, there are several unique potential advantages for covalent PAMs versus reversible PAMs of GPCRs, in particular more complete and prolonged target engagement.</div><div class="NLM_p">The unexpected reactivity of <b>52</b> and <b>53</b> in the presence of glutathione or 1,4-dithiothreitol led to studies to evaluate a covalent mechanism of action. Results from washout studies in which GLP-1R-expressing cells pretreated with <b>52</b> or <b>53</b> maintained their PAM activity after washout when activating the receptor with endogenous orthosteric agonist GLP-1(9â36)NH<sub>2</sub>. The irreversibility of the PAM activity of both compounds and the agonist activity of <b>53</b> is consistent with a covalent mechanism of action. A clickable analogue of BETP (<b>52</b>) called PETP (<b>56</b>) was synthesized to confirm a covalent mechanism of action. Moreover, <b>56</b> indicated the potential for BETP (<b>52</b>) to alkylate a broad range of other proteins. While the covalent mechanism of action offers certain advantages as discussed above, in this case, nonselective alkylation of a broad set of proteins might lead to safety and heightened immunogenicity risks.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0023.gif" alt="" id="fx14" /></img><div class="NLM_p">GLP-1R covalent PAMs contain electrophilic groups which can react with free thiol groups of cysteine residues, generating covalent adducts. BETP (<b>52</b>) reacts with several different cysteine residues present in the receptor, although the interaction with a specific cysteine residue (i.e., Cys347) is responsible to grant PAM responsiveness. An important part of future work will be to acquire a deeper understanding on how to modulate the electrophilic character of <b>52</b> and <b>53</b> to attain GLP-1R specificity.</div><div class="NLM_p">Another interesting example of the use of covalent allosteric modulation in drug discovery comes from studies with the cannabinoid 1 receptor (CB1R). This target is a class-A GPCR, expressed predominantly in the brain and implicated in several physiological processes, comprising learning, memory, mood, and cardiovascular regulation. Dysregulation of CB1R activity has been associated with neurodegenerative diseases and multiple sclerosis.<a onclick="showRef(event, 'ref95 ref96'); return false;" href="javascript:void(0);" class="ref ref95 ref96">(95,96)</a> To that end, multiple organizations have developed approaches toward the design of CB1R modulators.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> Org27569 (<b>57</b>) enhances the binding affinity of the orthosteric ligand CP55940 (<b>58</b>) while inhibiting its functional efficacy, being best described as a CB1R PAM/NAM (vide supra).<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> Recently an analogue of <b>57</b> containing an isothiocyanate reactive group at C5 was synthesized (<b>59</b>),<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> which interacts with CB1R in a covalent fashion has higher potency and efficacy than the parent, Org27569 (<b>57</b>), in CB1R-dependent Î²-arrestin recruitment and cAMP accumulation. In addition, compound <b>59</b> demonstrated the highest functional selectivity (83-fold) for recruiting Î²-arrestin relative to stimulating cAMP production. Importantly, it was also devoid of inverse agonism, a function previously associated with psychotropic side effects caused by CB1R orthosteric antagonists or inverse agonists.</div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0024.gif" alt="" id="fx15" /></img><div class="NLM_p">The design, synthesis, and pharmacological characterization of the first covalent PAM for a class C GPCR, the mGluR2 receptor, was recently reported.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> Positive allosteric modulation of the mGluR2 receptor has been pursued as a therapeutic approach for neurological disorders such as schizophrenia and anxiety.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> Although the structure of the extracellular domain of the mGluR2 receptor is known, the current structural understanding of the 7TM domain is based on the crystal structures of the mGluR1 and mGluR5 7TM domains. These were crystallized in an inactive state with a NAM bound in the allosteric binding pocket.<a onclick="showRef(event, 'ref102 ref103 ref104'); return false;" href="javascript:void(0);" class="ref ref102 ref103 ref104">(102â104)</a> Aiming to further understand mGluR2 PAM binding and receptor pharmacology, three putatively covalent mGluR2 PAMs, compounds <b>60</b>, <b>61</b>, and <b>62,</b> were designed to take advantage of the privileged nature of sulfonyl fluorides, which display the right balance of stability and reactivity toward nucleophilic protein residues.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> In vitro pharmacological characterization led to the identification of <b>60</b> as a chemical biology tool compound binding covalently to mGluR2.</div><div class="NLM_p">Kinetic parameters for JNJ-46281222 (<b>25</b>) were determined using classical binding experiments with [<sup>3</sup>H]-JNJ-46281222 (<b>63</b>), having a residence time (RT) of 12 min, association rate constant <i>k</i><sub>on</sub> of 1.2 Ã 10<sup>6</sup> M<sup>â1</sup> s<sup>â1</sup>, and dissociation rate constant <i>k</i><sub>off</sub> of 0.0013 s<sup>â1</sup>. In comparison to <b>63</b>, compound <b>60</b> displayed a much slower on-rate (<i>k</i><sub>on</sub> of 3.2 Ã 10<sup>3</sup> M<sup>â1</sup> s<sup>â1</sup>) and an insignificant off-rate (<i>k</i><sub>off</sub> of 3.2 Ã 10<sup>â13</sup> s<sup>â1</sup>), leading to an infinite RT. As a result, it was concluded that compound <b>60</b> was acting through an irreversible binding mode.</div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0025.gif" alt="" id="fx16" /></img><div class="NLM_p">In addition, computational docking identified several amino acid residues that could potentially form a covalent interaction with <b>60</b>. Subsequent mutagenesis studies identified T791<sup>7.29Ã30</sup> as the position of the covalent interaction. Because of its favorable allosteric properties, compound <b>60</b> was presented as a tool compound and a starting point to further evaluate the use of covalent ligands for mGluR2 structure elucidation and pharmacological characterization.</div><div class="NLM_p last">Covalent allosteric modulators have potential pharmacological merits, including increased biochemical efficiency and higher specificity, extended duration of action, and lower toxicity. The design of covalent allosteric modulators has, not surprisingly, proven arduous. An initial major hurdle is simply the identification of allosteric binding pockets, much less the good fortune to have a nucleophilic residue in proximity to covalently interact with an allosteric ligand in such a way that PAM or NAM activity is maintained. For these reasons, most covalent allosteric modulators have been found serendipitously.</div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Biased Allosteric Modulators</h3><div class="NLM_p">An agonist binding to a receptor can activate numerous signaling pathways. Recent evidence demonstrates that different ligands may lead to differential activation of the downstream pathways by stabilizing a limited range of receptor conformations. This concept, termed âbiased signalingâ (also called âstimulus trafficking,â âfunctional selectivity,â and more recently, âagonist biasâ) represents an exciting therapeutic opportunity to target specific pathways that elicit only desired effects while avoiding undesired effects mediated by different signaling cascades via preferential stabilization of selected conformational states. Different ligands acting on the same GPCR, in the same tissue, can give rise to markedly different cellular responses due to each ligand stabilizing different receptor conformations.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a></div><div class="NLM_p">While biased agonists activate selective downstream pathways, selective modulation of a specific receptor within a highly homologous family of receptors is challenging due to high sequence homology of the agonist binding site. In such cases, allosteric modulators that allow binding to a site other than the orthosteric site potentially enable selective modulation of the receptor. Because of the nature of binding at a nonorthosteric site, allosteric modulators allow refinement of signaling efficacy to desired levels. Recently, biased allosteric modulators have been reported that selectively modulate the ability of agonists to stabilize specific active conformations of the receptor and differentially alter the effects of the endogenous agonist on specific signaling pathways, such as compound <b>60</b>, as discussed above.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> Several examples follow wherein such biased modulation offers potential for an improved therapeutic window by limiting undesirable effects.</div><div class="NLM_p">NMDAR hypofunction plays an important role in the pathophysiology of schizophrenia and administration of agents that enhance NMDAR function provides symptomatic improvement in schizophrenic patients.<a onclick="showRef(event, 'ref107 ref108'); return false;" href="javascript:void(0);" class="ref ref107 ref108">(107,108)</a> Metabotropic glutamate receptor subtype 5 (mGluR5) is a closely associated signaling partner with the NMDAR and activation of mGluR5 potentiates NMDAR responses and NMDAR-mediated synaptic plasticity in forebrain regions implicated in the pathology of schizophrenia.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> However, excessive activation of NMDARs, including their potentiation by mGluR5 activation, can induce seizures and excitotoxicity in preclinical models. These adverse effects were reduced but not eliminated after chronic treatment with mGluR5 PAM 5PAM-523 (<b>64</b>).<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> This led to a hypothesis that a biased mGluR5 PAM could selectively dissociate the toxic NMDA modulating effects from the desired downstream effects of mGluR5 and therefore improve tolerability and broaden the therapeutic window. Indeed, efforts to dissociate NMDAR activation led to the identification of a biased mGluR5 PAM, VU0409551 (<b>26</b>), that potentiates mGluR5 coupling to G<sub>Î±q</sub>, Ca<sup>2+</sup> mobilization, and ERK phosphorylation but does not enhance mGluR5 modulation of NMDAR currents. Compound <b>26</b> produced robust antipsychotic-like and cognition-enhancing effects in rodent models,<a onclick="showRef(event, 'ref60 ref111 ref112'); return false;" href="javascript:void(0);" class="ref ref60 ref111 ref112">(60,111,112)</a> suggesting NMDAR-independent actions. This NMDAR sparing activity was associated with a better tolerability profile where chronic administration of VU0409551 had no adverse effects at doses over 100-fold those required to achieve in vivo efficacy.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> This data demonstrates that biased PAMs-mediated signaling of GPCRs can dissociate the signaling pathway(s) that produce undesirable effects.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0026.gif" alt="" id="fx17" /></img><div class="NLM_p">The CaSR is a family C GPCR with a variety of coupling partners including G<sub>g/11</sub>, G<sub>i/o</sub>, and G<sub>12/13</sub>, and its function is also linked to Î²-arrestin and filamin A. CaSR activation by its endogenous ligand Ca<sup>2+</sup> leads to a decrease in parathyroid hormone (PTH) release (desired activity for treating hyperparathyroidism) and an increase in calcitonin release (undesirable activity, leading to hypocalcemia). The calcimimetic drug cinacalcet (<b>49</b>) acts as a PAM of the CaSR and is used clinically to treat secondary hyperparathyroidism (elevated PTH). Clinical use of cinacalcet in hyperparathyroidism, however, is limited to treatment of only end-stage renal disease due to its enhancement of calcitonin release resulting in hypocalcemia. CaSR regulates extracellular Ca<sup>2+</sup> levels in the body. When Ca<sup>2+</sup> levels rise in the parathyroid gland, CaSR activation suppresses the secretion of parathyroid hormone (PTH), resulting in reduced renal Ca<sup>2+</sup> reabsorption and reduced bone resorption.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> In addition, CaSR also mediates numerous noncalciostatic roles.<a onclick="showRef(event, 'ref114 ref115 ref116'); return false;" href="javascript:void(0);" class="ref ref114 ref115 ref116">(114â116)</a> While drugs targeting CaSR have therapeutic applications, they are limited by adverse effects arising from actions in multiple tissues expressing the CaSR. Indeed, cinacalcet causes hypocalcemia,<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> likely due to reduced calcium reabsorption induced by CaSR in the kidney and calcitonin-mediated inhibition of bone resorption via CaSR activation in the thyroid C-cells.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a></div><div class="NLM_p">Biased modulation of CaSR to maximize suppression of PTH levels while minimizing the release of calcitonin is hypothesized to provide a more desirable profile for treating hyperparathyroidism and avoiding calcitonin-induced hypocalcemia. (<i>S</i>)-AC-265347 (<b>65</b>), a third-generation CaSR PAM, appears to have enhanced tissue-selective effects due to biased signaling. It inhibits PTH secretion at concentrations that do not induce calcitonin release in rats, hypothetically due to ligand-biased allosteric modulation toward pERK1/2 and IP1 accumulation.<a onclick="showRef(event, 'ref119 ref120'); return false;" href="javascript:void(0);" class="ref ref119 ref120">(119,120)</a> (<i>S</i>)-AC-265347 exhibited high cooperativity in pERK1/2 assays, maximally enhancing the potency of extracellular Ca<sup>2+</sup> nearly 10-fold, compared to 3-fold enhancement with cinacalcet. Thus, it is possible to selectively modulate CaSR for beneficial effects while avoiding undesirable effects using biased allosteric modulators. Further understanding of the effects of the signaling pathways will facilitate translation of preclinical observations to clinic.</div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0027.gif" alt="" id="fx18" /></img><div class="NLM_p">Ion channels may potentially display functional bias as they are modulated by allosteric ligands, which manifest itself as changes to the selectivity for permeant ions and/or the dynamic properties characterizing the opening/closing properties of the channel. These effects have been reported for voltage-gated,<a onclick="showRef(event, 'ref121 ref122 ref123'); return false;" href="javascript:void(0);" class="ref ref121 ref122 ref123">(121â123)</a> mechanosensitive,<a onclick="showRef(event, 'ref124 ref125'); return false;" href="javascript:void(0);" class="ref ref124 ref125">(124,125)</a> and ligand-gated ion channels.<a onclick="showRef(event, 'ref126 ref127'); return false;" href="javascript:void(0);" class="ref ref126 ref127">(126,127)</a> Mechanistically, ligands are thought to alter the quaternary structure of some channels or the tertiary structure of a given subunit. Likewise, the discovery that some ion channels regulate other receptors or signaling enzymes (e.g., ERK, PI3K, Rho) provides another mechanism by which ligands may impact the functional outcome of their interactions with ion channels in a biased way.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a></div><div class="NLM_p">These changes to ion channel protein dynamics by allosteric ligands are described through two parameters captured by the terms of type I and type II modulators. This behavior has been observed for a number of ion channels. For example, the Î±7 nicotinic acetylcholine receptor (nAChR) PAM chemical probes 5-HI (<b>66</b>) and genistein (<b>67</b>) predominantly affected the apparent peak current (type I), whereas PNU-120596 (<b>68</b>) and TQS (<b>69</b>) increased the apparent peak current and evoked a distinct weakly decaying current (type II).<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> This functional nomenclature has also been extended to NMDAR allosteric modulators, where type I PAMs such as PYD-106 (<b>70</b>) or oxysterols such as <b>37</b> or <b>38</b> modulate mainly peak current, and type II PAMs such as spermine (<b>71</b>) modulate current decay times, while pregnenolone sulfate (PS, <b>72</b>) seems to function as a mixed PAM with both type I and type II PAM effects.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> The same principles apply to NAMs of GABA<sub>A</sub> like PS, which acts mainly via a type II mechanism by both mostly increasing desensitization kinetics and, to a smaller degree, depressing peak chloride currents.<a onclick="showRef(event, 'ref131 ref132'); return false;" href="javascript:void(0);" class="ref ref131 ref132">(131,132)</a> Linking these in vitro effects to unique and distinct potentiation profiles in vivo could potentially offer unique opportunities for the development of tailored CNS therapeutics.</div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0028.gif" alt="" id="fx19" /></img><div class="NLM_p">(<i>S</i>)-2-Amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propanoic acid receptors (AMPARs) are among the most extensively studied ion channels. Numerous crystal structures of wild-type and mutant proteins obtained using different ligands led to models for receptor activation (channel opening by agonist binding) and desensitization (channel remains closed while agonist is still bound), inhibition by antagonists, and block of desensitization by PAMs.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> Mechanisms of ion channel functional modulation by allosteric ligands have been described in terms of alterations to molecular dynamics selectively triggering pre-existing cooperative motion modes, which are already encoded by the receptor structure. The effects may be felt by the receptor as a whole or by isolated protein domains and impact an extensive spectrum of dynamic rearrangements leading to changes to receptor function.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> While collectively these processes govern the magnitude and time course of synaptic transmission, individually they are thought to be independent of each other, leading to distinct patterns of modulation by allosteric ligands.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> For example, using two-electrode voltage clamped <i>Xenopus laevis</i> oocytes expressing GluA4i receptors, the AMPAR allosteric modulator NS1376 (<b>73</b>) showed functionally opposite effects, <i>reducing</i> 30-fold and 42-fold glutamate potency but <i>enhancing</i> glutamate efficacy by 3-fold and 5-fold at GluA4flip and GluA4flop, respectively.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a></div><div class="NLM_p">Most AMPAR PAMs studied to date appear to bind to a common, solvent-accessible allosteric binding region localized close to the plasma membrane at the interface between two subunits near the extracellular domain of AMPA receptors. Studies using a number of distinct AMPAR PAM chemotypes suggest the existence of as many as five âsubsitesâ with distinct modulator affinities and apparent efficacies.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> Upon binding to the allosteric site, these compounds enhance agonist response either by attenuating desensitization and/or by slowing receptors deactivation and facilitate induction and maintenance of long-term potentiation, a form of synaptic plasticity that is believed to underlie memory formation. The AMPAR PAM S 47445 (<b>74</b>) was characterized using receptors expressed either in <i>Xenopus laevis</i> oocytes or in HEK293 cells and rat cortical cell cultures. S 47445 robustly increased the amplitude of the glutamate-evoked current and prolonged the response time. Furthermore, low concentrations of S 47445 (below the EC<sub>50</sub>) added upon repetitive glutamate pulses induced a progressive potentiation of the glutamate-evoked currents. Of note, this effect was not accompanied by desensitization after several glutamate pulses.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a></div><div class="NLM_p">Among AMPAR NAMs, the most recognized example is perampanel (Fycompa, <b>75</b>), which obtained FDA approval in 2012 as an antiepileptic drug to treat partial seizures and generalized tonicâclonic seizures for people older than 12 years. The blocking mechanism of perampanel has recently been characterized as high-affinity (<i>K</i><sub>d</sub> = 60 nM in rat forebrain membranes), with similar affinities for the open and closed states of AMPA receptors and with no effect on AMPA receptor desensitization.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> Using whole-cell voltage-clamp recording in cultured rat hippocampal neurons, perampanel showed a slow, concentration-dependent inhibition of AMPA-evoked AMPAR currents. The rates of block and unblock of AMPA receptor currents indicated relatively slow but reversible block onset and recovery.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> Not much is known about the location and structure of binding sites for perampanel or other prototypical AMPAR NAMs such as GYKI-53,655 (<b>76</b>) and CP-465,022 (<b>77</b>). Work toward identifying NAM binding sites and binding modes is crucial to understand the molecular mechanism and can lead to future development of other NAMs.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a></div><div class="NLM_p">Allosteric modulation of kainate receptors (KRs) is not as well understood as for their AMPAR or NMDAR counterparts. Excellent progress in the area of structural biology has yielded important insights at the molecular level, including knowledge of binding modes of KRs agonists and antagonists.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> The same principles as for other ion channels seem to apply to KRs in terms of allosteric ligands exerting functional effects via impact on properties such as agonist-evoked peak current amplitude, deactivation, or desensitization kinetics.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> The difficulties in rationalizing, let alone predicting the functional consequences derived from allosteric ligands acting on ion channels, point to the challenging aspects of proactively designing and accurately translating in vivo pharmacological effects of allosteric modulators acting at membrane bound proteins.</div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0029.gif" alt="" id="fx20" /></img><div class="NLM_p last">Therefore, numerous examples exist of more traditional drug candidates that failed in the clinic for any number of reasons, many due to mechanism-based dose-limiting adverse effects and limited efficacy due to inadequate target coverage. In some of the examples above, biased signaling drug candidates demonstrated the ability to overcome these shortcomings to provide potentially safer and more efficacious therapeutics.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">3.  How? Allosteric Ecosystem and Protein Dynamics</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60341" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60341" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A view of the molecular mechanisms by which allosteric drugs exert their effects is developing on the basis of new perspectives gained from three major areas: structural biology, protein conformational dynamics, and the contribution of system chemistry to cellular homeostasis (the allosterome).<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> The number of publications and entries in the Protein Data Bank pertaining to structural information on allosteric modulators interacting with their protein targets is rapidly growing, including both GPCRs<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> and ion channels.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> This is partly due to improvements in protein purification and crystallization techniques for membrane bound proteins,<a onclick="showRef(event, 'ref147 ref148 ref149'); return false;" href="javascript:void(0);" class="ref ref147 ref148 ref149">(147â149)</a> as well as to the increasing resolution and availability of electron microscopy (Cryo-EM) for structural elucidation.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> Examples include identification of distinct binding sites for inhibitory or potentiating oxysterols at a chimeric GABA<sub>A</sub> homopentamer formed by Î²3 extracellular domains and Î±5-transmembrane domains<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> or high-resolution Cryo-EM structures of the human Î±1Î²2Î³2 GABA<sub>A</sub> receptor bound to flumazenil, used as first-line clinical treatment for benzodiazepine overdose.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> Likewise, crystallographic structures published recently for the NMDA receptor reveal new aspects of this complex receptor. For example, the discoveries of GNE-0723 (<b>78</b>) and GNE-9278 (<b>79</b>), GluN2A-selective NMDAR PAMs, were enabled by structure-based studies, showing distinct binding sites for these two structurally related compounds. The former binds the GluN1/GluN2A ligand binding domain interface at an analogous site to where AMPAR PAMs bind,<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> while the latter binding to a unique site on the extracellular surface of the transmembrane domain.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> These X-ray crystallography studies suggest chemically related allosteric modulators may bind at different receptor areas and impact receptor pharmacology in distinct ways.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0030.gif" alt="" id="fx21" /></img><div class="NLM_p">A recent retrospective analysis comparing and contrasting X-ray crystallography structures of a set of known (<b>45</b>, <b>80</b>â<b>82</b>) and novel (<b>83</b>, <b>84</b>) mGluR5 NAMs showed that small molecule allosteric ligands bind in the transmembrane domain of the mGluR5 receptor, with access to a narrow subpocket not accessible in other mGluR subtypes. In addition, this allosteric site of mGluR5 is located in a functional water channel, where the binding pocket is occupied by water molecules thought to affect signal transduction. The impact of a small ligand on these water molecules may provide favorable or unfavorable contributions to binding, depending on whether they displace high free-energy (âunhappyâ) water molecules or low free-energy (âhappyâ) water molecules.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a></div><div class="NLM_p">While these observations are important, gathering such insights in a prospective manner such as to guide SAR efforts would require routine access to multiple X-ray structures, unlikely for most groups working on transmembrane proteins. Substituting structural biology determinations with computational docking studies may be risky. For example, fenobam (<b>81</b>) showed a novel binding mode where the ligand is rotated 180Â° when compared with previous docking models.<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> This new orientation shown in the crystallographic work could be related to the different linker structural motif, an urea in <b>80</b> vs an acetylenic linker in M-MPEP (<b>81</b>) and mavoglurant (<b>82</b>), leading to different growing vectors identified for the head groups as well as unexpected water-mediated receptor interactions. Despite the differences between the crystallographic and the computationally docked poses, nanomolar potency compounds were obtained.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> Therefore, while some of these structural biology observations may explain differences among analogues, assessment of functional activity ultimately resides on an empirical evaluation through in vitro assays. The fate of GPCR allosteric modulator drug discovery projects is probably brighter when multiple, orthogonal approaches are pursued in parallel.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0031.gif" alt="" id="fx22" /></img><div class="NLM_p">Structural biology studies provide valuable insights on the allosteric binding location and relative orientation of ligands and residues in the receptor binding pocket, as well as protein conformational changes required for the binding event as reported in crystallographic studies. However, the ensuing functional effects (e.g., PAM or NAM) are not predicted from these solid-state studies, suggesting protein dynamics aspects are at play. Thus, learnings from structural biology of allosteric modulators of membrane bound receptors are not always as useful guiding SAR development by medicinal chemists as they might be in kinase inhibitor projects, for example, due to the inability to predict functional effect.</div><div class="NLM_p">The study of protein folding and molecular dynamics are gaining much appreciation. One classical view of protein biochemistry is that its amino acid sequence defines a single three-dimensional native conformation serving a single biological function. This view has strong support from X-ray crystallography studies, the most commonly used technique for structure determination. This view of the sequence-structureâfunction relationship has recently evolved as new experimental evidence suggests a far more complex nature of protein structure. Proteins often perform multiple functional tasks, in part due to their considerable structural flexibility. Thus, elements of structural dynamics and conformational plasticity are increasingly recognized as important attributes that contribute to protein function. This view is consistent with modern technologies like nuclear magnetic resonance spectroscopy and molecular dynamics computational calculations. Indeed, this new perspective led to proteins being described by qualifiers such as intrinsically disordered proteins, morpheeins, chameleonic sequences, and metamorphic proteins.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></div><div class="NLM_p">Allostery provides a mechanism by which functional biomolecules such as proteins or nucleic acids are able to sense the changing concentrations of molecules in the neighboring cellular matrix and respond with the appropriate functional effects to maintain cellular homeostasis. This adjusting takes place very rapidly, essentially at diffusion-controlled rates and in a reversible manner unlike covalent post-translational modifications (e.g., phosphorylation, dephosphorylation) and with a minimal energy cost. Thus, allosteric regulation of functional response provides a complementary mechanism of cellular regulation, with unique attributes from transcriptional or translational regulation, alternative splicing, post-translational covalent modifications, degradation, localization, or proteinâprotein interactions.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a></div><div class="NLM_p">How are protein dynamics and system chemistry relevant to allosteric drug function? In the simplest case, a protein bound to an orthosteric ligand exists in one of two states: active or inactive (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A). The minima are separated by a surmountable energy barrier, and the respective conformations interconvert between these states. Upon binding, the allosteric modulator modifies the free energy balance of the system, stabilizing (or destabilizing) a specific conformation, linked to a signal transduction pathway. This model is very much in line with lessons learned designing competitive ligands. However, it was not able to sufficiently explain observations from early days in allosteric dug research, where nonadditive or nonlinear structureâactivity relationships or switches in functional activity (e.g., PAM to NAM) caused concern among medicinal chemists about the chemical tractability of such targets. Furthermore, such switches appear to be a feature of GPCRs and ion channels, where small structural modifications to GPCR ligands often convert agonists to antagonists and vice versa, frequently accompanied by negligible changes in binding affinity. Examples of functional enhancer/inhibitor switches within the same chemical core have been reviewed for GPCRs and will not be discussed here.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a></div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/large/jm-2018-01651e_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Free energy versus conformation diagrams (A) Classical system with one active and one inactive protein confirmation and the changes produced by an allosteric ligand (PAM in this case). (B) Model considering a number of conformations, each one providing its own distinct contribution to the global functional response. Addition of an allosteric ligand creates a comparable number of local changes, and the resulting impact on global function.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/large/jm-2018-01651e_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01651&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Proteins are dynamic macromolecules and display many degrees of conformational freedom, reflected by ensembles of conformations with a certain distribution (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>B). Molecular dynamics simulations predict a proteinâs access to different shapes with unique signaling properties and functional states within such ensemble of conformers. âFunctional selectivityâ may be obtained if an allosteric ligand can induce a subset of the ensemble of responses.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> The biology associated with the protein is also modulated according to the residence time in each energy minimum. Allosteric modulator association and dissociation kinetics, which determine the residence time on the receptor, may differ for different conformations. The duration of a ligandâreceptor complex may then lead to changes in the conformational landscape over time, giving rise to the phenomenon called âkinetic biasâ.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a></div><div class="NLM_p last">In summary, the recognition of a receptor as the platform where the relevant chemical âallosteromeâ defines the global functional effects implies that these are determined by a number of conformationally distinct entities, linked among themselves by their dynamics.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">4.  Why? Is a Thorough Characterization of Allosteric Drug Effects Worth the Effort?</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82668" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82668" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The inherent difficulties and potential rewards of allosteric drug design are clear in many protein families, but GPCRs are likely the most contemporary (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). The early years of GPCR allosteric drug discovery faced many unexpected disconnections, as assumptions carried over from earlier medicinal chemistry learnings using competitive ligands were routinely challenged. One such example is seen in efforts targeting muscarinic acetylcholine receptors (mAChRs).<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> As discussed previously, these receptors are attractive drug targets due to their promising, yet unfulfilled, clinical therapeutic potential. Medicinal chemists have traditionally focused on developing selective mAChR agonists binding at the orthosteric acetylcholine binding site, particularly for the M<sub>1</sub> mAChR subtype. However, mounting research demonstrated that orthosteric M<sub>1</sub> ligands are nonsubtype selective due to high orthosteric site homology across members of the mAChR family (M<sub>1</sub>âM<sub>5</sub>). Moreover, acute agonism of muscarinic receptors yields side effects such as seizures and generalized convulsions. Considering these limitations, efforts have gradually shifted from M<sub>1</sub>-selective orthosteric agonists to M<sub>1</sub>-selective PAMs with minimal agonist activity, assuming functional enhancement based on allosteric ligands would circumvent side effects observed with orthosteric agonists.<a onclick="showRef(event, 'ref162 ref163'); return false;" href="javascript:void(0);" class="ref ref162 ref163">(162,163)</a></div><div class="NLM_p">One of the earliest putative M<sub>1</sub> PAMs, benzyl quinolone carboxylic acid BQCA (<b>8</b>), was first reported in 2008. Claims of BQCA allosteric activation of the M<sub>1</sub> receptor were supported by mouse EEG, laser Doppler blood flow, and sleep telemetry.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> A follow-up study bolstered these reports, demonstrating that <b>8</b> is >100-fold more selective for the M<sub>1</sub> receptor than its counterparts M<sub>2</sub>âM<sub>5</sub> (no changes to functional concentrationâresponse curve of acetylcholine in a Ca<sup>2+</sup> mobilization assay) and potentiates the effects of the agonist acetylcholine at M<sub>1</sub> up to 100-fold.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> While these studies were initially promising, further experiments revealed that <b>8</b> alone (no added agonist) also activates M<sub>1</sub> in cell types expressing high levels of the receptor.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> These data indicate that <b>8</b> itself weakly stabilizes an active conformation of the M<sub>1</sub> receptor, but functional effects are only observable when signalâresponse coupling is relatively robust (i.e., high receptor and second messenger expression) or <b>8</b> alone is at high-micromolar concentrations.<a onclick="showRef(event, 'ref165 ref166'); return false;" href="javascript:void(0);" class="ref ref165 ref166">(165,166)</a> As a result, <b>8</b> has been labeled as an âago-PAMâ because it acts both as an allosteric agonist (Ï<sub>Î²</sub> > 0) and as an allosteric potentiator of orthosteric ligand-mediated activity. This also underscores a need for careful interpretation of functional readouts obtained in Ca<sup>2+</sup> functional tests on allosteric ligands.</div><div class="NLM_p">Other attempts to create M<sub>1</sub> PAMs have encountered similar pitfalls and contradictions despite initially encouraging functional data. For example, two putative M<sub>1</sub> PAMs, VU0090157 (<b>85</b>), and VU0029767 (<b>86</b>) have different functional effects. Compound <b>85</b> selectively potentiated PLC activation, while <b>86</b> selectively potentiated PLD activation.<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> These findings suggest that different M<sub>1</sub> allosteric ligands regulate receptor coupling to downstream signaling pathways by distinct mechanisms, known as signal bias. Therefore, distinct pharmacological profiles may be encountered with these two M<sub>1</sub> PAMs, suggesting the benefits of deeper functional allosteric drug characterization.</div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0032.gif" alt="" id="fx23" /></img><div class="NLM_p">In a different case, MK-7622 (<b>10</b>), a reportedly highly selective M<sub>1</sub> PAM, was progressed to phase 2 clinical trials for a pro-cognitive end point in Alzheimerâs patients. Ultimately, the trial was terminated due to lack of efficacy shown by <b>10</b> as an adjunctive therapy to acetylcholinesterase inhibitors vs placebo in improving cognition in AD patients.<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a> Besides these findings, <b>10</b> independently was shown to induce seizures at high doses in mice, as well as directly agonize Ca<sup>2+</sup> flux in M<sub>1</sub>-expressing CHO cells with a Ï<sub>B</sub> > 0, indicating that <b>10</b> acts as an ago-PAM.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a></div><div class="NLM_p">Another clinical M<sub>1</sub> mAChR PAM, PF-06764427 (<b>11</b>), potentiates acetylcholine agonism at low concentrations but also directly activates the M<sub>1</sub> mAChR at increasing micromolar concentrations.<a onclick="showRef(event, 'ref169 ref170 ref171'); return false;" href="javascript:void(0);" class="ref ref169 ref170 ref171">(169â171)</a> Additional in vitro and in vivo studies have roundly characterized <b>11</b> as strong ago-PAM with adverse effects such as pronounced behavioral convulsions in mice.<a onclick="showRef(event, 'ref170 ref171 ref172'); return false;" href="javascript:void(0);" class="ref ref170 ref171 ref172">(170â172)</a></div><div class="NLM_p">Over the past decade, research on these difficult-to-characterize biased PAMs and ago-PAMs has made it clear that M<sub>1</sub> mAChR PAMs (and generally other GPCR allosteric modulators) exhibit different modulating properties depending on the orthosteric ligand used in in vitro assays, the relative expression, and/or coupling strength of the downstream G-protein signaling cascade, the modulatorâs bias toward one or more active conformation over others, receptor subtype selectivity, and so on.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> This suggests that different PAMs will modulate multifaceted receptor functional states in different ways, such that one or several functional conformations might be stabilized over others. In other words, medicinal chemistry research on allosteric modulators is revealing that the model where functional states of proteins are thought of as two-state systems (active/inactive) may be an oversimplification (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>).</div><div class="NLM_p">The unexpected pitfalls described above suggest that allosteric modulators may mitigate preventable risks and benefit from more nuanced approaches than customarily conducted with drugs designed to compete directly with orthosteric ligands. As discussed, this complexity demands an increased diversity of functional assays for compound characterization. In general, using a single in vitro assay (e.g., only an intracellular Ca<sup>2+</sup> mobilization assay) before moving to inherently more complex in vivo behavioral models may incompletely address the different molecular mechanisms of action and transduction pathways by which an allosteric ligand might modulate functional response. Informative functional assays that might be used as a supplement for GPCR projects include cAMP accumulation, [<sup>35</sup>S]-GTPÎ³S binding, whole-cell electrophysiology, Î²-arrestin screens, label free assays, and so on. These assays would be performed over a range of native ligand concentrations, PAM concentrations, and if possible, receptor expression levels, as demonstrated in the BQCA example. In a minimal case, exploration of biased modulation and physiologically relevant functional assays (e.g., in native tissues) are preferable before advancing to behavioral assays. In addition, due to probe dependency, the native ligand of a protein target (and potential endogenous allosteric ligands) is considered as ideal when conducting binding assays with allosteric compounds.</div><div class="NLM_p">An example of combining multiple functional assays to characterize potential PAM/ago-PAM activity comes from Vanderbilt University. Recently, robust PAM activity was demonstrated for VU0453595 (<b>87</b>) and VU0550164 (<b>88</b>) by contrasting these compounds with the ago-PAMs, MK-7622 (<b>10</b>), and PF-06764427 (<b>11</b>).<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> These compounds were characterized in a workflow situated within a physiologically relevant context that is properly suited to an allosteric model: wherever possible, native ligand was used to avoid probe-dependent artifacts and functional characterization was rigorously pursued both in vitro (i.e., Ca<sup>2+</sup> accumulation and whole cell electrophysiology) and in vivo (i.e., cortical extracellular field electrophysiology) before attempting behavioral assays.</div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0033.gif" alt="" id="GRAPHIC-d7e2660-autogenerated" /></img><div class="NLM_p">Through these comparisons of known ago-PAM, a compelling argument was made that <b>87</b> and <b>88</b> may indeed positively modulate acetylcholine without intrinsic agonist activity. However, a potential weakness in their presentation is that no assay addressed the possibility of biased modulation of G protein signaling pathways. This may problematically overlook these compoundâs unique modulation profiles.</div><div class="NLM_p last">In summary, research aiming to discover allosteric drugs would maximize its probability of success by conducting a nuanced, mechanistic approach to compound characterization and informing medicinal chemistry decision-making. Given the factors impacting allosteric drug effects that remain to be understood, such as in silico predictions of conformational free energy landscapes and folding kinetics, the empirical characterization of allosteric ligands must be as thorough as practically feasible. The benefit of such an approach is clear, as amply demonstrated by the example of M<sub>1</sub> mAChRs. Similar factors are most likely at play for the design of allosteric modulators of ion channel functional response. Classes of proteins that appear undruggable in the tradition of orthosteric pharmacology may very well be amenable to allosteric modulation. In such cases, the increased effort needed to characterize these ligands is well worth the reward. Time will tell, as Vanderbilt University is currently conducting clinical phase 1 studies with VU319 (structure undisclosed).<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">5.  Conclusions: Toward Translational Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78145" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78145" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">For decades, medicinal chemists have extracted useful information from binding affinity data using radioligand binding assays. Eventually, key caveats to SAR studies were recognized such as binding sites not fully overlapping, physiological relevance of assay conditions,<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> and effects of water networks, suggesting that ligandâprotein interactions are not the only factors, or even decisive for the binding of ligands to their targets.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> The toolbox of compound characterization then added powerful functional assays, which while still not perfect, complement binding information and are vital to deriving a mechanistic understanding for drug candidates, a key tenet in maximizing the probability of clinical success of drug discovery programs.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a></div><div class="NLM_p">Driven by these technological advances in measuring functional output of a drugâtarget interaction, allosteric modalities are now recognized as a major force to address some previously failed drug discovery efforts. Allostery is a universal phenomenon taking place among molecules interacting in the context of a chemical ecosystem, regardless of their relative sizes. Mechanistically, allosteric drug action is being linked to dynamic conformational changes that dictate the functional consequences of interactions within biologically relevant networks of molecules, both large and small. Concepts derived from studying allosteric drugs are key to understanding biological systems and diseases and has established a new paradigm in drug discovery representing an enormous opportunity.</div><div class="NLM_p">More recently, models where the effects on binding affinity (Î±) and functional cooperativity (Î²) caused by an allosteric ligand are considered to be independent of each other has led to a number of distinct allosteric modalities. When combined with the potential to bias signal transduction pathways, these modalities enable the exquisite fine-tuning of allosteric drug properties (the ADTP) consistent with molecular-level disease etiology knowledge, thus allowing a translational alignment with a mechanistic disease hypothesis. Of note, in light of new information derived from mechanistic studies, many drugs and tool compounds discovered in the past considered orthosteric agonists or antagonists have been reclassified as acting within a certain allosteric modality, yet in the literature they may be treated as agonists or antagonists, creating confusion and sometimes misleading conclusions. Among these are several benzodiazepines (PAMs referred to as agonists), and ifenprodil (<b>47</b>), a PAM/NAM called antagonist. These are not simply semantic differences, as oversimplification during drug characterization may lead to challenges in translation to clinical effects, thus making the investment in resources and intellect required to characterize allosteric drug candidates well worth the effort.</div><div class="NLM_p">As expected, the increased complexity of the biochemical processes underlying allosteric drug actions is reflected in the mathematics of the models aiming at representing them. However, the insights into compound differentiation and the mechanistic understanding obtained from experimentation based on such models justifies the effort and resources needed to execute this strategy.</div><div class="NLM_p">Finally, allosterism points to the existence of a molecular hierarchy among different ligands that interact and influence the functional effects of their protein hub, both qualitative and quantitatively. On one end, ligands that trigger receptor function on their own, and on the other end are those that cannot but are able to modify the magnitude and the signaling consequences of the functional effects of the former. This suggests that an understanding of the âallosteric ecosystemâ, including receptor oligomerization and components of the âmolecular systemâ are necessary, albeit not sufficient, to predicting receptor function and maximizing translational veracity of a drug candidate. The large number of such potential endogenous compounds, and possibly changing during disease states or aging, provides yet another reason to emphasize the importance of characterizing drug candidates using the most physiologically and therapeutically relevant systems whenever feasible. This is not a new idea. Indeed, the late Dr. James Black wrote,<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a><div class="quote"><p class="first last">â<i>If a number of chemical messengers each bring information from a different source and each deliver only a subthreshold stimulus but together mutually potentiate each other, then the desired information-rich switching can be achieved with minimum risk of miscuing... Bioassays can be designed to mimic and analyze such convergent control systems.</i>â</p></div></div><div class="NLM_p last">In summary, just as the genetic code has long been recognized as âthe first secret of lifeâ, our growing understanding of the concept of allostery and its relevance to biological systems argue for its consideration as âthe second secret of life.â<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a> The use of allosteric modalities in small molecule drug discovery programs is in its infancy, and we believe it holds a key to realizing the potential of programs where competitive or insufficiently characterized allosteric ligands have failed. The challenge for medicinal chemists is set.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b01651" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40047" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40047" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dario Doller</span> - <span class="hlFld-Affiliation affiliation">Exploratory
Research; ; . Sage Therapeutics, Inc. 215 First Street Cambridge, Massachusetts 02142, United States</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5944-383X" title="Orcid link">http://orcid.org/0000-0002-5944-383X</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#fe9a9f8c9791d09a9192929b8cbe8d9f999b8c86d09d9193"><span class="__cf_email__" data-cfemail="dbbfbaa9b2b4f5bfb4b7b7bea99ba8babcbea9a3f5b8b4b6">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Quinn Coughlin</span> - <span class="hlFld-Affiliation affiliation">Exploratory
Research; ; . Sage Therapeutics, Inc. 215 First Street Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Allen T. Hopper</span> - <span class="hlFld-Affiliation affiliation">Exploratory
Research; ; . Sage Therapeutics, Inc. 215 First Street Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maria-Jesus Blanco</span> - <span class="hlFld-Affiliation affiliation">Medicinal Chemistry; ; . Sage Therapeutics, Inc. 215 First Street Cambridge, Massachusetts 02142, United States</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4333-365X" title="Orcid link">http://orcid.org/0000-0003-4333-365X</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vijaya Tirunagaru</span> - <span class="hlFld-Affiliation affiliation">Exploratory
Research; ; . Sage Therapeutics, Inc. 215 First Street Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Albert J. Robichaud</span> - <span class="hlFld-Affiliation affiliation">Discovery & Nonclinical Development; ; . Sage Therapeutics, Inc. 215 First Street Cambridge, Massachusetts 02142, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): Sage Therapeutics is a company engaged in the discovery and development of allosteric modulators of CNS drug targets.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22502" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22502" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Quinn Coughlin</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01651&amp;id=BIO-d7e2714-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Quinn P. Coughlin</b> received his B.Sc. in Biochemistry from Boston College in 2018. After completion of a medicinal chemistry internship at Sage Therapeutics, he joined the companyâs Exploratory Research group in June 2018, working in allosteric modelling and project support. Prior to his entry into industry, Mr. Coughlin contributed to undergraduate research in developmental biology.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Allen T. Hopper</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01651&amp;id=BIO-d7e2719-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Allen T. Hopper</b> received his Ph.D. in Medicinal Chemistry from the Ohio State University in 1993 under the mentorship of Professor D. T. Witiak, followed by a postdoc position at the University of Wisconsin. Dr. Hopper is currently Director of Exploratory Research at Sage Therapeutics. Prior to joining Sage, he worked for a variety of Biotech companies including NPS Pharmaceuticals, Memory Pharmaceuticals, and Lundbeck. The majority of his 23-year career has been in the area of small molecule CNS drug discovery focused on compound design and building mechanistic links from target engagement to disease relevant biological consequences. As project leader, he contributed to discovery of clinical compounds targeting GlyT1, PDE4, and <i>T. gondii</i> DHFR. Allen is coauthor on over 50 patent applications and publications.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Maria-Jesus Blanco</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01651&amp;id=BIO-d7e2727-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Maria-Jesus Blanco</b> has >18 years of experience working in drug discovery and molecular drug design in the pharmaceutical industry, in both big pharma and biotech. She is Director of Medicinal Chemistry at Sage Therapeutics, contributing from early drug discovery to IND and clinical studies. Previously, Maria was Director of Discovery Chemistry Research & Technologies at Eli Lilly and member of the Discovery Chemistry management team. She has lead teams and actively contributed to the delivery of >10 compounds to clinical studies in CNS drug discovery. Maria has coauthored >65 scientific publications, presentations, and patent and patent applications. She obtained her B.S. and Ph.D. degree in Chemistry from the University of Santiago de Compostela, Spain, followed by postdoctoral positions at MIT and University of Strasbourg, France.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Vijaya Tirunagaru</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01651&amp;id=BIO-d7e2732-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Vijaya Tirunagaru</b> received Ph.D. in Biochemistry from the Center for Cellular and Molecular Biology, Hyderabad, India. She is currently VP and Head of Biology and Nonclinical Development at Rain Therapeutics. Prior to joining Rain, she was Associate Vice President and Head of Discovery Biology at GVK Biosciences, where she was responsible for overseeing a portfolio of 10 discovery programs across oncology, metabolic disorders, and pain therapeutic areas. She began her pharmaceutical career at AstraZeneca, where she was biology leader for project teams from concept to clinical phase 2, led discovery programs and was a member of psychiatry disease area strategy team.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Albert J. Robichaud</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01651&amp;id=BIO-d7e2737-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Albert J. Robichaud</b> joined Sage Therapeutics as CSO in 2011, where he provides leadership and drug discovery expertise to teams delivering drug candidates into clinical development. Most recently, as Vice President of Chemistry and Pharmacokinetic Sciences at Lundbeck Research USA, Al was responsible for the medicinal, analytical, and computational chemistry and pharmacokinetics departments within the synaptic transmission and neuroinflammation disease biology units. Earlier, as Head of the Neuroscience Discovery Chemistry Department of Wyeth Research, Al led a group that delivered 15 drug candidates into clinical development in neuroscience. He has coauthored more than 110 manuscripts and is a coinventor on 73 patents and patent applications. Al holds a B.S. in Chemistry from Rensselaer Polytechnic Institute, and a Ph.D. in Organic Chemistry from the University of California, Irvine.</p></figure></div><div class="bio" rid="ath6"><figure id="ath6" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Dario Doller</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01651&amp;id=BIO-d7e2742-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Dario Doller</b> leads the Exploratory Research group at Sage Therapeutics, building a pipeline of early projects to treat brain disorders. Mentored by Prof. Eduardo Gros, he earned a Ph.D. in Organic Chemistry from the Facultad de Ciencias Exactas y Naturales, UBA, Argentina. He conducted postdoctoral studies with Sir Derek Barton at Texas A&M University. His industrial career includes Rohm & Haas, Schering-Plough Research Institute, 3-Dimensional Pharmaceuticals, Gliatech, Neurogen, Lundbeck, and CoNCERT. He contributed to the discovery of the marketed PAR-1 antagonist vorapaxar and the clinical compounds NGD-4715, Lu AF09535, and CTP-692. Dario coauthored over 100 articles, patents or patent applications, and book chapters, and edited the book <i>Allosterism in Drug Discovery</i>. Current interests include molecular concepts at the chemistry/biology interface to enhance the translatability of preclinical research.</p></figure></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ADTP</td><td class="NLM_def"><p class="first last">allosteric drug target profile</p></td></tr><tr><td class="NLM_term">CaSR</td><td class="NLM_def"><p class="first last">calcium sensing receptor</p></td></tr><tr><td class="NLM_term">D<sub>1</sub>R</td><td class="NLM_def"><p class="first last">dopamine receptor type 1</p></td></tr><tr><td class="NLM_term">GABA<sub>A</sub></td><td class="NLM_def"><p class="first last">gamma-aminobutyric acid receptor type A</p></td></tr><tr><td class="NLM_term">NMDAR</td><td class="NLM_def"><p class="first last"><i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate receptor</p></td></tr><tr><td class="NLM_term">mAChR</td><td class="NLM_def"><p class="first last">muscarinic acetylcholine receptor</p></td></tr><tr><td class="NLM_term">nAChR</td><td class="NLM_def"><p class="first last">nicotinic acetylcholine receptor</p></td></tr><tr><td class="NLM_term">mGluR</td><td class="NLM_def"><p class="first last">metabotropic glutamate receptor</p></td></tr><tr><td class="NLM_term">Î´-OR</td><td class="NLM_def"><p class="first last">delta opioid receptor</p></td></tr><tr><td class="NLM_term">PPD</td><td class="NLM_def"><p class="first last">postpartum depression</p></td></tr><tr><td class="NLM_term">P2X7</td><td class="NLM_def"><p class="first last">P2 purinergic receptor type 7</p></td></tr><tr><td class="NLM_term">RO</td><td class="NLM_def"><p class="first last">receptor occupancy</p></td></tr><tr><td class="NLM_term">SNP</td><td class="NLM_def"><p class="first last">single-nucleotide polymorphism</p></td></tr><tr><td class="NLM_term">TI</td><td class="NLM_def"><p class="first last">therapeutic index</p></td></tr><tr><td class="NLM_term">WT</td><td class="NLM_def"><p class="first last">wild type</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16540" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16540" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 177 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, S. E.</span></span> <span> </span><span class="NLM_article-title">The daunting polygenicity of mental illness: making a new map</span>. <i>Philos. Trans. R. Soc., B</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>373</i></span> (<span class="NLM_issue">1742</span>),  <span class="NLM_fpage">20170031</span>, <span class="refDoi">Â DOI: 10.1098/rstb.2017.0031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1098%2Frstb.2017.0031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=29352030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFKgs7%252FE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2018&pages=20170031&issue=1742&author=S.+E.+Hyman&title=The+daunting+polygenicity+of+mental+illness%3A+making+a+new+map&doi=10.1098%2Frstb.2017.0031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The daunting polygenicity of mental illness: making a new map</span></div><div class="casAuthors">Hyman, Steven E.</div><div class="citationInfo"><span class="NLM_cas:title">Philosophical Transactions of the Royal Society, B: Biological Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">1742</span>),
    <span class="NLM_cas:pages">20170031/1-20170031/8</span>CODEN:
                <span class="NLM_cas:coden">PTRBAE</span>;
        ISSN:<span class="NLM_cas:issn">0962-8436</span>.
    
            (<span class="NLM_cas:orgname">Royal Society</span>)
        </div><div class="casAbstract">An epochal opportunity to elucidate the pathogenic mechanisms of psychiatric disorders has emerged from advances in genomic technol., new computational tools and the growth of international consortia committed to data sharing.  The resulting large-scale, unbiased genetic studies have begun to yield new biol. insights and with them the hope that a half century of stasis in psychiatric therapeutics will come to an end.  Yet a sobering picture is coming into view; it reveals daunting genetic and phenotypic complexity portending enormous challenges for neurobiol.  Successful exploitation of results from genetics will require eschewal of long-successful reductionist approaches to investigation of gene function, a commitment to supplanting much research now conducted in model organisms with human biol., and development of new exptl. systems and computational models to analyze polygenic causal influences.  In short, psychiatric neuroscience must develop a new scientific map to guide investigation through a polygenic terra incognita.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLIrVkeBu4HrVg90H21EOLACvtfcHk0ljYgaE9GmyMDg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFKgs7%252FE&md5=592f73ef0ac028d2d4fc326a276a83be</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1098%2Frstb.2017.0031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1098%252Frstb.2017.0031%26sid%3Dliteratum%253Aachs%26aulast%3DHyman%26aufirst%3DS.%2BE.%26atitle%3DThe%2520daunting%2520polygenicity%2520of%2520mental%2520illness%253A%2520making%2520a%2520new%2520map%26jtitle%3DPhilos.%2520Trans.%2520R.%2520Soc.%252C%2520B%26date%3D2018%26volume%3D373%26issue%3D1742%26spage%3D20170031%26doi%3D10.1098%2Frstb.2017.0031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Disney, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angelbello, A. J.</span></span> <span> </span><span class="NLM_article-title">Rational design of small molecules targeting oncogenic noncoding RNAs from sequence</span>. <i>Acc. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">2698</span>â <span class="NLM_lpage">2704</span>, <span class="refDoi">Â DOI: 10.1021/acs.accounts.6b00326</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.accounts.6b00326" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvV2ht7nJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2016&pages=2698-2704&author=M.+D.+Disneyauthor=A.+J.+Angelbello&title=Rational+design+of+small+molecules+targeting+oncogenic+noncoding+RNAs+from+sequence&doi=10.1021%2Facs.accounts.6b00326"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design of Small Molecules Targeting Oncogenic Noncoding RNAs from Sequence</span></div><div class="casAuthors">Disney, Matthew D.; Angelbello, Alicia J.</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2698-2704</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The discovery of RNA catalysis in the 1980s and the dissemination of the human genome sequence at the start of this century inspired investigations of the regulatory roles of noncoding RNAs in biol.  In fact, the Encyclopedia of DNA Elements (ENCODE) project has shown that only 1-2% of the human genome encodes protein, yet 75% is transcribed into RNA.  Functional studies both preceding and following the ENCODE project have shown that these noncoding RNAs have important roles that regulate gene expression, developmental timing, and other crit. functions.  RNA's diverse roles are often a consequence of the various folds that it adopts.  The single stranded nature of the biopolymer enables it to adopt intramol. folds with noncanonical pairings to lower its free energy (Figure ).  These folds can be scaffolds to bind proteins or to form frameworks to interact with other RNAs.  Not surprisingly, dysregulation of certain noncoding RNAs has been shown to be causative of disease.  Given this as a background, it is easy to see why it would be useful to develop methods to target RNA and manipulate its biol. in rational and predictable ways.  The antisense approach has afforded strategies to target RNAs via Watson-Crick based pairing and has typically focused on targeting partially unstructured regions of RNA.  Small mol. strategies to target RNA would be desirable, not only because compds. could be lead optimized via medicinal chem., but also because structured regions within an RNA of interest could be targeted in order to directly interfere with RNA folds that contribute to disease.  Addnl., small mols. have historically been the most successful drug candidates.  Until recently, the ability to design small mols. that target nonrRNAs has been elusive, creating the perception that they are "undruggable".  In this Account, approaches to demystify targeting RNA with small mols. are described.  Rather than bulk screening for compds. that bind to singular targets, which is the purview of the pharmaceutical industry and academic institutions with high throughput screening facilities, we focus on methods that allow for the rational design of small mols. toward biol. RNAs.  Enabling and foundational technologies that have been developed include two-dimensional combinatorial screening (2DCS), a library-vs.-library selection approach that allows the identification of the RNA motif binding preferences of small mols. from millions of combinations.  A landscape map of the 2DCS-defined and annotated RNA motif-small mol. interactions is then placed into Inforna, a computational tool that allows one to mine these interactions against an RNA of interest or an entire transcriptome.  Indeed, this approach has been enabled by tools to annotate RNA structure from sequence-an invaluable asset to the RNA community and this work-and has allowed for the rational identification of "druggable" RNAs in a target agnostic fashion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU-8j6q0xYYrVg90H21EOLACvtfcHk0ljUMcCrrohHkg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvV2ht7nJ&md5=14a75becddc19fd360e9b5dbd94eec48</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Facs.accounts.6b00326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.accounts.6b00326%26sid%3Dliteratum%253Aachs%26aulast%3DDisney%26aufirst%3DM.%2BD.%26aulast%3DAngelbello%26aufirst%3DA.%2BJ.%26atitle%3DRational%2520design%2520of%2520small%2520molecules%2520targeting%2520oncogenic%2520noncoding%2520RNAs%2520from%2520sequence%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2016%26volume%3D49%26spage%3D2698%26epage%3D2704%26doi%3D10.1021%2Facs.accounts.6b00326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stott, K.</span></span> <span> </span><span class="NLM_article-title">Pharmaâs broken business modelâPart 2: Scraping the barrel in drug discovery</span>.  <i>Endpoints News</i>; <span class="NLM_publisher-name">Endpoints Company</span>, May 2, 2018; <a href="https://endpts.com/pharmas-broken-business-model-part-2-scraping-the-barrel-in-drug-discovery/" class="extLink">https://endpts.com/pharmas-broken-business-model-part-2-scraping-the-barrel-in-drug-discovery/</a> Accessed on May 5, 2018.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Stott%2C+K.+Pharma%E2%80%99s+broken+business+model%E2%80%94Part+2%3A+Scraping+the+barrel+in+drug+discovery.+Endpoints+News%3B+Endpoints+Company%2C+May+2%2C+2018%3B+https%3A%2F%2Fendpts.com%2Fpharmas-broken-business-model-part-2-scraping-the-barrel-in-drug-discovery%2F+Accessed+on+May+5%2C+2018."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3DStott%26aufirst%3DK.%26atitle%3DPharma%25E2%2580%2599s%2520broken%2520business%2520model%25E2%2580%2594Part%25202%253A%2520Scraping%2520the%2520barrel%2520in%2520drug%2520discovery%26jtitle%3DEndpoints%2520News%26pub%3DEndpoints%2520Company" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Edfeldt, F. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folmer, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breeze, A. L.</span></span> <span> </span><span class="NLM_article-title">Fragment screening to predict druggability (ligandability) and lead discovery success</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">7â8</span>),  <span class="NLM_fpage">284</span>â <span class="NLM_lpage">287</span>, <span class="refDoi">Â DOI: 10.1016/j.drudis.2011.02.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.drudis.2011.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=21315179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3MXksFemsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=284-287&issue=7%E2%80%938&author=F.+N.+Edfeldtauthor=R.+H.+Folmerauthor=A.+L.+Breeze&title=Fragment+screening+to+predict+druggability+%28ligandability%29+and+lead+discovery+success&doi=10.1016%2Fj.drudis.2011.02.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment screening to predict druggability (ligandability) and lead discovery success</span></div><div class="casAuthors">Edfeldt, Fredrik N. B.; Folmer, Rutger H. A.; Breeze, Alexander L.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7/8</span>),
    <span class="NLM_cas:pages">284-287</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">This article discusses the use of fragment screening to predict ligandability which will be of great interest to the pharmaceutical industry.  Data presented in this article clearly show how fragment-based ligandability screening can be used in a truly predictive fashion and could be a powerful tool in reducing agent attrition by filtering out non-ligandable targets before entry into the portfolio.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSXfOy9wAHFLVg90H21EOLACvtfcHk0ljUMcCrrohHkg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXksFemsbs%253D&md5=7ba5adfe3d6a1eb4c9eaa3ce42c60044</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2011.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2011.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DEdfeldt%26aufirst%3DF.%2BN.%26aulast%3DFolmer%26aufirst%3DR.%2BH.%26aulast%3DBreeze%26aufirst%3DA.%2BL.%26atitle%3DFragment%2520screening%2520to%2520predict%2520druggability%2520%2528ligandability%2529%2520and%2520lead%2520discovery%2520success%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26issue%3D7%25E2%2580%25938%26spage%3D284%26epage%3D287%26doi%3D10.1016%2Fj.drudis.2011.02.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Valeur, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimonet, P.</span></span> <span> </span><span class="NLM_article-title">New modalities, technologies, and partnerships in probe and lead generation: enabling a mode-of-action centric paradigm</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">9004</span>â <span class="NLM_lpage">9029</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b00378</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00378" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVGjs77P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9004-9029&issue=20&author=E.+Valeurauthor=P.+Jimonet&title=New+modalities%2C+technologies%2C+and+partnerships+in+probe+and+lead+generation%3A+enabling+a+mode-of-action+centric+paradigm&doi=10.1021%2Facs.jmedchem.8b00378"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">New Modalities, Technologies, and Partnerships in Probe and Lead Generation: Enabling a Mode-of-Action Centric Paradigm</span></div><div class="casAuthors">Valeur, Eric; Jimonet, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9004-9029</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">With the rise of novel biol. and high potential target identification technologies originating from advances in genomics, medicinal chemists are progressively facing targets of increasing complexity and often unprecedented.  Novel hit finding technologies, combined with a wider choice of drug modalities, has resulted in a unique repertoire of options to address these challenging targets and to identify suitable starting points for optimization.  Furthermore, innovative solns. originating from a range of academic groups and biotech companies require new types of collaborative models to leverage and integrate them in the drug discovery process.  This perspective provides a guide for medicinal chemists covering contemporary probe and lead generation approaches and discusses the strengths and limitations of each strategy.  Moreover, the expansion of strategies to modulate proteins creates the opportunity of a modality-agnostic and mode-of-action centric hit finding paradigm.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS8l5d3NOahrVg90H21EOLACvtfcHk0lj765OjUcD19g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVGjs77P&md5=62e768509dac90567f3f021ed83b1df1</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00378&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00378%26sid%3Dliteratum%253Aachs%26aulast%3DValeur%26aufirst%3DE.%26aulast%3DJimonet%26aufirst%3DP.%26atitle%3DNew%2520modalities%252C%2520technologies%252C%2520and%2520partnerships%2520in%2520probe%2520and%2520lead%2520generation%253A%2520enabling%2520a%2520mode-of-action%2520centric%2520paradigm%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D20%26spage%3D9004%26epage%3D9029%26doi%3D10.1021%2Facs.jmedchem.8b00378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naylor, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bockus, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanco, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lokey, R. S.</span></span> <span> </span><span class="NLM_article-title">Cyclic peptide natural products chart the frontier of oral bioavailability in the pursuit of undruggable targets</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">141</span>â <span class="NLM_lpage">147</span>, <span class="refDoi">Â DOI: 10.1016/j.cbpa.2017.04.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.cbpa.2017.04.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=28570865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2sXovVSgsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2017&pages=141-147&author=M.+R.+Naylorauthor=A.+T.+Bockusauthor=M.+J.+Blancoauthor=R.+S.+Lokey&title=Cyclic+peptide+natural+products+chart+the+frontier+of+oral+bioavailability+in+the+pursuit+of+undruggable+targets&doi=10.1016%2Fj.cbpa.2017.04.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclic peptide natural products chart the frontier of oral bioavailability in the pursuit of undruggable targets</span></div><div class="casAuthors">Naylor, Matthew R.; Bockus, Andrew T.; Blanco, Maria-Jesus; Lokey, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">141-147</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">As interest in protein-protein interactions and other previously-undruggable targets increases, medicinal chemists are returning to natural products for design inspiration toward mols. that transcend the paradigm of small mol. drugs.  These compds., esp. peptides, often have poor ADME properties and thus require a more nuanced understanding of structure-property relationships to achieve desirable oral bioavailability.  Although there have been few clin. successes in this chem. space to date, recent work has identified opportunities to introduce favorable physicochem. properties to peptidic macrocycles that maintain activity and oral bioavailability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoanPrD1D-ePrVg90H21EOLACvtfcHk0lj765OjUcD19g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXovVSgsLw%253D&md5=175671ba338608979d38d340866df885</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2017.04.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2017.04.012%26sid%3Dliteratum%253Aachs%26aulast%3DNaylor%26aufirst%3DM.%2BR.%26aulast%3DBockus%26aufirst%3DA.%2BT.%26aulast%3DBlanco%26aufirst%3DM.%2BJ.%26aulast%3DLokey%26aufirst%3DR.%2BS.%26atitle%3DCyclic%2520peptide%2520natural%2520products%2520chart%2520the%2520frontier%2520of%2520oral%2520bioavailability%2520in%2520the%2520pursuit%2520of%2520undruggable%2520targets%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2017%26volume%3D38%26spage%3D141%26epage%3D147%26doi%3D10.1016%2Fj.cbpa.2017.04.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neklesa, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Targeted protein degradation by PROTACs</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">138</span>â <span class="NLM_lpage">144</span>, <span class="refDoi">Â DOI: 10.1016/j.pharmthera.2017.02.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.pharmthera.2017.02.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=28223226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtVemsbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2017&pages=138-144&author=T.+K.+Neklesaauthor=J.+D.+Winklerauthor=C.+M.+Crews&title=Targeted+protein+degradation+by+PROTACs&doi=10.1016%2Fj.pharmthera.2017.02.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted protein degradation by PROTACs</span></div><div class="casAuthors">Neklesa, Taavi K.; Winkler, James D.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">138-144</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Targeted protein degrdn. using the PROTAC technol. is emerging as a novel therapeutic method to address diseases driven by the aberrant expression of a disease-causing protein.  PROTAC mols. are bifunctional small mols. that simultaneously bind a target protein and an E3-ubiquitin ligase, thus causing ubiquitination and degrdn. of the target protein by the proteasome.  Like small mols., PROTAC mols. possess good tissue distribution and the ability to target intracellular proteins.  Herein, we highlight the advantages of protein degrdn. using PROTACs, and provide specific examples where degrdn. offers therapeutic benefit over classical enzyme inhibition.  Foremost, PROTACs can degrade proteins regardless of their function.  This includes the currently "undruggable" proteome, which comprises approx. 85% of all human proteins.  Other beneficial aspects of protein degrdn. include the ability to target overexpressed and mutated proteins, as well as the potential to demonstrate prolonged pharmacodynamics effect beyond drug exposure.  Lastly, due to their catalytic nature and the pre-requisite ubiquitination step, an exquisitely potent mols. with a high degree of degrdn. selectivity can be designed.  Impressive preclin. in vitro and in vivo PROTAC data have been published, and these data have propelled the development of clin. viable PROTACs.  With the mol. wt. falling in the 700-1000 Da range, the delivery and bioavailability of PROTACs remain the largest hurdles on the way to the clinic.  Solving these issues and demonstrating proof of concept clin. data will be the focus of many labs over the next few years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4RSLWYqqBMrVg90H21EOLACvtfcHk0lg9FvDHjNUHZQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtVemsbg%253D&md5=08a74402a274a13c8c484cd68167a5a1</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2017.02.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2017.02.027%26sid%3Dliteratum%253Aachs%26aulast%3DNeklesa%26aufirst%3DT.%2BK.%26aulast%3DWinkler%26aufirst%3DJ.%2BD.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DTargeted%2520protein%2520degradation%2520by%2520PROTACs%26jtitle%3DPharmacol.%2520Ther.%26date%3D2017%26volume%3D174%26spage%3D138%26epage%3D144%26doi%3D10.1016%2Fj.pharmthera.2017.02.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kung, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hixon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosinski, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cianchetta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Histen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Si, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeLaBarre, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popovici-Muller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salituro, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, L.</span></span> <span> </span><span class="NLM_article-title">AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>130</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1347</span>â <span class="NLM_lpage">1356</span>, <span class="refDoi">Â DOI: 10.1182/blood-2016-11-753525</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1182%2Fblood-2016-11-753525" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=28760888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFWjtLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2017&pages=1347-1356&issue=11&author=C.+Kungauthor=J.+Hixonauthor=P.+A.+Kosinskiauthor=G.+Cianchettaauthor=G.+Histenauthor=Y.+Chenauthor=C.+Hillauthor=S.+Grossauthor=Y.+Siauthor=K.+Johnsonauthor=B.+DeLaBarreauthor=Z.+Luoauthor=Z.+Guauthor=G.+Yaoauthor=H.+Tangauthor=C.+Fangauthor=Y.+Xuauthor=X.+Lvauthor=S.+Billerauthor=S.+M.+Suauthor=H.+Yangauthor=J.+Popovici-Mullerauthor=F.+Salituroauthor=L.+Silvermanauthor=L.+Dang&title=AG-348+enhances+pyruvate+kinase+activity+in+red+blood+cells+from+patients+with+pyruvate+kinase+deficiency&doi=10.1182%2Fblood-2016-11-753525"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency</span></div><div class="casAuthors">Kung, Charles; Hixon, Jeff; Kosinski, Penelope A.; Cianchetta, Giovanni; Histen, Gavin; Chen, Yue; Hill, Collin; Gross, Stefan; Si, Yaguang; Johnson, Kendall; De La Barre, Byron; Luo, Zhiyong; Gu, Zhiwei; Yao, Gui; Tang, Huachun; Fang, Cheng; Xu, Yingxia; Lv, Xiaobing; Biller, Scott; Su, Shin-San Michael; Yang, Hua; Popovici-Muller, Janeta; Salituro, Francesco; Silverman, Lee; Dang, Lenny</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1347-1356</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Pyruvate kinase (PK) deficiency is a rare genetic disease that causes chronic hemolytic anemia.  There are currently no targeted therapies for PK deficiency.  Here, we describe the identification and characterization of AG-348, an allosteric activator of PK that is currently in clin. trials for the treatment of PK deficiency.  We demonstrate that AG-348 can increase the activity of wild type and mutant PK enzymes in biochem. assays and in patient red blood cells treated ex vivo.  These data illustrate the potential for AG-348 to restore the glycolytic pathway activity in patients with PK deficiency and ultimately lead to clin. benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZFATqt6c8wbVg90H21EOLACvtfcHk0lg9FvDHjNUHZQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFWjtLk%253D&md5=1f35e40cdcecaebddc4962213273c857</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-11-753525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-11-753525%26sid%3Dliteratum%253Aachs%26aulast%3DKung%26aufirst%3DC.%26aulast%3DHixon%26aufirst%3DJ.%26aulast%3DKosinski%26aufirst%3DP.%2BA.%26aulast%3DCianchetta%26aufirst%3DG.%26aulast%3DHisten%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DHill%26aufirst%3DC.%26aulast%3DGross%26aufirst%3DS.%26aulast%3DSi%26aufirst%3DY.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DDeLaBarre%26aufirst%3DB.%26aulast%3DLuo%26aufirst%3DZ.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DYao%26aufirst%3DG.%26aulast%3DTang%26aufirst%3DH.%26aulast%3DFang%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DLv%26aufirst%3DX.%26aulast%3DBiller%26aufirst%3DS.%26aulast%3DSu%26aufirst%3DS.%2BM.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DPopovici-Muller%26aufirst%3DJ.%26aulast%3DSalituro%26aufirst%3DF.%26aulast%3DSilverman%26aufirst%3DL.%26aulast%3DDang%26aufirst%3DL.%26atitle%3DAG-348%2520enhances%2520pyruvate%2520kinase%2520activity%2520in%2520red%2520blood%2520cells%2520from%2520patients%2520with%2520pyruvate%2520kinase%2520deficiency%26jtitle%3DBlood%26date%3D2017%26volume%3D130%26issue%3D11%26spage%3D1347%26epage%3D1356%26doi%3D10.1182%2Fblood-2016-11-753525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pardridge, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boado, R. J.</span></span> <span> </span><span class="NLM_article-title">Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier</span>. <i>Methods Enzymol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>503</i></span>,  <span class="NLM_fpage">269</span>â <span class="NLM_lpage">292</span>, <span class="refDoi">Â DOI: 10.1016/B978-0-12-396962-0.00011-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2FB978-0-12-396962-0.00011-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=22230573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC38Xkt1CjsLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=503&publication_year=2012&pages=269-292&author=W.+M.+Pardridgeauthor=R.+J.+Boado&title=Reengineering+biopharmaceuticals+for+targeted+delivery+across+the+blood-brain+barrier&doi=10.1016%2FB978-0-12-396962-0.00011-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier</span></div><div class="casAuthors">Pardridge, William M.; Boado, Ruben J.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">503</span>
        (<span class="NLM_cas:issue">Protein Engineering for Therapeutics, Part B</span>),
    <span class="NLM_cas:pages">269-292</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Recombinant protein therapeutics cannot enter brain drug development because these large mol. drugs do not cross the blood-brain barrier (BBB).  However, recombinant proteins can be reengineered as BBB-penetrating IgG fusion proteins, where the IgG part is a genetically engineered monoclonal antibody (MAb) against an endogenous BBB receptor, such as the human insulin receptor (HIR) or the transferrin receptor (TfR).  The IgG binds the endogenous insulin receptor or TfR to trigger transport across the BBB and acts as a mol. Trojan horse (MTH) to ferry into brain the fused protein therapeutic.  The most potent MTH to date is a MAb against the HIR, designated the HIRMAb, which is active in humans and Old World primates, such as the Rhesus monkey.  There is no known MAb against the mouse insulin receptor.  For drug delivery in the mouse, protein therapeutics are fused to a chimeric MAb against the mouse TfR, designated the cTfRMAb.  The HIRMAb or cTfRMAb Trojan horses have been engineered and expressed as fusion proteins with multiple classes of protein therapeutics, including lysosomal enzymes, neurotrophins, decoy receptors, single chain Fv therapeutic antibodies, and avidin.  The pharmacokinetic (PK) properties of the IgG fusion proteins differ from that of typical MAb drugs and resemble the PK profiles of small mols. due to rapid uptake by peripheral tissues, as well as brain.  The brain uptake of the IgG fusion proteins, 2-3% of injected dose/brain, is comparable to the brain uptake of small mols.  The IgG fusion proteins have been administered chronically in mouse models, and the immune response is low titer and has no effect on the fusion protein clearance from blood or brain uptake in vivo.  The BBB MTH technol. enables the reengineering of a wide spectrum of recombinant protein therapeutics for targeted drug delivery to the brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjkLRy2RahB7Vg90H21EOLACvtfcHk0lj1riAwYkD3_w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xkt1CjsLc%253D&md5=38cb8b5131ba1251ba3997bc1d5160e4</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-396962-0.00011-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-396962-0.00011-2%26sid%3Dliteratum%253Aachs%26aulast%3DPardridge%26aufirst%3DW.%2BM.%26aulast%3DBoado%26aufirst%3DR.%2BJ.%26atitle%3DReengineering%2520biopharmaceuticals%2520for%2520targeted%2520delivery%2520across%2520the%2520blood-brain%2520barrier%26jtitle%3DMethods%2520Enzymol.%26date%3D2012%26volume%3D503%26spage%3D269%26epage%3D292%26doi%3D10.1016%2FB978-0-12-396962-0.00011-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Panowski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhakta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raab, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polakis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Junutula, J. R.</span></span> <span> </span><span class="NLM_article-title">Site-specific antibody drug conjugates for cancer therapy</span>. <i>MAbs.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">34</span>â <span class="NLM_lpage">45</span>, <span class="refDoi">Â DOI: 10.4161/mabs.27022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.4161%2Fmabs.27022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=24423619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A280%3ADC%252BC2cvnslaltw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=34-45&issue=1&author=S.+Panowskiauthor=S.+Bhaktaauthor=H.+Raabauthor=P.+Polakisauthor=J.+R.+Junutula&title=Site-specific+antibody+drug+conjugates+for+cancer+therapy&doi=10.4161%2Fmabs.27022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Site-specific antibody drug conjugates for cancer therapy</span></div><div class="casAuthors">Panowski Siler; Bhakta Sunil; Raab Helga; Polakis Paul; Junutula Jagath R</div><div class="citationInfo"><span class="NLM_cas:title">mAbs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">34-45</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Antibody therapeutics have revolutionized the treatment of cancer over the past two decades.  Antibodies that specifically bind tumor surface antigens can be effective therapeutics; however, many unmodified antibodies lack therapeutic activity.  These antibodies can instead be applied successfully as guided missiles to deliver potent cytotoxic drugs in the form of antibody drug conjugates (ADCs).  The success of ADCs is dependent on four factors--target antigen, antibody, linker, and payload.  The field has made great progress in these areas, marked by the recent approval by the US Food and Drug Administration of two ADCs, brentuximab vedotin (Adcetris) and ado-trastuzumab emtansine (Kadcyla).  However, the therapeutic window for many ADCs that are currently in pre-clinical or clinical development remains narrow and further improvements may be required to enhance the therapeutic potential of these ADCs.  Production of ADCs is an area where improvement is needed because current methods yield heterogeneous mixtures that may include 0-8 drug species per antibody molecule.  Site-specific conjugation has been recently shown to eliminate heterogeneity, improve conjugate stability, and increase the therapeutic window.  Here, we review and describe various site-specific conjugation strategies that are currently used for the production of ADCs, including use of engineered cysteine residues, unnatural amino acids, and enzymatic conjugation through glycotransferases and transglutaminases.  In addition, we also summarize differences among these methods and highlight critical considerations when building next-generation ADC therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQXMRlj6bTH0hOk4JA3soTqfW6udTcc2eaEdigbB_epLrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cvnslaltw%253D%253D&md5=9da883692122c03303f785e61f6c5db7</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.4161%2Fmabs.27022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fmabs.27022%26sid%3Dliteratum%253Aachs%26aulast%3DPanowski%26aufirst%3DS.%26aulast%3DBhakta%26aufirst%3DS.%26aulast%3DRaab%26aufirst%3DH.%26aulast%3DPolakis%26aufirst%3DP.%26aulast%3DJunutula%26aufirst%3DJ.%2BR.%26atitle%3DSite-specific%2520antibody%2520drug%2520conjugates%2520for%2520cancer%2520therapy%26jtitle%3DMAbs.%26date%3D2014%26volume%3D6%26issue%3D1%26spage%3D34%26epage%3D45%26doi%3D10.4161%2Fmabs.27022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Changeux, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span> <span> </span><span class="NLM_article-title">Allosteric modulation as a unifying mechanism for receptor function and regulation</span>. <i>Diabetes, Obes. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">4</span>â <span class="NLM_lpage">21</span>, <span class="refDoi">Â DOI: 10.1111/dom.12959</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1111%2Fdom.12959" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=28880476" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVGhsrjJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=4-21&author=J.-P.+Changeuxauthor=A.+Christopoulos&title=Allosteric+modulation+as+a+unifying+mechanism+for+receptor+function+and+regulation&doi=10.1111%2Fdom.12959"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric modulation as a unifying mechanism for receptor function and regulation</span></div><div class="casAuthors">Changeux, Jean-Pierre; Christopoulos, Arthur</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes, Obesity and Metabolism</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">S1</span>),
    <span class="NLM_cas:pages">4-21</span>CODEN:
                <span class="NLM_cas:coden">DOMEF6</span>;
        ISSN:<span class="NLM_cas:issn">1462-8902</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Four major receptor families enable cells to respond to chem. and phys. signals from their proximal environment.  The ligand- and voltage-gated ion channels, G-protein-coupled receptors, nuclear hormone receptors and receptor tyrosine kinases are all allosteric proteins that carry multiple, spatially distinct, yet conformationally linked ligand-binding sites.  Recent studies point to common mechanisms governing the allosteric transitions of these receptors, including the impact of oligomerization, pre-existing and functionally distinct conformational ensembles, intrinsically disordered regions, and the occurrence of allosteric modulatory sites.  Importantly, synthetic allosteric modulators are being discovered for these receptors, providing an enriched, yet challenging, landscape for novel therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprPiSFlez82bVg90H21EOLACvtfcHk0licMksY1W04LQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVGhsrjJ&md5=b36387593f7f407b7f78266989a4e4d9</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1111%2Fdom.12959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fdom.12959%26sid%3Dliteratum%253Aachs%26aulast%3DChangeux%26aufirst%3DJ.-P.%26aulast%3DChristopoulos%26aufirst%3DA.%26atitle%3DAllosteric%2520modulation%2520as%2520a%2520unifying%2520mechanism%2520for%2520receptor%2520function%2520and%2520regulation%26jtitle%3DDiabetes%252C%2520Obes.%2520Metab.%26date%3D2017%26volume%3D19%26spage%3D4%26epage%3D21%26doi%3D10.1111%2Fdom.12959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foster, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span> <span> </span><span class="NLM_article-title">Allosteric Modulation of GPCRs: new insights and potential utility for treatment of schizophrenia and other CNS disorders</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>94</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">431</span>â <span class="NLM_lpage">446</span>, <span class="refDoi">Â DOI: 10.1016/j.neuron.2017.03.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.neuron.2017.03.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=28472649" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntFeltbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2017&pages=431-446&issue=3&author=D.+J.+Fosterauthor=P.+J.+Conn&title=Allosteric+Modulation+of+GPCRs%3A+new+insights+and+potential+utility+for+treatment+of+schizophrenia+and+other+CNS+disorders&doi=10.1016%2Fj.neuron.2017.03.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Modulation of GPCRs: New Insights and Potential Utility for Treatment of Schizophrenia and Other CNS Disorders</span></div><div class="casAuthors">Foster, Daniel J.; Conn, P. Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">431-446</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">G-protein-coupled receptors (GPCRs) play crit. roles in regulating brain function.  Recent advances have greatly expanded our understanding of these receptors as complex signaling machines that can adopt numerous conformations and modulate multiple downstream signaling pathways.  While agonists and antagonists have traditionally been pursued to target GPCRs, allosteric modulators provide several mechanistic advantages, including the ability to distinguish between closely related receptor subtypes.  Recently, the discovery of allosteric ligands that confer bias and modulate some, but not all, of a given receptor's downstream signaling pathways can provide pharmacol. modulation of brain circuitry with remarkable precision.  In addn., allosteric modulators with unprecedented specificity have been developed that can differentiate between subpopulations of a given receptor subtype based on the receptor's dimerization state.  These advances are not only providing insight into the biol. roles of specific receptor populations, but hold great promise for treating numerous CNS disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosB9i2AL3HjbVg90H21EOLACvtfcHk0licMksY1W04LQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntFeltbY%253D&md5=8769a88b9afd7df7516eddcba05af805</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.neuron.2017.03.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuron.2017.03.016%26sid%3Dliteratum%253Aachs%26aulast%3DFoster%26aufirst%3DD.%2BJ.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26atitle%3DAllosteric%2520Modulation%2520of%2520GPCRs%253A%2520new%2520insights%2520and%2520potential%2520utility%2520for%2520treatment%2520of%2520schizophrenia%2520and%2520other%2520CNS%2520disorders%26jtitle%3DNeuron%26date%3D2017%26volume%3D94%26issue%3D3%26spage%3D431%26epage%3D446%26doi%3D10.1016%2Fj.neuron.2017.03.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flor, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acher, F. C.</span></span> <span> </span><span class="NLM_article-title">Orthosteric versus allosteric GPCR activation: the great challenge of group-III mGluRs</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>84</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">414</span>â <span class="NLM_lpage">424</span>, <span class="refDoi">Â DOI: 10.1016/j.bcp.2012.04.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.bcp.2012.04.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=22554564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvFKlsLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2012&pages=414-424&issue=4&author=P.+J.+Florauthor=F.+C.+Acher&title=Orthosteric+versus+allosteric+GPCR+activation%3A+the+great+challenge+of+group-III+mGluRs&doi=10.1016%2Fj.bcp.2012.04.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Orthosteric versus allosteric GPCR activation: The great challenge of group-III mGluRs</span></div><div class="casAuthors">Flor, Peter J.; Acher, Francine C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">414-424</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Group-III metabotropic glutamate receptors (mGluRs) comprise four structurally related brain and retinal G protein-coupled receptors (GPCRs), mGluR4, mGluR6, mGluR7 and mGluR8, which receive much attention as promising targets for nervous system drugs.  In particular, activation of mGluR4 is a major focus for the development of new therapeutics in Parkinson's disease, while mGluR7 activation is considered a potential approach for future treatments of specific psychiatric conditions.  The first generation group-III mGluR agonists, e.g.L-AP4 and L-SOP, are characterized by an essential phosphonate functional group, which became a major limitation for the development of systemically active, potent and receptor subtype-selective drugs.  Recently however, two approaches emerged in parallel providing resoln. to this constraint: in silico high-throughput screening of chem. libraries against a 3D-model of the mGluR4 extracellular domain identified a hit that was optimized into a series of potent and subtype-selective orthosteric agonists with drug-like properties and novel chemotype structures; secondly, high-throughput random screening of chem. libraries against recombinantly expressed group-III receptors identified diverse chem. sets of allosteric agonists and pos. modulators, which are drug-like, display selectivity for mGluR4, mGluR7, or mGluR8 and act via novel pharmacol. sites.Here, we illustrate new scientific insights obtained via the use of those strategies.  Also, we compare advantages and disadvantages of both approaches to identify the desired group-III mGluR activators and we conclude with suggestions how to employ those discovery strategies with success for the identification, optimization, and development of clin. drug candidates; this may have important implications for the entire field of GPCR research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxQ6zMsXPxnLVg90H21EOLACvtfcHk0lhI3VpkMCiBmA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvFKlsLk%253D&md5=d3969d201c3be6bc42ac3ed95f545efb</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2012.04.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2012.04.013%26sid%3Dliteratum%253Aachs%26aulast%3DFlor%26aufirst%3DP.%2BJ.%26aulast%3DAcher%26aufirst%3DF.%2BC.%26atitle%3DOrthosteric%2520versus%2520allosteric%2520GPCR%2520activation%253A%2520the%2520great%2520challenge%2520of%2520group-III%2520mGluRs%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2012%26volume%3D84%26issue%3D4%26spage%3D414%26epage%3D424%26doi%3D10.1016%2Fj.bcp.2012.04.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leidenheimer, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryder, K. G.</span></span> <span> </span><span class="NLM_article-title">Pharmacological chaperoning: a primer on mechanism and pharmacology</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">10</span>â <span class="NLM_lpage">19</span>, <span class="refDoi">Â DOI: 10.1016/j.phrs.2014.01.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.phrs.2014.01.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=24530489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjvFWjs70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2014&pages=10-19&author=N.+J.+Leidenheimerauthor=K.+G.+Ryder&title=Pharmacological+chaperoning%3A+a+primer+on+mechanism+and+pharmacology&doi=10.1016%2Fj.phrs.2014.01.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological chaperoning: A primer on mechanism and pharmacology</span></div><div class="casAuthors">Leidenheimer, Nancy J.; Ryder, Katelyn G.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10-19</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Approx. forty percent of diseases are attributable to protein misfolding, including those for which genetic mutation produces misfolding mutants.  Intriguingly, many of these mutants are not terminally misfolded since native-like folding, and subsequent trafficking to functional locations, can be induced by target-specific, small mols. variably termed pharmacol. chaperones, pharmacoperones, or pharmacochaperones (PCs).  PC targets include enzymes, receptors, transporters, and ion channels, revealing the breadth of proteins that can be engaged by ligand-assisted folding.  The purpose of this review is to provide an integrated primer of the diverse mechanisms and pharmacol. of PCs.  In this regard, we examine the structural mechanisms that underlie PC rescue of misfolding mutants, including the ability of PCs to act as surrogates for defective intramol. interactions and, at the intermol. level, overcome oligomerization deficiencies and dominant neg. effects, as well as influence the subunit stoichiometry of heteropentameric receptors.  Not surprisingly, PC-mediated structural correction of misfolding mutants normalizes interactions with mol. chaperones that participate in protein quality control and forward-trafficking.  A variety of small mols. have proven to be efficacious PCs and the advantages and disadvantages of employing orthostatic antagonists, active-site inhibitors, orthostatic agonists, and allosteric modulator PCs are considered.  Also examd. is the possibility that several therapeutic agents may have unrecognized activity as PCs, and this chaperoning activity may mediate/contribute to therapeutic action and/or account for adverse effects.  Lastly, we explore evidence that pharmacol. chaperoning exploits intrinsic ligand-assisted folding mechanisms.  Given the widespread applicability of PC rescue of mutants assocd. with protein folding disorders, both in vitro and in vivo, the therapeutic potential of PCs is vast.  This is most evident in the treatment of lysosomal storage disorders, cystic fibrosis, and nephrogenic diabetes insipidus, for which proof of principle in humans has been demonstrated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruUboB_YB89bVg90H21EOLACvtfcHk0lhI3VpkMCiBmA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjvFWjs70%253D&md5=34a1b58b182c064e8a72381d9e0f7e95</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2014.01.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2014.01.005%26sid%3Dliteratum%253Aachs%26aulast%3DLeidenheimer%26aufirst%3DN.%2BJ.%26aulast%3DRyder%26aufirst%3DK.%2BG.%26atitle%3DPharmacological%2520chaperoning%253A%2520a%2520primer%2520on%2520mechanism%2520and%2520pharmacology%26jtitle%3DPharmacol.%2520Res.%26date%3D2014%26volume%3D83%26spage%3D10%26epage%3D19%26doi%3D10.1016%2Fj.phrs.2014.01.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dishman, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volkman, B. F.</span></span> <span> </span><span class="NLM_article-title">Unfolding the mysteries of protein metamorphosis</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1438</span>â <span class="NLM_lpage">1446</span>, <span class="refDoi">Â DOI: 10.1021/acschembio.8b00276</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.8b00276" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpvVGrsr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=1438-1446&issue=6&author=A.+F.+Dishmanauthor=B.+F.+Volkman&title=Unfolding+the+mysteries+of+protein+metamorphosis&doi=10.1021%2Facschembio.8b00276"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Unfolding the Mysteries of Protein Metamorphosis</span></div><div class="casAuthors">Dishman, Acacia F.; Volkman, Brian F.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1438-1446</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Since the proposal of Anfinsen's thermodn. hypothesis in 1963, our understanding of protein folding and dynamics has gained significant appreciation of its nuance and complexity.  Intrinsically disordered proteins, chameleonic sequences, morpheeins, and metamorphic proteins have broadened the protein folding paradigm.  Here, we discuss noncanonical protein folding patterns, with an emphasis on metamorphic proteins, and we review known metamorphic proteins that occur naturally and that have been engineered in the lab.  Finally, we discuss research areas surrounding metamorphic proteins that are primed for future exploration, including evolution, drug discovery, and the quest for previously unrecognized metamorphs.  As we enter an age where we are capable of complex bioinformatic searches and de novo protein design, we are primed to search for previously unrecognized metamorphic proteins and to design our own metamorphs to act as targeted, switchable drugs, biosensors, and more.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9d37BsDJJkrVg90H21EOLACvtfcHk0lhI3VpkMCiBmA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpvVGrsr4%253D&md5=f3fe9cfe44feca89d59c3ed665794707</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facschembio.8b00276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.8b00276%26sid%3Dliteratum%253Aachs%26aulast%3DDishman%26aufirst%3DA.%2BF.%26aulast%3DVolkman%26aufirst%3DB.%2BF.%26atitle%3DUnfolding%2520the%2520mysteries%2520of%2520protein%2520metamorphosis%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2018%26volume%3D13%26issue%3D6%26spage%3D1438%26epage%3D1446%26doi%3D10.1021%2Facschembio.8b00276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barbash, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenzen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakmar, T. P.</span></span> <span> </span><span class="NLM_article-title">GPCRs globally coevolved with receptor activity-modifying proteins, RAMPs</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span> (<span class="NLM_issue">45</span>),  <span class="NLM_fpage">12015</span>â <span class="NLM_lpage">12020</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1713074114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1073%2Fpnas.1713074114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=29078385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslSktrfE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=12015-12020&issue=45&author=S.+Barbashauthor=E.+Lorenzenauthor=T.+Perssonauthor=T.+Huberauthor=T.+P.+Sakmar&title=GPCRs+globally+coevolved+with+receptor+activity-modifying+proteins%2C+RAMPs&doi=10.1073%2Fpnas.1713074114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">GPCRs globally coevolved with receptor activity-modifying proteins, RAMPs</span></div><div class="casAuthors">Barbash, Shahar; Lorenzen, Emily; Persson, Torbjorn; Huber, Thomas; Sakmar, Thomas P.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">12015-12020</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Receptor activity-modifying proteins (RAMPs) are widely expressed in human tissues and, in some cases, have been shown to affect surface expression or ligand specificity of G-protein-coupled receptors (GPCRs).  However, whether RAMP-GPCR interactions are widespread, and the nature of their functional consequences, remains largely unknown.  In humans, there are three RAMPs and over 800 expressed GPCRs, making direct exptl. approaches challenging.  We analyzed relevant genomic data from all currently available sequenced organisms.  We discovered that RAMPs and GPCRs tend to have orthologs in the same species and have correlated phylogenetic trees to the same extent, or higher than other interacting protein pairs that play key roles in cellular signaling.  In addn., the resulting RAMP-GPCR interaction map suggests that RAMP1 and RAMP3 interact with the same set of GPCRs, which implies functional redundancy.  We next analyzed human transcriptomes and found expression correlation for GPCRs and RAMPs.  Our results suggest global coevolution of GPCRs and RAMPS and support the hypothesis that GPCRs interact globally with RAMPs in cellular signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNNo_6SV6MSbVg90H21EOLACvtfcHk0liDXeIThceHsA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslSktrfE&md5=71c7f672427d7d97e2dd4c036e4ad9f7</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1713074114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1713074114%26sid%3Dliteratum%253Aachs%26aulast%3DBarbash%26aufirst%3DS.%26aulast%3DLorenzen%26aufirst%3DE.%26aulast%3DPersson%26aufirst%3DT.%26aulast%3DHuber%26aufirst%3DT.%26aulast%3DSakmar%26aufirst%3DT.%2BP.%26atitle%3DGPCRs%2520globally%2520coevolved%2520with%2520receptor%2520activity-modifying%2520proteins%252C%2520RAMPs%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2017%26volume%3D114%26issue%3D45%26spage%3D12015%26epage%3D12020%26doi%3D10.1073%2Fpnas.1713074114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmitte, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niswender, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span> <span> </span><span class="NLM_article-title">Practical strategies and concepts in GPCR allosteric modulator discovery: recent advances with metabotropic glutamate receptors</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>116</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">6707</span>â <span class="NLM_lpage">6741</span>, <span class="refDoi">Â DOI: 10.1021/acs.chemrev.5b00656</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.5b00656" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC28XisFahsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2016&pages=6707-6741&issue=11&author=C.+W.+Lindsleyauthor=K.+A.+Emmitteauthor=C.+R.+Hopkinsauthor=T.+M.+Bridgesauthor=K.+J.+Gregoryauthor=C.+M.+Niswenderauthor=P.+J.+Conn&title=Practical+strategies+and+concepts+in+GPCR+allosteric+modulator+discovery%3A+recent+advances+with+metabotropic+glutamate+receptors&doi=10.1021%2Facs.chemrev.5b00656"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors</span></div><div class="casAuthors">Lindsley, Craig W.; Emmitte, Kyle A.; Hopkins, Corey R.; Bridges, Thomas M.; Gregory, Karen J.; Niswender, Colleen M.; Conn, P. Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6707-6741</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Allosteric modulation of GPCRs has initiated a new era of basic and translational discovery, filled with therapeutic promise yet fraught with caveats.  Allosteric ligands stabilize unique conformations of the GPCR that afford fundamentally new receptors, capable of novel pharmacol., unprecedented subtype selectivity, and unique signal bias.  This review provides a comprehensive overview of the basics of GPCR allosteric pharmacol., medicinal chem., drug metab., and validated approaches to address each of the major challenges and caveats.  Then, the review narrows focus to highlight recent advances in the discovery of allosteric ligands for metabotropic glutamate receptor subtypes 1-5 and 7 (mGlu1-5,7) highlighting key concepts ("mol. switches", signal bias, heterodimers) and practical solns. to enable the development of tool compds. and clin. candidates.  The review closes with a section on late-breaking new advances with allosteric ligands for other GPCRs and emerging data for endogenous allosteric modulators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq18XJrjVel-7Vg90H21EOLACvtfcHk0liDXeIThceHsA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisFahsr8%253D&md5=c12704b6602b6c50add92e7fd9350382</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.5b00656&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.5b00656%26sid%3Dliteratum%253Aachs%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DEmmitte%26aufirst%3DK.%2BA.%26aulast%3DHopkins%26aufirst%3DC.%2BR.%26aulast%3DBridges%26aufirst%3DT.%2BM.%26aulast%3DGregory%26aufirst%3DK.%2BJ.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26atitle%3DPractical%2520strategies%2520and%2520concepts%2520in%2520GPCR%2520allosteric%2520modulator%2520discovery%253A%2520recent%2520advances%2520with%2520metabotropic%2520glutamate%2520receptors%26jtitle%3DChem.%2520Rev.%26date%3D2016%26volume%3D116%26issue%3D11%26spage%3D6707%26epage%3D6741%26doi%3D10.1021%2Facs.chemrev.5b00656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hauser, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attwood, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rask-Andersen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SchiÃ¶th, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloriam, D. E.</span></span> <span> </span><span class="NLM_article-title">Trends in GPCR drug discovery: new agents, targets and indications</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">829</span>â <span class="NLM_lpage">842</span>, <span class="refDoi">Â DOI: 10.1038/nrd.2017.178</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fnrd.2017.178" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=29075003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslansbzF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=829-842&issue=12&author=A.+S.+Hauserauthor=M.+M.+Attwoodauthor=M.+Rask-Andersenauthor=H.+B.+Schi%C3%B6thauthor=D.+E.+Gloriam&title=Trends+in+GPCR+drug+discovery%3A+new+agents%2C+targets+and+indications&doi=10.1038%2Fnrd.2017.178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Trends in GPCR drug discovery: new agents, targets and indications</span></div><div class="casAuthors">Hauser, Alexander S.; Attwood, Misty M.; Rask-Andersen, Mathias; Schioth, Helgi B.; Gloriam, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">829-842</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">G protein-coupled receptors (GPCRs) are the most intensively studied drug targets, mostly due to their substantial involvement in human pathophysiol. and their pharmacol. tractability.  Here, we report an up-to-date anal. of all GPCR drugs and agents in clin. trials, which reveals current trends across mol. types, drug targets and therapeutic indications, including showing that 475 drugs (â¼34% of all drugs approved by the US Food and Drug Administration (FDA)) act at 108 unique GPCRs.  Approx. 321 agents are currently in clin. trials, of which â¼20% target 66 potentially novel GPCR targets without an approved drug, and the no. of biol. drugs, allosteric modulators and biased agonists has increased.  The major disease indications for GPCR modulators show a shift towards diabetes, obesity and Alzheimer disease, although several central nervous system disorders are also highly represented.  The 224 (56%) non-olfactory GPCRs that have not yet been explored in clin. trials have broad untapped therapeutic potential, particularly in genetic and immune system disorders.  Finally, we provide an interactive online resource to analyze and infer trends in GPCR drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9iw1QqR9GKrVg90H21EOLACvtfcHk0lh20wWzfwfOkQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslansbzF&md5=560893258493bd96c0af24d3bef08b6f</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2017.178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2017.178%26sid%3Dliteratum%253Aachs%26aulast%3DHauser%26aufirst%3DA.%2BS.%26aulast%3DAttwood%26aufirst%3DM.%2BM.%26aulast%3DRask-Andersen%26aufirst%3DM.%26aulast%3DSchi%25C3%25B6th%26aufirst%3DH.%2BB.%26aulast%3DGloriam%26aufirst%3DD.%2BE.%26atitle%3DTrends%2520in%2520GPCR%2520drug%2520discovery%253A%2520new%2520agents%252C%2520targets%2520and%2520indications%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26issue%3D12%26spage%3D829%26epage%3D842%26doi%3D10.1038%2Fnrd.2017.178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christopher, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DorÃ©, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tehan, B. G.</span></span> <span> </span><span class="NLM_article-title">Potential for the rational design of allosteric modulators of class C GPCRs</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">71</span>â <span class="NLM_lpage">78</span>, <span class="refDoi">Â DOI: 10.2174/1568026616666160719165922</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.2174%2F1568026616666160719165922" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=71-78&issue=1&author=J.+A.+Christopherauthor=A.+S.+Dor%C3%A9author=B.+G.+Tehan&title=Potential+for+the+rational+design+of+allosteric+modulators+of+class+C+GPCRs&doi=10.2174%2F1568026616666160719165922"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.2174%2F1568026616666160719165922&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026616666160719165922%26sid%3Dliteratum%253Aachs%26aulast%3DChristopher%26aufirst%3DJ.%2BA.%26aulast%3DDor%25C3%25A9%26aufirst%3DA.%2BS.%26aulast%3DTehan%26aufirst%3DB.%2BG.%26atitle%3DPotential%2520for%2520the%2520rational%2520design%2520of%2520allosteric%2520modulators%2520of%2520class%2520C%2520GPCRs%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2016%26volume%3D17%26issue%3D1%26spage%3D71%26epage%3D78%26doi%3D10.2174%2F1568026616666160719165922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span> <span> </span><span class="NLM_article-title">Small molecule allosteric modulators of G-protein-coupled receptors: drug-target interactions</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">24</span>â <span class="NLM_lpage">45</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b01844</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01844" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFCgtb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=24-45&issue=1&author=S.+Luauthor=J.+Zhang&title=Small+molecule+allosteric+modulators+of+G-protein-coupled+receptors%3A+drug-target+interactions&doi=10.1021%2Facs.jmedchem.7b01844"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Allosteric Modulators of G-Protein-Coupled Receptors: Drug-Target Interactions</span></div><div class="casAuthors">Lu, Shaoyong; Zhang, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">24-45</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">G-protein-coupled receptors (GPCRs) are the largest class of signaling receptors that are most frequently targeted by therapeutic drugs.  Allosteric modulators bound to GPCRs at allosteric sites provide the potential for differential selectivity and improved safety compared with traditional orthosteric ligands.  The recent breakthroughs in GPCR structural biol. have made structures of GPCRs from classes A, B, C, and F complexed with small-mol. allosteric modulators available.  Knowledge of the detailed receptor-modulator interactions at the allosteric sites is useful for structure-based GPCR drug design of novel therapeutics.  This Perspective comprehensively summarizes the current status of structural complexes between GPCRs and their small-mol. allosteric modulators, particularly the key receptor-modulator interactions at the allosteric sites.  Then, the structural diversity of allosteric sites across four GPCR subfamilies is compared.  This study is expected to contribute to the design of GPCR allosteric drugs with an improved therapeutic action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVDf1DtcU6ZLVg90H21EOLACvtfcHk0lh20wWzfwfOkQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFCgtb0%253D&md5=7a41f4c00dadecd0661d135811644ad8</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01844&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01844%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DSmall%2520molecule%2520allosteric%2520modulators%2520of%2520G-protein-coupled%2520receptors%253A%2520drug-target%2520interactions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D1%26spage%3D24%26epage%3D45%26doi%3D10.1021%2Facs.jmedchem.7b01844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wold, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Allosteric modulation of class A GPCRs: targets, agents, and emerging concepts</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">88</span>â <span class="NLM_lpage">127</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b00875</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00875" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsV2lsLbK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=88-127&issue=1&author=E.+A.+Woldauthor=J.+Chenauthor=K.+A.+Cunninghamauthor=J.+Zhou&title=Allosteric+modulation+of+class+A+GPCRs%3A+targets%2C+agents%2C+and+emerging+concepts&doi=10.1021%2Facs.jmedchem.8b00875"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Modulation of Class A GPCRs: Targets, Agents, and Emerging Concepts</span></div><div class="casAuthors">Wold, Eric A.; Chen, Jianping; Cunningham, Kathryn A.; Zhou, Jia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">88-127</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">G-protein-coupled receptors (GPCRs) have been tractable drug targets for decades with over one-third of currently marketed drugs targeting GPCRs.  Of these, the class A GPCR superfamily is highly represented, and continued drug discovery for this family of receptors may provide novel therapeutics for a vast range of diseases.  GPCR allosteric modulation is an innovative targeting approach that broadens the available small mol. toolbox and is proving to be a viable drug discovery strategy, as evidenced by recent FDA approvals and clin. trials.  Numerous class A GPCR allosteric modulators have been discovered recently, and emerging trends such as the availability of GPCR crystal structures, diverse functional assays, and structure-based computational approaches are improving optimization and development.  This Perspective provides an update on allosterically targeted class A GPCRs and their disease indications and the medicinal chem. approaches toward novel allosteric modulators and highlights emerging trends and opportunities in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7zBEGIhRgD7Vg90H21EOLACvtfcHk0libnc81VhlgIQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsV2lsLbK&md5=c724b7cb534a9eb52c371961bb9c9b42</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00875%26sid%3Dliteratum%253Aachs%26aulast%3DWold%26aufirst%3DE.%2BA.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DAllosteric%2520modulation%2520of%2520class%2520A%2520GPCRs%253A%2520targets%252C%2520agents%252C%2520and%2520emerging%2520concepts%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D1%26spage%3D88%26epage%3D127%26doi%3D10.1021%2Facs.jmedchem.8b00875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albert, J. S.</span></span> <span> </span><span class="NLM_article-title">Pharmacological property optimization for allosteric ligands: a medicinal chemistry perspective</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2239</span>â <span class="NLM_lpage">2258</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2017.03.084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.bmcl.2017.03.084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=28408223" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtVensLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=2239-2258&issue=11&author=S.+Johnstoneauthor=J.+S.+Albert&title=Pharmacological+property+optimization+for+allosteric+ligands%3A+a+medicinal+chemistry+perspective&doi=10.1016%2Fj.bmcl.2017.03.084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective</span></div><div class="casAuthors">Johnstone, Shawn; Albert, Jeffrey S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2239-2258</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New strategies to potentially improve drug safety and efficacy emerge with allosteric programs.  Biased allosteric modulators can be designed with high subtype selectivity and defined receptor signaling endpoints, however, selecting the most meaningful parameters for optimization can be perplexing.  Historically, "potency hunting" at the expense of physicochem. and pharmacokinetic optimization has led to numerous tool compds. with excellent pharmacol. properties but no path to drug development.  Conversely, extensive physicochem. and pharmacokinetic screening with only post hoc bias and allosteric characterization has led to inefficacious compds. or compds. with on-target toxicities.  This field is rapidly evolving with new mechanistic understanding, changes in terminol., and novel opportunities.  The intent of this digest is to summarize current understanding and debates within the field.  The authors aim to discuss, from a medicinal chem. perspective, the parameter choices available to drive SAR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8rfWZTCvfzLVg90H21EOLACvtfcHk0libnc81VhlgIQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtVensLc%253D&md5=a1d1c5a8926f69c50338be012f37d8f6</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.03.084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.03.084%26sid%3Dliteratum%253Aachs%26aulast%3DJohnstone%26aufirst%3DS.%26aulast%3DAlbert%26aufirst%3DJ.%2BS.%26atitle%3DPharmacological%2520property%2520optimization%2520for%2520allosteric%2520ligands%253A%2520a%2520medicinal%2520chemistry%2520perspective%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26issue%3D11%26spage%3D2239%26epage%3D2258%26doi%3D10.1016%2Fj.bmcl.2017.03.084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burnell, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irvine, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sapkota, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jane, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monaghan, D. T.</span></span> <span> </span><span class="NLM_article-title">Positive and negative allosteric modulators of N-methyl-D-aspartate (NMDA) receptors: structure-activity relationships and mechanisms of action</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">3</span>â <span class="NLM_lpage">23</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b01640</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01640" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFCntbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3-23&issue=1&author=E.+S.+Burnellauthor=M.+Irvineauthor=G.+Fangauthor=K.+Sapkotaauthor=D.+E.+Janeauthor=D.+T.+Monaghan&title=Positive+and+negative+allosteric+modulators+of+N-methyl-D-aspartate+%28NMDA%29+receptors%3A+structure-activity+relationships+and+mechanisms+of+action&doi=10.1021%2Facs.jmedchem.7b01640"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Positive and Negative Allosteric Modulators of N-Methyl-D-aspartate (NMDA) Receptors: Structure-Activity Relationships and Mechanisms of Action</span></div><div class="casAuthors">Burnell, Erica S.; Irvine, Mark; Fang, Guangyu; Sapkota, Kiran; Jane, David E.; Monaghan, Daniel T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-23</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Excitatory activity in the CNS is predominately mediated by L-glutamate through several families of L-glutamate neurotransmitter receptors.  Of these, the N-methyl-D-aspartate receptor (NMDAR) family has many crit. roles in CNS function and in various neuropathol. and psychiatric conditions.  Until recently, the types of compds. available to regulate NMDAR function have been quite limited in terms of mechanism of action, subtype selectivity, and biol. effect.  However, several new classes of NMDAR agents have now been identified that are pos. or neg. allosteric modulators (PAMs and NAMs, resp.) with various patterns of NMDAR subtype selectivity.  These new agents act at several newly recognized binding sites on the NMDAR complex and offer significantly greater pharmacol. control over NMDAR activity than previously available agents.  The purpose of this review is to summarize the structure-activity relationships for these new NMDAR modulator drug classes and to describe the current understanding of their mechanisms of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDN2OGZJwr-LVg90H21EOLACvtfcHk0lju8gR_UjDDUA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFCntbk%253D&md5=2b9bc7f16ea2b763895334409c6beae0</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01640%26sid%3Dliteratum%253Aachs%26aulast%3DBurnell%26aufirst%3DE.%2BS.%26aulast%3DIrvine%26aufirst%3DM.%26aulast%3DFang%26aufirst%3DG.%26aulast%3DSapkota%26aufirst%3DK.%26aulast%3DJane%26aufirst%3DD.%2BE.%26aulast%3DMonaghan%26aufirst%3DD.%2BT.%26atitle%3DPositive%2520and%2520negative%2520allosteric%2520modulators%2520of%2520N-methyl-D-aspartate%2520%2528NMDA%2529%2520receptors%253A%2520structure-activity%2520relationships%2520and%2520mechanisms%2520of%2520action%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D1%26spage%3D3%26epage%3D23%26doi%3D10.1021%2Facs.jmedchem.7b01640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wold, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">GPCR allosteric modulators: mechanistic advantages and therapeutic applications</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2002</span>â <span class="NLM_lpage">2006</span>, <span class="refDoi">Â DOI: 10.2174/1568026619999190101151837</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.2174%2F1568026619999190101151837" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=2002-2006&author=E.+A.+Woldauthor=J.+Zhou&title=GPCR+allosteric+modulators%3A+mechanistic+advantages+and+therapeutic+applications&doi=10.2174%2F1568026619999190101151837"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.2174%2F1568026619999190101151837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026619999190101151837%26sid%3Dliteratum%253Aachs%26aulast%3DWold%26aufirst%3DE.%2BA.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DGPCR%2520allosteric%2520modulators%253A%2520mechanistic%2520advantages%2520and%2520therapeutic%2520applications%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2019%26volume%3D18%26spage%3D2002%26epage%3D2006%26doi%3D10.2174%2F1568026619999190101151837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haskell-Luevano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Allosteric modulators of drug targets</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">2</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b01902</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01902" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisF2rt7bE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1-2&author=C.+Haskell-Luevanoauthor=N.+A.+Meanwell&title=Allosteric+modulators+of+drug+targets&doi=10.1021%2Facs.jmedchem.8b01902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Modulators of Drug Targets</span></div><div class="casAuthors">Haskell-Luevano, Carrie; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-2</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCHCKCpbaEz7Vg90H21EOLACvtfcHk0lju8gR_UjDDUA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisF2rt7bE&md5=7b7f4bf08d95ea4a07c41633526fb654</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01902%26sid%3Dliteratum%253Aachs%26aulast%3DHaskell-Luevano%26aufirst%3DC.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DAllosteric%2520modulators%2520of%2520drug%2520targets%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1%26epage%3D2%26doi%3D10.1021%2Facs.jmedchem.8b01902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gunasekaran, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nussinov, R.</span></span> <span> </span><span class="NLM_article-title">Is allostery an intrinsic property of all dynamic proteins?</span>. <i>Proteins: Struct., Funct., Genet.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">433</span>â <span class="NLM_lpage">443</span>, <span class="refDoi">Â DOI: 10.1002/prot.20232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1002%2Fprot.20232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=15382234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BD2cXovVyjs70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2004&pages=433-443&author=K.+Gunasekaranauthor=B.+Maauthor=R.+Nussinov&title=Is+allostery+an+intrinsic+property+of+all+dynamic+proteins%3F&doi=10.1002%2Fprot.20232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Is allostery an intrinsic property of all dynamic proteins?</span></div><div class="casAuthors">Gunasekaran, K.; Ma, Buyong; Nussinov, Ruth</div><div class="citationInfo"><span class="NLM_cas:title">Proteins: Structure, Function, and Bioinformatics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">433-443</span>CODEN:
                <span class="NLM_cas:coden">PSFBAF</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review.  Allostery involves coupling of conformational changes between two widely sepd. binding sites.  The common view holds that allosteric proteins are sym. oligomers, with each subunit existing in "at least" two conformational states with a different affinity for ligands.  Recent observations such as the allosteric behavior of myoglobin, a classical example of a nonallosteric protein, call into question the existing allosteric dogma.  Here the authors argue that all (nonfibrous) proteins are potentially allosteric.  Allostery is a consequence of re-distributions of protein conformational ensembles.  In a nonallosteric protein, the binding site shape may not show a concerted second-site change and enzyme kinetics may not reflect an allosteric transition.  Nevertheless, appropriate ligands, point mutations, or external conditions may facilitate a population shift, leading a presumably nonallosteric protein to behave allosterically.  In principle, practically any potential drug binding to the protein surface can alter the conformational redistribution.  The question is its effectiveness in the redistribution of the ensemble, affecting the protein binding sites and its function.  Here, the authors review exptl. observations validating this view of protein allostery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpq3st6_arK-bVg90H21EOLACvtfcHk0lgxRyv7vi0W5w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXovVyjs70%253D&md5=dd5aeb604870f238c5ecd7bd785a8d40</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1002%2Fprot.20232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprot.20232%26sid%3Dliteratum%253Aachs%26aulast%3DGunasekaran%26aufirst%3DK.%26aulast%3DMa%26aufirst%3DB.%26aulast%3DNussinov%26aufirst%3DR.%26atitle%3DIs%2520allostery%2520an%2520intrinsic%2520property%2520of%2520all%2520dynamic%2520proteins%253F%26jtitle%3DProteins%253A%2520Struct.%252C%2520Funct.%252C%2520Genet.%26date%3D2004%26volume%3D57%26spage%3D433%26epage%3D443%26doi%3D10.1002%2Fprot.20232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nussinov, R.</span></span> <span> </span><span class="NLM_article-title">Allostery: an overview of its history, concepts, methods, and applications</span>. <i>PLoS Comput. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">e1004966</span>, <span class="refDoi">Â DOI: 10.1371/journal.pcbi.1004966</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1371%2Fjournal.pcbi.1004966" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=27253437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslWntbbJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=e1004966&issue=6&author=J.+Liuauthor=R.+Nussinov&title=Allostery%3A+an+overview+of+its+history%2C+concepts%2C+methods%2C+and+applications&doi=10.1371%2Fjournal.pcbi.1004966"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Allostery: an overview of its history, concepts, methods, and applications</span></div><div class="casAuthors">Liu, Jin; Nussinov, Ruth</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Computational Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e1004966/1-e1004966/5</span>CODEN:
                <span class="NLM_cas:coden">PCBLBG</span>;
        ISSN:<span class="NLM_cas:issn">1553-7358</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The concept of allostery has evolved in the past century.  In this Editorial, we briefly overview the history of allostery, from the pre-allostery nomenclature era starting with the Bohr effect (1904) to the birth of allostery by Monod and Jacob (1961).  We describe the evolution of the allostery concept, from a conformational change in a two-state model (1965, 1966) to dynamic allostery in the ensemble model (1999); from multi-subunit (1965) proteins to all proteins (2004).  We highlight the current available methods to study allostery and their applications in studies of conformational mechanisms, disease, and allosteric drug discovery.  We outline the challenges and future directions that we foresee.  Altogether, this Editorial narrates the history of this fundamental concept in the life sciences, its significance, methodologies to detect and predict it, and its application in a broad range of living systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUNj0xAGD3qrVg90H21EOLACvtfcHk0lgxRyv7vi0W5w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslWntbbJ&md5=1a753ef03a696bd2591eb1d7206f50d7</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1004966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1004966%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DNussinov%26aufirst%3DR.%26atitle%3DAllostery%253A%2520an%2520overview%2520of%2520its%2520history%252C%2520concepts%252C%2520methods%252C%2520and%2520applications%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2016%26volume%3D12%26issue%3D6%26spage%3De1004966%26doi%3D10.1371%2Fjournal.pcbi.1004966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nussinov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolynes, P. G.</span></span> <span> </span><span class="NLM_article-title">A second molecular biology revolution? The energy landscapes of biomolecular function</span>. <i>Phys. Chem. Chem. Phys.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">6321</span>â <span class="NLM_lpage">6322</span>, <span class="refDoi">Â DOI: 10.1039/c4cp90027h</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1039%2Fc4cp90027h" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=24608340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktV2itLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2014&pages=6321-6322&issue=14&author=R.+Nussinovauthor=P.+G.+Wolynes&title=A+second+molecular+biology+revolution%3F+The+energy+landscapes+of+biomolecular+function&doi=10.1039%2Fc4cp90027h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">A second molecular biology revolution? The energy landscapes of biomolecular function</span></div><div class="casAuthors">Nussinov, Ruth; Wolynes, Peter G.</div><div class="citationInfo"><span class="NLM_cas:title">Physical Chemistry Chemical Physics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6321-6322</span>CODEN:
                <span class="NLM_cas:coden">PPCPFQ</span>;
        ISSN:<span class="NLM_cas:issn">1463-9076</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  The free energy landscape concept has commanded the imagination of many scientists because those who have adopted and exploited it can more deeply grasp mechanisms in biol. than what can be achieved by the simple structure, function paradigm.  While X-ray structures capture snapshots from an ensemble, the changes of this ensemble under varying conditions ultimately give rise to the non-linear information flows needed for life.  By also depicting barriers between the active and inactive ensembles of states, the kinetics of information flow in the living cell can begin to be understood.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsnQ5jSrV2DbVg90H21EOLACvtfcHk0lgxRyv7vi0W5w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktV2itLo%253D&md5=ae9c01f544484a6465e0490b92dd2f91</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1039%2Fc4cp90027h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc4cp90027h%26sid%3Dliteratum%253Aachs%26aulast%3DNussinov%26aufirst%3DR.%26aulast%3DWolynes%26aufirst%3DP.%2BG.%26atitle%3DA%2520second%2520molecular%2520biology%2520revolution%253F%2520The%2520energy%2520landscapes%2520of%2520biomolecular%2520function%26jtitle%3DPhys.%2520Chem.%2520Chem.%2520Phys.%26date%3D2014%26volume%3D16%26issue%3D14%26spage%3D6321%26epage%3D6322%26doi%3D10.1039%2Fc4cp90027h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kenakin, T. P.</span></span> <i>A Pharmacology Primer</i>, <span class="NLM_edition">4th</span> ed.; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">Boston, MA</span>, <span class="NLM_year">2014</span>; Chapter 7, pp  <span class="NLM_fpage">155</span>â <span class="NLM_lpage">180</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2FB978-0-12-407663-1.00007-7" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&pages=155-180&author=T.+P.+Kenakin&title=A+Pharmacology+Primer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-407663-1.00007-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-12-407663-1.00007-7%26sid%3Dliteratum%253Aachs%26aulast%3DKenakin%26aufirst%3DT.%2BP.%26btitle%3DA%2520Pharmacology%2520Primer%26pub%3DAcademic%2520Press%26date%3D2014%26spage%3D155%26epage%3D180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Changeux, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catterall, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cidlowski, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neubig, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pin, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenakin, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehlert, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spedding, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langmead, C. J.</span></span> <span> </span><span class="NLM_article-title">International Union of Basic and Clinical Pharmacology. XC. Multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>66</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">918</span>â <span class="NLM_lpage">947</span>, <span class="refDoi">Â DOI: 10.1124/pr.114.008862</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1124%2Fpr.114.008862" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=25026896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFKht73N" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2014&pages=918-947&issue=4&author=A.+Christopoulosauthor=J.-P.+Changeuxauthor=W.+A.+Catterallauthor=D.+Fabbroauthor=T.+P.+Burrisauthor=J.+A.+Cidlowskiauthor=R.+W.+Olsenauthor=J.+A.+Petersauthor=R.+R.+Neubigauthor=J.+P.+Pinauthor=P.+M.+Sextonauthor=T.+P.+Kenakinauthor=F.+J.+Ehlertauthor=M.+Speddingauthor=C.+J.+Langmead&title=International+Union+of+Basic+and+Clinical+Pharmacology.+XC.+Multisite+pharmacology%3A+recommendations+for+the+nomenclature+of+receptor+allosterism+and+allosteric+ligands&doi=10.1124%2Fpr.114.008862"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">International Union of Basic and Clinical Pharmacology. XC. multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands</span></div><div class="casAuthors">Christopoulos, Arthur; Changeux, Jean-Pierre; Catterall, William A.; Fabbro, Doriano; Burris, Thomas P.; Cidlowski, John A.; Olsen, Richard W.; Peters, John A.; Neubig, Richard R.; Pin, Jean-Philippe; Sexton, Patrick M.; Kenakin, Terry P.; Ehlert, Frederick J.; Spedding, Michael; Langmead, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">918-947</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Allosteric interactions play vital roles in metabolic processes and signal transduction and, more recently, have become the focus of numerous pharmacol. studies because of the potential for discovering more target-selective chem. probes and therapeutic agents.  In addn. to classic early studies on enzymes, there are now examples of small mol. allosteric modulators for all superfamilies of receptors encoded by the genome, including ligand- and voltage-gated ion channels, G protein-coupled receptors, nuclear hormone receptors, and receptor tyrosine kinases.  As a consequence, a vast array of pharmacol. behaviors has been ascribed to allosteric ligands that can vary in a target-, ligand-, and cell-/tissue-dependent manner.  The current article presents an overview of allostery as applied to receptor families and approaches for detecting and validating allosteric interactions and gives recommendations for the nomenclature of allosteric ligands and their properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2h0E0L_c0J7Vg90H21EOLACvtfcHk0lhoKVWmyvG5RQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFKht73N&md5=cca779691cfc36cc3f06aaf495522c22</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1124%2Fpr.114.008862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.114.008862%26sid%3Dliteratum%253Aachs%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DChangeux%26aufirst%3DJ.-P.%26aulast%3DCatterall%26aufirst%3DW.%2BA.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DBurris%26aufirst%3DT.%2BP.%26aulast%3DCidlowski%26aufirst%3DJ.%2BA.%26aulast%3DOlsen%26aufirst%3DR.%2BW.%26aulast%3DPeters%26aufirst%3DJ.%2BA.%26aulast%3DNeubig%26aufirst%3DR.%2BR.%26aulast%3DPin%26aufirst%3DJ.%2BP.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DKenakin%26aufirst%3DT.%2BP.%26aulast%3DEhlert%26aufirst%3DF.%2BJ.%26aulast%3DSpedding%26aufirst%3DM.%26aulast%3DLangmead%26aufirst%3DC.%2BJ.%26atitle%3DInternational%2520Union%2520of%2520Basic%2520and%2520Clinical%2520Pharmacology.%2520XC.%2520Multisite%2520pharmacology%253A%2520recommendations%2520for%2520the%2520nomenclature%2520of%2520receptor%2520allosterism%2520and%2520allosteric%2520ligands%26jtitle%3DPharmacol.%2520Rev.%26date%3D2014%26volume%3D66%26issue%3D4%26spage%3D918%26epage%3D947%26doi%3D10.1124%2Fpr.114.008862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roche, D.</span>; <span class="NLM_string-name">Gil, D.</span>; <span class="NLM_string-name">Giraldo, J.</span></span> <span> </span><span class="NLM_article-title">Mathematical Modeling of G Protein-Coupled Receptor Function: What Can We Learn from Empirical and Mechanistic Models?</span> In  <i>G Protein-Coupled ReceptorsâModeling and Simulation. Advances in Experimental Medicine and Biology</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filizola, M.</span></span>, Ed.; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">Dordrecht, The Netherlands</span>, <span class="NLM_year">2014</span>. Vol.  <span class="NLM_volume">796</span>, pp  <span class="NLM_fpage">159</span>â <span class="NLM_lpage">181</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1007%2F978-94-007-7423-0_8" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&pages=159-181&author=D.+Roche&author=D.+Gil&author=J.+Giraldoauthor=M.+Filizola&title=G+Protein-Coupled+Receptors%E2%80%94Modeling+and+Simulation.+Advances+in+Experimental+Medicine+and+Biology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1007%2F978-94-007-7423-0_8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-94-007-7423-0_8%26sid%3Dliteratum%253Aachs%26aulast%3DRoche%26aufirst%3DD.%26atitle%3DMathematical%2520Modeling%2520of%2520G%2520Protein-Coupled%2520Receptor%2520Function%253A%2520What%2520Can%2520We%2520Learn%2520from%2520Empirical%2520and%2520Mechanistic%2520Models%253F%26btitle%3DG%2520Protein-Coupled%2520Receptors%25E2%2580%2594Modeling%2520and%2520Simulation.%2520Advances%2520in%2520Experimental%2520Medicine%2520and%2520Biology%26aulast%3DFilizola%26aufirst%3DM.%26pub%3DSpringer%26date%3D2014%26volume%3D796%26spage%3D159%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ehlert, F. J.</span></span> <span> </span><span class="NLM_article-title">What ligand-gated ion channels can tell us about the allosteric regulation of G protein-coupled receptors</span>. <i>Prog. Mol. Biol. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">291</span>â <span class="NLM_lpage">347</span>, <span class="refDoi">Â DOI: 10.1016/B978-0-12-394587-7.00007-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2FB978-0-12-394587-7.00007-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=23415097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotFeisLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2013&pages=291-347&author=F.+J.+Ehlert&title=What+ligand-gated+ion+channels+can+tell+us+about+the+allosteric+regulation+of+G+protein-coupled+receptors&doi=10.1016%2FB978-0-12-394587-7.00007-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">What ligand-gated ion channels can tell us about the allosteric regulation of G protein-coupled receptors</span></div><div class="casAuthors">Ehlert, Frederick J.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Molecular Biology and Translational Science</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">Oligomerization and Allosteric Modulation in G-Protein Coupled Receptors</span>),
    <span class="NLM_cas:pages">291-347</span>CODEN:
                <span class="NLM_cas:coden">PNARC5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The GABAA receptor is the target for a no. of important allosteric drugs used in medicine, including benzodiazepines and anesthetics.  These modulators have variable effects on the potency and maximal response of macroscopic currents elicited by different GABAA receptor agonists, yet this modulation is consistent with a two-state model in which the allosteric ligand has invariant affinity consts. for the active and inactive states.  Anal. of the effects of an allosteric agonist, like etomidate, on the population current provides a means of estg. the gating const. of the unliganded GABAA receptor (â¼10-4).  In contrast, allosteric interactions at the M2 muscarinic receptor are often inconsistent with a two-state model.  Analyzing allosterism within the constraints of a two-state model, nonetheless, provides an unbiased measure of probe dependence as well as clues to the mechanism of allosteric modulation.  The rather simple allosteric effect of affinity-only modulation is difficult to explain and suggests modulation of a peripheral orthosteric ligand-docking site on the M2 muscarinic receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXS4gVWfnxG7Vg90H21EOLACvtfcHk0lhoKVWmyvG5RQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotFeisLg%253D&md5=d45a6ae52edf0b68882d8ee30d7e61f4</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-394587-7.00007-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-394587-7.00007-5%26sid%3Dliteratum%253Aachs%26aulast%3DEhlert%26aufirst%3DF.%2BJ.%26atitle%3DWhat%2520ligand-gated%2520ion%2520channels%2520can%2520tell%2520us%2520about%2520the%2520allosteric%2520regulation%2520of%2520G%2520protein-coupled%2520receptors%26jtitle%3DProg.%2520Mol.%2520Biol.%2520Transl.%2520Sci.%26date%3D2013%26volume%3D115%26spage%3D291%26epage%3D347%26doi%3D10.1016%2FB978-0-12-394587-7.00007-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavana, M.</span></span> <span> </span><span class="NLM_article-title">Quantitative analysis of receptor allosterism and its implication for drug discovery</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">763</span>â <span class="NLM_lpage">780</span>, <span class="refDoi">Â DOI: 10.1517/17460441.2015.1041498</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1517%2F17460441.2015.1041498" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=25927503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVOktrnN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=763-780&issue=7&author=R.+Zhangauthor=M.+Kavana&title=Quantitative+analysis+of+receptor+allosterism+and+its+implication+for+drug+discovery&doi=10.1517%2F17460441.2015.1041498"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative analysis of receptor allosterism and its implication for drug discovery</span></div><div class="casAuthors">Zhang, Rumin; Kavana, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">763-780</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Introduction: G protein-coupled receptors represent the largest class of druggable targets and are known to be modulated by both orthosteric agonists and pos./neg. allosteric modulators (PAMs/NAMs).  Proper exptl. design and data anal. for the dose matrix between an agonist and PAM or NAM are crit. to elucidate the key parameters for understanding mol. mechanism and structure-activity relationship (SAR) in drug discovery.  Areas covered: The authors provide an overview and best practice recommendations on the quant. anal. of receptor allosterism.  The authors propose a simple classification system for receptor modulators on the basis of their efficacy and affinity modifiers.  The authors also outline the optimal assay designs for both fixed dose screening and dose matrix study of receptor modulators.  Expert opinion: The authors recommend the global curve fitting approach to reliably yield system- and modulator-specific parameters for SAR ranking.  Furthermore, the authors suggest that the uncertainty in maximal system response has insignificant impact on SAR ranking.  The authors anticipate that systems pharmacol. models integrating both binding kinetics and functional allosterism will be needed to address the inherent limitations of current allosterism models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2bd3jsIruMbVg90H21EOLACvtfcHk0lhoKVWmyvG5RQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVOktrnN&md5=f42d9d9c5fdfe97fcba484746605368d</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1517%2F17460441.2015.1041498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2015.1041498%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DKavana%26aufirst%3DM.%26atitle%3DQuantitative%2520analysis%2520of%2520receptor%2520allosterism%2520and%2520its%2520implication%2520for%2520drug%2520discovery%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2015%26volume%3D10%26issue%3D7%26spage%3D763%26epage%3D780%26doi%3D10.1517%2F17460441.2015.1041498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leach, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span> <span> </span><span class="NLM_article-title">Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">382</span>â <span class="NLM_lpage">389</span>, <span class="refDoi">Â DOI: 10.1016/j.tips.2007.06.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.tips.2007.06.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=17629965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotlWltLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2007&pages=382-389&issue=8&author=K.+Leachauthor=P.+M.+Sextonauthor=A.+Christopoulos&title=Allosteric+GPCR+modulators%3A+taking+advantage+of+permissive+receptor+pharmacology&doi=10.1016%2Fj.tips.2007.06.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology</span></div><div class="casAuthors">Leach, Katie; Sexton, Patrick M.; Christopoulos, Arthur</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">382-389</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The past decade has witnessed a dramatic increase in the identification of allosteric modulators of G-protein-coupled receptor (GPCR) activity.  Concomitantly, several new perspectives and hypotheses regarding the way ligands regulate GPCR signaling have also emerged.  Here, we briefly discuss how the concepts of collateral efficacy and permissive agonism-antagonism intersect the field of allosteric GPCR modulation.  Despite the challenges assocd. with detecting and quantifying the myriad of possible allosteric effects on GPCR activity, it is proposed that allosteric ligands offer the exciting prospect of engendering stimulus-bias in orthosteric ligand signaling, thus paving the way for not only receptor-selective but also signaling-pathway-selective therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpHb_QsIW3TbVg90H21EOLACvtfcHk0lg3if_vrIRf7g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotlWltLs%253D&md5=943da2312e7b136cb594ba0346e00301</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2007.06.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2007.06.004%26sid%3Dliteratum%253Aachs%26aulast%3DLeach%26aufirst%3DK.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DChristopoulos%26aufirst%3DA.%26atitle%3DAllosteric%2520GPCR%2520modulators%253A%2520taking%2520advantage%2520of%2520permissive%2520receptor%2520pharmacology%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2007%26volume%3D28%26issue%3D8%26spage%3D382%26epage%3D389%26doi%3D10.1016%2Fj.tips.2007.06.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K. J.</span>; <span class="NLM_string-name">Sexton, P. M.</span>; <span class="NLM_string-name">Christopoulos, A.</span></span> <span> </span><span class="NLM_article-title">Overview of receptor allosterism</span>.  <i>Current Protocols in Pharmacology</i>; <span class="NLM_publisher-name">John Wiley & Sons, Inc.</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>, <span class="NLM_year">2010</span>; Chapter 1, Unit 1.21.<span class="refDoi">Â DOI: 10.1002/0471141755.ph0121s51</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1002%2F0471141755.ph0121s51" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=K.+J.+Gregory&author=P.+M.+Sexton&author=A.+Christopoulos&title=Current+Protocols+in+Pharmacology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2F0471141755.ph0121s51&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F0471141755.ph0121s51%26sid%3Dliteratum%253Aachs%26aulast%3DGregory%26aufirst%3DK.%2BJ.%26atitle%3DOverview%2520of%2520receptor%2520allosterism%26btitle%3DCurrent%2520Protocols%2520in%2520Pharmacology%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26date%3D2010%26doi%3D10.1002%2F0471141755.ph0121s51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kenakin, T. P.</span></span> <span> </span><span class="NLM_article-title">Biased signaling and allosteric machines: new vistas and challenges for drug discovery</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>165</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1659</span>â <span class="NLM_lpage">1669</span>, <span class="refDoi">Â DOI: 10.1111/j.1476-5381.2011.01749.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1111%2Fj.1476-5381.2011.01749.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=22023017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsVKqur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2012&pages=1659-1669&issue=6&author=T.+P.+Kenakin&title=Biased+signaling+and+allosteric+machines%3A+new+vistas+and+challenges+for+drug+discovery&doi=10.1111%2Fj.1476-5381.2011.01749.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Biased signalling and allosteric machines: new vistas and challenges for drug discovery</span></div><div class="casAuthors">Kenakin, Terry P.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1659-1669</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Seven transmembrane receptors (7TMRs) are nature's prototype allosteric proteins made to bind mols. at one location to subsequently change their shape to affect the binding of another mol. at another location.  This paper attempts to describe the divergent 7TMR behaviors (i.e. 3rd party allostery, receptor oligomerization, biased agonism) obsd. in pharmacol. in terms of a homogeneous group of allosteric behaviors.  By considering the bodies involved as a vector defined by a modulator, conduit, and guest, these activities can all be described by a simple model of functional allostery made up of the Ehlert allosteric model and the Black/Leff operational model.  It will be shown how this model yields parameters that can be used to characterize the activity of any ligand or protein producing effect through allosteric interaction with a 7TMR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR5qQVOBA9jrVg90H21EOLACvtfcHk0lg3if_vrIRf7g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsVKqur4%253D&md5=8daf6ecc1de8b9a2c909d5f9c58dfb86</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01749.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01749.x%26sid%3Dliteratum%253Aachs%26aulast%3DKenakin%26aufirst%3DT.%2BP.%26atitle%3DBiased%2520signaling%2520and%2520allosteric%2520machines%253A%2520new%2520vistas%2520and%2520challenges%2520for%2520drug%2520discovery%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D165%26issue%3D6%26spage%3D1659%26epage%3D1669%26doi%3D10.1111%2Fj.1476-5381.2011.01749.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="note"><p class="first last">Simulations based on eq 1, using the following system parameters: <i>E</i><sub>m</sub> = 1000; p<i>K</i><sub>A</sub> = 5; p<i>K</i><sub>B</sub> = 7; Ï<sub>A</sub> = 0.23; Ï<sub>B</sub> = 0 (except for <i>c</i>); <i>n</i> = 1.5. Compound parameters differ for each curve as stated in text.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">WieroÅska, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zorn, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilc, A.</span></span> <span> </span><span class="NLM_article-title">Metabotropic glutamate receptors as targets for new antipsychotic drugs: historical perspective and critical comparative assessment</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">10</span>â <span class="NLM_lpage">27</span>, <span class="refDoi">Â DOI: 10.1016/j.pharmthera.2015.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.pharmthera.2015.10.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=26549541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVSks7vM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2016&pages=10-27&author=J.+M.+Wiero%C5%84skaauthor=S.+H.+Zornauthor=D.+Dollerauthor=A.+Pilc&title=Metabotropic+glutamate+receptors+as+targets+for+new+antipsychotic+drugs%3A+historical+perspective+and+critical+comparative+assessment&doi=10.1016%2Fj.pharmthera.2015.10.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Metabotropic glutamate receptors as targets for new antipsychotic drugs: Historical perspective and critical comparative assessment</span></div><div class="casAuthors">Wieronska, Joanna M.; Zorn, Stevin H.; Doller, Dario; Pilc, Andrzej</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10-27</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">In this review, we aim to present, discuss and clarify our current understanding regarding the prediction of possible antipsychotic effects of metabotropic glutamate (mGlu) receptor ligands.  The no. of preclin. trials clearly indicates, that this group of compds. constitutes an excellent alternative to presently used antipsychotic therapy, being effective not only to pos., but also neg. and cognitive symptoms of schizophrenia.  Although the results of clin. trials that were performed for the group of mGlu2/3 agonists were not so enthusiastic as in animal studies, they still showed that mGlu ligands do not induced variety of side effects typical for presently used antipsychotics, and were generally well tolerated.  The lack of satisfactory effectiveness towards schizophrenia symptoms of mGlu2/3 activators in humans could be a result of variety of uncontrolled factors and unidentified biomarkers different for each schizophrenia patient, that should be taken into consideration in the future set of clin. trials.  The subject is still open for further research, and the novel classes of mGlu5 or mGlu2/3 agonists/PAMs were recently introduced, including the large group of compds. from the third group of mGlu receptors, esp. of mGlu4 subtype.  Finally, more precise treatment based on simultaneous administration of minimal doses of the ligands for two or more receptors, seems to be promising in the context of symptoms-specific schizophrenia treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor64l-ntwmK7Vg90H21EOLACvtfcHk0lg3if_vrIRf7g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVSks7vM&md5=23b8ec790518a3ad5c92cb6c3895e618</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2015.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2015.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DWiero%25C5%2584ska%26aufirst%3DJ.%2BM.%26aulast%3DZorn%26aufirst%3DS.%2BH.%26aulast%3DDoller%26aufirst%3DD.%26aulast%3DPilc%26aufirst%3DA.%26atitle%3DMetabotropic%2520glutamate%2520receptors%2520as%2520targets%2520for%2520new%2520antipsychotic%2520drugs%253A%2520historical%2520perspective%2520and%2520critical%2520comparative%2520assessment%26jtitle%3DPharmacol.%2520Ther.%26date%3D2016%26volume%3D157%26spage%3D10%26epage%3D27%26doi%3D10.1016%2Fj.pharmthera.2015.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span> <i>GraphPad Curve
Fitting Guide</i>; <span class="NLM_publisher-name">GraphPad Software Inc.</span>, <span class="NLM_year">1995</span>; <a href="https://www.graphpad.com/guides/prism/8/pdf/Prism-8-Curve-Fitting.pdf" class="extLink">https://www.graphpad.com/guides/prism/8/pdf/Prism-8-Curve-Fitting.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+GraphPad+Curve%0AFitting+Guide%3B+GraphPad+Software+Inc.%2C+1995%3B+https%3A%2F%2Fwww.graphpad.com%2Fguides%2Fprism%2F8%2Fpdf%2FPrism-8-Curve-Fitting.pdf."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DGraphPad%2520Curve%250AFitting%2520Guide%26pub%3DGraphPad%2520Software%2520Inc%26date%3D1995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roche, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giraldo, J.</span></span> <span> </span><span class="NLM_article-title">Mechanistic analysis of the function of agonists and allosteric modulators: reconciling two-state and operational models</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>169</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1189</span>â <span class="NLM_lpage">1202</span>, <span class="refDoi">Â DOI: 10.1111/bph.12231</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1111%2Fbph.12231" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=23647200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVajsLbM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2013&pages=1189-1202&issue=6&author=D.+Rocheauthor=D.+Gilauthor=J.+Giraldo&title=Mechanistic+analysis+of+the+function+of+agonists+and+allosteric+modulators%3A+reconciling+two-state+and+operational+models&doi=10.1111%2Fbph.12231"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic analysis of the function of agonists and allosteric modulators: reconciling two-state and operational models</span></div><div class="casAuthors">Roche, David; Gil, Debora; Giraldo, Jesus</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1189-1202</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Two-state and operational models of both agonism and allosterism are compared to identify and characterize common pharmacol. parameters.  To account for the receptor-dependent basal response, constitutive receptor activity is considered in the operational models.  By arranging two-state models as the fraction of active receptors and operational models as the fractional response relative to the max. effect of the system, a one-by-one correspondence between parameters is found.  The comparative anal. allows a better understanding of complex allosteric interactions.  In particular, the inclusion of constitutive receptor activity in the operational model of allosterism allows the characterization of modulators able to lower the basal response of the system; i.e., allosteric modulators with neg. intrinsic efficacy.  Theor. simulations and overall goodness of fit of the models to simulated data suggest that it is feasible to apply the models to exptl. data and constitute one step forward in receptor theory formalism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqglhnNGCZeqbVg90H21EOLACvtfcHk0ljxn5X4ASBCsg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVajsLbM&md5=fae7e9e8032a0c4c66a44de4d8ee35bb</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1111%2Fbph.12231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12231%26sid%3Dliteratum%253Aachs%26aulast%3DRoche%26aufirst%3DD.%26aulast%3DGil%26aufirst%3DD.%26aulast%3DGiraldo%26aufirst%3DJ.%26atitle%3DMechanistic%2520analysis%2520of%2520the%2520function%2520of%2520agonists%2520and%2520allosteric%2520modulators%253A%2520reconciling%2520two-state%2520and%2520operational%2520models%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D169%26issue%3D6%26spage%3D1189%26epage%3D1202%26doi%3D10.1111%2Fbph.12231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hall, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Provins, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valade, A.</span></span> <span> </span><span class="NLM_article-title">Novel strategies to activate the dopamine D1 receptor: recent advances in orthosteric agonism and positive allosteric modulation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">128</span>â <span class="NLM_lpage">140</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b01767</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01767" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVKrsbjK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=128-140&issue=1&author=A.+Hallauthor=L.+Provinsauthor=A.+Valade&title=Novel+strategies+to+activate+the+dopamine+D1+receptor%3A+recent+advances+in+orthosteric+agonism+and+positive+allosteric+modulation&doi=10.1021%2Facs.jmedchem.8b01767"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Strategies To Activate the Dopamine D1 Receptor: Recent Advances in Orthosteric Agonism and Positive Allosteric Modulation</span></div><div class="casAuthors">Hall, Adrian; Provins, Laurent; Valade, Anne</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">128-140</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The five dopamine receptor subtypes (D1-5) are activated by the endogenous catecholamine dopamine.  Sustained research has sought to identify selective ligands for receptor subtypes.  In particular, activation of the D1 receptor has attracted attention due to its promising role in neurol. diseases.  Initial attempts to identify agonists yielded catechol derivs., mimicking dopamine, with suboptimal DMPK parameters and low selectivity over the D5 subtype.  However, more recent efforts to identify ligands capable of activating the D1 receptor have made substantial progress with the identification of non-catechol agonists with suitable properties to progress to clin. studies.  In addn., several research groups have identified pos. allosteric modulators that offer new potential.  Furthermore, structural studies have surprisingly uncovered two potential allosteric binding sites, the most characterized of which appears to be on intracellular loop 2 (ICL2).  This review highlights the recent progress in the field, covering both orthosteric and allosteric modes of activation, discusses the elucidation of the allosteric binding sites, and summarizes the clin. development status of various compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnfHl8QabACrVg90H21EOLACvtfcHk0ljxn5X4ASBCsg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVKrsbjK&md5=54aa53ee35e7c625f8265edad7eab804</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01767%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DA.%26aulast%3DProvins%26aufirst%3DL.%26aulast%3DValade%26aufirst%3DA.%26atitle%3DNovel%2520strategies%2520to%2520activate%2520the%2520dopamine%2520D1%2520receptor%253A%2520recent%2520advances%2520in%2520orthosteric%2520agonism%2520and%2520positive%2520allosteric%2520modulation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D1%26spage%3D128%26epage%3D140%26doi%3D10.1021%2Facs.jmedchem.8b01767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunihan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gentles, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beno, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrante, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendricson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knox, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molski, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cvijic, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockwell, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weed, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cacace, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westphal, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of D1 dopamine receptor positive allosteric modulators: characterization of pharmacology and identification of residues that regulate species selectivity</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>354</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">340</span>â <span class="NLM_lpage">349</span>, <span class="refDoi">Â DOI: 10.1124/jpet.115.224071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1124%2Fjpet.115.224071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=26109678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Ols7fJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=354&publication_year=2015&pages=340-349&issue=3&author=M.+A.+Lewisauthor=L.+Hunihanauthor=J.+Watsonauthor=R.+G.+Gentlesauthor=S.+Huauthor=Y.+Huangauthor=J.+Bronsonauthor=J.+E.+Macorauthor=B.+R.+Benoauthor=M.+Ferranteauthor=A.+Hendricsonauthor=R.+J.+Knoxauthor=T.+F.+Molskiauthor=Y.+Kongauthor=M.+E.+Cvijicauthor=K.+L.+Rockwellauthor=M.+R.+Weedauthor=A.+M.+Cacaceauthor=R.+S.+Westphalauthor=A.+Altauthor=J.+M.+Brown&title=Discovery+of+D1+dopamine+receptor+positive+allosteric+modulators%3A+characterization+of+pharmacology+and+identification+of+residues+that+regulate+species+selectivity&doi=10.1124%2Fjpet.115.224071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of D1 dopamine receptor positive allosteric modulators: characterization of pharmacology and identification of residues that regulate species selectivity</span></div><div class="casAuthors">Lewis, Martin A.; Hunihan, Lisa; Watson, John; Gentles, Robert G.; Hu, Shuanghua; Huang, Yazhong; Bronson, Joanne; Macor, John E.; Beno, Brett R.; Ferrante, Meredith; Hendricson, Adam; Knox, Ronald J.; Molski, Thaddeus F.; Kong, Yan; Cvijic, Mary Ellen; Rockwell, Kristin L.; Weed, Michael R.; Cacace, Angela M.; Westphal, Ryan S.; Alt, Andrew; Brown, Jeffrey M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">354</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">340-349</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The present studies represent the first published report of a dopamine D1 pos. allosteric modulator (PAM).  D1 receptors have been proposed as a therapeutic target for the treatment of cognitive deficits assocd. with schizophrenia.  However, the clin. utility of orthosteric agonist compds. is limited by cardiovascular side effects, poor pharmacokinetics, lack of D1 selectivity, and an inverted dose response.  A no. of these challenges may be overcome by utilization of a selective D1 PAM.  The current studies describe two chem. distinct D1 PAMs: Compd. A [1-((rel-1S,3R,6R)-6-(benzo[d][1,3]dioxol-5-yl)bicyclo[4.1.0]heptan-3-yl)-4-(2-bromo-5-chlorobenzyl)piperazine] and Compd. B [rel-(9R,10R,12S)-N-(2,6-dichloro-3-methylphenyl)-12-methyl-9,10-dihydro-9,10-ethanoanthracene-12-carboxamide].  Compd. A shows pure PAM activity, with an EC50 of 230 nM and agonist activity at the D2 receptor in D2-expressing human embryonic kidney cells.  Compd. B shows superior potency (EC50 of 43 nM) and selectivity for D1 vs. D2 dopamine receptors.  Unlike Compd. A, Compd. B is selective for human and nonhuman primate D1 receptors, but lacks activity at the rodent (rat and mouse) D1 receptors.  Using mol. biol. techniques, a single amino acid was identified at position 130, which mediates the species selectivity of Compd. B.  These data represent the first described D1-selective PAMs and define crit. amino acids that regulate species selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDNdz5evIitLVg90H21EOLACvtfcHk0li_3xtKz0G57g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Ols7fJ&md5=65b8c08ed7f8af31822c15ce662e5724</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1124%2Fjpet.115.224071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.115.224071%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DM.%2BA.%26aulast%3DHunihan%26aufirst%3DL.%26aulast%3DWatson%26aufirst%3DJ.%26aulast%3DGentles%26aufirst%3DR.%2BG.%26aulast%3DHu%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DBronson%26aufirst%3DJ.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26aulast%3DBeno%26aufirst%3DB.%2BR.%26aulast%3DFerrante%26aufirst%3DM.%26aulast%3DHendricson%26aufirst%3DA.%26aulast%3DKnox%26aufirst%3DR.%2BJ.%26aulast%3DMolski%26aufirst%3DT.%2BF.%26aulast%3DKong%26aufirst%3DY.%26aulast%3DCvijic%26aufirst%3DM.%2BE.%26aulast%3DRockwell%26aufirst%3DK.%2BL.%26aulast%3DWeed%26aufirst%3DM.%2BR.%26aulast%3DCacace%26aufirst%3DA.%2BM.%26aulast%3DWestphal%26aufirst%3DR.%2BS.%26aulast%3DAlt%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DJ.%2BM.%26atitle%3DDiscovery%2520of%2520D1%2520dopamine%2520receptor%2520positive%2520allosteric%2520modulators%253A%2520characterization%2520of%2520pharmacology%2520and%2520identification%2520of%2520residues%2520that%2520regulate%2520species%2520selectivity%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D354%26issue%3D3%26spage%3D340%26epage%3D349%26doi%3D10.1124%2Fjpet.115.224071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Svensson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinz, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaus, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krushinski, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhard, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellman, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getman, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menezes, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maren, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falcone, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morin, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knopp, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogovoy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okun, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suter, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Statnick, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehlert, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucaites, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emkey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeLapp, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiernicki, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cramer, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruns, R. F.</span></span> <span> </span><span class="NLM_article-title">An allosteric potentiator of the dopamine D1 receptor increases locomotor activity in human D1 knock-in mice without causing stereotypy or tachyphylaxis</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>360</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">117</span>â <span class="NLM_lpage">128</span>, <span class="refDoi">Â DOI: 10.1124/jpet.116.236372</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1124%2Fjpet.116.236372" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=27811173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2sXptVOjsbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=360&publication_year=2017&pages=117-128&issue=1&author=K.+A.+Svenssonauthor=B.+A.+Heinzauthor=J.+M.+Schausauthor=J.+P.+Beckauthor=J.+Haoauthor=J.+H.+Krushinskiauthor=M.+R.+Reinhardauthor=M.+P.+Cohenauthor=S.+L.+Hellmanauthor=B.+G.+Getmanauthor=X.+Wangauthor=M.+M.+Menezesauthor=D.+L.+Marenauthor=J.+F.+Falconeauthor=W.+H.+Andersonauthor=R.+A.+Wrightauthor=S.+M.+Morinauthor=K.+L.+Knoppauthor=B.+L.+Adamsauthor=B.+Rogovoyauthor=I.+Okunauthor=T.+M.+Suterauthor=M.+A.+Statnickauthor=D.+R.+Gehlertauthor=D.+L.+Nelsonauthor=V.+L.+Lucaitesauthor=R.+Emkeyauthor=N.+W.+DeLappauthor=T.+R.+Wiernickiauthor=J.+W.+Cramerauthor=C.+R.+Yangauthor=R.+F.+Bruns&title=An+allosteric+potentiator+of+the+dopamine+D1+receptor+increases+locomotor+activity+in+human+D1+knock-in+mice+without+causing+stereotypy+or+tachyphylaxis&doi=10.1124%2Fjpet.116.236372"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">An allosteric potentiator of the dopamine D1 receptor increases locomotor activity in human D1 knock-in mice without causing stereotypy or tachyphylaxis</span></div><div class="casAuthors">Svensson, Kjell A.; Heinz, Beverly A.; Schaus, John M.; Beck, James P.; Hao, Junliang; Krushinski, Joseph H.; Reinhard, Matthew R.; Cohen, Michael P.; Hellman, Sarah L.; Getman, Brian G.; Wang, Xushan; Menezes, Michelle M.; Maren, Deanna L.; Falcone, Julie F.; Anderson, Wesley H.; Wright, Rebecca A.; Morin, S. Michelle; Knopp, Kelly L.; Adams, Benjamin L.; Rogovoy, Borys; Okun, Ilya; Suter, Todd M.; Statnick, Michael A.; Gehlert, Donald R.; Nelson, David L.; Lucaites, Virginia L.; Emkey, Renee; DeLapp, Neil W.; Wiernicki, Todd R.; Cramer, Jeffrey W.; Yang, Charles R.; Bruns, Robert F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">360</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">117-128</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Allosteric potentiators amplify the sensitivity of physiol. control circuits, a mode of action that could provide therapeutic advantages.  This hypothesis was tested with the dopamine D1 receptor potentiator DETQ [2-(2,6-dichlorophenyl)-1-((1S,3R)-3-(hydroxymethyl)-5-(2-hydroxypropan-2-yl)-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one].  In human embryonic kidney 293 (HEK293) cells expressing the human D1 receptor, DETQ induced a 21-fold leftward shift in the cAMP response to dopamine, with a Kb of 26 nM.  The max. response to DETQ alone was â¼12% of the max. response to dopamine, suggesting weak allosteric agonist activity.  DETQ was â¼30-fold less potent at rat and mouse D1 receptors and was inactive at the human D5 receptor.  To enable studies in rodents, an hD1 knock-in mouse was generated.  DETQ (3-20 mg/kg orally) caused a robust (â¼10-fold) increase in locomotor activity (LMA) in habituated hD1 mice but was inactive in wild-type mice.  The LMA response to DETQ was blocked by the D1 antagonist SCH39166 and was dependent on endogenous dopamine.  LMA reached a plateau at higher doses (30-240 mg/kg) even though free brain levels of DETQ continued to increase over the entire dose range.  In contrast, the D1 agonists SKF 82958, A-77636, and dihydrexidine showed bell-shaped dose-response curves with a profound redn. in LMA at higher doses; video-tracking confirmed that the redn. in LMA caused by SKF 82958 was due to competing stereotyped behaviors.  When dosed daily for 4 days, DETQ continued to elicit an increase in LMA, whereas the D1 agonist A-77636 showed complete tachyphylaxis by day 2.  These results confirm that allosteric potentiators may have advantages compared with direct-acting agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrslzO-nYslkLVg90H21EOLACvtfcHk0li_3xtKz0G57g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXptVOjsbg%253D&md5=3c9777e82d3ba85fa9f2ac40b8f4437b</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1124%2Fjpet.116.236372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.116.236372%26sid%3Dliteratum%253Aachs%26aulast%3DSvensson%26aufirst%3DK.%2BA.%26aulast%3DHeinz%26aufirst%3DB.%2BA.%26aulast%3DSchaus%26aufirst%3DJ.%2BM.%26aulast%3DBeck%26aufirst%3DJ.%2BP.%26aulast%3DHao%26aufirst%3DJ.%26aulast%3DKrushinski%26aufirst%3DJ.%2BH.%26aulast%3DReinhard%26aufirst%3DM.%2BR.%26aulast%3DCohen%26aufirst%3DM.%2BP.%26aulast%3DHellman%26aufirst%3DS.%2BL.%26aulast%3DGetman%26aufirst%3DB.%2BG.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DMenezes%26aufirst%3DM.%2BM.%26aulast%3DMaren%26aufirst%3DD.%2BL.%26aulast%3DFalcone%26aufirst%3DJ.%2BF.%26aulast%3DAnderson%26aufirst%3DW.%2BH.%26aulast%3DWright%26aufirst%3DR.%2BA.%26aulast%3DMorin%26aufirst%3DS.%2BM.%26aulast%3DKnopp%26aufirst%3DK.%2BL.%26aulast%3DAdams%26aufirst%3DB.%2BL.%26aulast%3DRogovoy%26aufirst%3DB.%26aulast%3DOkun%26aufirst%3DI.%26aulast%3DSuter%26aufirst%3DT.%2BM.%26aulast%3DStatnick%26aufirst%3DM.%2BA.%26aulast%3DGehlert%26aufirst%3DD.%2BR.%26aulast%3DNelson%26aufirst%3DD.%2BL.%26aulast%3DLucaites%26aufirst%3DV.%2BL.%26aulast%3DEmkey%26aufirst%3DR.%26aulast%3DDeLapp%26aufirst%3DN.%2BW.%26aulast%3DWiernicki%26aufirst%3DT.%2BR.%26aulast%3DCramer%26aufirst%3DJ.%2BW.%26aulast%3DYang%26aufirst%3DC.%2BR.%26aulast%3DBruns%26aufirst%3DR.%2BF.%26atitle%3DAn%2520allosteric%2520potentiator%2520of%2520the%2520dopamine%2520D1%2520receptor%2520increases%2520locomotor%2520activity%2520in%2520human%2520D1%2520knock-in%2520mice%2520without%2520causing%2520stereotypy%2520or%2520tachyphylaxis%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2017%26volume%3D360%26issue%3D1%26spage%3D117%26epage%3D128%26doi%3D10.1124%2Fjpet.116.236372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruns, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wafford, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanks, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâNeill, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastwood, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaus, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witkin, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chernet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katner, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryder, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masquelin, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Love, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maren, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falcone, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menezes, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svensson, K. A.</span></span> <span> </span><span class="NLM_article-title">Preclinical profile of a dopamine D1 potentiator suggests therapeutic utility in neurological and psychiatric disorders</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">351</span>â <span class="NLM_lpage">365</span>, <span class="refDoi">Â DOI: 10.1016/j.neuropharm.2017.10.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.neuropharm.2017.10.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=29102759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslygs7jN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2018&pages=351-365&author=R.+F.+Brunsauthor=S.+N.+Mitchellauthor=K.+A.+Waffordauthor=A.+J.+Harperauthor=E.+A.+Shanksauthor=G.+Carterauthor=M.+J.+O%E2%80%99Neillauthor=T.+K.+Murrayauthor=B.+J.+Eastwoodauthor=J.+M.+Schausauthor=J.+P.+Beckauthor=J.+Haoauthor=J.+M.+Witkinauthor=X.+Liauthor=E.+Chernetauthor=J.+S.+Katnerauthor=H.+Wangauthor=J.+W.+Ryderauthor=M.+E.+Masquelinauthor=L.+K.+Thompsonauthor=P.+L.+Loveauthor=D.+L.+Marenauthor=J.+F.+Falconeauthor=M.+M.+Menezesauthor=L.+Zhangauthor=C.+R.+Yangauthor=K.+A.+Svensson&title=Preclinical+profile+of+a+dopamine+D1+potentiator+suggests+therapeutic+utility+in+neurological+and+psychiatric+disorders&doi=10.1016%2Fj.neuropharm.2017.10.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical profile of a dopamine D1 potentiator suggests therapeutic utility in neurological and psychiatric disorders</span></div><div class="casAuthors">Bruns, Robert F.; Mitchell, Stephen N.; Wafford, Keith A.; Harper, Alex J.; Shanks, Elaine A.; Carter, Guy; O'Neill, Michael J.; Murray, Tracey K.; Eastwood, Brian J.; Schaus, John M.; Beck, James P.; Hao, Junliang; Witkin, Jeffrey M.; Li, Xia; Chernet, Eyassu; Katner, Jason S.; Wang, Hong; Ryder, John W.; Masquelin, Meghane E.; Thompson, Linda K.; Love, Patrick L.; Maren, Deanna L.; Falcone, Julie F.; Menezes, Michelle M.; Zhang, Linli; Yang, Charles R.; Svensson, Kjell A.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">351-365</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">DETQ, an allosteric potentiator of the dopamine D1 receptor, was tested in therapeutic models that were known to respond to D1 agonists.  Because of a species difference in affinity for DETQ, all rodent expts. used transgenic mice expressing the human D1 receptor (hD1 mice).  When given alone, DETQ reversed the locomotor depression caused by a low dose of reserpine.  DETQ also acted synergistically with L-DOPA to reverse the strong hypokinesia seen with a higher dose of reserpine.  These results indicate potential as both monotherapy and adjunct treatment in Parkinson's disease.  DETQ markedly increased release of both acetylcholine and histamine in the prefrontal cortex, and increased levels of histamine metabolites in the striatum.  In the hippocampus, the combination of DETQ and the cholinesterase inhibitor rivastigmine increased ACh to a greater degree than either agent alone.  DETQ also increased phosphorylation of the AMPA receptor (GluR1) and the transcription factor CREB in the striatum, consistent with enhanced synaptic plasticity.  In the Y-maze, DETQ increased arm entries but (unlike a D1 agonist) did not reduce spontaneous alternation between arms at high doses.  DETQ enhanced wakefulness in EEG studies in hD1 mice and decreased immobility in the forced-swim test, a model for antidepressant-like activity.  In rhesus monkeys, DETQ increased spontaneous eye-blink rate, a measure that is known to be depressed in Parkinson's disease.  Together, these results provide support for potential utility of D1 potentiators in the treatment of several neuropsychiatric disorders, including Parkinson's disease, Alzheimer's disease, cognitive impairment in schizophrenia, and major depressive disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbYbhSCBxGE7Vg90H21EOLACvtfcHk0li_3xtKz0G57g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslygs7jN&md5=4d7d7fb8c685b303b53ff90b7cd32b52</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2017.10.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2017.10.032%26sid%3Dliteratum%253Aachs%26aulast%3DBruns%26aufirst%3DR.%2BF.%26aulast%3DMitchell%26aufirst%3DS.%2BN.%26aulast%3DWafford%26aufirst%3DK.%2BA.%26aulast%3DHarper%26aufirst%3DA.%2BJ.%26aulast%3DShanks%26aufirst%3DE.%2BA.%26aulast%3DCarter%26aufirst%3DG.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DM.%2BJ.%26aulast%3DMurray%26aufirst%3DT.%2BK.%26aulast%3DEastwood%26aufirst%3DB.%2BJ.%26aulast%3DSchaus%26aufirst%3DJ.%2BM.%26aulast%3DBeck%26aufirst%3DJ.%2BP.%26aulast%3DHao%26aufirst%3DJ.%26aulast%3DWitkin%26aufirst%3DJ.%2BM.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DChernet%26aufirst%3DE.%26aulast%3DKatner%26aufirst%3DJ.%2BS.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DRyder%26aufirst%3DJ.%2BW.%26aulast%3DMasquelin%26aufirst%3DM.%2BE.%26aulast%3DThompson%26aufirst%3DL.%2BK.%26aulast%3DLove%26aufirst%3DP.%2BL.%26aulast%3DMaren%26aufirst%3DD.%2BL.%26aulast%3DFalcone%26aufirst%3DJ.%2BF.%26aulast%3DMenezes%26aufirst%3DM.%2BM.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DC.%2BR.%26aulast%3DSvensson%26aufirst%3DK.%2BA.%26atitle%3DPreclinical%2520profile%2520of%2520a%2520dopamine%2520D1%2520potentiator%2520suggests%2520therapeutic%2520utility%2520in%2520neurological%2520and%2520psychiatric%2520disorders%26jtitle%3DNeuropharmacology%26date%3D2018%26volume%3D128%26spage%3D351%26epage%3D365%26doi%3D10.1016%2Fj.neuropharm.2017.10.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huryn, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosford, N. D. P.</span></span> <span> </span><span class="NLM_article-title">The molecular libraries screening center network (MLSCN): identifying chemical probes of biological systems</span>. <i>Annu. Rep. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">401</span>â <span class="NLM_lpage">416</span>, <span class="refDoi">Â DOI: 10.1016/S0065-7743(07)42026-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2FS0065-7743%2807%2942026-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BD1cXksFOgsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2007&pages=401-416&author=D.+M.+Hurynauthor=N.+D.+P.+Cosford&title=The+molecular+libraries+screening+center+network+%28MLSCN%29%3A+identifying+chemical+probes+of+biological+systems&doi=10.1016%2FS0065-7743%2807%2942026-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">The molecular libraries screening center network (MLSCN): identifying chemical probes of biological systems</span></div><div class="casAuthors">Huryn, Donna M.; Cosford, Nicholas D. P.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Reports in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">401-416</span>CODEN:
                <span class="NLM_cas:coden">ARMCBI</span>;
        ISSN:<span class="NLM_cas:issn">0065-7743</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The NIH Mol. Libraries Screening Center Network (MLSCN) is a subset of the Mol. Libraries Initiative (MLI) component of the NIH Roadmap for Medical Research.  It consists of a consortium of 10 centers, each having expertise in assay development, high-throughput screening (HTS), chem. and informatics.  Using a centralized screening library of approx. 100,000 small mols. and assays from the research community, scientists at each center optimize assays, carry out high-throughput screens, and deposit the results into PubChem.  Based on the data from those assays, chemists at each center further optimize the initial hits in order to develop unique, small mol. probes of biol. systems.  Informaticists contribute to data handling and anal. throughout this process.  The chem. probes developed are available to researchers (both public and private sectors) via data deposition into PubChem, and in the future, via access to samples and synthetic protocols to prep. the probes.  These efforts support the ultimate goals of the MLSCN and the MLI, which is to "expand the availability, flexibility, and use of small-mol. chem. probes for basic research".  The completion of the human genome project, a coordinated effort between government, academia, and industry, has prompted a vast expanse of medical research focused on the understanding of the fundamental causes of human disease.  The Mol. Libraries and Imaging initiative is a natural extension of that ground-breaking effort.  By providing access to assays, HTS capabilities, small mol. libraries and chem. optimization expertise, novel chem. probes are being developed that will allow the study of gene function, biochem. pathways, and cellular biol.  It is also possible that through this initiative, starting points for new drugs, particularly of rare diseases, will be identified.  The data deposited into PubChem via this effort will also serve as an unprecedented source of information for scientists in all biomedical disciplines.  The availability of large datasets of biol. activity on a common set of compds. should serve to stimulate advances in computational and predictive models of biol. activities and chem. properties.  This dataset should also expedite biomedical research through its use to evaluate selectivity, toxicity, and off-target activities of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJo-AOD73gmLVg90H21EOLACvtfcHk0ljkLiqwyvC9gA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXksFOgsw%253D%253D&md5=8c3b1d51eb5b11b0cc8631dc23665d58</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2FS0065-7743%2807%2942026-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-7743%252807%252942026-7%26sid%3Dliteratum%253Aachs%26aulast%3DHuryn%26aufirst%3DD.%2BM.%26aulast%3DCosford%26aufirst%3DN.%2BD.%2BP.%26atitle%3DThe%2520molecular%2520libraries%2520screening%2520center%2520network%2520%2528MLSCN%2529%253A%2520identifying%2520chemical%2520probes%2520of%2520biological%2520systems%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2007%26volume%3D42%26spage%3D401%26epage%3D416%26doi%3D10.1016%2FS0065-7743%2807%2942026-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luderman, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conroy, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Free, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Southall, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Soto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moritz, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willette, B. K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fyfe, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Titus, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazelwood, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">AubÃ©, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frankowski, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span> <span> </span><span class="NLM_article-title">Identification of positive allosteric modulators of the D1 dopamine receptor that act at diverse binding sites</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>94</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1197</span>â <span class="NLM_lpage">1209</span>, <span class="refDoi">Â DOI: 10.1124/mol.118.113175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1124%2Fmol.118.113175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=30068735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVGgt7fM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2018&pages=1197-1209&issue=4&author=K.+D.+Ludermanauthor=J.+L.+Conroyauthor=R.+B.+Freeauthor=N.+Southallauthor=M.+Ferrerauthor=M.+Sanchez-Sotoauthor=A.+E.+Moritzauthor=B.+K.+A.+Willetteauthor=T.+J.+Fyfeauthor=P.+Jainauthor=S.+Titusauthor=L.+A.+Hazelwoodauthor=J.+Aub%C3%A9author=J.+R.+Laneauthor=K.+J.+Frankowskiauthor=D.+R.+Sibley&title=Identification+of+positive+allosteric+modulators+of+the+D1+dopamine+receptor+that+act+at+diverse+binding+sites&doi=10.1124%2Fmol.118.113175"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of positive allosteric modulators of the D1 dopamine receptor that act at diverse binding sites</span></div><div class="casAuthors">Luderman, Kathryn D.; Conroy, Jennie L.; Free, R. Benjamin; Southall, Noel; Ferrer, Marc; Sanchez-Soto, Marta; Moritz, Amy E.; Willette, Blair K. A.; Fyfe, Tim J.; Jain, Prashi; Titus, Steve; Hazelwood, Lisa A.; Aube, Jeffrey; Lane, J. Robert; Frankowski, Kevin J.; Sibley, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1197-1209</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The D1 dopamine receptor is linked to a variety of neuropsychiatric disorders and represents an attractive drug target for the enhancement of cognition in schizophrenia, Alzheimer disease, and other disorders.  Pos. allosteric modulators (PAMs), with their potential for greater selectivity and larger therapeutic windows, may represent a viable drug development strategy, as orthosteric D1 receptor agonists possess known clin. liabilities.  We discovered two structurally distinct D1 receptor PAMs, MLS6585 and MLS1082, via a high-throughput screen of the NIH Mol. Libraries program small-mol. library.  Both compds. potentiate dopamine-stimulated G protein- and Î²-arrestin-mediated signaling and increase the affinity of dopamine for the D1 receptor with low micromolar potencies.  Neither compd. displayed any intrinsic agonist activity.  Both compds. were also found to potentiate the efficacy of partial agonists.  We tested maximally effective concns. of each PAM in combination to det. if the compds. might act at sep. or similar sites.  In combination, MLS1082 + MLS6585 produced an additive potentiation of dopamine potency beyond that caused by either PAM alone for both Î²-arrestin recruitment and cAMP accumulation, suggesting diverse sites of action.  In addn., MLS6585, but not MLS1082, had additive activity with the previously described D1 receptor PAM "Compd. B," suggesting that MLS1082 and Compd. B may share a common binding site.  A point mutation (R130Q) in the D1 receptor was found to abrogate MLS1082 activity without affecting that of MLS6585, suggesting this residue may be involved in the binding/activity of MLS1082 but not that of MLS6585.  Together, MLS1082 and MLS6585 may serve as important tool compds. for the characterization of diverse allosteric sites on the D1 receptor as well as the development of optimized lead compds. for therapeutic use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFUUoar8r06LVg90H21EOLACvtfcHk0ljkLiqwyvC9gA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVGgt7fM&md5=6d87d7a6fe63049c6fe61ff342f5c897</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1124%2Fmol.118.113175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.118.113175%26sid%3Dliteratum%253Aachs%26aulast%3DLuderman%26aufirst%3DK.%2BD.%26aulast%3DConroy%26aufirst%3DJ.%2BL.%26aulast%3DFree%26aufirst%3DR.%2BB.%26aulast%3DSouthall%26aufirst%3DN.%26aulast%3DFerrer%26aufirst%3DM.%26aulast%3DSanchez-Soto%26aufirst%3DM.%26aulast%3DMoritz%26aufirst%3DA.%2BE.%26aulast%3DWillette%26aufirst%3DB.%2BK.%2BA.%26aulast%3DFyfe%26aufirst%3DT.%2BJ.%26aulast%3DJain%26aufirst%3DP.%26aulast%3DTitus%26aufirst%3DS.%26aulast%3DHazelwood%26aufirst%3DL.%2BA.%26aulast%3DAub%25C3%25A9%26aufirst%3DJ.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26aulast%3DFrankowski%26aufirst%3DK.%2BJ.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26atitle%3DIdentification%2520of%2520positive%2520allosteric%2520modulators%2520of%2520the%2520D1%2520dopamine%2520receptor%2520that%2520act%2520at%2520diverse%2520binding%2520sites%26jtitle%3DMol.%2520Pharmacol.%26date%3D2018%26volume%3D94%26issue%3D4%26spage%3D1197%26epage%3D1209%26doi%3D10.1124%2Fmol.118.113175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burford, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livingston, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canals, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budenholzer, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâConnell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banks, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filizola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassoni, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehrman, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerritz, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alt, A.</span></span> <span> </span><span class="NLM_article-title">Discovery, synthesis, and molecular pharmacology of selective positive allosteric modulators of the Î´-opioid receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4220</span>â <span class="NLM_lpage">4229</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00007</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00007" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmvVyms70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4220-4229&issue=10&author=N.+T.+Burfordauthor=K.+E.+Livingstonauthor=M.+Canalsauthor=M.+R.+Ryanauthor=L.+M.+Budenholzerauthor=Y.+Hanauthor=Y.+Shangauthor=J.+J.+Herbstauthor=J.+O%E2%80%99Connellauthor=M.+Banksauthor=L.+Zhangauthor=M.+Filizolaauthor=D.+L.+Bassoniauthor=T.+S.+Wehrmanauthor=A.+Christopoulosauthor=J.+R.+Traynorauthor=S.+W.+Gerritzauthor=A.+Alt&title=Discovery%2C+synthesis%2C+and+molecular+pharmacology+of+selective+positive+allosteric+modulators+of+the+%CE%B4-opioid+receptor&doi=10.1021%2Facs.jmedchem.5b00007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery, Synthesis, and Molecular Pharmacology of Selective Positive Allosteric Modulators of the Î´-Opioid Receptor</span></div><div class="casAuthors">Burford, Neil T.; Livingston, Kathryn E.; Canals, Meritxell; Ryan, Molly R.; Budenholzer, Lauren M. L.; Han, Ying; Shang, Yi; Herbst, John J.; O'Connell, Jonathan; Banks, Martyn; Zhang, Litao; Filizola, Marta; Bassoni, Daniel L.; Wehrman, Tom S.; Christopoulos, Arthur; Traynor, John R.; Gerritz, Samuel W.; Alt, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4220-4229</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Allosteric modulators of G protein-coupled receptors (GPCRs) have a no. of potential advantages compared to agonists or antagonists that bind to the orthosteric site of the receptor.  These include the potential for receptor selectivity, maintenance of the temporal and spatial fidelity of signaling in vivo, the ceiling effect of the allosteric cooperativity which may prevent overdose issues, and engendering bias by differentially modulating distinct signaling pathways.  Here we describe the discovery, synthesis, and mol. pharmacol. of Î´-opioid receptor-selective pos. allosteric modulators (Î´ PAMs).  These Î´ PAMs increase the affinity and/or efficacy of the orthosteric agonists leu-enkephalin, SNC80 and TAN67, as measured by receptor binding, G protein activation, Î²-arrestin recruitment, adenylyl cyclase inhibition, and extracellular signal-regulated kinases (ERK) activation.  As such, these compds. are useful pharmacol. tools to probe the mol. pharmacol. of the Î´ receptor and to explore the therapeutic potential of Î´ PAMs in diseases such as chronic pain and depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqp9cc465_u0bVg90H21EOLACvtfcHk0lg4bQ0z8t4zKA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmvVyms70%253D&md5=3019381e050f2928f244954fa7d2bd46</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00007%26sid%3Dliteratum%253Aachs%26aulast%3DBurford%26aufirst%3DN.%2BT.%26aulast%3DLivingston%26aufirst%3DK.%2BE.%26aulast%3DCanals%26aufirst%3DM.%26aulast%3DRyan%26aufirst%3DM.%2BR.%26aulast%3DBudenholzer%26aufirst%3DL.%2BM.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DShang%26aufirst%3DY.%26aulast%3DHerbst%26aufirst%3DJ.%2BJ.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DJ.%26aulast%3DBanks%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DFilizola%26aufirst%3DM.%26aulast%3DBassoni%26aufirst%3DD.%2BL.%26aulast%3DWehrman%26aufirst%3DT.%2BS.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26aulast%3DGerritz%26aufirst%3DS.%2BW.%26aulast%3DAlt%26aufirst%3DA.%26atitle%3DDiscovery%252C%2520synthesis%252C%2520and%2520molecular%2520pharmacology%2520of%2520selective%2520positive%2520allosteric%2520modulators%2520of%2520the%2520%25CE%25B4-opioid%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D10%26spage%3D4220%26epage%3D4229%26doi%3D10.1021%2Facs.jmedchem.5b00007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ali, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurijssens, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostenfeld, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHugh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stylianou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott-Stevens, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosking, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewit, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic and pharmacodynamic profiling of a P2 Ã 7 receptor allosteric modulator GSK1482160 in healthy human subjects</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>75</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">197</span>â <span class="NLM_lpage">207</span>, <span class="refDoi">Â DOI: 10.1111/j.1365-2125.2012.04320.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1111%2Fj.1365-2125.2012.04320.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=22568863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVGmsbnF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2013&pages=197-207&issue=1&author=Z.+Aliauthor=B.+Laurijssensauthor=T.+Ostenfeldauthor=S.+McHughauthor=A.+Stylianouauthor=P.+Scott-Stevensauthor=L.+Hoskingauthor=O.+Dewitauthor=J.+C.+Richardsonauthor=C.+Chen&title=Pharmacokinetic+and+pharmacodynamic+profiling+of+a+P2+%C3%97+7+receptor+allosteric+modulator+GSK1482160+in+healthy+human+subjects&doi=10.1111%2Fj.1365-2125.2012.04320.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic and pharmacodynamic profiling of a P2X7 receptor allosteric modulator GSK1482160 in healthy human subjects</span></div><div class="casAuthors">Ali, Zahid; Laurijssens, Bart; Ostenfeld, Thor; McHugh, Simon; Stylianou, Anastasia; Scott-Stevens, Paul; Hosking, Louise; Dewit, Odile; Richardson, Jill C.; Chen, Chao</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">197-207</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT â¢ P2X7 receptors are involved in the prodn. of pro-inflammatory cytokines, such as Il-1Î², by central and peripheral immune cells.  Il-1Î² has been implicated as an important mediator of inflammation.  Therefore, the P2X7 receptor is an attractive therapeutic target for inflammatory diseases.  WHAT THIS STUDY ADDS â¢ Findings in pharmacokinetics, pharmacodynamics, safety and tolerability of a P2X7 receptor modulator, GSK1482160, from the first human study for the mol. are described.  A pharmacokinetic/pharmacodynamic model for LPS-stimulated ATP-induced Il-1Î² prodn. in blood allowed the integration of all relevant data and provided in vivo evidence of the nature of the drug-receptor interaction.  The model has the potential to be used to simulate future trials.  AIMS This paper describes findings from the first-in-human study for GSK1482160, an orally available allosteric P2X7 receptor modulator.  The study aimed to assess the pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of the compd. in healthy subjects.  METHODS Escalating single doses of up to 1 g were administered to healthy subjects in a single-blind and placebo-controlled fashion.  Safety, tolerability, blood drug concns. and ex vivo Il-1Î² prodn. in blood were evaluated.  RESULTS. Drug concn. peaked within 3.5 h of dosing under fasting conditions and declined thereafter with a relatively short half-life of less than 4.5 h.  Exposure was proportional to dose with between subject variability of less than 60%.  A PK/PD model quantified Il-1Î² as a function of drug exposure.  The model allowed simulation of in vivo pharmacol. for various untested dose levels and regimens.  Furthermore, the mechanistic model supported the hypothesis that the compd. reduces the efficacy of ATP at the P2X7 receptor without affecting its affinity.  No major safety or tolerability concerns were identified in this small study (n= 29), except for one case of asymptomatic accelerated idioventricular rhythm at the top dose.  CONCLUSION. The model-based approach maximized anal. power by integrating all biomarker data and revealed mechanistic insight into the pharmacol. of P2X7 modulation by GSK1482160.  Simulations by this model ultimately led to the discontinuation of the development of this compd.  The therapeutic relevance of the P2X7 receptor remains to be tested in patients.  The mechanistic-model-based approach can be applied widely to drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr41Bz54gV-qLVg90H21EOLACvtfcHk0lg4bQ0z8t4zKA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVGmsbnF&md5=835023636e0c5b039245344c2a9a207a</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2012.04320.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2012.04320.x%26sid%3Dliteratum%253Aachs%26aulast%3DAli%26aufirst%3DZ.%26aulast%3DLaurijssens%26aufirst%3DB.%26aulast%3DOstenfeld%26aufirst%3DT.%26aulast%3DMcHugh%26aufirst%3DS.%26aulast%3DStylianou%26aufirst%3DA.%26aulast%3DScott-Stevens%26aufirst%3DP.%26aulast%3DHosking%26aufirst%3DL.%26aulast%3DDewit%26aufirst%3DO.%26aulast%3DRichardson%26aufirst%3DJ.%2BC.%26aulast%3DChen%26aufirst%3DC.%26atitle%3DPharmacokinetic%2520and%2520pharmacodynamic%2520profiling%2520of%2520a%2520P2%2520%25C3%2597%25207%2520receptor%2520allosteric%2520modulator%2520GSK1482160%2520in%2520healthy%2520human%2520subjects%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D75%26issue%3D1%26spage%3D197%26epage%3D207%26doi%3D10.1111%2Fj.1365-2125.2012.04320.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mistry, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valant, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuano, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scammells, P. J.</span></span> <span> </span><span class="NLM_article-title">Synthesis and pharmacological profiling of analogues of benzyl quinolone carboxylic acid (BQCA) as allosteric modulators of the M<sub>1</sub> muscarinic receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">5151</span>â <span class="NLM_lpage">5172</span>, <span class="refDoi">Â DOI: 10.1021/jm400540b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400540b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3sXosVaqtbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5151-5172&issue=12&author=S.+N.+Mistryauthor=C.+Valantauthor=P.+M.+Sextonauthor=B.+Capuanoauthor=A.+Christopoulosauthor=P.+J.+Scammells&title=Synthesis+and+pharmacological+profiling+of+analogues+of+benzyl+quinolone+carboxylic+acid+%28BQCA%29+as+allosteric+modulators+of+the+M1+muscarinic+receptor&doi=10.1021%2Fjm400540b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Pharmacological Profiling of Analogues of Benzyl Quinolone Carboxylic Acid (BQCA) as Allosteric Modulators of the M1 Muscarinic Receptor</span></div><div class="casAuthors">Mistry, Shailesh N.; Valant, Celine; Sexton, Patrick M.; Capuano, Ben; Christopoulos, Arthur; Scammells, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5151-5172</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Established therapy in Alzheimer's disease involves potentiation of the endogenous orthosteric ligand, acetylcholine, at the M1 muscarinic receptors found in higher concns. in the cortex and hippocampus.  Adverse effects, due to indiscriminate activation of other muscarinic receptor subtypes, are common.  M1 muscarinic pos. allosteric modulators/allosteric agonists such as BQCA [1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, I] offer an attractive soln., being exquisitely M1-selective over other muscarinic subtypes.  A common difficulty with allosteric ligands is interpreting SAR, based on composite potency values derived in the presence of fixed concn. of agonist.  In reality these values encompass multiple pharmacol. parameters, each potentially and differentially sensitive to structural modification of the ligand.  We report novel BQCA analogs which appear to augment ligand affinity for the receptor (pKB), intrinsic efficacy (ÏB), and both binding (Î±) and functional (Î²) cooperativity with acetylcholine.  Ultimately, development of such enriched SAR surrounding allosteric modulators will provide insight into their mode of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoigST7OJR7vbVg90H21EOLACvtfcHk0lg4bQ0z8t4zKA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXosVaqtbs%253D&md5=ab134e0b5400aa825916695eaf1203b1</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm400540b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400540b%26sid%3Dliteratum%253Aachs%26aulast%3DMistry%26aufirst%3DS.%2BN.%26aulast%3DValant%26aufirst%3DC.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DCapuano%26aufirst%3DB.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26atitle%3DSynthesis%2520and%2520pharmacological%2520profiling%2520of%2520analogues%2520of%2520benzyl%2520quinolone%2520carboxylic%2520acid%2520%2528BQCA%2529%2520as%2520allosteric%2520modulators%2520of%2520the%2520M1%2520muscarinic%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D12%26spage%3D5151%26epage%3D5172%26doi%3D10.1021%2Fjm400540b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span> Value of Î± calculated assuming Î² = 1.<span class="NLM_contrib-group"><span class="NLM_string-name">Davoren, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnsey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettersen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodney, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edgerton, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortin, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimwood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkinson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenakin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazzaro, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotarski, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nottebaum, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâNeil, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popiolek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steyn, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorn, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, D.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of Î³- and Î´-Lactam M<sub>1</sub> positive allosteric modulators (PAMs): convulsion and cholinergic toxicity of an M1-selective PAM with weak agonist activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">6649</span>â <span class="NLM_lpage">6663</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b00597</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00597" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpslSktbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=6649-6663&issue=15&author=J.+E.+Davorenauthor=M.+Garnseyauthor=B.+Pettersenauthor=M.+A.+Brodneyauthor=J.+R.+Edgertonauthor=J.+P.+Fortinauthor=S.+Grimwoodauthor=A.+R.+Harrisauthor=S.+Jenkinsonauthor=T.+Kenakinauthor=J.+T.+Lazzaroauthor=C.+W.+Leeauthor=S.+M.+Lotarskiauthor=L.+Nottebaumauthor=S.+V.+O%E2%80%99Neilauthor=M.+Popiolekauthor=S.+Ramseyauthor=S.+J.+Steynauthor=C.+A.+Thornauthor=L.+Zhangauthor=D.+Webb&title=Design+and+synthesis+of+%CE%B3-+and+%CE%B4-Lactam+M1+positive+allosteric+modulators+%28PAMs%29%3A+convulsion+and+cholinergic+toxicity+of+an+M1-selective+PAM+with+weak+agonist+activity&doi=10.1021%2Facs.jmedchem.7b00597"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Î³- and Î´-Lactam M1 Positive Allosteric Modulators (PAMs): Convulsion and Cholinergic Toxicity of an M1-Selective PAM with Weak Agonist Activity</span></div><div class="casAuthors">Davoren, Jennifer E.; Garnsey, Michelle; Pettersen, Betty; Brodney, Michael A.; Edgerton, Jeremy R.; Fortin, Jean-Philippe; Grimwood, Sarah; Harris, Anthony R.; Jenkinson, Stephen; Kenakin, Terry; Lazzaro, John T.; Lee, Che-Wah; Lotarski, Susan M.; Nottebaum, Lisa; O'Neil, Steven V.; Popiolek, Michael; Ramsey, Simeon; Steyn, Stefanus J.; Thorn, Catherine A.; Zhang, Lei; Webb, Damien</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6649-6663</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recent data demonstrated that activation of the muscarinic M1 receptor by a subtype-selective pos. allosteric modulator (PAM) contributes to the gastrointestinal (GI) and cardiovascular (CV) cholinergic adverse events (AEs) previously attributed to M2 and M3 activation.  These studies were conducted using PAMs that also exhibited allosteric agonist activity, leaving open the possibility that direct activation by allosteric agonism, rather than allosteric modulation, could be responsible for the adverse effects.  This article describes the design and synthesis of lactam-derived M1 PAMs that address this hypothesis.  The lead mol. from this series, compd. I (PF-06827443), is a potent, low-clearance, orally bioavailable and CNS-penetrant M1-selective PAM with minimal agonist activity.  Compd. I was tested in dose escalation studies in rats and dogs and was found to induce cholinergic AEs and convulsion at therapeutic indexes similar to previous compds. with more agonist activity.  These findings provide preliminary evidence that pos. allosteric modulation of M1 is sufficient to elicit cholinergic AEs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsdLnKqXoZLrVg90H21EOLACvtfcHk0lgFKP_VEoDI4A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpslSktbg%253D&md5=abd7e12d7dc959269a0bae608467f827</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00597%26sid%3Dliteratum%253Aachs%26aulast%3DDavoren%26aufirst%3DJ.%2BE.%26aulast%3DGarnsey%26aufirst%3DM.%26aulast%3DPettersen%26aufirst%3DB.%26aulast%3DBrodney%26aufirst%3DM.%2BA.%26aulast%3DEdgerton%26aufirst%3DJ.%2BR.%26aulast%3DFortin%26aufirst%3DJ.%2BP.%26aulast%3DGrimwood%26aufirst%3DS.%26aulast%3DHarris%26aufirst%3DA.%2BR.%26aulast%3DJenkinson%26aufirst%3DS.%26aulast%3DKenakin%26aufirst%3DT.%26aulast%3DLazzaro%26aufirst%3DJ.%2BT.%26aulast%3DLee%26aufirst%3DC.%2BW.%26aulast%3DLotarski%26aufirst%3DS.%2BM.%26aulast%3DNottebaum%26aufirst%3DL.%26aulast%3DO%25E2%2580%2599Neil%26aufirst%3DS.%2BV.%26aulast%3DPopiolek%26aufirst%3DM.%26aulast%3DRamsey%26aufirst%3DS.%26aulast%3DSteyn%26aufirst%3DS.%2BJ.%26aulast%3DThorn%26aufirst%3DC.%2BA.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DWebb%26aufirst%3DD.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520%25CE%25B3-%2520and%2520%25CE%25B4-Lactam%2520M1%2520positive%2520allosteric%2520modulators%2520%2528PAMs%2529%253A%2520convulsion%2520and%2520cholinergic%2520toxicity%2520of%2520an%2520M1-selective%2520PAM%2520with%2520weak%2520agonist%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D15%26spage%3D6649%26epage%3D6663%26doi%3D10.1021%2Facs.jmedchem.7b00597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beshore, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMarco, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greshock, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seager, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeplinger, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuerst, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilodeau, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuduk, S. D.</span></span> <span> </span><span class="NLM_article-title">MK-7622: a first in class M<sub>1</sub> positive allosteric modulator development candidate</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">652</span>â <span class="NLM_lpage">656</span>, <span class="refDoi">Â DOI: 10.1021/acsmedchemlett.8b00095</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00095" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXos1Gmtbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=652-656&issue=7&author=D.+C.+Beshoreauthor=C.+N.+DiMarcoauthor=R.+K.+Changauthor=T.+J.+Greshockauthor=L.+Maauthor=M.+Wittmannauthor=M.+A.+Seagerauthor=K.+A.+Koeplingerauthor=C.+D.+Thompsonauthor=J.+Fuerstauthor=G.+D.+Hartmanauthor=M.+T.+Bilodeauauthor=W.+J.+Rayauthor=S.+D.+Kuduk&title=MK-7622%3A+a+first+in+class+M1+positive+allosteric+modulator+development+candidate&doi=10.1021%2Facsmedchemlett.8b00095"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">MK-7622: A First-in-Class M1 Positive Allosteric Modulator Development Candidate</span></div><div class="casAuthors">Beshore, Douglas C.; Di Marco, Christina N.; Chang, Ronald K.; Greshock, Thomas J.; Ma, Lei; Wittmann, Marion; Seager, Matthew A.; Koeplinger, Kenneth A.; Thompson, Charles D.; Fuerst, Joy; Hartman, George D.; Bilodeau, Mark T.; Ray, William J.; Kuduk, Scott D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">652-656</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Identification of ligands that selectively activate the M1 muscarinic signaling pathway was sought for decades to treat a range of neurol. and cognitive disorders.  Herein, we describe the optimization efforts focused on addressing key physicochem. and safety properties, ultimately leading to the clin. candidate MK-7622, a highly selective pos. allosteric modulator of the M1 muscarinic receptor that has entered Phase II studies in patients with Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO43jxaoq6QbVg90H21EOLACvtfcHk0lgFKP_VEoDI4A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXos1Gmtbg%253D&md5=892787348c2ceabab0536d05e0e6d9b5</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00095%26sid%3Dliteratum%253Aachs%26aulast%3DBeshore%26aufirst%3DD.%2BC.%26aulast%3DDiMarco%26aufirst%3DC.%2BN.%26aulast%3DChang%26aufirst%3DR.%2BK.%26aulast%3DGreshock%26aufirst%3DT.%2BJ.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DWittmann%26aufirst%3DM.%26aulast%3DSeager%26aufirst%3DM.%2BA.%26aulast%3DKoeplinger%26aufirst%3DK.%2BA.%26aulast%3DThompson%26aufirst%3DC.%2BD.%26aulast%3DFuerst%26aufirst%3DJ.%26aulast%3DHartman%26aufirst%3DG.%2BD.%26aulast%3DBilodeau%26aufirst%3DM.%2BT.%26aulast%3DRay%26aufirst%3DW.%2BJ.%26aulast%3DKuduk%26aufirst%3DS.%2BD.%26atitle%3DMK-7622%253A%2520a%2520first%2520in%2520class%2520M1%2520positive%2520allosteric%2520modulator%2520development%2520candidate%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26issue%3D7%26spage%3D652%26epage%3D656%26doi%3D10.1021%2Facsmedchemlett.8b00095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davoren, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâNeil, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodney, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chenard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dlugolenski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edgerton, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnsey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimwood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kauffman, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaChapelle, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazzaro, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotarski, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nason, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhart, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salomon-Ferrer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steyn, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span> <span> </span><span class="NLM_article-title">Design and optimization of selective azaindole amide M<sub>1</sub> positive allosteric modulators</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">650</span>â <span class="NLM_lpage">655</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2015.11.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.bmcl.2015.11.053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=26631313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFant73L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=650-655&issue=2&author=J.+E.+Davorenauthor=S.+V.+O%E2%80%99Neilauthor=D.+P.+Andersonauthor=M.+A.+Brodneyauthor=L.+Chenardauthor=K.+Dlugolenskiauthor=J.+R.+Edgertonauthor=M.+Greenauthor=M.+Garnseyauthor=S.+Grimwoodauthor=A.+R.+Harrisauthor=G.+W.+Kauffmanauthor=E.+LaChapelleauthor=J.+T.+Lazzaroauthor=C.+W.+Leeauthor=S.+M.+Lotarskiauthor=D.+M.+Nasonauthor=R.+S.+Obachauthor=V.+Reinhartauthor=R.+Salomon-Ferrerauthor=S.+J.+Steynauthor=D.+Webbauthor=J.+Yanauthor=L.+Zhang&title=Design+and+optimization+of+selective+azaindole+amide+M1+positive+allosteric+modulators&doi=10.1016%2Fj.bmcl.2015.11.053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Design and optimization of selective azaindole amide M1 positive allosteric modulators</span></div><div class="casAuthors">Davoren, Jennifer E.; O'Neil, Steven V.; Anderson, Dennis P.; Brodney, Michael A.; Chenard, Lois; Dlugolenski, Keith; Edgerton, Jeremy R.; Green, Michael; Garnsey, Michelle; Grimwood, Sarah; Harris, Anthony R.; Kauffman, Gregory W.; LaChapelle, Erik; Lazzaro, John T.; Lee, Che-Wah; Lotarski, Susan M.; Nason, Deane M.; Obach, R. Scott; Reinhart, Veronica; Salomon-Ferrer, Romelia; Steyn, Stefanus J.; Webb, Damien; Yan, Jiangli; Zhang, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">650-655</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Selective activation of the M1 receptor via a pos. allosteric modulator (PAM) is a new approach for the treatment of the cognitive impairments assocd. with schizophrenia and Alzheimer's disease.  A novel series of azaindole amides and their key pharmacophore elements are described.  The nitrogen of the azaindole core is a key design element as it forms an intramol. hydrogen bond with the amide N-H thus reinforcing the bioactive conformation predicted by published SAR and the authors' homol. model.  Representative compd. 25 is a potent and selective M1 PAM that has well aligned physicochem. properties, adequate brain penetration and pharmacokinetic (PK) properties, and is active in vivo.  These favorable properties indicate that this series possesses suitable qualities for further development and studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOEhH8MxkKIrVg90H21EOLACvtfcHk0lg0GbSWUePCJQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFant73L&md5=5c227d1371fe4f0cc3348af8314dd370</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.11.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.11.053%26sid%3Dliteratum%253Aachs%26aulast%3DDavoren%26aufirst%3DJ.%2BE.%26aulast%3DO%25E2%2580%2599Neil%26aufirst%3DS.%2BV.%26aulast%3DAnderson%26aufirst%3DD.%2BP.%26aulast%3DBrodney%26aufirst%3DM.%2BA.%26aulast%3DChenard%26aufirst%3DL.%26aulast%3DDlugolenski%26aufirst%3DK.%26aulast%3DEdgerton%26aufirst%3DJ.%2BR.%26aulast%3DGreen%26aufirst%3DM.%26aulast%3DGarnsey%26aufirst%3DM.%26aulast%3DGrimwood%26aufirst%3DS.%26aulast%3DHarris%26aufirst%3DA.%2BR.%26aulast%3DKauffman%26aufirst%3DG.%2BW.%26aulast%3DLaChapelle%26aufirst%3DE.%26aulast%3DLazzaro%26aufirst%3DJ.%2BT.%26aulast%3DLee%26aufirst%3DC.%2BW.%26aulast%3DLotarski%26aufirst%3DS.%2BM.%26aulast%3DNason%26aufirst%3DD.%2BM.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DReinhart%26aufirst%3DV.%26aulast%3DSalomon-Ferrer%26aufirst%3DR.%26aulast%3DSteyn%26aufirst%3DS.%2BJ.%26aulast%3DWebb%26aufirst%3DD.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DDesign%2520and%2520optimization%2520of%2520selective%2520azaindole%2520amide%2520M1%2520positive%2520allosteric%2520modulators%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26issue%3D2%26spage%3D650%26epage%3D655%26doi%3D10.1016%2Fj.bmcl.2015.11.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flohr, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutter, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohnert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellisson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaffhauser, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of the first low-shift positive allosteric modulators for the muscarinic M<sub>1</sub> receptor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">5415</span>â <span class="NLM_lpage">5419</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2017.11.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.bmcl.2017.11.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=29146472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVWnurbN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=5415-5419&issue=24&author=A.+Flohrauthor=R.+Hutterauthor=B.+Muellerauthor=C.+Bohnertauthor=M.+Pellissonauthor=H.+Schaffhauser&title=Discovery+of+the+first+low-shift+positive+allosteric+modulators+for+the+muscarinic+M1+receptor&doi=10.1016%2Fj.bmcl.2017.11.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the first low-shift positive allosteric modulators for the muscarinic M1 receptor</span></div><div class="casAuthors">Flohr, Alexander; Hutter, Roman; Mueller, Barbara; Bohnert, Claudia; Pellisson, Melanie; Schaffhauser, Herve</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5415-5419</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Pos. modulation of the muscarinic M1-receptor has for a long time attracted scientists and drug developers for the potential treatment of Alzheimer's disease or Schizophrenia.  The precognitive potential of M1 activation has however not been clin. demonstrated as a result of side effects assocd. both with agonists and pos. allosteric modulators (PAM's) of the M1-receptor.  To avoid excessive activation of the M1-receptor the authors have designed a new screening format and developed the first low-shift pos. allosteric modulators for the M1 receptor.  Low-shift PAM's offer the potential of "use-dependent" attenuation of transmitter-signaling while avoiding pseudo-agonistic behavior in vivo as a common limitation of the so far described high-shift PAM's.  With these novel M1-PAM's, the M1 receptor is potentially the first GPCR for which both, high- and low shift PAM's have become available.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV5toqiOhU7LVg90H21EOLACvtfcHk0lg0GbSWUePCJQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVWnurbN&md5=285ddb376445245ba500498c008ae9d7</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.11.008%26sid%3Dliteratum%253Aachs%26aulast%3DFlohr%26aufirst%3DA.%26aulast%3DHutter%26aufirst%3DR.%26aulast%3DMueller%26aufirst%3DB.%26aulast%3DBohnert%26aufirst%3DC.%26aulast%3DPellisson%26aufirst%3DM.%26aulast%3DSchaffhauser%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520the%2520first%2520low-shift%2520positive%2520allosteric%2520modulators%2520for%2520the%2520muscarinic%2520M1%2520receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26issue%3D24%26spage%3D5415%26epage%3D5419%26doi%3D10.1016%2Fj.bmcl.2017.11.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahring, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">StrÃ¸bÃ¦k, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartiadi, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chebib, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Absalom, N.</span></span> <span> </span><span class="NLM_article-title">A pharmacological assessment of agonists and modulators at Î±4Î²2Î³2 and Î±4Î²2Î´ GABAA receptors: the challenge in comparing apples with oranges</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">563</span>â <span class="NLM_lpage">576</span>, <span class="refDoi">Â DOI: 10.1016/j.phrs.2016.05.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.phrs.2016.05.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=27178730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1yhu7fM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2016&pages=563-576&author=P.+K.+Ahringauthor=L.+H.+Bangauthor=M.+L.+Jensenauthor=D.+Str%C3%B8b%C3%A6kauthor=L.+Y.+Hartiadiauthor=M.+Chebibauthor=N.+Absalom&title=A+pharmacological+assessment+of+agonists+and+modulators+at+%CE%B14%CE%B22%CE%B32+and+%CE%B14%CE%B22%CE%B4+GABAA+receptors%3A+the+challenge+in+comparing+apples+with+oranges&doi=10.1016%2Fj.phrs.2016.05.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">A pharmacological assessment of agonists and modulators at Î±4Î²2Î³2 and Î±4Î²2Î´ GABAA receptors: The challenge in comparing apples with oranges</span></div><div class="casAuthors">Ahring, Philip K.; Bang, Line H.; Jensen, Marianne L.; Stroebaek, Dorte; Hartiadi, Leonny Y.; Chebib, Mary; Absalom, Nathan</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">563-576</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Extrasynaptically located Î³-aminobutyric acid (GABA) receptors type A are often characterized by the presence of a Î´ subunit in the receptor complex. Î´-Contg. receptors respond to low ambient concns. of GABA, or respond to spillover of GABA from the synapse, and give rise to tonic inhibitory currents.  In certain brain regions, e.g. thalamocortical neurons, tonic inhibition is estd. to represent the majority of total GABA-mediated inhibition, which has raised substantial interest in extrasynaptic receptors as potential drug targets.  Thalamocortical neurons typically express Î±4Î²2/3Î´ receptors, however, these have proven difficult to study in recombinant in vitro expression systems due to the inherently low current levels elicited in response to GABA.  In this study, we sought to characterize a range of agonists and pos. allosteric modulators at Î±4Î²2Î´ and Î±4Î²2Î³2 receptors.  All tested agonists (GABA, THIP, muscimol, and taurine) displayed between 8 and 22 fold increase in potency at the Î±4Î²2Î´ receptor.  In contrast, modulatory potencies of steroids (allopregnanolone, THDOC and alfaxalone), anesthetics (etomidate, pentobarbital) and Delta-Selective agents 1 and 2 (DS1 and DS2) were similar at Î±4Î²2Î´ and Î±4Î²2Î³2 receptors.  When evaluating modulatory efficacies, the neurosteroids and anesthetics displayed highest efficacy at Î±4Î²2Î³2 receptors whereas DS1 and in particular DS2 had highest efficacy at Î±4Î²2Î´ receptors.  Overall, several key messages emerged: (i) none of the tested compds. displayed significant selectivity and a great need for identifying new Î´-selective compds. remains; (ii) Î±4Î²2Î´ and Î±4Î²2Î³2 receptors have such divergent intrinsic activation properties that valid comparisons of modulator efficacies are at best challenging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZlw3cES06qrVg90H21EOLACvtfcHk0lg0GbSWUePCJQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1yhu7fM&md5=de88bf1f60cf6498d21b655efd4584b7</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2016.05.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2016.05.014%26sid%3Dliteratum%253Aachs%26aulast%3DAhring%26aufirst%3DP.%2BK.%26aulast%3DBang%26aufirst%3DL.%2BH.%26aulast%3DJensen%26aufirst%3DM.%2BL.%26aulast%3DStr%25C3%25B8b%25C3%25A6k%26aufirst%3DD.%26aulast%3DHartiadi%26aufirst%3DL.%2BY.%26aulast%3DChebib%26aufirst%3DM.%26aulast%3DAbsalom%26aufirst%3DN.%26atitle%3DA%2520pharmacological%2520assessment%2520of%2520agonists%2520and%2520modulators%2520at%2520%25CE%25B14%25CE%25B22%25CE%25B32%2520and%2520%25CE%25B14%25CE%25B22%25CE%25B4%2520GABAA%2520receptors%253A%2520the%2520challenge%2520in%2520comparing%2520apples%2520with%2520oranges%26jtitle%3DPharmacol.%2520Res.%26date%3D2016%26volume%3D111%26spage%3D563%26epage%3D576%26doi%3D10.1016%2Fj.phrs.2016.05.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Langmead, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span> <span> </span><span class="NLM_article-title">Supra-physiological efficacy at GPCRs: superstition or super agonists?</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>169</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">353</span>â <span class="NLM_lpage">356</span>, <span class="refDoi">Â DOI: 10.1111/bph.12142</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1111%2Fbph.12142" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=23441648" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvFSgt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2013&pages=353-356&issue=2&author=C.+J.+Langmeadauthor=A.+Christopoulos&title=Supra-physiological+efficacy+at+GPCRs%3A+superstition+or+super+agonists%3F&doi=10.1111%2Fbph.12142"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Supra-physiological efficacy at GPCRs: superstition or super agonists?</span></div><div class="casAuthors">Langmead, Christopher J.; Christopoulos, Arthur</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">353-356</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The concept of "super agonism" has been described since the discovery of peptide hormone analogs that yielded greater functional responses than the endogenous agonists, in the early 1980s.  It has remained an area of debate as to whether such compds. can really display greater efficacy than an endogenous agonist.  However, recent pharmacol. data, combined with crystal structures of different GPCR conformations and improved anal. methods for quantifying drug action, are starting to shed light on this phenomenon and indicate that super agonists may be more than superstition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrquBL04A_rILVg90H21EOLACvtfcHk0liYPLBnoUlQ7g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmvFSgt7g%253D&md5=50b127c3cda2d82b859df07e556dc463</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1111%2Fbph.12142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12142%26sid%3Dliteratum%253Aachs%26aulast%3DLangmead%26aufirst%3DC.%2BJ.%26aulast%3DChristopoulos%26aufirst%3DA.%26atitle%3DSupra-physiological%2520efficacy%2520at%2520GPCRs%253A%2520superstition%2520or%2520super%2520agonists%253F%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D169%26issue%3D2%26spage%3D353%26epage%3D356%26doi%3D10.1111%2Fbph.12142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dale, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodbeck, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doller, D.</span></span> <span> </span><span class="NLM_article-title">Chemical biology of mGlu4 receptor activation: dogmas, challenges, strategies and opportunities</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">1755</span>â <span class="NLM_lpage">1770</span>, <span class="refDoi">Â DOI: 10.2174/1568026614666140902143830</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.2174%2F1568026614666140902143830" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=25183417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslGqur3P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=1755-1770&issue=15&author=X.+Huangauthor=E.+Daleauthor=R.+M.+Brodbeckauthor=D.+Doller&title=Chemical+biology+of+mGlu4+receptor+activation%3A+dogmas%2C+challenges%2C+strategies+and+opportunities&doi=10.2174%2F1568026614666140902143830"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical Biology of mGlu4 Receptor Activation: Dogmas, Challenges, Strategies and Opportunities</span></div><div class="casAuthors">Huang, Xinyan; Dale, Elena; Brodbeck, Robbin M.; Doller, Dario</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1755-1770</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Drug design necessitates a clear understanding of the phenotypic response to be elicited by a given ligand-target interaction.  This relationship is relatively well understood for classical biol. targets of drug action, but for some novel targets, notably those amenable to allosteric modulation, developing such understanding may represent a more challenging task.  In order to gain knowledge on the nature of the functional response derived from mGlu4 receptor activation, its mol. and cell biol. are reviewed, including signalling pathways involved, receptor localization in central nervous system and beyond, and potential genetic links to disease.  Broadly held views for both, orthosteric agonists as well as allosteric modulators, are compared with specific observations for the case of mGlu4 receptor activation via orthosteric and allosteric mechanisms.  First, sub-type selectivity and brain penetration of amino acid mGlu4 receptor agonists are discussed, followed by the quantification of functional allosteric effects, the potential role of heterodimers in the functional response, and the observation of supra-physiol. efficacy of mGlu4 receptor PAMs.  We show that, in our anal., these attributes differ from those that may be expected by extrapolating from broad knowledge.  In addn., recent progress with mGlu4 receptor radioligands and PET ligands is summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdK5_t0giBdbVg90H21EOLACvtfcHk0liYPLBnoUlQ7g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslGqur3P&md5=57caba4e324058a3d85f5abd11b39a69</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.2174%2F1568026614666140902143830&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026614666140902143830%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DDale%26aufirst%3DE.%26aulast%3DBrodbeck%26aufirst%3DR.%2BM.%26aulast%3DDoller%26aufirst%3DD.%26atitle%3DChemical%2520biology%2520of%2520mGlu4%2520receptor%2520activation%253A%2520dogmas%252C%2520challenges%252C%2520strategies%2520and%2520opportunities%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2014%26volume%3D14%26issue%3D15%26spage%3D1755%26epage%3D1770%26doi%3D10.2174%2F1568026614666140902143830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lavreysen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahnaou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drinkenburg, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langlois, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pype, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LÃ¼tjens, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Poul, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trabanco, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">NuÃ±ez, J. M.</span></span> <span> </span><span class="NLM_article-title">Pharmacological and pharmacokinetic properties of JNJ-40411813, a positive allosteric modulator of the mGlu2 receptor</span>. <i>Pharmacol. Res. Perspect.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">e00096</span>, <span class="refDoi">Â DOI: 10.1002/prp2.96</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1002%2Fprp2.96" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=25692015" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&pages=e00096&issue=1&author=H.+Lavreysenauthor=A.+Ahnaouauthor=W.+Drinkenburgauthor=X.+Langloisauthor=C.+Mackieauthor=S.+Pypeauthor=R.+L%C3%BCtjensauthor=E.+Le+Poulauthor=A.+A.+Trabancoauthor=J.+M.+Nu%C3%B1ez&title=Pharmacological+and+pharmacokinetic+properties+of+JNJ-40411813%2C+a+positive+allosteric+modulator+of+the+mGlu2+receptor&doi=10.1002%2Fprp2.96"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1002%2Fprp2.96&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprp2.96%26sid%3Dliteratum%253Aachs%26aulast%3DLavreysen%26aufirst%3DH.%26aulast%3DAhnaou%26aufirst%3DA.%26aulast%3DDrinkenburg%26aufirst%3DW.%26aulast%3DLanglois%26aufirst%3DX.%26aulast%3DMackie%26aufirst%3DC.%26aulast%3DPype%26aufirst%3DS.%26aulast%3DL%25C3%25BCtjens%26aufirst%3DR.%26aulast%3DLe%2BPoul%26aufirst%3DE.%26aulast%3DTrabanco%26aufirst%3DA.%2BA.%26aulast%3DNu%25C3%25B1ez%26aufirst%3DJ.%2BM.%26atitle%3DPharmacological%2520and%2520pharmacokinetic%2520properties%2520of%2520JNJ-40411813%252C%2520a%2520positive%2520allosteric%2520modulator%2520of%2520the%2520mGlu2%2520receptor%26jtitle%3DPharmacol.%2520Res.%2520Perspect.%26date%3D2015%26volume%3D3%26issue%3D1%26spage%3De00096%26doi%3D10.1002%2Fprp2.96" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Justinova, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panlilio, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Secci, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redhi, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mrzljak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medd, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaham, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, S. R.</span></span> <span> </span><span class="NLM_article-title">The novel metabotropic glutamate receptor 2 positive allosteric modulator, AZD8529, decreases nicotine self-administration and relapse in squirrel monkeys</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">452</span>â <span class="NLM_lpage">462</span>, <span class="refDoi">Â DOI: 10.1016/j.biopsych.2015.01.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.biopsych.2015.01.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=25802079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltFelurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2015&pages=452-462&issue=7&author=Z.+Justinovaauthor=L.+V.+Panlilioauthor=M.+E.+Secciauthor=G.+H.+Redhiauthor=C.+W.+Schindlerauthor=A.+J.+Crossauthor=L.+Mrzljakauthor=A.+Meddauthor=Y.+Shahamauthor=S.+R.+Goldberg&title=The+novel+metabotropic+glutamate+receptor+2+positive+allosteric+modulator%2C+AZD8529%2C+decreases+nicotine+self-administration+and+relapse+in+squirrel+monkeys&doi=10.1016%2Fj.biopsych.2015.01.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">The Novel Metabotropic Glutamate Receptor 2 Positive Allosteric Modulator, AZD8529, Decreases Nicotine Self-Administration and Relapse in Squirrel Monkeys</span></div><div class="casAuthors">Justinova, Zuzana; Panlilio, Leigh V.; Secci, Maria E.; Redhi, Godfrey H.; Schindler, Charles W.; Cross, Alan J.; Mrzljak, Ladislav; Medd, Amy; Shaham, Yavin; Goldberg, Steven R.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">452-462</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Based on rodent studies, group II metabotropic glutamate receptors (mGluR2 and mGluR3) were suggested as targets for addiction treatment.  However, LY379268 and other group II agonists do not discriminate between the mainly presynaptic inhibitory mGluR2 (the proposed treatment target) and mGluR3.  These agonists also produce tolerance over repeated administration and are no longer considered for addiction treatment.  Here, we detd. the effects of AZD8529, a selective pos. allosteric modulator of mGluR2, on abuse-related effects of nicotine in squirrel monkeys and rats.  We first assessed modulation of mGluR2 function by AZD8529 using functional in vitro assays in membranes prepd. from a cell line expressing human mGluR2 and in primate brain slices.  We then detd. AZD8529 (.03-10 mg/kg, i.m. injection) effects on i.v. nicotine self-administration and reinstatement of nicotine seeking induced by nicotine priming or nicotine-assocd. cues.  We also detd. AZD8529 effects on food self-administration in monkeys and nicotine-induced dopamine release in accumbens shell in rats.  AZD8529 potentiated agonist-induced activation of mGluR2 in the membrane-binding assay and in primate cortex, hippocampus, and striatum.  In monkeys, AZD8529 decreased nicotine self-administration at doses (.3-3 mg/kg) that did not affect food self-administration.  AZD8529 also reduced nicotine priming- and cue-induced reinstatement of nicotine seeking after extinction of the drug-reinforced responding.  In rats, AZD8529 decreased nicotine-induced accumbens dopamine release.  These results provide evidence for efficacy of pos. allosteric modulators of mGluR2 in nonhuman primate models of nicotine reinforcement and relapse.  This drug class should be considered for nicotine addiction treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiwrmhIL13xLVg90H21EOLACvtfcHk0liYPLBnoUlQ7g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltFelurg%253D&md5=3f9db3d76c99c14165eaa287a8032eae</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2015.01.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2015.01.014%26sid%3Dliteratum%253Aachs%26aulast%3DJustinova%26aufirst%3DZ.%26aulast%3DPanlilio%26aufirst%3DL.%2BV.%26aulast%3DSecci%26aufirst%3DM.%2BE.%26aulast%3DRedhi%26aufirst%3DG.%2BH.%26aulast%3DSchindler%26aufirst%3DC.%2BW.%26aulast%3DCross%26aufirst%3DA.%2BJ.%26aulast%3DMrzljak%26aufirst%3DL.%26aulast%3DMedd%26aufirst%3DA.%26aulast%3DShaham%26aufirst%3DY.%26aulast%3DGoldberg%26aufirst%3DS.%2BR.%26atitle%3DThe%2520novel%2520metabotropic%2520glutamate%2520receptor%25202%2520positive%2520allosteric%2520modulator%252C%2520AZD8529%252C%2520decreases%2520nicotine%2520self-administration%2520and%2520relapse%2520in%2520squirrel%2520monkeys%26jtitle%3DBiol.%2520Psychiatry%26date%3D2015%26volume%3D78%26issue%3D7%26spage%3D452%26epage%3D462%26doi%3D10.1016%2Fj.biopsych.2015.01.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doornbos, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">PÃ©rez-Benito, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tresadern, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulder-Krieger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biesmans, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trabanco, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cid, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavreysen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">IJzerman, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitman, L. H.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanism of positive allosteric modulation of the metabotropic glutamate receptor 2 by JNJ-46281222</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>173</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">588</span>â <span class="NLM_lpage">600</span>, <span class="refDoi">Â DOI: 10.1111/bph.13390</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1111%2Fbph.13390" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=26589404" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvVOlsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2016&pages=588-600&issue=3&author=M.+L.+Doornbosauthor=L.+P%C3%A9rez-Benitoauthor=G.+Tresadernauthor=T.+Mulder-Kriegerauthor=I.+Biesmansauthor=A.+A.+Trabancoauthor=J.+M.+Cidauthor=H.+Lavreysenauthor=A.+P.+IJzermanauthor=L.+H.+Heitman&title=Molecular+mechanism+of+positive+allosteric+modulation+of+the+metabotropic+glutamate+receptor+2+by+JNJ-46281222&doi=10.1111%2Fbph.13390"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanism of positive allosteric modulation of the metabotropic glutamate receptor 2 by JNJ-46281222</span></div><div class="casAuthors">Doornbos, Maarten L. J.; Perez-Benito, Laura; Tresadern, Gary; Mulder-Krieger, Thea; Biesmans, Ilse; Trabanco, Andres A.; Cid, Jose Maria; Lavreysen, Hilde; IJzerman, Adriaan P.; Heitman, Laura H.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">588-600</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : Allosteric modulation of the mGlu2 receptor is a potential strategy for treatment of various neurol. and psychiatric disorders.  Here, we describe the in vitro characterization of the mGlu2 pos. allosteric modulator (PAM) JNJ-46281222 and its radiolabeled counterpart [3H]-JNJ-46281222.  Using this novel tool, we also describe the allosteric effect of orthosteric glutamate binding and the presence of a bound G protein on PAM binding and use computational approaches to further investigate the binding mode.  Exptl. Approach : We have used radioligand binding studies, functional assays, site-directed mutagenesis, homol. modeling and mol. dynamics to study the binding of JNJ-46281222.  Key Results : JNJ-46281222 is an mGlu2-selective, highly potent PAM with nanomolar affinity (KD = 1.7 nM).  Binding of [3H]-JNJ-46281222 was increased by the presence of glutamate and greatly reduced by the presence of GTP, indicating the preference for a G protein bound state of the receptor for PAM binding.  Its allosteric binding site was visualized and analyzed by a computational docking and mol. dynamics study.  The simulations revealed amino acid movements in regions expected to be important for activation.  The binding mode was supported by [3H]-JNJ-46281222 binding expts. on mutant receptors.  Conclusion and Implications : Our results obtained with JNJ-46281222 in unlabeled and tritiated form further contribute to our understanding of mGlu2 allosteric modulation.  The computational simulations and mutagenesis provide a plausible binding mode with indications of how the ligand permits allosteric activation.  This study is therefore of interest for mGlu2 and class C receptor drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbLKlJtG-BPrVg90H21EOLACvtfcHk0lhyjMM44yjk0g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvVOlsw%253D%253D&md5=fdbe099d035338dac3c036bd40d91f69</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1111%2Fbph.13390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13390%26sid%3Dliteratum%253Aachs%26aulast%3DDoornbos%26aufirst%3DM.%2BL.%26aulast%3DP%25C3%25A9rez-Benito%26aufirst%3DL.%26aulast%3DTresadern%26aufirst%3DG.%26aulast%3DMulder-Krieger%26aufirst%3DT.%26aulast%3DBiesmans%26aufirst%3DI.%26aulast%3DTrabanco%26aufirst%3DA.%2BA.%26aulast%3DCid%26aufirst%3DJ.%2BM.%26aulast%3DLavreysen%26aufirst%3DH.%26aulast%3DIJzerman%26aufirst%3DA.%2BP.%26aulast%3DHeitman%26aufirst%3DL.%2BH.%26atitle%3DMolecular%2520mechanism%2520of%2520positive%2520allosteric%2520modulation%2520of%2520the%2520metabotropic%2520glutamate%2520receptor%25202%2520by%2520JNJ-46281222%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2016%26volume%3D173%26issue%3D3%26spage%3D588%26epage%3D600%26doi%3D10.1111%2Fbph.13390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conde-Ceide, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MartÃ­nez-Viturro, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">AlcÃ¡zar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Barrantes, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavreysen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinson, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rook, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Megens, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langlois, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drinkenburg, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahnaou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niswender, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steckler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BartolomÃ©-Nebreda, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of VU0409551/JNJ-46778212: an mGlu5 positive allosteric modulator clinical candidate targeting schizophrenia</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">716</span>â <span class="NLM_lpage">720</span>, <span class="refDoi">Â DOI: 10.1021/acsmedchemlett.5b00181</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00181" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2MXovVSgu78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=716-720&issue=6&author=S.+Conde-Ceideauthor=C.+M.+Mart%C3%ADnez-Viturroauthor=J.+Alc%C3%A1zarauthor=P.+M.+Garcia-Barrantesauthor=H.+Lavreysenauthor=C.+Mackieauthor=P.+N.+Vinsonauthor=J.+M.+Rookauthor=T.+M.+Bridgesauthor=J.+S.+Danielsauthor=A.+Megensauthor=X.+Langloisauthor=W.+H.+Drinkenburgauthor=A.+Ahnaouauthor=C.+M.+Niswenderauthor=C.+K.+Jonesauthor=G.+J.+Macdonaldauthor=T.+Stecklerauthor=P.+J.+Connauthor=S.+R.+Staufferauthor=J.+M.+Bartolom%C3%A9-Nebredaauthor=C.+W.+Lindsley&title=Discovery+of+VU0409551%2FJNJ-46778212%3A+an+mGlu5+positive+allosteric+modulator+clinical+candidate+targeting+schizophrenia&doi=10.1021%2Facsmedchemlett.5b00181"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of VU0409551/JNJ-46778212: An mGlu5 Positive Allosteric Modulator Clinical Candidate Targeting Schizophrenia</span></div><div class="casAuthors">Conde-Ceide, Susana; Martinez-Viturro, Carlos M.; Alcazar, Jesus; Garcia-Barrantes, Pedro M.; Lavreysen, Hilde; Mackie, Claire; Vinson, Paige N.; Rook, Jerri M.; Bridges, Thomas M.; Daniels, J. Scott; Megens, Anton; Langlois, Xavier; Drinkenburg, Wilhelmus H.; Ahnaou, Abdellah; Niswender, Colleen M.; Jones, Carrie K.; Macdonald, Gregor J.; Steckler, Thomas; Conn, P. Jeffrey; Stauffer, Shaun R.; Bartolome-Nebreda, Jose Manuel; Lindsley, Craig W.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">716-720</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein, the authors report the structure-activity relationship of a novel series of potent, selective, and orally bioavailable metabotropic glutamate receptor subtype 5 (mGlu5) pos. allosteric modulators.  On the basis of its robust in vitro potency and in vivo efficacy in multiple preclin. models of multiple domains of schizophrenia, coupled with a good DMPK profile and an acceptable therapeutic window, I (VU0409551/JNJ-46778212) was selected as a candidate for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqz4F4S2MCNz7Vg90H21EOLACvtfcHk0lhyjMM44yjk0g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXovVSgu78%253D&md5=d92cd4c79b31d664deb53cafee809798</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00181%26sid%3Dliteratum%253Aachs%26aulast%3DConde-Ceide%26aufirst%3DS.%26aulast%3DMart%25C3%25ADnez-Viturro%26aufirst%3DC.%2BM.%26aulast%3DAlc%25C3%25A1zar%26aufirst%3DJ.%26aulast%3DGarcia-Barrantes%26aufirst%3DP.%2BM.%26aulast%3DLavreysen%26aufirst%3DH.%26aulast%3DMackie%26aufirst%3DC.%26aulast%3DVinson%26aufirst%3DP.%2BN.%26aulast%3DRook%26aufirst%3DJ.%2BM.%26aulast%3DBridges%26aufirst%3DT.%2BM.%26aulast%3DDaniels%26aufirst%3DJ.%2BS.%26aulast%3DMegens%26aufirst%3DA.%26aulast%3DLanglois%26aufirst%3DX.%26aulast%3DDrinkenburg%26aufirst%3DW.%2BH.%26aulast%3DAhnaou%26aufirst%3DA.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DJones%26aufirst%3DC.%2BK.%26aulast%3DMacdonald%26aufirst%3DG.%2BJ.%26aulast%3DSteckler%26aufirst%3DT.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DStauffer%26aufirst%3DS.%2BR.%26aulast%3DBartolom%25C3%25A9-Nebreda%26aufirst%3DJ.%2BM.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26atitle%3DDiscovery%2520of%2520VU0409551%252FJNJ-46778212%253A%2520an%2520mGlu5%2520positive%2520allosteric%2520modulator%2520clinical%2520candidate%2520targeting%2520schizophrenia%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26issue%3D6%26spage%3D716%26epage%3D720%26doi%3D10.1021%2Facsmedchemlett.5b00181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degnan, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balakrishnan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Easton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulianello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matchett, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santone, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senapati, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shields, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivarao, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westphal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiterock, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span> <span> </span><span class="NLM_article-title">Oxazolidinone-based allosteric modulators of mGluR5: defining molecular switches to create a pharmacological tool box</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">4165</span>â <span class="NLM_lpage">4169</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2016.07.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.bmcl.2016.07.065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=27496211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht12gu7bO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=4165-4169&issue=17&author=H.+Huangauthor=A.+P.+Degnanauthor=A.+Balakrishnanauthor=A.+Eastonauthor=M.+Gulianelloauthor=Y.+Huangauthor=M.+Matchettauthor=G.+Mattsonauthor=R.+Millerauthor=K.+S.+Santoneauthor=A.+Senapatiauthor=E.+E.+Shieldsauthor=D.+V.+Sivaraoauthor=L.+B.+Snyderauthor=R.+Westphalauthor=V.+J.+Whiterockauthor=F.+Yangauthor=J.+J.+Bronsonauthor=J.+E.+Macor&title=Oxazolidinone-based+allosteric+modulators+of+mGluR5%3A+defining+molecular+switches+to+create+a+pharmacological+tool+box&doi=10.1016%2Fj.bmcl.2016.07.065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Oxazolidinone-based allosteric modulators of mGluR5: Defining molecular switches to create a pharmacological tool box</span></div><div class="casAuthors">Huang, Hong; Degnan, Andrew P.; Balakrishnan, Anand; Easton, Amy; Gulianello, Michael; Huang, Yanling; Matchett, Michele; Mattson, Gail; Miller, Regina; Santone, Kenneth S.; Senapati, Arun; Shields, Eric E.; Sivarao, Digavalli V.; Snyder, Lawrence B.; Westphal, Ryan; Whiterock, Valerie J.; Yang, Fukang; Bronson, Joanne J.; Macor, John E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4165-4169</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Herein we describe the structure activity relationships uncovered in the pursuit of an mGluR5 pos. allosteric modulator (PAM) for the treatment of schizophrenia.  It was discovered that certain modifications of an oxazolidinone-based chemotype afforded predictable changes in the pharmacol. profile to give analogs with a wide range of functional activities.  The discovery of potent silent allosteric modulators (SAMs) allowed interrogation of the mechanism-based liabilities assocd. with mGluR5 activation and drove our medicinal chem. effort toward the discovery of low efficacy (fold shift) PAMs devoid of agonist activity.  This work resulted in the identification of dipyridyl 22 (BMS-952048), a compd. with a favorable free fraction, efficacy in a rodent-based cognition model, and low potential for convulsions in mouse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx6sChNZapurVg90H21EOLACvtfcHk0lhfJJ5fTOXOSw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht12gu7bO&md5=0b4e0da6c693d8e11e6237c77d679cca</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.07.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.07.065%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DDegnan%26aufirst%3DA.%2BP.%26aulast%3DBalakrishnan%26aufirst%3DA.%26aulast%3DEaston%26aufirst%3DA.%26aulast%3DGulianello%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DMatchett%26aufirst%3DM.%26aulast%3DMattson%26aufirst%3DG.%26aulast%3DMiller%26aufirst%3DR.%26aulast%3DSantone%26aufirst%3DK.%2BS.%26aulast%3DSenapati%26aufirst%3DA.%26aulast%3DShields%26aufirst%3DE.%2BE.%26aulast%3DSivarao%26aufirst%3DD.%2BV.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26aulast%3DWestphal%26aufirst%3DR.%26aulast%3DWhiterock%26aufirst%3DV.%2BJ.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DBronson%26aufirst%3DJ.%2BJ.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26atitle%3DOxazolidinone-based%2520allosteric%2520modulators%2520of%2520mGluR5%253A%2520defining%2520molecular%2520switches%2520to%2520create%2520a%2520pharmacological%2520tool%2520box%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26issue%3D17%26spage%3D4165%26epage%3D4169%26doi%3D10.1016%2Fj.bmcl.2016.07.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haas, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salazar, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herber, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degnan, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balakrishnan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albright, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strittmatter, S. M.</span></span> <span> </span><span class="NLM_article-title">Silent allosteric modulation of mGluR5 maintains glutamate signaling while rescuing Alzheimerâs mouse phenotypes</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">76</span>â <span class="NLM_lpage">88</span>, <span class="refDoi">Â DOI: 10.1016/j.celrep.2017.06.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.celrep.2017.06.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=28683325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFartbnN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2017&pages=76-88&issue=1&author=L.+T.+Haasauthor=S.+V.+Salazarauthor=L.+M.+Smithauthor=H.+R.+Zhaoauthor=T.+O.+Coxauthor=C.+S.+Herberauthor=A.+P.+Degnanauthor=A.+Balakrishnanauthor=J.+E.+Macorauthor=C.+F.+Albrightauthor=S.+M.+Strittmatter&title=Silent+allosteric+modulation+of+mGluR5+maintains+glutamate+signaling+while+rescuing+Alzheimer%E2%80%99s+mouse+phenotypes&doi=10.1016%2Fj.celrep.2017.06.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Silent Allosteric Modulation of mGluR5 Maintains Glutamate Signaling while Rescuing Alzheimer's Mouse Phenotypes</span></div><div class="casAuthors">Haas, Laura T.; Salazar, Santiago V.; Smith, Levi M.; Zhao, Helen R.; Cox, Timothy O.; Herber, Charlotte S.; Degnan, Andrew P.; Balakrishnan, Anand; Macor, John E.; Albright, Charles F.; Strittmatter, Stephen M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">76-88</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Metabotropic glutamate receptor 5 (mGluR5) has been implicated in Alzheimer's disease (AD) pathol.  We sought to understand whether mGluR5's role in AD requires glutamate signaling.  We used a potent mGluR5 silent allosteric modulator (SAM, BMS-984923) to sep. its well-known physiol. role in glutamate signaling from a pathol. role in mediating amyloid-Î² oligomer (AÎ²o) action.  Binding of the SAM to mGluR5 does not change glutamate signaling but strongly reduces mGluR5 interaction with cellular prion protein (PrPC) bound to AÎ²o.  The SAM compd. prevents AÎ²o-induced signal transduction in brain slices and in an AD transgenic mouse model, the APPswe/PS1ÎE9 strain.  Critically, 4 wk of SAM treatment rescues memory deficits and synaptic depletion in the APPswe/PS1ÎE9 transgenic mouse brain.  Our data show that mGluR5's role in AÎ²o-dependent AD phenotypes is sep. from its role in glutamate signaling and silent allosteric modulation of mGluR5 has promise as a disease-modifying AD intervention with a broad therapeutic window.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiq45bkzh9ebVg90H21EOLACvtfcHk0lhfJJ5fTOXOSw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFartbnN&md5=3e3e1a787fb58397ac649068f0ccd07e</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2017.06.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2017.06.023%26sid%3Dliteratum%253Aachs%26aulast%3DHaas%26aufirst%3DL.%2BT.%26aulast%3DSalazar%26aufirst%3DS.%2BV.%26aulast%3DSmith%26aufirst%3DL.%2BM.%26aulast%3DZhao%26aufirst%3DH.%2BR.%26aulast%3DCox%26aufirst%3DT.%2BO.%26aulast%3DHerber%26aufirst%3DC.%2BS.%26aulast%3DDegnan%26aufirst%3DA.%2BP.%26aulast%3DBalakrishnan%26aufirst%3DA.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26aulast%3DAlbright%26aufirst%3DC.%2BF.%26aulast%3DStrittmatter%26aufirst%3DS.%2BM.%26atitle%3DSilent%2520allosteric%2520modulation%2520of%2520mGluR5%2520maintains%2520glutamate%2520signaling%2520while%2520rescuing%2520Alzheimer%25E2%2580%2599s%2520mouse%2520phenotypes%26jtitle%3DCell%2520Rep.%26date%3D2017%26volume%3D20%26issue%3D1%26spage%3D76%26epage%3D88%26doi%3D10.1016%2Fj.celrep.2017.06.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turkmen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundgren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birzniece, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zingmark, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BÃ¤ckstrÃ¶m, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansson, I. M.</span></span> <span> </span><span class="NLM_article-title">3Î²,20Î²-dihydroxy-5Î±-pregnane (UC1011) antagonism of the GABA potentiation and the learning impairment induced in rats by allopregnanolone</span>. <i>Eur. J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1604</span>â <span class="NLM_lpage">1612</span>, <span class="refDoi">Â DOI: 10.1111/j.1460-9568.2004.03610.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1111%2Fj.1460-9568.2004.03610.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=15355327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A280%3ADC%252BD2cvksl2kuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2004&pages=1604-1612&issue=6&author=S.+Turkmenauthor=P.+Lundgrenauthor=V.+Birznieceauthor=E.+Zingmarkauthor=T.+B%C3%A4ckstr%C3%B6mauthor=I.+M.+Johansson&title=3%CE%B2%2C20%CE%B2-dihydroxy-5%CE%B1-pregnane+%28UC1011%29+antagonism+of+the+GABA+potentiation+and+the+learning+impairment+induced+in+rats+by+allopregnanolone&doi=10.1111%2Fj.1460-9568.2004.03610.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">3beta-20beta-dihydroxy-5alpha-pregnane (UC1011) antagonism of the GABA potentiation and the learning impairment induced in rats by allopregnanolone</span></div><div class="casAuthors">Turkmen Sahruh; Lundgren Per; Birzniece Vita; Zingmark Elisabeth; Backstrom Torbjorn; Johansson Inga-Maj</div><div class="citationInfo"><span class="NLM_cas:title">The European journal of neuroscience</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1604-12</span>
        ISSN:<span class="NLM_cas:issn">0953-816X</span>.
    </div><div class="casAbstract">Allopregnanolone is a progesterone metabolite and GABA-A receptor modulator with benzodiazepine like effects, including decreased learning and memory.  In vitro 3beta-hydroxypregnane steroids antagonize allopregnanolone-induced effects, but no antagonism has been shown in vivo.  Our purpose was to evaluate 3beta-20beta-dihydroxy-5alpha-pregnane (UC1011) as a blocker of allopregnanolone-induced effects in vivo and in vitro in rats.  We tested adult male Wistar rats in the Morris water maze 8 min after daily injections (i.v.) of allopregnanolone 2 mg/kg (n = 21); allopregnanolone : UC1011 2 : 6 (n = 7), 2 : 8 (n = 7), 2 : 20 (n = 14) mg/kg; UC1011 20 mg/kg (n = 14); or vehicle (10% 2-hydroxypropyl-beta-cyclodextrin, n = 4).  Studies of chloride ion uptake into cortical and hippocampal membrane preparations were performed.  The latency to find the hidden platform was still high in the allopregnanolone-injected group on day 6.  Day 3-6 rats injected with allopregnanolone and UC1011 (2 : 20 mg/kg) had lower latency (P < 0.05), compared to the allopregnanolone-injected group.  The group that only received UC1011 learned the location of the platform as fast as the controls.  There was no significant difference in swim speed between groups.  The time spent swimming close to the pool wall was in the allopregnanolone : UC1011 group (2 : 20 mg/kg) significantly decreased (P < 0.05, day 3-6), compared to the allopregnanolone-injected group.  The increased chloride ion uptake induced by increasing dosage of allopregnanolone in the presence of 10 micro m GABA was significantly decreased with UC1011 (P < 0.01), in both cortical and hippocampal homogenates.  In conclusion, UC1011 can via antagonism at the GABA-A receptor reduce the negative allopregnanolone effect on learning in the water maze.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSa5E42Hae79f6BottYdIAWfW6udTcc2eYDka_aWRcaZrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2cvksl2kuw%253D%253D&md5=817bab3820053fa9be0175a3a3b313d8</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1111%2Fj.1460-9568.2004.03610.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1460-9568.2004.03610.x%26sid%3Dliteratum%253Aachs%26aulast%3DTurkmen%26aufirst%3DS.%26aulast%3DLundgren%26aufirst%3DP.%26aulast%3DBirzniece%26aufirst%3DV.%26aulast%3DZingmark%26aufirst%3DE.%26aulast%3DB%25C3%25A4ckstr%25C3%25B6m%26aufirst%3DT.%26aulast%3DJohansson%26aufirst%3DI.%2BM.%26atitle%3D3%25CE%25B2%252C20%25CE%25B2-dihydroxy-5%25CE%25B1-pregnane%2520%2528UC1011%2529%2520antagonism%2520of%2520the%2520GABA%2520potentiation%2520and%2520the%2520learning%2520impairment%2520induced%2520in%2520rats%2520by%2520allopregnanolone%26jtitle%3DEur.%2520J.%2520Neurosci.%26date%3D2004%26volume%3D20%26issue%3D6%26spage%3D1604%26epage%3D1612%26doi%3D10.1111%2Fj.1460-9568.2004.03610.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johansson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">StrÃ¶mberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragagnin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doverskog, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BÃ¤ckstrÃ¶m, T.</span></span> <span> </span><span class="NLM_article-title">GABAA receptor modulating steroid antagonists (GAMSA) are functional in vivo</span>. <i>J. Steroid Biochem. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>160</i></span>,  <span class="NLM_fpage">98</span>â <span class="NLM_lpage">105</span>, <span class="refDoi">Â DOI: 10.1016/j.jsbmb.2015.10.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.jsbmb.2015.10.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=26523675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsl2gsLrL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2016&pages=98-105&author=M.+Johanssonauthor=J.+Str%C3%B6mbergauthor=G.+Ragagninauthor=M.+Doverskogauthor=T.+B%C3%A4ckstr%C3%B6m&title=GABAA+receptor+modulating+steroid+antagonists+%28GAMSA%29+are+functional+in+vivo&doi=10.1016%2Fj.jsbmb.2015.10.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">GABAA receptor modulating steroid antagonists (GAMSA) are functional in vivo</span></div><div class="casAuthors">Johansson, Maja; Stroemberg, Jessica; Ragagnin, Gianna; Doverskog, Magnus; Baeckstroem, Torbjoern</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Steroid Biochemistry and Molecular Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">98-105</span>CODEN:
                <span class="NLM_cas:coden">JSBBEZ</span>;
        ISSN:<span class="NLM_cas:issn">0960-0760</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">GABAA receptor modulating steroid antagonists (GAMSA) selectively inhibit neurosteroid-mediated enhancement of GABA-evoked currents at the GABAA receptor.  3Î±-Hydroxy-neurosteroids, notably allopregnanolone and tetrahydrodeoxycorticosterone (THDOC), potentiate GABAA receptor-mediated currents.  On the contrary, various 3Î²-hydroxy-steroids antagonize this pos. neurosteroid-mediated modulation.  Importantly, GAMSAs are specific antagonists of the pos. neurosteroid-modulation of the receptor and do not inhibit GABA-evoked currents.  Allopregnanolone and THDOC have both neg. and pos. actions.  Allopregnanolone can impair encoding/consolidation and retrieval of memories.  Chronic administration of a physiol. allopregnanolone concn. reduces cognition in mice models of Alzheimer's disease.  In humans an allopregnanolone challenge impairs episodic memory and in hepatic encephalopathy cognitive deficits are accompanied by increased brain ammonia and allopregnanolone.  Hippocampal slices react in vitro to ammonia by allopregnanolone synthesis in CA1 neurons, which blocks long-term potentiation (LTP).  Thus, allopregnanolone may impair learning and memory by interfering with hippocampal LTP.  Contrary, pharmacol. treatment with allopregnanolone can promote neurogenesis and pos. influence learning and memory of trace eye-blink conditioning in mice.  In rat the GAMSA UC1011 inhibits an allopregnanolone-induced learning impairment and the GAMSA GR3027 restores learning and motor coordination in rats with hepatic encephalopathy.  In addn., the GAMSA isoallopregnanolone antagonizes allopregnanolone-induced anesthesia in rats, and in humans it antagonizes allopregnanolone-induced sedation and redns. in saccadic eye velocity.  17PA is also an effective GAMSA in vivo, as it antagonizes allopregnanolone-induced anesthesia and spinal analgesia in rats.  In vitro the allopregnanolone/THDOC-increased GABA-mediated GABAA receptor activity is antagonized by isoallopregnanolone, UC1011, GR3027 and 17PA, while the effect of GABA itself is not affected.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh3EEnyc79dbVg90H21EOLACvtfcHk0lg3TBbt6e3w3Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsl2gsLrL&md5=8f75d41aeda34176dd8b8ca138d96c15</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fj.jsbmb.2015.10.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jsbmb.2015.10.019%26sid%3Dliteratum%253Aachs%26aulast%3DJohansson%26aufirst%3DM.%26aulast%3DStr%25C3%25B6mberg%26aufirst%3DJ.%26aulast%3DRagagnin%26aufirst%3DG.%26aulast%3DDoverskog%26aufirst%3DM.%26aulast%3DB%25C3%25A4ckstr%25C3%25B6m%26aufirst%3DT.%26atitle%3DGABAA%2520receptor%2520modulating%2520steroid%2520antagonists%2520%2528GAMSA%2529%2520are%2520functional%2520in%2520vivo%26jtitle%3DJ.%2520Steroid%2520Biochem.%2520Mol.%2520Biol.%26date%3D2016%26volume%3D160%26spage%3D98%26epage%3D105%26doi%3D10.1016%2Fj.jsbmb.2015.10.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blanco, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coughlin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salituro, F. G.</span></span> <span> </span><span class="NLM_article-title">Breakthroughs in neuroactive steroid drug discovery</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">61</span>â <span class="NLM_lpage">70</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2017.11.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.bmcl.2017.11.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=29223589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFejur3L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=61-70&issue=2&author=M.+J.+Blancoauthor=D.+Laauthor=Q.+Coughlinauthor=C.+Newmanauthor=A.+Griffinauthor=B.+L.+Harrisonauthor=F.+G.+Salituro&title=Breakthroughs+in+neuroactive+steroid+drug+discovery&doi=10.1016%2Fj.bmcl.2017.11.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Breakthroughs in neuroactive steroid drug discovery</span></div><div class="casAuthors">Blanco, Maria-Jesus; La, Daniel; Coughlin, Quinn; Newman, Caitlin A.; Griffin, Andrew M.; Harrison, Boyd L.; Salituro, Francesco G.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">61-70</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Endogenous and synthetic neuroactive steroids (NASs) or neurosteroids are effective modulators of multiple signaling pathways including receptors for the Î³-aminobutyric acid A (GABAA) and glutamate, in particular N-methyl-D-aspartate (NMDA).  These receptors are the major inhibitory and excitatory neurotransmitters in the central nervous system (CNS), and there is growing evidence suggesting that dysregulation of neurosteroid prodn. plays a role in numerous neurol. disorders.  The significant unmet medical need for treatment of CNS disorders has increased the interest for these types of compds.  In this review, we highlight recent progress in the clin. development of NAS drug candidates, in addn. to preclin. breakthroughs in the identification of novel NASs, mainly for GABAA and NMDA receptor modulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0S63TwFqhHbVg90H21EOLACvtfcHk0lg3TBbt6e3w3Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFejur3L&md5=321a2fbf7f8d5d4f90356633ab02f16e</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.11.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.11.043%26sid%3Dliteratum%253Aachs%26aulast%3DBlanco%26aufirst%3DM.%2BJ.%26aulast%3DLa%26aufirst%3DD.%26aulast%3DCoughlin%26aufirst%3DQ.%26aulast%3DNewman%26aufirst%3DC.%26aulast%3DGriffin%26aufirst%3DA.%26aulast%3DHarrison%26aufirst%3DB.%2BL.%26aulast%3DSalituro%26aufirst%3DF.%2BG.%26atitle%3DBreakthroughs%2520in%2520neuroactive%2520steroid%2520drug%2520discovery%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26issue%3D2%26spage%3D61%26epage%3D70%26doi%3D10.1016%2Fj.bmcl.2017.11.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span> <i>Marinus Pharmaceuticals</i>; <span class="NLM_publisher-name">Marinus
Pharmaceuticals</span>: <span class="NLM_publisher-loc">Radnor, PA</span>, <span class="NLM_year">2019</span>; <a href="http://www.marinuspharma.com/pipeline/" class="extLink">http://www.marinuspharma.com/pipeline/</a> (accessed on July 20,
2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Marinus+Pharmaceuticals%3B+Marinus%0APharmaceuticals%3A+Radnor%2C+PA%2C+2019%3B+http%3A%2F%2Fwww.marinuspharma.com%2Fpipeline%2F+%28accessed+on+July+20%2C%0A2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DMarinus%2520Pharmaceuticals%26pub%3DMarinus%250APharmaceuticals%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinez Botella, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salituro, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beresis, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanco, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belfort, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loya, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ackley, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Althaus, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossman, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robichaud, A. J.</span></span> <span> </span><span class="NLM_article-title">Neuroactive Steroids. 2. 3Î±-Hydroxy-3Î²-methyl-21-(4-cyano-1H-pyrazol-1â²-yl)-19-nor-5Î²-pregnan-20-one (SAGE-217): a clinical next generation neuroactive steroid positive allosteric modulator of the (Î³-aminobutyric acid)A receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">7810</span>â <span class="NLM_lpage">7819</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b00846</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00846" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A280%3ADC%252BC1cfitFSgsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7810-7819&issue=18&author=G.+Martinez+Botellaauthor=F.+G.+Salituroauthor=B.+L.+Harrisonauthor=R.+T.+Beresisauthor=Z.+Baiauthor=M.+J.+Blancoauthor=G.+M.+Belfortauthor=J.+Daiauthor=C.+M.+Loyaauthor=M.+A.+Ackleyauthor=A.+L.+Althausauthor=S.+J.+Grossmanauthor=E.+Hoffmannauthor=J.+J.+Dohertyauthor=A.+J.+Robichaud&title=Neuroactive+Steroids.+2.+3%CE%B1-Hydroxy-3%CE%B2-methyl-21-%284-cyano-1H-pyrazol-1%E2%80%B2-yl%29-19-nor-5%CE%B2-pregnan-20-one+%28SAGE-217%29%3A+a+clinical+next+generation+neuroactive+steroid+positive+allosteric+modulator+of+the+%28%CE%B3-aminobutyric+acid%29A+receptor&doi=10.1021%2Facs.jmedchem.7b00846"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroactive Steroids. 2. 3Î±-Hydroxy-3Î²-methyl-21-(4-cyano-1H-pyrazol-1'-yl)-19-nor-5Î²-pregnan-20-one (SAGE-217): A Clinical Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (Î³-Aminobutyric Acid)A Receptor</span></div><div class="casAuthors">Martinez Botella Gabriel; Salituro Francesco G; Harrison Boyd L; Blanco Maria-Jesus; Belfort Gabriel M; Dai Jing; Loya Carlos M; Ackley Michael A; Althaus Alison L; Grossman Scott J; Hoffmann Ethan; Doherty James J; Robichaud Albert J; Beresis Richard T; Bai Zhu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7810-7819</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Certain classes of neuroactive steroids (NASs) are positive allosteric modulators (PAM) of synaptic and extrasynaptic GABAA receptors.  Herein, we report new SAR insights in a series of 5Î²-nor-19-pregnan-20-one analogues bearing substituted pyrazoles and triazoles at C-21, culminating in the discovery of 3Î±-hydroxy-3Î²-methyl-21-(4-cyano-1H-pyrazol-1'-yl)-19-nor-5Î²-pregnan-20-one (SAGE-217, 3), a potent GABAA receptor modulator at both synaptic and extrasynaptic receptor subtypes, with excellent oral DMPK properties.  Compound 3 has completed a phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial and is currently being studied in parallel phase 2 clinical trials for the treatment of postpartum depression (PPD), major depressive disorder (MDD), and essential tremor (ET).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTiySZLUBmmmoUSrryheKE6fW6udTcc2ebzi9Ksr-R_Z7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cfitFSgsg%253D%253D&md5=d9cb22ed2087152aa0e67d0906faa583</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00846&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00846%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez%2BBotella%26aufirst%3DG.%26aulast%3DSalituro%26aufirst%3DF.%2BG.%26aulast%3DHarrison%26aufirst%3DB.%2BL.%26aulast%3DBeresis%26aufirst%3DR.%2BT.%26aulast%3DBai%26aufirst%3DZ.%26aulast%3DBlanco%26aufirst%3DM.%2BJ.%26aulast%3DBelfort%26aufirst%3DG.%2BM.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DLoya%26aufirst%3DC.%2BM.%26aulast%3DAckley%26aufirst%3DM.%2BA.%26aulast%3DAlthaus%26aufirst%3DA.%2BL.%26aulast%3DGrossman%26aufirst%3DS.%2BJ.%26aulast%3DHoffmann%26aufirst%3DE.%26aulast%3DDoherty%26aufirst%3DJ.%2BJ.%26aulast%3DRobichaud%26aufirst%3DA.%2BJ.%26atitle%3DNeuroactive%2520Steroids.%25202.%25203%25CE%25B1-Hydroxy-3%25CE%25B2-methyl-21-%25284-cyano-1H-pyrazol-1%25E2%2580%25B2-yl%2529-19-nor-5%25CE%25B2-pregnan-20-one%2520%2528SAGE-217%2529%253A%2520a%2520clinical%2520next%2520generation%2520neuroactive%2520steroid%2520positive%2520allosteric%2520modulator%2520of%2520the%2520%2528%25CE%25B3-aminobutyric%2520acid%2529A%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D18%26spage%3D7810%26epage%3D7819%26doi%3D10.1021%2Facs.jmedchem.7b00846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bixo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekberg, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poromaa, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirschberg, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonasson, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">AndrÃ©en, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timby, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wulff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrenborg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BÃ¤ckstrÃ¶m, T.</span></span> <span> </span><span class="NLM_article-title">Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC1010)-A randomized controlled trial</span>. <i>Psychoneuroendocrinology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">46</span>â <span class="NLM_lpage">55</span>, <span class="refDoi">Â DOI: 10.1016/j.psyneuen.2017.02.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.psyneuen.2017.02.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=28319848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2sXks1ShtLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2017&pages=46-55&author=M.+Bixoauthor=K.+Ekbergauthor=I.+S.+Poromaaauthor=A.+L.+Hirschbergauthor=A.+F.+Jonassonauthor=L.+Andr%C3%A9enauthor=E.+Timbyauthor=M.+Wulffauthor=A.+Ehrenborgauthor=T.+B%C3%A4ckstr%C3%B6m&title=Treatment+of+premenstrual+dysphoric+disorder+with+the+GABAA+receptor+modulating+steroid+antagonist+Sepranolone+%28UC1010%29-A+randomized+controlled+trial&doi=10.1016%2Fj.psyneuen.2017.02.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC1010)-A randomized controlled trial</span></div><div class="casAuthors">Bixo, Marie; Ekberg, Karin; Poromaa, Inger Sundstroem; Hirschberg, Angelica Linden; Jonasson, Aino Fianu; Andreen, Lotta; Timby, Erika; Wulff, Marianne; Ehrenborg, Agneta; Baeckstroem, Torbjoern</div><div class="citationInfo"><span class="NLM_cas:title">Psychoneuroendocrinology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">46-55</span>CODEN:
                <span class="NLM_cas:coden">PSYCDE</span>;
        ISSN:<span class="NLM_cas:issn">0306-4530</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Allopregnanolone is a metabolite from progesterone and a pos. modulator of the GABAA receptor.  This endogenous steroid may induce neg. mood in sensitive women when present in serum levels comparable to the premenstrual phase.  Its endogenous isomer, isoallopregnanolone, has been shown to antagonize allopregnanolone effects in exptl. animal and human models.  The objective was to test whether inhibition of allopregnanolone by treatment with the GABAA modulating steroid antagonist (GAMSA) Sepranolone (UC1010) during the premenstrual phase could reduce symptoms of the premenstrual dysphoric disorder (PMDD).  The pharmacokinetic parameters of UC1010 when given as a s.c. injection were measured in healthy women prior to the study in women with PMDD.  This was an explorative randomized, double-blind, placebo-controlled study.  Swedish multicentre study with 10 centers.  Participants were 26 healthy women in a pharmacokinetic phase I study part, and 126 women with PMDD in a phase II study part.  Diagnosis followed the criteria for PMDD in DSM-5 using Daily Record of Severity of Problems (DRSP) and Endicott's algorithm.  Subjects were randomized to treatment with UC1010 (10 or 16 mg) s.c. every second day during the luteal phase or placebo during one menstrual cycle.  The primary outcome measure was the sum of all 21 items in DRSP (Total DRSP score).  Secondary outcomes were Neg. mood score i.e. the ratings of the 4 key symptoms in PMDD (anger/irritability, depression, anxiety and lability) and impairment (impact on daily life).26 healthy women completed the pharmacokinetic phase I study and the dosing in the following trial was adjusted according to the results. 106 of the 126 women completed the phase II study.  Within this group, a significant treatment effect with UC1010 compared to placebo was obtained for the Total DRSP score (p = 0.041) and borderline significance (p = 0.051) for the sum of Neg. mood score.  Nineteen participants however showed symptoms during the follicular phase that might be signs of an underlying other conditions, and 27 participants had not received the medication as intended during the symptomatic phase.  Hence, to secure that the significant result described above was not due to chance, a post hoc sub-group anal. was performed, including only women with pure PMDD who completed the trial as intended (n = 60).  In this group UC1010 reduced Total DRSP scores by 75% compared with 47% following placebo; the effect size 0.7 (p = 0.006), and for sum of Neg. mood score (p = 0.003) and impairment (p = 0.010) with the effect size 0.6.  No severe adverse events were reported during the treatment and safety parameters (vital signs and blood chem.) remained normal during the study.  This explorative study indicates promising results for UC1010 as a potential treatment for PMDD.  The effect size was comparable to that of SSRIs and drospirenone contg. oral contraceptives.  UC1010 was well tolerated and deemed safe.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGog3DmRroK10bVg90H21EOLACvtfcHk0lixz5u7-QiEsQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXks1ShtLs%253D&md5=359aa13bf0094df0015523aadd1f6967</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.psyneuen.2017.02.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.psyneuen.2017.02.031%26sid%3Dliteratum%253Aachs%26aulast%3DBixo%26aufirst%3DM.%26aulast%3DEkberg%26aufirst%3DK.%26aulast%3DPoromaa%26aufirst%3DI.%2BS.%26aulast%3DHirschberg%26aufirst%3DA.%2BL.%26aulast%3DJonasson%26aufirst%3DA.%2BF.%26aulast%3DAndr%25C3%25A9en%26aufirst%3DL.%26aulast%3DTimby%26aufirst%3DE.%26aulast%3DWulff%26aufirst%3DM.%26aulast%3DEhrenborg%26aufirst%3DA.%26aulast%3DB%25C3%25A4ckstr%25C3%25B6m%26aufirst%3DT.%26atitle%3DTreatment%2520of%2520premenstrual%2520dysphoric%2520disorder%2520with%2520the%2520GABAA%2520receptor%2520modulating%2520steroid%2520antagonist%2520Sepranolone%2520%2528UC1010%2529-A%2520randomized%2520controlled%2520trial%26jtitle%3DPsychoneuroendocrinology%26date%3D2017%26volume%3D80%26spage%3D46%26epage%3D55%26doi%3D10.1016%2Fj.psyneuen.2017.02.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johansson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MÃ¥nsson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lins, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scharschmidt, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doverskog, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BÃ¤ckstrÃ¶m, T.</span></span> <span> </span><span class="NLM_article-title">GR3027 reversal of neurosteroid-induced, GABA-A receptor-mediated inhibition of human brain function: an allopregnanolone challenge study</span>. <i>Psychopharmacology (Berl)</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>235</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1533</span>â <span class="NLM_lpage">1543</span>, <span class="refDoi">Â DOI: 10.1007/s00213-018-4864-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1007%2Fs00213-018-4864-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=29492615" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A280%3ADC%252BC1MrmsFSrsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=235&publication_year=2018&pages=1533-1543&issue=5&author=M.+Johanssonauthor=M.+M%C3%A5nssonauthor=L.+E.+Linsauthor=B.+Scharschmidtauthor=M.+Doverskogauthor=T.+B%C3%A4ckstr%C3%B6m&title=GR3027+reversal+of+neurosteroid-induced%2C+GABA-A+receptor-mediated+inhibition+of+human+brain+function%3A+an+allopregnanolone+challenge+study&doi=10.1007%2Fs00213-018-4864-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">GR3027 reversal of neurosteroid-induced, GABA-A receptor-mediated inhibition of human brain function: an allopregnanolone challenge study</span></div><div class="casAuthors">Johansson Maja; Mansson Maria; Lins Lars-Eric; Scharschmidt Bruce; Doverskog Magnus; Backstrom Torbjorn; Johansson Maja; Backstrom Torbjorn</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">235</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1533-1543</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">RATIONALE:  GR3027 is a novel small molecule GABA-A receptor-modulating steroid antagonist, which in non-clinical studies has shown promise for treatment of human disorders due to allosteric over-activation of GABA-A receptors by neurosteroids, such as allopregnanolone.  We here studied its safety, pharmacokinetics, and ability to inhibit allopregnanolone effects in humans.  METHODS:  Safety and pharmacokinetics were studied in healthy adult males receiving ascending single or multiple oral GR3027 vs. placebo.  GR3027-mediated reversal of allopregnanolone effect on maximal saccadic eye velocity (SEV), and self-rated somnolence was studied in a double-blind, placebo-controlled, three-part cross-over study in which 3 or 30 mg oral GR3027 preceded 0.05 mg/kg of i.v. allopregnanolone.  RESULTS:  GR3027 was well tolerated, adverse events were generally mild and transient, and no dose-limiting toxicity or grade 3 adverse events were observed up to the highest single (200 mg) or multiple (100 mg every 12 h for 5 days) doses.  The maximum concentration (Cmax) and systemic exposure (area under the plasma concentration-time curve from dose extrapolated to infinity [AUC0-â] and/or AUC during the dosing interval [AUCÏ]) varied linearly with dose; with dose-dependent accumulation ratios of 1.3-1.6.  Allopregnanolone decreased SEV and induced somnolence in most, but not all subjects.  By predefined analyses, 30 mg GR3027 significantly inhibited allopregnanolone-induced decrease in SEV (p = 0.03); 3 and 30 mg GR3027 non-significantly inhibited allopregnanolone-induced sedation.  By post hoc analyses restricted to subjects with allopregnanolone-induced changes and the time period over which they occurred, GR3027 dose dependently inhibited allopregnanolone-induced decrease in SEV (p = 0.04 at 30 mg, non-significant at 3 mg) and allopregnanolone-induced sedation (p = 0.01/0.05 at 3/30 mg doses).  CONCLUSION:  Oral GR3027 mitigates inhibition of brain function induced by allopregnanolone at doses which are clinically well tolerated and associated with linear pharmacokinetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTDJhfcFAoVnBwLZxei1HN8fW6udTcc2eZd3rU0ns6Lxrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrmsFSrsQ%253D%253D&md5=9b89c9a17b9edd83f862badb682bb668</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1007%2Fs00213-018-4864-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-018-4864-1%26sid%3Dliteratum%253Aachs%26aulast%3DJohansson%26aufirst%3DM.%26aulast%3DM%25C3%25A5nsson%26aufirst%3DM.%26aulast%3DLins%26aufirst%3DL.%2BE.%26aulast%3DScharschmidt%26aufirst%3DB.%26aulast%3DDoverskog%26aufirst%3DM.%26aulast%3DB%25C3%25A4ckstr%25C3%25B6m%26aufirst%3DT.%26atitle%3DGR3027%2520reversal%2520of%2520neurosteroid-induced%252C%2520GABA-A%2520receptor-mediated%2520inhibition%2520of%2520human%2520brain%2520function%253A%2520an%2520allopregnanolone%2520challenge%2520study%26jtitle%3DPsychopharmacology%2520%2528Berl%2529%26date%3D2018%26volume%3D235%26issue%3D5%26spage%3D1533%26epage%3D1543%26doi%3D10.1007%2Fs00213-018-4864-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Linsenbardt, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emnett, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covey, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zorumski, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mennerick, S.</span></span> <span> </span><span class="NLM_article-title">Different oxysterols have opposing actions at <i>N</i>-methyl-D-aspartate receptors</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">232</span>â <span class="NLM_lpage">242</span>, <span class="refDoi">Â DOI: 10.1016/j.neuropharm.2014.05.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.neuropharm.2014.05.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=24878244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFyhtb7K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2014&pages=232-242&author=A.+J.+Linsenbardtauthor=A.+Taylorauthor=C.+M.+Emnettauthor=J.+J.+Dohertyauthor=K.+Krishnanauthor=D.+F.+Coveyauthor=S.+M.+Paulauthor=C.+F.+Zorumskiauthor=S.+Mennerick&title=Different+oxysterols+have+opposing+actions+at+N-methyl-D-aspartate+receptors&doi=10.1016%2Fj.neuropharm.2014.05.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Different oxysterols have opposing actions at N-methyl-D-aspartate receptors</span></div><div class="casAuthors">Linsenbardt, Andrew J.; Taylor, Amanda; Emnett, Christine M.; Doherty, James J.; Krishnan, Kathiresan; Covey, Douglas F.; Paul, Steven M.; Zorumski, Charles F.; Mennerick, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">232-242</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Oxysterols have emerged as important biomarkers in disease and as signaling mols.  We recently showed that the oxysterol 24(S)-hydroxycholesterol, the major brain cholesterol metabolite, potently and selectively enhances NMDA receptor function at a site distinct from other modulators.  Here we further characterize the pharmacol. mechanisms of 24(S)-hydroxycholesterol and its synthetic analog SGE201.  We describe an oxysterol antagonist of this pos. allosteric modulation, 25-hydroxycholesterol.  We found that 24(S)-hydroxycholesterol and SGE201 primarily increased the efficacy of NMDAR agonists but did not directly gate the channel or increase functional receptor no.  Rather than binding to a direct aq.-accessible site, oxysterols may partition into the plasma membrane to access the NMDAR, likely explaining slow onset and offset kinetics of modulation.  Interestingly, oxysterols were ineffective when applied to the cytosolic face of inside-out membrane patches or through a whole-cell pipet soln., suggesting a non-intracellular site.  We also found that another natural oxysterol, 25-hydroxycholesterol, although exhibiting slight potentiation on its own, non-competitively and enantioselectively antagonized the effects of 24(S)-hydroxycholesterol analogs.  In summary, we suggest two novel allosteric sites on NMDARs that sep. modulate channel gating, but together oppose each other.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMfECHj13EKLVg90H21EOLACvtfcHk0ljOGufGEjuENQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFyhtb7K&md5=0fbd27a7cb8e4ac2db9fe70abe12466b</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2014.05.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2014.05.027%26sid%3Dliteratum%253Aachs%26aulast%3DLinsenbardt%26aufirst%3DA.%2BJ.%26aulast%3DTaylor%26aufirst%3DA.%26aulast%3DEmnett%26aufirst%3DC.%2BM.%26aulast%3DDoherty%26aufirst%3DJ.%2BJ.%26aulast%3DKrishnan%26aufirst%3DK.%26aulast%3DCovey%26aufirst%3DD.%2BF.%26aulast%3DPaul%26aufirst%3DS.%2BM.%26aulast%3DZorumski%26aufirst%3DC.%2BF.%26aulast%3DMennerick%26aufirst%3DS.%26atitle%3DDifferent%2520oxysterols%2520have%2520opposing%2520actions%2520at%2520N-methyl-D-aspartate%2520receptors%26jtitle%3DNeuropharmacology%26date%3D2014%26volume%3D85%26spage%3D232%26epage%3D242%26doi%3D10.1016%2Fj.neuropharm.2014.05.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paul, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robichaud, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belfort, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linsenbardt, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mennerick, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zorumski, C. F.</span></span> <span> </span><span class="NLM_article-title">The major brain cholesterol metabolite 24(<i>S</i>)-hydroxycholesterol is a potent allosteric modulator of <i>N</i>-methyl-D-aspartate receptors</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">44</span>),  <span class="NLM_fpage">17290</span>â <span class="NLM_lpage">17300</span>, <span class="refDoi">Â DOI: 10.1523/JNEUROSCI.2619-13.2013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1523%2FJNEUROSCI.2619-13.2013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=24174662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslCjtrbI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2013&pages=17290-17300&issue=44&author=S.+M.+Paulauthor=J.+J.+Dohertyauthor=A.+J.+Robichaudauthor=G.+M.+Belfortauthor=B.+Y.+Chowauthor=R.+S.+Hammondauthor=D.+C.+Crawfordauthor=A.+J.+Linsenbardtauthor=H.+J.+Shuauthor=Y.+Izumiauthor=S.+J.+Mennerickauthor=C.+F.+Zorumski&title=The+major+brain+cholesterol+metabolite+24%28S%29-hydroxycholesterol+is+a+potent+allosteric+modulator+of+N-methyl-D-aspartate+receptors&doi=10.1523%2FJNEUROSCI.2619-13.2013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">The major brain cholesterol metabolite 24(S)-hydroxycholesterol is a potent allosteric modulator of N-methyl-D-aspartate receptors</span></div><div class="casAuthors">Paul, Steven M.; Doherty, James J.; Robichaud, Albert J.; Belfort, Gabriel M.; Chow, Brian Y.; Hammond, Rebecca S.; Crawford, Devon C.; Linsenbardt, Andrew J.; Shu, Hong-Jin; Izumi, Yukitoshi; Mennerick, Steven J.; Zorumski, Charles F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">17290-17300</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">N-methyl-D-aspartate receptors (NMDARs) are glutamate-gated ion channels that are crit. to the regulation of excitatory synaptic function in the CNS.  NMDARs govern experience-dependent synaptic plasticity and have been implicated in the pathophysiol. of various neuropsychiatric disorders including the cognitive deficits of schizophrenia and certain forms of autism.  Certain neurosteroids modulate NMDARs exptl. but their low potency, poor selectivity, and very low brain concns. make them poor candidates as endogenous ligands or therapeutic agents.  Here we show that the major brain-derived cholesterol metabolite 24(S)-hydroxycholesterol (24(S)-HC) is a very potent, direct, and selective pos. allosteric modulator of NMDARs with a mechanism that does not overlap that of other allosteric modulators.  At submicromolar concns. 24(S)-HC potentiates NMDAR-mediated EPSCs in rat hippocampal neurons but fails to affect AMPAR or GABAA receptors (GABAARs)-mediated responses.  Cholesterol itself and other naturally occurring oxysterols present in brain do not modulate NMDARs at concns. â¤10 Î¼M.  In hippocampal slices, 24(S)-HC enhances the ability of subthreshold stimuli to induce long-term potentiation (LTP).  24(S)-HC also reverses hippocampal LTP deficits induced by the NMDAR channel blocker ketamine.  Finally, we show that synthetic drug-like derivs. of 24(S)-HC, which potently enhance NMDAR-mediated EPSCs and LTP, restore behavioral and cognitive deficits in rodents treated with NMDAR channel blockers.  Thus, 24(S)-HC may function as an endogenous modulator of NMDARs acting at a novel oxysterol modulatory site that also represents a target for therapeutic drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDNdn3JBVmtLVg90H21EOLACvtfcHk0ljtiaKQh655dQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslCjtrbI&md5=35ab8bb8030a4ac752f224f8cd942fb4</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.2619-13.2013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.2619-13.2013%26sid%3Dliteratum%253Aachs%26aulast%3DPaul%26aufirst%3DS.%2BM.%26aulast%3DDoherty%26aufirst%3DJ.%2BJ.%26aulast%3DRobichaud%26aufirst%3DA.%2BJ.%26aulast%3DBelfort%26aufirst%3DG.%2BM.%26aulast%3DChow%26aufirst%3DB.%2BY.%26aulast%3DHammond%26aufirst%3DR.%2BS.%26aulast%3DCrawford%26aufirst%3DD.%2BC.%26aulast%3DLinsenbardt%26aufirst%3DA.%2BJ.%26aulast%3DShu%26aufirst%3DH.%2BJ.%26aulast%3DIzumi%26aufirst%3DY.%26aulast%3DMennerick%26aufirst%3DS.%2BJ.%26aulast%3DZorumski%26aufirst%3DC.%2BF.%26atitle%3DThe%2520major%2520brain%2520cholesterol%2520metabolite%252024%2528S%2529-hydroxycholesterol%2520is%2520a%2520potent%2520allosteric%2520modulator%2520of%2520N-methyl-D-aspartate%2520receptors%26jtitle%3DJ.%2520Neurosci.%26date%3D2013%26volume%3D33%26issue%3D44%26spage%3D17290%26epage%3D17300%26doi%3D10.1523%2FJNEUROSCI.2619-13.2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nickolls, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurrell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Amerongen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kammonen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stead, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mead, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fish, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitlock, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Gerven, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dua, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butt, R. P.</span></span> <span> </span><span class="NLM_article-title">Pharmacology in translation: the preclinical and early clinical profile of the novel Î±2/3 functionally selective GABA<sub>A</sub> receptor positive allosteric modulator PF-06372865</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>175</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">708</span>â <span class="NLM_lpage">725</span>, <span class="refDoi">Â DOI: 10.1111/bph.14119</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1111%2Fbph.14119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=29214652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFKrtrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2018&pages=708-725&issue=4&author=S.+A.+Nickollsauthor=R.+Gurrellauthor=G.+van+Amerongenauthor=J.+Kammonenauthor=L.+Caoauthor=A.+R.+Brownauthor=C.+Steadauthor=A.+Meadauthor=C.+Watsonauthor=C.+Hsuauthor=R.+M.+Owenauthor=A.+Pikeauthor=R.+L.+Fishauthor=L.+Chenauthor=R.+Qiuauthor=E.+D.+Morrisauthor=G.+Fengauthor=M.+Whitlockauthor=D.+Gormanauthor=J.+van+Gervenauthor=D.+S.+Reynoldsauthor=P.+Duaauthor=R.+P.+Butt&title=Pharmacology+in+translation%3A+the+preclinical+and+early+clinical+profile+of+the+novel+%CE%B12%2F3+functionally+selective+GABAA+receptor+positive+allosteric+modulator+PF-06372865&doi=10.1111%2Fbph.14119"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology in translation: the preclinical and early clinical profile of the novel Î±2/3 functionally selective GABAA receptor positive allosteric modulator PF-06372865</span></div><div class="casAuthors">Nickolls, Sarah A.; Gurrell, Rachel; van Amerongen, Guido; Kammonen, Juha; Cao, Lishuang; Brown, Adam R.; Stead, Clara; Mead, Andy; Watson, Christine; Hsu, Cathleen; Owen, Robert M.; Pike, Andy; Fish, Rebecca L.; Chen, Laigao; Qiu, Ruolun; Morris, Evan D.; Feng, Gang; Whitlock, Mark; Gorman, Donal; van Gerven, Joop; Reynolds, David S.; Dua, Pinky; Butt, Richard P.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">708-725</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose: Benzodiazepines, non-selective pos. allosteric modulators (PAMs) of GABAA receptors, have significant side effects that limit their clin. utility.  As many of these side effects are mediated by the Î±1 subunit, there has been a concerted effort to develop Î±2/3 subtype-selective PAMs.  Exptl. Approach: In vitro screening assays were used to identify mols. with functional selectivity for receptors contg. Î±2/3 subunits over those contg. Î±1 subunits.  In vivo receptor occupancy (RO) was conducted, prior to confirmation of in vivo Î±2/3 and Î±1 pharmacol. through quant. EEG (qEEG) beta frequency and zolpidem drug discrimination in rats resp.  PF-06372865 was then progressed to Phase 1 clin. trials.  Key Results: PF-06372865 exhibited functional selectivity for those receptors contg. Î±2/3/5 subunits, with significant pos. allosteric modulation (90-140%) but negligible activity (â¤20%) at GABAA receptors contg. Î±1 subunits.  PF-06372865 exhibited concn.-dependent occupancy of GABAA receptors in preclin. species.  There was an occupancy-dependent increase in qEEG beta frequency and no generalization to a GABAA Î±1 cue in the drug-discrimination assay, clearly demonstrating the lack of modulation at the GABAA receptors contg. an Î±1 subtype.  In a Phase 1 single ascending dose study in healthy volunteers, evaluation of the pharmacodynamics of PF-06372865 demonstrated a robust increase in saccadic peak velocity (a marker of Î±2/3 pharmacol.), increases in beta frequency qEEG and a slight satg. increase in body sway.  Conclusions and Implications: PF-06372865 has a unique clin. pharmacol. profile and a highly predictive translational data package from preclin. species to the clin. setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppCgUwgmVaq7Vg90H21EOLACvtfcHk0ljtiaKQh655dQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFKrtrY%253D&md5=fea6d4ebedc564f92a73250d1dc8115d</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1111%2Fbph.14119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.14119%26sid%3Dliteratum%253Aachs%26aulast%3DNickolls%26aufirst%3DS.%2BA.%26aulast%3DGurrell%26aufirst%3DR.%26aulast%3Dvan%2BAmerongen%26aufirst%3DG.%26aulast%3DKammonen%26aufirst%3DJ.%26aulast%3DCao%26aufirst%3DL.%26aulast%3DBrown%26aufirst%3DA.%2BR.%26aulast%3DStead%26aufirst%3DC.%26aulast%3DMead%26aufirst%3DA.%26aulast%3DWatson%26aufirst%3DC.%26aulast%3DHsu%26aufirst%3DC.%26aulast%3DOwen%26aufirst%3DR.%2BM.%26aulast%3DPike%26aufirst%3DA.%26aulast%3DFish%26aufirst%3DR.%2BL.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DQiu%26aufirst%3DR.%26aulast%3DMorris%26aufirst%3DE.%2BD.%26aulast%3DFeng%26aufirst%3DG.%26aulast%3DWhitlock%26aufirst%3DM.%26aulast%3DGorman%26aufirst%3DD.%26aulast%3Dvan%2BGerven%26aufirst%3DJ.%26aulast%3DReynolds%26aufirst%3DD.%2BS.%26aulast%3DDua%26aufirst%3DP.%26aulast%3DButt%26aufirst%3DR.%2BP.%26atitle%3DPharmacology%2520in%2520translation%253A%2520the%2520preclinical%2520and%2520early%2520clinical%2520profile%2520of%2520the%2520novel%2520%25CE%25B12%252F3%2520functionally%2520selective%2520GABAA%2520receptor%2520positive%2520allosteric%2520modulator%2520PF-06372865%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2018%26volume%3D175%26issue%3D4%26spage%3D708%26epage%3D725%26doi%3D10.1111%2Fbph.14119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doller, D.</span></span> <span> </span><span class="NLM_article-title">Recent developments in group I metabotropic glutamate receptor allosteric modulators for the treatment of psychiatric and neurological disorders (2014-May 2015)</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">29</span>),  <span class="NLM_fpage">3470</span>â <span class="NLM_lpage">3526</span>, <span class="refDoi">Â DOI: 10.2174/1568026616666160405113536</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.2174%2F1568026616666160405113536" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=27048271" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslKksLzE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=3470-3526&issue=29&author=G.+Liauthor=M.+Jorgensenauthor=B.+M.+Campbellauthor=D.+Doller&title=Recent+developments+in+group+I+metabotropic+glutamate+receptor+allosteric+modulators+for+the+treatment+of+psychiatric+and+neurological+disorders+%282014-May+2015%29&doi=10.2174%2F1568026616666160405113536"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Developments in Group I Metabotropic Glutamate Receptor Allosteric Modulators for the Treatment of Psychiatric and Neurological Disorders (2014-May 2015)</span></div><div class="casAuthors">Li, Guiying; Jorgensen, Morten; Campbell, Brian M.; Doller, Dario</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">3470-3526</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">In the last â¼30 years, scientists have made great strides in understanding the biol. function of group I metabotropic glutamate receptors (mGlu) in health and disease, as well as developing a broad array of potent and selective agents able to activate or inhibit these receptors.  This article provides a comprehensive review of the most recent group I mGlu modulators published in patent and non-patent literatures from 2014 to May, 2015, including design, structure-activity relationship, in silico, in vitro and in vivo properties of key compds.  The current status of clin. mGlu5 neg. allosteric modulators (NAMs) and the development of mGlu1 and mGlu5 PET ligands are also highlighted.  While the therapeutic potential for group I mGlu modulating agents appears high, significant challenges remain.  Strategies to reduce clin. development risks and mitigate important side effects, including psychotomimetic events obsd. with several mGlu5 NAMs and cellular toxicity assocd. with mGlu5 pos. allosteric modulators (PAMs), while retaining therapeutic efficacy through approaches such as biased ligand signaling are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlCrD4Oz3xJLVg90H21EOLACvtfcHk0ljtiaKQh655dQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslKksLzE&md5=d931187d0a9c499c0fe875b823725ad3</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.2174%2F1568026616666160405113536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026616666160405113536%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DG.%26aulast%3DJorgensen%26aufirst%3DM.%26aulast%3DCampbell%26aufirst%3DB.%2BM.%26aulast%3DDoller%26aufirst%3DD.%26atitle%3DRecent%2520developments%2520in%2520group%2520I%2520metabotropic%2520glutamate%2520receptor%2520allosteric%2520modulators%2520for%2520the%2520treatment%2520of%2520psychiatric%2520and%2520neurological%2520disorders%2520%25282014-May%25202015%2529%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2016%26volume%3D16%26issue%3D29%26spage%3D3470%26epage%3D3526%26doi%3D10.2174%2F1568026616666160405113536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Youssef, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry-Kravis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czech, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagerman, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hessl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabbia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deptula, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinch, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewitt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindemann, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcinowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langland, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontoura, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santarelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quiroz, J. A.</span></span>; <span class="NLM_contrib-group">FragXis study group</span> <span> </span><span class="NLM_article-title">Effect of the mGluR5-NAM basimglurant on behavior in adolescents and adults with fragile X syndrome in a randomized, double-blind, placebo-controlled trial: FragXis phase 2 results</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">503</span>â <span class="NLM_lpage">512</span>, <span class="refDoi">Â DOI: 10.1038/npp.2017.177</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fnpp.2017.177" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=28816242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFantrbI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2018&pages=503-512&issue=3&author=E.+A.+Youssefauthor=E.+Berry-Kravisauthor=C.+Czechauthor=R.+J.+Hagermanauthor=D.+Hesslauthor=C.+Y.+Wongauthor=M.+Rabbiaauthor=D.+Deptulaauthor=A.+Johnauthor=R.+Kinchauthor=P.+Drewittauthor=L.+Lindemannauthor=M.+Marcinowskiauthor=R.+Langlandauthor=C.+Hornauthor=P.+Fontouraauthor=L.+Santarelliauthor=J.+A.+Quirozauthor=FragXis+study+group&title=Effect+of+the+mGluR5-NAM+basimglurant+on+behavior+in+adolescents+and+adults+with+fragile+X+syndrome+in+a+randomized%2C+double-blind%2C+placebo-controlled+trial%3A+FragXis+phase+2+results&doi=10.1038%2Fnpp.2017.177"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results</span></div><div class="casAuthors">Youssef, Eriene A.; Berry-Kravis, Elizabeth; Czech, Christian; Hagerman, Randi J.; Hessl, David; Wong, Chin Y.; Rabbia, Michael; Deptula, Dennis; John, Amy; Kinch, Russell; Drewitt, Philip; Lindemann, Lothar; Marcinowski, Moritz; Langland, Rachel; Horn, Carsten; Fontoura, Paulo; Santarelli, Luca; Quiroz, Jorge A.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">503-512</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Preclin. data suggest that inhibition of the metabotropic glutamate receptor 5 (mGluR5) receptor might hold therapeutic benefits in Fragile X syndrome (FXS).  Treatment of Fmr1 knockout mice with mGluR5-neg. allosteric modulators (NAMs) has been reported to correct a broad range of phenotypes related to FXS.  The early short-term clin. trials with mGluR5 NAMs, including basimglurant, assessing the effects in individuals with FXS, were supportive of further exploration in larger, well-controlled trials.  We evaluated basimglurant, a potent and selective mGluR5 NAM, in a 12-wk, double-blind, parallel-group study of 183 adults and adolescents (aged 14-50, mean 23.4 years) with FXS.  Individuals with an FMR1 full mutation were randomized to placebo or one of two doses of basimglurant.  The primary efficacy endpoint was the change from baseline in behavioral symptoms using the Anxiety Depression and Mood Scale (ADAMS) total score.  All treatment arms showed marked behavioral improvements from baseline to week 12 with less improvement in the basimglurant 1.5 mg arm than placebo; however, basimglurant 0.5 mg was inferior to placebo in the ADAMs total score.  Treatment with basimglurant was overall well-tolerated.  A higher incidence of adverse events classified as psychiatric disorders were reported in patients treated with basimglurant, including three patients with hallucinations or psychosis.  In this phase 2 clin. trial, basimglurant did not demonstrate improvement over placebo.  Evaluation of the overall risk-benefit in younger patient populations is an important consideration for the design of potential further investigations of efficacy with this class of medications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaxLdgyuHLnrVg90H21EOLACvtfcHk0lhMr6bTAKStDQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFantrbI&md5=7759b9d123916553747889db318aa343</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2017.177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2017.177%26sid%3Dliteratum%253Aachs%26aulast%3DYoussef%26aufirst%3DE.%2BA.%26aulast%3DBerry-Kravis%26aufirst%3DE.%26aulast%3DCzech%26aufirst%3DC.%26aulast%3DHagerman%26aufirst%3DR.%2BJ.%26aulast%3DHessl%26aufirst%3DD.%26aulast%3DWong%26aufirst%3DC.%2BY.%26aulast%3DRabbia%26aufirst%3DM.%26aulast%3DDeptula%26aufirst%3DD.%26aulast%3DJohn%26aufirst%3DA.%26aulast%3DKinch%26aufirst%3DR.%26aulast%3DDrewitt%26aufirst%3DP.%26aulast%3DLindemann%26aufirst%3DL.%26aulast%3DMarcinowski%26aufirst%3DM.%26aulast%3DLangland%26aufirst%3DR.%26aulast%3DHorn%26aufirst%3DC.%26aulast%3DFontoura%26aufirst%3DP.%26aulast%3DSantarelli%26aufirst%3DL.%26aulast%3DQuiroz%26aufirst%3DJ.%2BA.%26aulast%3D%26atitle%3DEffect%2520of%2520the%2520mGluR5-NAM%2520basimglurant%2520on%2520behavior%2520in%2520adolescents%2520and%2520adults%2520with%2520fragile%2520X%2520syndrome%2520in%2520a%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520trial%253A%2520FragXis%2520phase%25202%2520results%26jtitle%3DNeuropsychopharmacology%26date%3D2018%26volume%3D43%26issue%3D3%26spage%3D503%26epage%3D512%26doi%3D10.1038%2Fnpp.2017.177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gould, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amato, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bubser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joffe, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nedelcovych, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickols, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuh, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felts, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byers, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rook, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niswender, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmitte, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. K.</span></span> <span> </span><span class="NLM_article-title">Partial mGlu<sub>5</sub> negative allosteric modulators attenuate cocaine-mediated behaviors and lack psychotomimetic-like effects</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>41</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1166</span>â <span class="NLM_lpage">1178</span>, <span class="refDoi">Â DOI: 10.1038/npp.2015.265</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fnpp.2015.265" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=26315507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2htrnE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2016&pages=1166-1178&issue=4&author=R.+W.+Gouldauthor=R.+J.+Amatoauthor=M.+Bubserauthor=M.+E.+Joffeauthor=M.+T.+Nedelcovychauthor=A.+D.+Thompsonauthor=H.+H.+Nickolsauthor=J.+P.+Yuhauthor=X.+Zhanauthor=A.+S.+Feltsauthor=A.+L.+Rodriguezauthor=R.+D.+Morrisonauthor=F.+W.+Byersauthor=J.+M.+Rookauthor=J.+S.+Danielsauthor=C.+M.+Niswenderauthor=P.+J.+Connauthor=K.+A.+Emmitteauthor=C.+W.+Lindsleyauthor=C.+K.+Jones&title=Partial+mGlu5+negative+allosteric+modulators+attenuate+cocaine-mediated+behaviors+and+lack+psychotomimetic-like+effects&doi=10.1038%2Fnpp.2015.265"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Partial mGlu5 Negative Allosteric Modulators Attenuate Cocaine-Mediated Behaviors and Lack Psychotomimetic-Like Effects</span></div><div class="casAuthors">Gould, Robert W.; Amato, Russell J.; Bubser, Michael; Joffe, Max E.; Nedelcovych, Michael T.; Thompson, Analisa D.; Nickols, Hilary H.; Yuh, Johannes P.; Zhan, Xiaoyan; Felts, Andrew S.; Rodriguez, Alice L.; Morrison, Ryan D.; Byers, Frank W.; Rook, Jerri M.; Daniels, John S.; Niswender, Colleen M.; Conn, P. Jeffrey; Emmitte, Kyle A.; Lindsley, Craig W.; Jones, Carrie K.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1166-1178</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cocaine abuse remains a public health concern for which pharmacotherapies are largely ineffective.  Comorbidities between cocaine abuse, depression, and anxiety support the development of novel treatments targeting multiple symptom clusters.  Selective neg. allosteric modulators (NAMs) targeting the metabotropic glutamate receptor 5 (mGlu5) subtype are currently in clin. trials for the treatment of multiple neuropsychiatric disorders and have shown promise in preclin. models of substance abuse.  However, complete blockade or inverse agonist activity by some full mGlu5 NAM chemotypes demonstrated adverse effects, including psychosis in humans and psychotomimetic-like effects in animals, suggesting a narrow therapeutic window.  Development of partial mGlu5 NAMs, characterized by their submaximal but saturable levels of blockade, may represent a novel approach to broaden the therapeutic window.  To understand potential therapeutic vs adverse effects in preclin. behavioral assays, we examd. the partial mGlu5 NAMs, M-5MPEP and Br-5MPEPy, in comparison with the full mGlu5 NAM MTEP across models of addiction and psychotomimetic-like activity.  M-5MPEP, Br-5MPEPy, and MTEP dose-dependently decreased cocaine self-administration and attenuated the discriminative stimulus effects of cocaine.  M-5MPEP and Br-5MPEPy also demonstrated antidepressant- and anxiolytic-like activity.  Dose-dependent effects of partial and full mGlu5 NAMs in these assays corresponded with increasing in vivo mGlu5 occupancy, demonstrating an orderly occupancy-to-efficacy relationship.  PCP-induced hyperlocomotion was potentiated by MTEP, but not by M-5MPEP and Br-5MPEPy.  Further, MTEP, but not M-5MPEP, potentiated the discriminative-stimulus effects of PCP.  The present data suggest that partial mGlu5 NAM activity is sufficient to produce therapeutic effects similar to full mGlu5 NAMs, but with a broader therapeutic index.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZe4O0o7NSy7Vg90H21EOLACvtfcHk0lhMr6bTAKStDQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2htrnE&md5=5b6ebd4049872b33d32cfbadade1bdb3</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2015.265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2015.265%26sid%3Dliteratum%253Aachs%26aulast%3DGould%26aufirst%3DR.%2BW.%26aulast%3DAmato%26aufirst%3DR.%2BJ.%26aulast%3DBubser%26aufirst%3DM.%26aulast%3DJoffe%26aufirst%3DM.%2BE.%26aulast%3DNedelcovych%26aufirst%3DM.%2BT.%26aulast%3DThompson%26aufirst%3DA.%2BD.%26aulast%3DNickols%26aufirst%3DH.%2BH.%26aulast%3DYuh%26aufirst%3DJ.%2BP.%26aulast%3DZhan%26aufirst%3DX.%26aulast%3DFelts%26aufirst%3DA.%2BS.%26aulast%3DRodriguez%26aufirst%3DA.%2BL.%26aulast%3DMorrison%26aufirst%3DR.%2BD.%26aulast%3DByers%26aufirst%3DF.%2BW.%26aulast%3DRook%26aufirst%3DJ.%2BM.%26aulast%3DDaniels%26aufirst%3DJ.%2BS.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DEmmitte%26aufirst%3DK.%2BA.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DJones%26aufirst%3DC.%2BK.%26atitle%3DPartial%2520mGlu5%2520negative%2520allosteric%2520modulators%2520attenuate%2520cocaine-mediated%2520behaviors%2520and%2520lack%2520psychotomimetic-like%2520effects%26jtitle%3DNeuropsychopharmacology%26date%3D2016%26volume%3D41%26issue%3D4%26spage%3D1166%26epage%3D1178%26doi%3D10.1038%2Fnpp.2015.265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nickols, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuh, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmitte, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bubser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nedelcovych, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niswender, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span> <span> </span><span class="NLM_article-title">VU0477573: partial negative allosteric modulator of the subtype 5 metabotropic glutamate receptor with in vivo efficacy</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>356</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">123</span>â <span class="NLM_lpage">136</span>, <span class="refDoi">Â DOI: 10.1124/jpet.115.226597</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1124%2Fjpet.115.226597" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=26503377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhsleks78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2016&pages=123-136&issue=1&author=H.+H.+Nickolsauthor=J.+P.+Yuhauthor=K.+J.+Gregoryauthor=R.+D.+Morrisonauthor=B.+S.+Batesauthor=S.+R.+Staufferauthor=K.+A.+Emmitteauthor=M.+Bubserauthor=W.+Pengauthor=M.+T.+Nedelcovychauthor=A.+Thompsonauthor=X.+Lvauthor=Z.+Xiangauthor=J.+S.+Danielsauthor=C.+M.+Niswenderauthor=C.+W.+Lindsleyauthor=C.+K.+Jonesauthor=P.+J.+Conn&title=VU0477573%3A+partial+negative+allosteric+modulator+of+the+subtype+5+metabotropic+glutamate+receptor+with+in+vivo+efficacy&doi=10.1124%2Fjpet.115.226597"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">VU0477573: partial negative allosteric modulator of the subtype 5 metabotropic glutamate receptor with in vivo efficacy</span></div><div class="casAuthors">Nickols, Hilary Highfield; Yuh, Joannes P.; Gregory, Karen J.; Morrison, Ryan D.; Bates, Brittney S.; Stauffer, Shaun R.; Emmitte, Kyle A.; Bubser, Michael; Peng, Weimin; Nedelcovych, Michael T.; Thompson, Analisa; Lv, Xiaohui; Xiang, Zixiu; Daniels, J. Scott; Niswender, Colleen M.; Lindsley, Craig W.; Jones, Carrie K.; Conn, P. Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">123-136</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Neg. allosteric modulators (NAMs) of metabotropic glutamate receptor subtype 5 (mGlu5) have potential applications in the treatment of fragile X syndrome, levodopa-induced dyskinesia in Parkinson disease, Alzheimer disease, addiction, and anxiety; however, clin. and preclin. studies raise concerns that complete blockade of mGlu5 and inverse agonist activity of current mGlu5 NAMs contribute to adverse effects that limit the therapeutic use of these compds.  We report the discovery and characterization of a novel mGlu5 NAM, N,N-diethyl-5-((3-fluorophenyl)ethynyl)picolinamide (VU0477573) that binds to the same allosteric site as the prototypical mGlu5 NAM MPEP but displays weak neg. cooperativity.  Because of this weak cooperativity, VU0477573 acts as a "partial NAM" so that full occupancy of the MPEP site does not completely inhibit maximal effects of mGlu5 agonists on intracellular calcium mobilization, inositol phosphate (IP) accumulation, or inhibition of synaptic transmission at the hippocampal Schaffer collateral-CA1 synapse.  Unlike previous mGlu5 NAMs, VU0477573 displays no inverse agonist activity assessed using measures of effects on basal [3H]inositol phosphate (IP) accumulation.  VU0477573 acts as a full NAM when measuring effects on mGlu5-mediated extracellular signal-related kinases 1/2 phosphorylation, which may indicate functional bias.  VU0477573 exhibits an excellent pharmacokinetic profile and good brain penetration in rodents and provides dose-dependent full mGlu5 occupancy in the central nervous system (CNS) with systemic administration.  Interestingly, VU0477573 shows robust efficacy, comparable to the mGlu5 NAM MTEP, in models of anxiolytic activity at doses that provide full CNS occupancy of mGlu5 and demonstrate an excellent CNS occupancy-efficacy relationship.  VU0477573 provides an exciting new tool to investigate the efficacy of partial NAMs in animal models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopb5YLSgOc37Vg90H21EOLACvtfcHk0ljlSDPubsQ3Qw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhsleks78%253D&md5=913f14cbfff58c61e1302fc2eeba52e2</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1124%2Fjpet.115.226597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.115.226597%26sid%3Dliteratum%253Aachs%26aulast%3DNickols%26aufirst%3DH.%2BH.%26aulast%3DYuh%26aufirst%3DJ.%2BP.%26aulast%3DGregory%26aufirst%3DK.%2BJ.%26aulast%3DMorrison%26aufirst%3DR.%2BD.%26aulast%3DBates%26aufirst%3DB.%2BS.%26aulast%3DStauffer%26aufirst%3DS.%2BR.%26aulast%3DEmmitte%26aufirst%3DK.%2BA.%26aulast%3DBubser%26aufirst%3DM.%26aulast%3DPeng%26aufirst%3DW.%26aulast%3DNedelcovych%26aufirst%3DM.%2BT.%26aulast%3DThompson%26aufirst%3DA.%26aulast%3DLv%26aufirst%3DX.%26aulast%3DXiang%26aufirst%3DZ.%26aulast%3DDaniels%26aufirst%3DJ.%2BS.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DJones%26aufirst%3DC.%2BK.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26atitle%3DVU0477573%253A%2520partial%2520negative%2520allosteric%2520modulator%2520of%2520the%2520subtype%25205%2520metabotropic%2520glutamate%2520receptor%2520with%2520in%2520vivo%2520efficacy%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2016%26volume%3D356%26issue%3D1%26spage%3D123%26epage%3D136%26doi%3D10.1124%2Fjpet.115.226597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keov, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span> <span> </span><span class="NLM_article-title">Allosteric modulation of G protein-coupled receptors: a pharmacological perspective</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">24</span>â <span class="NLM_lpage">35</span>, <span class="refDoi">Â DOI: 10.1016/j.neuropharm.2010.07.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.neuropharm.2010.07.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=20637785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVaitLzO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2011&pages=24-35&author=P.+Keovauthor=P.+M.+Sextonauthor=A.+Christopoulos&title=Allosteric+modulation+of+G+protein-coupled+receptors%3A+a+pharmacological+perspective&doi=10.1016%2Fj.neuropharm.2010.07.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric modulation of G protein-coupled receptors: A pharmacological perspective</span></div><div class="casAuthors">Keov, Peter; Sexton, Patrick M.; Christopoulos, Arthur</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">24-35</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  G protein-coupled receptor (GPCR)-based drug discovery has traditionally focused on targeting the orthosteric site for the endogenous agonist.  However, many GPCRs possess allosteric sites that offer enormous potential for greater selectivity in drug action.  The complex behaviors ascribed to allosteric ligands also present challenges to those interested in preclin. lead discovery.  These challenges include the need to detect and quantify various phenomena when screening for allosteric ligands, such as saturability of effect, probe dependence, differential effects on orthosteric ligand affinity vs. efficacy, system-dependent allosteric agonism, stimulus-bias (functional selectivity), and the potential existence of bitopic (hybrid orthosteric/allosteric) ligands.  These issues are also crit. when interpreting structure-function studies of allosteric GPCR modulators because mutations in receptor structure, either engineered or naturally occurring, can differentially affect not only modulator affinity, but also the nature, magnitude and direction of the allosteric effect on orthosteric ligand function.  The ever-expanding array of allosteric modulators arising from both academic and industrial research also highlights the need for the development of a uniform approach to nomenclature of such compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnUP5NIe912rVg90H21EOLACvtfcHk0ljlSDPubsQ3Qw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVaitLzO&md5=42e41090cf9788ad016f02753f727432</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2010.07.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2010.07.010%26sid%3Dliteratum%253Aachs%26aulast%3DKeov%26aufirst%3DP.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DChristopoulos%26aufirst%3DA.%26atitle%3DAllosteric%2520modulation%2520of%2520G%2520protein-coupled%2520receptors%253A%2520a%2520pharmacological%2520perspective%26jtitle%3DNeuropharmacology%26date%3D2011%26volume%3D60%26spage%3D24%26epage%3D35%26doi%3D10.1016%2Fj.neuropharm.2010.07.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Im, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bundy, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VonVoigtlander, P. F.</span></span> <span> </span><span class="NLM_article-title">PNU-107484A with alpha isoform-dependent functional changes in alpha(x)beta2gamma2 subtypes of rat recombinant GABA(A) receptors</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>122</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">821</span>â <span class="NLM_lpage">824</span>, <span class="refDoi">Â DOI: 10.1038/sj.bjp.0701450</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fsj.bjp.0701450" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=9384496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADyaK2sXnt1Squ74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=1997&pages=821-824&issue=5&author=H.+K.+Imauthor=W.+B.+Imauthor=D.+B.+Carterauthor=T.+M.+Schwartzauthor=G.+L.+Bundyauthor=P.+F.+VonVoigtlander&title=PNU-107484A+with+alpha+isoform-dependent+functional+changes+in+alpha%28x%29beta2gamma2+subtypes+of+rat+recombinant+GABA%28A%29+receptors&doi=10.1038%2Fsj.bjp.0701450"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">PNU-107484A with Î± isoform-dependent functional changes in Î±xÎ²2Î³2 subtypes of rat recombinant GABAA receptors</span></div><div class="casAuthors">Im, Haesook K.; Im, Wha Bin; Carter, Donald B.; Schwartz, Theresa M.; Bundy, Gordon L.; VonVoigtlander, Philip F.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">821-824</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Stockton</span>)
        </div><div class="casAbstract">1. We discovered a novel Î³-aminobutyric acidA (GABAA) receptor ligand displaying seemingly opposite functionalities, depending on the Î± isoform of the Î±xÎ²2Î³2 subtypes.  PNU-107484A enhanced GABA-induced Cl- currents in the Î±1Î²2Î³2 subtype, but inhibited the currents in the Î±3Î²2Î³2 and Î±6Î²2Î³2 subtypes, and its half-maximal concns. in the subtypes were 3.1, 4.2, and 3.5 Î¼M, resp., without showing much dependency on Î± isoforms.  2. In the Î±1Î²2 subtype, the drug at concns. up to 40 Î¼M showed no effect on GABA-induced Cl- currents, suggesting the requirement of the Î³ subunit for its action.  3. PNU-107484A behaved like a pos. allosteric modulator of the Î±1Î²2Î³2 subtype with its binding site distinct from those for benzodiazepines, barbiturates and neurosteroids.  With the Î±3Î²2Î³2 subtype, the drug behaved like a non-competitive inhibitor of GABA, thus blocking Cl- currents by GABA alone or in the presence of pentobarbitone and neurosteroids.  4. It appears that PNU-107484A is a unique GABAA receptor ligand with Î± isoform-dependent functionalities, which may provide a basis for development of Î± isoform-selective ligands, and it could be useful as a probe to investigate the physiol. roles of the various Î± isoform subtypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhb9po8QvQorVg90H21EOLACvtfcHk0ljlSDPubsQ3Qw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnt1Squ74%253D&md5=8a9e71ab228690dc5493eba4f53f6756</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0701450&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0701450%26sid%3Dliteratum%253Aachs%26aulast%3DIm%26aufirst%3DH.%2BK.%26aulast%3DIm%26aufirst%3DW.%2BB.%26aulast%3DCarter%26aufirst%3DD.%2BB.%26aulast%3DSchwartz%26aufirst%3DT.%2BM.%26aulast%3DBundy%26aufirst%3DG.%2BL.%26aulast%3DVonVoigtlander%26aufirst%3DP.%2BF.%26atitle%3DPNU-107484A%2520with%2520alpha%2520isoform-dependent%2520functional%2520changes%2520in%2520alpha%2528x%2529beta2gamma2%2520subtypes%2520of%2520rat%2520recombinant%2520GABA%2528A%2529%2520receptors%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1997%26volume%3D122%26issue%3D5%26spage%3D821%26epage%3D824%26doi%3D10.1038%2Fsj.bjp.0701450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kenakin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strachan, R. T.</span></span> <span> </span><span class="NLM_article-title">PAM-Antagonists: a better way to block pathological receptor signaling?</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">748</span>â <span class="NLM_lpage">765</span>, <span class="refDoi">Â DOI: 10.1016/j.tips.2018.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.tips.2018.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=29885909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVaisrnO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2018&pages=748-765&issue=8&author=T.+Kenakinauthor=R.+T.+Strachan&title=PAM-Antagonists%3A+a+better+way+to+block+pathological+receptor+signaling%3F&doi=10.1016%2Fj.tips.2018.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">PAM-Antagonists: A Better Way to Block Pathological Receptor Signaling?</span></div><div class="casAuthors">Kenakin, Terry; Strachan, Ryan T.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">748-765</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Seven transmembrane receptor (7TMR) responses are modulated by orthosteric and allosteric ligands to great therapeutic advantage.  Here we introduce a unique class of neg. allosteric modulator (NAM) - the pos. allosteric modulator (PAM)-antagonist - that increases the affinity of the receptor for the agonist but concomitantly decreases agonist efficacy when cobound.  Notably, the reciprocation of allosteric energy causes the orthosteric agonist to increase the affinity of the receptor for the PAM-antagonist; thus, this modulator seeks out and destroys agonist-bound receptor complexes.  When contrasted with std. orthosteric and allosteric antagonists it is clear that PAM-antagonists are uniquely well suited to reversing ongoing persistent agonism and provide favorable target coverage in vivo.  Specifically, the therapeutic application of PAM-antagonists to reverse pathol. overactivation (e.g., endothelin vasoconstriction) is emphasized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3htZbLIJO2LVg90H21EOLACvtfcHk0liY7Dw4eIUhBw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVaisrnO&md5=6a4b81c139f321490deb9e5b3bd8c3cb</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2018.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2018.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DKenakin%26aufirst%3DT.%26aulast%3DStrachan%26aufirst%3DR.%2BT.%26atitle%3DPAM-Antagonists%253A%2520a%2520better%2520way%2520to%2520block%2520pathological%2520receptor%2520signaling%253F%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2018%26volume%3D39%26issue%3D8%26spage%3D748%26epage%3D765%26doi%3D10.1016%2Fj.tips.2018.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kew, J. N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trube, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemp, J. A.</span></span> <span> </span><span class="NLM_article-title">A novel mechanism of activity-dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurons</span>. <i>J. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>497</i></span>,  <span class="NLM_fpage">761</span>â <span class="NLM_lpage">772</span>, <span class="refDoi">Â DOI: 10.1113/jphysiol.1996.sp021807</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1113%2Fjphysiol.1996.sp021807" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=9003561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADyaK2sXisVGltg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=497&publication_year=1996&pages=761-772&author=J.+N.+C.+Kewauthor=G.+Trubeauthor=J.+A.+Kemp&title=A+novel+mechanism+of+activity-dependent+NMDA+receptor+antagonism+describes+the+effect+of+ifenprodil+in+rat+cultured+cortical+neurons&doi=10.1113%2Fjphysiol.1996.sp021807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">A novel mechanism of activity-dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurons</span></div><div class="casAuthors">Kew, James N. C.; Trube, Gerhard; Kemp, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physiology (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">497</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">761-772</span>CODEN:
                <span class="NLM_cas:coden">JPHYA7</span>;
        ISSN:<span class="NLM_cas:issn">0022-3751</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">Ifenprodil is a selective, atypical non-competitive antagonist of NMDA receptors that contain the NR2B subunit with an undefined mechanism of action.  Ifenprodil is neuroprotective in in vivo models of cerebral ischemia but lacks many of the undesirable side-effects assocd. with NMDA antagonists.  Using whole-cell voltage-clamp recordings, the authors have studied the mechanism of inhibition of NMDA-evoked currents by ifenprodil in rat cultured cortical neurons in the presence of satg. concns. of glycine.  Ifenprodil antagonized NMDA receptors in an activity-dependent manner, while also increasing the receptor affinity for glutamate recognition-site agonists.  Ifenprodil inhibition curves against 10 and 100 Î¼M NMDA-evoked currents yielded IC50 values of 0.88 and 0.17 Î¼M, resp.  Thus, the apparent affinity of ifenprodil for the NMDA receptor is increased in an NMDA concn.-dependent manner.  Currents evoked by 0.3 and 1 Î¼M NMDA were potentiated to approx. 200% of control levels in the presence of 3 Î¼M ifenprodil.  Thus, with increasing concn. of NMDA the effect of ifenprodil on NMDA-evoked currents changed from one of potentiation to one of increasing inhibition.  These results are predicted by a reaction scheme in which ifenprodil exhibits a 39- and 50-fold higher affinity for the agonist-bound activated and desensitized states of the NMDA receptor, resp., relative to the resting, agonist-unbound state.  Furthermore, ifenprodil binding to the NMDA receptor results in a 6-fold higher affinity for glutamate site agonists.  This represents a novel mechanism of NMDA receptor antagonism that, together with the subunit selectivity, probably contributes to the attractive neuropharmacol. profile of this and related compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJg3J0KtQC3bVg90H21EOLACvtfcHk0liY7Dw4eIUhBw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXisVGltg%253D%253D&md5=d5b7b5abc0831974cab0cf7c312ab1a5</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1113%2Fjphysiol.1996.sp021807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1113%252Fjphysiol.1996.sp021807%26sid%3Dliteratum%253Aachs%26aulast%3DKew%26aufirst%3DJ.%2BN.%2BC.%26aulast%3DTrube%26aufirst%3DG.%26aulast%3DKemp%26aufirst%3DJ.%2BA.%26atitle%3DA%2520novel%2520mechanism%2520of%2520activity-dependent%2520NMDA%2520receptor%2520antagonism%2520describes%2520the%2520effect%2520of%2520ifenprodil%2520in%2520rat%2520cultured%2520cortical%2520neurons%26jtitle%3DJ.%2520Physiol.%26date%3D1996%26volume%3D497%26spage%3D761%26epage%3D772%26doi%3D10.1113%2Fjphysiol.1996.sp021807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fedele, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newcombe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topf, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smart, T. G.</span></span> <span> </span><span class="NLM_article-title">Disease-associated missense mutations in GluN2B subunit alter NMDA receptor ligand binding and ion channel properties</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">957</span>, <span class="refDoi">Â DOI: 10.1038/s41467-018-02927-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fs41467-018-02927-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=29511171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A280%3ADC%252BC1Mrotlekug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=957&issue=1&author=L.+Fedeleauthor=J.+Newcombeauthor=M.+Topfauthor=A.+Gibbauthor=R.+J.+Harveyauthor=T.+G.+Smart&title=Disease-associated+missense+mutations+in+GluN2B+subunit+alter+NMDA+receptor+ligand+binding+and+ion+channel+properties&doi=10.1038%2Fs41467-018-02927-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Disease-associated missense mutations in GluN2B subunit alter NMDA receptor ligand binding and ion channel properties</span></div><div class="casAuthors">Fedele Laura; Fedele Laura; Gibb Alasdair; Smart Trevor G; Newcombe Joseph; Topf Maya; Harvey Robert J; Harvey Robert J</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">957</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Genetic and bioinformatic analyses have identified missense mutations in GRIN2B encoding the NMDA receptor GluN2B subunit in autism, intellectual disability, Lennox Gastaut and West Syndromes.  Here, we investigated several such mutations using a near-complete, hybrid 3D model of the human NMDAR and studied their consequences with kinetic modelling and electrophysiology.  The mutants revealed reductions in glutamate potency; increased receptor desensitisation; and ablation of voltage-dependent Mg(2+) block.  In addition, we provide new views on Mg(2+) and NMDA channel blocker binding sites.  We demonstrate that these mutants have significant impact on excitatory transmission in developing neurons, revealing profound changes that could underlie their associated neurological disorders.  Of note, the NMDAR channel mutant GluN2B(V618G) unusually allowed Mg(2+) permeation, whereas nearby N615I reduced Ca(2+) permeability.  By identifying the binding site for an NMDAR antagonist that is used in the clinic to rescue gain-of-function phenotypes, we show that drug binding may be modified by some GluN2B disease-causing mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQwZXm-VCGgULrIbt-tGZmxfW6udTcc2eaUXJplPL8Xfrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mrotlekug%253D%253D&md5=3aa23d44fe8935cbdf496bcc077eb5e9</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-02927-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-02927-4%26sid%3Dliteratum%253Aachs%26aulast%3DFedele%26aufirst%3DL.%26aulast%3DNewcombe%26aufirst%3DJ.%26aulast%3DTopf%26aufirst%3DM.%26aulast%3DGibb%26aufirst%3DA.%26aulast%3DHarvey%26aufirst%3DR.%2BJ.%26aulast%3DSmart%26aufirst%3DT.%2BG.%26atitle%3DDisease-associated%2520missense%2520mutations%2520in%2520GluN2B%2520subunit%2520alter%2520NMDA%2520receptor%2520ligand%2520binding%2520and%2520ion%2520channel%2520properties%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26issue%3D1%26spage%3D957%26doi%3D10.1038%2Fs41467-018-02927-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mullier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sands, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghisdal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muglia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminski, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">AndrÃ©, V. M.</span></span> <span> </span><span class="NLM_article-title">GRIN2B gain of function mutations are sensitive to radiprodil, a negative allosteric modulator of GluN2B-containing NMDA receptors</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">322</span>â <span class="NLM_lpage">331</span>, <span class="refDoi">Â DOI: 10.1016/j.neuropharm.2017.05.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.neuropharm.2017.05.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=28533163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2sXosFWjtbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2017&pages=322-331&author=B.+Mullierauthor=C.+Wolffauthor=Z.+A.+Sandsauthor=P.+Ghisdalauthor=P.+Mugliaauthor=R.+M.+Kaminskiauthor=V.+M.+Andr%C3%A9&title=GRIN2B+gain+of+function+mutations+are+sensitive+to+radiprodil%2C+a+negative+allosteric+modulator+of+GluN2B-containing+NMDA+receptors&doi=10.1016%2Fj.neuropharm.2017.05.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">GRIN2B gain of function mutations are sensitive to radiprodil, a negative allosteric modulator of GluN2B-containing NMDA receptors</span></div><div class="casAuthors">Mullier, Brice; Wolff, Christian; Sands, Zara Amanda; Ghisdal, Philippe; Muglia, Pierandrea; Kaminski, Rafal Marian; Andre, Veronique Marie</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">322-331</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">De novo gain of function mutations in GRIN2B encoding the GluN2B subunit of the N-methyl-D-aspartate (NMDA) receptor have been linked with epileptic encephalopathies, including infantile spasms.  We investigated the effects of radiprodil, a selective GluN2B neg. allosteric modulator and other non-selective NMDA receptor inhibitors on glutamate currents mediated by NMDA receptors contg. mutated GluN2B subunits.  The expts. were performed in Xenopus oocytes co-injected with the following human mRNAs: GRIN1/GRIN2B, GRIN1/GRIN2B-R540H, GRIN1/GRIN2B-N615I and GRIN1/GRIN2B-V618G.  Glutamate displayed slightly increased potency in the R540H variant, but not in N615I and V618G variants.  However, the inhibition by Mg2+ was completely abolished in N615I and V618G variants.  In fact, Mg2+ enhanced glutamate responses in those variants.  The potency of radiprodil to block glutamate-evoked currents was not affected in any of the variants, while the effects by non-selective NMDA inhibitors were greatly reduced in some of the variants.  Addnl., in the Mg2+ insensitive variants, radiprodil blocked glutamate-activated currents with the same potency as in the absence of Mg2+.  The gain of function obsd. in the reported GRIN2B variants could be a key pathophysiol. factor leading to neuronal hyper-excitability in epileptic encephalopathies.  The GluN2B-selective inhibitor radiprodil fully retained its pharmacol. profile under these conditions, while other non-selective NMDA receptor antagonists lost their potency.  Consequently, our data suggest that radiprodil may be a valuable therapeutic option for treatment of pediatric epileptic encephalopathies assocd. with GRIN2B mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8FdYTEU85qrVg90H21EOLACvtfcHk0lihAywNNCIXTw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXosFWjtbg%253D&md5=0378c86d810af763ea1316a7133e4444</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2017.05.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2017.05.017%26sid%3Dliteratum%253Aachs%26aulast%3DMullier%26aufirst%3DB.%26aulast%3DWolff%26aufirst%3DC.%26aulast%3DSands%26aufirst%3DZ.%2BA.%26aulast%3DGhisdal%26aufirst%3DP.%26aulast%3DMuglia%26aufirst%3DP.%26aulast%3DKaminski%26aufirst%3DR.%2BM.%26aulast%3DAndr%25C3%25A9%26aufirst%3DV.%2BM.%26atitle%3DGRIN2B%2520gain%2520of%2520function%2520mutations%2520are%2520sensitive%2520to%2520radiprodil%252C%2520a%2520negative%2520allosteric%2520modulator%2520of%2520GluN2B-containing%2520NMDA%2520receptors%26jtitle%3DNeuropharmacology%26date%3D2017%26volume%3D123%26spage%3D322%26epage%3D331%26doi%3D10.1016%2Fj.neuropharm.2017.05.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leach, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conigrave, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span> <span> </span><span class="NLM_article-title">Impact of clinically relevant mutations on the pharmacoregulation and signaling bias of the calcium-sensing receptor by positive and negative allosteric modulators</span>. <i>Endocrinology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>154</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1105</span>â <span class="NLM_lpage">1116</span>, <span class="refDoi">Â DOI: 10.1210/en.2012-1887</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1210%2Fen.2012-1887" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=23372019" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsF2rsbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2013&pages=1105-1116&issue=3&author=K.+Leachauthor=A.+Wenauthor=A.+E.+Cookauthor=P.+M.+Sextonauthor=A.+D.+Conigraveauthor=A.+Christopoulos&title=Impact+of+clinically+relevant+mutations+on+the+pharmacoregulation+and+signaling+bias+of+the+calcium-sensing+receptor+by+positive+and+negative+allosteric+modulators&doi=10.1210%2Fen.2012-1887"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of clinically relevant mutations on the pharmacoregulation and signaling bias of the calcium-sensing receptor by positive and negative allosteric modulators</span></div><div class="casAuthors">Leach, Katie; Wen, Adriel; Cook, Anna E.; Sexton, Patrick M.; Conigrave, Arthur D.; Christopoulos, Arthur</div><div class="citationInfo"><span class="NLM_cas:title">Endocrinology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1105-1116</span>CODEN:
                <span class="NLM_cas:coden">ENDOAO</span>;
        ISSN:<span class="NLM_cas:issn">0013-7227</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Cinacalcet is predominantly used to treat secondary hyperparathyroidism due to end-stage renal failure, but, more recently, its potential clin. efficacy in treating patients with loss-of-function mutations in the calcium-sensing receptor (CaSR) has been recognized.  Many clin. relevant CaSR mutations are located in the heptahelical membrane spanning and extracellular loop regions of the receptor, where allosteric modulators are predicted to bind.  The aim of the present study was to investigate the impact of such mutations on the pharmacoregulation of the CaSR by the pos. and neg. allosteric modulators, cinacalcet and NPS-2143, resp.  Both cinacalcet and NPS-2143 effectively rescued mutants whose cell surface expression was substantially impaired, suggesting that both classes of drug can stabilize a receptor conformation that is trafficked more effectively to the cell surface.  In addn., functional impairments in almost all mutant CaSRs were rescued by either cinacalcet or NPS-2143 via restoration of intracellular signaling.  There was a significantly greater ability of both compds. to modulate agonist-stimulated intracellular Ca2+ mobilization than ERK1/2 phosphorylation, indicating that the allosteric modulators engender bias in agonist-stimulated CaSR signaling to different pathways.  Three mutations (G670R, P748R, and L773R) altered the binding affinity of allosteric modulators to the CaSR, and 3 mutations (V817I, L773R, and E767K) altered the cooperativity between the allosteric modulator and Ca2+o.  These findings have important implications for the treatment of diseases assocd. with CaSR mutations using allosteric CaSR modulators and for analyzing the effects of mutations on the function and pharmacoregulation of the CaSR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmgGmBvUfahrVg90H21EOLACvtfcHk0lihAywNNCIXTw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsF2rsbc%253D&md5=66939270cd67c0ed6f6f51ba536f86f7</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1210%2Fen.2012-1887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fen.2012-1887%26sid%3Dliteratum%253Aachs%26aulast%3DLeach%26aufirst%3DK.%26aulast%3DWen%26aufirst%3DA.%26aulast%3DCook%26aufirst%3DA.%2BE.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DConigrave%26aufirst%3DA.%2BD.%26aulast%3DChristopoulos%26aufirst%3DA.%26atitle%3DImpact%2520of%2520clinically%2520relevant%2520mutations%2520on%2520the%2520pharmacoregulation%2520and%2520signaling%2520bias%2520of%2520the%2520calcium-sensing%2520receptor%2520by%2520positive%2520and%2520negative%2520allosteric%2520modulators%26jtitle%3DEndocrinology%26date%3D2013%26volume%3D154%26issue%3D3%26spage%3D1105%26epage%3D1116%26doi%3D10.1210%2Fen.2012-1887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dalmau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graus, F.</span></span> <span> </span><span class="NLM_article-title">Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune diseases of the central nervous system</span>. <i>Physiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>97</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">839</span>â <span class="NLM_lpage">887</span>, <span class="refDoi">Â DOI: 10.1152/physrev.00010.2016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1152%2Fphysrev.00010.2016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=28298428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnsVOhurc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2017&pages=839-887&issue=2&author=J.+Dalmauauthor=C.+Geisauthor=F.+Graus&title=Autoantibodies+to+synaptic+receptors+and+neuronal+cell+surface+proteins+in+autoimmune+diseases+of+the+central+nervous+system&doi=10.1152%2Fphysrev.00010.2016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune diseases of the central nervous system</span></div><div class="casAuthors">Dalmau, Josep; Geis, Christian; Graus, Francesc</div><div class="citationInfo"><span class="NLM_cas:title">Physiological Reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">839-887</span>CODEN:
                <span class="NLM_cas:coden">PHREA7</span>;
        ISSN:<span class="NLM_cas:issn">0031-9333</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">Investigations in the last 10 years have revealed a new category of neurol. diseases mediated by antibodies against cell surface and synaptic proteins.  There are currently 16 such diseases all characterized by autoantibodies against neuronal proteins involved in synaptic signaling and plasticity.  In clin. practice these findings have changed the diagnostic and treatment approach to potentially lethal, but now treatable, neurol. and psychiatric syndromes previously considered idiopathic or not even suspected to be immune-mediated.  Studies show that patients' antibodies can impair the surface dynamics of the target receptors eliminating them from synapses (e.g., NMDA receptor), block the function of the antigens without changing their synaptic d. (e.g., GABAb receptor), interfere with synaptic protein-protein interactions (LGI1, Caspr2), alter synapse formation (e.g., neurexin-3Î±), or by unclear mechanisms assoc. to a new form of tauopathy (IgLON5).  Here we first trace the process of discovery of these diseases, describing the triggers and symptoms related to each autoantigen, and then review in detail the structural and functional alterations caused by the autoantibodies with special emphasis in those (NMDA receptor, amphiphysin) that have been modeled in animals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpD4Vp379HAhLVg90H21EOLACvtfcHk0lihAywNNCIXTw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnsVOhurc%253D&md5=e9be9781d75db66ebe7cdc81ec8ee8f6</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1152%2Fphysrev.00010.2016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fphysrev.00010.2016%26sid%3Dliteratum%253Aachs%26aulast%3DDalmau%26aufirst%3DJ.%26aulast%3DGeis%26aufirst%3DC.%26aulast%3DGraus%26aufirst%3DF.%26atitle%3DAutoantibodies%2520to%2520synaptic%2520receptors%2520and%2520neuronal%2520cell%2520surface%2520proteins%2520in%2520autoimmune%2520diseases%2520of%2520the%2520central%2520nervous%2520system%26jtitle%3DPhysiol.%2520Rev.%26date%3D2017%26volume%3D97%26issue%3D2%26spage%3D839%26epage%3D887%26doi%3D10.1152%2Fphysrev.00010.2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Warikoo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunwasser, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quirk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piccio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zorumski, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mennerick, S.</span></span> <span> </span><span class="NLM_article-title">Positive allosteric modulation as a potential therapeutic strategy in Anti-NMDA Receptor Encephalitis</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">3218</span>â <span class="NLM_lpage">3229</span>, <span class="refDoi">Â DOI: 10.1523/JNEUROSCI.3377-17.2018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1523%2FJNEUROSCI.3377-17.2018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=29476014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslartrbK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=3218-3229&issue=13&author=N.+Warikooauthor=S.+J.+Brunwasserauthor=A.+Benzauthor=H.+J.+Shuauthor=S.+M.+Paulauthor=M.+Lewisauthor=J.+Dohertyauthor=M.+Quirkauthor=L.+Piccioauthor=C.+F.+Zorumskiauthor=G.+S.+Dayauthor=S.+Mennerick&title=Positive+allosteric+modulation+as+a+potential+therapeutic+strategy+in+Anti-NMDA+Receptor+Encephalitis&doi=10.1523%2FJNEUROSCI.3377-17.2018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Positive allosteric modulation as a potential therapeutic strategy in anti-NMDA receptor encephalitis</span></div><div class="casAuthors">Warikoo, Natasha; Brunwasser, Samuel J.; Benz, Ann; Shu, Hong-Jin; Paul, Steven M.; Lewis, Michael; Doherty, James; Quirk, Michael; Piccio, Laura; Zorumski, Charles F.; Day, Gregory S.; Mennerick, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3218/1-3218/12</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">1529-2401</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">N-methyl-D-aspartate receptors (NMDARs) are ionotropic glutamate receptors important for synaptic plasticity, memory, and neuropsychiatric health.  NMDAR hypofunction contributes to multiple disorders, including anti-NMDAR encephalitis (NMDARE), an autoimmune disease of the CNS assocd. with GluN1 antibody-mediated NMDAR internalization.  Here we characterize the functional/pharmacol. consequences of exposure to CSF from female human NMDARE patients on NMDAR function, and we characterize the effects of intervention with recently described pos. allosteric modulators (PAMs) of NMDARs.  Incubation (48 h) of rat hippocampal neurons of both sexes in confirmed NMDARE patient CSF, but not control CSF, attenuated NMDA-induced current.  Residual NMDAR function was characterized by lack of change in channel open probability, indiscriminate loss of synaptic and extrasynaptic NMDARs, and indiscriminate loss of GluN2B-contg. and GluN2B-lacking NMDARs.  NMDARs tagged with N-terminal pHluorin fluorescence demonstrated loss of surface receptors.  Thus, function of residualNMDARsfollowing CSF exposure was indistinguishable from baseline, and deficits appear wholly accounted for by receptor loss.  Coapplication of CSF and PAMs of NMDARs (SGE-301 or SGE-550, oxysterolmimetic) for 24 h restored NMDAR function following 24 h incubation in patient CSF.  Curiously, restoration of NMDAR function was obsd. despite washout of PAMs before electrophysiol. recordings.  Subsequent expts. suggested that residual allosteric potentiation ofNMDARfunction explained the persistent rescue.  Further studies of the pathogenesis of NMDARE and intervention with PAMs may inform new treatments for NMDARE and other disorders assocd. with NMDAR hypofunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpA_rpJSpgz7bVg90H21EOLACvtfcHk0lg8HiO510N0Gg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslartrbK&md5=4153aa478fbf9712c8925c927a82e53f</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.3377-17.2018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.3377-17.2018%26sid%3Dliteratum%253Aachs%26aulast%3DWarikoo%26aufirst%3DN.%26aulast%3DBrunwasser%26aufirst%3DS.%2BJ.%26aulast%3DBenz%26aufirst%3DA.%26aulast%3DShu%26aufirst%3DH.%2BJ.%26aulast%3DPaul%26aufirst%3DS.%2BM.%26aulast%3DLewis%26aufirst%3DM.%26aulast%3DDoherty%26aufirst%3DJ.%26aulast%3DQuirk%26aufirst%3DM.%26aulast%3DPiccio%26aufirst%3DL.%26aulast%3DZorumski%26aufirst%3DC.%2BF.%26aulast%3DDay%26aufirst%3DG.%2BS.%26aulast%3DMennerick%26aufirst%3DS.%26atitle%3DPositive%2520allosteric%2520modulation%2520as%2520a%2520potential%2520therapeutic%2520strategy%2520in%2520Anti-NMDA%2520Receptor%2520Encephalitis%26jtitle%3DJ.%2520Neurosci.%26date%3D2018%26volume%3D38%26issue%3D13%26spage%3D3218%26epage%3D3229%26doi%3D10.1523%2FJNEUROSCI.3377-17.2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petter, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitty, A.</span></span> <span> </span><span class="NLM_article-title">The resurgence of covalent drugs</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">307</span>, <span class="refDoi">Â DOI: 10.1038/nrd3410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fnrd3410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=21455239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=307&issue=4&author=J.+Singhauthor=R.+C.+Petterauthor=T.+A.+Baillieauthor=A.+Whitty&title=The+resurgence+of+covalent+drugs&doi=10.1038%2Fnrd3410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">The resurgence of covalent drugs</span></div><div class="casAuthors">Singh, Juswinder; Petter, Russell C.; Baillie, Thomas A.; Whitty, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-317</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Covalent drugs haveproved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project.  There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium.  This Review surveys the prevalence and pharmacol. advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreDCEmORV_NbVg90H21EOLACvtfcHk0lg8HiO510N0Gg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D&md5=2190289081e151416c097be4a5b04460</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1038%2Fnrd3410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3410%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DWhitty%26aufirst%3DA.%26atitle%3DThe%2520resurgence%2520of%2520covalent%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26issue%3D4%26spage%3D307%26doi%3D10.1038%2Fnrd3410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span> <span> </span><span class="NLM_article-title">Designed covalent allosteric modulators: an emerging paradigm in drug discovery</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">447</span>â <span class="NLM_lpage">453</span>, <span class="refDoi">Â DOI: 10.1016/j.drudis.2016.11.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.drudis.2016.11.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=27888140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFOju7zJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=447-453&issue=2&author=S.+Luauthor=J.+Zhang&title=Designed+covalent+allosteric+modulators%3A+an+emerging+paradigm+in+drug+discovery&doi=10.1016%2Fj.drudis.2016.11.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Designed covalent allosteric modulators: an emerging paradigm in drug discovery</span></div><div class="casAuthors">Lu, Shaoyong; Zhang, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">447-453</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Covalent allosteric modulators possess the pharmacol. advantages (high potency, extended duration of action and low drug resistance) of covalent ligands and the addnl. benefit of the higher specificity and lower toxicity of allosteric modulators.  This approach is gaining increasing recognition as a valuable tool in drug discovery.  Here, we review the recent advances in the design of covalent allosteric modulators with an emphasis on successful examples.  A broad spectrum of protein targets capable of being modulated by them reflects the prevalence of this strategy.  We also discuss the challenges and future directions in the development of covalent allosteric modulators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnMtSOrLWxdrVg90H21EOLACvtfcHk0lg8HiO510N0Gg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFOju7zJ&md5=bc656114f3f956ce44ba06c1a7669da4</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2016.11.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2016.11.013%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DDesigned%2520covalent%2520allosteric%2520modulators%253A%2520an%2520emerging%2520paradigm%2520in%2520drug%2520discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2017%26volume%3D22%26issue%3D2%26spage%3D447%26epage%3D453%26doi%3D10.1016%2Fj.drudis.2016.11.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nolte, W. M.</span>; <span class="NLM_string-name">Carpino, P. A.</span></span> <span> </span><span class="NLM_article-title">Positive Allosteric Modulators of G-Protein-Coupled Receptors that Act via Covalent Mechanisms of Action</span>. In  <i>Allosterism in Drug Discovery</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doller, D.</span></span>, Ed; <span class="NLM_publisher-name">Royal Society of Chemistry</span>: <span class="NLM_publisher-loc">Cambridge, UK</span>, <span class="NLM_year">2017</span>; pp  <span class="NLM_fpage">271</span>â <span class="NLM_lpage">280</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=271-280&author=W.+M.+Nolte&author=P.+A.+Carpinoauthor=D.+Doller&title=Allosterism+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DNolte%26aufirst%3DW.%2BM.%26atitle%3DPositive%2520Allosteric%2520Modulators%2520of%2520G-Protein-Coupled%2520Receptors%2520that%2520Act%2520via%2520Covalent%2520Mechanisms%2520of%2520Action%26btitle%3DAllosterism%2520in%2520Drug%2520Discovery%26aulast%3DDoller%26aufirst%3DD.%26pub%3DRoyal%2520Society%2520of%2520Chemistry%26date%3D2017%26spage%3D271%26epage%3D280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Samson, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garber, A.</span></span> <span> </span><span class="NLM_article-title">GLP-1R agonist therapy for diabetes: benefits and potential risks</span>. <i>Curr. Opin. Endocrinol., Diabetes Obes.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">87</span>â <span class="NLM_lpage">97</span>, <span class="refDoi">Â DOI: 10.1097/MED.0b013e32835edb32</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1097%2FMED.0b013e32835edb32" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=23403741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtF2ntrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=87-97&issue=2&author=S.+L.+Samsonauthor=A.+Garber&title=GLP-1R+agonist+therapy+for+diabetes%3A+benefits+and+potential+risks&doi=10.1097%2FMED.0b013e32835edb32"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">GLP-1R agonist therapy for diabetes: benefits and potential risks</span></div><div class="casAuthors">Samson, Susan L.; Garber, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Endocrinology, Diabetes and Obesity</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">87-97</span>CODEN:
                <span class="NLM_cas:coden">COEDFK</span>;
        ISSN:<span class="NLM_cas:issn">1752-296X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: Glucagon-like peptide 1 receptor (GLP-1R) agonists provide good glycemic control combined with low hypoglycemia risk and wt. loss.  Here, we summarize the recently published data for this therapy class, focusing on sustainability of action, use in combination with basal insulin, and the efficacy of longer acting agents currently in development.  The safety profile of GLP-1R agonists is also examd.  Recent findings: GLP-1R agonists provide sustained efficacy and their combination with basal insulin is well tolerated, providing addnl. glycemic control and wt. benefits compared with basal insulin alone.  Data suggest that the convenience of longer acting agents may be at the expense of efficacy.  Despite the initial concerns, most evidence indicates that GLP-1R agonists do not increase the risk of pancreatitis or thyroid cancer.  However, the extremely low incidence of these events means further investigations are required before a causal link can be eliminated.  Large-scale clin. trials investigating the long-term cardiovascular safety of this therapy class are ongoing and may also provide important insights into pancreatic and thyroid safety.  Summary: GLP-1R agonists offer sustained glycemic efficacy, wt. loss benefits, and a low risk of hypoglycemia.  The results of ongoing trials should help to clarify the safety of this therapy class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqk_39-CujErVg90H21EOLACvtfcHk0lhOY3RUcI9vyA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtF2ntrs%253D&md5=683f66371cb0cc77de01f9e90db77203</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1097%2FMED.0b013e32835edb32&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMED.0b013e32835edb32%26sid%3Dliteratum%253Aachs%26aulast%3DSamson%26aufirst%3DS.%2BL.%26aulast%3DGarber%26aufirst%3DA.%26atitle%3DGLP-1R%2520agonist%2520therapy%2520for%2520diabetes%253A%2520benefits%2520and%2520potential%2520risks%26jtitle%3DCurr.%2520Opin.%2520Endocrinol.%252C%2520Diabetes%2520Obes.%26date%3D2013%26volume%3D20%26issue%3D2%26spage%3D87%26epage%3D97%26doi%3D10.1097%2FMED.0b013e32835edb32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nolte, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortin, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aspnes, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoth, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathiowetz, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limberakis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hepworth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpino, P. A.</span></span> <span> </span><span class="NLM_article-title">A potentiator of orthosteric ligand activity at GLP-1R acts via covalent modification</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">629</span>, <span class="refDoi">Â DOI: 10.1038/nchembio.1581</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fnchembio.1581" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=24997604" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFSlsLrO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=629&issue=8&author=W.+M.+Nolteauthor=J.+P.+Fortinauthor=B.+D.+Stevensauthor=G.+E.+Aspnesauthor=D.+A.+Griffithauthor=L.+R.+Hothauthor=R.+B.+Ruggeriauthor=A.+M.+Mathiowetzauthor=C.+Limberakisauthor=D.+Hepworthauthor=P.+A.+Carpino&title=A+potentiator+of+orthosteric+ligand+activity+at+GLP-1R+acts+via+covalent+modification&doi=10.1038%2Fnchembio.1581"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">A potentiator of orthosteric ligand activity at GLP-1R acts via covalent modification</span></div><div class="casAuthors">Nolte, Whitney M.; Fortin, Jean-Philippe; Stevens, Benjamin D.; Aspnes, Gary E.; Griffith, David A.; Hoth, Lise R.; Ruggeri, Roger B.; Mathiowetz, Alan M.; Limberakis, Chris; Hepworth, David; Carpino, Philip A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">629-631</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We report that 4-(3-(benzyloxy)phenyl)-2-ethylsulfinyl-6-(trifluoromethyl)pyrimidine (BETP), which behaves as a pos. allosteric modulator at the glucagon-like peptide-1 receptor (GLP-1R), covalently modifies cysteines 347 and 438 in GLP-1R.  C347, located in intracellular loop 3 of GLP-1R, is crit. to the activity of BETP and a structurally distinct GLP-1R ago-allosteric modulator, N-(tert-butyl)-6,7-dichloro-3-(methylsulfonyl)quinoxalin-2-amine.  We further show that substitution of cysteine for phenylalanine 345 in the glucagon receptor is sufficient to confer sensitivity to BETP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRJ3ys4ywhgLVg90H21EOLACvtfcHk0lhOY3RUcI9vyA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFSlsLrO&md5=9b0d431ea2c96e8889f774c50fdf9452</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1581%26sid%3Dliteratum%253Aachs%26aulast%3DNolte%26aufirst%3DW.%2BM.%26aulast%3DFortin%26aufirst%3DJ.%2BP.%26aulast%3DStevens%26aufirst%3DB.%2BD.%26aulast%3DAspnes%26aufirst%3DG.%2BE.%26aulast%3DGriffith%26aufirst%3DD.%2BA.%26aulast%3DHoth%26aufirst%3DL.%2BR.%26aulast%3DRuggeri%26aufirst%3DR.%2BB.%26aulast%3DMathiowetz%26aufirst%3DA.%2BM.%26aulast%3DLimberakis%26aufirst%3DC.%26aulast%3DHepworth%26aufirst%3DD.%26aulast%3DCarpino%26aufirst%3DP.%2BA.%26atitle%3DA%2520potentiator%2520of%2520orthosteric%2520ligand%2520activity%2520at%2520GLP-1R%2520acts%2520via%2520covalent%2520modification%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D10%26issue%3D8%26spage%3D629%26doi%3D10.1038%2Fnchembio.1581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coopman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willars, G. B.</span></span> <span> </span><span class="NLM_article-title">Comparative effects of the endogenous agonist glucagon-like peptide-1 (GLP-1)-(7â36) amide and the small-molecule ago-allosteric agent âcompound 2â at the GLP-1 receptor</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>334</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">795</span>â <span class="NLM_lpage">808</span>, <span class="refDoi">Â DOI: 10.1124/jpet.110.166009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1124%2Fjpet.110.166009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=20507928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFyksL%252FJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=334&publication_year=2010&pages=795-808&issue=3&author=K.+Coopmanauthor=Y.+Huangauthor=N.+Johnstonauthor=S.+J.+Bradleyauthor=G.+F.+Wilkinsonauthor=G.+B.+Willars&title=Comparative+effects+of+the+endogenous+agonist+glucagon-like+peptide-1+%28GLP-1%29-%287%E2%80%9336%29+amide+and+the+small-molecule+ago-allosteric+agent+%E2%80%9Ccompound+2%E2%80%9D+at+the+GLP-1+receptor&doi=10.1124%2Fjpet.110.166009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative effects of the endogenous agonist glucagon-like peptide-1 (GLP-1)-(7-36) amide and the small-molecule agoallosteric agent compound 2 at the GLP-1 receptor</span></div><div class="casAuthors">Coopman, Karen; Huang, Yan; Johnston, Neil; Bradley, Sophie J.; Wilkinson, Graeme F.; Willars, Gary B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">334</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">795-808</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Glucagon-like peptide-1 (GLP-1) mediates antidiabetogenic effects through the GLP-1 receptor (GLP-1R), which is targeted for the treatment of type 2 diabetes.  Small-mol. GLP-1R agonists have been sought due to difficulties with peptide therapeutics.  Recently, 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline (compd. 2) has been described as a GLP-1R allosteric modulator and agonist.  Using human embryonic kidney-293 cells expressing human GLP-1Rs, we extended this work to consider the impact of compd. 2 on G protein activation, Ca2+ signaling and receptor internalization and particularly to compare compd. 2 and GLP-1 across a range of functional assays in intact cells.  GLP-1 and compd. 2 activated GÎ±s in cell membranes and increased cellular cAMP in intact cells, with compd. 2 being a partial and almost full agonist, resp.  GLP-1 increased intracellular [Ca2+] by release from intracellular stores, which was mimicked by compd. 2, with slower kinetics.  In either intact cells or membranes, the orthosteric antagonist exendin-(9-39), inhibited GLP-1 cAMP generation but increased the efficacy of compd. 2.  GLP-1 internalized enhanced green fluorescent protein-tagged GLP-1Rs, but the speed and magnitude evoked by compd. 2 were less.  Exendin-(9-39) inhibited internalization by GLP-1 and also surprisingly that by compd. 2.  Compd. 2 displays GLP-1R agonism consistent with action at an allosteric site, although an orthosteric antagonist increased its efficacy on cAMP and blocked compd. 2-mediated receptor internalization.  Full assessment of the properties of compd. 2 was potentially hampered by damaging effects that were particularly manifest in either longer term assays with intact cells or in acute assays with membranes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6y2rihMfShbVg90H21EOLACvtfcHk0lhOY3RUcI9vyA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFyksL%252FJ&md5=0134b03ec49f7c33c30e809b438417af</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.166009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.166009%26sid%3Dliteratum%253Aachs%26aulast%3DCoopman%26aufirst%3DK.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DJohnston%26aufirst%3DN.%26aulast%3DBradley%26aufirst%3DS.%2BJ.%26aulast%3DWilkinson%26aufirst%3DG.%2BF.%26aulast%3DWillars%26aufirst%3DG.%2BB.%26atitle%3DComparative%2520effects%2520of%2520the%2520endogenous%2520agonist%2520glucagon-like%2520peptide-1%2520%2528GLP-1%2529-%25287%25E2%2580%259336%2529%2520amide%2520and%2520the%2520small-molecule%2520ago-allosteric%2520agent%2520%25E2%2580%259Ccompound%25202%25E2%2580%259D%2520at%2520the%2520GLP-1%2520receptor%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2010%26volume%3D334%26issue%3D3%26spage%3D795%26epage%3D808%26doi%3D10.1124%2Fjpet.110.166009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koole, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wootten, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simms, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valant, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodman, O. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summers, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span> <span> </span><span class="NLM_article-title">Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">456</span>â <span class="NLM_lpage">465</span>, <span class="refDoi">Â DOI: 10.1124/mol.110.065664</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1124%2Fmol.110.065664" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=20547734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFersbvE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2010&pages=456-465&issue=3&author=C.+Kooleauthor=D.+Woottenauthor=J.+Simmsauthor=C.+Valantauthor=R.+Sridharauthor=O.+L.+Woodmanauthor=L.+J.+Millerauthor=R.+J.+Summersauthor=A.+Christopoulosauthor=P.+M.+Sexton&title=Allosteric+ligands+of+the+glucagon-like+peptide+1+receptor+%28GLP-1R%29+differentially+modulate+endogenous+and+exogenous+peptide+responses+in+a+pathway-selective+manner%3A+implications+for+drug+screening&doi=10.1124%2Fmol.110.065664"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening</span></div><div class="casAuthors">Koole, Cassandra; Wootten, Denise; Simms, John; Valant, Celine; Sridhar, Rohan; Woodman, Owen L.; Miller, Laurence J.; Summers, Roger J.; Christopoulos, Arthur; Sexton, Patrick M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">456-465</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The glucagon-like peptide-1 (GLP-1) receptor is a key regulator of insulin secretion and a major therapeutic target for treatment of diabetes.  However, GLP-1 receptor function is complex, with multiple endogenous peptides that can interact with the receptor, including full-length (1-37) and truncated (7-37) forms of GLP-1 that can each exist in an amidated form and the related peptide oxyntomodulin.  We have investigated two GLP-1 receptor allosteric modulators, Novo Nordisk compd. 2 (6,7-dichloro2-methylsulfonyl-3-tert-butylaminoquinoxaline) and quercetin, and their ability to modify binding and signaling (cAMP formation, intracellular Ca2+ mobilization, and extracellular signal-regulated kinase 1/2 phosphorylation) of each of the naturally occurring endogenous peptide agonists, as well as the clin. used peptide mimetic exendin-4.  We identified and quantified stimulus bias across multiple endogenous peptides, with response profiles for truncated GLP-1 peptides distinct from those of either the full-length GLP-1 peptides or oxyntomodulin, the first demonstration of such behavior at the GLP-1 receptor.  Compd. 2 selectively augmented cAMP signaling but did so in a peptide-agonist dependent manner having greatest effect on oxyntomodulin, weaker effect on truncated GLP-1 peptides, and negligible effect on other peptide responses; these effects were principally driven by parallel changes in peptide agonist affinity.  In contrast, quercetin selectively modulated calcium signaling but with effects only on truncated GLP-1 peptides or exendin and not oxyntomodulin or full-length peptides.  These data have significant implications for how GLP-1 receptor targeted drugs are screened and developed, whereas the allosterically driven, agonist-selective, stimulus bias highlights the potential for distinct clin. efficacy depending on the properties of individual drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGourKpA5lnWprVg90H21EOLACvtfcHk0lhiA8F_d0v3oQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFersbvE&md5=e88185a2ecad28e4b6b37fa773aa0b14</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1124%2Fmol.110.065664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.110.065664%26sid%3Dliteratum%253Aachs%26aulast%3DKoole%26aufirst%3DC.%26aulast%3DWootten%26aufirst%3DD.%26aulast%3DSimms%26aufirst%3DJ.%26aulast%3DValant%26aufirst%3DC.%26aulast%3DSridhar%26aufirst%3DR.%26aulast%3DWoodman%26aufirst%3DO.%2BL.%26aulast%3DMiller%26aufirst%3DL.%2BJ.%26aulast%3DSummers%26aufirst%3DR.%2BJ.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26atitle%3DAllosteric%2520ligands%2520of%2520the%2520glucagon-like%2520peptide%25201%2520receptor%2520%2528GLP-1R%2529%2520differentially%2520modulate%2520endogenous%2520and%2520exogenous%2520peptide%2520responses%2520in%2520a%2520pathway-selective%2520manner%253A%2520implications%2520for%2520drug%2520screening%26jtitle%3DMol.%2520Pharmacol.%26date%3D2010%26volume%3D78%26issue%3D3%26spage%3D456%26epage%3D465%26doi%3D10.1124%2Fmol.110.065664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morris, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nance, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gentry, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Days, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niswender, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locuson, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niswender, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of (<i>S</i>)-2-cyclopentyl-<i>N</i>-((1-isopropylpyrrolidin2-yl)-9-methyl-1-oxo-2,9-dihydro-1H-pyrrido[3,4-b]indole-4-carboxamide (VU0453379): a novel, CNS penetrant glucagon-like peptide 1 receptor (GLP-1R) positive allosteric modulator (PAM)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">10192</span>â <span class="NLM_lpage">10197</span>, <span class="refDoi">Â DOI: 10.1021/jm501375c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501375c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFOhtrbE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=10192-10197&issue=23&author=L.+C.+Morrisauthor=K.+D.+Nanceauthor=P.+R.+Gentryauthor=E.+L.+Daysauthor=C.+D.+Weaverauthor=C.+M.+Niswenderauthor=A.+D.+Thompsonauthor=C.+K.+Jonesauthor=C.+W.+Locusonauthor=R.+D.+Morrisonauthor=J.+S.+Danielsauthor=K.+D.+Niswenderauthor=C.+W.+Lindsley&title=Discovery+of+%28S%29-2-cyclopentyl-N-%28%281-isopropylpyrrolidin2-yl%29-9-methyl-1-oxo-2%2C9-dihydro-1H-pyrrido%5B3%2C4-b%5Dindole-4-carboxamide+%28VU0453379%29%3A+a+novel%2C+CNS+penetrant+glucagon-like+peptide+1+receptor+%28GLP-1R%29+positive+allosteric+modulator+%28PAM%29&doi=10.1021%2Fjm501375c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (S)-2-Cyclopentyl-N-((1-isopropylpyrrolidin-2-yl)-9-methyl-1-oxo-2,9-dihydro-1H-pyrido[3,4-b]indole-4-carboxamide (VU0453379): A Novel, CNS Penetrant Glucagon-Like Peptide 1 Receptor (GLP-1R) Positive Allosteric Modulator (PAM)</span></div><div class="casAuthors">Morris, Lindsey C.; Nance, Kellie D.; Gentry, Patrick R.; Days, Emily L.; Weaver, C. David; Niswender, Colleen M.; Thompson, Analisa D.; Jones, Carrie K.; Locuson, Chuck W.; Morrison, Ryan D.; Daniels, J. Scott; Niswender, Kevin D.; Lindsley, Craig W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10192-10197</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A duplexed, functional multiaddn. high throughput screening and subsequent iterative parallel synthesis effort identified the first highly selective and CNS penetrant glucagon-like peptide-1R (GLP-1R) pos. allosteric modulator (PAM).  PAM 1H-pyrido[3,4-b]indole-4-carboxamide deriv. I potentiated low-dose exenatide to augment insulin secretion in primary mouse pancreatic islets, and it alone was effective in potentiating endogenous GLP-1R to reverse haloperidol-induced catalepsy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHpe3U-qyvtbVg90H21EOLACvtfcHk0lhiA8F_d0v3oQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFOhtrbE&md5=e2b51406183729a3429e9d666df12e7b</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1021%2Fjm501375c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501375c%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DL.%2BC.%26aulast%3DNance%26aufirst%3DK.%2BD.%26aulast%3DGentry%26aufirst%3DP.%2BR.%26aulast%3DDays%26aufirst%3DE.%2BL.%26aulast%3DWeaver%26aufirst%3DC.%2BD.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DThompson%26aufirst%3DA.%2BD.%26aulast%3DJones%26aufirst%3DC.%2BK.%26aulast%3DLocuson%26aufirst%3DC.%2BW.%26aulast%3DMorrison%26aufirst%3DR.%2BD.%26aulast%3DDaniels%26aufirst%3DJ.%2BS.%26aulast%3DNiswender%26aufirst%3DK.%2BD.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26atitle%3DDiscovery%2520of%2520%2528S%2529-2-cyclopentyl-N-%2528%25281-isopropylpyrrolidin2-yl%2529-9-methyl-1-oxo-2%252C9-dihydro-1H-pyrrido%255B3%252C4-b%255Dindole-4-carboxamide%2520%2528VU0453379%2529%253A%2520a%2520novel%252C%2520CNS%2520penetrant%2520glucagon-like%2520peptide%25201%2520receptor%2520%2528GLP-1R%2529%2520positive%2520allosteric%2520modulator%2520%2528PAM%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D23%26spage%3D10192%26epage%3D10197%26doi%3D10.1021%2Fjm501375c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Erve, J. C. L.</span></span> <span> </span><span class="NLM_article-title">Chemical toxicology: Reactive intermediates and their role in pharmacology and toxicology</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">923</span>â <span class="NLM_lpage">946</span>, <span class="refDoi">Â DOI: 10.1517/17425255.2.6.923</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1517%2F17425255.2.6.923" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=17125409" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1eks7nK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=923-946&issue=6&author=J.+C.+L.+Erve&title=Chemical+toxicology%3A+Reactive+intermediates+and+their+role+in+pharmacology+and+toxicology&doi=10.1517%2F17425255.2.6.923"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical toxicology: reactive intermediates and their role in pharmacology and toxicology</span></div><div class="casAuthors">Erve, John C. L.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">923-946</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Reactive intermediates formed during the metab. of drugs have been investigated extensively over the past decades.  Today, interest in reactive intermediates in drug discovery is focused on minimizing bioactivation in hopes of reducing the risk of causing so-called idiosyncratic toxicity.  These efforts are justified based on the hapten hypothesis', namely, that on binding to protein, reactive intermediates may elicit an immune response to the modified protein, leading to a cascade of events that ultimately manifests as a toxic outcome.  However, the pharmacol. action of certain drugs depends on reactive intermediates that modify crit. amino acid residues of proteins, typically enzymes, thereby altering their activity.  Thus, the notion that reactive intermediates are inherently dangerous is unjustified.  When a reactive intermediate is necessary for the desired pharmacol. effect of a drug, the selectivity it displays towards the target protein is crucial, as off-target binding may produce unwanted toxicities.  On the other hand, reactive intermediates may play no role in toxicity.  This review provides a balanced perspective, primarily focusing on the proposed role of reactive intermediates in drug toxicity, while also highlighting examples in which they are involved in causing the desired pharmacol.  It is hoped that this knowledge can help scientists involved in drug discovery and development in their challenging task of producing safe and effective drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBIFLSUGUWN7Vg90H21EOLACvtfcHk0lhiA8F_d0v3oQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1eks7nK&md5=320b9ade5e38e5d21b92a4e2781e9e62</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1517%2F17425255.2.6.923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.2.6.923%26sid%3Dliteratum%253Aachs%26aulast%3DErve%26aufirst%3DJ.%2BC.%2BL.%26atitle%3DChemical%2520toxicology%253A%2520Reactive%2520intermediates%2520and%2520their%2520role%2520in%2520pharmacology%2520and%2520toxicology%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2006%26volume%3D2%26issue%3D6%26spage%3D923%26epage%3D946%26doi%3D10.1517%2F17425255.2.6.923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borgan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veronese, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marques, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogdaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howes, O.</span></span> <span> </span><span class="NLM_article-title">F229. Cannabinoid 1 receptor and memory function in first episode psychosis: a multi-modal PET-fMRI study</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>83</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">S327</span>â <span class="NLM_lpage">328</span>, <span class="refDoi">Â DOI: 10.1016/j.biopsych.2018.02.843</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.biopsych.2018.02.843" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2018&pages=S327-328&issue=9&author=F.+Borganauthor=M.+Veroneseauthor=T.+Marquesauthor=M.+Rogdakiauthor=O.+Howes&title=F229.+Cannabinoid+1+receptor+and+memory+function+in+first+episode+psychosis%3A+a+multi-modal+PET-fMRI+study&doi=10.1016%2Fj.biopsych.2018.02.843"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2018.02.843&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2018.02.843%26sid%3Dliteratum%253Aachs%26aulast%3DBorgan%26aufirst%3DF.%26aulast%3DVeronese%26aufirst%3DM.%26aulast%3DMarques%26aufirst%3DT.%26aulast%3DRogdaki%26aufirst%3DM.%26aulast%3DHowes%26aufirst%3DO.%26atitle%3DF229.%2520Cannabinoid%25201%2520receptor%2520and%2520memory%2520function%2520in%2520first%2520episode%2520psychosis%253A%2520a%2520multi-modal%2520PET-fMRI%2520study%26jtitle%3DBiol.%2520Psychiatry%26date%3D2018%26volume%3D83%26issue%3D9%26spage%3DS327%26epage%3D328%26doi%3D10.1016%2Fj.biopsych.2018.02.843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span> <span> </span><span class="NLM_article-title">Endocannabinoid metabolism in neurodegenerative diseases</span>. <i>Neuroimmunol. Neuroinflamm.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">268</span>â <span class="NLM_lpage">270</span>, <span class="refDoi">Â DOI: 10.20517/2347-8659.2016.46</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.20517%2F2347-8659.2016.46" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=28638858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A280%3ADC%252BC1cjgs12rtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2016&pages=268-270&author=C.+Chen&title=Endocannabinoid+metabolism+in+neurodegenerative+diseases&doi=10.20517%2F2347-8659.2016.46"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Endocannabinoid metabolism in neurodegenerative diseases</span></div><div class="casAuthors">Chen Chu</div><div class="citationInfo"><span class="NLM_cas:title">Neuroimmunology and neuroinflammation</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">268-270</span>
        ISSN:<span class="NLM_cas:issn">2347-8659</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQb_ecrGl5b6UEgZCMqtRBifW6udTcc2eZRbNrCk6Fkpbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjgs12rtQ%253D%253D&md5=c595b2231af027b7dcff65d4e694b91e</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.20517%2F2347-8659.2016.46&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.20517%252F2347-8659.2016.46%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%26atitle%3DEndocannabinoid%2520metabolism%2520in%2520neurodegenerative%2520diseases%26jtitle%3DNeuroimmunol.%2520Neuroinflamm.%26date%3D2016%26volume%3D3%26spage%3D268%26epage%3D270%26doi%3D10.20517%2F2347-8659.2016.46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alaverdashvili, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laprairie, R. B.</span></span> <span> </span><span class="NLM_article-title">The future of type 1 cannabinoid receptor allosteric ligands</span>. <i>Drug Metab. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">14</span>â <span class="NLM_lpage">25</span>, <span class="refDoi">Â DOI: 10.1080/03602532.2018.1428341</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1080%2F03602532.2018.1428341" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=29355038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2hsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2018&pages=14-25&issue=1&author=M.+Alaverdashviliauthor=R.+B.+Laprairie&title=The+future+of+type+1+cannabinoid+receptor+allosteric+ligands&doi=10.1080%2F03602532.2018.1428341"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">The future of type 1 cannabinoid receptor allosteric ligands</span></div><div class="casAuthors">Alaverdashvili, Mariam; Laprairie, Robert B.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">14-25</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Allosteric modulation of the type 1 cannabinoid receptor (CB1R) holds great therapeutic potential.  This is because allosteric modulators do not possess intrinsic efficacy, but instead augment (pos. allosteric modulation) or diminish (neg. allosteric modulation) the receptor's response to endogenous ligand.  Consequently, CB1R allosteric modulators have an effect ceiling which allows for the tempering of CB1R signaling without the desensitization, tolerance, dependence, and psychoactivity assocd. with orthosteric compds.  Pain, movement disorders, epilepsy, obesity are all potential therapeutic targets for CB1R allosteric modulation.  Several challenges exist for the development of CB1R allosteric modulators, such as receptor subtype specificity, translation to in vivo systems, and mixed allosteric/agonist/inverse agonist activity.  Despite these challenges, elucidation of crystal structures of CB1R and compd. design based on structure-activity relationships will advance the field.  In this review, we will cover recent progress for CB1R allosteric modulators and discuss the future promise of this research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZhuoErXo_VrVg90H21EOLACvtfcHk0ljJuNSoSkVbAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2hsr8%253D&md5=5acbaf05214d4ab5e34421b5201c469b</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1080%2F03602532.2018.1428341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F03602532.2018.1428341%26sid%3Dliteratum%253Aachs%26aulast%3DAlaverdashvili%26aufirst%3DM.%26aulast%3DLaprairie%26aufirst%3DR.%2BB.%26atitle%3DThe%2520future%2520of%2520type%25201%2520cannabinoid%2520receptor%2520allosteric%2520ligands%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D2018%26volume%3D50%26issue%3D1%26spage%3D14%26epage%3D25%26doi%3D10.1080%2F03602532.2018.1428341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahmoud, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shim, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kendall, D. A.</span></span> <span> </span><span class="NLM_article-title">Distinct roles of Î²-arrestin 1 and Î²-arrestin 2 in ORG27569-induced biased signaling and internalization of the cannabinoid receptor 1 (CB1)</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">9790</span>â <span class="NLM_lpage">9800</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M112.438804</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1074%2Fjbc.M112.438804" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=23449980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlsVCqurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=9790-9800&issue=14&author=K.+H.+Ahnauthor=M.+M.+Mahmoudauthor=J.+Y.+Shimauthor=D.+A.+Kendall&title=Distinct+roles+of+%CE%B2-arrestin+1+and+%CE%B2-arrestin+2+in+ORG27569-induced+biased+signaling+and+internalization+of+the+cannabinoid+receptor+1+%28CB1%29&doi=10.1074%2Fjbc.M112.438804"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Distinct Roles of Î²-Arrestin 1 and Î²-Arrestin 2 in ORG27569-induced Biased Signaling and Internalization of the Cannabinoid Receptor 1 (CB1)</span></div><div class="casAuthors">Ahn, Kwang H.; Mahmoud, Mariam M.; Shim, Joong-Youn; Kendall, Debra A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">9790-9800</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The cannabinoid receptor 1 (CB1) is a G protein-coupled receptor primarily expressed in brain tissue that has been implicated in several disease states.  CB1 allosteric compds., such as ORG27569, offer enormous potential as drugs over orthosteric ligands, but their mechanistic, structural, and downstream effects upon receptor binding have not been established.  Previously, we showed that ORG27569 enhances agonist binding affinity to CB1 but inhibits G protein-dependent agonist signaling efficacy in HEK293 cells and rat brain expressing the CB1 receptor.  Here, we identify the mediators of CB1 receptor internalization and ORG27569-induced G protein-independent signaling.  Using siRNA technol., we elucidate an ORG27569-induced signaling mechanism for CB1 wherein Î²-arrestin 1 mediates short term signaling to ERK1/2 with a peak at 5 min and other upstream kinase components including MEK1/2 and c-Src.  Consistent with these findings, we demonstrate co-localization of CB1-GFP with red fluorescent protein-Î²-arrestin 1 upon ORG27569 treatment using confocal microscopy.  In contrast, we show the crit. role of Î²-arrestin 2 in CB1 receptor internalization upon treatment with CP55940 (agonist) or treatment with ORG27569.  These results demonstrate for the first time the involvement of Î²-arrestin in CB1-biased signaling by a CB1 allosteric modulator and also define the differential role of the two Î²-arrestin isoforms in CB1 signaling and internalization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJX0Q8DB2Y97Vg90H21EOLACvtfcHk0ljJuNSoSkVbAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlsVCqurg%253D&md5=9bda79f796b19398ff444210a51526ac</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M112.438804&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M112.438804%26sid%3Dliteratum%253Aachs%26aulast%3DAhn%26aufirst%3DK.%2BH.%26aulast%3DMahmoud%26aufirst%3DM.%2BM.%26aulast%3DShim%26aufirst%3DJ.%2BY.%26aulast%3DKendall%26aufirst%3DD.%2BA.%26atitle%3DDistinct%2520roles%2520of%2520%25CE%25B2-arrestin%25201%2520and%2520%25CE%25B2-arrestin%25202%2520in%2520ORG27569-induced%2520biased%2520signaling%2520and%2520internalization%2520of%2520the%2520cannabinoid%2520receptor%25201%2520%2528CB1%2529%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26issue%3D14%26spage%3D9790%26epage%3D9800%26doi%3D10.1074%2Fjbc.M112.438804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tichkule, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laprairie, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denovan-Wright, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janero, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvonok, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makriyannis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascio, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertwee, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, G. A.</span></span> <span> </span><span class="NLM_article-title">Novel electrophilic and photoaffinity covalent probes for mapping the cannabinoid 1 receptor allosteric site(s)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">44</span>â <span class="NLM_lpage">60</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b01303</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01303" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslKlsbvN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=44-60&issue=1&author=P.+M.+Kulkarniauthor=A.+R.+Kulkarniauthor=A.+Kordeauthor=R.+B.+Tichkuleauthor=R.+B.+Laprairieauthor=E.+M.+Denovan-Wrightauthor=H.+Zhouauthor=D.+R.+Janeroauthor=N.+Zvonokauthor=A.+Makriyannisauthor=M.+G.+Cascioauthor=R.+G.+Pertweeauthor=G.+A.+Thakur&title=Novel+electrophilic+and+photoaffinity+covalent+probes+for+mapping+the+cannabinoid+1+receptor+allosteric+site%28s%29&doi=10.1021%2Facs.jmedchem.5b01303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Electrophilic and Photoaffinity Covalent Probes for Mapping the Cannabinoid 1 Receptor Allosteric Site(s)</span></div><div class="casAuthors">Kulkarni, Pushkar M.; Kulkarni, Abhijit R.; Korde, Anisha; Tichkule, Ritesh B.; Laprairie, Robert B.; Denovan-Wright, Eileen M.; Zhou, Han; Janero, David R.; Zvonok, Nikolai; Makriyannis, Alexandros; Cascio, Maria G.; Pertwee, Roger G.; Thakur, Ganesh A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">44-60</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Undesirable side effects assocd. with orthosteric agonists/antagonists of cannabinoid 1 receptor (CB1R), a tractable target for treating several pathologies affecting humans, have greatly limited their translational potential.  Recent discovery of CB1R neg. allosteric modulators (NAMs) has renewed interest in CB1R by offering a potentially safer therapeutic avenue.  To elucidate the CB1R allosteric binding motif and thereby facilitate rational drug discovery, we report the synthesis and biochem. characterization of first covalent ligands designed to bind irreversibly to the CB1R allosteric site.  Either an electrophilic or a photoactivatable group was introduced at key positions of two classical CB1R NAMs: Org27569 (1) and PSNCBAM-1 (2).  Among these, 20 (GAT100) emerged as the most potent NAM in functional assays, did not exhibit inverse agonism, and behaved as a robust pos. allosteric modulator of binding of orthosteric agonist CP55,940.  This novel covalent probe can serve as a useful tool for characterizing CB1R allosteric ligand-binding motifs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbbmPHS4hBwrVg90H21EOLACvtfcHk0liHt4OcCDlPOg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslKlsbvN&md5=bdd1f5e67ef28ecf57773817c7c2c00f</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01303%26sid%3Dliteratum%253Aachs%26aulast%3DKulkarni%26aufirst%3DP.%2BM.%26aulast%3DKulkarni%26aufirst%3DA.%2BR.%26aulast%3DKorde%26aufirst%3DA.%26aulast%3DTichkule%26aufirst%3DR.%2BB.%26aulast%3DLaprairie%26aufirst%3DR.%2BB.%26aulast%3DDenovan-Wright%26aufirst%3DE.%2BM.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DJanero%26aufirst%3DD.%2BR.%26aulast%3DZvonok%26aufirst%3DN.%26aulast%3DMakriyannis%26aufirst%3DA.%26aulast%3DCascio%26aufirst%3DM.%2BG.%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26aulast%3DThakur%26aufirst%3DG.%2BA.%26atitle%3DNovel%2520electrophilic%2520and%2520photoaffinity%2520covalent%2520probes%2520for%2520mapping%2520the%2520cannabinoid%25201%2520receptor%2520allosteric%2520site%2528s%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D1%26spage%3D44%26epage%3D60%26doi%3D10.1021%2Facs.jmedchem.5b01303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doornbos, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermond, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peeters, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">PÃ©rez-Benito, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trabanco, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavreysen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cid, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitman, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tresadern, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">IJzerman, A. P.</span></span> <span> </span><span class="NLM_article-title">Covalent allosteric probe for the metabotropic glutamate receptor 2: design, synthesis, and pharmacological characterization</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">223</span>â <span class="NLM_lpage">233</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b00051</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00051" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjs1Cgs78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=223-233&issue=1&author=M.+L.+Doornbosauthor=X.+Wangauthor=S.+C.+Vermondauthor=L.+Peetersauthor=L.+P%C3%A9rez-Benitoauthor=A.+A.+Trabancoauthor=H.+Lavreysenauthor=J.+M.+Cidauthor=L.+H.+Heitmanauthor=G.+Tresadernauthor=A.+P.+IJzerman&title=Covalent+allosteric+probe+for+the+metabotropic+glutamate+receptor+2%3A+design%2C+synthesis%2C+and+pharmacological+characterization&doi=10.1021%2Facs.jmedchem.8b00051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent Allosteric Probe for the Metabotropic Glutamate Receptor 2: Design, Synthesis, and Pharmacological Characterization</span></div><div class="casAuthors">Doornbos, Maarten L. J.; Wang, Xuesong; Vermond, Sophie C.; Peeters, Luc; Perez-Benito, Laura; Trabanco, Andres A.; Lavreysen, Hilde; Cid, Jose Maria; Heitman, Laura H.; Tresadern, Gary; IJzerman, Adriaan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">223-233</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Covalent labeling of G protein-coupled receptors (GPCRs) by small mols. is a powerful approach to understand binding modes, mechanism of action, pharmacol., and even facilitate structure elucidation.  We report the first covalent pos. allosteric modulator (PAM) for a class C GPCR, the mGlu2 receptor.  Three putatively covalent mGlu2 PAMs were designed and synthesized.  Pharmacol. characterization identified 2 to bind the receptor covalently.  Computational modeling combined with receptor mutagenesis revealed T7917.29Ã30 as the likely position of covalent interaction.  We show how this covalent ligand can be used to characterize the PAM binding mode and that it is a valuable tool compd. in studying receptor function and binding kinetics.  Our findings advance the understanding of the mGlu2 PAM interaction and suggest that 2 is a valuable probe for further structural and chem. biol. approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2VB7O45PSArVg90H21EOLACvtfcHk0liHt4OcCDlPOg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjs1Cgs78%253D&md5=5d4cafa60439bbcdb81667789326099a</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00051%26sid%3Dliteratum%253Aachs%26aulast%3DDoornbos%26aufirst%3DM.%2BL.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DVermond%26aufirst%3DS.%2BC.%26aulast%3DPeeters%26aufirst%3DL.%26aulast%3DP%25C3%25A9rez-Benito%26aufirst%3DL.%26aulast%3DTrabanco%26aufirst%3DA.%2BA.%26aulast%3DLavreysen%26aufirst%3DH.%26aulast%3DCid%26aufirst%3DJ.%2BM.%26aulast%3DHeitman%26aufirst%3DL.%2BH.%26aulast%3DTresadern%26aufirst%3DG.%26aulast%3DIJzerman%26aufirst%3DA.%2BP.%26atitle%3DCovalent%2520allosteric%2520probe%2520for%2520the%2520metabotropic%2520glutamate%2520receptor%25202%253A%2520design%252C%2520synthesis%252C%2520and%2520pharmacological%2520characterization%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D1%26spage%3D223%26epage%3D233%26doi%3D10.1021%2Facs.jmedchem.8b00051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meiler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niswender, C. M.</span></span> <span> </span><span class="NLM_article-title">Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">692</span>, <span class="refDoi">Â DOI: 10.1038/nrd4308</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fnrd4308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=25176435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVCrtbzL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=692&issue=9&author=P.+J.+Connauthor=C.+W.+Lindsleyauthor=J.+Meilerauthor=C.+M.+Niswender&title=Opportunities+and+challenges+in+the+discovery+of+allosteric+modulators+of+GPCRs+for+treating+CNS+disorders&doi=10.1038%2Fnrd4308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders</span></div><div class="casAuthors">Conn, P. Jeffrey; Lindsley, Craig W.; Meiler, Jens; Niswender, Colleen M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">692-708</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Novel allosteric modulators of G protein-coupled receptors (GPCRs) are providing fundamental advances in the development of GPCR ligands with high subtype selectivity and novel modes of efficacy that have not been possible with traditional approaches.  As new allosteric modulators are advancing as drug candidates, we are developing an increased understanding of the major advantages and broad range of activities that can be achieved with these agents through selective modulation of specific signalling pathways, differential effects on GPCR homodimers vs. heterodimers, and other properties.  This understanding creates exciting opportunities, as well as unique challenges, in the optimization of novel therapeutic agents for disorders of the central nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS1YQIo2v0lLVg90H21EOLACvtfcHk0liOHjf3X8bBjw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVCrtbzL&md5=07571da612fc9344e5d6af86aa3eaf83</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1038%2Fnrd4308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4308%26sid%3Dliteratum%253Aachs%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DMeiler%26aufirst%3DJ.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26atitle%3DOpportunities%2520and%2520challenges%2520in%2520the%2520discovery%2520of%2520allosteric%2520modulators%2520of%2520GPCRs%2520for%2520treating%2520CNS%2520disorders%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26issue%3D9%26spage%3D692%26doi%3D10.1038%2Fnrd4308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MÃ¸ller, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno-Delgado, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pin, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kniazeff, J.</span></span> <span> </span><span class="NLM_article-title">Class C G protein-coupled receptors: reviving old couples with new partners</span>. <i>Biophysics Reports</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">4â6</span>),  <span class="NLM_fpage">57</span>â <span class="NLM_lpage">63</span>, <span class="refDoi">Â DOI: 10.1007/s41048-017-0036-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1007%2Fs41048-017-0036-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=29238742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A280%3ADC%252BC1Mzht12isQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=57-63&issue=4%E2%80%936&author=T.+C.+M%C3%B8llerauthor=D.+Moreno-Delgadoauthor=J.+P.+Pinauthor=J.+Kniazeff&title=Class+C+G+protein-coupled+receptors%3A+reviving+old+couples+with+new+partners&doi=10.1007%2Fs41048-017-0036-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Class C G protein-coupled receptors: reviving old couples with new partners</span></div><div class="casAuthors">Moller Thor C; Moreno-Delgado David; Pin Jean-Philippe; Kniazeff Julie</div><div class="citationInfo"><span class="NLM_cas:title">Biophysics reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">57-63</span>
        ISSN:<span class="NLM_cas:issn">2364-3439</span>.
    </div><div class="casAbstract">G protein-coupled receptors (GPCRs) are key players in cell communication and are encoded by the largest family in our genome.  As such, GPCRs represent the main targets in drug development programs.  Sequence analysis revealed several classes of GPCRs: the class A rhodopsin-like receptors represent the majority, the class B includes the secretin-like and adhesion GPCRs, the class F includes the frizzled receptors, and the class C includes receptors for the main neurotransmitters, glutamate and GABA, and those for sweet and umami taste and calcium receptors.  Class C receptors are far more complex than other GPCRs, being mandatory dimers, with each subunit being composed of several domains.  In this review, we summarize our actual knowledge regarding the activation mechanism and subunit organization of class C GPCRs, and how this brings information for many other GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS1b0tR6zomhJ6KlWarZTAzfW6udTcc2eZ1UOQQGYsmwLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mzht12isQ%253D%253D&md5=d0576153a93c6e0991081468b0c94b4b</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1007%2Fs41048-017-0036-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs41048-017-0036-9%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25B8ller%26aufirst%3DT.%2BC.%26aulast%3DMoreno-Delgado%26aufirst%3DD.%26aulast%3DPin%26aufirst%3DJ.%2BP.%26aulast%3DKniazeff%26aufirst%3DJ.%26atitle%3DClass%2520C%2520G%2520protein-coupled%2520receptors%253A%2520reviving%2520old%2520couples%2520with%2520new%2520partners%26jtitle%3DBiophysics%2520Reports%26date%3D2017%26volume%3D3%26issue%3D4%25E2%2580%25936%26spage%3D57%26epage%3D63%26doi%3D10.1007%2Fs41048-017-0036-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xue, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rovira, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholler, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pin, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rondard, P.</span></span> <span> </span><span class="NLM_article-title">Major ligand-induced rearrangement of the heptahelical domain interface in a GPCR dimer</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">134</span>, <span class="refDoi">Â DOI: 10.1038/nchembio.1711</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fnchembio.1711" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=25503927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFKltL%252FI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=134&issue=2&author=L.+Xueauthor=X.+Roviraauthor=P.+Schollerauthor=H.+Zhaoauthor=J.+Liuauthor=J.+P.+Pinauthor=P.+Rondard&title=Major+ligand-induced+rearrangement+of+the+heptahelical+domain+interface+in+a+GPCR+dimer&doi=10.1038%2Fnchembio.1711"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Major ligand-induced rearrangement of the heptahelical domain interface in a GPCR dimer</span></div><div class="casAuthors">Xue, Li; Rovira, Xavier; Scholler, Pauline; Zhao, Han; Liu, Jianfeng; Pin, Jean-Philippe; Rondard, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">134-140</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">G protein-coupled receptors (GPCRs) are major players in cell communication.  Although they form functional monomers, increasing evidence indicates that GPCR dimerization has a crit. role in cooperative phenomena that are important for cell signal integration.  However, the structural bases of these phenomena remain elusive.  Here, using well-characterized receptor dimers, the metabotropic glutamate receptors (mGluRs), the authors show that structural changes at the dimer interface are linked to receptor activation.  The authors demonstrate that the main dimer interface is formed by transmembrane Î± helix 4 (TM4) and TM5 in the inactive state and by TM6 in the active state.  This major change in the dimer interface is required for receptor activity because locking the TM4-TM5 interface prevents activation by agonist, whereas locking the TM6 interface leads to a constitutively active receptor.  These data provide important information on the activation mechanism of mGluRs and improve the authors' understanding of the structural basis of the neg. cooperativity obsd. in these GPCR dimers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohcfUTDGoDNbVg90H21EOLACvtfcHk0liOHjf3X8bBjw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFKltL%252FI&md5=0b9901b138949ad704a261bc435d0c9c</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1711&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1711%26sid%3Dliteratum%253Aachs%26aulast%3DXue%26aufirst%3DL.%26aulast%3DRovira%26aufirst%3DX.%26aulast%3DScholler%26aufirst%3DP.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DPin%26aufirst%3DJ.%2BP.%26aulast%3DRondard%26aufirst%3DP.%26atitle%3DMajor%2520ligand-induced%2520rearrangement%2520of%2520the%2520heptahelical%2520domain%2520interface%2520in%2520a%2520GPCR%2520dimer%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2015%26volume%3D11%26issue%3D2%26spage%3D134%26doi%3D10.1038%2Fnchembio.1711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christopher, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aves, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DorÃ©, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Errey, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jazayeri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okrasa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano-Vega, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tehan, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiggin, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span> <span> </span><span class="NLM_article-title">Fragment and structure-based drug discovery for a class C GPCR: discovery of the mGlu5 negative allosteric modulator HTL14242 (3-chloro-5-[6-(5-fluoropyridin-2-yl) pyrimidin-4-yl] benzonitrile)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">6653</span>â <span class="NLM_lpage">6664</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00892</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00892" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Gms7%252FP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6653-6664&issue=16&author=J.+A.+Christopherauthor=S.+J.+Avesauthor=K.+A.+Bennettauthor=A.+S.+Dor%C3%A9author=J.+C.+Erreyauthor=A.+Jazayeriauthor=F.+H.+Marshallauthor=K.+Okrasaauthor=M.+J.+Serrano-Vegaauthor=B.+G.+Tehanauthor=G.+R.+Wigginauthor=M.+Congreve&title=Fragment+and+structure-based+drug+discovery+for+a+class+C+GPCR%3A+discovery+of+the+mGlu5+negative+allosteric+modulator+HTL14242+%283-chloro-5-%5B6-%285-fluoropyridin-2-yl%29+pyrimidin-4-yl%5D+benzonitrile%29&doi=10.1021%2Facs.jmedchem.5b00892"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile)</span></div><div class="casAuthors">Christopher, John A.; Aves, Sarah J.; Bennett, Kirstie A.; Dore, Andrew S.; Errey, James C.; Jazayeri, Ali; Marshall, Fiona H.; Okrasa, Krzysztof; Serrano-Vega, Maria J.; Tehan, Benjamin G.; Wiggin, Giselle R.; Congreve, Miles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6653-6664</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Fragment screening of a thermostabilized mGlu5 receptor using a high-concn. radioligand binding assay enabled the identification of moderate affinity, high ligand efficiency (LE) pyrimidine hit.  Subsequent optimization using structure-based drug discovery methods led to the selection of I, HTL14242, as an advanced lead compd. for further development.  Structures of the stabilized mGlu5 receptor complexed with I and another mol. in the series, II, were detd. at resolns. of 2.6 and 3.1 Ã, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL70K7U4oxI7Vg90H21EOLACvtfcHk0ljyV0zodVbs3A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Gms7%252FP&md5=7b5365ee069dc4c79e99f77fe68a781c</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00892&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00892%26sid%3Dliteratum%253Aachs%26aulast%3DChristopher%26aufirst%3DJ.%2BA.%26aulast%3DAves%26aufirst%3DS.%2BJ.%26aulast%3DBennett%26aufirst%3DK.%2BA.%26aulast%3DDor%25C3%25A9%26aufirst%3DA.%2BS.%26aulast%3DErrey%26aufirst%3DJ.%2BC.%26aulast%3DJazayeri%26aufirst%3DA.%26aulast%3DMarshall%26aufirst%3DF.%2BH.%26aulast%3DOkrasa%26aufirst%3DK.%26aulast%3DSerrano-Vega%26aufirst%3DM.%2BJ.%26aulast%3DTehan%26aufirst%3DB.%2BG.%26aulast%3DWiggin%26aufirst%3DG.%2BR.%26aulast%3DCongreve%26aufirst%3DM.%26atitle%3DFragment%2520and%2520structure-based%2520drug%2520discovery%2520for%2520a%2520class%2520C%2520GPCR%253A%2520discovery%2520of%2520the%2520mGlu5%2520negative%2520allosteric%2520modulator%2520HTL14242%2520%25283-chloro-5-%255B6-%25285-fluoropyridin-2-yl%2529%2520pyrimidin-4-yl%255D%2520benzonitrile%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D16%26spage%3D6653%26epage%3D6664%26doi%3D10.1021%2Facs.jmedchem.5b00892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L. H.</span></span> <span> </span><span class="NLM_article-title">Sulfonyl fluorides as privileged warheads in chemical biology</span>. <i>Chem, Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2650</span>â <span class="NLM_lpage">2659</span>, <span class="refDoi">Â DOI: 10.1039/C5SC00408J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1039%2FC5SC00408J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=28706662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksVamurc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=2650-2659&issue=5&author=A.+Narayananauthor=L.+H.+Jones&title=Sulfonyl+fluorides+as+privileged+warheads+in+chemical+biology&doi=10.1039%2FC5SC00408J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfonyl fluorides as privileged warheads in chemical biology</span></div><div class="casAuthors">Narayanan, Arjun; Jones, Lyn H.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2650-2659</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Sulfonyl fluoride electrophiles have found significant utility as reactive probes in chem. biol. and mol. pharmacol.  As warheads they possess the right balance of biocompatibility (including aq. stability) and protein reactivity.  Their functionality is privileged in this regard as they are known to modify not only reactive serines (resulting in their common use as protease inhibitors), but also context-specific threonine, lysine, tyrosine, cysteine and histidine residues.  This review describes the application of sulfonyl fluoride probes across various areas of research and explores new approaches that could further enhance the chem. biol. toolkit.  We believe that sulfonyl fluoride probes will find greater utility in areas such as covalent enzyme inhibition, target identification and validation, and the mapping of enzyme binding sites, substrates and protein-protein interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAuadIMxOl2bVg90H21EOLACvtfcHk0ljyV0zodVbs3A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksVamurc%253D&md5=0009feb4068e912b4784fb8411cdb702</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1039%2FC5SC00408J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5SC00408J%26sid%3Dliteratum%253Aachs%26aulast%3DNarayanan%26aufirst%3DA.%26aulast%3DJones%26aufirst%3DL.%2BH.%26atitle%3DSulfonyl%2520fluorides%2520as%2520privileged%2520warheads%2520in%2520chemical%2520biology%26jtitle%3DChem%252C%2520Sci.%26date%3D2015%26volume%3D6%26issue%3D5%26spage%3D2650%26epage%3D2659%26doi%3D10.1039%2FC5SC00408J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wootten, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marti-Solano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of signalling and biased agonism in G protein-coupled receptors</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">638</span>â <span class="NLM_lpage">653</span>, <span class="refDoi">Â DOI: 10.1038/s41580-018-0049-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fs41580-018-0049-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=30104700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFSqtbzO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=638-653&issue=10&author=D.+Woottenauthor=A.+Christopoulosauthor=M.+Marti-Solanoauthor=M.+M.+Babuauthor=P.+M.+Sexton&title=Mechanisms+of+signalling+and+biased+agonism+in+G+protein-coupled+receptors&doi=10.1038%2Fs41580-018-0049-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of signalling and biased agonism in G protein-coupled receptors</span></div><div class="casAuthors">Wootten, Denise; Christopoulos, Arthur; Marti-Solano, Maria; Babu, M. Madan; Sexton, Patrick M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">638-653</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  G protein-coupled receptors (GPCRs) are the largest group of cell surface receptors in humans that signal in response to diverse inputs and regulate a plethora of cellular processes.  Hence, they constitute one of the primary drug target classes.  Progress in our understanding of GPCR dynamics, activation and signalling has opened new possibilities for selective drug development.  A key advancement has been provided by the concept of biased agonism, which describes the ability of ligands acting at the same GPCR to elicit distinct cellular signalling profiles by preferentially stabilizing different active conformational states of the receptor.  Application of this concept raises the prospect of 'designer' biased agonists as optimized therapeutics with improved efficacy and/or reduced side-effect profiles.  However, this application will require a detailed understanding of the spectrum of drug actions and a structural understanding of the drug-receptor interactions that drive distinct pharmacologies.  The recent revolution in GPCR structural biol. provides unprecedented insights into ligand binding, conformational dynamics and the control of signalling outcomes.  These insights, together with new approaches to multi-dimensional anal. of drug action, are allowing refined classification of drugs according to their pharmacodynamic profiles, which can be linked to receptor structure and predictions of preclin. drug efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHJ3GkBUq00rVg90H21EOLACvtfcHk0ljyV0zodVbs3A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFSqtbzO&md5=61ffa3780b7da6df8a8ccee2365354ae</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1038%2Fs41580-018-0049-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41580-018-0049-3%26sid%3Dliteratum%253Aachs%26aulast%3DWootten%26aufirst%3DD.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DMarti-Solano%26aufirst%3DM.%26aulast%3DBabu%26aufirst%3DM.%2BM.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26atitle%3DMechanisms%2520of%2520signalling%2520and%2520biased%2520agonism%2520in%2520G%2520protein-coupled%2520receptors%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2018%26volume%3D19%26issue%3D10%26spage%3D638%26epage%3D653%26doi%3D10.1038%2Fs41580-018-0049-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coyle, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benneyworth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konopaske, G.</span></span> <span> </span><span class="NLM_article-title">Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications</span>. <i>Handb. Exp. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>213</i></span>,  <span class="NLM_fpage">267</span>â <span class="NLM_lpage">295</span>, <span class="refDoi">Â DOI: 10.1007/978-3-642-25758-2_10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1007%2F978-3-642-25758-2_10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=23027419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3sXns1Giu7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=213&publication_year=2012&pages=267-295&author=J.+T.+Coyleauthor=A.+Basuauthor=M.+Benneyworthauthor=D.+Baluauthor=G.+Konopaske&title=Glutamatergic+synaptic+dysregulation+in+schizophrenia%3A+therapeutic+implications&doi=10.1007%2F978-3-642-25758-2_10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications</span></div><div class="casAuthors">Coyle, Joseph T.; Basu, Alo; Benneyworth, Michael; Balu, Darrick; Konopaske, Glenn</div><div class="citationInfo"><span class="NLM_cas:title">Handbook of Experimental Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">213</span>
        (<span class="NLM_cas:issue">Novel Antischizophrenia Treatments</span>),
    <span class="NLM_cas:pages">267-295</span>CODEN:
                <span class="NLM_cas:coden">HEPHD2</span>;
        ISSN:<span class="NLM_cas:issn">0171-2004</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  Schizophrenia affects approx. 1% of the population and continues to be assocd. with poor outcome because of the limited efficacy of and noncompliance with existing antipsychotic medications.  An alternative hypothesis invoking the excitatory neurotransmitter, glutamate, arose out of clin. observations that NMDA receptor antagonists, the dissociative anesthetics like ketamine, can replicate in normal individuals the full range of symptoms of schizophrenia including psychosis, neg. symptoms, and cognitive impairments.  Low dose ketamine can also re-create a no. of physiol. abnormalities characteristic of schizophrenia.  Postmortem studies have revealed abnormalities in endogenous modulators of NMDA receptors in schizophrenia as well as components of a postsynaptic d. where NMDA receptors are localized.  Gene assocn. studies have revealed several genes that affect NMDA receptor function whose allelic variants are assocd. with increased risk for schizophrenia including genes encoding D-amino acid oxidase, its modulator G72, dysbindin, and neuregulin.  The parvalbumin-pos., fast-firing GABAergic interneurons that provide recurrent inhibition to cortical-limbic pyramidal neurons seem to be most sensitive to NMDA receptor hypofunction.  As a consequence, disinhibition of glutamatergic efferents disrupts cortical processing, causing cognitive impairments and neg. symptoms, and drives subcortical dopamine release, resulting in psychosis.  Drugs designed to correct the cortical-limbic dysregulated glutamatergic neurotransmission show promise for reducing neg. and cognitive symptoms of schizophrenia as well as its pos. symptoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCUOYchIYYK7Vg90H21EOLACvtfcHk0lgMLQIFgINjHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXns1Giu7w%253D&md5=1cda996ff05ed79c6ff89bc9cac0d050</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1007%2F978-3-642-25758-2_10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-642-25758-2_10%26sid%3Dliteratum%253Aachs%26aulast%3DCoyle%26aufirst%3DJ.%2BT.%26aulast%3DBasu%26aufirst%3DA.%26aulast%3DBenneyworth%26aufirst%3DM.%26aulast%3DBalu%26aufirst%3DD.%26aulast%3DKonopaske%26aufirst%3DG.%26atitle%3DGlutamatergic%2520synaptic%2520dysregulation%2520in%2520schizophrenia%253A%2520therapeutic%2520implications%26jtitle%3DHandb.%2520Exp.%2520Pharmacol.%26date%3D2012%26volume%3D213%26spage%3D267%26epage%3D295%26doi%3D10.1007%2F978-3-642-25758-2_10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Field, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span> <span> </span><span class="NLM_article-title">Targeting glutamate synapses in schizophrenia</span>. <i>Trends Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">689</span>â <span class="NLM_lpage">698</span>, <span class="refDoi">Â DOI: 10.1016/j.molmed.2011.08.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.molmed.2011.08.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=21955406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFGjtrvE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=689-698&author=J.+R.+Fieldauthor=A.+G.+Walkerauthor=P.+J.+Conn&title=Targeting+glutamate+synapses+in+schizophrenia&doi=10.1016%2Fj.molmed.2011.08.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting glutamate synapses in schizophrenia</span></div><div class="casAuthors">Field, Julie R.; Walker, Adam G.; Conn, P. Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Molecular Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">689-698</span>CODEN:
                <span class="NLM_cas:coden">TMMRCY</span>;
        ISSN:<span class="NLM_cas:issn">1471-4914</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Although early clin. observations implicated dopamine dysfunction in the neuropathol. of schizophrenia, accumulating evidence suggests that multiple neurotransmitter pathways are dysregulated.  The psychotomimetic actions of NMDA receptor antagonists point to an imbalance of glutamatergic signaling.  Encouragingly, numerous preclin. and clin. studies have elucidated several potential targets for increasing NMDA receptor function and equilibrating glutamatergic tone, including the metabotropic glutamate receptors 2, 3 and 5, the muscarinic acetylcholine receptors M1 and M4, and the glycine transporter GlyT1.  Highly specific allosteric and orthosteric ligands have been developed that modify the activity of these novel target proteins, and in this review we summarize both the glutamatergic mechanisms and the novel compds. that are increasing the promise for a multifaceted pharmacol. approach to treat schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR9OJUk-K7YbVg90H21EOLACvtfcHk0lgMLQIFgINjHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFGjtrvE&md5=f0704a3b57aaa67754cc6924a58f6793</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.molmed.2011.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmed.2011.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DField%26aufirst%3DJ.%2BR.%26aulast%3DWalker%26aufirst%3DA.%2BG.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26atitle%3DTargeting%2520glutamate%2520synapses%2520in%2520schizophrenia%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2011%26volume%3D17%26spage%3D689%26epage%3D698%26doi%3D10.1016%2Fj.molmed.2011.08.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Timms, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorschner, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wechsler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkwood, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girirajan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichler, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korvatska, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roche, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horwitz, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuang, D. W.</span></span> <span> </span><span class="NLM_article-title">Support for the <i>N</i>-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia from exome sequencing in multiplex families. <i>JAMA</i></span>. <i>Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">582</span>â <span class="NLM_lpage">590</span>, <span class="refDoi">Â DOI: 10.1001/jamapsychiatry.2013.1195</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1001%2Fjamapsychiatry.2013.1195" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpslClt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2013&pages=582-590&author=A.+E.+Timmsauthor=M.+O.+Dorschnerauthor=J.+Wechslerauthor=K.+Y.+Choiauthor=R.+Kirkwoodauthor=S.+Girirajanauthor=C.+Bakerauthor=E.+E.+Eichlerauthor=O.+Korvatskaauthor=K.+W.+Rocheauthor=M.+S.+Horwitzauthor=D.+W.+Tsuang&title=Support+for+the+N-methyl-D-aspartate+receptor+hypofunction+hypothesis+of+schizophrenia+from+exome+sequencing+in+multiplex+families.+JAMA&doi=10.1001%2Fjamapsychiatry.2013.1195"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Support for the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia from exome sequencing in multiplex families</span></div><div class="casAuthors">Timms, Andrew E.; Dorschner, Michael O.; Wechsler, Jeremy; Choi, Kyu Yeong; Kirkwood, Robert; Girirajan, Santhosh; Baker, Carl; Eichler, Evan E.; Korvatska, Olena; Roche, Katherine W.; Horwitz, Marshall S.; Tsuang, Debby W.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA Psychiatry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">582-590</span>CODEN:
                <span class="NLM_cas:coden">JPASDP</span>;
        ISSN:<span class="NLM_cas:issn">2168-622X</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Importance: Schizophrenia is a complex genetic disorder demonstrating considerable heritability.  Genetic studies have implicated many different genes and pathways, but much of the genetic liability remains unaccounted for.  Investigation of genetic forms of schizophrenia will lead to a better understanding of the underlying mol. pathways, which will then enable targeted approaches for disease prevention and treatment.  Objective: To identify new genetic factors strongly predisposing to schizophrenia in families with multiple affected individuals with schizophrenia.  Design: We performed genome-wide array comparative genomic hybridization, linkage anal., and exome sequencing in multiplex families with schizophrenia.  Setting: Probands and their family members were recruited from academic medical centers.  Participants: We intended to identify rare disease-causing mutations in 5 large families where schizophrenia transmission appears consistent with single-gene inheritance.  Intervention: Array comparative genomic hybridization was used to identify copy no. variants, while exome sequencing was used to identify variants shared in all affected individuals and linkage anal. was used to further filter shared variants of interest.  Anal. of select variants was performed in cultured cells to assess their functional consequences.  Main Outcome Measures: Rare inherited disease-related genetic mutations.  Results: No segregating rare copy no. variants were detected by array comparative genomic hybridization.  However, in all 5 families, exome sequencing detected rare protein-altering variants in 1 of 3 genes assocd. with the N-methyl-D-aspartate (NMDA) receptor.  One pedigree shared a missense and frameshift substitution of GRM5, encoding the metabotropic glutamate receptor subtype 5 (mGluR5), which is coupled to the NMDA receptor and potentiates its signaling; the frameshift disrupts binding to the scaffolding protein tamalin and increases mGluR5 internalization.  Another pedigree transmitted a missense substitution in PPEF2, encoding a calmodulin-binding protein phosphatase, which we show influences mGluR5 levels.  Three pedigrees demonstrated different missense substitutions within LRP1B, encoding a low-d. lipoprotein receptor-related protein tied to both the NMDA receptor and located in a chromosome 2q22 region previously strongly linked to schizophrenia.  Conclusions and Relevance: Exome sequencing of multiplex pedigrees uncovers new genes assocd. with risk for developing schizophrenia and suggests potential novel therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpi2DhCqTUgtLVg90H21EOLACvtfcHk0lgMLQIFgINjHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpslClt7g%253D&md5=8b2491ea10896299b3a5f1ab3de75e69</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1001%2Fjamapsychiatry.2013.1195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamapsychiatry.2013.1195%26sid%3Dliteratum%253Aachs%26aulast%3DTimms%26aufirst%3DA.%2BE.%26aulast%3DDorschner%26aufirst%3DM.%2BO.%26aulast%3DWechsler%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DK.%2BY.%26aulast%3DKirkwood%26aufirst%3DR.%26aulast%3DGirirajan%26aufirst%3DS.%26aulast%3DBaker%26aufirst%3DC.%26aulast%3DEichler%26aufirst%3DE.%2BE.%26aulast%3DKorvatska%26aufirst%3DO.%26aulast%3DRoche%26aufirst%3DK.%2BW.%26aulast%3DHorwitz%26aufirst%3DM.%2BS.%26aulast%3DTsuang%26aufirst%3DD.%2BW.%26atitle%3DSupport%2520for%2520the%2520N-methyl-D-aspartate%2520receptor%2520hypofunction%2520hypothesis%2520of%2520schizophrenia%2520from%2520exome%2520sequencing%2520in%2520multiplex%2520families.%2520JAMA%26jtitle%3DPsychiatry%26date%3D2013%26volume%3D70%26spage%3D582%26epage%3D590%26doi%3D10.1001%2Fjamapsychiatry.2013.1195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parmentier-Batteur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutson, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uslaner, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattson, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâBrien, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magliaro, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forest, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stump, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tynebor, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anthony, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huszar, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambeng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">FaurÃ©, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Poul, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosahl, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocher, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargreaves, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, T. M.</span></span> <span> </span><span class="NLM_article-title">Mechanism based neurotoxicity of mGlu5 positive allosteric modulatorsâdevelopment challenges for a promising novel antipsychotic target</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">161</span>â <span class="NLM_lpage">173</span>, <span class="refDoi">Â DOI: 10.1016/j.neuropharm.2012.12.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.neuropharm.2012.12.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=23291536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitlelsrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2014&pages=161-173&author=S.+Parmentier-Batteurauthor=P.+H.+Hutsonauthor=K.+Menzelauthor=J.+M.+Uslanerauthor=B.+A.+Mattsonauthor=J.+A.+O%E2%80%99Brienauthor=B.+C.+Magliaroauthor=T.+Forestauthor=C.+A.+Stumpauthor=R.+M.+Tyneborauthor=N.+J.+Anthonyauthor=T.+J.+Tuckerauthor=X.+F.+Zhangauthor=R.+Gomezauthor=S.+L.+Huszarauthor=N.+Lambengauthor=H.+Faur%C3%A9author=E.+Le+Poulauthor=S.+Poliauthor=T.+W.+Rosahlauthor=J.+P.+Rocherauthor=R.+Hargreavesauthor=T.+M.+Williams&title=Mechanism+based+neurotoxicity+of+mGlu5+positive+allosteric+modulators%E2%80%94development+challenges+for+a+promising+novel+antipsychotic+target&doi=10.1016%2Fj.neuropharm.2012.12.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism based neurotoxicity of mGlu5 positive allosteric modulators - Development challenges for a promising novel antipsychotic target</span></div><div class="casAuthors">Parmentier-Batteur, Sophie; Hutson, Peter H.; Menzel, Karsten; Uslaner, Jason M.; Mattson, Britta A.; O'Brien, Julie A.; Magliaro, Brian C.; Forest, Thomas; Stump, Craig A.; Tynebor, Robert M.; Anthony, Neville J.; Tucker, Thomas J.; Zhang, Xu-Fang; Gomez, Robert; Huszar, Sarah L.; Lambeng, Nathalie; Faure, H.; Le Poul, Emannuel; Poli, Sonia; Rosahl, Thomas W.; Rocher, Jean-Philippe; Hargreaves, Richard; Williams, Theresa M.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">161-173</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Previous work has suggested that activation of mGlu5 receptor augments NMDA receptor function and thereby may constitute a rational approach addressing glutamate hypofunction in schizophrenia and a target for novel antipsychotic drug development.  Here, we report the in vitro activity, in vivo efficacy and safety profile of 5PAM523 (4-Fluorophenyl){(2R,5S)-5-[5-(5-fluoropyridin-2-yl)-1,2,4-oxadiazol-3-yl]-2-methylpiperidin-1-yl}methanone, a structurally novel pos. allosteric modulator selective of mGlu5.  In cells expressing human mGlu5 receptor, 5PAM523 potentiated threshold responses to glutamate in fluorometric calcium assays, but does not have any intrinsic agonist activity. 5PAM523 acts as an allosteric modulator as suggested by the binding studies showing that 5PAM523 did not displace the binding of the orthosteric ligand quisqualic acid, but did partially compete with the neg. allosteric modulator, MPyEP.  In vivo, 5PAM523 reversed amphetamine-induced locomotor activity in rats.  Therefore, both the in vitro and in vivo data demonstrate that 5PAM523 acts as a selective mGlu5 PAM and exhibits anti-psychotic like activity.  To study the potential for adverse effects and particularly neurotoxicity, brain histopathol. exams were performed in rats treated for 4 days with 5PAM523 or vehicle.  The brain exam revealed moderate to severe neuronal necrosis in the rats treated with the doses of 30 and 50 mg/kg, particularly in the auditory cortex and hippocampus.  To investigate whether this neurotoxicity is mechanism specific to 5PAM523, similar safety studies were carried out with three other structurally distinct selective mGlu5 PAMs.  Results revealed a comparable pattern of neuronal cell death.  Finally, 5PAM523 was tested in mGlu5 knock-out (KO) and wild type (WT) mice. mGlu5 WT mice treated with 5PAM523 for 4 days at 100 mg/kg presented significant neuronal death in the auditory cortex and hippocampus.  Conversely, mGlu5 KO mice did not show any neuronal loss by histopathol., suggesting that enhancement of mGlu5 function is responsible for the toxicity of 5PAM523.  This study reveals for the first time that augmentation of mGlu5 function with selective allosteric modulators results in neurotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQKYyrycXxerVg90H21EOLACvtfcHk0lgjMIcovNTwsA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitlelsrY%253D&md5=133389ccec73b22e9a6baa6518f987ab</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2012.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2012.12.003%26sid%3Dliteratum%253Aachs%26aulast%3DParmentier-Batteur%26aufirst%3DS.%26aulast%3DHutson%26aufirst%3DP.%2BH.%26aulast%3DMenzel%26aufirst%3DK.%26aulast%3DUslaner%26aufirst%3DJ.%2BM.%26aulast%3DMattson%26aufirst%3DB.%2BA.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DJ.%2BA.%26aulast%3DMagliaro%26aufirst%3DB.%2BC.%26aulast%3DForest%26aufirst%3DT.%26aulast%3DStump%26aufirst%3DC.%2BA.%26aulast%3DTynebor%26aufirst%3DR.%2BM.%26aulast%3DAnthony%26aufirst%3DN.%2BJ.%26aulast%3DTucker%26aufirst%3DT.%2BJ.%26aulast%3DZhang%26aufirst%3DX.%2BF.%26aulast%3DGomez%26aufirst%3DR.%26aulast%3DHuszar%26aufirst%3DS.%2BL.%26aulast%3DLambeng%26aufirst%3DN.%26aulast%3DFaur%25C3%25A9%26aufirst%3DH.%26aulast%3DLe%2BPoul%26aufirst%3DE.%26aulast%3DPoli%26aufirst%3DS.%26aulast%3DRosahl%26aufirst%3DT.%2BW.%26aulast%3DRocher%26aufirst%3DJ.%2BP.%26aulast%3DHargreaves%26aufirst%3DR.%26aulast%3DWilliams%26aufirst%3DT.%2BM.%26atitle%3DMechanism%2520based%2520neurotoxicity%2520of%2520mGlu5%2520positive%2520allosteric%2520modulators%25E2%2580%2594development%2520challenges%2520for%2520a%2520promising%2520novel%2520antipsychotic%2520target%26jtitle%3DNeuropharmacology%26date%3D2014%26volume%3D82%26spage%3D161%26epage%3D173%26doi%3D10.1016%2Fj.neuropharm.2012.12.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rook, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghoshal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickerson, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinson, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byun, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bubser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nedelcovych, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gould, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niswender, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavreysen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conde-Ceide, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcazar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BartolomÃ©-Nebreda, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talpos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steckler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span> <span> </span><span class="NLM_article-title">Biased mGlu5-positive allosteric modulators provide in vivo efficacy without potentiating mGlu5 modulation of NMDAR currents</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">1029</span>â <span class="NLM_lpage">1040</span>, <span class="refDoi">Â DOI: 10.1016/j.neuron.2015.03.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.neuron.2015.03.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=25937172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnslOisLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2015&pages=1029-1040&author=J.+M.+Rookauthor=Z.+Xiangauthor=X.+Lvauthor=A.+Ghoshalauthor=J.+W.+Dickersonauthor=T.+M.+Bridgesauthor=K.+A.+Johnsonauthor=D.+J.+Fosterauthor=K.+J.+Gregoryauthor=P.+N.+Vinsonauthor=A.+D.+Thompsonauthor=N.+Byunauthor=R.+L.+Collierauthor=M.+Bubserauthor=M.+T.+Nedelcovychauthor=R.+W.+Gouldauthor=S.+R.+Staufferauthor=J.+S.+Danielsauthor=C.+M.+Niswenderauthor=H.+Lavreysenauthor=C.+Mackieauthor=S.+Conde-Ceideauthor=J.+Alcazarauthor=J.+M.+Bartolom%C3%A9-Nebredaauthor=G.+J.+Macdonaldauthor=J.+C.+Talposauthor=T.+Stecklerauthor=C.+K.+Jonesauthor=C.+W.+Lindsleyauthor=P.+J.+Conn&title=Biased+mGlu5-positive+allosteric+modulators+provide+in+vivo+efficacy+without+potentiating+mGlu5+modulation+of+NMDAR+currents&doi=10.1016%2Fj.neuron.2015.03.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR Currents</span></div><div class="casAuthors">Rook, Jerri M.; Xiang, Zixiu; Lv, Xiaohui; Ghoshal, Ayan; Dickerson, Jonathan W.; Bridges, Thomas M.; Johnson, Kari A.; Foster, Daniel J.; Gregory, Karen J.; Vinson, Paige N.; Thompson, Analisa D.; Byun, Nellie; Collier, Rebekah L.; Bubser, Michael; Nedelcovych, Michael T.; Gould, Robert W.; Stauffer, Shaun R.; Daniels, J. Scott; Niswender, Colleen M.; Lavreysen, Hilde; Mackie, Claire; Conde-Ceide, Susana; Alcazar, Jesus; Bartolome-Nebreda, Jose M.; MacDonald, Gregor J.; Talpos, John C.; Steckler, Thomas; Jones, Carrie K.; Lindsley, Craig W.; Conn, P. Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1029-1040</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Schizophrenia is assocd. with disruptions in N-methyl-D-aspartate glutamate receptor subtype (NMDAR)-mediated excitatory synaptic signaling.  The metabotropic glutamate receptor subtype 5 (mGlu5) is a closely assocd. signaling partner with NMDARs and regulates NMDAR function in forebrain regions implicated in the pathol. of schizophrenia.  Efficacy of mGlu5 pos. allosteric modulators (PAMs) in animal models of psychosis and cognition was previously attributed to potentiation of NMDAR function.  To directly test this hypothesis, we identified VU0409551 as a novel mGlu5 PAM that exhibits distinct stimulus bias and selectively potentiates mGlu5 coupling to GÎ±q-mediated signaling but not mGlu5 modulation of NMDAR currents or NMDAR-dependent synaptic plasticity in the rat hippocampus.  Interestingly, VU0409551 produced robust antipsychotic-like and cognition-enhancing activity in animal models.  These data provide surprising new mechanistic insights into the actions of mGlu5 PAMs and suggest that modulation of NMDAR currents is not crit. for in vivo efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouKRBBcza96rVg90H21EOLACvtfcHk0lgjMIcovNTwsA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnslOisLc%253D&md5=c5f0a8cf83e1b2d8e0d3541a39cd0529</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2Fj.neuron.2015.03.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuron.2015.03.063%26sid%3Dliteratum%253Aachs%26aulast%3DRook%26aufirst%3DJ.%2BM.%26aulast%3DXiang%26aufirst%3DZ.%26aulast%3DLv%26aufirst%3DX.%26aulast%3DGhoshal%26aufirst%3DA.%26aulast%3DDickerson%26aufirst%3DJ.%2BW.%26aulast%3DBridges%26aufirst%3DT.%2BM.%26aulast%3DJohnson%26aufirst%3DK.%2BA.%26aulast%3DFoster%26aufirst%3DD.%2BJ.%26aulast%3DGregory%26aufirst%3DK.%2BJ.%26aulast%3DVinson%26aufirst%3DP.%2BN.%26aulast%3DThompson%26aufirst%3DA.%2BD.%26aulast%3DByun%26aufirst%3DN.%26aulast%3DCollier%26aufirst%3DR.%2BL.%26aulast%3DBubser%26aufirst%3DM.%26aulast%3DNedelcovych%26aufirst%3DM.%2BT.%26aulast%3DGould%26aufirst%3DR.%2BW.%26aulast%3DStauffer%26aufirst%3DS.%2BR.%26aulast%3DDaniels%26aufirst%3DJ.%2BS.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DLavreysen%26aufirst%3DH.%26aulast%3DMackie%26aufirst%3DC.%26aulast%3DConde-Ceide%26aufirst%3DS.%26aulast%3DAlcazar%26aufirst%3DJ.%26aulast%3DBartolom%25C3%25A9-Nebreda%26aufirst%3DJ.%2BM.%26aulast%3DMacdonald%26aufirst%3DG.%2BJ.%26aulast%3DTalpos%26aufirst%3DJ.%2BC.%26aulast%3DSteckler%26aufirst%3DT.%26aulast%3DJones%26aufirst%3DC.%2BK.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26atitle%3DBiased%2520mGlu5-positive%2520allosteric%2520modulators%2520provide%2520in%2520vivo%2520efficacy%2520without%2520potentiating%2520mGlu5%2520modulation%2520of%2520NMDAR%2520currents%26jtitle%3DNeuron%26date%3D2015%26volume%3D86%26spage%3D1029%26epage%3D1040%26doi%3D10.1016%2Fj.neuron.2015.03.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balu, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takagi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Presti, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramikie, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rook, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolshakov, V. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coyle, J. T.</span></span> <span> </span><span class="NLM_article-title">An mGlu5-positive allosteric modulator rescues the neuroplasticity deficits in a genetic model of NMDA receptor hypofunction in schizophrenia</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">2052</span>â <span class="NLM_lpage">2061</span>, <span class="refDoi">Â DOI: 10.1038/npp.2016.2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fnpp.2016.2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=26741285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFyjsbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2016&pages=2052-2061&author=D.+T.+Baluauthor=Y.+Liauthor=S.+Takagiauthor=K.+T.+Prestiauthor=T.+S.+Ramikieauthor=J.+M.+Rookauthor=C.+K.+Jonesauthor=C.+W.+Lindsleyauthor=P.+J.+Connauthor=V.+Y.+Bolshakovauthor=J.+T.+Coyle&title=An+mGlu5-positive+allosteric+modulator+rescues+the+neuroplasticity+deficits+in+a+genetic+model+of+NMDA+receptor+hypofunction+in+schizophrenia&doi=10.1038%2Fnpp.2016.2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">An mGlu5-Positive Allosteric Modulator Rescues the Neuroplasticity Deficits in a Genetic Model of NMDA Receptor Hypofunction in Schizophrenia</span></div><div class="casAuthors">Balu, Darrick T.; Li, Yan; Takagi, Shunsuke; Presti, Kendall Taylor; Ramikie, Teniel S.; Rook, Jerri M.; Jones, Carrie K.; Lindsley, Craig W.; Conn, P. Jeffrey; Bolshakov, Vadim Y.; Coyle, Joseph T.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2052-2061</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">There is substantial evidence that NMDA receptor (NMDAR) hypofunction contributes to the pathophysiol. of schizophrenia (SCZ).  A recent large-scale genome-wide assocn. study identified serine racemase (SR), the enzyme that produces the NMDAR co-agonist D-serine, as a risk gene for SCZ.  Serine racemase knockout (SR-/-) mice, which lack D-serine, exhibit many of the neurochem. and behavioral abnormalities obsd. in SCZ.  Metabotropic glutamate receptor 5 (mGlu5)-pos. allosteric modulators (PAMs) are currently being developed to treat cognitive dysfunction.  We used in vitro electrophysiol. to det. whether the mGlu5 PAM VU0409551 directly enhances NMDAR function in hippocampal slices from adult male SR-/- mice.  We administered VU0409551 systemically for 5 days to adult male wild-type C57BL/6 animals to det. the optimal dose to test in SR-/- mice.  We used western blot analyses and trace-fear conditioning to det. whether 5 days of VU0409551 treatment could reverse the neuroplasticity and learning deficits, resp., in SR-/- mice.  We show that VU0409551 enhances NMDAR function and rescues long-term potentiation in hippocampal slices obtained from SR-/- mice.  Systemic treatment with VU0409551 (10 and 30 mg/kg) to wild-type mice causes a dose-dependent increase in the Akt/GS3KÎ±/Î² signaling pathway, which is reduced in SR-/- mice and in SCZ.  Furthermore, the administration of VU0409551 to SR-/- mice reverses their deficits in several neuroplasticity signaling pathways and improves their contextual fear memory.  These results support pos. allosteric modulation of mGlu5, particularly with VU0409551, as a viable mechanism to reverse the deficits in NMDAR function, synaptic plasticity, and memory that are known to be impaired in SCZ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVtWueFnsQx7Vg90H21EOLACvtfcHk0lgwQn4Vwxv2YA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFyjsbg%253D&md5=0f86b437795d4fcfb53759e59a7bc110</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2016.2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2016.2%26sid%3Dliteratum%253Aachs%26aulast%3DBalu%26aufirst%3DD.%2BT.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DTakagi%26aufirst%3DS.%26aulast%3DPresti%26aufirst%3DK.%2BT.%26aulast%3DRamikie%26aufirst%3DT.%2BS.%26aulast%3DRook%26aufirst%3DJ.%2BM.%26aulast%3DJones%26aufirst%3DC.%2BK.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DBolshakov%26aufirst%3DV.%2BY.%26aulast%3DCoyle%26aufirst%3DJ.%2BT.%26atitle%3DAn%2520mGlu5-positive%2520allosteric%2520modulator%2520rescues%2520the%2520neuroplasticity%2520deficits%2520in%2520a%2520genetic%2520model%2520of%2520NMDA%2520receptor%2520hypofunction%2520in%2520schizophrenia%26jtitle%3DNeuropsychopharmacology%26date%3D2016%26volume%3D41%26spage%3D2052%26epage%3D2061%26doi%3D10.1038%2Fnpp.2016.2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, E. M.</span></span> <span> </span><span class="NLM_article-title">Role of the calcium-sensing receptor in extracellular calcium homeostasis</span>. <i>Best Pract. Res. Clin. Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">333</span>â <span class="NLM_lpage">343</span>, <span class="refDoi">Â DOI: 10.1016/j.beem.2013.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.beem.2013.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=23856263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktlCgtbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=333-343&author=E.+M.+Brown&title=Role+of+the+calcium-sensing+receptor+in+extracellular+calcium+homeostasis&doi=10.1016%2Fj.beem.2013.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the calcium-sensing receptor in extracellular calcium homeostasis</span></div><div class="casAuthors">Brown, Edward M.</div><div class="citationInfo"><span class="NLM_cas:title">Best Practice & Research, Clinical Endocrinology & Metabolism</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">333-343</span>CODEN:
                <span class="NLM_cas:coden">BPRCE9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Maintaining a const. level of blood Ca2+ is essential because of calcium's myriad intracellular and extracellular roles.  The CaSR plays key roles in maintaining \\Ca2+o\\ homeostasis by detecting small changes in blood Ca2+ and modulating the prodn./secretion of the Ca2+-regulating hormones, PTH, CT, FGF23 and 1,25(OH)2D3, so as to appropriately regulate Ca2+ transport into or out of blood via kidney, intestine, and/or bone.  When Ca2+ is high, the CaSR suppresses PTH synthesis and secretion, promotes its degrdn., and inhibits parathyroid cellular proliferation.  It has just the opposite effects on the C-cell, stimulating CT when \\Ca2+o\\ is high.  In bone, Ca2+, acting via the CaSR, stimulates recruitment and proliferation of preosteoblasts, their differentiation to mature osteoblasts, and synthesis and mineralization of bone proteins.  Conversely, \\Ca2+o\\ inhibits the formation and activity and promotes apoptosis of osteoclasts, likely via the CaSR.  These actions tend to mobilize skeletal Ca2+ during \\Ca2+o\\ deficiency and retain it when Ca2+ is plentiful.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKviIOVjKkTrVg90H21EOLACvtfcHk0lgwQn4Vwxv2YA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktlCgtbg%253D&md5=67ff8283fc93be514d04588aca22becc</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.beem.2013.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.beem.2013.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DE.%2BM.%26atitle%3DRole%2520of%2520the%2520calcium-sensing%2520receptor%2520in%2520extracellular%2520calcium%2520homeostasis%26jtitle%3DBest%2520Pract.%2520Res.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2013%26volume%3D27%26spage%3D333%26epage%3D343%26doi%3D10.1016%2Fj.beem.2013.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alam, M. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirton, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towers, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouhi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vizard, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sage, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riccardi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canfield, A. E.</span></span> <span> </span><span class="NLM_article-title">Calcification is associated with loss of functional calcium-sensing receptor in vascular smooth muscle cells</span>. <i>Cardiovasc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">260</span>â <span class="NLM_lpage">268</span>, <span class="refDoi">Â DOI: 10.1093/cvr/cvn279</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1093%2Fcvr%2Fcvn279" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=18852253" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntVOhsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2009&pages=260-268&author=M.+U.+Alamauthor=J.+P.+Kirtonauthor=F.+L.+Wilkinsonauthor=E.+Towersauthor=S.+Sinhaauthor=M.+Rouhiauthor=T.+N.+Vizardauthor=A.+P.+Sageauthor=D.+Martinauthor=D.+T.+Wardauthor=M.+Y.+Alexanderauthor=D.+Riccardiauthor=A.+E.+Canfield&title=Calcification+is+associated+with+loss+of+functional+calcium-sensing+receptor+in+vascular+smooth+muscle+cells&doi=10.1093%2Fcvr%2Fcvn279"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Calcification is associated with loss of functional calcium-sensing receptor in vascular smooth muscle cells</span></div><div class="casAuthors">Alam, Masih-ul; Kirton, John Paul; Wilkinson, Fiona L.; Towers, Emily; Sinha, Smeeta; Rouhi, Mansour; Vizard, Thomas N.; Sage, Andrew P.; Martin, David; Ward, Donald T.; Alexander, Marie Yvonne; Riccardi, Daniela; Canfield, Ann E.</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">260-268</span>CODEN:
                <span class="NLM_cas:coden">CVREAU</span>;
        ISSN:<span class="NLM_cas:issn">0008-6363</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Vascular calcification (VC) is highly correlated with increased morbidity and mortality in advanced chronic kidney disease (CKD) patients.  Allosteric modulation of the calcium-sensing receptor (CaR) by calcimimetics inhibits VC in animal models of advanced CKD.  Here, we investigated the expression of the CaR in the vasculature and tested the ability of calcimimetics to prevent vascular smooth muscle cell (VSMC) calcification in vitro.  Immunohistochem. staining demonstrated that CaR protein is present in VSMC in normal, non-calcified human arteries.  In contrast, low levels of CaR immunoreactivity were detected in atherosclerotic, calcified arteries.  Immunfluorescence and immunoblotting revealed that CaR protein was also expressed by human and bovine VSMC in vitro.  Acute stimulation of VSMC with increased Ca2+ stimulated extracellular signal-regulated kinase (ERK1/2) phosphorylation, suggesting that the VSMC CaR is functional.  VSMC CaR expression decreased when these cells deposited a mineralized matrix or following 24 h incubation in mineralization medium with increased (i.e. 1.8 or 2.5 mM) Ca2+.  Culturing VSMC in mineralization medium contg. 1.8 and 2.5 mM Ca2+ or with the membrane-impermeant CaR agonist Gd3+ enhanced mineral deposition compared with that obsd. in 1.2 mM Ca2+.  Over-expression of dominant-neg. (R185Q) CaR enhanced, whereas the calcimimetic R-568 attenuated, VSMC mineral deposition.  These results demonstrate that: (i) VSMCs express a functional CaR; (ii) a redn. in CaR expression is assocd. with increased mineralization in vivo and in vitro; (iii) calcimimetics decrease mineral deposition by VSMC.  These data suggest that calcimimetics may inhibit the development of VC in CKD patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7MsBUaLuxeLVg90H21EOLACvtfcHk0lgwQn4Vwxv2YA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntVOhsw%253D%253D&md5=94a8f26c71aebdf7619c68ec335e3a87</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1093%2Fcvr%2Fcvn279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcvr%252Fcvn279%26sid%3Dliteratum%253Aachs%26aulast%3DAlam%26aufirst%3DM.%2BU.%26aulast%3DKirton%26aufirst%3DJ.%2BP.%26aulast%3DWilkinson%26aufirst%3DF.%2BL.%26aulast%3DTowers%26aufirst%3DE.%26aulast%3DSinha%26aufirst%3DS.%26aulast%3DRouhi%26aufirst%3DM.%26aulast%3DVizard%26aufirst%3DT.%2BN.%26aulast%3DSage%26aufirst%3DA.%2BP.%26aulast%3DMartin%26aufirst%3DD.%26aulast%3DWard%26aufirst%3DD.%2BT.%26aulast%3DAlexander%26aufirst%3DM.%2BY.%26aulast%3DRiccardi%26aufirst%3DD.%26aulast%3DCanfield%26aufirst%3DA.%2BE.%26atitle%3DCalcification%2520is%2520associated%2520with%2520loss%2520of%2520functional%2520calcium-sensing%2520receptor%2520in%2520vascular%2520smooth%2520muscle%2520cells%26jtitle%3DCardiovasc.%2520Res.%26date%3D2009%26volume%3D81%26spage%3D260%26epage%3D268%26doi%3D10.1093%2Fcvr%2Fcvn279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coy, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollak, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wank, S. A.</span></span> <span> </span><span class="NLM_article-title">Calcium-sensing receptor is a physiologic multimodal chemosensor regulating gastric G-cell growth and gastrin secretion</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">17791</span>â <span class="NLM_lpage">17796</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1009078107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1073%2Fpnas.1009078107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=20876097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlalt7jN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=17791-17796&author=J.+Fengauthor=C.+D.+Petersenauthor=D.+H.+Coyauthor=J.+K.+Jiangauthor=C.+J.+Thomasauthor=M.+R.+Pollakauthor=S.+A.+Wank&title=Calcium-sensing+receptor+is+a+physiologic+multimodal+chemosensor+regulating+gastric+G-cell+growth+and+gastrin+secretion&doi=10.1073%2Fpnas.1009078107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Calcium-sensing receptor is a physiologic multimodal chemosensor regulating gastric G-cell growth and gastrin secretion</span></div><div class="casAuthors">Feng, Jianying; Petersen, Clark D.; Coy, David H.; Jiang, Jian-Kang; Thomas, Craig J.; Pollak, Martin R.; Wank, Stephen A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">17791-17796, S17791/1-S17791/4</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The calcium-sensing receptor (CaR) is the major sensor and regulator of extracellular Ca2+, whose activity is allosterically regulated by amino acids and pH.  Recently, CaR has been identified in the stomach and intestinal tract, where it has been proposed to function in a non-Ca2+ homeostatic capacity.  Luminal nutrients, such as Ca2+ and amino acids, have been recognized for decades as potent stimulants for gastrin and acid secretion, although the mol. basis for their recognition remains unknown.  The expression of CaR on gastrin-secreting G cells in the stomach and their shared activation by Ca2+, amino acids, and elevated pH suggest that CaR may function as the elusive physiol. sensor regulating gastrin and acid secretion.  The genetic and pharmacol. studies presented here comparing CaR-null mice and wild-type littermates support this hypothesis.  Gavage of Ca2+, peptone, phenylalanine, Hepes buffer (pH 7.4), and CaR-specific calcimimetic, cinacalcet, stimulated gastrin and acid secretion, whereas the calcilytic, NPS 2143, inhibited secretion only in the wild-type mouse.  Consistent with known growth and developmental functions of CaR, G-cell no. was progressively reduced between 30 and 90 d of age by more than 65% in CaR-null mice.  These studies of nutrient-regulated G-cell gastrin secretion and growth provide definitive evidence that CaR functions as a physiol. relevant multimodal sensor.  Medicinals targeting diseases of Ca2+ homeostasis should be reviewed for effects outside traditional Ca2+-regulating tissues in view of the broader distribution and function of CaR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-cdTzypSyDbVg90H21EOLACvtfcHk0liBtHQIx30MaQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlalt7jN&md5=e195c80cef7f31a5bba25d12929f3f37</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1009078107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1009078107%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DPetersen%26aufirst%3DC.%2BD.%26aulast%3DCoy%26aufirst%3DD.%2BH.%26aulast%3DJiang%26aufirst%3DJ.%2BK.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26aulast%3DPollak%26aufirst%3DM.%2BR.%26aulast%3DWank%26aufirst%3DS.%2BA.%26atitle%3DCalcium-sensing%2520receptor%2520is%2520a%2520physiologic%2520multimodal%2520chemosensor%2520regulating%2520gastric%2520G-cell%2520growth%2520and%2520gastrin%2520secretion%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D17791%26epage%3D17796%26doi%3D10.1073%2Fpnas.1009078107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mace, O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span> <span> </span><span class="NLM_article-title">The regulation of K- and L-cell activity by GLUT2 and the calcium-sensing receptor CaS receptor in rat small intestine</span>. <i>J. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>590</i></span>,  <span class="NLM_fpage">2917</span>â <span class="NLM_lpage">2936</span>, <span class="refDoi">Â DOI: 10.1113/jphysiol.2011.223800</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1113%2Fjphysiol.2011.223800" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=22495587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFehtLjE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=590&publication_year=2012&pages=2917-2936&author=O.+J.+Maceauthor=M.+Schindlerauthor=S.+Patel&title=The+regulation+of+K-+and+L-cell+activity+by+GLUT2+and+the+calcium-sensing+receptor+CaS+receptor+in+rat+small+intestine&doi=10.1113%2Fjphysiol.2011.223800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">The regulation of K- and L-cell activity by GLUT2 and the calcium-sensing receptor CasR in rat small intestine</span></div><div class="casAuthors">Mace, Oliver J.; Schindler, Marcus; Patel, Sonal</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physiology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">590</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2917-2936</span>CODEN:
                <span class="NLM_cas:coden">JPHYA7</span>;
        ISSN:<span class="NLM_cas:issn">0022-3751</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Intestinal enteroendocrine cells (IECs) secrete gut peptides in response to both nutrients and non-nutrients.  Glucose and amino acids both stimulate gut peptide secretion.  Our hypothesis was that the facilitative glucose transporter, GLUT2, could act as a glucose sensor and the calcium-sensing receptor, CasR, could detect amino acids in the intestine to modify gut peptide secretion.  We used isolated loops of rat small intestine to study the secretion of gluco-insulinotropic peptide (GIP), glucagon-like peptide-1 (GLP-1) and peptide tyrosine tyrosine (PYY) secretion stimulated by luminal perfusion of nutrients or bile acid.  Inhibition of the sodium-dependent glucose cotransporter 1 (SGLT1) with phloridzin partially inhibited GIP, GLP-1 and PYY secretion by 45%, suggesting another glucose sensor might be involved in modulating peptide secretion.  The response was completely abolished in the presence of the GLUT2 inhibitors phloretin or cytochalasin B.  Given that GLUT2 modified gut peptide secretion stimulated by glucose, we investigated whether it was involved in the secretion of gut peptide by other gut peptide secretagogues.  Phloretin completely abolished gut peptide secretion stimulated by artificial sweetener (sucralose), dipeptide (glycylsarcosine), lipid (oleoylethanolamine), short chain fatty acid (propionate) and major rat bile acid (taurocholate) indicating a fundamental position for GLUT2 in the gut peptide secretory mechanism.  We investigated how GLUT2 was able to influence gut peptide secretion mediated by a diverse range of stimulators and discovered that GLUT2 affected membrane depolarization through the closure of K+ATP-sensitive channels.  In the absence of SGLT1 activity (or presence of phloridzin), the secretion of GIP, GLP-1 and PYY was sensitive to K+ATP-sensitive channel modulators tolbutamide and diazoxide.  L-Amino acids phenylalanine (Phe), tryptophan (Trp), asparagine (Asn), arginine (Arg) and glutamine (Gln) also stimulated GIP, GLP-1 and PYY secretion, which was completely abolished when extracellular Ca2+ was absent.  The gut peptide response stimulated by the amino acids was also blocked by the CasR inhibitor Calhex 231 and augmented by the CasR agonist NPS-R568.  GLUT2 and CasR regulate K- and L-cell activity in response to nutrient and non-nutrient stimuli.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT8oKxZEsLw7Vg90H21EOLACvtfcHk0liBtHQIx30MaQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFehtLjE&md5=59b351a85cf9a0d7105e7788fec6a710</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1113%2Fjphysiol.2011.223800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1113%252Fjphysiol.2011.223800%26sid%3Dliteratum%253Aachs%26aulast%3DMace%26aufirst%3DO.%2BJ.%26aulast%3DSchindler%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DS.%26atitle%3DThe%2520regulation%2520of%2520K-%2520and%2520L-cell%2520activity%2520by%2520GLUT2%2520and%2520the%2520calcium-sensing%2520receptor%2520CaS%2520receptor%2520in%2520rat%2520small%2520intestine%26jtitle%3DJ.%2520Physiol.%26date%3D2012%26volume%3D590%26spage%3D2917%26epage%3D2936%26doi%3D10.1113%2Fjphysiol.2011.223800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chonchol, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locatelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abboud, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charytan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Francisco, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jolly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roger, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albizem, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mix, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Block, G. A.</span></span> <span> </span><span class="NLM_article-title">A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis</span>. <i>Am. J. Kidney Dis.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">197</span>â <span class="NLM_lpage">207</span>, <span class="refDoi">Â DOI: 10.1053/j.ajkd.2008.09.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1053%2Fj.ajkd.2008.09.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=19110359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVWgsb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2009&pages=197-207&author=M.+Choncholauthor=F.+Locatelliauthor=H.+E.+Abboudauthor=C.+Charytanauthor=A.+L.+de+Franciscoauthor=S.+Jollyauthor=M.+Kaplanauthor=S.+D.+Rogerauthor=S.+Sarkarauthor=M.+B.+Albizemauthor=T.+C.+Mixauthor=Y.+Kuboauthor=G.+A.+Block&title=A+randomized%2C+double-blind%2C+placebo-controlled+study+to+assess+the+efficacy+and+safety+of+cinacalcet+HCl+in+participants+with+CKD+not+receiving+dialysis&doi=10.1053%2Fj.ajkd.2008.09.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCI in participants with CKD not receiving dialysis</span></div><div class="casAuthors">Chonchol, Michel; Locatelli, Francesco; Abboud, Hanna E.; Charytan, Chaim; de Francisco, Angel L. M.; Jolly, Shivinder; Kaplan, Mark; Roger, Simon D.; Sarkar, Shyamal; Albizem, Moetaz B.; Mix, T. Christian H.; Kubo, Yumi; Block, Geoffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Kidney Diseases</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">197-207</span>CODEN:
                <span class="NLM_cas:coden">AJKDDP</span>;
        ISSN:<span class="NLM_cas:issn">0272-6386</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Secondary hyperparathyroidism is obsd. in patients with early chronic kidney disease (CKD).  This study investigated the safety and efficacy of cinacalcet for secondary hyperparathyroidism in participants with CKD not receiving dialysis.  Double-blind, randomized, 32-wk, phase 3 study.  Setting & Participants: 404 participants with stage 3 or 4 CKD from 73 centers in 9 countries.  Interventions: Cinacalcet:placebo (3:1 ratio).  Proportion of participants with a mean decrease of 30% or greater in intact parathyroid hormone (iPTH) level, proportion with iPTH level of 70 or less or 110 or less pg/mL (stage 3 and 4 CKD, resp.), and mean percentage of iPTH change from baseline, all during the efficacy-assessment phase.  A greater proportion of cinacalcet than placebo participants achieved a 30% or greater decrease in iPTH level (74% vs. 28%; P < 0.001), corresponding to a 43.1% decrease in iPTH level from baseline (cinacalcet) compared with a 1.1% increase (placebo).  At week 32, serum calcium levels were 8.9 Â± 0.8 mg/dL (-8.9%; cinacalcet) and 9.9 Â± 0.6 mg/dL (+0.8%; placebo), phosphorus levels were 4.5 Â± 1.0 mg/dL (+21.4%) and 4.0 Â± 0.7 mg/dL (+6.8%), and calcium-phosphorus product values were 40.1 Â± 8.3 mg2/dL2 (+18.9%) and 38.9 Â± 6.9 mg2/dL2 (+17.1%), resp.  During the study course, 62% (cinacalcet) and 1% (placebo) of participants experienced 2 consecutive serum calcium concns. less than 8.4 mg/dL.  They generally were asymptomatic and without significant clin. consequences.  Treatment generally was well tolerated, and most adverse events were mild to moderate in severity.  The study was not designed to assess the effects of cinacalcet on vascular calcification, bone histomorphometric parameters, or other clin. outcomes.  It is not known whether the obsd. differences in changes in iPTH levels are clin. more important than obsd. differences in changes in serum calcium or phosphorus levels or dosages of vitamin D sterols and phosphate binders.  These data show that cinacalcet treatment in patients with CKD not receiving dialysis can decrease plasma iPTH levels, but with frequent (albeit generally asymptomatic) serum calcium levels less than 8.4 mg/dL and increases in serum phosphorus levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodMRfeR8K80bVg90H21EOLACvtfcHk0liBtHQIx30MaQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVWgsb4%253D&md5=98834ae0ddc6bfd428548434a3c5e20b</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1053%2Fj.ajkd.2008.09.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.ajkd.2008.09.021%26sid%3Dliteratum%253Aachs%26aulast%3DChonchol%26aufirst%3DM.%26aulast%3DLocatelli%26aufirst%3DF.%26aulast%3DAbboud%26aufirst%3DH.%2BE.%26aulast%3DCharytan%26aufirst%3DC.%26aulast%3Dde%2BFrancisco%26aufirst%3DA.%2BL.%26aulast%3DJolly%26aufirst%3DS.%26aulast%3DKaplan%26aufirst%3DM.%26aulast%3DRoger%26aufirst%3DS.%2BD.%26aulast%3DSarkar%26aufirst%3DS.%26aulast%3DAlbizem%26aufirst%3DM.%2BB.%26aulast%3DMix%26aufirst%3DT.%2BC.%26aulast%3DKubo%26aufirst%3DY.%26aulast%3DBlock%26aufirst%3DG.%2BA.%26atitle%3DA%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520study%2520to%2520assess%2520the%2520efficacy%2520and%2520safety%2520of%2520cinacalcet%2520HCl%2520in%2520participants%2520with%2520CKD%2520not%2520receiving%2520dialysis%26jtitle%3DAm.%2520J.%2520Kidney%2520Dis.%26date%3D2009%26volume%3D53%26spage%3D197%26epage%3D207%26doi%3D10.1053%2Fj.ajkd.2008.09.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arenas, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Fuente, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">RodrÃ­guez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">AlmadÃ©n, Y.</span></span> <span> </span><span class="NLM_article-title">Pharmacodynamics of cinacalcet over 48 h in patients with controlled secondary hyperparathyroidism: useful data in clinical practice</span>. <i>J. Clin. Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">1718</span>â <span class="NLM_lpage">1725</span>, <span class="refDoi">Â DOI: 10.1210/jc.2012-4003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1210%2Fjc.2012-4003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=23463658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtFehtb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2013&pages=1718-1725&author=M.+D.+Arenasauthor=V.+de+la+Fuenteauthor=P.+Delgadoauthor=M.+T.+Gilauthor=P.+Gutierrezauthor=J.+Riberoauthor=M.+Rodr%C3%ADguezauthor=Y.+Almad%C3%A9n&title=Pharmacodynamics+of+cinacalcet+over+48+h+in+patients+with+controlled+secondary+hyperparathyroidism%3A+useful+data+in+clinical+practice&doi=10.1210%2Fjc.2012-4003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacodynamics of cinacalcet over 48 hours in patients with controlled secondary hyperparathyroidism: useful data in clinical practice</span></div><div class="casAuthors">Arenas, M. Dolores; de la Fuente, Vanesa; Delgado, Pablo; Gil, Maria Teresa; Gutierrez, Patricia; Ribero, Jorge; Rodriguez, Mariano; Almaden, Yolanda</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1718-1725</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Cinacalcet induces immediate changes in serum PTH levels, but the pharmacodynamic effect throughout the daily dosing interval in controlled patients is unknown.  Also, in patients with reduced PTH, it is unknown what happens in the first 24 h after withdrawal.  Our aim was to describe the effect over 48 h of cinacalcet in hemodialysis patients with controlled secondary hyperparathyroidism.  This was a phase 4, open-label, single-arm, single-dose, single-center clin. trial.  The study was conducted at a public hospital (Hospital Perpetuo Socorro, Alicante, Spain).  We included 10 patients on cinacalcet for 6 mo or longer with intact PTH (iPTH) levels 100-400 pg/mL [8 men, mean age of 66 years (range 39-82 years)], chronically treated with 30 mg (n = 6), 60 mg (n = 3), or 90 mg (n = 1) of cinacalcet.  A single dose (30-90 mg) was administered at baseline.  IPTH (Duo Kit Scantibodies and Elecsys Roche), PTH 1-84, ionized calcium, phosphorus (P), and calcitonin were detd. at baseline and at 1, 3, 6, 12, 24, and 48 h.  There was a significant redn. in iPTH between 1 and 6 h, and values returned to baseline at 24 h [max. mean (95% confidence interval) percent change from baseline: -50%(-34; -66) at 3 h].  A transient increase in calcitonin and a decrease in P were also obsd., with no changes in calcium.  At 48 h, there was a significant increase in iPTH [+51% (26; 76)] and P.  Changes in PTH were similar with the 3 detn. methods.  In hemodialysis patients with secondary hyperparathyroidism controlled by cinacalcet, a transient (1-6 h) redn. in PTH and P and an increase in calcitonin are obsd. after each daily dose, with return to baseline at 24 h.  After calcimimetics discontinuation, PTH was significantly increased at 48 h.  The assay used to measure PTH does not influence relative changes induced by cinacalcet.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQLwgkc0KXFbVg90H21EOLACvtfcHk0ljigK3REjbVlg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtFehtb8%253D&md5=880f7204fc37ae3f824f4bd5c6cf8e97</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1210%2Fjc.2012-4003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjc.2012-4003%26sid%3Dliteratum%253Aachs%26aulast%3DArenas%26aufirst%3DM.%2BD.%26aulast%3Dde%2Bla%2BFuente%26aufirst%3DV.%26aulast%3DDelgado%26aufirst%3DP.%26aulast%3DGil%26aufirst%3DM.%2BT.%26aulast%3DGutierrez%26aufirst%3DP.%26aulast%3DRibero%26aufirst%3DJ.%26aulast%3DRodr%25C3%25ADguez%26aufirst%3DM.%26aulast%3DAlmad%25C3%25A9n%26aufirst%3DY.%26atitle%3DPharmacodynamics%2520of%2520cinacalcet%2520over%252048%2520h%2520in%2520patients%2520with%2520controlled%2520secondary%2520hyperparathyroidism%253A%2520useful%2520data%2520in%2520clinical%2520practice%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2013%26volume%3D98%26spage%3D1718%26epage%3D1725%26doi%3D10.1210%2Fjc.2012-4003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Henley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morony, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shatzen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pretorius, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St. Jean, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fotsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reagan, J. D.</span></span> <span> </span><span class="NLM_article-title">Discovery of a calcimimetic with differential effects on parathyroid hormone and calcitonin secretion</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>337</i></span>,  <span class="NLM_fpage">681</span>â <span class="NLM_lpage">691</span>, <span class="refDoi">Â DOI: 10.1124/jpet.110.178681</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1124%2Fjpet.110.178681" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=21422163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvFeiurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=337&publication_year=2011&pages=681-691&author=C.+Henleyauthor=Y.+Yangauthor=J.+Davisauthor=J.+Y.+Luauthor=S.+Moronyauthor=W.+Fanauthor=M.+Florioauthor=B.+Sunauthor=E.+Shatzenauthor=J.+K.+Pretoriusauthor=W.+G.+Richardsauthor=D.+J.+St.+Jeanauthor=C.+Fotschauthor=J.+D.+Reagan&title=Discovery+of+a+calcimimetic+with+differential+effects+on+parathyroid+hormone+and+calcitonin+secretion&doi=10.1124%2Fjpet.110.178681"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a calcimimetic with differential effects on parathyroid hormone and calcitonin secretion</span></div><div class="casAuthors">Henley, Charles, III; Yang, Yuhua; Davis, James; Lu, Jenny Ying Lin; Morony, Sean; Fan, Wei; Florio, Monica; Sun, Banghua; Shatzen, Edward; Pretorius, James K.; Richards, William G.; St. Jean, David J., Jr.; Fotsch, Christopher; Reagan, Jeff D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">337</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">681-691</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Calcimimetics are pos. allosteric modulators to the calcium-sensing receptor (CaSR).  Activation of the CaSR inhibits the secretion of parathyroid hormone (PTH), stimulates the secretion of calcitonin, and decreases serum calcium (Ca2+).  Cinacalcet, a second-generation calcimimetic, is used therapeutically to control PTH in patients with chronic kidney disease who are on dialysis with secondary hyperparathyroidism.  A calcimimetic that displays increased sepn. of PTH vs. Ca2+ lowering in patients would potentially allow the use of calcimimetics to treat patients in earlier stages of renal disease because hypocalcemia can develop in this population.  Toward this end, we developed a third-generation calcimimetic, detd. the mol. pharmacol. properties of it using an operation model of allosteric modulation/agonism, and measured the compd. effects on PTH, serum ionized Ca2+, and calcitonin levels in 5/6 nephrectomized rats.  We found the new mol. effectively reduced PTH levels without promoting calcitonin secretion or hypocalcemia.  Furthermore, our third-generation mol. was less efficacious at promoting calcitonin secretion from human thyroid carcinoma cells compared with 3-(2-chlorophenyl)-N-((1R)-1-(3-methoxyphenyl)ethyl)-1-propanamine (R-568), a first-generation calcimimetic.  These data provide evidence that calcimimetics with increased potency can be used to lower PTH without prodn. of significant hypocalcemia because the threshold for inhibition of PTH secretion is much lower than the threshold for calcitonin secretion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaiYjVcexvsLVg90H21EOLACvtfcHk0ljigK3REjbVlg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvFeiurw%253D&md5=0e303e288f29a0d80c375f0e4ce76dfb</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.178681&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.178681%26sid%3Dliteratum%253Aachs%26aulast%3DHenley%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DDavis%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DJ.%2BY.%26aulast%3DMorony%26aufirst%3DS.%26aulast%3DFan%26aufirst%3DW.%26aulast%3DFlorio%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DB.%26aulast%3DShatzen%26aufirst%3DE.%26aulast%3DPretorius%26aufirst%3DJ.%2BK.%26aulast%3DRichards%26aufirst%3DW.%2BG.%26aulast%3DSt.%2BJean%26aufirst%3DD.%2BJ.%26aulast%3DFotsch%26aufirst%3DC.%26aulast%3DReagan%26aufirst%3DJ.%2BD.%26atitle%3DDiscovery%2520of%2520a%2520calcimimetic%2520with%2520differential%2520effects%2520on%2520parathyroid%2520hormone%2520and%2520calcitonin%2520secretion%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D337%26spage%3D681%26epage%3D691%26doi%3D10.1124%2Fjpet.110.178681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafsson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabatabaei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmelzer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burstein, E. S.</span></span> <span> </span><span class="NLM_article-title">Characterization of highly efficacious allosteric agonists of the human calcium-sensing receptor</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>337</i></span>,  <span class="NLM_fpage">275</span>â <span class="NLM_lpage">284</span>, <span class="refDoi">Â DOI: 10.1124/jpet.110.178194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1124%2Fjpet.110.178194" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=21239511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGqu7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=337&publication_year=2011&pages=275-284&author=J.+N.+Maauthor=M.+Owensauthor=M.+Gustafssonauthor=J.+Jensenauthor=A.+Tabatabaeiauthor=K.+Schmelzerauthor=R.+Olssonauthor=E.+S.+Burstein&title=Characterization+of+highly+efficacious+allosteric+agonists+of+the+human+calcium-sensing+receptor&doi=10.1124%2Fjpet.110.178194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of highly efficacious allosteric agonists of the human calcium-sensing receptor</span></div><div class="casAuthors">Ma, Jian-Nong; Owens, Michelle; Gustafsson, Magnus; Jensen, Jacob; Tabatabaei, Ali; Schmelzer, Kara; Olsson, Roger; Burstein, Ethan S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">337</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">275-284</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We discovered structurally novel human calcium-sensing receptor (CaSR) allosteric agonists and compared their pharmacol. to phenylalkylamine calcimimetics.  1-Benzothiazol-2-yl-1-(2,4-dimethyl-phenyl)-ethanol (AC-265347) activated CaSR signaling in cellular proliferation and phosphatidylinositol (PI) hydrolysis assays with potencies of 30 and 10 nM, resp. (S)-1-Benzothiazol-2-yl-1-(2,4-dimethyl-phenyl)-ethanol [(S)-AC-265347], the S-enantiomer of AC-265347, was approx. 10- to 20-fold more potent than (R)-1-benzothiazol-2-yl-1-(2,4-dimethyl-phenyl)-ethanol [(R)-AC-265347].  The phenylalkylamines cinacalcet and calindol had activity similar to that of AC-265347 in cellular proliferation assays but less activity in PI assays.  All compds. had reduced activity when extracellular Ca2+ was removed, indicating that they cooperate with Ca2+ to activate CaSRs, and all activated CaSR isoforms with the N-terminal extracellular domain deleted, indicating that they interact with the transmembrane domains.  In both cases, AC-265347 and therefore (S)-AC-265347 were significantly more efficacious than the phenylalkylamines.  Mutations E837A7.39 and I841A7.43 strongly reduced phenylalkylamine-induced signaling, but not AC-265347- or (S)-AC-265347-induced signaling, suggesting different modes of binding.  AC-265347 and (S)-AC-265347 stimulated significantly greater responses than cinacalcet or calindol at each of 4 loss-of-function human polymorphic CaSR variants.  AC-265347 did not inhibit the CYP2D6 cytochrome P 450 isoenzyme, unlike cinacalcet, which is a potent CYP2D6 inhibitor.  In rats, AC-265347, (S)-AC-265347, and (R)-AC-265347 each reduced serum parathyroid hormone (PTH) with a rank order potency correlated with their in vitro potencies.  AC-265347 and (S)-AC-265347 also reduced plasma ionizable Ca ([Ca2+]o).  AC-265347 was orally active, and its plasma concns. correlated well with its effects on serum PTH.  Thus, these highly efficacious CaSR allosteric agonists represent leads for developing therapeutic agents with potential advantages over existing therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3kSepRESavLVg90H21EOLACvtfcHk0ljigK3REjbVlg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGqu7Y%253D&md5=797ba8b3059d82c04c4b9259149d9fe4</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.178194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.178194%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DJ.%2BN.%26aulast%3DOwens%26aufirst%3DM.%26aulast%3DGustafsson%26aufirst%3DM.%26aulast%3DJensen%26aufirst%3DJ.%26aulast%3DTabatabaei%26aufirst%3DA.%26aulast%3DSchmelzer%26aufirst%3DK.%26aulast%3DOlsson%26aufirst%3DR.%26aulast%3DBurstein%26aufirst%3DE.%2BS.%26atitle%3DCharacterization%2520of%2520highly%2520efficacious%2520allosteric%2520agonists%2520of%2520the%2520human%2520calcium-sensing%2520receptor%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D337%26spage%3D275%26epage%3D284%26doi%3D10.1124%2Fjpet.110.178194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roux, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BernÃ¨che, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egwolf, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lev, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noskov, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowley, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span> <span> </span><span class="NLM_article-title">Ion selectivity in channels and transporters</span>. <i>J. Gen. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>137</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">415</span>â <span class="NLM_lpage">426</span>, <span class="refDoi">Â DOI: 10.1085/jgp.201010577</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1085%2Fjgp.201010577" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=21518830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntlygsb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2011&pages=415-426&issue=5&author=B.+Rouxauthor=S.+Bern%C3%A8cheauthor=B.+Egwolfauthor=B.+Levauthor=S.+Y.+Noskovauthor=C.+N.+Rowleyauthor=H.+Yu&title=Ion+selectivity+in+channels+and+transporters&doi=10.1085%2Fjgp.201010577"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Ion selectivity in channels and transporters</span></div><div class="casAuthors">Roux, Benoit; Berneche, Simon; Egwolf, Bernhard; Lev, Bogdan; Noskov, Sergei Y.; Rowley, Christopher N.; Yu, Haibo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of General Physiology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">415-426</span>CODEN:
                <span class="NLM_cas:coden">JGPLAD</span>;
        ISSN:<span class="NLM_cas:issn">0022-1295</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">A review presents the understanding of ion selectivity as it has evolved over about 15 years from studies based on various specific structures: gramicidin A channels, the KcsA channel, the NaK channel, the LeuT transporter, and the Na/K pump.  It also discusses the insights that can be gained from simple models, which can be used to illustrate and clarify fundamental phys. principles governing ion selectivity in channels and transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPgn25Zh5M_rVg90H21EOLACvtfcHk0lijavDwYO0FNw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntlygsb8%253D&md5=8d79ac76351ae06dd9e85c4957b4509b</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1085%2Fjgp.201010577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1085%252Fjgp.201010577%26sid%3Dliteratum%253Aachs%26aulast%3DRoux%26aufirst%3DB.%26aulast%3DBern%25C3%25A8che%26aufirst%3DS.%26aulast%3DEgwolf%26aufirst%3DB.%26aulast%3DLev%26aufirst%3DB.%26aulast%3DNoskov%26aufirst%3DS.%2BY.%26aulast%3DRowley%26aufirst%3DC.%2BN.%26aulast%3DYu%26aufirst%3DH.%26atitle%3DIon%2520selectivity%2520in%2520channels%2520and%2520transporters%26jtitle%3DJ.%2520Gen.%2520Physiol.%26date%3D2011%26volume%3D137%26issue%3D5%26spage%3D415%26epage%3D426%26doi%3D10.1085%2Fjgp.201010577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noskov, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BernÃ¨che, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roux, B.</span></span> <span> </span><span class="NLM_article-title">Control of ion selectivity in potassium channels by electrostatic and dynamic properties of carbonyl ligands</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>431</i></span> (<span class="NLM_issue">7010</span>),  <span class="NLM_fpage">830</span>â <span class="NLM_lpage">834</span>, <span class="refDoi">Â DOI: 10.1038/nature02943</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fnature02943" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=15483608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotl2ktr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=431&publication_year=2004&pages=830-834&issue=7010&author=S.+Y.+Noskovauthor=S.+Bern%C3%A8cheauthor=B.+Roux&title=Control+of+ion+selectivity+in+potassium+channels+by+electrostatic+and+dynamic+properties+of+carbonyl+ligands&doi=10.1038%2Fnature02943"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Control of ion selectivity in potassium channels by electrostatic and dynamic properties of carbonyl ligands</span></div><div class="casAuthors">Noskov, Sergei Yu.; Berneche, Simon; Roux, Benoit</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">431</span>
        (<span class="NLM_cas:issue">7010</span>),
    <span class="NLM_cas:pages">830-834</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Potassium channels are essential for maintaining a normal ionic balance across cell membranes.  Central to this function is the ability of such channels to support transmembrane ion conduction at nearly diffusion-limited rates while discriminating for K+ over Na+ by more than a thousand-fold.  This selectivity arises because the transfer of the K+ ion into the channel pore is energetically favored, a feature commonly attributed to a structurally precise fit between the K+ ion and carbonyl groups lining the rigid and narrow pore.  But proteins are relatively flexible structures that undergo rapid thermal at. fluctuations larger than the small difference in ionic radius between K+ and Na+.  Here we present mol. dynamics simulations for the potassium channel KcsA, which show that the carbonyl groups coordinating the ion in the narrow pore are indeed very dynamic ('liq.-like') and that their intrinsic electrostatic properties control ion selectivity.  This finding highlights the importance of the classical concept of field strength.  Selectivity for K+ is seen to emerge as a robust feature of a flexible fluctuating pore lined by carbonyl groups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe-L8WaSy2VLVg90H21EOLACvtfcHk0lijavDwYO0FNw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotl2ktr8%253D&md5=86396f17214821a6de671d059e134ab9</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1038%2Fnature02943&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature02943%26sid%3Dliteratum%253Aachs%26aulast%3DNoskov%26aufirst%3DS.%2BY.%26aulast%3DBern%25C3%25A8che%26aufirst%3DS.%26aulast%3DRoux%26aufirst%3DB.%26atitle%3DControl%2520of%2520ion%2520selectivity%2520in%2520potassium%2520channels%2520by%2520electrostatic%2520and%2520dynamic%2520properties%2520of%2520carbonyl%2520ligands%26jtitle%3DNature%26date%3D2004%26volume%3D431%26issue%3D7010%26spage%3D830%26epage%3D834%26doi%3D10.1038%2Fnature02943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noskov, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roux, B.</span></span> <span> </span><span class="NLM_article-title">Ion selectivity in potassium channels</span>. <i>Biophys. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>124</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">279</span>â <span class="NLM_lpage">291</span>, <span class="refDoi">Â DOI: 10.1016/j.bpc.2006.05.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.bpc.2006.05.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=16843584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Sgs7%252FL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2006&pages=279-291&issue=3&author=S.+Y.+Noskovauthor=B.+Roux&title=Ion+selectivity+in+potassium+channels&doi=10.1016%2Fj.bpc.2006.05.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Ion selectivity in potassium channels</span></div><div class="casAuthors">Noskov, Sergei Yu.; Roux, Benoit</div><div class="citationInfo"><span class="NLM_cas:title">Biophysical Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">279-291</span>CODEN:
                <span class="NLM_cas:coden">BICIAZ</span>;
        ISSN:<span class="NLM_cas:issn">0301-4622</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  K+ channels are tetrameric membrane-spanning proteins that provide a selective pore for the conduction of K+ across the cell membranes.  One of the main physiol. functions of potassium channels is efficient and very selective transport of K+ ions through the membrane to the cell.  Classical views of ion selectivity are summarized within a historical perspective, and contrasted with the mol. dynamics (MD) simulations free energy perturbation (FEP) performed on the basis of the crystallog. structure of the KcsA phospholipid membrane.  The results show that the KcsA channel does not select for K+ ions by providing a binding site of an appropriate (fixed) cavity size.  Rather, selectivity for K+ arises directly from the intrinsic local phys. properties of the ligands coordinating the cation in the binding site, and is a robust feature of a pore sym. lined by backbone carbonyl groups.  Further anal. reveals that it is the interplay between the attractive ion-ligand (favoring smaller cation) and repulsive ligand-ligand interactions (favoring larger cations) that is the basic element governing Na+/K+ selectivity in flexible protein binding sites.  Because the no. and the type of ligands coordinating an ion directly modulate such local interactions, this provides a potent mol. mechanism to achieve and maintain a high selectivity in protein binding sites despite a significant conformational flexibility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0eM2SobhOtbVg90H21EOLACvtfcHk0lijavDwYO0FNw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Sgs7%252FL&md5=8c1bd8607651ede9375923bf3c1c95bb</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2Fj.bpc.2006.05.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bpc.2006.05.033%26sid%3Dliteratum%253Aachs%26aulast%3DNoskov%26aufirst%3DS.%2BY.%26aulast%3DRoux%26aufirst%3DB.%26atitle%3DIon%2520selectivity%2520in%2520potassium%2520channels%26jtitle%3DBiophys.%2520Chem.%26date%3D2006%26volume%3D124%26issue%3D3%26spage%3D279%26epage%3D291%26doi%3D10.1016%2Fj.bpc.2006.05.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chung, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GÃ¼ler, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caterina, M. J.</span></span> <span> </span><span class="NLM_article-title">TRPV1 shows dynamic ionic selectivity during agonist stimulation</span>. <i>Nat. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">555</span>â <span class="NLM_lpage">564</span>, <span class="refDoi">Â DOI: 10.1038/nn.2102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fnn.2102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=18391945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltFerur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2008&pages=555-564&issue=5&author=M.+K.+Chungauthor=A.+D.+G%C3%BClerauthor=M.+J.+Caterina&title=TRPV1+shows+dynamic+ionic+selectivity+during+agonist+stimulation&doi=10.1038%2Fnn.2102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">TRPV1 shows dynamic ionic selectivity during agonist stimulation</span></div><div class="casAuthors">Chung, Man-Kyo; Gueler, Ali D.; Caterina, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Neuroscience</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">555-564</span>CODEN:
                <span class="NLM_cas:coden">NANEFN</span>;
        ISSN:<span class="NLM_cas:issn">1097-6256</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Transient receptor potential vanilloid 1 (TRPV1) is an ion channel that is gated by noxious heat, capsaicin and other diverse stimuli.  It is a nonselective cation channel that prefers Ca2+ over Na+.  These permeability characteristics, as in most channels, are widely presumed to be static.  On the contrary, we found that activation of native or recombinant rat TRPV1 leads to time- and agonist concn.-dependent increases in relative permeability to large cations and changes in Ca2+ permeability.  Using the substituted cysteine accessibility method, we saw that these changes were attributable to alterations in the TRPV1 selectivity filter.  TRPV1 agonists showed different capabilities for evoking ionic selectivity changes.  Furthermore, protein kinase C-dependent phosphorylation of Ser-800 in the TRPV1 C terminus potentiated agonist-evoked ionic selectivity changes.  Thus, the qual. signaling properties of TRPV1 are dynamically modulated during channel activation, a process that probably shapes TRPV1 participation in pain, cytotoxicity and neurotransmitter release.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7FflcBBlyU7Vg90H21EOLACvtfcHk0lhrlbCiCGdvfg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltFerur4%253D&md5=1fb8ab48220de8feb4f9925d2371a851</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1038%2Fnn.2102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnn.2102%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DM.%2BK.%26aulast%3DG%25C3%25BCler%26aufirst%3DA.%2BD.%26aulast%3DCaterina%26aufirst%3DM.%2BJ.%26atitle%3DTRPV1%2520shows%2520dynamic%2520ionic%2520selectivity%2520during%2520agonist%2520stimulation%26jtitle%3DNat.%2520Neurosci.%26date%3D2008%26volume%3D11%26issue%3D5%26spage%3D555%26epage%3D564%26doi%3D10.1038%2Fnn.2102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarov-Yarovoy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span> <span> </span><span class="NLM_article-title">The conformational wave in capsaicin activation of transient receptor potential vanilloid 1 ion channel</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2879</span>, <span class="refDoi">Â DOI: 10.1038/s41467-018-05339-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fs41467-018-05339-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=30038260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A280%3ADC%252BB3c7htFyntA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=2879&author=F.+Yangauthor=X.+Xiaoauthor=B.+H.+Leeauthor=S.+Vuauthor=W.+Yangauthor=V.+Yarov-Yarovoyauthor=J.+Zheng&title=The+conformational+wave+in+capsaicin+activation+of+transient+receptor+potential+vanilloid+1+ion+channel&doi=10.1038%2Fs41467-018-05339-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">The conformational wave in capsaicin activation of transient receptor potential vanilloid 1 ion channel</span></div><div class="casAuthors">Yang Fan; Yang Wei; Yang Fan; Xiao Xian; Lee Bo Hyun; Vu Simon; Yarov-Yarovoy Vladimir; Zheng Jie; Xiao Xian; Lee Bo Hyun</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2879</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The capsaicin receptor TRPV1 has been intensively studied by cryo-electron microscopy and functional tests.  However, though the apo and capsaicin-bound structural models are available, the dynamic process of capsaicin activation remains intangible, largely due to the lack of a capsaicin-induced open structural model and the low occupancy of the transition states.  Here we report that reducing temperature toward the freezing point substantially increased channel closure events even in the presence of saturating capsaicin.  We further used a combination of fluorescent unnatural amino acid (fUAA) incorporation, computational modeling, and rate-equilibrium linear free-energy relationships analysis (Î¦-analysis) to derive the fully open capsaicin-bound state model, and reveal how the channel transits from the apo to the open state.  We observed that capsaicin initiates a conformational wave that propagates through the S4-S5 linker towards the S6 bundle and finally reaching the selectivity filter.  Our study provides a temporal mechanism for capsaicin activation of TRPV1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSyt2qNcfvG-FMGsG_HTXYFfW6udTcc2ebXcm6weaUDebntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7htFyntA%253D%253D&md5=5fee8ae1beb7402e3eeb9e193042342f</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-05339-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-05339-6%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DF.%26aulast%3DXiao%26aufirst%3DX.%26aulast%3DLee%26aufirst%3DB.%2BH.%26aulast%3DVu%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DYarov-Yarovoy%26aufirst%3DV.%26aulast%3DZheng%26aufirst%3DJ.%26atitle%3DThe%2520conformational%2520wave%2520in%2520capsaicin%2520activation%2520of%2520transient%2520receptor%2520potential%2520vanilloid%25201%2520ion%2520channel%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D2879%26doi%3D10.1038%2Fs41467-018-05339-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peverini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beudez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunning, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chataigneau, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grutter, T.</span></span> <span> </span><span class="NLM_article-title">New insights into permeation of large cations through ATP-gated P2X receptors</span>. <i>Front. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">265</span>, <span class="refDoi">Â DOI: 10.3389/fnmol.2018.00265</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.3389%2Ffnmol.2018.00265" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=30108481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslahsLrL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=265&author=L.+Peveriniauthor=J.+Beudezauthor=K.+Dunningauthor=T.+Chataigneauauthor=T.+Grutter&title=New+insights+into+permeation+of+large+cations+through+ATP-gated+P2X+receptors&doi=10.3389%2Ffnmol.2018.00265"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">New insights into permeation of large cations through ATP-gated P2X receptors</span></div><div class="casAuthors">Peverini, Laurie; Beudez, Juline; Dunning, Kate; Chataigneau, Thierry; Grutter, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Molecular Neuroscience</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">265/1-265/12</span>CODEN:
                <span class="NLM_cas:coden">FMNRAJ</span>;
        ISSN:<span class="NLM_cas:issn">1662-5099</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">The permeability of large cations through the P2X pore has remained arguably the most controversial and complicated topic in P2X-related research, with the emergence of conflicting studies on the existence, mechanism and physiol. relevance of a so-called "dilated" state.  Due to the important role of several "dilating" P2X subtypes in numerous diseases, a clear and detailed understanding of this phenomenon represents a research priority.  Recent advances, however, have challenged the existence of a progressive, ATP-induced pore dilation, by demonstrating that this phenomenon is an artifact of the method employed.  Here, we discuss briefly the history of this controversial and enigmatic dilated state, from its initial discovery to its recent reconsideration.  We will discuss the literature in which mechanistic pathways to a large cation-permeable state are proposed, as well as important advances in the methodol. employed to study this elusive state.  Considering recent literature, we will also open the discussion as to whether an intrinsically dilating P2X pore exists, as well as the physiol. relevance of such a large cation-permeable pore and its potential use as therapeutic pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVAkXlj36-trVg90H21EOLACvtfcHk0lhrlbCiCGdvfg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslahsLrL&md5=e6076d32a9dff60af533193141e7d2f8</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2018.00265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2018.00265%26sid%3Dliteratum%253Aachs%26aulast%3DPeverini%26aufirst%3DL.%26aulast%3DBeudez%26aufirst%3DJ.%26aulast%3DDunning%26aufirst%3DK.%26aulast%3DChataigneau%26aufirst%3DT.%26aulast%3DGrutter%26aufirst%3DT.%26atitle%3DNew%2520insights%2520into%2520permeation%2520of%2520large%2520cations%2520through%2520ATP-gated%2520P2X%2520receptors%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2018%26volume%3D11%26spage%3D265%26doi%3D10.3389%2Ffnmol.2018.00265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khakh, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, X. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labarca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lester, H. A.</span></span> <span> </span><span class="NLM_article-title">Neuronal P2X transmitter-gated cation channels change their ion selectivity in seconds</span>. <i>Nat. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">322</span>â <span class="NLM_lpage">330</span>, <span class="refDoi">Â DOI: 10.1038/7233</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2F7233" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10204538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADyaK1MXitFGjs74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1999&pages=322-330&issue=4&author=B.+S.+Khakhauthor=X.+R.+Baoauthor=C.+Labarcaauthor=H.+A.+Lester&title=Neuronal+P2X+transmitter-gated+cation+channels+change+their+ion+selectivity+in+seconds&doi=10.1038%2F7233"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Neuronal P2X transmitter-gated cation channels change their ion selectivity in seconds</span></div><div class="casAuthors">Khakh, Baljit S.; Bao, Xiaoyan R.; Labarca, Cesar; Lester, Henry A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Neuroscience</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">322-330</span>CODEN:
                <span class="NLM_cas:coden">NANEFN</span>;
        ISSN:<span class="NLM_cas:issn">1097-6256</span>.
    
            (<span class="NLM_cas:orgname">Nature America</span>)
        </div><div class="casAbstract">Fast synaptic transmission depends on the selective ionic permeability of transmitter-gated ion channels.  Here we show changes in the ion selectivity of neuronal P2X transmitter-gated cation channels as a function of time (on the order of seconds) and previous ATP exposure.  Heterologously expressed P2X2, P2X2/P2X3 and P2X4 channels as well as native neuronal P2X channels possess various combinations of mono- or biphasic responses and permeability changes, measured by NMDG+ and fluorescent dye.  Furthermore, in P2X4 receptors, this ability to alter ion selectivity can be increased or decreased by altering an amino-acid residue thought to line the ion permeation pathway, identifying a region that governs this activity-dependent change.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKnoB1C_Kgg7Vg90H21EOLACvtfcHk0lhrlbCiCGdvfg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXitFGjs74%253D&md5=d215f0d6289154b43fd181a20bb9451d</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1038%2F7233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F7233%26sid%3Dliteratum%253Aachs%26aulast%3DKhakh%26aufirst%3DB.%2BS.%26aulast%3DBao%26aufirst%3DX.%2BR.%26aulast%3DLabarca%26aufirst%3DC.%26aulast%3DLester%26aufirst%3DH.%2BA.%26atitle%3DNeuronal%2520P2X%2520transmitter-gated%2520cation%2520channels%2520change%2520their%2520ion%2520selectivity%2520in%2520seconds%26jtitle%3DNat.%2520Neurosci.%26date%3D1999%26volume%3D2%26issue%3D4%26spage%3D322%26epage%3D330%26doi%3D10.1038%2F7233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herrington, J.</span>; <span class="NLM_string-name">Arey, B. J.</span></span> <span> </span><span class="NLM_article-title">Conformational Mechanisms of Signaling Bias of Ion Channels</span>. In  <i>Biased Signaling in Physiology, Pharmacology and Therapeutics</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arey, B.</span></span>, Ed.; <span class="NLM_publisher-name">Elsevier</span>: <span class="NLM_publisher-loc">Amsterdam</span>, <span class="NLM_year">2014</span>; Chapter 6, pp  <span class="NLM_fpage">173</span>â <span class="NLM_lpage">207</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2FB978-0-12-411460-9.00006-9" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&pages=173-207&author=J.+Herrington&author=B.+J.+Areyauthor=B.+Arey&title=Biased+Signaling+in+Physiology%2C+Pharmacology+and+Therapeutics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-411460-9.00006-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-12-411460-9.00006-9%26sid%3Dliteratum%253Aachs%26aulast%3DHerrington%26aufirst%3DJ.%26atitle%3DConformational%2520Mechanisms%2520of%2520Signaling%2520Bias%2520of%2520Ion%2520Channels%26btitle%3DBiased%2520Signaling%2520in%2520Physiology%252C%2520Pharmacology%2520and%2520Therapeutics%26aulast%3DArey%26aufirst%3DB.%26pub%3DElsevier%26date%3D2014%26spage%3D173%26epage%3D207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Halvard GrÃ¸nlien, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">HÃ¥kerud, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ween, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorin-Hagene, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briggs, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopalakrishnan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malysz, J.</span></span> <span> </span><span class="NLM_article-title">Distinct profiles of alpha7 nAChR positive allosteric modulation revealed by structurally diverse chemotypes</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">715</span>â <span class="NLM_lpage">724</span>, <span class="refDoi">Â DOI: 10.1124/mol.107.035410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1124%2Fmol.107.035410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=17565004" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2007&pages=715-724&author=J.+Halvard+Gr%C3%B8nlienauthor=M.+H%C3%A5kerudauthor=H.+Weenauthor=K.+Thorin-Hageneauthor=C.+A.+Briggsauthor=M.+Gopalakrishnanauthor=J.+Malysz&title=Distinct+profiles+of+alpha7+nAChR+positive+allosteric+modulation+revealed+by+structurally+diverse+chemotypes&doi=10.1124%2Fmol.107.035410"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1124%2Fmol.107.035410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.107.035410%26sid%3Dliteratum%253Aachs%26aulast%3DHalvard%2BGr%25C3%25B8nlien%26aufirst%3DJ.%26aulast%3DH%25C3%25A5kerud%26aufirst%3DM.%26aulast%3DWeen%26aufirst%3DH.%26aulast%3DThorin-Hagene%26aufirst%3DK.%26aulast%3DBriggs%26aufirst%3DC.%2BA.%26aulast%3DGopalakrishnan%26aufirst%3DM.%26aulast%3DMalysz%26aufirst%3DJ.%26atitle%3DDistinct%2520profiles%2520of%2520alpha7%2520nAChR%2520positive%2520allosteric%2520modulation%2520revealed%2520by%2520structurally%2520diverse%2520chemotypes%26jtitle%3DMol.%2520Pharmacol.%26date%3D2007%26volume%3D72%26spage%3D715%26epage%3D724%26doi%3D10.1124%2Fmol.107.035410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hackos, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, J. E.</span></span> <span> </span><span class="NLM_article-title">Diverse modes of NMDA receptor positive allosteric modulation: mechanisms and consequences</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">34</span>â <span class="NLM_lpage">45</span>, <span class="refDoi">Â DOI: 10.1016/j.neuropharm.2016.07.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.neuropharm.2016.07.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=27484578" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht12ksL%252FF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2017&pages=34-45&author=D.+H.+Hackosauthor=J.+E.+Hanson&title=Diverse+modes+of+NMDA+receptor+positive+allosteric+modulation%3A+mechanisms+and+consequences&doi=10.1016%2Fj.neuropharm.2016.07.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Diverse modes of NMDA receptor positive allosteric modulation: Mechanisms and consequences</span></div><div class="casAuthors">Hackos, David H.; Hanson, Jesse E.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">Part_A</span>),
    <span class="NLM_cas:pages">34-45</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">NMDA Receptors (NMDARs) play key roles in synaptic physiol. and NMDAR hypofunction has been implicated in various neurol. conditions.  In recent years an increasing no. of pos. allosteric modulators (PAMs) of NMDARs have been discovered and characterized.  These diverse PAM classes vary not only in their binding sites and GluN2 subunit selectivity profiles, but also in the nature of their impacts on channel function.  Major differences exist in the degree of slowing of channel deactivation and shifting of apparent agonist affinity between different classes of PAMs.  Here we review the diverse modes of potentiation by the currently known classes of NMDAR PAMs and discuss the potential consequences of different types of potentiation in terms of desirable and undesirable effects on brain function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_GGIqatskgrVg90H21EOLACvtfcHk0ljHpCxPf3jnNQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht12ksL%252FF&md5=ca79bbb01b992e8df19275399ad1fe12</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2016.07.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2016.07.037%26sid%3Dliteratum%253Aachs%26aulast%3DHackos%26aufirst%3DD.%2BH.%26aulast%3DHanson%26aufirst%3DJ.%2BE.%26atitle%3DDiverse%2520modes%2520of%2520NMDA%2520receptor%2520positive%2520allosteric%2520modulation%253A%2520mechanisms%2520and%2520consequences%26jtitle%3DNeuropharmacology%26date%3D2017%26volume%3D112%26spage%3D34%26epage%3D45%26doi%3D10.1016%2Fj.neuropharm.2016.07.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seljeset, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bright, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smart, T. G.</span></span> <span> </span><span class="NLM_article-title">Probing GABAA receptors with inhibitory neurosteroids</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">23</span>â <span class="NLM_lpage">36</span>, <span class="refDoi">Â DOI: 10.1016/j.neuropharm.2018.02.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.neuropharm.2018.02.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=29447845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtFOju7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2018&pages=23-36&author=S.+Seljesetauthor=D.+P.+Brightauthor=P.+Thomasauthor=T.+G.+Smart&title=Probing+GABAA+receptors+with+inhibitory+neurosteroids&doi=10.1016%2Fj.neuropharm.2018.02.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Probing GABAA receptors with inhibitory neurosteroids</span></div><div class="casAuthors">Seljeset, Sandra; Bright, Damian P.; Thomas, Philip; Smart, Trevor G.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">Part_A</span>),
    <span class="NLM_cas:pages">23-36</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Î³-aminobutyric acid type A receptors (GABAARs) are important components of the central nervous system and they are functionally tasked with controlling neuronal excitability.  These receptors are subject to post-translational modification and also to modulation by endogenous regulators, such as the neurosteroids.  These modulators can either potentiate or inhibit GABAAR function.  While the former class of neurosteroids are considered to bind to and act from the transmembrane domain of the receptor, the domains that are important for the inhibitory neurosteroids remain less clear.  In this study, we systematically compare a panel of recombinant synaptic-type and extrasynaptic-type GABAARs expressed in heterologous cell systems for their sensitivity to inhibition by the classic inhibitory neurosteroid, pregnenolone sulfate.  Generally, peak GABA current responses were inhibited less compared to steady-state currents, implicating the desensitized state in inhibition.  Moreover, pregnenolone sulfate inhibition increased with GABA concn., but showed minimal voltage dependence.  There was no strong dependence of inhibition on receptor subunit compn., the exception being the Ï1 receptor, which is markedly less sensitive.  By using competition expts. with pregnenolone sulfate and the GABA channel blocker picrotoxinin, discrete binding sites are proposed.  Furthermore, by assessing inhibition using site-directed mutagenesis and receptor chimeras comprising Î±, Î² or Î³ subunits with Ï1 subunits, the receptor transmembrane domains are strongly implicated in mediating inhibition and most likely the binding location for pregnenolone sulfate in GABAARs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe8Dgr53CyJbVg90H21EOLACvtfcHk0ljHpCxPf3jnNQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtFOju7k%253D&md5=d1af3467edd3408b40911bcf1a173480</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2018.02.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2018.02.008%26sid%3Dliteratum%253Aachs%26aulast%3DSeljeset%26aufirst%3DS.%26aulast%3DBright%26aufirst%3DD.%2BP.%26aulast%3DThomas%26aufirst%3DP.%26aulast%3DSmart%26aufirst%3DT.%2BG.%26atitle%3DProbing%2520GABAA%2520receptors%2520with%2520inhibitory%2520neurosteroids%26jtitle%3DNeuropharmacology%26date%3D2018%26volume%3D136%26spage%3D23%26epage%3D36%26doi%3D10.1016%2Fj.neuropharm.2018.02.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mennerick, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covey, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zorumski, C. F.</span></span> <span> </span><span class="NLM_article-title">Pregnenolone sulfate modulates inhibitory synaptic transmission by enhancing GABAA receptor desensitization</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">3571</span>â <span class="NLM_lpage">3579</span>, <span class="refDoi">Â DOI: 10.1523/JNEUROSCI.20-10-03571.2000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1523%2FJNEUROSCI.20-10-03571.2000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10804198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjtlKqs74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2000&pages=3571-3579&issue=10&author=W.+Shenauthor=S.+Mennerickauthor=D.+F.+Coveyauthor=C.+F.+Zorumski&title=Pregnenolone+sulfate+modulates+inhibitory+synaptic+transmission+by+enhancing+GABAA+receptor+desensitization&doi=10.1523%2FJNEUROSCI.20-10-03571.2000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Pregnenolone sulfate modulates inhibitory synaptic transmission by enhancing GABAA receptor desensitization</span></div><div class="casAuthors">Shen, Weixing; Mennerick, Steven; Covey, Douglas F.; Zorumski, Charles F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3571-3579</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">We examd. the effects of the neurosteroid pregnenolone sulfate (PS) on GABAA receptor-mediated synaptic currents and currents elicited by rapid applications of GABA onto nucleated outside-out patches in cultured postnatal rat hippocampal neurons.  At 10 Î¼M, PS significantly depressed peak responses and accelerated the decay of evoked inhibitory synaptic currents.  In nucleated outside-out patches, PS depressed peak currents and speeded deactivation after 5 ms applications of a satg. concn. of GABA.  PS also increased the rate and degree of macroscopic GABA receptor desensitization during prolonged GABA applications.  In a paired GABA application paradigm, PS slowed the rate of recovery from desensitization.  In contrast to its prominent effects on currents produced by satg. GABA concns., PS had only small effects on peak currents and failed to alter deactivation after brief applications of the weakly desensitizing GABAA receptor agonists taurine and Î²-alanine.  However, when Î²-alanine was applied for a sufficient duration to promote receptor desensitization, PS augmented macroscopic desensitization and slowed deactivation.  These results suggest that PS inhibits GABA-gated chloride currents by enhancing receptor desensitization and stabilizing desensitized states.  This contention is supported by kinetic modeling studies in which increases in the rate of entry into doubly liganded desensitized states mimic most effects of PS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFzC2r06wvdbVg90H21EOLACvtfcHk0liPLxaLrotqmg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjtlKqs74%253D&md5=f318b1ee38221e899fb970a971d92dc5</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.20-10-03571.2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.20-10-03571.2000%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DW.%26aulast%3DMennerick%26aufirst%3DS.%26aulast%3DCovey%26aufirst%3DD.%2BF.%26aulast%3DZorumski%26aufirst%3DC.%2BF.%26atitle%3DPregnenolone%2520sulfate%2520modulates%2520inhibitory%2520synaptic%2520transmission%2520by%2520enhancing%2520GABAA%2520receptor%2520desensitization%26jtitle%3DJ.%2520Neurosci.%26date%3D2000%26volume%3D20%26issue%3D10%26spage%3D3571%26epage%3D3579%26doi%3D10.1523%2FJNEUROSCI.20-10-03571.2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">PÃ¸hlsgaard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frydenvang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madsen, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastrup, J. S.</span></span> <span> </span><span class="NLM_article-title">Lessons from more than 80 structures of the GluA2 ligand-binding domain in complex with agonists, antagonists and allosteric modulators</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">135</span>â <span class="NLM_lpage">150</span>, <span class="refDoi">Â DOI: 10.1016/j.neuropharm.2010.08.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.neuropharm.2010.08.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=20713069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVaitL%252FK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2011&pages=135-150&issue=1&author=J.+P%C3%B8hlsgaardauthor=K.+Frydenvangauthor=U.+Madsenauthor=J.+S.+Kastrup&title=Lessons+from+more+than+80+structures+of+the+GluA2+ligand-binding+domain+in+complex+with+agonists%2C+antagonists+and+allosteric+modulators&doi=10.1016%2Fj.neuropharm.2010.08.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons from more than 80 structures of the GluA2 ligand-binding domain in complex with agonists, antagonists and allosteric modulators</span></div><div class="casAuthors">Pohlsgaard, Jacob; Frydenvang, Karla; Madsen, Ulf; Kastrup, Jette Sandholm</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">135-150</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Ionotropic glutamate receptors (iGluRs) constitute a family of ligand-gated ion channels that are essential for mediating fast synaptic transmission in the central nervous system.  These receptors play an important role for the development and function of the nervous system, and are essential in learning and memory.  However, iGluRs are also implicated in or have causal roles for several brain disorders, e.g. epilepsy, Alzheimer's disease, Parkinson's disease and schizophrenia.  Their involvement in neurol. diseases has stimulated widespread interest in their structure and function.  Since the first publication in 1998 of the structure of a recombinant sol. protein comprising the ligand-binding domain of GluA2 extensive studies have afforded numerous crystal structures of wildtype and mutant proteins including different ligands.  The structural information obtained combined with functional data have led to models for receptor activation and desensitization by agonists, inhibition by antagonists and block of desensitization by pos. allosteric modulators.  Furthermore, the structural and functional studies have formed a powerful platform for the design of new selective compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA5_dFKFmce7Vg90H21EOLACvtfcHk0liPLxaLrotqmg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVaitL%252FK&md5=cade4bfad431cb7da3f8620d56c9926b</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2010.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2010.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DP%25C3%25B8hlsgaard%26aufirst%3DJ.%26aulast%3DFrydenvang%26aufirst%3DK.%26aulast%3DMadsen%26aufirst%3DU.%26aulast%3DKastrup%26aufirst%3DJ.%2BS.%26atitle%3DLessons%2520from%2520more%2520than%252080%2520structures%2520of%2520the%2520GluA2%2520ligand-binding%2520domain%2520in%2520complex%2520with%2520agonists%252C%2520antagonists%2520and%2520allosteric%2520modulators%26jtitle%3DNeuropharmacology%26date%3D2011%26volume%3D60%26issue%3D1%26spage%3D135%26epage%3D150%26doi%3D10.1016%2Fj.neuropharm.2010.08.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krieger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greger, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahar, I.</span></span> <span> </span><span class="NLM_article-title">Activation and desensitization of ionotropic glutamate receptors by selectively triggering pre-existing motions</span>. <i>Neurosci. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>, <span class="refDoi">Â DOI: 10.1016/j.neulet.2018.02.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.neulet.2018.02.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=29481851" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=J.+Kriegerauthor=J.+Y.+Leeauthor=I.+H.+Gregerauthor=I.+Bahar&title=Activation+and+desensitization+of+ionotropic+glutamate+receptors+by+selectively+triggering+pre-existing+motions&doi=10.1016%2Fj.neulet.2018.02.050"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1016%2Fj.neulet.2018.02.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neulet.2018.02.050%26sid%3Dliteratum%253Aachs%26aulast%3DKrieger%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%2BY.%26aulast%3DGreger%26aufirst%3DI.%2BH.%26aulast%3DBahar%26aufirst%3DI.%26atitle%3DActivation%2520and%2520desensitization%2520of%2520ionotropic%2520glutamate%2520receptors%2520by%2520selectively%2520triggering%2520pre-existing%2520motions%26jtitle%3DNeurosci.%2520Lett.%26date%3D2018%26doi%3D10.1016%2Fj.neulet.2018.02.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleck, M. W.</span></span> <span> </span><span class="NLM_article-title">Targeting AMPA receptor gating processes with allosteric modulators and mutations</span>. <i>Biophys. J.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>92</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2392</span>â <span class="NLM_lpage">2402</span>, <span class="refDoi">Â DOI: 10.1529/biophysj.106.095091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1529%2Fbiophysj.106.095091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=17208968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjs1Kjsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2007&pages=2392-2402&issue=7&author=N.+A.+Mitchellauthor=M.+W.+Fleck&title=Targeting+AMPA+receptor+gating+processes+with+allosteric+modulators+and+mutations&doi=10.1529%2Fbiophysj.106.095091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting AMPA receptor gating processes with allosteric modulators and mutations</span></div><div class="casAuthors">Mitchell, Nicholas A.; Fleck, Mark W.</div><div class="citationInfo"><span class="NLM_cas:title">Biophysical Journal</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2392-2402</span>CODEN:
                <span class="NLM_cas:coden">BIOJAU</span>;
        ISSN:<span class="NLM_cas:issn">0006-3495</span>.
    
            (<span class="NLM_cas:orgname">Biophysical Society</span>)
        </div><div class="casAbstract">Allosteric modulators and mutations that slow AMPAR desensitization have addnl. effects on deactivation and agonist potency.  We investigated whether these are independent actions or the natural consequence of slowing desensitization.  Effects of cyclothiazide (CTZ), trichlormethiazide (TCM), and CX614 were compared at wild-type GluR1 and "nondesensitizing" GluR1-L497Y mutant receptors by patch-clamp recording with ultrafast perfusion.  CTZ, TCM, or L/Y mutation all essentially blocked GluR1 desensitization; however, the effects of L/Y mutation on deactivation and glutamate EC50 were three to five times greater than for modulators.  CTZ and TCM further slowed desensitization of L/Y mutant receptors but paradoxically accelerated deactivation and increased agonist EC50.  Results indicate that CTZ and TCM target deactivation and agonist potency independently of desensitization, most likely by modifying agonist dissocn. (koff).  Conversely, CX614 slowed desensitization and deactivation without affecting EC50 in both wild-type and L/Y receptors.  The S750Q or combined L497Y-S750Q mutations abolished all CTZ and TCM actions without disrupting CX614 activity.  Notably, the S/Q mutation also restored L/Y deactivation and EC50 to wild-type levels without restoring desensitization, further demonstrating that desensitization can be modulated independently of deactivation and EC50 by mutagenesis and possibly by allosteric modulators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpw2a6Bj1pqLVg90H21EOLACvtfcHk0liPLxaLrotqmg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjs1Kjsbs%253D&md5=6fa66738843990ce75a687118d101922</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1529%2Fbiophysj.106.095091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1529%252Fbiophysj.106.095091%26sid%3Dliteratum%253Aachs%26aulast%3DMitchell%26aufirst%3DN.%2BA.%26aulast%3DFleck%26aufirst%3DM.%2BW.%26atitle%3DTargeting%2520AMPA%2520receptor%2520gating%2520processes%2520with%2520allosteric%2520modulators%2520and%2520mutations%26jtitle%3DBiophys.%2520J.%26date%3D2007%26volume%3D92%26issue%3D7%26spage%3D2392%26epage%3D2402%26doi%3D10.1529%2Fbiophysj.106.095091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christiansen, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harbak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hede, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gouliaev, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frydenvang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egebjerg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastrup, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holm, M. M.</span></span> <span> </span><span class="NLM_article-title">A novel dualistic profile of an allosteric AMPA receptor modulator identified through studies on recombinant receptors, mouse hippocampal synapses and crystal structures</span>. <i>Neuroscience</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>310</i></span>,  <span class="NLM_fpage">709</span>â <span class="NLM_lpage">722</span>, <span class="refDoi">Â DOI: 10.1016/j.neuroscience.2015.09.073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.neuroscience.2015.09.073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=26450748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1ertLzL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=310&publication_year=2015&pages=709-722&author=G.+B.+Christiansenauthor=B.+Harbakauthor=S.+E.+Hedeauthor=A.+H.+Gouliaevauthor=L.+Olsenauthor=K.+Frydenvangauthor=J.+Egebjergauthor=J.+S.+Kastrupauthor=M.+M.+Holm&title=A+novel+dualistic+profile+of+an+allosteric+AMPA+receptor+modulator+identified+through+studies+on+recombinant+receptors%2C+mouse+hippocampal+synapses+and+crystal+structures&doi=10.1016%2Fj.neuroscience.2015.09.073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">A novel dualistic profile of an allosteric AMPA receptor modulator identified through studies on recombinant receptors, mouse hippocampal synapses and crystal structures</span></div><div class="casAuthors">Christiansen, G. B.; Harbak, B.; Hede, S. E.; Gouliaev, A. H.; Olsen, L.; Frydenvang, K.; Egebjerg, J.; Kastrup, J. S.; Holm, M. M.</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">310</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">709-722</span>CODEN:
                <span class="NLM_cas:coden">NRSCDN</span>;
        ISSN:<span class="NLM_cas:issn">0306-4522</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Pos. allosteric modulators (PAMs) of 2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid (AMPA) receptors receive increasing interest as therapeutic drugs and have long served as important exptl. tools in the study of the mol. mechanisms underlying glutamate-mediated neurotransmission.  The aim of this study was to investigate functional and structural aspects of a novel analog of the AMPA receptor PAM cyclothiazide (CTZ) on recombinant and native glutamate receptors.  We expressed rat GluA4flip and flop in Xenopus oocytes and characterized NS1376 and CTZ under two-electrode voltage-clamp.  The dose-response analyses revealed dual effects of NS1376.  The modulator induced 30-fold and 42-fold redns. in glutamate potency and increased the glutamate efficacy by 3.2-fold and 5.3-fold at GluA4flip and GluA4flop, resp.  Rapid application of glutamate to excised outside-out patches showed that NS1376 markedly attenuated desensitization, supporting the increased efficacy obsd. in the oocytes.  Furthermore, when applied to acutely isolated mouse brain slices, NS1376 reduced the field excitatory postsynaptic potentials (fEPSPs) in the hippocampus to 51.6 Â± 4.3% of baseline, likely as a consequence of reduced glutamate potency.  However, the modulator displayed no effects on a sub-maximal long-term potentiation (LTP) protocol.  We confirmed that CTZ increases presynaptic transmitter release, a property which was not shared by NS1376.  Finally, we obtained detailed mol. information through X-ray structures, docking and mol. dynamics, which revealed that NS1376 interacts at the dimer interface of the ligand-binding domain in a manner overall similar to CTZ.  NS1376 reveals that minor structural changes in CTZ can result in an altered modulatory profile, both enhancing agonist efficacy while markedly reducing agonist potency.  These unique properties add new aspects to the complexity of allosteric modulations in neuronal systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvn4gyfAbCo7Vg90H21EOLACvtfcHk0lhh_lIIoKLigA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1ertLzL&md5=b1816630204783cd7a56d3c7e978e267</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroscience.2015.09.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroscience.2015.09.073%26sid%3Dliteratum%253Aachs%26aulast%3DChristiansen%26aufirst%3DG.%2BB.%26aulast%3DHarbak%26aufirst%3DB.%26aulast%3DHede%26aufirst%3DS.%2BE.%26aulast%3DGouliaev%26aufirst%3DA.%2BH.%26aulast%3DOlsen%26aufirst%3DL.%26aulast%3DFrydenvang%26aufirst%3DK.%26aulast%3DEgebjerg%26aufirst%3DJ.%26aulast%3DKastrup%26aufirst%3DJ.%2BS.%26aulast%3DHolm%26aufirst%3DM.%2BM.%26atitle%3DA%2520novel%2520dualistic%2520profile%2520of%2520an%2520allosteric%2520AMPA%2520receptor%2520modulator%2520identified%2520through%2520studies%2520on%2520recombinant%2520receptors%252C%2520mouse%2520hippocampal%2520synapses%2520and%2520crystal%2520structures%26jtitle%3DNeuroscience%26date%3D2015%26volume%3D310%26spage%3D709%26epage%3D722%26doi%3D10.1016%2Fj.neuroscience.2015.09.073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weeks, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harms, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Partin, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benveniste, M.</span></span> <span> </span><span class="NLM_article-title">Functional insight into development of positive allosteric modulators of AMPA receptors</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">57</span>â <span class="NLM_lpage">66</span>, <span class="refDoi">Â DOI: 10.1016/j.neuropharm.2014.05.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.neuropharm.2014.05.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=24878241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFyhtLfJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2014&pages=57-66&author=A.+M.+Weeksauthor=J.+E.+Harmsauthor=K.+M.+Partinauthor=M.+Benveniste&title=Functional+insight+into+development+of+positive+allosteric+modulators+of+AMPA+receptors&doi=10.1016%2Fj.neuropharm.2014.05.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Functional insight into development of positive allosteric modulators of AMPA receptors</span></div><div class="casAuthors">Weeks, Autumn M.; Harms, Jonathan E.; Partin, Kathryn M.; Benveniste, Morris</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">57-66</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Pos. allosteric modulators of Î±-amino-3-hydroxy-5-methyl-isoxazole-propionic acid (AMPA) ionotropic glutamate receptors facilitate synaptic plasticity and contribute essentially to learning and memory, properties which make AMPA receptors targets for drug discovery and development.  One region at which several different classes of pos. allosteric modulators bind lies at the dimer interface between the ligand-binding core of the second, membrane-proximal, extracellular domain of AMPA receptors.  This solvent-accessible binding pocket has been the target of drug discovery efforts, leading to the recent delineation of five "subsites" which differentially allow access to modulator moieties, and for which distinct modulator affinities and apparent efficacies are attributed.  Here we use the voltage-clamp technique in conjunction with rapid drug application to study the effects of mutants lining subsites "A" and "B" of the allosteric modulator pocket to assess affinity and efficacy of allosteric modulation by cyclothiazide, CX614, CMPDA and CMPDB.  A novel anal. of the decay of current produced by the onset of desensitization has allowed us to est. both affinity and efficacy from single concns. of modulator.  Such an approach may be useful for effective high throughput screening of new target compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo04Hb_Ig1ZPrVg90H21EOLACvtfcHk0lhh_lIIoKLigA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFyhtLfJ&md5=419d67b3b2e882e24e723463f7b9149d</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2014.05.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2014.05.022%26sid%3Dliteratum%253Aachs%26aulast%3DWeeks%26aufirst%3DA.%2BM.%26aulast%3DHarms%26aufirst%3DJ.%2BE.%26aulast%3DPartin%26aufirst%3DK.%2BM.%26aulast%3DBenveniste%26aufirst%3DM.%26atitle%3DFunctional%2520insight%2520into%2520development%2520of%2520positive%2520allosteric%2520modulators%2520of%2520AMPA%2520receptors%26jtitle%3DNeuropharmacology%26date%3D2014%26volume%3D85%26spage%3D57%26epage%3D66%26doi%3D10.1016%2Fj.neuropharm.2014.05.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bretin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seguin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Challal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogez, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albinet, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iop, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villain, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krazem, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BÃ©rachochÃ©a, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billiald, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tordjman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lestage, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danober, L.</span></span> <span> </span><span class="NLM_article-title">Pharmacological characterisation of S 47445, a novel positive allosteric modulator of AMPA receptors</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">e0184429</span>, <span class="refDoi">Â DOI: 10.1371/journal.pone.0184429</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1371%2Fjournal.pone.0184429" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=28886144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXosVSitLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=e0184429&issue=9&author=S.+Bretinauthor=C.+Louisauthor=L.+Seguinauthor=S.+Wagnerauthor=J.+Y.+Thomasauthor=S.+Challalauthor=N.+Rogezauthor=K.+Albinetauthor=F.+Iopauthor=N.+Villainauthor=S.+Bertrandauthor=A.+Krazemauthor=D.+B%C3%A9rachoch%C3%A9aauthor=S.+Billialdauthor=C.+Tordjmanauthor=A.+Cordiauthor=D.+Bertrandauthor=P.+Lestageauthor=L.+Danober&title=Pharmacological+characterisation+of+S+47445%2C+a+novel+positive+allosteric+modulator+of+AMPA+receptors&doi=10.1371%2Fjournal.pone.0184429"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterisation of S 47445, a novel positive allosteric modulator of AMPA receptors</span></div><div class="casAuthors">Bretin, Sylvie; Louis, Caroline; Seguin, Laure; Wagner, Stephanie; Thomas, Jean-Yves; Challal, Sylvie; Rogez, Nathalie; Albinet, Karine; Iop, Fabrice; Villain, Nadege; Bertrand, Sonia; Krazem, Ali; Berachochea, Daniel; Billiald, Stephanie; Tordjman, Charles; Cordi, Alex; Bertrand, Daniel; Lestage, Pierre; Danober, Laurence</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e0184429/1-e0184429/28</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">S 47445 is a novel pos. allosteric modulator of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors (AMPA-PAM).  S 47445 enhanced glutamate's action at AMPA receptors on human and rat receptors and was inactive at NMDA and kainate receptors.  Potentiation did not differ among the different AMPA receptors subtypes (GluA1/2/4 flip and flop variants) (EC50 between 2.5-5.4 Î¼M), except a higher EC50 value for GluA4 flop (0.7 Î¼M) and a greater amt. of potentiation on GluA1 flop.  A low concn. of S 47445 (0.1 Î¼M) decreased receptor response decay time of GluA1flop/GluA2flip AMPA receptors and increased the sensitivity to glutamate.  Furthermore, S 47445 (0.1 and 0.3 Î¼M) in presence of repetitive glutamate pulses induced a progressive potentiation of the glutamate-evoked currents from the second pulse of glutamate confirming a rapid-enhancing effect of S 47445 at low concns.  The potentiating effect of S 47445 (1 Î¼M) was concn.-dependently reversed by the selective AMPA receptor antagonist GYKI52466 demonstrating the selective modulatory effect of S 47445 on AMPA receptors.  Using an AMPA-kainate chimera approach, it was confirmed that S 47445 binds to the common binding pocket of AMPA-PAMs.  S 47445 did not demonstrate neurotoxic effect against glutamate-mediated excitotoxicity in vitro, in contrast significantly protected rat cortical neurons at 10 Î¼M.  S 47445 was shown to improve both episodic and spatial working memory in adult rodents at 0.3 mg/kg, as measured in the natural forgetting condition of object recognition and T-maze tasks.  Finally, no deleterious effect on spontaneous locomotion and general behavior was obsd. up to 1000 mg/kg of S 47445 given acutely in rodents, neither occurrence of convulsion or tremors.  Collectively, these results indicate that S 47445 is a potent and selective AMPA-PAM presenting procognitive and potential neuroprotective properties.  This drug is currently evaluated in clin. phase 2 studies in Alzheimer's disease and in Major Depressive Disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJwB6oGr2kgLVg90H21EOLACvtfcHk0lhh_lIIoKLigA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXosVSitLc%253D&md5=bd7305e26b25e6721f0fe7e2d524262a</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0184429&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0184429%26sid%3Dliteratum%253Aachs%26aulast%3DBretin%26aufirst%3DS.%26aulast%3DLouis%26aufirst%3DC.%26aulast%3DSeguin%26aufirst%3DL.%26aulast%3DWagner%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DJ.%2BY.%26aulast%3DChallal%26aufirst%3DS.%26aulast%3DRogez%26aufirst%3DN.%26aulast%3DAlbinet%26aufirst%3DK.%26aulast%3DIop%26aufirst%3DF.%26aulast%3DVillain%26aufirst%3DN.%26aulast%3DBertrand%26aufirst%3DS.%26aulast%3DKrazem%26aufirst%3DA.%26aulast%3DB%25C3%25A9rachoch%25C3%25A9a%26aufirst%3DD.%26aulast%3DBilliald%26aufirst%3DS.%26aulast%3DTordjman%26aufirst%3DC.%26aulast%3DCordi%26aufirst%3DA.%26aulast%3DBertrand%26aufirst%3DD.%26aulast%3DLestage%26aufirst%3DP.%26aulast%3DDanober%26aufirst%3DL.%26atitle%3DPharmacological%2520characterisation%2520of%2520S%252047445%252C%2520a%2520novel%2520positive%2520allosteric%2520modulator%2520of%2520AMPA%2520receptors%26jtitle%3DPLoS%2520One%26date%3D2017%26volume%3D12%26issue%3D9%26spage%3De0184429%26doi%3D10.1371%2Fjournal.pone.0184429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rogawski, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanada, T.</span></span> <span> </span><span class="NLM_article-title">Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist</span>. <i>Acta Neurol. Scand.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">19</span>â <span class="NLM_lpage">24</span>, <span class="refDoi">Â DOI: 10.1111/ane.12100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1111%2Fane.12100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=22494246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsVCls70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2013&pages=19-24&author=M.+A.+Rogawskiauthor=T.+Hanada&title=Preclinical+pharmacology+of+perampanel%2C+a+selective+non-competitive+AMPA+receptor+antagonist&doi=10.1111%2Fane.12100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist</span></div><div class="casAuthors">Rogawski, M. A.; Hanada, T.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Neurologica Scandinavica</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">Suppl. 197</span>),
    <span class="NLM_cas:pages">19-24</span>CODEN:
                <span class="NLM_cas:coden">ANRSAS</span>;
        ISSN:<span class="NLM_cas:issn">1600-0404</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Perampanel [2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile; E2007] is a potent, selective, orally active non-competitive AMPA receptor antagonist developed for the treatment of epilepsy.  Perampanel has a 2,3'-bipyridin-6'-one core structure, distinguishing it chem. from other AMPA receptor antagonist classes.  Studies in various physiol. systems indicate that perampanel selectively inhibits AMPA receptor-mediated synaptic excitation without affecting NMDA receptor responses.  Blocking of AMPA receptors occurs at an allosteric site that is distinct from the glutamate recognition site.  Radioligand-binding studies suggest that the blocking site coincides with that of the non-competitive antagonist GYKI 52466, believed to be on linker peptide segments of AMPA receptor subunits that transduce agonist binding into channel opening.  As is typical for AMPA receptor antagonists, perampanel exhibits broad-spectrum antiseizure activity in diverse animal seizure models.  Perampanel has high oral bioavailability, dose-proportional kinetics, and undergoes oxidative metab., primarily via CYP3A4, followed by glucuronidation.  The terminal half-life (t1/2) in humans is 105 h; however, in the presence of a strong CYP3A4 inducer (such as carbamazepine), the t1/2 can be reduced.  In sum, perampanel is a selective, centrally acting, neg. allosteric modulator of AMPA receptors with good oral bioavailability and favorable pharmacokinetic properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpL0LRy4ANcZLVg90H21EOLACvtfcHk0lh5smGiLi_B8Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsVCls70%253D&md5=7bd906fa7dc2767dc8c81fdc4ba9ff99</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1111%2Fane.12100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fane.12100%26sid%3Dliteratum%253Aachs%26aulast%3DRogawski%26aufirst%3DM.%2BA.%26aulast%3DHanada%26aufirst%3DT.%26atitle%3DPreclinical%2520pharmacology%2520of%2520perampanel%252C%2520a%2520selective%2520non-competitive%2520AMPA%2520receptor%2520antagonist%26jtitle%3DActa%2520Neurol.%2520Scand.%26date%3D2013%26volume%3D127%26spage%3D19%26epage%3D24%26doi%3D10.1111%2Fane.12100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hell, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogawski, M. A.</span></span> <span> </span><span class="NLM_article-title">Perampanel inhibition of AMPA receptor currents in cultured hippocampal neurons</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">e108021</span>, <span class="refDoi">Â DOI: 10.1371/journal.pone.0108021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1371%2Fjournal.pone.0108021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=25229608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslShtrzO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e108021&issue=9&author=C.+Y.+Chenauthor=L.+Mattauthor=J.+W.+Hellauthor=M.+A.+Rogawski&title=Perampanel+inhibition+of+AMPA+receptor+currents+in+cultured+hippocampal+neurons&doi=10.1371%2Fjournal.pone.0108021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Perampanel inhibition of AMPA receptor currents in cultured hippocampal neurons</span></div><div class="casAuthors">Chen, Chao-Yin; Matt, Lucas; Hell, Johannes Wilhelm; Rogawski, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e108021/1-e108021/7, 7 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Perampanel is an aryl substituted 2-pyridone AMPA receptor antagonist that was recently approved as a treatment for epilepsy.  The drug potently inhibits AMPA receptor responses but the mode of block has not been characterized.  Here the action of perampanel on AMPA receptors was investigated by whole-cell voltage-clamp recording in cultured rat hippocampal neurons.  Perampanel caused a slow (Ïâ¼1 s at 3 Î¼M), concn.-dependent inhibition of AMPA receptor currents evoked by AMPA and kainate.  The rates of block and unblock of AMPA receptor currents were 1.5 Ã 105 M-1 s-1 and 0.58 s-1, resp.  Perampanel did not affect NMDA receptor currents.  The extent of block of non-desensitizing kainate-evoked currents (IC50, 0.56 Î¼M) was similar at all kainate concns. (3-100 Î¼M), demonstrating a noncompetitive blocking action.  Parampanel did not alter the trajectory of AMPA evoked currents indicating that it does not influence AMPA receptor desensitization.  Perampanel is a selective neg. allosteric AMPA receptor antagonist of high-affinity and slow blocking kinetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrexa_W9wJuhrVg90H21EOLACvtfcHk0lh5smGiLi_B8Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslShtrzO&md5=96e6d5c0631943ff7766830bd2db1d9d</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0108021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0108021%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%2BY.%26aulast%3DMatt%26aufirst%3DL.%26aulast%3DHell%26aufirst%3DJ.%2BW.%26aulast%3DRogawski%26aufirst%3DM.%2BA.%26atitle%3DPerampanel%2520inhibition%2520of%2520AMPA%2520receptor%2520currents%2520in%2520cultured%2520hippocampal%2520neurons%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26issue%3D9%26spage%3De108021%26doi%3D10.1371%2Fjournal.pone.0108021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stenum-Berg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abiega, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thisted, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kristensen, A. S.</span></span> <span> </span><span class="NLM_article-title">Identification and characterization of the binding pocket for negative allosteric modulators in AMPA receptors</span>. <i>Biophys. J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>112</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">418a</span>, <span class="refDoi">Â DOI: 10.1016/j.bpj.2016.11.2236</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.bpj.2016.11.2236" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2017&pages=418a&issue=3&author=C.+Stenum-Bergauthor=S.+C.+Abiegaauthor=C.+L.+Thistedauthor=A.+S.+Kristensen&title=Identification+and+characterization+of+the+binding+pocket+for+negative+allosteric+modulators+in+AMPA+receptors&doi=10.1016%2Fj.bpj.2016.11.2236"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1016%2Fj.bpj.2016.11.2236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bpj.2016.11.2236%26sid%3Dliteratum%253Aachs%26aulast%3DStenum-Berg%26aufirst%3DC.%26aulast%3DAbiega%26aufirst%3DS.%2BC.%26aulast%3DThisted%26aufirst%3DC.%2BL.%26aulast%3DKristensen%26aufirst%3DA.%2BS.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520the%2520binding%2520pocket%2520for%2520negative%2520allosteric%2520modulators%2520in%2520AMPA%2520receptors%26jtitle%3DBiophys.%2520J.%26date%3D2017%26volume%3D112%26issue%3D3%26spage%3D418a%26doi%3D10.1016%2Fj.bpj.2016.11.2236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MÃ¸llerud, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frydenvang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickering, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastrup, J. S.</span></span> <span> </span><span class="NLM_article-title">Lessons from crystal structures of kainate receptors</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">16</span>â <span class="NLM_lpage">28</span>, <span class="refDoi">Â DOI: 10.1016/j.neuropharm.2016.05.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.neuropharm.2016.05.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=27236079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252FksVWhsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2017&pages=16-28&author=S.+M%C3%B8llerudauthor=K.+Frydenvangauthor=D.+S.+Pickeringauthor=J.+S.+Kastrup&title=Lessons+from+crystal+structures+of+kainate+receptors&doi=10.1016%2Fj.neuropharm.2016.05.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons from crystal structures of kainate receptors</span></div><div class="casAuthors">Mollerud Stine; Frydenvang Karla; Pickering Darryl S; Kastrup Jette Sandholm</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">Pt A</span>),
    <span class="NLM_cas:pages">16-28</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Kainate receptors belong to the family of ionotropic glutamate receptors.  These receptors assemble from five subunits (GluK1-5) into tetrameric ion channels.  Kainate receptors are located at both pre- and postsynaptic membranes in the central nervous system where they contribute to excitatory synaptic transmission and modulate network excitability by regulating neurotransmitter release.  Dysfunction of kainate receptors has been implicated in several neurological disorders such as epilepsy, schizophrenia and depression.  Here we provide a review on the current understanding of kainate receptor structure and how they bind agonists, antagonists and ions.  The first structure of the ligand-binding domain of the GluK1 subunit was reported in 2005, seven years after publication of the crystal structure of a soluble construct of the ligand-binding domain of the AMPA-type subunit GluA2.  Today, a full-length structure has been determined of GluK2 by cryo electron microscopy to 7.6 ÃA resolution as well as 84 high-resolution crystal structures of N-terminal domains and ligand-binding domains, including agonist and antagonist bound structures, modulatory ions and mutations.  However, there are still many unanswered questions and challenges in front of us.  This article is part of the Special Issue entitled 'Ionotropic glutamate receptors'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSorFhi6dO1iNhSDZx9hyjKfW6udTcc2eZAYHO7QxJNorntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252FksVWhsw%253D%253D&md5=7b98312e2ef8a69ecac23e2d2a045bb7</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2016.05.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2016.05.014%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25B8llerud%26aufirst%3DS.%26aulast%3DFrydenvang%26aufirst%3DK.%26aulast%3DPickering%26aufirst%3DD.%2BS.%26aulast%3DKastrup%26aufirst%3DJ.%2BS.%26atitle%3DLessons%2520from%2520crystal%2520structures%2520of%2520kainate%2520receptors%26jtitle%3DNeuropharmacology%26date%3D2017%26volume%3D112%26spage%3D16%26epage%3D28%26doi%3D10.1016%2Fj.neuropharm.2016.05.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">FiÃ¨vre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frydenvang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francotte, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirotte, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastrup, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulle, C.</span></span> <span> </span><span class="NLM_article-title">Identification and structure-function study of positive allosteric modulators of kainate receptors</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>91</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">576</span>â <span class="NLM_lpage">585</span>, <span class="refDoi">Â DOI: 10.1124/mol.116.107599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1124%2Fmol.116.107599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=28360094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Wlsrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2017&pages=576-585&issue=6&author=A.+P.+Larsenauthor=S.+Fi%C3%A8vreauthor=K.+Frydenvangauthor=P.+Francotteauthor=B.+Pirotteauthor=J.+S.+Kastrupauthor=C.+Mulle&title=Identification+and+structure-function+study+of+positive+allosteric+modulators+of+kainate+receptors&doi=10.1124%2Fmol.116.107599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and structure-function study of positive allosteric modulators of kainate receptors</span></div><div class="casAuthors">Larsen, Anja Probst; Fievre, Sabine; Frydenvang, Karla; Francotte, Pierre; Pirotte, Bernard; Kastrup, Jette Sandholm; Mulle, Christophe</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">576-585</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Kainate receptors (KARs) consist of a class of ionotropic glutamate receptors, which exert diverse pre- and postsynaptic functions through complex signaling regulating the activity of neural circuits.  Whereas numerous small-mol. pos. allosteric modulators of the ligand-binding domain of (S)-2- amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propanoic acid (AMPA) receptors have been reported, no such ligands are available for KARs.  In this study, we investigated the ability of three benzothiadiazine-based modulators to potentiate glutamate-evoked currents at recombinantly expressed KARs.  4-Cyclopropyl-7-fluoro-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide (BPAM344) potentiated glutamate-evoked currents of GluK2a 21-fold at the highest concn. tested (200 mM), with an EC50 of 79 mM.  BPAM344 markedly decreased desensitization kinetics (from 5.5 to 775 ms), whereas it only had a minor effect on deactivation kinetics.  4-Cyclopropyl-7-hydroxy-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide (BPAM521) potentiated the recorded peak current amplitude of GluK2a 12-fold at a concn. of 300 mM with an EC50 value of 159 mM, whereas no potentiation of the glutamate-evoked response was obsd. for 7-chloro-4-(2-fluoroethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine1,1-dioxide (BPAM121) at the highest concn. of modulator tested (300 mM).  BPAM344 (100 Î¼M) also potentiated the peak current amplitude of KAR subunits GluK3a (59-fold), GluK2a (15- fold), GluK1b (5-fold), as well as the AMPA receptor subunit GluA1i (5-fold).  X-ray structures of the three modulators in the GluK1 ligand-binding domain were detd., locating two modulator binding sites at the GluK1 dimer interface.  In conclusion, this study may enable the design of new pos. allosteric modulators selective for KARs, which will be of great interest for further investigation of the function of KARs in vivo and may prove useful for pharmacol. controlling the activity of neuronal networks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeApVTPg0Rt7Vg90H21EOLACvtfcHk0ljcKQusxZIeRg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Wlsrw%253D&md5=7df2c091dd2bc7f08ea441b166924ed3</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1124%2Fmol.116.107599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.116.107599%26sid%3Dliteratum%253Aachs%26aulast%3DLarsen%26aufirst%3DA.%2BP.%26aulast%3DFi%25C3%25A8vre%26aufirst%3DS.%26aulast%3DFrydenvang%26aufirst%3DK.%26aulast%3DFrancotte%26aufirst%3DP.%26aulast%3DPirotte%26aufirst%3DB.%26aulast%3DKastrup%26aufirst%3DJ.%2BS.%26aulast%3DMulle%26aufirst%3DC.%26atitle%3DIdentification%2520and%2520structure-function%2520study%2520of%2520positive%2520allosteric%2520modulators%2520of%2520kainate%2520receptors%26jtitle%3DMol.%2520Pharmacol.%26date%3D2017%26volume%3D91%26issue%3D6%26spage%3D576%26epage%3D585%26doi%3D10.1124%2Fmol.116.107599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutter, J.</span></span> <span> </span><span class="NLM_article-title">Whence cometh the allosterome?</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>103</i></span> (<span class="NLM_issue">28</span>),  <span class="NLM_fpage">10533</span>â <span class="NLM_lpage">10535</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0604452103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1073%2Fpnas.0604452103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=16818878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BD28XntFWnu7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=10533-10535&issue=28&author=J.+E.+Lindsleyauthor=J.+Rutter&title=Whence+cometh+the+allosterome%3F&doi=10.1073%2Fpnas.0604452103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Whence cometh the allosterome?</span></div><div class="casAuthors">Lindsley, Janet E.; Rutter, Jared</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">10533-10535</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">A review.  Regulation of cellular functions can be accomplished by many mechanisms, including transcriptional regulation, alternative splicing, translational regulation, phosphorylation and other posttranslational covalent modifications, degrdn., localization, protein-protein interactions, and small-mol. allosteric effectors.  Largely because of advances in the techniques of mol. biol. in the past few decades, our knowledge of regulation by most of these mechanisms has expanded enormously.  Regulation by small-mol., allosteric interactions is an exception.  Many of the best-known allosteric regulators were discovered decades ago, when we knew little about all of these other forms of regulation.  Allostery is the most direct, rapid, and efficient regulatory mechanism to sense changes in the concn. of small mols. and alter cellular responses to maintain homeostasis.  In this perspective, we present the argument that allosteric regulation is underappreciated in the systems biol. world and that many allosteric effectors remain to be discovered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkAICaQa4tBLVg90H21EOLACvtfcHk0ljcKQusxZIeRg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntFWnu7c%253D&md5=bc69a071dea38cc7d9ca74b0cfde472f</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0604452103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0604452103%26sid%3Dliteratum%253Aachs%26aulast%3DLindsley%26aufirst%3DJ.%2BE.%26aulast%3DRutter%26aufirst%3DJ.%26atitle%3DWhence%2520cometh%2520the%2520allosterome%253F%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26issue%3D28%26spage%3D10533%26epage%3D10535%26doi%3D10.1073%2Fpnas.0604452103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oswald, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, F. H.</span></span> <span> </span><span class="NLM_article-title">Applying structure-based drug design approaches to allosteric modulators of GPCRs</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">837</span>â <span class="NLM_lpage">847</span>, <span class="refDoi">Â DOI: 10.1016/j.tips.2017.05.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.tips.2017.05.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=28648526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVWrt7jE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2017&pages=837-847&issue=9&author=M.+Congreveauthor=C.+Oswaldauthor=F.+H.+Marshall&title=Applying+structure-based+drug+design+approaches+to+allosteric+modulators+of+GPCRs&doi=10.1016%2Fj.tips.2017.05.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Applying Structure-Based Drug Design Approaches to Allosteric Modulators of GPCRs</span></div><div class="casAuthors">Congreve, Miles; Oswald, Christine; Marshall, Fiona H.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">837-847</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Structural insights have been revealed from X-ray co-complexes of a range of G protein-coupled receptors (GPCRs) and their allosteric ligands.  The understanding of how small mols. can modulate the function of this important class of receptors by binding to a diverse range of pockets on and inside the proteins has had a profound impact on the structure-based drug design (SBDD) of new classes of therapeutic agents.  The types of allosteric pockets and the mode of modulation as well as the advantages and disadvantages of targeting allosteric pockets (as opposed to the natural orthosteric site) are considered in the context of these new structural findings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfYALhpSpc37Vg90H21EOLACvtfcHk0ljcKQusxZIeRg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVWrt7jE&md5=396af7b468f28376184c970ba72fe21f</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2017.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2017.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DOswald%26aufirst%3DC.%26aulast%3DMarshall%26aufirst%3DF.%2BH.%26atitle%3DApplying%2520structure-based%2520drug%2520design%2520approaches%2520to%2520allosteric%2520modulators%2520of%2520GPCRs%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2017%26volume%3D38%26issue%3D9%26spage%3D837%26epage%3D847%26doi%3D10.1016%2Fj.tips.2017.05.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moraes, I.</span></span> <span> </span><span class="NLM_article-title">Structural biology and structure-function relationships of membrane proteins</span>. <i>Biochem. Soc. Trans.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_fpage">BST20180269</span>, <span class="refDoi">Â DOI: 10.1042/BST20180269</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1042%2FBST20180269" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=30559269" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&pages=BST20180269&author=R.+Reisauthor=I.+Moraes&title=Structural+biology+and+structure-function+relationships+of+membrane+proteins&doi=10.1042%2FBST20180269"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1042%2FBST20180269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST20180269%26sid%3Dliteratum%253Aachs%26aulast%3DReis%26aufirst%3DR.%26aulast%3DMoraes%26aufirst%3DI.%26atitle%3DStructural%2520biology%2520and%2520structure-function%2520relationships%2520of%2520membrane%2520proteins%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2018%26spage%3DBST20180269%26doi%3D10.1042%2FBST20180269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baker, M.</span></span> <span> </span><span class="NLM_article-title">Making membrane proteins for structures: a trillion tiny tweaks</span>. <i>Nat. Methods</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">429</span>â <span class="NLM_lpage">434</span>, <span class="refDoi">Â DOI: 10.1038/nmeth0610-429</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fnmeth0610-429" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=20508636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmsF2it7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=429-434&issue=6&author=M.+Baker&title=Making+membrane+proteins+for+structures%3A+a+trillion+tiny+tweaks&doi=10.1038%2Fnmeth0610-429"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Making membrane proteins for structures: a trillion tiny tweaks</span></div><div class="casAuthors">Baker, Monya</div><div class="citationInfo"><span class="NLM_cas:title">Nature Methods</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">429-434</span>CODEN:
                <span class="NLM_cas:coden">NMAEA3</span>;
        ISSN:<span class="NLM_cas:issn">1548-7091</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review on multiple means to get high-quality membrane proteins for x-ray crystallog. and NMR spectroscopy studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU_8BLLqQ3SbVg90H21EOLACvtfcHk0lhXGkGYtNyIog"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmsF2it7o%253D&md5=45cec959130da53eaf570f3767dd9087</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1038%2Fnmeth0610-429&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnmeth0610-429%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DM.%26atitle%3DMaking%2520membrane%2520proteins%2520for%2520structures%253A%2520a%2520trillion%2520tiny%2520tweaks%26jtitle%3DNat.%2520Methods%26date%3D2010%26volume%3D7%26issue%3D6%26spage%3D429%26epage%3D434%26doi%3D10.1038%2Fnmeth0610-429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bill, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunji, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neutze, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newstead, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poolman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tate, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, H.</span></span> <span> </span><span class="NLM_article-title">Overcoming barriers to membrane protein structure determination</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">335</span>â <span class="NLM_lpage">340</span>, <span class="refDoi">Â DOI: 10.1038/nbt.1833</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fnbt.1833" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=21478852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3MXksVCkurY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=335-340&issue=4&author=R.+M.+Billauthor=P.+J.+Hendersonauthor=S.+Iwataauthor=E.+R.+Kunjiauthor=H.+Michelauthor=R.+Neutzeauthor=S.+Newsteadauthor=B.+Poolmanauthor=C.+G.+Tateauthor=H.+Vogel&title=Overcoming+barriers+to+membrane+protein+structure+determination&doi=10.1038%2Fnbt.1833"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming barriers to membrane protein structure determination</span></div><div class="casAuthors">Bill, Roslyn M.; Henderson, Peter J. F.; Iwata, So; Kunji, Edmund R. S.; Michel, Hartmut; Neutze, Richard; Newstead, Simon; Poolman, Bert; Tate, Christopher G.; Vogel, Horst</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">335-340</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  After decades of slow progress, the pace of research on membrane protein structures is beginning to quicken thanks to various improvements in technol., including protein engineering and microfocus X-ray diffraction.  Here we review these developments and, where possible, highlight generic new approaches to solving membrane protein structures based on recent technol. advances.  Rational approaches to overcoming the bottlenecks in the field are urgently required as membrane proteins, which typically comprise â¼30% of the proteomes of organisms, are dramatically under-represented in the structural database of the Protein Data Bank.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplLuk_M6X-RrVg90H21EOLACvtfcHk0lhXGkGYtNyIog"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXksVCkurY%253D&md5=17cf34dfa2caeab434f940020f4c54e2</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1833&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1833%26sid%3Dliteratum%253Aachs%26aulast%3DBill%26aufirst%3DR.%2BM.%26aulast%3DHenderson%26aufirst%3DP.%2BJ.%26aulast%3DIwata%26aufirst%3DS.%26aulast%3DKunji%26aufirst%3DE.%2BR.%26aulast%3DMichel%26aufirst%3DH.%26aulast%3DNeutze%26aufirst%3DR.%26aulast%3DNewstead%26aufirst%3DS.%26aulast%3DPoolman%26aufirst%3DB.%26aulast%3DTate%26aufirst%3DC.%2BG.%26aulast%3DVogel%26aufirst%3DH.%26atitle%3DOvercoming%2520barriers%2520to%2520membrane%2520protein%2520structure%2520determination%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26issue%3D4%26spage%3D335%26epage%3D340%26doi%3D10.1038%2Fnbt.1833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bill, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jawhari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothnie, A. J.</span></span> <span> </span><span class="NLM_article-title">Overcoming bottlenecks in the membrane protein structural biology pipeline</span>. <i>Biochem. Soc. Trans.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">838</span>â <span class="NLM_lpage">844</span>, <span class="refDoi">Â DOI: 10.1042/BST20160049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1042%2FBST20160049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=27284049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC28Xps1Wmt7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=838-844&issue=3&author=D.+Hardyauthor=R.+M.+Billauthor=A.+Jawhariauthor=A.+J.+Rothnie&title=Overcoming+bottlenecks+in+the+membrane+protein+structural+biology+pipeline&doi=10.1042%2FBST20160049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming bottlenecks in the membrane protein structural biology pipeline</span></div><div class="casAuthors">Hardy, David; Bill, Roslyn M.; Jawhari, Anass; Rothnie, Alice J.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">838-844</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Membrane proteins account for a third of the eukaryotic proteome, but are greatly under-represented in the Protein Data Bank.  Unfortunately, recent technol. advances in X-ray crystallog. and EM cannot account for the poor soly. and stability of membrane protein samples.  A limitation of conventional detergent-based methods is that detergent mols. destabilize membrane proteins, leading to their aggregation.  The use of orthologues, mutants and fusion tags has helped improve protein stability, but at the expense of not working with the sequence of interest.  Novel detergents such as glucose neopentyl glycol (GNG), maltose neopentyl glycol (MNG) and calixarene-based detergents can improve protein stability without compromising their solubilizing properties.  Styrene maleic acid lipid particles (SMALPs) focus on retaining the native lipid bilayer of a membrane protein during purifn. and biophys. anal.  Overcoming bottlenecks in the membrane protein structural biol. pipeline, primarily by maintaining protein stability, will facilitate the elucidation of many more membrane protein structures in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqK0zW9Wt0KurVg90H21EOLACvtfcHk0lhXGkGYtNyIog"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xps1Wmt7c%253D&md5=f10ec64f172fb2f9954c8476f5ef6473</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1042%2FBST20160049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST20160049%26sid%3Dliteratum%253Aachs%26aulast%3DHardy%26aufirst%3DD.%26aulast%3DBill%26aufirst%3DR.%2BM.%26aulast%3DJawhari%26aufirst%3DA.%26aulast%3DRothnie%26aufirst%3DA.%2BJ.%26atitle%3DOvercoming%2520bottlenecks%2520in%2520the%2520membrane%2520protein%2520structural%2520biology%2520pipeline%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2016%26volume%3D44%26issue%3D3%26spage%3D838%26epage%3D844%26doi%3D10.1042%2FBST20160049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. W.</span></span> <span> </span><span class="NLM_article-title">How cryo-electron microscopy and X-ray crystallography complement each other</span>. <i>Protein Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">32</span>â <span class="NLM_lpage">39</span>, <span class="refDoi">Â DOI: 10.1002/pro.3022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1002%2Fpro.3022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=27543495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOmur3P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2017&pages=32-39&issue=1&author=H.+W.+Wangauthor=J.+W.+Wang&title=How+cryo-electron+microscopy+and+X-ray+crystallography+complement+each+other&doi=10.1002%2Fpro.3022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">How Cryo-Electron Microscopy and X-ray Crystallography Complement Each Other</span></div><div class="casAuthors">Wang, Hong-Wei; Wang, Jia-Wei</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-39</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">1469-896X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">With the ability to resolve structures of macromols. at at. resoln., X-ray crystallog. has been the most powerful tool in modern structural biol.  At the same time, recent tech. improvements have triggered a resoln. revolution in the single particle cryo-EM method.  While the two methods are different in many respects, from sample prepn. to structure detn., they both have the power to solve macromol. structures at at. resoln.  It is important to understand the unique advantages and caveats of the two methods in solving structures and to appreciate the complementary nature of the two methods in structural biol.  In this review we provide some examples, and discuss how X-ray crystallog. and cryo-EM can be combined in deciphering structures of macromols. for our full understanding of their biol. mechanisms.  This article is protected by copyright.  All rights reserved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzL3Iy4EWUqbVg90H21EOLACvtfcHk0lhhvR6SuVl30A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOmur3P&md5=d67669a793d965772c2b657f56ab79a8</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1002%2Fpro.3022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpro.3022%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%2BW.%26aulast%3DWang%26aufirst%3DJ.%2BW.%26atitle%3DHow%2520cryo-electron%2520microscopy%2520and%2520X-ray%2520crystallography%2520complement%2520each%2520other%26jtitle%3DProtein%2520Sci.%26date%3D2017%26volume%3D26%26issue%3D1%26spage%3D32%26epage%3D39%26doi%3D10.1002%2Fpro.3022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masiulis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Colibus, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steyaert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aricescu, A. R.</span></span> <span> </span><span class="NLM_article-title">Structural basis for GABAA receptor potentiation by neurosteroids</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">986</span>â <span class="NLM_lpage">992</span>, <span class="refDoi">Â DOI: 10.1038/nsmb.3484</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fnsmb.3484" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=28991263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1aisrzM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=986-992&issue=11&author=P.+S.+Millerauthor=S.+Scottauthor=S.+Masiulisauthor=L.+De+Colibusauthor=E.+Pardonauthor=J.+Steyaertauthor=A.+R.+Aricescu&title=Structural+basis+for+GABAA+receptor+potentiation+by+neurosteroids&doi=10.1038%2Fnsmb.3484"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for GABAA receptor potentiation by neurosteroids</span></div><div class="casAuthors">Miller, Paul S.; Scott, Suzanne; Masiulis, Simonas; De Colibus, Luigi; Pardon, Els; Steyaert, Jan; Aricescu, A. Radu</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">986-992</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Type A Î³-aminobutyric acid receptors (GABAARs) are the principal mediators of inhibitory neurotransmission in the human brain.  Endogenous neurosteroids interact with GABAARs to regulate acute and chronic anxiety and are potent sedative, analgesic, anticonvulsant and anesthetic agents.  Their mode of binding and mechanism of receptor potentiation, however, remain unknown.  Here we report crystal structures of a chimeric GABAAR construct in apo and pregnanolone-bound states.  The neurosteroid-binding site is mech. coupled to the helixes lining the ion channel pore and modulates the desensitization-gate conformation.  We demonstrate that the equiv. site is responsible for physiol., heteromeric GABAAR potentiation and explain the contrasting modulatory properties of 3a vs. 3b neurosteroid epimers.  These results illustrate how peripheral lipid ligands can regulate the desensitization gate of GABAARs, a process of broad relevance to pentameric ligand-gated ion channels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_rFOSeRpWIrVg90H21EOLACvtfcHk0lhhvR6SuVl30A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1aisrzM&md5=8587877033cb81d7bc285fcdc5c62e86</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.3484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.3484%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DP.%2BS.%26aulast%3DScott%26aufirst%3DS.%26aulast%3DMasiulis%26aufirst%3DS.%26aulast%3DDe%2BColibus%26aufirst%3DL.%26aulast%3DPardon%26aufirst%3DE.%26aulast%3DSteyaert%26aufirst%3DJ.%26aulast%3DAricescu%26aufirst%3DA.%2BR.%26atitle%3DStructural%2520basis%2520for%2520GABAA%2520receptor%2520potentiation%2520by%2520neurosteroids%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2017%26volume%3D24%26issue%3D11%26spage%3D986%26epage%3D992%26doi%3D10.1038%2Fnsmb.3484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noviello, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, R. M.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hibbs, R. E.</span></span> <span> </span><span class="NLM_article-title">Structure of a human synaptic GABA<sub>A</sub> receptor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>559</i></span> (<span class="NLM_issue">7712</span>),  <span class="NLM_fpage">67</span>â <span class="NLM_lpage">72</span>, <span class="refDoi">Â DOI: 10.1038/s41586-018-0255-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fs41586-018-0255-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=29950725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1eisrzE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=559&publication_year=2018&pages=67-72&issue=7712&author=S.+Zhuauthor=C.+M.+Novielloauthor=J.+Tengauthor=R.+M.+Walshauthor=J.+J.+Kimauthor=R.+E.+Hibbs&title=Structure+of+a+human+synaptic+GABAA+receptor&doi=10.1038%2Fs41586-018-0255-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of a human synaptic GABAA receptor</span></div><div class="casAuthors">Zhu, Shaotong; Noviello, Colleen M.; Teng, Jinfeng; Walsh, Richard M., Jr.; Kim, Jeong Joo; Hibbs, Ryan E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">559</span>
        (<span class="NLM_cas:issue">7712</span>),
    <span class="NLM_cas:pages">67-72</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Fast inhibitory neurotransmission in the brain is principally mediated by the neurotransmitter GABA (Î³-aminobutyric acid) and its synaptic target, the type A GABA receptor (GABAA receptor).  Dysfunction of this receptor results in neurol. disorders and mental illnesses including epilepsy, anxiety and insomnia.  The GABAA receptor is also a prolific target for therapeutic, illicit and recreational drugs, including benzodiazepines, barbiturates, anesthetics and ethanol.  Here we present high-resoln. cryo-electron microscopy structures of the human Î±1Î²2Î³2 GABAA receptor, the predominant isoform in the adult brain, in complex with GABA and the benzodiazepine site antagonist flumazenil, the first-line clin. treatment for benzodiazepine overdose.  The receptor architecture reveals unique heteromeric interactions for this important class of inhibitory neurotransmitter receptor.  This work provides a template for understanding receptor modulation by GABA and benzodiazepines, and will assist rational approaches to therapeutic targeting of this receptor for neurol. disorders and mental illness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyjjS2mR9GnrVg90H21EOLACvtfcHk0lhhvR6SuVl30A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1eisrzE&md5=821bc718642c7b52811846149f696097</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1038%2Fs41586-018-0255-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-018-0255-3%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DS.%26aulast%3DNoviello%26aufirst%3DC.%2BM.%26aulast%3DTeng%26aufirst%3DJ.%26aulast%3DWalsh%26aufirst%3DR.%2BM.%26aulast%3DKim%26aufirst%3DJ.%2BJ.%26aulast%3DHibbs%26aufirst%3DR.%2BE.%26atitle%3DStructure%2520of%2520a%2520human%2520synaptic%2520GABAA%2520receptor%26jtitle%3DNature%26date%3D2018%26volume%3D559%26issue%3D7712%26spage%3D67%26epage%3D72%26doi%3D10.1038%2Fs41586-018-0255-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hackos, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupardus, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grand, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallweber, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volgraf, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paoletti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, J. E.</span></span> <span> </span><span class="NLM_article-title">Positive allosteric modulators of GluN2A-containing NMDARs with distinct modes of action and impacts on circuit function</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>89</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">983</span>â <span class="NLM_lpage">999</span>, <span class="refDoi">Â DOI: 10.1016/j.neuron.2016.01.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.neuron.2016.01.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=26875626" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC28XisFSrtbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2016&pages=983-999&issue=5&author=D.+H.+Hackosauthor=P.+J.+Lupardusauthor=T.+Grandauthor=Y.+Chenauthor=T.+M.+Wangauthor=P.+Reynenauthor=A.+Gustafsonauthor=H.+J.+Wallweberauthor=M.+Volgrafauthor=B.+D.+Sellersauthor=J.+B.+Schwarzauthor=P.+Paolettiauthor=M.+Shengauthor=Q.+Zhouauthor=J.+E.+Hanson&title=Positive+allosteric+modulators+of+GluN2A-containing+NMDARs+with+distinct+modes+of+action+and+impacts+on+circuit+function&doi=10.1016%2Fj.neuron.2016.01.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Positive Allosteric Modulators of GluN2A-Containing NMDARs with Distinct Modes of Action and Impacts on Circuit Function</span></div><div class="casAuthors">Hackos, David H.; Lupardus, Patrick J.; Grand, Teddy; Chen, Yelin; Wang, Tzu-Ming; Reynen, Paul; Gustafson, Amy; Wallweber, Heidi J. A.; Volgraf, Matthew; Sellers, Benjamin D.; Schwarz, Jacob B.; Paoletti, Pierre; Sheng, Morgan; Zhou, Qiang; Hanson, Jesse E.</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">983-999</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">To enhance physiol. function of NMDA receptors (NMDARs), we identified pos. allosteric modulators (PAMs) of NMDARs with selectivity for GluN2A subunit-contg. receptors.  X-ray crystallog. revealed a binding site at the GluN1-GluN2A dimer interface of the extracellular ligand-binding domains (LBDs).  Despite the similarity between the LBDs of NMDARs and AMPA receptors (AMPARs), GluN2A PAMs with good selectivity against AMPARs were identified.  Potentiation was obsd. with recombinant triheteromeric GluN1/GluN2A/GluN2B NMDARs and with synaptically activated NMDARs in brain slices from wild-type (WT), but not GluN2A knockout (KO), mice.  Individual GluN2A PAMs exhibited variable degrees of glutamate (Glu) dependence, impact on NMDAR Glu EC50, and slowing of channel deactivation.  These distinct PAMs also exhibited differential impacts during synaptic plasticity induction.  The identification of a new NMDAR modulatory site and characterization of GluN2A-selective PAMs provide powerful mol. tools to dissect NMDAR function and demonstrate the feasibility of a therapeutically desirable type of NMDAR enhancement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGros48fNAsozLVg90H21EOLACvtfcHk0lgTp4a7vZvpkg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisFSrtbw%253D&md5=38661a9f898df39ba616e77f0bdf34e9</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1016%2Fj.neuron.2016.01.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuron.2016.01.016%26sid%3Dliteratum%253Aachs%26aulast%3DHackos%26aufirst%3DD.%2BH.%26aulast%3DLupardus%26aufirst%3DP.%2BJ.%26aulast%3DGrand%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DT.%2BM.%26aulast%3DReynen%26aufirst%3DP.%26aulast%3DGustafson%26aufirst%3DA.%26aulast%3DWallweber%26aufirst%3DH.%2BJ.%26aulast%3DVolgraf%26aufirst%3DM.%26aulast%3DSellers%26aufirst%3DB.%2BD.%26aulast%3DSchwarz%26aufirst%3DJ.%2BB.%26aulast%3DPaoletti%26aufirst%3DP.%26aulast%3DSheng%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DHanson%26aufirst%3DJ.%2BE.%26atitle%3DPositive%2520allosteric%2520modulators%2520of%2520GluN2A-containing%2520NMDARs%2520with%2520distinct%2520modes%2520of%2520action%2520and%2520impacts%2520on%2520circuit%2520function%26jtitle%3DNeuron%26date%3D2016%26volume%3D89%26issue%3D5%26spage%3D983%26epage%3D999%26doi%3D10.1016%2Fj.neuron.2016.01.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupardus, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallweber, H. J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volgraf, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackos, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, J. E.</span></span> <span> </span><span class="NLM_article-title">A novel NMDA receptor positive allosteric modulator that acts via the transmembrane domain</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">204</span>â <span class="NLM_lpage">218</span>, <span class="refDoi">Â DOI: 10.1016/j.neuropharm.2017.04.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.neuropharm.2017.04.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=28457974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnsFentLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2017&pages=204-218&author=T.+M.+Wangauthor=B.+M.+Brownauthor=L.+Dengauthor=B.+D.+Sellersauthor=P.+J.+Lupardusauthor=H.+J.+A.+Wallweberauthor=A.+Gustafsonauthor=E.+Wongauthor=M.+Volgrafauthor=J.+B.+Schwarzauthor=D.+H.+Hackosauthor=J.+E.+Hanson&title=A+novel+NMDA+receptor+positive+allosteric+modulator+that+acts+via+the+transmembrane+domain&doi=10.1016%2Fj.neuropharm.2017.04.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">A novel NMDA receptor positive allosteric modulator that acts via the transmembrane domain</span></div><div class="casAuthors">Wang, Tzu-Ming; Brown, Brandon M.; Deng, Lunbin; Sellers, Benjamin D.; Lupardus, Patrick J.; Wallweber, Heidi J. A.; Gustafson, Amy; Wong, Evera; Volgraf, Matthew; Schwarz, Jacob B.; Hackos, David H.; Hanson, Jesse E.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">204-218</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Ionotropic glutamate receptors (iGluRs) mediate fast excitatory neurotransmission and are key nervous system drug targets.  While diverse pharmacol. tools have yielded insight into iGluR extracellular domain function, less is known about mol. mechanisms underlying the ion conduction gating process within the transmembrane domain (TMD).  We have discovered a novel NMDAR pos. allosteric modulator (PAM), GNE-9278, with a unique binding site on the extracellular surface of the TMD.  Mutation of a single residue near the Lurcher motif on GluN1 M3 can convert GNE-9278 modulation from pos. to neg., and replacing three AMPAR pre-M1 residues with corresponding NMDAR residues can confer GNE-9278 sensitivity to AMPARs.  Modulation by GNE-9278 is state-dependent and significantly alters extracellular domain pharmacol.  The unique properties and structural determinants of GNE-9278 reveal new modulatory potential of the iGluR TMD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlpDlNo3PXSrVg90H21EOLACvtfcHk0lgTp4a7vZvpkg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnsFentLk%253D&md5=e868c18884abbb5c63de5adb5873660c</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2017.04.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2017.04.041%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%2BM.%26aulast%3DBrown%26aufirst%3DB.%2BM.%26aulast%3DDeng%26aufirst%3DL.%26aulast%3DSellers%26aufirst%3DB.%2BD.%26aulast%3DLupardus%26aufirst%3DP.%2BJ.%26aulast%3DWallweber%26aufirst%3DH.%2BJ.%2BA.%26aulast%3DGustafson%26aufirst%3DA.%26aulast%3DWong%26aufirst%3DE.%26aulast%3DVolgraf%26aufirst%3DM.%26aulast%3DSchwarz%26aufirst%3DJ.%2BB.%26aulast%3DHackos%26aufirst%3DD.%2BH.%26aulast%3DHanson%26aufirst%3DJ.%2BE.%26atitle%3DA%2520novel%2520NMDA%2520receptor%2520positive%2520allosteric%2520modulator%2520that%2520acts%2520via%2520the%2520transmembrane%2520domain%26jtitle%3DNeuropharmacology%26date%3D2017%26volume%3D121%26spage%3D204%26epage%3D218%26doi%3D10.1016%2Fj.neuropharm.2017.04.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Volgraf, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ly, C. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villemure, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastor, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuen, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupardus, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallweber, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liederer, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plise, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrington, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dirksen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietz, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scearce-Levie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, J. B.</span></span> <span> </span><span class="NLM_article-title">Discovery of GluN2A-selective NMDA receptor positive allosteric modulators (PAMs): tuning deactivation kinetics via structure-based design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2760</span>â <span class="NLM_lpage">2779</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b02010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b02010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjt1ynt70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2760-2779&issue=6&author=M.+Volgrafauthor=B.+D.+Sellersauthor=Y.+Jiangauthor=G.+Wuauthor=C.+Q.+Lyauthor=E.+Villemureauthor=R.+M.+Pastorauthor=P.+W.+Yuenauthor=A.+Luauthor=X.+Luoauthor=M.+Liuauthor=S.+Zhangauthor=L.+Sunauthor=Y.+Fuauthor=P.+J.+Lupardusauthor=H.+J.+Wallweberauthor=B.+M.+Liedererauthor=G.+Deshmukhauthor=E.+Pliseauthor=S.+Tayauthor=P.+Reynenauthor=J.+Herringtonauthor=A.+Gustafsonauthor=Y.+Liuauthor=A.+Dirksenauthor=M.+G.+Dietzauthor=Y.+Liuauthor=T.+M.+Wangauthor=J.+E.+Hansonauthor=D.+Hackosauthor=K.+Scearce-Levieauthor=J.+B.+Schwarz&title=Discovery+of+GluN2A-selective+NMDA+receptor+positive+allosteric+modulators+%28PAMs%29%3A+tuning+deactivation+kinetics+via+structure-based+design&doi=10.1021%2Facs.jmedchem.5b02010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of GluN2A-Selective NMDA Receptor Positive Allosteric Modulators (PAMs): Tuning Deactivation Kinetics via Structure-Based Design</span></div><div class="casAuthors">Volgraf, Matthew; Sellers, Benjamin D.; Jiang, Yu; Wu, Guosheng; Ly, Cuong Q.; Villemure, Elisia; Pastor, Richard M.; Yuen, Po-wai; Lu, Aijun; Luo, Xifeng; Liu, Mingcui; Zhang, Shun; Sun, Liang; Fu, Yuhong; Lupardus, Patrick J.; Wallweber, Heidi J. A.; Liederer, Bianca M.; Deshmukh, Gauri; Plise, Emile; Tay, Suzanne; Reynen, Paul; Herrington, James; Gustafson, Amy; Liu, Yichin; Dirksen, Akim; Dietz, Matthias G. A.; Liu, Yanzhou; Wang, Tzu-Ming; Hanson, Jesse E.; Hackos, David; Scearce-Levie, Kimberly; Schwarz, Jacob B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2760-2779</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The N-methyl-D-aspartate receptor (NMDAR) is a Na+ and Ca2+ permeable ionotropic glutamate receptor that is activated by the coagonists glycine and glutamate.  NMDARs are crit. to synaptic signaling and plasticity, and their dysfunction has been implicated in a no. of neurol. disorders, including schizophrenia, depression, and Alzheimer's disease.  Herein we describe the discovery of potent GluN2A-selective NMDAR pos. allosteric modulators (PAMs) starting from a high-throughput screening hit.  Using structure-based design, we sought to increase potency at the GluN2A subtype, while improving selectivity against related Î±-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs).  The structure-activity relationship of channel deactivation kinetics was studied using a combination of electrophysiol. and protein crystallog.  Effective incorporation of these strategies resulted in the discovery of GNE-0723 (46), a highly potent and brain penetrant GluN2A-selective NMDAR PAM suitable for in vivo characterization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdza-qdjBnZbVg90H21EOLACvtfcHk0lgTp4a7vZvpkg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjt1ynt70%253D&md5=2d9f7199cd3d9d9ac513006612e9bb01</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b02010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b02010%26sid%3Dliteratum%253Aachs%26aulast%3DVolgraf%26aufirst%3DM.%26aulast%3DSellers%26aufirst%3DB.%2BD.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DLy%26aufirst%3DC.%2BQ.%26aulast%3DVillemure%26aufirst%3DE.%26aulast%3DPastor%26aufirst%3DR.%2BM.%26aulast%3DYuen%26aufirst%3DP.%2BW.%26aulast%3DLu%26aufirst%3DA.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DFu%26aufirst%3DY.%26aulast%3DLupardus%26aufirst%3DP.%2BJ.%26aulast%3DWallweber%26aufirst%3DH.%2BJ.%26aulast%3DLiederer%26aufirst%3DB.%2BM.%26aulast%3DDeshmukh%26aufirst%3DG.%26aulast%3DPlise%26aufirst%3DE.%26aulast%3DTay%26aufirst%3DS.%26aulast%3DReynen%26aufirst%3DP.%26aulast%3DHerrington%26aufirst%3DJ.%26aulast%3DGustafson%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DDirksen%26aufirst%3DA.%26aulast%3DDietz%26aufirst%3DM.%2BG.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DT.%2BM.%26aulast%3DHanson%26aufirst%3DJ.%2BE.%26aulast%3DHackos%26aufirst%3DD.%26aulast%3DScearce-Levie%26aufirst%3DK.%26aulast%3DSchwarz%26aufirst%3DJ.%2BB.%26atitle%3DDiscovery%2520of%2520GluN2A-selective%2520NMDA%2520receptor%2520positive%2520allosteric%2520modulators%2520%2528PAMs%2529%253A%2520tuning%2520deactivation%2520kinetics%2520via%2520structure-based%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D6%26spage%3D2760%26epage%3D2779%26doi%3D10.1021%2Facs.jmedchem.5b02010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christopher, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OrgovÃ¡n, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DorÃ©, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Errey, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okrasa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rucktooa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano-Vega, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferenczy, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">KeserÅ±, G. M.</span></span> <span> </span><span class="NLM_article-title">Structure-based optimization strategies for G protein-coupled receptor (GPCR) allosteric modulators: a case study from analyses of new metabotropic glutamate receptor 5 (mGlu5) x-ray structures</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">207</span>â <span class="NLM_lpage">222</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b01722</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01722" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFCnt70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=207-222&issue=1&author=J.+A.+Christopherauthor=Z.+Orgov%C3%A1nauthor=M.+Congreveauthor=A.+S.+Dor%C3%A9author=J.+C.+Erreyauthor=F.+H.+Marshallauthor=J.+S.+Masonauthor=K.+Okrasaauthor=P.+Rucktooaauthor=M.+J.+Serrano-Vegaauthor=G.+G.+Ferenczyauthor=G.+M.+Keser%C5%B1&title=Structure-based+optimization+strategies+for+G+protein-coupled+receptor+%28GPCR%29+allosteric+modulators%3A+a+case+study+from+analyses+of+new+metabotropic+glutamate+receptor+5+%28mGlu5%29+x-ray+structures&doi=10.1021%2Facs.jmedchem.7b01722"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Optimization Strategies for G Protein-Coupled Receptor (GPCR) Allosteric Modulators: A Case Study from Analyses of New Metabotropic Glutamate Receptor 5 (mGlu5) X-ray Structures</span></div><div class="casAuthors">Christopher, John A.; Orgovan, Zoltan; Congreve, Miles; Dore, Andrew S.; Errey, James C.; Marshall, Fiona H.; Mason, Jonathan S.; Okrasa, Krzysztof; Rucktooa, Prakash; Serrano-Vega, Maria J.; Ferenczy, Gyorgy G.; Keseru, Gyorgy M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">207-222</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two interesting new X-ray structures of neg. allosteric modulator (NAM) ligands for the mGlu5 receptor, M-MPEP (3) and fenobam (4), are reported.  The new structures show how the binding of the ligands induces different receptor water channel conformations to previously published structures.  The structure of fenobam, where a urea replaces the acetylenic linker in M-MPEP and mavoglurant, reveals a binding mode where the ligand is rotated by 180Â° compared to a previously proposed docking model.  The need for multiple ligand structures for accurate GPCR structure-based drug design is demonstrated by the different growing vectors identified for the head groups of M-MPEP and mavoglurant and by the unexpected water-mediated receptor interactions of a new chemotype represented by fenobam.  The implications of the new structures for ligand design are discussed, with extensive anal. of the energetics of the water networks of both pseudoapo and bound structures providing a new design strategy for allosteric modulators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEggCq8N6KILVg90H21EOLACvtfcHk0lhagtNUHD6XMA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFCnt70%253D&md5=6ba235f3016b0637cd17dce6cffe0d14</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01722%26sid%3Dliteratum%253Aachs%26aulast%3DChristopher%26aufirst%3DJ.%2BA.%26aulast%3DOrgov%25C3%25A1n%26aufirst%3DZ.%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DDor%25C3%25A9%26aufirst%3DA.%2BS.%26aulast%3DErrey%26aufirst%3DJ.%2BC.%26aulast%3DMarshall%26aufirst%3DF.%2BH.%26aulast%3DMason%26aufirst%3DJ.%2BS.%26aulast%3DOkrasa%26aufirst%3DK.%26aulast%3DRucktooa%26aufirst%3DP.%26aulast%3DSerrano-Vega%26aufirst%3DM.%2BJ.%26aulast%3DFerenczy%26aufirst%3DG.%2BG.%26aulast%3DKeser%25C5%25B1%26aufirst%3DG.%2BM.%26atitle%3DStructure-based%2520optimization%2520strategies%2520for%2520G%2520protein-coupled%2520receptor%2520%2528GPCR%2529%2520allosteric%2520modulators%253A%2520a%2520case%2520study%2520from%2520analyses%2520of%2520new%2520metabotropic%2520glutamate%2520receptor%25205%2520%2528mGlu5%2529%2520x-ray%2520structures%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D1%26spage%3D207%26epage%3D222%26doi%3D10.1021%2Facs.jmedchem.7b01722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anighoro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graziani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettinelli, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cilia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Toma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longhi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangiarotti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menegon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirona, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poggesi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riva, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rastelli, G.</span></span> <span> </span><span class="NLM_article-title">Insights into the interaction of negative allosteric modulators with the metabotropic glutamate receptor 5: discovery and computational modeling of a new series of ligands with nanomolar affinity</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3040</span>â <span class="NLM_lpage">3058</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2015.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.bmc.2015.05.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=26014480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotlGrsbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=3040-3058&author=A.+Anighoroauthor=D.+Grazianiauthor=I.+Bettinelliauthor=A.+Ciliaauthor=C.+De+Tomaauthor=M.+Longhiauthor=F.+Mangiarottiauthor=S.+Menegonauthor=L.+Pironaauthor=E.+Poggesiauthor=C.+Rivaauthor=G.+Rastelli&title=Insights+into+the+interaction+of+negative+allosteric+modulators+with+the+metabotropic+glutamate+receptor+5%3A+discovery+and+computational+modeling+of+a+new+series+of+ligands+with+nanomolar+affinity&doi=10.1016%2Fj.bmc.2015.05.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into the interaction of negative allosteric modulators with the metabotropic glutamate receptor 5: Discovery and computational modeling of a new series of ligands with nanomolar affinity</span></div><div class="casAuthors">Anighoro, Andrew; Graziani, Davide; Bettinelli, Ilaria; Cilia, Antonio; De Toma, Carlo; Longhi, Matteo; Mangiarotti, Fabio; Menegon, Sergio; Pirona, Lorenza; Poggesi, Elena; Riva, Carlo; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3040-3058</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Metabotropic glutamate receptor 5 (mGlu5) is a biol. target implicated in major neurol. and psychiatric disorders.  In the present study, we have investigated structural determinants of the interaction of neg. allosteric modulators (NAMs) with the seven-transmembrane (7TM) domain of mGlu5.  A homol. model of the 7TM receptor domain built on the crystal structure of the mGlu1 template was obtained, and the binding modes of known NAMs, namely MPEP and fenobam, were investigated by docking and mol. dynamics simulations.  The results were validated by comparison with mutagenesis data available in the literature for these two ligands, and subsequently corroborated by the recently described mGlu5 crystal structure.  Moreover, a new series of NAMs was synthesized and tested, providing compds. with nanomolar affinity.  Several structural modifications were sequentially introduced with the aim of identifying structural features important for receptor binding.  The synthesized NAMs were docked in the validated homol. model and binding modes were used to interpret and discuss structure-activity relationships within this new series of compds.  Finally, the models of the interaction of NAMs with mGlu5 were extended to include important non-aryl alkyne mGlu5 NAMs taken from the literature.  Overall, the results provide useful insights into the mol. interaction of neg. allosteric modulators with mGlu5 and may facilitate the design of new modulators for this class of receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8hEyrYvgTFbVg90H21EOLACvtfcHk0lhagtNUHD6XMA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotlGrsbg%253D&md5=829cd7eced83a48dcd216a1afa490cc7</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DAnighoro%26aufirst%3DA.%26aulast%3DGraziani%26aufirst%3DD.%26aulast%3DBettinelli%26aufirst%3DI.%26aulast%3DCilia%26aufirst%3DA.%26aulast%3DDe%2BToma%26aufirst%3DC.%26aulast%3DLonghi%26aufirst%3DM.%26aulast%3DMangiarotti%26aufirst%3DF.%26aulast%3DMenegon%26aufirst%3DS.%26aulast%3DPirona%26aufirst%3DL.%26aulast%3DPoggesi%26aufirst%3DE.%26aulast%3DRiva%26aufirst%3DC.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DInsights%2520into%2520the%2520interaction%2520of%2520negative%2520allosteric%2520modulators%2520with%2520the%2520metabotropic%2520glutamate%2520receptor%25205%253A%2520discovery%2520and%2520computational%2520modeling%2520of%2520a%2520new%2520series%2520of%2520ligands%2520with%2520nanomolar%2520affinity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D3040%26epage%3D3058%26doi%3D10.1016%2Fj.bmc.2015.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dosa, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amin, E. A.</span></span> <span> </span><span class="NLM_article-title">Tactical approaches to interconverting GPCR agonists and antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">810</span>â <span class="NLM_lpage">840</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00982</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00982" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFamsr7P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=810-840&issue=3&author=P.+I.+Dosaauthor=E.+A.+Amin&title=Tactical+approaches+to+interconverting+GPCR+agonists+and+antagonists&doi=10.1021%2Facs.jmedchem.5b00982"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Tactical Approaches to Interconverting GPCR Agonists and Antagonists</span></div><div class="casAuthors">Dosa, Peter I.; Amin, Elizabeth Ambrose</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">810-840</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There are many reported examples of small structural modifications to GPCR-targeted ligands leading to major changes in their functional activity, converting agonists into antagonists or vice versa.  These shifts in functional activity are often accompanied by negligible changes in binding affinity.  The current perspective focuses on outlining and analyzing various approaches that have been used to interconvert GPCR agonists, partial agonists, and antagonists in order to achieve the intended functional activity at a GPCR of therapeutic interest.  An improved understanding of specific structural modifications that are likely to alter the functional activity of a GPCR ligand may be of use to researchers designing GPCR-targeted drugs and/or probe compds., specifically in cases where a particular ligand exhibits good potency but not the preferred functional activity at the GPCR of choice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohWg2-DQHq3LVg90H21EOLACvtfcHk0lhcOnrrH_PQEw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFamsr7P&md5=99ffc0b892eb9c10aaf5d52a7d5dd8bc</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00982%26sid%3Dliteratum%253Aachs%26aulast%3DDosa%26aufirst%3DP.%2BI.%26aulast%3DAmin%26aufirst%3DE.%2BA.%26atitle%3DTactical%2520approaches%2520to%2520interconverting%2520GPCR%2520agonists%2520and%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D3%26spage%3D810%26epage%3D840%26doi%3D10.1021%2Facs.jmedchem.5b00982" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">PiÃ±eyro, G.</span></span> <span> </span><span class="NLM_article-title">Membrane signalling complexes: implications for development of functionally selective ligands modulating heptahelical receptor signalling</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">179</span>â <span class="NLM_lpage">185</span>, <span class="refDoi">Â DOI: 10.1016/j.cellsig.2008.08.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.cellsig.2008.08.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=18790047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFamtLfJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2009&pages=179-185&issue=2&author=G.+Pi%C3%B1eyro&title=Membrane+signalling+complexes%3A+implications+for+development+of+functionally+selective+ligands+modulating+heptahelical+receptor+signalling&doi=10.1016%2Fj.cellsig.2008.08.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Membrane signalling complexes: Implications for development of functionally selective ligands modulating heptahelical receptor signalling</span></div><div class="casAuthors">Pineyro, Graciela</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-185</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Technol. development has considerably changed the way in which we evaluate drug efficacy and has led to a conceptual revolution in pharmacol. theory.  In particular, mol. resoln. assays have revealed that heptahelical receptors may adopt multiple active conformations with unique signalling properties.  It is therefore becoming widely accepted that ligand ability to stabilize receptor conformations with distinct signalling profiles may allow to direct the stimulus generated by an activated receptor towards a specific signalling pathway.  This capacity to induce only a subset of the ensemble of responses regulated by a given receptor has been termed "functional selectivity" (or "stimulus trafficking"), and provides the bases for a highly specific regulation of receptor signalling.  Concomitant with these observations, heptahelical receptors have been shown to assoc. with G proteins and effectors to form multimeric arrays.  These complexes are constitutively formed during protein synthesis and are targeted to the cell surface as integral signalling units.  Herein we summarize evidence supporting the existence of such constitutive signalling arrays and analyze the possibility that they may constitute viable targets for developing ligands with "functional selectivity".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFyV0hMr8DT7Vg90H21EOLACvtfcHk0lhcOnrrH_PQEw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFamtLfJ&md5=8e448db53eab5dd57c6e8c55f025bf54</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2008.08.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2008.08.013%26sid%3Dliteratum%253Aachs%26aulast%3DPi%25C3%25B1eyro%26aufirst%3DG.%26atitle%3DMembrane%2520signalling%2520complexes%253A%2520implications%2520for%2520development%2520of%2520functionally%2520selective%2520ligands%2520modulating%2520heptahelical%2520receptor%2520signalling%26jtitle%3DCell.%2520Signalling%26date%3D2009%26volume%3D21%26issue%3D2%26spage%3D179%26epage%3D185%26doi%3D10.1016%2Fj.cellsig.2008.08.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klein Herenbrink, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sykes, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donthamsetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canals, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coudrat, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shonberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scammells, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuano, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span> <span> </span><span class="NLM_article-title">The role of kinetic context in apparent biased agonism at GPCRs</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">10842</span>, <span class="refDoi">Â DOI: 10.1038/ncomms10842</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fncomms10842" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=26905976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjt1emtbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=10842&author=C.+Klein+Herenbrinkauthor=D.+A.+Sykesauthor=P.+Donthamsettiauthor=M.+Canalsauthor=T.+Coudratauthor=J.+Shonbergauthor=P.+J.+Scammellsauthor=B.+Capuanoauthor=P.+M.+Sextonauthor=S.+J.+Charltonauthor=J.+A.+Javitchauthor=A.+Christopoulosauthor=J.+R.+Lane&title=The+role+of+kinetic+context+in+apparent+biased+agonism+at+GPCRs&doi=10.1038%2Fncomms10842"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">The role of kinetic context in apparent biased agonism at GPCRs</span></div><div class="casAuthors">Klein Herenbrink, Carmen; Sykes, David A.; Donthamsetti, Prashant; Canals, Meritxell; Coudrat, Thomas; Shonberg, Jeremy; Scammells, Peter J.; Capuano, Ben; Sexton, Patrick M.; Charlton, Steven J.; Javitch, Jonathan A.; Christopoulos, Arthur; Lane, J. Robert</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10842</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Biased agonism describes the ability of ligands to stabilize different conformations of a GPCR linked to distinct functional outcomes and offers the prospect of designing pathway-specific drugs that avoid on-target side effects.  This mechanism is usually inferred from pharmacol. data with the assumption that the confounding influences of observational (i.e., assay dependent) and system (i.e., cell background dependent) bias are excluded by exptl. design and anal.  Here we reveal that 'kinetic context', as detd. by ligand-binding kinetics and the temporal pattern of receptor-signalling processes, can have a profound influence on the apparent bias of a series of agonists for the dopamine D2 receptor and can even lead to reversals in the direction of bias.  We propose that kinetic context must be acknowledged in the design and interpretation of studies of biased agonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoboe6-_23rF7Vg90H21EOLACvtfcHk0lhcOnrrH_PQEw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjt1emtbk%253D&md5=3afdebd5ad1c8a8b1db93478e9b2c7d4</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1038%2Fncomms10842&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms10842%26sid%3Dliteratum%253Aachs%26aulast%3DKlein%2BHerenbrink%26aufirst%3DC.%26aulast%3DSykes%26aufirst%3DD.%2BA.%26aulast%3DDonthamsetti%26aufirst%3DP.%26aulast%3DCanals%26aufirst%3DM.%26aulast%3DCoudrat%26aufirst%3DT.%26aulast%3DShonberg%26aufirst%3DJ.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DCapuano%26aufirst%3DB.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520role%2520of%2520kinetic%2520context%2520in%2520apparent%2520biased%2520agonism%2520at%2520GPCRs%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D10842%26doi%3D10.1038%2Fncomms10842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, A. D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacCoss, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heer, J. P.</span></span> <span> </span><span class="NLM_article-title">Importance of rigidity in designing small molecule drugs to tackle proteinâprotein interactions (PPIs) through stabilization of desired conformers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4283</span>â <span class="NLM_lpage">4289</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b01120</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01120" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVWqtb7J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4283-4289&issue=10&author=A.+D.+G.+Lawsonauthor=M.+MacCossauthor=J.+P.+Heer&title=Importance+of+rigidity+in+designing+small+molecule+drugs+to+tackle+protein%E2%80%93protein+interactions+%28PPIs%29+through+stabilization+of+desired+conformers&doi=10.1021%2Facs.jmedchem.7b01120"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Importance of Rigidity in Designing Small Molecule Drugs To Tackle Protein-Protein Interactions (PPIs) through Stabilization of Desired Conformers</span></div><div class="casAuthors">Lawson, Alastair D. G.; MacCoss, Malcolm; Heer, Jag P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4283-4289</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tackling PPIs, particularly by stabilizing clin. favored conformations of target proteins, with orally available, bona fide small mols. remains a significant but immensely worthwhile challenge for the pharmaceutical industry.  Success may be more likely through the application of nature's learnings to build intrinsic rigidity into the design of clin. candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN_JJHmVzv_rVg90H21EOLACvtfcHk0lhcOnrrH_PQEw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVWqtb7J&md5=665f95b08aeea2757f0a3b4dc4f813ed</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01120%26sid%3Dliteratum%253Aachs%26aulast%3DLawson%26aufirst%3DA.%2BD.%2BG.%26aulast%3DMacCoss%26aufirst%3DM.%26aulast%3DHeer%26aufirst%3DJ.%2BP.%26atitle%3DImportance%2520of%2520rigidity%2520in%2520designing%2520small%2520molecule%2520drugs%2520to%2520tackle%2520protein%25E2%2580%2593protein%2520interactions%2520%2528PPIs%2529%2520through%2520stabilization%2520of%2520desired%2520conformers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D10%26spage%3D4283%26epage%3D4289%26doi%3D10.1021%2Facs.jmedchem.7b01120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gautam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wess, J.</span></span> <span> </span><span class="NLM_article-title">Muscarinic acetylcholine receptors: novel opportunities for drug development</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">549</span>â <span class="NLM_lpage">560</span>, <span class="refDoi">Â DOI: 10.1038/nrd4295</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fnrd4295" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=24903776" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptlOitbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=549-560&issue=7&author=A.+C.+Kruseauthor=B.+K.+Kobilkaauthor=D.+Gautamauthor=P.+M.+Sextonauthor=A.+Christopoulosauthor=J.+Wess&title=Muscarinic+acetylcholine+receptors%3A+novel+opportunities+for+drug+development&doi=10.1038%2Fnrd4295"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Muscarinic acetylcholine receptors: novel opportunities for drug development</span></div><div class="casAuthors">Kruse, Andrew C.; Kobilka, Brian K.; Gautam, Dinesh; Sexton, Patrick M.; Christopoulos, Arthur; Wess, Jurgen</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">549-560</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The muscarinic acetylcholine receptors are a subfamily of G protein-coupled receptors that regulate numerous fundamental functions of the central and peripheral nervous system.  The past few years have witnessed unprecedented new insights into muscarinic receptor physiol., pharmacol. and structure.  These advances include the first structural views of muscarinic receptors in both inactive and active conformations, as well as a better understanding of the mol. underpinnings of muscarinic receptor regulation by allosteric modulators.  These recent findings should facilitate the development of new muscarinic receptor subtype-selective ligands that could prove to be useful for the treatment of many severe pathophysiol. conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnDtWGoryjILVg90H21EOLACvtfcHk0lh9iq6Jm2R9tQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptlOitbc%253D&md5=cc31a22098b5c613afac26df629d2a47</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1038%2Fnrd4295&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4295%26sid%3Dliteratum%253Aachs%26aulast%3DKruse%26aufirst%3DA.%2BC.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26aulast%3DGautam%26aufirst%3DD.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DWess%26aufirst%3DJ.%26atitle%3DMuscarinic%2520acetylcholine%2520receptors%253A%2520novel%2520opportunities%2520for%2520drug%2520development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26issue%3D7%26spage%3D549%26epage%3D560%26doi%3D10.1038%2Fnrd4295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span> <span> </span><span class="NLM_article-title">Subtype-Selective Allosteric modulators of muscarinic receptors for the treatment of CNS disorders</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">148</span>â <span class="NLM_lpage">155</span>, <span class="refDoi">Â DOI: 10.1016/j.tips.2008.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.tips.2008.12.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=19201489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVGguro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=148-155&issue=3&author=P.+J.+Connauthor=C.+K.+Jonesauthor=C.+W.+Lindsley&title=Subtype-Selective+Allosteric+modulators+of+muscarinic+receptors+for+the+treatment+of+CNS+disorders&doi=10.1016%2Fj.tips.2008.12.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders</span></div><div class="casAuthors">Conn, P. Jeffrey; Jones, Carrie K.; Lindsley, Craig W.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">148-155</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Muscarinic acetylcholine receptors (mAChRs) have long been viewed as viable targets for novel therapeutic agents for the treatment of Alzheimer's disease (AD) and other disorders involving impaired cognitive function.  More recent evidence indicates that mAChR activators might also have utility in treating psychosis and other symptoms assocd. with schizophrenia and other central nervous system (CNS) disorders.  Efforts to develop mAChR subtype-selective agonists have been hampered by difficulty in achieving high selectivity for individual mAChR subtypes important for CNS function (M1 and M4) and adverse effects due to activation of peripheral mAChRs (esp. M2 and M3).  Major advances have now been achieved in the discovery of allosteric agonists and pos. allosteric modulators of M1 and M4 that show greater selectivity for individual mAChR subtypes than do previous mAChR agonists.  Early studies indicate that these allosteric mAChR activators have properties needed for optimization as potential clin. candidates and have robust effects in animal models that predict efficacy in the treatment of AD, schizophrenia and related disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn8LX_geAENrVg90H21EOLACvtfcHk0lhBMSNe02E4sA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVGguro%253D&md5=65cf3e1dee603502b5eb72f60a98be98</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2008.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2008.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DJones%26aufirst%3DC.%2BK.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26atitle%3DSubtype-Selective%2520Allosteric%2520modulators%2520of%2520muscarinic%2520receptors%2520for%2520the%2520treatment%2520of%2520CNS%2520disorders%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2009%26volume%3D30%26issue%3D3%26spage%3D148%26epage%3D155%26doi%3D10.1016%2Fj.tips.2008.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ray, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seager, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getty, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marlatt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crouthamel, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sankaranarayananan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graufields, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bickel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posavec, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuduk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sur, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipe, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinney, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascarella, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seabrook, G.</span></span> <span> </span><span class="NLM_article-title">Allosteric potentiation of the M<sub>1</sub> muscarinic receptor provides unprecedented selectivity and a novel therapeutic strategy for the treatment of Alzheimerâs disease</span>. <i>Alzheimer's Dementia</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">T761</span>, <span class="refDoi">Â DOI: 10.1016/j.jalz.2008.05.2375</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.jalz.2008.05.2375" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=T761&issue=4&author=W.+J.+Rayauthor=M.+Seagerauthor=L.+Maauthor=M.+Wittmannauthor=K.+Gettyauthor=M.+Marlattauthor=M.-C.+Crouthamelauthor=G.+Wuauthor=S.+Sankaranarayanananauthor=A.+Simonauthor=M.+Burnoauthor=K.+Jonesauthor=V.+K.+Graufieldsauthor=D.+Bickelauthor=D.+Posavecauthor=J.+Cookauthor=L.+Vengauthor=S.+Kudukauthor=C.+Surauthor=W.+Shipeauthor=C.+Lindsleyauthor=G.+Kinneyauthor=D.+Pascarellaauthor=M.+Jacobsonauthor=G.+Seabrook&title=Allosteric+potentiation+of+the+M1+muscarinic+receptor+provides+unprecedented+selectivity+and+a+novel+therapeutic+strategy+for+the+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.jalz.2008.05.2375"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1016%2Fj.jalz.2008.05.2375&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jalz.2008.05.2375%26sid%3Dliteratum%253Aachs%26aulast%3DRay%26aufirst%3DW.%2BJ.%26aulast%3DSeager%26aufirst%3DM.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DWittmann%26aufirst%3DM.%26aulast%3DGetty%26aufirst%3DK.%26aulast%3DMarlatt%26aufirst%3DM.%26aulast%3DCrouthamel%26aufirst%3DM.-C.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DSankaranarayananan%26aufirst%3DS.%26aulast%3DSimon%26aufirst%3DA.%26aulast%3DBurno%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DK.%26aulast%3DGraufields%26aufirst%3DV.%2BK.%26aulast%3DBickel%26aufirst%3DD.%26aulast%3DPosavec%26aufirst%3DD.%26aulast%3DCook%26aufirst%3DJ.%26aulast%3DVeng%26aufirst%3DL.%26aulast%3DKuduk%26aufirst%3DS.%26aulast%3DSur%26aufirst%3DC.%26aulast%3DShipe%26aufirst%3DW.%26aulast%3DLindsley%26aufirst%3DC.%26aulast%3DKinney%26aufirst%3DG.%26aulast%3DPascarella%26aufirst%3DD.%26aulast%3DJacobson%26aufirst%3DM.%26aulast%3DSeabrook%26aufirst%3DG.%26atitle%3DAllosteric%2520potentiation%2520of%2520the%2520M1%2520muscarinic%2520receptor%2520provides%2520unprecedented%2520selectivity%2520and%2520a%2520novel%2520therapeutic%2520strategy%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DAlzheimer%2527s%2520Dementia%26date%3D2008%26volume%3D4%26issue%3D4%26spage%3DT761%26doi%3D10.1016%2Fj.jalz.2008.05.2375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seager, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bickel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graufelds, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCampbell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaspar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shughrue, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danziger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascarella, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreatsoulas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipe, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuduk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sur, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinney, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seabrook, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, W. J.</span></span> <span> </span><span class="NLM_article-title">Selective activation of the M<sub>1</sub> muscarinic acetylcholine receptor achieved by allosteric potentiation</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span> (<span class="NLM_issue">37</span>),  <span class="NLM_fpage">15950</span>â <span class="NLM_lpage">15955</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0900903106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1073%2Fpnas.0900903106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=19717450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFOqt7nL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=15950-15955&issue=37&author=L.+Maauthor=M.+A.+Seagerauthor=M.+Wittmannauthor=M.+Jacobsonauthor=D.+Bickelauthor=M.+Burnoauthor=K.+Jonesauthor=V.+K.+Graufeldsauthor=G.+Xuauthor=M.+Pearsonauthor=A.+McCampbellauthor=R.+Gasparauthor=P.+Shughrueauthor=A.+Danzigerauthor=C.+Reganauthor=R.+Flickauthor=D.+Pascarellaauthor=S.+Garsonauthor=S.+Doranauthor=C.+Kreatsoulasauthor=L.+Vengauthor=C.+W.+Lindsleyauthor=W.+Shipeauthor=S.+Kudukauthor=C.+Surauthor=G.+Kinneyauthor=G.+R.+Seabrookauthor=W.+J.+Ray&title=Selective+activation+of+the+M1+muscarinic+acetylcholine+receptor+achieved+by+allosteric+potentiation&doi=10.1073%2Fpnas.0900903106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation</span></div><div class="casAuthors">Ma, Lei; Seager, Matthew; Wittmann, Marion; Jacobson, Marlene; Bickel, Denise; Burno, Maryann; Jones, Keith; Graufelds, Valerie Kuzmick; Xu, Guangping; Pearson, Michelle; McCampbell, Alexander; Gaspar, Renee; Shughrue, Paul; Danziger, Andrew; Regan, Christopher; Flick, Rose; Pascarella, Danette; Garson, Susan; Doran, Scott; Kreatsoulas, Constantine; Veng, Lone; Lindsley, Craig W.; Shipe, William; Kuduk, Scott; Sur, Cyrille; Kinney, Gene; Seabrook, Guy R.; Ray, William J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">15950-15955, S15950/1-S15950/9</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The forebrain cholinergic system promotes higher brain function in part by signaling through the M, muscarinic acetylcholine receptor (mAChR).  During Alzheimer's disease (AD), these cholinergic neurons degenerate, therefore selectively activating M1 receptors could improve cognitive function in these patients while avoiding unwanted peripheral responses assocd. with non-selective muscarinic agonists.  We describe here benzyl quinolone carboxylic acid (BQCA), a highly selective allosteric potentiator of the M1 mAChR.  BQCA reduces the concn. of ACh required to activate M1 up to 129-fold with an inflection point value of 845 nM.  No potentiation, agonism, or antagonism activity on other mAChRs is obsd. up to 100 ArM.  Furthermore studies in M1-/- mice demonstrates that BQCA requires M1 to promote inositol phosphate turnover in primary neurons and to increase c-fos and arc RNA expression and ERK phosphorylation in the brain.  Radioligand-binding assays, mol. modeling, and site-directed mutagenesis expts. indicate that BQCA acts at an allosteric site involving residues Y179 and W400.  BQCA reverses scopolamine-induced memory deficits in contextual fear conditioning, increases blood flow to the cerebral cortex, and increases wakefulness while reducing delta sleep.  In contrast to M1 allosteric agonists, which do not improve memory in scopolamine-challenged mice in contextual fear conditioning, BQCA induces 13-arrestin recruitment to M1, suggesting a role for this signal transduction mechanism in the cholinergic modulation of memory.  In summary, BQCA exploits an allosteric potentiation mechanism to provide selectivity for the M1 receptor and represents a promising therapeutic strategy for cognitive disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0SGRL-coGErVg90H21EOLACvtfcHk0lhT472hbyiNfQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFOqt7nL&md5=4470732fd762f761a18d2bc96220dcb1</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0900903106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0900903106%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DL.%26aulast%3DSeager%26aufirst%3DM.%2BA.%26aulast%3DWittmann%26aufirst%3DM.%26aulast%3DJacobson%26aufirst%3DM.%26aulast%3DBickel%26aufirst%3DD.%26aulast%3DBurno%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DK.%26aulast%3DGraufelds%26aufirst%3DV.%2BK.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DPearson%26aufirst%3DM.%26aulast%3DMcCampbell%26aufirst%3DA.%26aulast%3DGaspar%26aufirst%3DR.%26aulast%3DShughrue%26aufirst%3DP.%26aulast%3DDanziger%26aufirst%3DA.%26aulast%3DRegan%26aufirst%3DC.%26aulast%3DFlick%26aufirst%3DR.%26aulast%3DPascarella%26aufirst%3DD.%26aulast%3DGarson%26aufirst%3DS.%26aulast%3DDoran%26aufirst%3DS.%26aulast%3DKreatsoulas%26aufirst%3DC.%26aulast%3DVeng%26aufirst%3DL.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DShipe%26aufirst%3DW.%26aulast%3DKuduk%26aufirst%3DS.%26aulast%3DSur%26aufirst%3DC.%26aulast%3DKinney%26aufirst%3DG.%26aulast%3DSeabrook%26aufirst%3DG.%2BR.%26aulast%3DRay%26aufirst%3DW.%2BJ.%26atitle%3DSelective%2520activation%2520of%2520the%2520M1%2520muscarinic%2520acetylcholine%2520receptor%2520achieved%2520by%2520allosteric%2520potentiation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2009%26volume%3D106%26issue%3D37%26spage%3D15950%26epage%3D15955%26doi%3D10.1073%2Fpnas.0900903106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Canals, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scammells, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span> <span> </span><span class="NLM_article-title">A Monod-Wyman-Changeux mechanism can explain G protein-coupled receptor (GPCR) allosteric modulation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>287</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">650</span>â <span class="NLM_lpage">659</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M111.314278</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1074%2Fjbc.M111.314278" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=22086918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC38XotVGh" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2012&pages=650-659&issue=1&author=M.+Canalsauthor=J.+R.+Laneauthor=A.+Wenauthor=P.+J.+Scammellsauthor=P.+M.+Sextonauthor=A.+Christopoulos&title=A+Monod-Wyman-Changeux+mechanism+can+explain+G+protein-coupled+receptor+%28GPCR%29+allosteric+modulation&doi=10.1074%2Fjbc.M111.314278"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">A Monod-Wyman-Changeux Mechanism Can Explain G Protein-coupled Receptor (GPCR) Allosteric Modulation</span></div><div class="casAuthors">Canals, Meritxell; Lane, J. Robert; Wen, Adriel; Scammells, Peter J.; Sexton, Patrick M.; Christopoulos, Arthur</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">287</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">650-659</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The Monod-Wyman-Changeux (MWC) model was initially proposed to describe the allosteric properties of regulatory enzymes and subsequently extended to receptors.  Yet despite GPCRs representing the largest family of receptors and drug targets, no study has systematically evaluated the MWC mechanism as it applies to GPCR allosteric ligands.  We reveal how the recently described allosteric modulator, benzyl quinolone carboxylic acid (BQCA), behaves according to a strict, two-state MWC mechanism at the M1 muscarinic acetylcholine receptor (mAChR).  Despite having a low affinity for the M1 mAChR, BQCA demonstrated state dependence, exhibiting high pos. cooperativity with orthosteric agonists in a manner that correlated with efficacy but neg. cooperativity with inverse agonists.  The activity of BQCA was significantly increased at a constitutively active M1 mAChR but abolished at an inactive mutant.  Interestingly, BQCA possessed intrinsic signaling efficacy, ranging from near-quiescence to full agonism depending on the coupling efficiency of the chosen intracellular pathway.  This latter cellular property also detd. the difference in magnitude of pos. cooperativity between BQCA and the orthosteric agonist, carbachol, across pathways.  The lack of addnl., pathway-biased, allosteric modulation by BQCA was confirmed in genetically engineered yeast strains expressing different chimeras between the endogenous yeast Gpa1 protein and human GÎ± subunits.  These findings define a chem. biol. framework that can be applied to the study and classification of allosteric modulators across different GPCR families.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrrH0vtUu5lbVg90H21EOLACvtfcHk0lhT472hbyiNfQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotVGh&md5=45d079afd141a137baf24fe171180124</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M111.314278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M111.314278%26sid%3Dliteratum%253Aachs%26aulast%3DCanals%26aufirst%3DM.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26aulast%3DWen%26aufirst%3DA.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DChristopoulos%26aufirst%3DA.%26atitle%3DA%2520Monod-Wyman-Changeux%2520mechanism%2520can%2520explain%2520G%2520protein-coupled%2520receptor%2520%2528GPCR%2529%2520allosteric%2520modulation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2012%26volume%3D287%26issue%3D1%26spage%3D650%26epage%3D659%26doi%3D10.1074%2Fjbc.M111.314278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marlo, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niswender, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Days, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirey, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brady, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nalywajko, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span> <span> </span><span class="NLM_article-title">Discovery and characterization of novel allosteric potentiators of m<sub>1</sub> muscarinic receptors reveals multiple modes of activity</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>75</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">577</span>â <span class="NLM_lpage">588</span>, <span class="refDoi">Â DOI: 10.1124/mol.108.052886</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1124%2Fmol.108.052886" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=19047481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BD1MXis1ajsr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2009&pages=577-588&issue=3&author=J.+E.+Marloauthor=C.+M.+Niswenderauthor=E.+L.+Daysauthor=T.+M.+Bridgesauthor=Y.+Xiangauthor=A.+L.+Rodriguezauthor=J.+K.+Shireyauthor=A.+E.+Bradyauthor=T.+Nalywajkoauthor=Q.+Luoauthor=C.+A.+Austinauthor=M.+B.+Williamsauthor=K.+Kimauthor=R.+Williamsauthor=D.+Ortonauthor=H.+A.+Brownauthor=C.+W.+Lindsleyauthor=C.+D.+Weaverauthor=P.+J.+Conn&title=Discovery+and+characterization+of+novel+allosteric+potentiators+of+m1+muscarinic+receptors+reveals+multiple+modes+of+activity&doi=10.1124%2Fmol.108.052886"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity</span></div><div class="casAuthors">Marlo, Joy E.; Niswender, Colleen M.; Days, Emily L.; Bridges, Thomas M.; Xiang, Yun; Rodriguez, Alice L.; Shirey, Jana K.; Brady, Ashley E.; Nalywajko, Tasha; Luo, Qingwei; Austin, Cheryl A.; Williams, Michael Baxter; Kim, Kwangho; Williams, Richard; Orton, Darren; Brown, H. Alex; Lindsley, Craig W.; Weaver, C. David; Conn, P. Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">577-588</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Activators of M1 muscarinic acetylcholine receptors (mAChRs) may provide novel treatments for schizophrenia and Alzheimer's disease.  Unfortunately, the development of M1-active compds. has resulted in nonselective activation of the highly related M2 to M5 mAChR subtypes, which results in dose-limiting side effects.  Using a functional screening approach, the authors identified several novel ligands that potentiated agonist activation of M1 with low micromolar potencies and induced 5-fold or greater leftward shifts of the acetylcholine (ACh) concn.-response curve.  These ligands did not compete for binding at the ACh binding site, indicating that they modulate receptor activity by binding to allosteric sites.  The two most selective compds., cyclopentyl 1,6-dimethyl-4-(6-nitrobenzo[d][1,3]dioxol-5-yl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (VU0090157) and (E)-2-(4-ethoxyphenylamino)-N'-((2-hydroxynaphthalen-1-yl)methylene)acetohydrazide (VU0029767), induced progressive shifts in ACh affinity at M1 that were consistent with their effects in a functional assay, suggesting that the mechanism for enhancement of M1 activity by these compds. is by increasing agonist affinity.  These compds. were strikingly different, however, in their ability to potentiate responses at a mutant M1 receptor with decreased affinity for ACh and in their ability to affect responses of the allosteric M1 agonist, 1-[1'-(2-tolyl)-1,4'-bipiperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one.  Furthermore, these two compds. were distinct in their abilities to potentiate M1-mediated activation of phosphoinositide hydrolysis and phospholipase D.  The discovery of multiple structurally distinct pos. allosteric modulators of M1 is an exciting advance in establishing the potential of allosteric modulators for selective activation of this receptor.  These data also suggest that structurally diverse M1 potentiators may act by distinct mechanisms and differentially regulate receptor coupling to downstream signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpVs4dgdrjCbVg90H21EOLACvtfcHk0lgdN4C_K4HYBQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXis1ajsr0%253D&md5=deef44340efd29e5719692b255e50665</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1124%2Fmol.108.052886&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.108.052886%26sid%3Dliteratum%253Aachs%26aulast%3DMarlo%26aufirst%3DJ.%2BE.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DDays%26aufirst%3DE.%2BL.%26aulast%3DBridges%26aufirst%3DT.%2BM.%26aulast%3DXiang%26aufirst%3DY.%26aulast%3DRodriguez%26aufirst%3DA.%2BL.%26aulast%3DShirey%26aufirst%3DJ.%2BK.%26aulast%3DBrady%26aufirst%3DA.%2BE.%26aulast%3DNalywajko%26aufirst%3DT.%26aulast%3DLuo%26aufirst%3DQ.%26aulast%3DAustin%26aufirst%3DC.%2BA.%26aulast%3DWilliams%26aufirst%3DM.%2BB.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DWilliams%26aufirst%3DR.%26aulast%3DOrton%26aufirst%3DD.%26aulast%3DBrown%26aufirst%3DH.%2BA.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DWeaver%26aufirst%3DC.%2BD.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520novel%2520allosteric%2520potentiators%2520of%2520m1%2520muscarinic%2520receptors%2520reveals%2520multiple%2520modes%2520of%2520activity%26jtitle%3DMol.%2520Pharmacol.%26date%3D2009%26volume%3D75%26issue%3D3%26spage%3D577%26epage%3D588%26doi%3D10.1124%2Fmol.108.052886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span> </span><span class="NLM_article-title">Efficacy and safety of MK-7622 as adjunct
therapy in participants with Alzheimerâs disease (MK-7622â012)</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National
Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2018</span>; <a href="https://clinicaltrials.gov/ct2/show/NCT01852110" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01852110</a> (accessed Jun 27, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Efficacy+and+safety+of+MK-7622+as+adjunct%0Atherapy+in+participants+with+Alzheimer%E2%80%99s+disease+%28MK-7622%E2%80%93012%29.+ClinicalTrials.gov%3B+U.S.+National%0AInstitutes+of+Health%3A+Bethesda%2C+MD%2C+2018%3B+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01852110+%28accessed+Jun+27%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DEfficacy%2520and%2520safety%2520of%2520MK-7622%2520as%2520adjunct%250Atherapy%2520in%2520participants%2520with%2520Alzheimer%25E2%2580%2599s%2520disease%2520%2528MK-7622%25E2%2580%2593012%2529%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%250AInstitutes%2520of%2520Health%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moran, S.
P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickerson, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maksymetz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remke, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doyle, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajan, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niswender, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engers, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rook, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span> <span> </span><span class="NLM_article-title">M<sub>1</sub>-positive allosteric modulators lacking agonist activity provide the optimal profile for enhancing cognition</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1763</span>â <span class="NLM_lpage">1771</span>, <span class="refDoi">Â DOI: 10.1038/s41386-018-0033-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fs41386-018-0033-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=29581537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Cgt7%252FE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2018&pages=1763-1771&issue=8&author=S.%0AP.+Moranauthor=J.+W.+Dickersonauthor=H.+P.+Choauthor=Z.+Xiangauthor=J.+Maksymetzauthor=D.+H.+Remkeauthor=X.+Lvauthor=C.+A.+Doyleauthor=D.+H.+Rajanauthor=C.+M.+Niswenderauthor=D.+W.+Engersauthor=C.+W.+Lindsleyauthor=J.+M.+Rookauthor=P.+J.+Conn&title=M1-positive+allosteric+modulators+lacking+agonist+activity+provide+the+optimal+profile+for+enhancing+cognition&doi=10.1038%2Fs41386-018-0033-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">M1-positive allosteric modulators lacking agonist activity provide the optimal profile for enhancing cognition</span></div><div class="casAuthors">Moran, Sean P.; Dickerson, Jonathan W.; Cho, Hyekyung P.; Xiang, Zixiu; Maksymetz, James; Remke, Daniel H.; Lv, Xiaohui; Doyle, Catherine A.; Rajan, Deepa H.; Niswender, Colleen M.; Engers, Darren W.; Lindsley, Craig W.; Rook, Jerri M.; Conn, P. Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1763-1771</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Highly selective pos. allosteric modulators (PAMs) of the M1 subtype of muscarinic acetylcholine receptor have emerged as an exciting new approach for improving cognitive function in patients suffering from Alzheimer's disease and schizophrenia.  However, excessive activation of M1 is known to induce seizure activity and have actions in the prefrontal cortex (PFC) that could impair cognitive function.  We now report a series of pharmacol., electrophysiol., and behavioral studies in which we find that recently reported M1 PAMs, PF-06764427 and MK-7622, have robust agonist activity in cell lines and agonist effects in the mouse PFC, and have the potential to overactivate the M1 receptor and disrupt PFC function.  In contrast, structurally distinct M1 PAMs (VU0453595 and VU0550164) are devoid of agonist activity in cell lines and maintain activity dependence of M1 activation in the PFC.  Consistent with the previously reported effect of PF-06764427, the ago-PAM MK-7622 induces severe behavioral convulsions in mice.  In contrast, VU0453595 does not induce behavioral convulsions at doses well above those required for maximal efficacy in enhancing cognitive function.  Furthermore, in contrast to the robust efficacy of VU0453595, the ago-PAM MK-7622 failed to improve novel object recognition, a rodent assay of cognitive function.  These findings suggest that in vivo cognition-enhancing efficacy of M1 PAMs can be obsd. with PAMs lacking intrinsic agonist activity and that intrinsic agonist activity of M1 PAMs may contribute to adverse effects and reduced efficacy in improving cognitive function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoqZdwN9mb1LVg90H21EOLACvtfcHk0lgdN4C_K4HYBQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Cgt7%252FE&md5=1cdf212e1b161858689181afad6a1d61</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1038%2Fs41386-018-0033-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41386-018-0033-9%26sid%3Dliteratum%253Aachs%26aulast%3DMoran%26aufirst%3DS.%2BP.%26aulast%3DDickerson%26aufirst%3DJ.%2BW.%26aulast%3DCho%26aufirst%3DH.%2BP.%26aulast%3DXiang%26aufirst%3DZ.%26aulast%3DMaksymetz%26aufirst%3DJ.%26aulast%3DRemke%26aufirst%3DD.%2BH.%26aulast%3DLv%26aufirst%3DX.%26aulast%3DDoyle%26aufirst%3DC.%2BA.%26aulast%3DRajan%26aufirst%3DD.%2BH.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DEngers%26aufirst%3DD.%2BW.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DRook%26aufirst%3DJ.%2BM.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26atitle%3DM1-positive%2520allosteric%2520modulators%2520lacking%2520agonist%2520activity%2520provide%2520the%2520optimal%2520profile%2520for%2520enhancing%2520cognition%26jtitle%3DNeuropsychopharmacology%26date%3D2018%26volume%3D43%26issue%3D8%26spage%3D1763%26epage%3D1771%26doi%3D10.1038%2Fs41386-018-0033-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davoren, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâNeil, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodney, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chenard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dlugolenski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edgerton, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnsey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimwood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kauffman, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaChapelle, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazzaro, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotarski, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nason, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhart, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salomon-Ferrer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steyn, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span> <span> </span><span class="NLM_article-title">Design and optimization of selective azaindole amide M<sub>1</sub> positive allosteric modulators</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">650</span>â <span class="NLM_lpage">655</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2015.11.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.bmcl.2015.11.053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=26631313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFant73L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=650-655&issue=2&author=J.+E.+Davorenauthor=S.+V.+O%E2%80%99Neilauthor=D.+P.+Andersonauthor=M.+A.+Brodneyauthor=L.+Chenardauthor=K.+Dlugolenskiauthor=J.+R.+Edgertonauthor=M.+Greenauthor=M.+Garnseyauthor=S.+Grimwoodauthor=A.+R.+Harrisauthor=G.+W.+Kauffmanauthor=E.+LaChapelleauthor=J.+T.+Lazzaroauthor=C.+W.+Leeauthor=S.+M.+Lotarskiauthor=D.+M.+Nasonauthor=R.+S.+Obachauthor=V.+Reinhartauthor=R.+Salomon-Ferrerauthor=S.+J.+Steynauthor=D.+Webbauthor=J.+Yanauthor=L.+Zhang&title=Design+and+optimization+of+selective+azaindole+amide+M1+positive+allosteric+modulators&doi=10.1016%2Fj.bmcl.2015.11.053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Design and optimization of selective azaindole amide M1 positive allosteric modulators</span></div><div class="casAuthors">Davoren, Jennifer E.; O'Neil, Steven V.; Anderson, Dennis P.; Brodney, Michael A.; Chenard, Lois; Dlugolenski, Keith; Edgerton, Jeremy R.; Green, Michael; Garnsey, Michelle; Grimwood, Sarah; Harris, Anthony R.; Kauffman, Gregory W.; LaChapelle, Erik; Lazzaro, John T.; Lee, Che-Wah; Lotarski, Susan M.; Nason, Deane M.; Obach, R. Scott; Reinhart, Veronica; Salomon-Ferrer, Romelia; Steyn, Stefanus J.; Webb, Damien; Yan, Jiangli; Zhang, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">650-655</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Selective activation of the M1 receptor via a pos. allosteric modulator (PAM) is a new approach for the treatment of the cognitive impairments assocd. with schizophrenia and Alzheimer's disease.  A novel series of azaindole amides and their key pharmacophore elements are described.  The nitrogen of the azaindole core is a key design element as it forms an intramol. hydrogen bond with the amide N-H thus reinforcing the bioactive conformation predicted by published SAR and the authors' homol. model.  Representative compd. 25 is a potent and selective M1 PAM that has well aligned physicochem. properties, adequate brain penetration and pharmacokinetic (PK) properties, and is active in vivo.  These favorable properties indicate that this series possesses suitable qualities for further development and studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOEhH8MxkKIrVg90H21EOLACvtfcHk0liRfoxIUj5QqQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFant73L&md5=5c227d1371fe4f0cc3348af8314dd370</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.11.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.11.053%26sid%3Dliteratum%253Aachs%26aulast%3DDavoren%26aufirst%3DJ.%2BE.%26aulast%3DO%25E2%2580%2599Neil%26aufirst%3DS.%2BV.%26aulast%3DAnderson%26aufirst%3DD.%2BP.%26aulast%3DBrodney%26aufirst%3DM.%2BA.%26aulast%3DChenard%26aufirst%3DL.%26aulast%3DDlugolenski%26aufirst%3DK.%26aulast%3DEdgerton%26aufirst%3DJ.%2BR.%26aulast%3DGreen%26aufirst%3DM.%26aulast%3DGarnsey%26aufirst%3DM.%26aulast%3DGrimwood%26aufirst%3DS.%26aulast%3DHarris%26aufirst%3DA.%2BR.%26aulast%3DKauffman%26aufirst%3DG.%2BW.%26aulast%3DLaChapelle%26aufirst%3DE.%26aulast%3DLazzaro%26aufirst%3DJ.%2BT.%26aulast%3DLee%26aufirst%3DC.%2BW.%26aulast%3DLotarski%26aufirst%3DS.%2BM.%26aulast%3DNason%26aufirst%3DD.%2BM.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DReinhart%26aufirst%3DV.%26aulast%3DSalomon-Ferrer%26aufirst%3DR.%26aulast%3DSteyn%26aufirst%3DS.%2BJ.%26aulast%3DWebb%26aufirst%3DD.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DDesign%2520and%2520optimization%2520of%2520selective%2520azaindole%2520amide%2520M1%2520positive%2520allosteric%2520modulators%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26issue%3D2%26spage%3D650%26epage%3D655%26doi%3D10.1016%2Fj.bmcl.2015.11.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Popiolek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhart, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edgerton, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harms, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotarski, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steyn, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davoren, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimwood, S.</span></span> <span> </span><span class="NLM_article-title">Inositol phosphate accumulation in vivo provides a measure of muscarinic M<sub>1</sub> receptor activation</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">51</span>),  <span class="NLM_fpage">7073</span>â <span class="NLM_lpage">7085</span>, <span class="refDoi">Â DOI: 10.1021/acs.biochem.6b00688</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.6b00688" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCjt73K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=7073-7085&issue=51&author=M.+Popiolekauthor=D.+P.+Nguyenauthor=V.+Reinhartauthor=J.+R.+Edgertonauthor=J.+Harmsauthor=S.+M.+Lotarskiauthor=S.+J.+Steynauthor=J.+E.+Davorenauthor=S.+Grimwood&title=Inositol+phosphate+accumulation+in+vivo+provides+a+measure+of+muscarinic+M1+receptor+activation&doi=10.1021%2Facs.biochem.6b00688"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Inositol Phosphate Accumulation in Vivo Provides a Measure of Muscarinic M1 Receptor Activation</span></div><div class="casAuthors">Popiolek, Michael; Nguyen, David P.; Reinhart, Veronica; Edgerton, Jeremy R.; Harms, John; Lotarski, Susan M.; Steyn, Stefanus J.; Davoren, Jennifer E.; Grimwood, Sarah</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">7073-7085</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The rationale for using M1 selective muscarinic acetylcholine receptor activators for the treatment of cognitive impairment assocd. with psychiatric and neurodegenerative disease is well-established in the literature.  Here, we investigate measurement of inositol phosphate accumulation, an end point immediately downstream of the M1 muscarinic acetylcholine receptor signaling cascade, as an in vivo biochem. readout for M1 muscarinic acetylcholine receptor activation.  Five brain penetrant M1-subtype selective activators from three structurally distinct chem. series were pharmacol. profiled for functional activity in vitro using recombinant cell calcium mobilization and inositol phosphate assays, and a native tissue hippocampal slice electrophysiol. assay, to show that all five compds. presented a pos. allosteric modulator agonist profile, within a narrow range of potencies.  In vivo characterization using an amphetamine-stimulated locomotor activity behavioral assay and the inositol phosphate accumulation biochem. assay demonstrated that the latter has utility for assessing functional potency of M1 activators.  Efficacy measured by inositol phosphate accumulation in mouse striatum compared favorably to efficacy in reversing amphetamine-induced locomotor activity, suggesting that the inositol phosphate accumulation assay has utility for the evaluation of M1 muscarinic acetylcholine receptor activators in vivo.  The benefits of this in vivo biochem. approach include a wide response window, interrogation of specific brain circuit activation, an ability to model responses in the context of brain exposure, an ability to rank order compds. based on in vivo efficacy, and minimization of animal use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpubNvtFbullrVg90H21EOLACvtfcHk0liRfoxIUj5QqQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCjt73K&md5=ea1c7134941fe3e4d722e469f21385cb</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.6b00688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.6b00688%26sid%3Dliteratum%253Aachs%26aulast%3DPopiolek%26aufirst%3DM.%26aulast%3DNguyen%26aufirst%3DD.%2BP.%26aulast%3DReinhart%26aufirst%3DV.%26aulast%3DEdgerton%26aufirst%3DJ.%2BR.%26aulast%3DHarms%26aufirst%3DJ.%26aulast%3DLotarski%26aufirst%3DS.%2BM.%26aulast%3DSteyn%26aufirst%3DS.%2BJ.%26aulast%3DDavoren%26aufirst%3DJ.%2BE.%26aulast%3DGrimwood%26aufirst%3DS.%26atitle%3DInositol%2520phosphate%2520accumulation%2520in%2520vivo%2520provides%2520a%2520measure%2520of%2520muscarinic%2520M1%2520receptor%2520activation%26jtitle%3DBiochemistry%26date%3D2016%26volume%3D55%26issue%3D51%26spage%3D7073%26epage%3D7085%26doi%3D10.1021%2Facs.biochem.6b00688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rook, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nance, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luscombe, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickerson, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remke, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Barrantes, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engers, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engers, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blobaum, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niswender, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span> <span> </span><span class="NLM_article-title">Diverse effects on M<sub>1</sub> signaling and adverse effect liability within a series of M<sub>1</sub> ago-PAMs</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">866</span>â <span class="NLM_lpage">883</span>, <span class="refDoi">Â DOI: 10.1021/acschemneuro.6b00429</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.6b00429" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFaiurzK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=866-883&issue=4&author=J.+M.+Rookauthor=M.+Abeauthor=H.+P.+Choauthor=K.+D.+Nanceauthor=V.+B.+Luscombeauthor=J.+J.+Adamsauthor=J.+W.+Dickersonauthor=D.+H.+Remkeauthor=P.+M.+Garcia-Barrantesauthor=D.+W.+Engersauthor=J.+L.+Engersauthor=S.+Changauthor=J.+J.+Fosterauthor=A.+L.+Blobaumauthor=C.+M.+Niswenderauthor=C.+K.+Jonesauthor=P.+J.+Connauthor=C.+W.+Lindsley&title=Diverse+effects+on+M1+signaling+and+adverse+effect+liability+within+a+series+of+M1+ago-PAMs&doi=10.1021%2Facschemneuro.6b00429"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Diverse Effects on M1 Signaling and Adverse Effect Liability within a Series of M1 Ago-PAMs</span></div><div class="casAuthors">Rook, Jerri M.; Abe, Masahito; Cho, Hyekyung P.; Nance, Kellie D.; Luscombe, Vincent B.; Adams, Jeffrey J.; Dickerson, Jonathan W.; Remke, Daniel H.; Garcia-Barrantes, Pedro M.; Engers, Darren W.; Engers, Julie L.; Chang, Sichen; Foster, Jarrett J.; Blobaum, Anna L.; Niswender, Colleen M.; Jones, Carrie K.; Conn, P. Jeffrey; Lindsley, Craig W.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">866-883</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Both historical clin. and recent preclin. data suggest that the M1 muscarinic acetylcholine receptor is an exciting target for the treatment of Alzheimer's disease and the cognitive and neg. symptom clusters in schizophrenia; however, early drug discovery efforts targeting the orthosteric binding site have failed to afford selective M1 activation.  Efforts then shifted to focus on selective activation of M1 via either allosteric agonists or pos. allosteric modulators (PAMs).  While M1 PAMs have robust efficacy in rodent models, some chemotypes can induce cholinergic adverse effects (AEs) that could limit their clin. utility.  Here, the authors report studies aimed at understanding the subtle structural and pharmacol. nuances that differentiate efficacy from adverse effect liability within an indole-based series of M1 ago-PAMs.  The authors' data demonstrate that closely related M1 PAMs can display striking differences in their in vivo activities, and esp. their propensities to induce adverse effects.  The authors report the discovery of a novel PAM in this series that is devoid of observable adverse effect liability.  Interestingly, the mol. pharmacol. profile of this novel PAM is similar to that of a representative M1 PAM that induces severe AEs.  For instance, both compds. are potent ago-PAMs that demonstrate significant interaction with the orthosteric site (either bi-topic or neg. cooperativity).  However, there are subtle differences in efficacies of the compds. at potentiating M1 responses, agonist potencies, and abilities to induce receptor internalization.  While these differences may contribute to the differential in vivo profiles of these compds., the in vitro differences are relatively subtle and highlight the complexities of allosteric modulators and the need to focus on in vivo phenotypic screening to identify safe and effective M1 PAMs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTbiEiZmJq3bVg90H21EOLACvtfcHk0liRfoxIUj5QqQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFaiurzK&md5=06d92ac4fccfaf7ea8ff3be807dacdc5</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.6b00429&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.6b00429%26sid%3Dliteratum%253Aachs%26aulast%3DRook%26aufirst%3DJ.%2BM.%26aulast%3DAbe%26aufirst%3DM.%26aulast%3DCho%26aufirst%3DH.%2BP.%26aulast%3DNance%26aufirst%3DK.%2BD.%26aulast%3DLuscombe%26aufirst%3DV.%2BB.%26aulast%3DAdams%26aufirst%3DJ.%2BJ.%26aulast%3DDickerson%26aufirst%3DJ.%2BW.%26aulast%3DRemke%26aufirst%3DD.%2BH.%26aulast%3DGarcia-Barrantes%26aufirst%3DP.%2BM.%26aulast%3DEngers%26aufirst%3DD.%2BW.%26aulast%3DEngers%26aufirst%3DJ.%2BL.%26aulast%3DChang%26aufirst%3DS.%26aulast%3DFoster%26aufirst%3DJ.%2BJ.%26aulast%3DBlobaum%26aufirst%3DA.%2BL.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DJones%26aufirst%3DC.%2BK.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26atitle%3DDiverse%2520effects%2520on%2520M1%2520signaling%2520and%2520adverse%2520effect%2520liability%2520within%2520a%2520series%2520of%2520M1%2520ago-PAMs%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2017%26volume%3D8%26issue%3D4%26spage%3D866%26epage%3D883%26doi%3D10.1021%2Facschemneuro.6b00429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span> </span><span class="NLM_article-title">Putative Cognitive Enhancer VU319</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National
Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2017</span>; <a href="https://www.clinicaltrials.gov/ct2/show/NCT03220295?term=nct03220295&amp;rank=1" class="extLink">https://www.clinicaltrials.gov/ct2/show/NCT03220295?term=nct03220295&rank=1</a> (accessed on July 5, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Putative+Cognitive+Enhancer+VU319.+ClinicalTrials.gov%3B+U.S.+National%0AInstitutes+of+Health%3A+Bethesda%2C+MD%2C+2017%3B+https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT03220295%3Fterm%3Dnct03220295%26rank%3D1+%28accessed+on+July+5%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DPutative%2520Cognitive%2520Enhancer%2520VU319%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%250AInstitutes%2520of%2520Health%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwaid, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornella-Taracido, I.</span></span> <span> </span><span class="NLM_article-title">Causes and significance of increased compound potency in cellular or physiological contexts</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1767</span>â <span class="NLM_lpage">1773</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b00762</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00762" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlCmsrvP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1767-1773&issue=5&author=A.+G.+Schwaidauthor=I.+Cornella-Taracido&title=Causes+and+significance+of+increased+compound+potency+in+cellular+or+physiological+contexts&doi=10.1021%2Facs.jmedchem.7b00762"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Causes and Significance of Increased Compound Potency in Cellular or Physiological Contexts</span></div><div class="casAuthors">Schwaid, Adam G.; Cornella-Taracido, Ivan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1767-1773</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Compd. potency is a key metric that is often used to drive medicinal chem. programs.  Compd. potency is also taken into account when identifying the mechanism of action of compds. whose pharmacol. target is unknown, particularly when these compds. are identified in phenotypic screens.  Often compd. potency is detd. from assays using recombinantly generated, purified protein.  It is well understood in the medicinal chem. community that potency measured with recombinant enzyme and potency measured in cell may not entirely coincide.  Decreases in cellular vs. recombinant potency are often anticipated or explainable.  What is less often realized is that compd. potency can increase in a cellular environment due to several factors including cellular metab. of compds., protein-protein interactions, post-translational modifications, and asym. intracellular localization of compd.  Here the authors discuss these factors and highlight examples where increases in cellular compd. potency were crit. to the development of probes or drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK01NxoWrY9rVg90H21EOLACvtfcHk0li8gJN1iP7AjQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlCmsrvP&md5=faa234aab3bd4a9d9a11ab118128d4f4</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00762%26sid%3Dliteratum%253Aachs%26aulast%3DSchwaid%26aufirst%3DA.%2BG.%26aulast%3DCornella-Taracido%26aufirst%3DI.%26atitle%3DCauses%2520and%2520significance%2520of%2520increased%2520compound%2520potency%2520in%2520cellular%2520or%2520physiological%2520contexts%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D5%26spage%3D1767%26epage%3D1773%26doi%3D10.1021%2Facs.jmedchem.7b00762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bunnage, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hett, E. C.</span></span> <span> </span><span class="NLM_article-title">Know your target, know your molecule</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">368</span>â <span class="NLM_lpage">372</span>, <span class="refDoi">Â DOI: 10.1038/nchembio.1813</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fnchembio.1813" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=25978985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFemtrvK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=368-372&issue=6&author=M.+E.+Bunnageauthor=A.+M.+Gilbertauthor=L.+H.+Jonesauthor=E.+C.+Hett&title=Know+your+target%2C+know+your+molecule&doi=10.1038%2Fnchembio.1813"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Know your target, know your molecule</span></div><div class="casAuthors">Bunnage, Mark E.; Gilbert, Adam M.; Jones, Lyn H.; Hett, Erik C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">368-372</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review. The pharmaceutical industry continues to experience significant attrition of drug candidates during phase 2 proof-of-concept clin. studies.  We describe some questions about the characteristics of protein targets and small-mol. drugs that may be important to consider in drug-discovery projects and could improve prospects for future clin. success.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRthCFSFvOXrVg90H21EOLACvtfcHk0li8gJN1iP7AjQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFemtrvK&md5=f9606135ccea6af432040d8afb630ede</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1813&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1813%26sid%3Dliteratum%253Aachs%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DGilbert%26aufirst%3DA.%2BM.%26aulast%3DJones%26aufirst%3DL.%2BH.%26aulast%3DHett%26aufirst%3DE.%2BC.%26atitle%3DKnow%2520your%2520target%252C%2520know%2520your%2520molecule%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2015%26volume%3D11%26issue%3D6%26spage%3D368%26epage%3D372%26doi%3D10.1038%2Fnchembio.1813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Black, J. W.</span></span> <span> </span><span class="NLM_article-title">A personal view of pharmacology</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">33</span>, <span class="refDoi">Â DOI: 10.1146/annurev.pa.36.040196.000245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1146%2Fannurev.pa.36.040196.000245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=8725380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADyaK28Xis1ertLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1996&pages=1-33&author=J.+W.+Black&title=A+personal+view+of+pharmacology&doi=10.1146%2Fannurev.pa.36.040196.000245"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">A personal view of pharmacology</span></div><div class="casAuthors">Black, James</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-33</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">This essay is an account of the author's experience in trying to interpret the action of drugs as seen in in vitro bioassays.  The central theme is how the development of simple math. models has assisted in the interpretation of drug actions.  Starting from encounters with partial agonists, the essay described the development of an operational model of agonist activity, the significance of receptor distribution, the anal. of indirect competitive antagonism and various two-receptor systems, followed by examples of pharmacol. resultant activity.  Analyses of tissue and species variations are described.  The essay ends with an assessment of the future of bioassay in pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBZnHuCF9EXrVg90H21EOLACvtfcHk0li8gJN1iP7AjQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xis1ertLo%253D&md5=fcf2be6ec8823486522e6adfff5aa6df</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pa.36.040196.000245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pa.36.040196.000245%26sid%3Dliteratum%253Aachs%26aulast%3DBlack%26aufirst%3DJ.%2BW.%26atitle%3DA%2520personal%2520view%2520of%2520pharmacology%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D1996%26volume%3D36%26spage%3D1%26epage%3D33%26doi%3D10.1146%2Fannurev.pa.36.040196.000245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Monod, J.</span></span> <i>Chance and Necessity: An Essay on the Natural Philosophy of Modern Biology</i>; <span class="NLM_publisher-name">Alfred A. Knopf</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">1971</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1971&author=J.+Monod&title=Chance+and+Necessity%3A+An+Essay+on+the+Natural+Philosophy+of+Modern+Biology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMonod%26aufirst%3DJ.%26btitle%3DChance%2520and%2520Necessity%253A%2520An%2520Essay%2520on%2520the%2520Natural%2520Philosophy%2520of%2520Modern%2520Biology%26pub%3DAlfred%2520A.%2520Knopf%26date%3D1971" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':[],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 7 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Yanyun Zhang, Ke Wang, <span class="NLM_string-name hlFld-ContribAuthor">Zhiyi Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Drug Development in Channelopathies: Allosteric Modulation of Ligand-Gated and Voltage-Gated Ion Channels. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (24)
                                     , 15258-15278. <a href="https://doi.org/10.1021/acs.jmedchem.0c01304" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01304</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01304%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDrug%252BDevelopment%252Bin%252BChannelopathies%25253A%252BAllosteric%252BModulation%252Bof%252BLigand-Gated%252Band%252BVoltage-Gated%252BIon%252BChannels%26aulast%3DZhang%26aufirst%3DYanyun%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D27072020%26date%3D30112020%26volume%3D63%26issue%3D24%26spage%3D15258%26epage%3D15278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Bingsong Han, Francesco G. Salituro, <span class="NLM_string-name hlFld-ContribAuthor">Maria-Jesus Blanco</span>. </span><span class="cited-content_cbyCitation_article-title">Impact of Allosteric Modulation in Drug Discovery: Innovation in Emerging Chemical Modalities. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (10)
                                     , 1810-1819. <a href="https://doi.org/10.1021/acsmedchemlett.9b00655" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00655</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00655%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DImpact%252Bof%252BAllosteric%252BModulation%252Bin%252BDrug%252BDiscovery%25253A%252BInnovation%252Bin%252BEmerging%252BChemical%252BModalities%26aulast%3DHan%26aufirst%3DBingsong%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D26122019%26date%3D10032020%26date%3D20032020%26date%3D10032020%26volume%3D11%26issue%3D10%26spage%3D1810%26epage%3D1819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xufen Yu, Xi-Ping Huang, Terry P. Kenakin, Samuel T. Slocum, Xin Chen, Michael L. Martini, Jing Liu, <span class="NLM_string-name hlFld-ContribAuthor">Jian Jin</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Characterization of Ogerin-Based Positive Allosteric Modulators for G Protein-Coupled Receptor 68 (GPR68). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (16)
                                     , 7557-7574. <a href="https://doi.org/10.1021/acs.jmedchem.9b00869" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00869</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00869&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00869%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BCharacterization%252Bof%252BOgerin-Based%252BPositive%252BAllosteric%252BModulators%252Bfor%252BG%252BProtein-Coupled%252BReceptor%252B68%252B%252528GPR68%252529%26aulast%3DYu%26aufirst%3DXufen%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D29052019%26date%3D01082019%26date%3D12072019%26volume%3D62%26issue%3D16%26spage%3D7557%26epage%3D7574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">L.  Maggi</span>, <span class="hlFld-ContribAuthor ">P.  Carloni</span>, <span class="hlFld-ContribAuthor ">G.  Rossetti</span>. </span><span class="cited-content_cbyCitation_article-title">Modeling the allosteric modulation on a G-Protein Coupled Receptor: the case of M2 muscarinic Acetylcholine Receptor in complex with LY211960. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2020,</strong> <em>10 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-020-59289-5" title="DOI URL">https://doi.org/10.1038/s41598-020-59289-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-020-59289-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-020-59289-5%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DModeling%252Bthe%252Ballosteric%252Bmodulation%252Bon%252Ba%252BG-Protein%252BCoupled%252BReceptor%25253A%252Bthe%252Bcase%252Bof%252BM2%252Bmuscarinic%252BAcetylcholine%252BReceptor%252Bin%252Bcomplex%252Bwith%252BLY211960%26aulast%3DMaggi%26aufirst%3DL.%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dario  Doller</span>, <span class="hlFld-ContribAuthor ">Anton  Bespalov</span>, <span class="hlFld-ContribAuthor ">Rob  Miller</span>, <span class="hlFld-ContribAuthor ">Malgorzata  Pietraszek</span>, <span class="hlFld-ContribAuthor ">Mikhail  Kalinichev</span>. </span><span class="cited-content_cbyCitation_article-title">A case study of foliglurax, the first clinical mGluR4 PAM for symptomatic treatment of Parkinsonâs disease: translational gaps or a failing industry innovation model?. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Investigational Drugs</span><span> <strong>2020,</strong> <em>29 </em>
                                    (12)
                                     , 1323-1338. <a href="https://doi.org/10.1080/13543784.2020.1839047" title="DOI URL">https://doi.org/10.1080/13543784.2020.1839047</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543784.2020.1839047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543784.2020.1839047%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Investigational%2520Drugs%26atitle%3DA%252Bcase%252Bstudy%252Bof%252Bfoliglurax%25252C%252Bthe%252Bfirst%252Bclinical%252BmGluR4%252BPAM%252Bfor%252Bsymptomatic%252Btreatment%252Bof%252BParkinson%2525E2%252580%252599s%252Bdisease%25253A%252Btranslational%252Bgaps%252Bor%252Ba%252Bfailing%252Bindustry%252Binnovation%252Bmodel%25253F%26aulast%3DDoller%26aufirst%3DDario%26date%3D2020%26date%3D2020%26volume%3D29%26issue%3D12%26spage%3D1323%26epage%3D1338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuo  Yuan</span>, <span class="hlFld-ContribAuthor ">Bin  Yu</span>, <span class="hlFld-ContribAuthor ">Hong-Min  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">New drug approvals for 2019: Synthesis and clinical applications. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>205 </em>, 112667. <a href="https://doi.org/10.1016/j.ejmech.2020.112667" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112667</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112667%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNew%252Bdrug%252Bapprovals%252Bfor%252B2019%25253A%252BSynthesis%252Band%252Bclinical%252Bapplications%26aulast%3DYuan%26aufirst%3DShuo%26date%3D2020%26volume%3D205%26spage%3D112667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Melissa J.  Buskes</span>, <span class="hlFld-ContribAuthor ">Maria-Jesus  Blanco</span>. </span><span class="cited-content_cbyCitation_article-title">Impact of Cross-Coupling Reactions in Drug Discovery and Development. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (15)
                                     , 3493. <a href="https://doi.org/10.3390/molecules25153493" title="DOI URL">https://doi.org/10.3390/molecules25153493</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25153493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25153493%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DImpact%252Bof%252BCross-Coupling%252BReactions%252Bin%252BDrug%252BDiscovery%252Band%252BDevelopment%26aulast%3DBuskes%26aufirst%3DMelissa%2BJ.%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D15%26spage%3D3493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0034.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/large/jm-2018-01651e_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01651&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/large/jm-2018-01651e_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. PubMed hits from searches related to allosterism in drug discovery (accessed on March 8, 2018).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/large/jm-2018-01651e_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01651&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/large/jm-2018-01651e_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Examples of simulated concentration response curves for an agonist in the presence of saturating concentration of functionally distinct allosteric modulators.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/large/jm-2018-01651e_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01651&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/large/jm-2018-01651e_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Modeling of concentrationâresponse curves (CRCs) for different combinations of Î± and Î² parameters tested under conditions to detect enhancers ((A), [Agonist] = EC<sub>20</sub>) or inhibitors ((B), [Agonist] = EC<sub>80</sub>) of functional response. Additional parameters used are p<i>K</i><sub>A</sub> = 7, p<i>K</i><sub>B</sub> = 7, Ï<sub>A</sub> = 1, Ï<sub>B</sub> = 0, and <i>n</i> = 1.5.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/large/jm-2018-01651e_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01651&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/large/jm-2018-01651e_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Example of an SAR table for developing SAR for a putative set of PAMs using classical parameters versus those in eq 1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/large/jm-2018-01651e_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01651&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/large/jm-2018-01651e_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Comparison of allosteric parameters obtained from the Leach equation on functional readouts from screens using PAM <b>4</b> and either orthosteric agonist <b>5</b> or <b>6</b>. <i>K</i><sub>A</sub> and <i>K</i><sub>B</sub> values are in nM. Graphics obtained using data from ref <a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/large/jm-2018-01651e_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01651&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/large/jm-2018-01651e_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Strategy used to uncover low FS M<sub>1</sub> mAChR PAMs binding to a novel binding site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/large/jm-2018-01651e_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01651&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/large/jm-2018-01651e_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Modulation of efficacy for GABA-evoked Î±4Î²2Î´ and Î±4Î²2Î³2 currents in <i>Xenopus laevis</i> oocytes. Values are relative to efficacies at saturating GABA concentrations. Graphic made with data reported in ref <a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/large/jm-2018-01651e_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01651&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/large/jm-2018-01651e_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Structure activity relationship of a set of oxazolidinones as allosteric modulators of mGluR5 with a range of functional activities. Data from ref <a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/large/jm-2018-01651e_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01651&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/medium/jm-2018-01651e_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/large/jm-2018-01651e_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Free energy versus conformation diagrams (A) Classical system with one active and one inactive protein confirmation and the changes produced by an allosteric ligand (PAM in this case). (B) Model considering a number of conformations, each one providing its own distinct contribution to the global functional response. Addition of an allosteric ligand creates a comparable number of local changes, and the resulting impact on global function.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01651/20190705/images/large/jm-2018-01651e_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01651&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i26">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25383" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25383" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 177 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, S. E.</span></span> <span> </span><span class="NLM_article-title">The daunting polygenicity of mental illness: making a new map</span>. <i>Philos. Trans. R. Soc., B</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>373</i></span> (<span class="NLM_issue">1742</span>),  <span class="NLM_fpage">20170031</span>, <span class="refDoi">Â DOI: 10.1098/rstb.2017.0031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1098%2Frstb.2017.0031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=29352030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFKgs7%252FE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2018&pages=20170031&issue=1742&author=S.+E.+Hyman&title=The+daunting+polygenicity+of+mental+illness%3A+making+a+new+map&doi=10.1098%2Frstb.2017.0031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The daunting polygenicity of mental illness: making a new map</span></div><div class="casAuthors">Hyman, Steven E.</div><div class="citationInfo"><span class="NLM_cas:title">Philosophical Transactions of the Royal Society, B: Biological Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">1742</span>),
    <span class="NLM_cas:pages">20170031/1-20170031/8</span>CODEN:
                <span class="NLM_cas:coden">PTRBAE</span>;
        ISSN:<span class="NLM_cas:issn">0962-8436</span>.
    
            (<span class="NLM_cas:orgname">Royal Society</span>)
        </div><div class="casAbstract">An epochal opportunity to elucidate the pathogenic mechanisms of psychiatric disorders has emerged from advances in genomic technol., new computational tools and the growth of international consortia committed to data sharing.  The resulting large-scale, unbiased genetic studies have begun to yield new biol. insights and with them the hope that a half century of stasis in psychiatric therapeutics will come to an end.  Yet a sobering picture is coming into view; it reveals daunting genetic and phenotypic complexity portending enormous challenges for neurobiol.  Successful exploitation of results from genetics will require eschewal of long-successful reductionist approaches to investigation of gene function, a commitment to supplanting much research now conducted in model organisms with human biol., and development of new exptl. systems and computational models to analyze polygenic causal influences.  In short, psychiatric neuroscience must develop a new scientific map to guide investigation through a polygenic terra incognita.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLIrVkeBu4HrVg90H21EOLACvtfcHk0li-GOR96ZXiGQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFKgs7%252FE&md5=592f73ef0ac028d2d4fc326a276a83be</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1098%2Frstb.2017.0031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1098%252Frstb.2017.0031%26sid%3Dliteratum%253Aachs%26aulast%3DHyman%26aufirst%3DS.%2BE.%26atitle%3DThe%2520daunting%2520polygenicity%2520of%2520mental%2520illness%253A%2520making%2520a%2520new%2520map%26jtitle%3DPhilos.%2520Trans.%2520R.%2520Soc.%252C%2520B%26date%3D2018%26volume%3D373%26issue%3D1742%26spage%3D20170031%26doi%3D10.1098%2Frstb.2017.0031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Disney, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angelbello, A. J.</span></span> <span> </span><span class="NLM_article-title">Rational design of small molecules targeting oncogenic noncoding RNAs from sequence</span>. <i>Acc. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">2698</span>â <span class="NLM_lpage">2704</span>, <span class="refDoi">Â DOI: 10.1021/acs.accounts.6b00326</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.accounts.6b00326" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvV2ht7nJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2016&pages=2698-2704&author=M.+D.+Disneyauthor=A.+J.+Angelbello&title=Rational+design+of+small+molecules+targeting+oncogenic+noncoding+RNAs+from+sequence&doi=10.1021%2Facs.accounts.6b00326"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design of Small Molecules Targeting Oncogenic Noncoding RNAs from Sequence</span></div><div class="casAuthors">Disney, Matthew D.; Angelbello, Alicia J.</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2698-2704</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The discovery of RNA catalysis in the 1980s and the dissemination of the human genome sequence at the start of this century inspired investigations of the regulatory roles of noncoding RNAs in biol.  In fact, the Encyclopedia of DNA Elements (ENCODE) project has shown that only 1-2% of the human genome encodes protein, yet 75% is transcribed into RNA.  Functional studies both preceding and following the ENCODE project have shown that these noncoding RNAs have important roles that regulate gene expression, developmental timing, and other crit. functions.  RNA's diverse roles are often a consequence of the various folds that it adopts.  The single stranded nature of the biopolymer enables it to adopt intramol. folds with noncanonical pairings to lower its free energy (Figure ).  These folds can be scaffolds to bind proteins or to form frameworks to interact with other RNAs.  Not surprisingly, dysregulation of certain noncoding RNAs has been shown to be causative of disease.  Given this as a background, it is easy to see why it would be useful to develop methods to target RNA and manipulate its biol. in rational and predictable ways.  The antisense approach has afforded strategies to target RNAs via Watson-Crick based pairing and has typically focused on targeting partially unstructured regions of RNA.  Small mol. strategies to target RNA would be desirable, not only because compds. could be lead optimized via medicinal chem., but also because structured regions within an RNA of interest could be targeted in order to directly interfere with RNA folds that contribute to disease.  Addnl., small mols. have historically been the most successful drug candidates.  Until recently, the ability to design small mols. that target nonrRNAs has been elusive, creating the perception that they are "undruggable".  In this Account, approaches to demystify targeting RNA with small mols. are described.  Rather than bulk screening for compds. that bind to singular targets, which is the purview of the pharmaceutical industry and academic institutions with high throughput screening facilities, we focus on methods that allow for the rational design of small mols. toward biol. RNAs.  Enabling and foundational technologies that have been developed include two-dimensional combinatorial screening (2DCS), a library-vs.-library selection approach that allows the identification of the RNA motif binding preferences of small mols. from millions of combinations.  A landscape map of the 2DCS-defined and annotated RNA motif-small mol. interactions is then placed into Inforna, a computational tool that allows one to mine these interactions against an RNA of interest or an entire transcriptome.  Indeed, this approach has been enabled by tools to annotate RNA structure from sequence-an invaluable asset to the RNA community and this work-and has allowed for the rational identification of "druggable" RNAs in a target agnostic fashion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU-8j6q0xYYrVg90H21EOLACvtfcHk0li-GOR96ZXiGQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvV2ht7nJ&md5=14a75becddc19fd360e9b5dbd94eec48</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Facs.accounts.6b00326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.accounts.6b00326%26sid%3Dliteratum%253Aachs%26aulast%3DDisney%26aufirst%3DM.%2BD.%26aulast%3DAngelbello%26aufirst%3DA.%2BJ.%26atitle%3DRational%2520design%2520of%2520small%2520molecules%2520targeting%2520oncogenic%2520noncoding%2520RNAs%2520from%2520sequence%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2016%26volume%3D49%26spage%3D2698%26epage%3D2704%26doi%3D10.1021%2Facs.accounts.6b00326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stott, K.</span></span> <span> </span><span class="NLM_article-title">Pharmaâs broken business modelâPart 2: Scraping the barrel in drug discovery</span>.  <i>Endpoints News</i>; <span class="NLM_publisher-name">Endpoints Company</span>, May 2, 2018; <a href="https://endpts.com/pharmas-broken-business-model-part-2-scraping-the-barrel-in-drug-discovery/" class="extLink">https://endpts.com/pharmas-broken-business-model-part-2-scraping-the-barrel-in-drug-discovery/</a> Accessed on May 5, 2018.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Stott%2C+K.+Pharma%E2%80%99s+broken+business+model%E2%80%94Part+2%3A+Scraping+the+barrel+in+drug+discovery.+Endpoints+News%3B+Endpoints+Company%2C+May+2%2C+2018%3B+https%3A%2F%2Fendpts.com%2Fpharmas-broken-business-model-part-2-scraping-the-barrel-in-drug-discovery%2F+Accessed+on+May+5%2C+2018."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3DStott%26aufirst%3DK.%26atitle%3DPharma%25E2%2580%2599s%2520broken%2520business%2520model%25E2%2580%2594Part%25202%253A%2520Scraping%2520the%2520barrel%2520in%2520drug%2520discovery%26jtitle%3DEndpoints%2520News%26pub%3DEndpoints%2520Company" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Edfeldt, F. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folmer, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breeze, A. L.</span></span> <span> </span><span class="NLM_article-title">Fragment screening to predict druggability (ligandability) and lead discovery success</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">7â8</span>),  <span class="NLM_fpage">284</span>â <span class="NLM_lpage">287</span>, <span class="refDoi">Â DOI: 10.1016/j.drudis.2011.02.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.drudis.2011.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=21315179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3MXksFemsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=284-287&issue=7%E2%80%938&author=F.+N.+Edfeldtauthor=R.+H.+Folmerauthor=A.+L.+Breeze&title=Fragment+screening+to+predict+druggability+%28ligandability%29+and+lead+discovery+success&doi=10.1016%2Fj.drudis.2011.02.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment screening to predict druggability (ligandability) and lead discovery success</span></div><div class="casAuthors">Edfeldt, Fredrik N. B.; Folmer, Rutger H. A.; Breeze, Alexander L.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7/8</span>),
    <span class="NLM_cas:pages">284-287</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">This article discusses the use of fragment screening to predict ligandability which will be of great interest to the pharmaceutical industry.  Data presented in this article clearly show how fragment-based ligandability screening can be used in a truly predictive fashion and could be a powerful tool in reducing agent attrition by filtering out non-ligandable targets before entry into the portfolio.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSXfOy9wAHFLVg90H21EOLACvtfcHk0lgM9DSXPNdtpg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXksFemsbs%253D&md5=7ba5adfe3d6a1eb4c9eaa3ce42c60044</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2011.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2011.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DEdfeldt%26aufirst%3DF.%2BN.%26aulast%3DFolmer%26aufirst%3DR.%2BH.%26aulast%3DBreeze%26aufirst%3DA.%2BL.%26atitle%3DFragment%2520screening%2520to%2520predict%2520druggability%2520%2528ligandability%2529%2520and%2520lead%2520discovery%2520success%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26issue%3D7%25E2%2580%25938%26spage%3D284%26epage%3D287%26doi%3D10.1016%2Fj.drudis.2011.02.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Valeur, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimonet, P.</span></span> <span> </span><span class="NLM_article-title">New modalities, technologies, and partnerships in probe and lead generation: enabling a mode-of-action centric paradigm</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">9004</span>â <span class="NLM_lpage">9029</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b00378</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00378" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVGjs77P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9004-9029&issue=20&author=E.+Valeurauthor=P.+Jimonet&title=New+modalities%2C+technologies%2C+and+partnerships+in+probe+and+lead+generation%3A+enabling+a+mode-of-action+centric+paradigm&doi=10.1021%2Facs.jmedchem.8b00378"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">New Modalities, Technologies, and Partnerships in Probe and Lead Generation: Enabling a Mode-of-Action Centric Paradigm</span></div><div class="casAuthors">Valeur, Eric; Jimonet, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9004-9029</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">With the rise of novel biol. and high potential target identification technologies originating from advances in genomics, medicinal chemists are progressively facing targets of increasing complexity and often unprecedented.  Novel hit finding technologies, combined with a wider choice of drug modalities, has resulted in a unique repertoire of options to address these challenging targets and to identify suitable starting points for optimization.  Furthermore, innovative solns. originating from a range of academic groups and biotech companies require new types of collaborative models to leverage and integrate them in the drug discovery process.  This perspective provides a guide for medicinal chemists covering contemporary probe and lead generation approaches and discusses the strengths and limitations of each strategy.  Moreover, the expansion of strategies to modulate proteins creates the opportunity of a modality-agnostic and mode-of-action centric hit finding paradigm.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS8l5d3NOahrVg90H21EOLACvtfcHk0lgM9DSXPNdtpg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVGjs77P&md5=62e768509dac90567f3f021ed83b1df1</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00378&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00378%26sid%3Dliteratum%253Aachs%26aulast%3DValeur%26aufirst%3DE.%26aulast%3DJimonet%26aufirst%3DP.%26atitle%3DNew%2520modalities%252C%2520technologies%252C%2520and%2520partnerships%2520in%2520probe%2520and%2520lead%2520generation%253A%2520enabling%2520a%2520mode-of-action%2520centric%2520paradigm%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D20%26spage%3D9004%26epage%3D9029%26doi%3D10.1021%2Facs.jmedchem.8b00378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naylor, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bockus, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanco, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lokey, R. S.</span></span> <span> </span><span class="NLM_article-title">Cyclic peptide natural products chart the frontier of oral bioavailability in the pursuit of undruggable targets</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">141</span>â <span class="NLM_lpage">147</span>, <span class="refDoi">Â DOI: 10.1016/j.cbpa.2017.04.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.cbpa.2017.04.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=28570865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2sXovVSgsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2017&pages=141-147&author=M.+R.+Naylorauthor=A.+T.+Bockusauthor=M.+J.+Blancoauthor=R.+S.+Lokey&title=Cyclic+peptide+natural+products+chart+the+frontier+of+oral+bioavailability+in+the+pursuit+of+undruggable+targets&doi=10.1016%2Fj.cbpa.2017.04.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclic peptide natural products chart the frontier of oral bioavailability in the pursuit of undruggable targets</span></div><div class="casAuthors">Naylor, Matthew R.; Bockus, Andrew T.; Blanco, Maria-Jesus; Lokey, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">141-147</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">As interest in protein-protein interactions and other previously-undruggable targets increases, medicinal chemists are returning to natural products for design inspiration toward mols. that transcend the paradigm of small mol. drugs.  These compds., esp. peptides, often have poor ADME properties and thus require a more nuanced understanding of structure-property relationships to achieve desirable oral bioavailability.  Although there have been few clin. successes in this chem. space to date, recent work has identified opportunities to introduce favorable physicochem. properties to peptidic macrocycles that maintain activity and oral bioavailability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoanPrD1D-ePrVg90H21EOLACvtfcHk0lgM9DSXPNdtpg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXovVSgsLw%253D&md5=175671ba338608979d38d340866df885</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2017.04.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2017.04.012%26sid%3Dliteratum%253Aachs%26aulast%3DNaylor%26aufirst%3DM.%2BR.%26aulast%3DBockus%26aufirst%3DA.%2BT.%26aulast%3DBlanco%26aufirst%3DM.%2BJ.%26aulast%3DLokey%26aufirst%3DR.%2BS.%26atitle%3DCyclic%2520peptide%2520natural%2520products%2520chart%2520the%2520frontier%2520of%2520oral%2520bioavailability%2520in%2520the%2520pursuit%2520of%2520undruggable%2520targets%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2017%26volume%3D38%26spage%3D141%26epage%3D147%26doi%3D10.1016%2Fj.cbpa.2017.04.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neklesa, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Targeted protein degradation by PROTACs</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">138</span>â <span class="NLM_lpage">144</span>, <span class="refDoi">Â DOI: 10.1016/j.pharmthera.2017.02.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.pharmthera.2017.02.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=28223226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtVemsbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2017&pages=138-144&author=T.+K.+Neklesaauthor=J.+D.+Winklerauthor=C.+M.+Crews&title=Targeted+protein+degradation+by+PROTACs&doi=10.1016%2Fj.pharmthera.2017.02.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted protein degradation by PROTACs</span></div><div class="casAuthors">Neklesa, Taavi K.; Winkler, James D.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">138-144</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Targeted protein degrdn. using the PROTAC technol. is emerging as a novel therapeutic method to address diseases driven by the aberrant expression of a disease-causing protein.  PROTAC mols. are bifunctional small mols. that simultaneously bind a target protein and an E3-ubiquitin ligase, thus causing ubiquitination and degrdn. of the target protein by the proteasome.  Like small mols., PROTAC mols. possess good tissue distribution and the ability to target intracellular proteins.  Herein, we highlight the advantages of protein degrdn. using PROTACs, and provide specific examples where degrdn. offers therapeutic benefit over classical enzyme inhibition.  Foremost, PROTACs can degrade proteins regardless of their function.  This includes the currently "undruggable" proteome, which comprises approx. 85% of all human proteins.  Other beneficial aspects of protein degrdn. include the ability to target overexpressed and mutated proteins, as well as the potential to demonstrate prolonged pharmacodynamics effect beyond drug exposure.  Lastly, due to their catalytic nature and the pre-requisite ubiquitination step, an exquisitely potent mols. with a high degree of degrdn. selectivity can be designed.  Impressive preclin. in vitro and in vivo PROTAC data have been published, and these data have propelled the development of clin. viable PROTACs.  With the mol. wt. falling in the 700-1000 Da range, the delivery and bioavailability of PROTACs remain the largest hurdles on the way to the clinic.  Solving these issues and demonstrating proof of concept clin. data will be the focus of many labs over the next few years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4RSLWYqqBMrVg90H21EOLACvtfcHk0lh3f3FCp-rz7Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtVemsbg%253D&md5=08a74402a274a13c8c484cd68167a5a1</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2017.02.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2017.02.027%26sid%3Dliteratum%253Aachs%26aulast%3DNeklesa%26aufirst%3DT.%2BK.%26aulast%3DWinkler%26aufirst%3DJ.%2BD.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DTargeted%2520protein%2520degradation%2520by%2520PROTACs%26jtitle%3DPharmacol.%2520Ther.%26date%3D2017%26volume%3D174%26spage%3D138%26epage%3D144%26doi%3D10.1016%2Fj.pharmthera.2017.02.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kung, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hixon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosinski, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cianchetta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Histen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Si, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeLaBarre, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popovici-Muller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salituro, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, L.</span></span> <span> </span><span class="NLM_article-title">AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>130</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1347</span>â <span class="NLM_lpage">1356</span>, <span class="refDoi">Â DOI: 10.1182/blood-2016-11-753525</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1182%2Fblood-2016-11-753525" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=28760888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFWjtLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2017&pages=1347-1356&issue=11&author=C.+Kungauthor=J.+Hixonauthor=P.+A.+Kosinskiauthor=G.+Cianchettaauthor=G.+Histenauthor=Y.+Chenauthor=C.+Hillauthor=S.+Grossauthor=Y.+Siauthor=K.+Johnsonauthor=B.+DeLaBarreauthor=Z.+Luoauthor=Z.+Guauthor=G.+Yaoauthor=H.+Tangauthor=C.+Fangauthor=Y.+Xuauthor=X.+Lvauthor=S.+Billerauthor=S.+M.+Suauthor=H.+Yangauthor=J.+Popovici-Mullerauthor=F.+Salituroauthor=L.+Silvermanauthor=L.+Dang&title=AG-348+enhances+pyruvate+kinase+activity+in+red+blood+cells+from+patients+with+pyruvate+kinase+deficiency&doi=10.1182%2Fblood-2016-11-753525"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency</span></div><div class="casAuthors">Kung, Charles; Hixon, Jeff; Kosinski, Penelope A.; Cianchetta, Giovanni; Histen, Gavin; Chen, Yue; Hill, Collin; Gross, Stefan; Si, Yaguang; Johnson, Kendall; De La Barre, Byron; Luo, Zhiyong; Gu, Zhiwei; Yao, Gui; Tang, Huachun; Fang, Cheng; Xu, Yingxia; Lv, Xiaobing; Biller, Scott; Su, Shin-San Michael; Yang, Hua; Popovici-Muller, Janeta; Salituro, Francesco; Silverman, Lee; Dang, Lenny</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1347-1356</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Pyruvate kinase (PK) deficiency is a rare genetic disease that causes chronic hemolytic anemia.  There are currently no targeted therapies for PK deficiency.  Here, we describe the identification and characterization of AG-348, an allosteric activator of PK that is currently in clin. trials for the treatment of PK deficiency.  We demonstrate that AG-348 can increase the activity of wild type and mutant PK enzymes in biochem. assays and in patient red blood cells treated ex vivo.  These data illustrate the potential for AG-348 to restore the glycolytic pathway activity in patients with PK deficiency and ultimately lead to clin. benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZFATqt6c8wbVg90H21EOLACvtfcHk0lh3f3FCp-rz7Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFWjtLk%253D&md5=1f35e40cdcecaebddc4962213273c857</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-11-753525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-11-753525%26sid%3Dliteratum%253Aachs%26aulast%3DKung%26aufirst%3DC.%26aulast%3DHixon%26aufirst%3DJ.%26aulast%3DKosinski%26aufirst%3DP.%2BA.%26aulast%3DCianchetta%26aufirst%3DG.%26aulast%3DHisten%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DHill%26aufirst%3DC.%26aulast%3DGross%26aufirst%3DS.%26aulast%3DSi%26aufirst%3DY.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DDeLaBarre%26aufirst%3DB.%26aulast%3DLuo%26aufirst%3DZ.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DYao%26aufirst%3DG.%26aulast%3DTang%26aufirst%3DH.%26aulast%3DFang%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DLv%26aufirst%3DX.%26aulast%3DBiller%26aufirst%3DS.%26aulast%3DSu%26aufirst%3DS.%2BM.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DPopovici-Muller%26aufirst%3DJ.%26aulast%3DSalituro%26aufirst%3DF.%26aulast%3DSilverman%26aufirst%3DL.%26aulast%3DDang%26aufirst%3DL.%26atitle%3DAG-348%2520enhances%2520pyruvate%2520kinase%2520activity%2520in%2520red%2520blood%2520cells%2520from%2520patients%2520with%2520pyruvate%2520kinase%2520deficiency%26jtitle%3DBlood%26date%3D2017%26volume%3D130%26issue%3D11%26spage%3D1347%26epage%3D1356%26doi%3D10.1182%2Fblood-2016-11-753525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pardridge, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boado, R. J.</span></span> <span> </span><span class="NLM_article-title">Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier</span>. <i>Methods Enzymol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>503</i></span>,  <span class="NLM_fpage">269</span>â <span class="NLM_lpage">292</span>, <span class="refDoi">Â DOI: 10.1016/B978-0-12-396962-0.00011-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2FB978-0-12-396962-0.00011-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=22230573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC38Xkt1CjsLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=503&publication_year=2012&pages=269-292&author=W.+M.+Pardridgeauthor=R.+J.+Boado&title=Reengineering+biopharmaceuticals+for+targeted+delivery+across+the+blood-brain+barrier&doi=10.1016%2FB978-0-12-396962-0.00011-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier</span></div><div class="casAuthors">Pardridge, William M.; Boado, Ruben J.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">503</span>
        (<span class="NLM_cas:issue">Protein Engineering for Therapeutics, Part B</span>),
    <span class="NLM_cas:pages">269-292</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Recombinant protein therapeutics cannot enter brain drug development because these large mol. drugs do not cross the blood-brain barrier (BBB).  However, recombinant proteins can be reengineered as BBB-penetrating IgG fusion proteins, where the IgG part is a genetically engineered monoclonal antibody (MAb) against an endogenous BBB receptor, such as the human insulin receptor (HIR) or the transferrin receptor (TfR).  The IgG binds the endogenous insulin receptor or TfR to trigger transport across the BBB and acts as a mol. Trojan horse (MTH) to ferry into brain the fused protein therapeutic.  The most potent MTH to date is a MAb against the HIR, designated the HIRMAb, which is active in humans and Old World primates, such as the Rhesus monkey.  There is no known MAb against the mouse insulin receptor.  For drug delivery in the mouse, protein therapeutics are fused to a chimeric MAb against the mouse TfR, designated the cTfRMAb.  The HIRMAb or cTfRMAb Trojan horses have been engineered and expressed as fusion proteins with multiple classes of protein therapeutics, including lysosomal enzymes, neurotrophins, decoy receptors, single chain Fv therapeutic antibodies, and avidin.  The pharmacokinetic (PK) properties of the IgG fusion proteins differ from that of typical MAb drugs and resemble the PK profiles of small mols. due to rapid uptake by peripheral tissues, as well as brain.  The brain uptake of the IgG fusion proteins, 2-3% of injected dose/brain, is comparable to the brain uptake of small mols.  The IgG fusion proteins have been administered chronically in mouse models, and the immune response is low titer and has no effect on the fusion protein clearance from blood or brain uptake in vivo.  The BBB MTH technol. enables the reengineering of a wide spectrum of recombinant protein therapeutics for targeted drug delivery to the brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjkLRy2RahB7Vg90H21EOLACvtfcHk0lh3f3FCp-rz7Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xkt1CjsLc%253D&md5=38cb8b5131ba1251ba3997bc1d5160e4</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-396962-0.00011-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-396962-0.00011-2%26sid%3Dliteratum%253Aachs%26aulast%3DPardridge%26aufirst%3DW.%2BM.%26aulast%3DBoado%26aufirst%3DR.%2BJ.%26atitle%3DReengineering%2520biopharmaceuticals%2520for%2520targeted%2520delivery%2520across%2520the%2520blood-brain%2520barrier%26jtitle%3DMethods%2520Enzymol.%26date%3D2012%26volume%3D503%26spage%3D269%26epage%3D292%26doi%3D10.1016%2FB978-0-12-396962-0.00011-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Panowski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhakta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raab, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polakis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Junutula, J. R.</span></span> <span> </span><span class="NLM_article-title">Site-specific antibody drug conjugates for cancer therapy</span>. <i>MAbs.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">34</span>â <span class="NLM_lpage">45</span>, <span class="refDoi">Â DOI: 10.4161/mabs.27022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.4161%2Fmabs.27022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=24423619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A280%3ADC%252BC2cvnslaltw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=34-45&issue=1&author=S.+Panowskiauthor=S.+Bhaktaauthor=H.+Raabauthor=P.+Polakisauthor=J.+R.+Junutula&title=Site-specific+antibody+drug+conjugates+for+cancer+therapy&doi=10.4161%2Fmabs.27022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Site-specific antibody drug conjugates for cancer therapy</span></div><div class="casAuthors">Panowski Siler; Bhakta Sunil; Raab Helga; Polakis Paul; Junutula Jagath R</div><div class="citationInfo"><span class="NLM_cas:title">mAbs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">34-45</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Antibody therapeutics have revolutionized the treatment of cancer over the past two decades.  Antibodies that specifically bind tumor surface antigens can be effective therapeutics; however, many unmodified antibodies lack therapeutic activity.  These antibodies can instead be applied successfully as guided missiles to deliver potent cytotoxic drugs in the form of antibody drug conjugates (ADCs).  The success of ADCs is dependent on four factors--target antigen, antibody, linker, and payload.  The field has made great progress in these areas, marked by the recent approval by the US Food and Drug Administration of two ADCs, brentuximab vedotin (Adcetris) and ado-trastuzumab emtansine (Kadcyla).  However, the therapeutic window for many ADCs that are currently in pre-clinical or clinical development remains narrow and further improvements may be required to enhance the therapeutic potential of these ADCs.  Production of ADCs is an area where improvement is needed because current methods yield heterogeneous mixtures that may include 0-8 drug species per antibody molecule.  Site-specific conjugation has been recently shown to eliminate heterogeneity, improve conjugate stability, and increase the therapeutic window.  Here, we review and describe various site-specific conjugation strategies that are currently used for the production of ADCs, including use of engineered cysteine residues, unnatural amino acids, and enzymatic conjugation through glycotransferases and transglutaminases.  In addition, we also summarize differences among these methods and highlight critical considerations when building next-generation ADC therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQXMRlj6bTH0hOk4JA3soTqfW6udTcc2eY8YR5FU_zBDbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cvnslaltw%253D%253D&md5=9da883692122c03303f785e61f6c5db7</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.4161%2Fmabs.27022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fmabs.27022%26sid%3Dliteratum%253Aachs%26aulast%3DPanowski%26aufirst%3DS.%26aulast%3DBhakta%26aufirst%3DS.%26aulast%3DRaab%26aufirst%3DH.%26aulast%3DPolakis%26aufirst%3DP.%26aulast%3DJunutula%26aufirst%3DJ.%2BR.%26atitle%3DSite-specific%2520antibody%2520drug%2520conjugates%2520for%2520cancer%2520therapy%26jtitle%3DMAbs.%26date%3D2014%26volume%3D6%26issue%3D1%26spage%3D34%26epage%3D45%26doi%3D10.4161%2Fmabs.27022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Changeux, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span> <span> </span><span class="NLM_article-title">Allosteric modulation as a unifying mechanism for receptor function and regulation</span>. <i>Diabetes, Obes. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">4</span>â <span class="NLM_lpage">21</span>, <span class="refDoi">Â DOI: 10.1111/dom.12959</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1111%2Fdom.12959" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=28880476" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVGhsrjJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=4-21&author=J.-P.+Changeuxauthor=A.+Christopoulos&title=Allosteric+modulation+as+a+unifying+mechanism+for+receptor+function+and+regulation&doi=10.1111%2Fdom.12959"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric modulation as a unifying mechanism for receptor function and regulation</span></div><div class="casAuthors">Changeux, Jean-Pierre; Christopoulos, Arthur</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes, Obesity and Metabolism</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">S1</span>),
    <span class="NLM_cas:pages">4-21</span>CODEN:
                <span class="NLM_cas:coden">DOMEF6</span>;
        ISSN:<span class="NLM_cas:issn">1462-8902</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Four major receptor families enable cells to respond to chem. and phys. signals from their proximal environment.  The ligand- and voltage-gated ion channels, G-protein-coupled receptors, nuclear hormone receptors and receptor tyrosine kinases are all allosteric proteins that carry multiple, spatially distinct, yet conformationally linked ligand-binding sites.  Recent studies point to common mechanisms governing the allosteric transitions of these receptors, including the impact of oligomerization, pre-existing and functionally distinct conformational ensembles, intrinsically disordered regions, and the occurrence of allosteric modulatory sites.  Importantly, synthetic allosteric modulators are being discovered for these receptors, providing an enriched, yet challenging, landscape for novel therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprPiSFlez82bVg90H21EOLACvtfcHk0lipjSuI5CwbJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVGhsrjJ&md5=b36387593f7f407b7f78266989a4e4d9</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1111%2Fdom.12959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fdom.12959%26sid%3Dliteratum%253Aachs%26aulast%3DChangeux%26aufirst%3DJ.-P.%26aulast%3DChristopoulos%26aufirst%3DA.%26atitle%3DAllosteric%2520modulation%2520as%2520a%2520unifying%2520mechanism%2520for%2520receptor%2520function%2520and%2520regulation%26jtitle%3DDiabetes%252C%2520Obes.%2520Metab.%26date%3D2017%26volume%3D19%26spage%3D4%26epage%3D21%26doi%3D10.1111%2Fdom.12959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foster, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span> <span> </span><span class="NLM_article-title">Allosteric Modulation of GPCRs: new insights and potential utility for treatment of schizophrenia and other CNS disorders</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>94</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">431</span>â <span class="NLM_lpage">446</span>, <span class="refDoi">Â DOI: 10.1016/j.neuron.2017.03.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.neuron.2017.03.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=28472649" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntFeltbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2017&pages=431-446&issue=3&author=D.+J.+Fosterauthor=P.+J.+Conn&title=Allosteric+Modulation+of+GPCRs%3A+new+insights+and+potential+utility+for+treatment+of+schizophrenia+and+other+CNS+disorders&doi=10.1016%2Fj.neuron.2017.03.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Modulation of GPCRs: New Insights and Potential Utility for Treatment of Schizophrenia and Other CNS Disorders</span></div><div class="casAuthors">Foster, Daniel J.; Conn, P. Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">431-446</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">G-protein-coupled receptors (GPCRs) play crit. roles in regulating brain function.  Recent advances have greatly expanded our understanding of these receptors as complex signaling machines that can adopt numerous conformations and modulate multiple downstream signaling pathways.  While agonists and antagonists have traditionally been pursued to target GPCRs, allosteric modulators provide several mechanistic advantages, including the ability to distinguish between closely related receptor subtypes.  Recently, the discovery of allosteric ligands that confer bias and modulate some, but not all, of a given receptor's downstream signaling pathways can provide pharmacol. modulation of brain circuitry with remarkable precision.  In addn., allosteric modulators with unprecedented specificity have been developed that can differentiate between subpopulations of a given receptor subtype based on the receptor's dimerization state.  These advances are not only providing insight into the biol. roles of specific receptor populations, but hold great promise for treating numerous CNS disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosB9i2AL3HjbVg90H21EOLACvtfcHk0lipjSuI5CwbJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntFeltbY%253D&md5=8769a88b9afd7df7516eddcba05af805</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.neuron.2017.03.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuron.2017.03.016%26sid%3Dliteratum%253Aachs%26aulast%3DFoster%26aufirst%3DD.%2BJ.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26atitle%3DAllosteric%2520Modulation%2520of%2520GPCRs%253A%2520new%2520insights%2520and%2520potential%2520utility%2520for%2520treatment%2520of%2520schizophrenia%2520and%2520other%2520CNS%2520disorders%26jtitle%3DNeuron%26date%3D2017%26volume%3D94%26issue%3D3%26spage%3D431%26epage%3D446%26doi%3D10.1016%2Fj.neuron.2017.03.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flor, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acher, F. C.</span></span> <span> </span><span class="NLM_article-title">Orthosteric versus allosteric GPCR activation: the great challenge of group-III mGluRs</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>84</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">414</span>â <span class="NLM_lpage">424</span>, <span class="refDoi">Â DOI: 10.1016/j.bcp.2012.04.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.bcp.2012.04.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=22554564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvFKlsLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2012&pages=414-424&issue=4&author=P.+J.+Florauthor=F.+C.+Acher&title=Orthosteric+versus+allosteric+GPCR+activation%3A+the+great+challenge+of+group-III+mGluRs&doi=10.1016%2Fj.bcp.2012.04.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Orthosteric versus allosteric GPCR activation: The great challenge of group-III mGluRs</span></div><div class="casAuthors">Flor, Peter J.; Acher, Francine C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">414-424</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Group-III metabotropic glutamate receptors (mGluRs) comprise four structurally related brain and retinal G protein-coupled receptors (GPCRs), mGluR4, mGluR6, mGluR7 and mGluR8, which receive much attention as promising targets for nervous system drugs.  In particular, activation of mGluR4 is a major focus for the development of new therapeutics in Parkinson's disease, while mGluR7 activation is considered a potential approach for future treatments of specific psychiatric conditions.  The first generation group-III mGluR agonists, e.g.L-AP4 and L-SOP, are characterized by an essential phosphonate functional group, which became a major limitation for the development of systemically active, potent and receptor subtype-selective drugs.  Recently however, two approaches emerged in parallel providing resoln. to this constraint: in silico high-throughput screening of chem. libraries against a 3D-model of the mGluR4 extracellular domain identified a hit that was optimized into a series of potent and subtype-selective orthosteric agonists with drug-like properties and novel chemotype structures; secondly, high-throughput random screening of chem. libraries against recombinantly expressed group-III receptors identified diverse chem. sets of allosteric agonists and pos. modulators, which are drug-like, display selectivity for mGluR4, mGluR7, or mGluR8 and act via novel pharmacol. sites.Here, we illustrate new scientific insights obtained via the use of those strategies.  Also, we compare advantages and disadvantages of both approaches to identify the desired group-III mGluR activators and we conclude with suggestions how to employ those discovery strategies with success for the identification, optimization, and development of clin. drug candidates; this may have important implications for the entire field of GPCR research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxQ6zMsXPxnLVg90H21EOLACvtfcHk0lipjSuI5CwbJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvFKlsLk%253D&md5=d3969d201c3be6bc42ac3ed95f545efb</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2012.04.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2012.04.013%26sid%3Dliteratum%253Aachs%26aulast%3DFlor%26aufirst%3DP.%2BJ.%26aulast%3DAcher%26aufirst%3DF.%2BC.%26atitle%3DOrthosteric%2520versus%2520allosteric%2520GPCR%2520activation%253A%2520the%2520great%2520challenge%2520of%2520group-III%2520mGluRs%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2012%26volume%3D84%26issue%3D4%26spage%3D414%26epage%3D424%26doi%3D10.1016%2Fj.bcp.2012.04.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leidenheimer, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryder, K. G.</span></span> <span> </span><span class="NLM_article-title">Pharmacological chaperoning: a primer on mechanism and pharmacology</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">10</span>â <span class="NLM_lpage">19</span>, <span class="refDoi">Â DOI: 10.1016/j.phrs.2014.01.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.phrs.2014.01.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=24530489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjvFWjs70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2014&pages=10-19&author=N.+J.+Leidenheimerauthor=K.+G.+Ryder&title=Pharmacological+chaperoning%3A+a+primer+on+mechanism+and+pharmacology&doi=10.1016%2Fj.phrs.2014.01.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological chaperoning: A primer on mechanism and pharmacology</span></div><div class="casAuthors">Leidenheimer, Nancy J.; Ryder, Katelyn G.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10-19</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Approx. forty percent of diseases are attributable to protein misfolding, including those for which genetic mutation produces misfolding mutants.  Intriguingly, many of these mutants are not terminally misfolded since native-like folding, and subsequent trafficking to functional locations, can be induced by target-specific, small mols. variably termed pharmacol. chaperones, pharmacoperones, or pharmacochaperones (PCs).  PC targets include enzymes, receptors, transporters, and ion channels, revealing the breadth of proteins that can be engaged by ligand-assisted folding.  The purpose of this review is to provide an integrated primer of the diverse mechanisms and pharmacol. of PCs.  In this regard, we examine the structural mechanisms that underlie PC rescue of misfolding mutants, including the ability of PCs to act as surrogates for defective intramol. interactions and, at the intermol. level, overcome oligomerization deficiencies and dominant neg. effects, as well as influence the subunit stoichiometry of heteropentameric receptors.  Not surprisingly, PC-mediated structural correction of misfolding mutants normalizes interactions with mol. chaperones that participate in protein quality control and forward-trafficking.  A variety of small mols. have proven to be efficacious PCs and the advantages and disadvantages of employing orthostatic antagonists, active-site inhibitors, orthostatic agonists, and allosteric modulator PCs are considered.  Also examd. is the possibility that several therapeutic agents may have unrecognized activity as PCs, and this chaperoning activity may mediate/contribute to therapeutic action and/or account for adverse effects.  Lastly, we explore evidence that pharmacol. chaperoning exploits intrinsic ligand-assisted folding mechanisms.  Given the widespread applicability of PC rescue of mutants assocd. with protein folding disorders, both in vitro and in vivo, the therapeutic potential of PCs is vast.  This is most evident in the treatment of lysosomal storage disorders, cystic fibrosis, and nephrogenic diabetes insipidus, for which proof of principle in humans has been demonstrated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruUboB_YB89bVg90H21EOLACvtfcHk0lg4s3BbBHvMTg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjvFWjs70%253D&md5=34a1b58b182c064e8a72381d9e0f7e95</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2014.01.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2014.01.005%26sid%3Dliteratum%253Aachs%26aulast%3DLeidenheimer%26aufirst%3DN.%2BJ.%26aulast%3DRyder%26aufirst%3DK.%2BG.%26atitle%3DPharmacological%2520chaperoning%253A%2520a%2520primer%2520on%2520mechanism%2520and%2520pharmacology%26jtitle%3DPharmacol.%2520Res.%26date%3D2014%26volume%3D83%26spage%3D10%26epage%3D19%26doi%3D10.1016%2Fj.phrs.2014.01.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dishman, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volkman, B. F.</span></span> <span> </span><span class="NLM_article-title">Unfolding the mysteries of protein metamorphosis</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1438</span>â <span class="NLM_lpage">1446</span>, <span class="refDoi">Â DOI: 10.1021/acschembio.8b00276</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.8b00276" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpvVGrsr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=1438-1446&issue=6&author=A.+F.+Dishmanauthor=B.+F.+Volkman&title=Unfolding+the+mysteries+of+protein+metamorphosis&doi=10.1021%2Facschembio.8b00276"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Unfolding the Mysteries of Protein Metamorphosis</span></div><div class="casAuthors">Dishman, Acacia F.; Volkman, Brian F.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1438-1446</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Since the proposal of Anfinsen's thermodn. hypothesis in 1963, our understanding of protein folding and dynamics has gained significant appreciation of its nuance and complexity.  Intrinsically disordered proteins, chameleonic sequences, morpheeins, and metamorphic proteins have broadened the protein folding paradigm.  Here, we discuss noncanonical protein folding patterns, with an emphasis on metamorphic proteins, and we review known metamorphic proteins that occur naturally and that have been engineered in the lab.  Finally, we discuss research areas surrounding metamorphic proteins that are primed for future exploration, including evolution, drug discovery, and the quest for previously unrecognized metamorphs.  As we enter an age where we are capable of complex bioinformatic searches and de novo protein design, we are primed to search for previously unrecognized metamorphic proteins and to design our own metamorphs to act as targeted, switchable drugs, biosensors, and more.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9d37BsDJJkrVg90H21EOLACvtfcHk0lg4s3BbBHvMTg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpvVGrsr4%253D&md5=f3fe9cfe44feca89d59c3ed665794707</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facschembio.8b00276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.8b00276%26sid%3Dliteratum%253Aachs%26aulast%3DDishman%26aufirst%3DA.%2BF.%26aulast%3DVolkman%26aufirst%3DB.%2BF.%26atitle%3DUnfolding%2520the%2520mysteries%2520of%2520protein%2520metamorphosis%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2018%26volume%3D13%26issue%3D6%26spage%3D1438%26epage%3D1446%26doi%3D10.1021%2Facschembio.8b00276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barbash, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenzen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakmar, T. P.</span></span> <span> </span><span class="NLM_article-title">GPCRs globally coevolved with receptor activity-modifying proteins, RAMPs</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span> (<span class="NLM_issue">45</span>),  <span class="NLM_fpage">12015</span>â <span class="NLM_lpage">12020</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1713074114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1073%2Fpnas.1713074114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=29078385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslSktrfE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=12015-12020&issue=45&author=S.+Barbashauthor=E.+Lorenzenauthor=T.+Perssonauthor=T.+Huberauthor=T.+P.+Sakmar&title=GPCRs+globally+coevolved+with+receptor+activity-modifying+proteins%2C+RAMPs&doi=10.1073%2Fpnas.1713074114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">GPCRs globally coevolved with receptor activity-modifying proteins, RAMPs</span></div><div class="casAuthors">Barbash, Shahar; Lorenzen, Emily; Persson, Torbjorn; Huber, Thomas; Sakmar, Thomas P.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">12015-12020</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Receptor activity-modifying proteins (RAMPs) are widely expressed in human tissues and, in some cases, have been shown to affect surface expression or ligand specificity of G-protein-coupled receptors (GPCRs).  However, whether RAMP-GPCR interactions are widespread, and the nature of their functional consequences, remains largely unknown.  In humans, there are three RAMPs and over 800 expressed GPCRs, making direct exptl. approaches challenging.  We analyzed relevant genomic data from all currently available sequenced organisms.  We discovered that RAMPs and GPCRs tend to have orthologs in the same species and have correlated phylogenetic trees to the same extent, or higher than other interacting protein pairs that play key roles in cellular signaling.  In addn., the resulting RAMP-GPCR interaction map suggests that RAMP1 and RAMP3 interact with the same set of GPCRs, which implies functional redundancy.  We next analyzed human transcriptomes and found expression correlation for GPCRs and RAMPs.  Our results suggest global coevolution of GPCRs and RAMPS and support the hypothesis that GPCRs interact globally with RAMPs in cellular signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNNo_6SV6MSbVg90H21EOLACvtfcHk0lg4s3BbBHvMTg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslSktrfE&md5=71c7f672427d7d97e2dd4c036e4ad9f7</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1713074114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1713074114%26sid%3Dliteratum%253Aachs%26aulast%3DBarbash%26aufirst%3DS.%26aulast%3DLorenzen%26aufirst%3DE.%26aulast%3DPersson%26aufirst%3DT.%26aulast%3DHuber%26aufirst%3DT.%26aulast%3DSakmar%26aufirst%3DT.%2BP.%26atitle%3DGPCRs%2520globally%2520coevolved%2520with%2520receptor%2520activity-modifying%2520proteins%252C%2520RAMPs%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2017%26volume%3D114%26issue%3D45%26spage%3D12015%26epage%3D12020%26doi%3D10.1073%2Fpnas.1713074114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmitte, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niswender, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span> <span> </span><span class="NLM_article-title">Practical strategies and concepts in GPCR allosteric modulator discovery: recent advances with metabotropic glutamate receptors</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>116</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">6707</span>â <span class="NLM_lpage">6741</span>, <span class="refDoi">Â DOI: 10.1021/acs.chemrev.5b00656</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.5b00656" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC28XisFahsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2016&pages=6707-6741&issue=11&author=C.+W.+Lindsleyauthor=K.+A.+Emmitteauthor=C.+R.+Hopkinsauthor=T.+M.+Bridgesauthor=K.+J.+Gregoryauthor=C.+M.+Niswenderauthor=P.+J.+Conn&title=Practical+strategies+and+concepts+in+GPCR+allosteric+modulator+discovery%3A+recent+advances+with+metabotropic+glutamate+receptors&doi=10.1021%2Facs.chemrev.5b00656"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors</span></div><div class="casAuthors">Lindsley, Craig W.; Emmitte, Kyle A.; Hopkins, Corey R.; Bridges, Thomas M.; Gregory, Karen J.; Niswender, Colleen M.; Conn, P. Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6707-6741</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Allosteric modulation of GPCRs has initiated a new era of basic and translational discovery, filled with therapeutic promise yet fraught with caveats.  Allosteric ligands stabilize unique conformations of the GPCR that afford fundamentally new receptors, capable of novel pharmacol., unprecedented subtype selectivity, and unique signal bias.  This review provides a comprehensive overview of the basics of GPCR allosteric pharmacol., medicinal chem., drug metab., and validated approaches to address each of the major challenges and caveats.  Then, the review narrows focus to highlight recent advances in the discovery of allosteric ligands for metabotropic glutamate receptor subtypes 1-5 and 7 (mGlu1-5,7) highlighting key concepts ("mol. switches", signal bias, heterodimers) and practical solns. to enable the development of tool compds. and clin. candidates.  The review closes with a section on late-breaking new advances with allosteric ligands for other GPCRs and emerging data for endogenous allosteric modulators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq18XJrjVel-7Vg90H21EOLACvtfcHk0ljBn8dYaYoRsA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisFahsr8%253D&md5=c12704b6602b6c50add92e7fd9350382</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.5b00656&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.5b00656%26sid%3Dliteratum%253Aachs%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DEmmitte%26aufirst%3DK.%2BA.%26aulast%3DHopkins%26aufirst%3DC.%2BR.%26aulast%3DBridges%26aufirst%3DT.%2BM.%26aulast%3DGregory%26aufirst%3DK.%2BJ.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26atitle%3DPractical%2520strategies%2520and%2520concepts%2520in%2520GPCR%2520allosteric%2520modulator%2520discovery%253A%2520recent%2520advances%2520with%2520metabotropic%2520glutamate%2520receptors%26jtitle%3DChem.%2520Rev.%26date%3D2016%26volume%3D116%26issue%3D11%26spage%3D6707%26epage%3D6741%26doi%3D10.1021%2Facs.chemrev.5b00656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hauser, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attwood, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rask-Andersen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SchiÃ¶th, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloriam, D. E.</span></span> <span> </span><span class="NLM_article-title">Trends in GPCR drug discovery: new agents, targets and indications</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">829</span>â <span class="NLM_lpage">842</span>, <span class="refDoi">Â DOI: 10.1038/nrd.2017.178</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fnrd.2017.178" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=29075003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslansbzF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=829-842&issue=12&author=A.+S.+Hauserauthor=M.+M.+Attwoodauthor=M.+Rask-Andersenauthor=H.+B.+Schi%C3%B6thauthor=D.+E.+Gloriam&title=Trends+in+GPCR+drug+discovery%3A+new+agents%2C+targets+and+indications&doi=10.1038%2Fnrd.2017.178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Trends in GPCR drug discovery: new agents, targets and indications</span></div><div class="casAuthors">Hauser, Alexander S.; Attwood, Misty M.; Rask-Andersen, Mathias; Schioth, Helgi B.; Gloriam, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">829-842</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">G protein-coupled receptors (GPCRs) are the most intensively studied drug targets, mostly due to their substantial involvement in human pathophysiol. and their pharmacol. tractability.  Here, we report an up-to-date anal. of all GPCR drugs and agents in clin. trials, which reveals current trends across mol. types, drug targets and therapeutic indications, including showing that 475 drugs (â¼34% of all drugs approved by the US Food and Drug Administration (FDA)) act at 108 unique GPCRs.  Approx. 321 agents are currently in clin. trials, of which â¼20% target 66 potentially novel GPCR targets without an approved drug, and the no. of biol. drugs, allosteric modulators and biased agonists has increased.  The major disease indications for GPCR modulators show a shift towards diabetes, obesity and Alzheimer disease, although several central nervous system disorders are also highly represented.  The 224 (56%) non-olfactory GPCRs that have not yet been explored in clin. trials have broad untapped therapeutic potential, particularly in genetic and immune system disorders.  Finally, we provide an interactive online resource to analyze and infer trends in GPCR drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9iw1QqR9GKrVg90H21EOLACvtfcHk0ljBn8dYaYoRsA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslansbzF&md5=560893258493bd96c0af24d3bef08b6f</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2017.178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2017.178%26sid%3Dliteratum%253Aachs%26aulast%3DHauser%26aufirst%3DA.%2BS.%26aulast%3DAttwood%26aufirst%3DM.%2BM.%26aulast%3DRask-Andersen%26aufirst%3DM.%26aulast%3DSchi%25C3%25B6th%26aufirst%3DH.%2BB.%26aulast%3DGloriam%26aufirst%3DD.%2BE.%26atitle%3DTrends%2520in%2520GPCR%2520drug%2520discovery%253A%2520new%2520agents%252C%2520targets%2520and%2520indications%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26issue%3D12%26spage%3D829%26epage%3D842%26doi%3D10.1038%2Fnrd.2017.178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christopher, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DorÃ©, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tehan, B. G.</span></span> <span> </span><span class="NLM_article-title">Potential for the rational design of allosteric modulators of class C GPCRs</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">71</span>â <span class="NLM_lpage">78</span>, <span class="refDoi">Â DOI: 10.2174/1568026616666160719165922</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.2174%2F1568026616666160719165922" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=71-78&issue=1&author=J.+A.+Christopherauthor=A.+S.+Dor%C3%A9author=B.+G.+Tehan&title=Potential+for+the+rational+design+of+allosteric+modulators+of+class+C+GPCRs&doi=10.2174%2F1568026616666160719165922"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.2174%2F1568026616666160719165922&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026616666160719165922%26sid%3Dliteratum%253Aachs%26aulast%3DChristopher%26aufirst%3DJ.%2BA.%26aulast%3DDor%25C3%25A9%26aufirst%3DA.%2BS.%26aulast%3DTehan%26aufirst%3DB.%2BG.%26atitle%3DPotential%2520for%2520the%2520rational%2520design%2520of%2520allosteric%2520modulators%2520of%2520class%2520C%2520GPCRs%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2016%26volume%3D17%26issue%3D1%26spage%3D71%26epage%3D78%26doi%3D10.2174%2F1568026616666160719165922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span> <span> </span><span class="NLM_article-title">Small molecule allosteric modulators of G-protein-coupled receptors: drug-target interactions</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">24</span>â <span class="NLM_lpage">45</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b01844</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01844" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFCgtb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=24-45&issue=1&author=S.+Luauthor=J.+Zhang&title=Small+molecule+allosteric+modulators+of+G-protein-coupled+receptors%3A+drug-target+interactions&doi=10.1021%2Facs.jmedchem.7b01844"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Allosteric Modulators of G-Protein-Coupled Receptors: Drug-Target Interactions</span></div><div class="casAuthors">Lu, Shaoyong; Zhang, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">24-45</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">G-protein-coupled receptors (GPCRs) are the largest class of signaling receptors that are most frequently targeted by therapeutic drugs.  Allosteric modulators bound to GPCRs at allosteric sites provide the potential for differential selectivity and improved safety compared with traditional orthosteric ligands.  The recent breakthroughs in GPCR structural biol. have made structures of GPCRs from classes A, B, C, and F complexed with small-mol. allosteric modulators available.  Knowledge of the detailed receptor-modulator interactions at the allosteric sites is useful for structure-based GPCR drug design of novel therapeutics.  This Perspective comprehensively summarizes the current status of structural complexes between GPCRs and their small-mol. allosteric modulators, particularly the key receptor-modulator interactions at the allosteric sites.  Then, the structural diversity of allosteric sites across four GPCR subfamilies is compared.  This study is expected to contribute to the design of GPCR allosteric drugs with an improved therapeutic action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVDf1DtcU6ZLVg90H21EOLACvtfcHk0lhe0Ukkc8kaHA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFCgtb0%253D&md5=7a41f4c00dadecd0661d135811644ad8</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01844&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01844%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DSmall%2520molecule%2520allosteric%2520modulators%2520of%2520G-protein-coupled%2520receptors%253A%2520drug-target%2520interactions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D1%26spage%3D24%26epage%3D45%26doi%3D10.1021%2Facs.jmedchem.7b01844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wold, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Allosteric modulation of class A GPCRs: targets, agents, and emerging concepts</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">88</span>â <span class="NLM_lpage">127</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b00875</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00875" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsV2lsLbK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=88-127&issue=1&author=E.+A.+Woldauthor=J.+Chenauthor=K.+A.+Cunninghamauthor=J.+Zhou&title=Allosteric+modulation+of+class+A+GPCRs%3A+targets%2C+agents%2C+and+emerging+concepts&doi=10.1021%2Facs.jmedchem.8b00875"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Modulation of Class A GPCRs: Targets, Agents, and Emerging Concepts</span></div><div class="casAuthors">Wold, Eric A.; Chen, Jianping; Cunningham, Kathryn A.; Zhou, Jia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">88-127</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">G-protein-coupled receptors (GPCRs) have been tractable drug targets for decades with over one-third of currently marketed drugs targeting GPCRs.  Of these, the class A GPCR superfamily is highly represented, and continued drug discovery for this family of receptors may provide novel therapeutics for a vast range of diseases.  GPCR allosteric modulation is an innovative targeting approach that broadens the available small mol. toolbox and is proving to be a viable drug discovery strategy, as evidenced by recent FDA approvals and clin. trials.  Numerous class A GPCR allosteric modulators have been discovered recently, and emerging trends such as the availability of GPCR crystal structures, diverse functional assays, and structure-based computational approaches are improving optimization and development.  This Perspective provides an update on allosterically targeted class A GPCRs and their disease indications and the medicinal chem. approaches toward novel allosteric modulators and highlights emerging trends and opportunities in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7zBEGIhRgD7Vg90H21EOLACvtfcHk0lhe0Ukkc8kaHA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsV2lsLbK&md5=c724b7cb534a9eb52c371961bb9c9b42</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00875%26sid%3Dliteratum%253Aachs%26aulast%3DWold%26aufirst%3DE.%2BA.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DAllosteric%2520modulation%2520of%2520class%2520A%2520GPCRs%253A%2520targets%252C%2520agents%252C%2520and%2520emerging%2520concepts%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D1%26spage%3D88%26epage%3D127%26doi%3D10.1021%2Facs.jmedchem.8b00875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albert, J. S.</span></span> <span> </span><span class="NLM_article-title">Pharmacological property optimization for allosteric ligands: a medicinal chemistry perspective</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2239</span>â <span class="NLM_lpage">2258</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2017.03.084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.bmcl.2017.03.084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=28408223" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtVensLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=2239-2258&issue=11&author=S.+Johnstoneauthor=J.+S.+Albert&title=Pharmacological+property+optimization+for+allosteric+ligands%3A+a+medicinal+chemistry+perspective&doi=10.1016%2Fj.bmcl.2017.03.084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective</span></div><div class="casAuthors">Johnstone, Shawn; Albert, Jeffrey S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2239-2258</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New strategies to potentially improve drug safety and efficacy emerge with allosteric programs.  Biased allosteric modulators can be designed with high subtype selectivity and defined receptor signaling endpoints, however, selecting the most meaningful parameters for optimization can be perplexing.  Historically, "potency hunting" at the expense of physicochem. and pharmacokinetic optimization has led to numerous tool compds. with excellent pharmacol. properties but no path to drug development.  Conversely, extensive physicochem. and pharmacokinetic screening with only post hoc bias and allosteric characterization has led to inefficacious compds. or compds. with on-target toxicities.  This field is rapidly evolving with new mechanistic understanding, changes in terminol., and novel opportunities.  The intent of this digest is to summarize current understanding and debates within the field.  The authors aim to discuss, from a medicinal chem. perspective, the parameter choices available to drive SAR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8rfWZTCvfzLVg90H21EOLACvtfcHk0lg4kfjNWs1rwQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtVensLc%253D&md5=a1d1c5a8926f69c50338be012f37d8f6</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.03.084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.03.084%26sid%3Dliteratum%253Aachs%26aulast%3DJohnstone%26aufirst%3DS.%26aulast%3DAlbert%26aufirst%3DJ.%2BS.%26atitle%3DPharmacological%2520property%2520optimization%2520for%2520allosteric%2520ligands%253A%2520a%2520medicinal%2520chemistry%2520perspective%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26issue%3D11%26spage%3D2239%26epage%3D2258%26doi%3D10.1016%2Fj.bmcl.2017.03.084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burnell, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irvine, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sapkota, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jane, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monaghan, D. T.</span></span> <span> </span><span class="NLM_article-title">Positive and negative allosteric modulators of N-methyl-D-aspartate (NMDA) receptors: structure-activity relationships and mechanisms of action</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">3</span>â <span class="NLM_lpage">23</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b01640</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01640" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFCntbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3-23&issue=1&author=E.+S.+Burnellauthor=M.+Irvineauthor=G.+Fangauthor=K.+Sapkotaauthor=D.+E.+Janeauthor=D.+T.+Monaghan&title=Positive+and+negative+allosteric+modulators+of+N-methyl-D-aspartate+%28NMDA%29+receptors%3A+structure-activity+relationships+and+mechanisms+of+action&doi=10.1021%2Facs.jmedchem.7b01640"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Positive and Negative Allosteric Modulators of N-Methyl-D-aspartate (NMDA) Receptors: Structure-Activity Relationships and Mechanisms of Action</span></div><div class="casAuthors">Burnell, Erica S.; Irvine, Mark; Fang, Guangyu; Sapkota, Kiran; Jane, David E.; Monaghan, Daniel T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-23</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Excitatory activity in the CNS is predominately mediated by L-glutamate through several families of L-glutamate neurotransmitter receptors.  Of these, the N-methyl-D-aspartate receptor (NMDAR) family has many crit. roles in CNS function and in various neuropathol. and psychiatric conditions.  Until recently, the types of compds. available to regulate NMDAR function have been quite limited in terms of mechanism of action, subtype selectivity, and biol. effect.  However, several new classes of NMDAR agents have now been identified that are pos. or neg. allosteric modulators (PAMs and NAMs, resp.) with various patterns of NMDAR subtype selectivity.  These new agents act at several newly recognized binding sites on the NMDAR complex and offer significantly greater pharmacol. control over NMDAR activity than previously available agents.  The purpose of this review is to summarize the structure-activity relationships for these new NMDAR modulator drug classes and to describe the current understanding of their mechanisms of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDN2OGZJwr-LVg90H21EOLACvtfcHk0lg4kfjNWs1rwQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFCntbk%253D&md5=2b9bc7f16ea2b763895334409c6beae0</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01640%26sid%3Dliteratum%253Aachs%26aulast%3DBurnell%26aufirst%3DE.%2BS.%26aulast%3DIrvine%26aufirst%3DM.%26aulast%3DFang%26aufirst%3DG.%26aulast%3DSapkota%26aufirst%3DK.%26aulast%3DJane%26aufirst%3DD.%2BE.%26aulast%3DMonaghan%26aufirst%3DD.%2BT.%26atitle%3DPositive%2520and%2520negative%2520allosteric%2520modulators%2520of%2520N-methyl-D-aspartate%2520%2528NMDA%2529%2520receptors%253A%2520structure-activity%2520relationships%2520and%2520mechanisms%2520of%2520action%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D1%26spage%3D3%26epage%3D23%26doi%3D10.1021%2Facs.jmedchem.7b01640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wold, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">GPCR allosteric modulators: mechanistic advantages and therapeutic applications</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2002</span>â <span class="NLM_lpage">2006</span>, <span class="refDoi">Â DOI: 10.2174/1568026619999190101151837</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.2174%2F1568026619999190101151837" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=2002-2006&author=E.+A.+Woldauthor=J.+Zhou&title=GPCR+allosteric+modulators%3A+mechanistic+advantages+and+therapeutic+applications&doi=10.2174%2F1568026619999190101151837"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.2174%2F1568026619999190101151837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026619999190101151837%26sid%3Dliteratum%253Aachs%26aulast%3DWold%26aufirst%3DE.%2BA.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DGPCR%2520allosteric%2520modulators%253A%2520mechanistic%2520advantages%2520and%2520therapeutic%2520applications%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2019%26volume%3D18%26spage%3D2002%26epage%3D2006%26doi%3D10.2174%2F1568026619999190101151837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haskell-Luevano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Allosteric modulators of drug targets</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">2</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b01902</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01902" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisF2rt7bE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1-2&author=C.+Haskell-Luevanoauthor=N.+A.+Meanwell&title=Allosteric+modulators+of+drug+targets&doi=10.1021%2Facs.jmedchem.8b01902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Modulators of Drug Targets</span></div><div class="casAuthors">Haskell-Luevano, Carrie; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-2</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCHCKCpbaEz7Vg90H21EOLACvtfcHk0ljjB21dxRQFqA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisF2rt7bE&md5=7b7f4bf08d95ea4a07c41633526fb654</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01902%26sid%3Dliteratum%253Aachs%26aulast%3DHaskell-Luevano%26aufirst%3DC.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DAllosteric%2520modulators%2520of%2520drug%2520targets%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1%26epage%3D2%26doi%3D10.1021%2Facs.jmedchem.8b01902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gunasekaran, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nussinov, R.</span></span> <span> </span><span class="NLM_article-title">Is allostery an intrinsic property of all dynamic proteins?</span>. <i>Proteins: Struct., Funct., Genet.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">433</span>â <span class="NLM_lpage">443</span>, <span class="refDoi">Â DOI: 10.1002/prot.20232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1002%2Fprot.20232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=15382234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BD2cXovVyjs70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2004&pages=433-443&author=K.+Gunasekaranauthor=B.+Maauthor=R.+Nussinov&title=Is+allostery+an+intrinsic+property+of+all+dynamic+proteins%3F&doi=10.1002%2Fprot.20232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Is allostery an intrinsic property of all dynamic proteins?</span></div><div class="casAuthors">Gunasekaran, K.; Ma, Buyong; Nussinov, Ruth</div><div class="citationInfo"><span class="NLM_cas:title">Proteins: Structure, Function, and Bioinformatics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">433-443</span>CODEN:
                <span class="NLM_cas:coden">PSFBAF</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review.  Allostery involves coupling of conformational changes between two widely sepd. binding sites.  The common view holds that allosteric proteins are sym. oligomers, with each subunit existing in "at least" two conformational states with a different affinity for ligands.  Recent observations such as the allosteric behavior of myoglobin, a classical example of a nonallosteric protein, call into question the existing allosteric dogma.  Here the authors argue that all (nonfibrous) proteins are potentially allosteric.  Allostery is a consequence of re-distributions of protein conformational ensembles.  In a nonallosteric protein, the binding site shape may not show a concerted second-site change and enzyme kinetics may not reflect an allosteric transition.  Nevertheless, appropriate ligands, point mutations, or external conditions may facilitate a population shift, leading a presumably nonallosteric protein to behave allosterically.  In principle, practically any potential drug binding to the protein surface can alter the conformational redistribution.  The question is its effectiveness in the redistribution of the ensemble, affecting the protein binding sites and its function.  Here, the authors review exptl. observations validating this view of protein allostery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpq3st6_arK-bVg90H21EOLACvtfcHk0ljjB21dxRQFqA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXovVyjs70%253D&md5=dd5aeb604870f238c5ecd7bd785a8d40</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1002%2Fprot.20232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprot.20232%26sid%3Dliteratum%253Aachs%26aulast%3DGunasekaran%26aufirst%3DK.%26aulast%3DMa%26aufirst%3DB.%26aulast%3DNussinov%26aufirst%3DR.%26atitle%3DIs%2520allostery%2520an%2520intrinsic%2520property%2520of%2520all%2520dynamic%2520proteins%253F%26jtitle%3DProteins%253A%2520Struct.%252C%2520Funct.%252C%2520Genet.%26date%3D2004%26volume%3D57%26spage%3D433%26epage%3D443%26doi%3D10.1002%2Fprot.20232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nussinov, R.</span></span> <span> </span><span class="NLM_article-title">Allostery: an overview of its history, concepts, methods, and applications</span>. <i>PLoS Comput. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">e1004966</span>, <span class="refDoi">Â DOI: 10.1371/journal.pcbi.1004966</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1371%2Fjournal.pcbi.1004966" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=27253437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslWntbbJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=e1004966&issue=6&author=J.+Liuauthor=R.+Nussinov&title=Allostery%3A+an+overview+of+its+history%2C+concepts%2C+methods%2C+and+applications&doi=10.1371%2Fjournal.pcbi.1004966"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Allostery: an overview of its history, concepts, methods, and applications</span></div><div class="casAuthors">Liu, Jin; Nussinov, Ruth</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Computational Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e1004966/1-e1004966/5</span>CODEN:
                <span class="NLM_cas:coden">PCBLBG</span>;
        ISSN:<span class="NLM_cas:issn">1553-7358</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The concept of allostery has evolved in the past century.  In this Editorial, we briefly overview the history of allostery, from the pre-allostery nomenclature era starting with the Bohr effect (1904) to the birth of allostery by Monod and Jacob (1961).  We describe the evolution of the allostery concept, from a conformational change in a two-state model (1965, 1966) to dynamic allostery in the ensemble model (1999); from multi-subunit (1965) proteins to all proteins (2004).  We highlight the current available methods to study allostery and their applications in studies of conformational mechanisms, disease, and allosteric drug discovery.  We outline the challenges and future directions that we foresee.  Altogether, this Editorial narrates the history of this fundamental concept in the life sciences, its significance, methodologies to detect and predict it, and its application in a broad range of living systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUNj0xAGD3qrVg90H21EOLACvtfcHk0ljjB21dxRQFqA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslWntbbJ&md5=1a753ef03a696bd2591eb1d7206f50d7</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1004966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1004966%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DNussinov%26aufirst%3DR.%26atitle%3DAllostery%253A%2520an%2520overview%2520of%2520its%2520history%252C%2520concepts%252C%2520methods%252C%2520and%2520applications%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2016%26volume%3D12%26issue%3D6%26spage%3De1004966%26doi%3D10.1371%2Fjournal.pcbi.1004966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nussinov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolynes, P. G.</span></span> <span> </span><span class="NLM_article-title">A second molecular biology revolution? The energy landscapes of biomolecular function</span>. <i>Phys. Chem. Chem. Phys.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">6321</span>â <span class="NLM_lpage">6322</span>, <span class="refDoi">Â DOI: 10.1039/c4cp90027h</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1039%2Fc4cp90027h" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=24608340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktV2itLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2014&pages=6321-6322&issue=14&author=R.+Nussinovauthor=P.+G.+Wolynes&title=A+second+molecular+biology+revolution%3F+The+energy+landscapes+of+biomolecular+function&doi=10.1039%2Fc4cp90027h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">A second molecular biology revolution? The energy landscapes of biomolecular function</span></div><div class="casAuthors">Nussinov, Ruth; Wolynes, Peter G.</div><div class="citationInfo"><span class="NLM_cas:title">Physical Chemistry Chemical Physics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6321-6322</span>CODEN:
                <span class="NLM_cas:coden">PPCPFQ</span>;
        ISSN:<span class="NLM_cas:issn">1463-9076</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  The free energy landscape concept has commanded the imagination of many scientists because those who have adopted and exploited it can more deeply grasp mechanisms in biol. than what can be achieved by the simple structure, function paradigm.  While X-ray structures capture snapshots from an ensemble, the changes of this ensemble under varying conditions ultimately give rise to the non-linear information flows needed for life.  By also depicting barriers between the active and inactive ensembles of states, the kinetics of information flow in the living cell can begin to be understood.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsnQ5jSrV2DbVg90H21EOLACvtfcHk0ljfJTzfPjkWTA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktV2itLo%253D&md5=ae9c01f544484a6465e0490b92dd2f91</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1039%2Fc4cp90027h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc4cp90027h%26sid%3Dliteratum%253Aachs%26aulast%3DNussinov%26aufirst%3DR.%26aulast%3DWolynes%26aufirst%3DP.%2BG.%26atitle%3DA%2520second%2520molecular%2520biology%2520revolution%253F%2520The%2520energy%2520landscapes%2520of%2520biomolecular%2520function%26jtitle%3DPhys.%2520Chem.%2520Chem.%2520Phys.%26date%3D2014%26volume%3D16%26issue%3D14%26spage%3D6321%26epage%3D6322%26doi%3D10.1039%2Fc4cp90027h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kenakin, T. P.</span></span> <i>A Pharmacology Primer</i>, <span class="NLM_edition">4th</span> ed.; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">Boston, MA</span>, <span class="NLM_year">2014</span>; Chapter 7, pp  <span class="NLM_fpage">155</span>â <span class="NLM_lpage">180</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2FB978-0-12-407663-1.00007-7" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&pages=155-180&author=T.+P.+Kenakin&title=A+Pharmacology+Primer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-407663-1.00007-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-12-407663-1.00007-7%26sid%3Dliteratum%253Aachs%26aulast%3DKenakin%26aufirst%3DT.%2BP.%26btitle%3DA%2520Pharmacology%2520Primer%26pub%3DAcademic%2520Press%26date%3D2014%26spage%3D155%26epage%3D180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Changeux, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catterall, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cidlowski, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neubig, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pin, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenakin, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehlert, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spedding, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langmead, C. J.</span></span> <span> </span><span class="NLM_article-title">International Union of Basic and Clinical Pharmacology. XC. Multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>66</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">918</span>â <span class="NLM_lpage">947</span>, <span class="refDoi">Â DOI: 10.1124/pr.114.008862</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1124%2Fpr.114.008862" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=25026896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFKht73N" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2014&pages=918-947&issue=4&author=A.+Christopoulosauthor=J.-P.+Changeuxauthor=W.+A.+Catterallauthor=D.+Fabbroauthor=T.+P.+Burrisauthor=J.+A.+Cidlowskiauthor=R.+W.+Olsenauthor=J.+A.+Petersauthor=R.+R.+Neubigauthor=J.+P.+Pinauthor=P.+M.+Sextonauthor=T.+P.+Kenakinauthor=F.+J.+Ehlertauthor=M.+Speddingauthor=C.+J.+Langmead&title=International+Union+of+Basic+and+Clinical+Pharmacology.+XC.+Multisite+pharmacology%3A+recommendations+for+the+nomenclature+of+receptor+allosterism+and+allosteric+ligands&doi=10.1124%2Fpr.114.008862"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">International Union of Basic and Clinical Pharmacology. XC. multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands</span></div><div class="casAuthors">Christopoulos, Arthur; Changeux, Jean-Pierre; Catterall, William A.; Fabbro, Doriano; Burris, Thomas P.; Cidlowski, John A.; Olsen, Richard W.; Peters, John A.; Neubig, Richard R.; Pin, Jean-Philippe; Sexton, Patrick M.; Kenakin, Terry P.; Ehlert, Frederick J.; Spedding, Michael; Langmead, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">918-947</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Allosteric interactions play vital roles in metabolic processes and signal transduction and, more recently, have become the focus of numerous pharmacol. studies because of the potential for discovering more target-selective chem. probes and therapeutic agents.  In addn. to classic early studies on enzymes, there are now examples of small mol. allosteric modulators for all superfamilies of receptors encoded by the genome, including ligand- and voltage-gated ion channels, G protein-coupled receptors, nuclear hormone receptors, and receptor tyrosine kinases.  As a consequence, a vast array of pharmacol. behaviors has been ascribed to allosteric ligands that can vary in a target-, ligand-, and cell-/tissue-dependent manner.  The current article presents an overview of allostery as applied to receptor families and approaches for detecting and validating allosteric interactions and gives recommendations for the nomenclature of allosteric ligands and their properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2h0E0L_c0J7Vg90H21EOLACvtfcHk0ljfJTzfPjkWTA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFKht73N&md5=cca779691cfc36cc3f06aaf495522c22</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1124%2Fpr.114.008862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.114.008862%26sid%3Dliteratum%253Aachs%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DChangeux%26aufirst%3DJ.-P.%26aulast%3DCatterall%26aufirst%3DW.%2BA.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DBurris%26aufirst%3DT.%2BP.%26aulast%3DCidlowski%26aufirst%3DJ.%2BA.%26aulast%3DOlsen%26aufirst%3DR.%2BW.%26aulast%3DPeters%26aufirst%3DJ.%2BA.%26aulast%3DNeubig%26aufirst%3DR.%2BR.%26aulast%3DPin%26aufirst%3DJ.%2BP.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DKenakin%26aufirst%3DT.%2BP.%26aulast%3DEhlert%26aufirst%3DF.%2BJ.%26aulast%3DSpedding%26aufirst%3DM.%26aulast%3DLangmead%26aufirst%3DC.%2BJ.%26atitle%3DInternational%2520Union%2520of%2520Basic%2520and%2520Clinical%2520Pharmacology.%2520XC.%2520Multisite%2520pharmacology%253A%2520recommendations%2520for%2520the%2520nomenclature%2520of%2520receptor%2520allosterism%2520and%2520allosteric%2520ligands%26jtitle%3DPharmacol.%2520Rev.%26date%3D2014%26volume%3D66%26issue%3D4%26spage%3D918%26epage%3D947%26doi%3D10.1124%2Fpr.114.008862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roche, D.</span>; <span class="NLM_string-name">Gil, D.</span>; <span class="NLM_string-name">Giraldo, J.</span></span> <span> </span><span class="NLM_article-title">Mathematical Modeling of G Protein-Coupled Receptor Function: What Can We Learn from Empirical and Mechanistic Models?</span> In  <i>G Protein-Coupled ReceptorsâModeling and Simulation. Advances in Experimental Medicine and Biology</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filizola, M.</span></span>, Ed.; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">Dordrecht, The Netherlands</span>, <span class="NLM_year">2014</span>. Vol.  <span class="NLM_volume">796</span>, pp  <span class="NLM_fpage">159</span>â <span class="NLM_lpage">181</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1007%2F978-94-007-7423-0_8" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&pages=159-181&author=D.+Roche&author=D.+Gil&author=J.+Giraldoauthor=M.+Filizola&title=G+Protein-Coupled+Receptors%E2%80%94Modeling+and+Simulation.+Advances+in+Experimental+Medicine+and+Biology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1007%2F978-94-007-7423-0_8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-94-007-7423-0_8%26sid%3Dliteratum%253Aachs%26aulast%3DRoche%26aufirst%3DD.%26atitle%3DMathematical%2520Modeling%2520of%2520G%2520Protein-Coupled%2520Receptor%2520Function%253A%2520What%2520Can%2520We%2520Learn%2520from%2520Empirical%2520and%2520Mechanistic%2520Models%253F%26btitle%3DG%2520Protein-Coupled%2520Receptors%25E2%2580%2594Modeling%2520and%2520Simulation.%2520Advances%2520in%2520Experimental%2520Medicine%2520and%2520Biology%26aulast%3DFilizola%26aufirst%3DM.%26pub%3DSpringer%26date%3D2014%26volume%3D796%26spage%3D159%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ehlert, F. J.</span></span> <span> </span><span class="NLM_article-title">What ligand-gated ion channels can tell us about the allosteric regulation of G protein-coupled receptors</span>. <i>Prog. Mol. Biol. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">291</span>â <span class="NLM_lpage">347</span>, <span class="refDoi">Â DOI: 10.1016/B978-0-12-394587-7.00007-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2FB978-0-12-394587-7.00007-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=23415097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotFeisLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2013&pages=291-347&author=F.+J.+Ehlert&title=What+ligand-gated+ion+channels+can+tell+us+about+the+allosteric+regulation+of+G+protein-coupled+receptors&doi=10.1016%2FB978-0-12-394587-7.00007-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">What ligand-gated ion channels can tell us about the allosteric regulation of G protein-coupled receptors</span></div><div class="casAuthors">Ehlert, Frederick J.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Molecular Biology and Translational Science</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">Oligomerization and Allosteric Modulation in G-Protein Coupled Receptors</span>),
    <span class="NLM_cas:pages">291-347</span>CODEN:
                <span class="NLM_cas:coden">PNARC5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The GABAA receptor is the target for a no. of important allosteric drugs used in medicine, including benzodiazepines and anesthetics.  These modulators have variable effects on the potency and maximal response of macroscopic currents elicited by different GABAA receptor agonists, yet this modulation is consistent with a two-state model in which the allosteric ligand has invariant affinity consts. for the active and inactive states.  Anal. of the effects of an allosteric agonist, like etomidate, on the population current provides a means of estg. the gating const. of the unliganded GABAA receptor (â¼10-4).  In contrast, allosteric interactions at the M2 muscarinic receptor are often inconsistent with a two-state model.  Analyzing allosterism within the constraints of a two-state model, nonetheless, provides an unbiased measure of probe dependence as well as clues to the mechanism of allosteric modulation.  The rather simple allosteric effect of affinity-only modulation is difficult to explain and suggests modulation of a peripheral orthosteric ligand-docking site on the M2 muscarinic receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXS4gVWfnxG7Vg90H21EOLACvtfcHk0li1s9e8WSMoKA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotFeisLg%253D&md5=d45a6ae52edf0b68882d8ee30d7e61f4</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-394587-7.00007-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-394587-7.00007-5%26sid%3Dliteratum%253Aachs%26aulast%3DEhlert%26aufirst%3DF.%2BJ.%26atitle%3DWhat%2520ligand-gated%2520ion%2520channels%2520can%2520tell%2520us%2520about%2520the%2520allosteric%2520regulation%2520of%2520G%2520protein-coupled%2520receptors%26jtitle%3DProg.%2520Mol.%2520Biol.%2520Transl.%2520Sci.%26date%3D2013%26volume%3D115%26spage%3D291%26epage%3D347%26doi%3D10.1016%2FB978-0-12-394587-7.00007-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavana, M.</span></span> <span> </span><span class="NLM_article-title">Quantitative analysis of receptor allosterism and its implication for drug discovery</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">763</span>â <span class="NLM_lpage">780</span>, <span class="refDoi">Â DOI: 10.1517/17460441.2015.1041498</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1517%2F17460441.2015.1041498" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=25927503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVOktrnN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=763-780&issue=7&author=R.+Zhangauthor=M.+Kavana&title=Quantitative+analysis+of+receptor+allosterism+and+its+implication+for+drug+discovery&doi=10.1517%2F17460441.2015.1041498"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative analysis of receptor allosterism and its implication for drug discovery</span></div><div class="casAuthors">Zhang, Rumin; Kavana, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">763-780</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Introduction: G protein-coupled receptors represent the largest class of druggable targets and are known to be modulated by both orthosteric agonists and pos./neg. allosteric modulators (PAMs/NAMs).  Proper exptl. design and data anal. for the dose matrix between an agonist and PAM or NAM are crit. to elucidate the key parameters for understanding mol. mechanism and structure-activity relationship (SAR) in drug discovery.  Areas covered: The authors provide an overview and best practice recommendations on the quant. anal. of receptor allosterism.  The authors propose a simple classification system for receptor modulators on the basis of their efficacy and affinity modifiers.  The authors also outline the optimal assay designs for both fixed dose screening and dose matrix study of receptor modulators.  Expert opinion: The authors recommend the global curve fitting approach to reliably yield system- and modulator-specific parameters for SAR ranking.  Furthermore, the authors suggest that the uncertainty in maximal system response has insignificant impact on SAR ranking.  The authors anticipate that systems pharmacol. models integrating both binding kinetics and functional allosterism will be needed to address the inherent limitations of current allosterism models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2bd3jsIruMbVg90H21EOLACvtfcHk0li1s9e8WSMoKA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVOktrnN&md5=f42d9d9c5fdfe97fcba484746605368d</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1517%2F17460441.2015.1041498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2015.1041498%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DKavana%26aufirst%3DM.%26atitle%3DQuantitative%2520analysis%2520of%2520receptor%2520allosterism%2520and%2520its%2520implication%2520for%2520drug%2520discovery%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2015%26volume%3D10%26issue%3D7%26spage%3D763%26epage%3D780%26doi%3D10.1517%2F17460441.2015.1041498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leach, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span> <span> </span><span class="NLM_article-title">Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">382</span>â <span class="NLM_lpage">389</span>, <span class="refDoi">Â DOI: 10.1016/j.tips.2007.06.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.tips.2007.06.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=17629965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotlWltLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2007&pages=382-389&issue=8&author=K.+Leachauthor=P.+M.+Sextonauthor=A.+Christopoulos&title=Allosteric+GPCR+modulators%3A+taking+advantage+of+permissive+receptor+pharmacology&doi=10.1016%2Fj.tips.2007.06.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology</span></div><div class="casAuthors">Leach, Katie; Sexton, Patrick M.; Christopoulos, Arthur</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">382-389</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The past decade has witnessed a dramatic increase in the identification of allosteric modulators of G-protein-coupled receptor (GPCR) activity.  Concomitantly, several new perspectives and hypotheses regarding the way ligands regulate GPCR signaling have also emerged.  Here, we briefly discuss how the concepts of collateral efficacy and permissive agonism-antagonism intersect the field of allosteric GPCR modulation.  Despite the challenges assocd. with detecting and quantifying the myriad of possible allosteric effects on GPCR activity, it is proposed that allosteric ligands offer the exciting prospect of engendering stimulus-bias in orthosteric ligand signaling, thus paving the way for not only receptor-selective but also signaling-pathway-selective therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpHb_QsIW3TbVg90H21EOLACvtfcHk0li1s9e8WSMoKA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotlWltLs%253D&md5=943da2312e7b136cb594ba0346e00301</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2007.06.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2007.06.004%26sid%3Dliteratum%253Aachs%26aulast%3DLeach%26aufirst%3DK.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DChristopoulos%26aufirst%3DA.%26atitle%3DAllosteric%2520GPCR%2520modulators%253A%2520taking%2520advantage%2520of%2520permissive%2520receptor%2520pharmacology%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2007%26volume%3D28%26issue%3D8%26spage%3D382%26epage%3D389%26doi%3D10.1016%2Fj.tips.2007.06.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K. J.</span>; <span class="NLM_string-name">Sexton, P. M.</span>; <span class="NLM_string-name">Christopoulos, A.</span></span> <span> </span><span class="NLM_article-title">Overview of receptor allosterism</span>.  <i>Current Protocols in Pharmacology</i>; <span class="NLM_publisher-name">John Wiley & Sons, Inc.</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>, <span class="NLM_year">2010</span>; Chapter 1, Unit 1.21.<span class="refDoi">Â DOI: 10.1002/0471141755.ph0121s51</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1002%2F0471141755.ph0121s51" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=K.+J.+Gregory&author=P.+M.+Sexton&author=A.+Christopoulos&title=Current+Protocols+in+Pharmacology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2F0471141755.ph0121s51&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F0471141755.ph0121s51%26sid%3Dliteratum%253Aachs%26aulast%3DGregory%26aufirst%3DK.%2BJ.%26atitle%3DOverview%2520of%2520receptor%2520allosterism%26btitle%3DCurrent%2520Protocols%2520in%2520Pharmacology%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26date%3D2010%26doi%3D10.1002%2F0471141755.ph0121s51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kenakin, T. P.</span></span> <span> </span><span class="NLM_article-title">Biased signaling and allosteric machines: new vistas and challenges for drug discovery</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>165</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1659</span>â <span class="NLM_lpage">1669</span>, <span class="refDoi">Â DOI: 10.1111/j.1476-5381.2011.01749.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1111%2Fj.1476-5381.2011.01749.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=22023017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsVKqur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2012&pages=1659-1669&issue=6&author=T.+P.+Kenakin&title=Biased+signaling+and+allosteric+machines%3A+new+vistas+and+challenges+for+drug+discovery&doi=10.1111%2Fj.1476-5381.2011.01749.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Biased signalling and allosteric machines: new vistas and challenges for drug discovery</span></div><div class="casAuthors">Kenakin, Terry P.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1659-1669</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Seven transmembrane receptors (7TMRs) are nature's prototype allosteric proteins made to bind mols. at one location to subsequently change their shape to affect the binding of another mol. at another location.  This paper attempts to describe the divergent 7TMR behaviors (i.e. 3rd party allostery, receptor oligomerization, biased agonism) obsd. in pharmacol. in terms of a homogeneous group of allosteric behaviors.  By considering the bodies involved as a vector defined by a modulator, conduit, and guest, these activities can all be described by a simple model of functional allostery made up of the Ehlert allosteric model and the Black/Leff operational model.  It will be shown how this model yields parameters that can be used to characterize the activity of any ligand or protein producing effect through allosteric interaction with a 7TMR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR5qQVOBA9jrVg90H21EOLACvtfcHk0lhsfFurGf4TRA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsVKqur4%253D&md5=8daf6ecc1de8b9a2c909d5f9c58dfb86</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01749.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01749.x%26sid%3Dliteratum%253Aachs%26aulast%3DKenakin%26aufirst%3DT.%2BP.%26atitle%3DBiased%2520signaling%2520and%2520allosteric%2520machines%253A%2520new%2520vistas%2520and%2520challenges%2520for%2520drug%2520discovery%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D165%26issue%3D6%26spage%3D1659%26epage%3D1669%26doi%3D10.1111%2Fj.1476-5381.2011.01749.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="note"><p class="first last">Simulations based on eq 1, using the following system parameters: <i>E</i><sub>m</sub> = 1000; p<i>K</i><sub>A</sub> = 5; p<i>K</i><sub>B</sub> = 7; Ï<sub>A</sub> = 0.23; Ï<sub>B</sub> = 0 (except for <i>c</i>); <i>n</i> = 1.5. Compound parameters differ for each curve as stated in text.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">WieroÅska, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zorn, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilc, A.</span></span> <span> </span><span class="NLM_article-title">Metabotropic glutamate receptors as targets for new antipsychotic drugs: historical perspective and critical comparative assessment</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">10</span>â <span class="NLM_lpage">27</span>, <span class="refDoi">Â DOI: 10.1016/j.pharmthera.2015.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.pharmthera.2015.10.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=26549541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVSks7vM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2016&pages=10-27&author=J.+M.+Wiero%C5%84skaauthor=S.+H.+Zornauthor=D.+Dollerauthor=A.+Pilc&title=Metabotropic+glutamate+receptors+as+targets+for+new+antipsychotic+drugs%3A+historical+perspective+and+critical+comparative+assessment&doi=10.1016%2Fj.pharmthera.2015.10.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Metabotropic glutamate receptors as targets for new antipsychotic drugs: Historical perspective and critical comparative assessment</span></div><div class="casAuthors">Wieronska, Joanna M.; Zorn, Stevin H.; Doller, Dario; Pilc, Andrzej</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10-27</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">In this review, we aim to present, discuss and clarify our current understanding regarding the prediction of possible antipsychotic effects of metabotropic glutamate (mGlu) receptor ligands.  The no. of preclin. trials clearly indicates, that this group of compds. constitutes an excellent alternative to presently used antipsychotic therapy, being effective not only to pos., but also neg. and cognitive symptoms of schizophrenia.  Although the results of clin. trials that were performed for the group of mGlu2/3 agonists were not so enthusiastic as in animal studies, they still showed that mGlu ligands do not induced variety of side effects typical for presently used antipsychotics, and were generally well tolerated.  The lack of satisfactory effectiveness towards schizophrenia symptoms of mGlu2/3 activators in humans could be a result of variety of uncontrolled factors and unidentified biomarkers different for each schizophrenia patient, that should be taken into consideration in the future set of clin. trials.  The subject is still open for further research, and the novel classes of mGlu5 or mGlu2/3 agonists/PAMs were recently introduced, including the large group of compds. from the third group of mGlu receptors, esp. of mGlu4 subtype.  Finally, more precise treatment based on simultaneous administration of minimal doses of the ligands for two or more receptors, seems to be promising in the context of symptoms-specific schizophrenia treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor64l-ntwmK7Vg90H21EOLACvtfcHk0lhsfFurGf4TRA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVSks7vM&md5=23b8ec790518a3ad5c92cb6c3895e618</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2015.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2015.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DWiero%25C5%2584ska%26aufirst%3DJ.%2BM.%26aulast%3DZorn%26aufirst%3DS.%2BH.%26aulast%3DDoller%26aufirst%3DD.%26aulast%3DPilc%26aufirst%3DA.%26atitle%3DMetabotropic%2520glutamate%2520receptors%2520as%2520targets%2520for%2520new%2520antipsychotic%2520drugs%253A%2520historical%2520perspective%2520and%2520critical%2520comparative%2520assessment%26jtitle%3DPharmacol.%2520Ther.%26date%3D2016%26volume%3D157%26spage%3D10%26epage%3D27%26doi%3D10.1016%2Fj.pharmthera.2015.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span> <i>GraphPad Curve
Fitting Guide</i>; <span class="NLM_publisher-name">GraphPad Software Inc.</span>, <span class="NLM_year">1995</span>; <a href="https://www.graphpad.com/guides/prism/8/pdf/Prism-8-Curve-Fitting.pdf" class="extLink">https://www.graphpad.com/guides/prism/8/pdf/Prism-8-Curve-Fitting.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+GraphPad+Curve%0AFitting+Guide%3B+GraphPad+Software+Inc.%2C+1995%3B+https%3A%2F%2Fwww.graphpad.com%2Fguides%2Fprism%2F8%2Fpdf%2FPrism-8-Curve-Fitting.pdf."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DGraphPad%2520Curve%250AFitting%2520Guide%26pub%3DGraphPad%2520Software%2520Inc%26date%3D1995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roche, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giraldo, J.</span></span> <span> </span><span class="NLM_article-title">Mechanistic analysis of the function of agonists and allosteric modulators: reconciling two-state and operational models</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>169</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1189</span>â <span class="NLM_lpage">1202</span>, <span class="refDoi">Â DOI: 10.1111/bph.12231</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1111%2Fbph.12231" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=23647200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVajsLbM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2013&pages=1189-1202&issue=6&author=D.+Rocheauthor=D.+Gilauthor=J.+Giraldo&title=Mechanistic+analysis+of+the+function+of+agonists+and+allosteric+modulators%3A+reconciling+two-state+and+operational+models&doi=10.1111%2Fbph.12231"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic analysis of the function of agonists and allosteric modulators: reconciling two-state and operational models</span></div><div class="casAuthors">Roche, David; Gil, Debora; Giraldo, Jesus</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1189-1202</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Two-state and operational models of both agonism and allosterism are compared to identify and characterize common pharmacol. parameters.  To account for the receptor-dependent basal response, constitutive receptor activity is considered in the operational models.  By arranging two-state models as the fraction of active receptors and operational models as the fractional response relative to the max. effect of the system, a one-by-one correspondence between parameters is found.  The comparative anal. allows a better understanding of complex allosteric interactions.  In particular, the inclusion of constitutive receptor activity in the operational model of allosterism allows the characterization of modulators able to lower the basal response of the system; i.e., allosteric modulators with neg. intrinsic efficacy.  Theor. simulations and overall goodness of fit of the models to simulated data suggest that it is feasible to apply the models to exptl. data and constitute one step forward in receptor theory formalism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqglhnNGCZeqbVg90H21EOLACvtfcHk0lhsfFurGf4TRA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVajsLbM&md5=fae7e9e8032a0c4c66a44de4d8ee35bb</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1111%2Fbph.12231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12231%26sid%3Dliteratum%253Aachs%26aulast%3DRoche%26aufirst%3DD.%26aulast%3DGil%26aufirst%3DD.%26aulast%3DGiraldo%26aufirst%3DJ.%26atitle%3DMechanistic%2520analysis%2520of%2520the%2520function%2520of%2520agonists%2520and%2520allosteric%2520modulators%253A%2520reconciling%2520two-state%2520and%2520operational%2520models%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D169%26issue%3D6%26spage%3D1189%26epage%3D1202%26doi%3D10.1111%2Fbph.12231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hall, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Provins, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valade, A.</span></span> <span> </span><span class="NLM_article-title">Novel strategies to activate the dopamine D1 receptor: recent advances in orthosteric agonism and positive allosteric modulation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">128</span>â <span class="NLM_lpage">140</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b01767</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01767" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVKrsbjK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=128-140&issue=1&author=A.+Hallauthor=L.+Provinsauthor=A.+Valade&title=Novel+strategies+to+activate+the+dopamine+D1+receptor%3A+recent+advances+in+orthosteric+agonism+and+positive+allosteric+modulation&doi=10.1021%2Facs.jmedchem.8b01767"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Strategies To Activate the Dopamine D1 Receptor: Recent Advances in Orthosteric Agonism and Positive Allosteric Modulation</span></div><div class="casAuthors">Hall, Adrian; Provins, Laurent; Valade, Anne</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">128-140</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The five dopamine receptor subtypes (D1-5) are activated by the endogenous catecholamine dopamine.  Sustained research has sought to identify selective ligands for receptor subtypes.  In particular, activation of the D1 receptor has attracted attention due to its promising role in neurol. diseases.  Initial attempts to identify agonists yielded catechol derivs., mimicking dopamine, with suboptimal DMPK parameters and low selectivity over the D5 subtype.  However, more recent efforts to identify ligands capable of activating the D1 receptor have made substantial progress with the identification of non-catechol agonists with suitable properties to progress to clin. studies.  In addn., several research groups have identified pos. allosteric modulators that offer new potential.  Furthermore, structural studies have surprisingly uncovered two potential allosteric binding sites, the most characterized of which appears to be on intracellular loop 2 (ICL2).  This review highlights the recent progress in the field, covering both orthosteric and allosteric modes of activation, discusses the elucidation of the allosteric binding sites, and summarizes the clin. development status of various compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnfHl8QabACrVg90H21EOLACvtfcHk0liJo2oWuetl7w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVKrsbjK&md5=54aa53ee35e7c625f8265edad7eab804</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01767%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DA.%26aulast%3DProvins%26aufirst%3DL.%26aulast%3DValade%26aufirst%3DA.%26atitle%3DNovel%2520strategies%2520to%2520activate%2520the%2520dopamine%2520D1%2520receptor%253A%2520recent%2520advances%2520in%2520orthosteric%2520agonism%2520and%2520positive%2520allosteric%2520modulation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D1%26spage%3D128%26epage%3D140%26doi%3D10.1021%2Facs.jmedchem.8b01767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunihan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gentles, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beno, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrante, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendricson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knox, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molski, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cvijic, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockwell, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weed, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cacace, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westphal, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of D1 dopamine receptor positive allosteric modulators: characterization of pharmacology and identification of residues that regulate species selectivity</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>354</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">340</span>â <span class="NLM_lpage">349</span>, <span class="refDoi">Â DOI: 10.1124/jpet.115.224071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1124%2Fjpet.115.224071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=26109678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Ols7fJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=354&publication_year=2015&pages=340-349&issue=3&author=M.+A.+Lewisauthor=L.+Hunihanauthor=J.+Watsonauthor=R.+G.+Gentlesauthor=S.+Huauthor=Y.+Huangauthor=J.+Bronsonauthor=J.+E.+Macorauthor=B.+R.+Benoauthor=M.+Ferranteauthor=A.+Hendricsonauthor=R.+J.+Knoxauthor=T.+F.+Molskiauthor=Y.+Kongauthor=M.+E.+Cvijicauthor=K.+L.+Rockwellauthor=M.+R.+Weedauthor=A.+M.+Cacaceauthor=R.+S.+Westphalauthor=A.+Altauthor=J.+M.+Brown&title=Discovery+of+D1+dopamine+receptor+positive+allosteric+modulators%3A+characterization+of+pharmacology+and+identification+of+residues+that+regulate+species+selectivity&doi=10.1124%2Fjpet.115.224071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of D1 dopamine receptor positive allosteric modulators: characterization of pharmacology and identification of residues that regulate species selectivity</span></div><div class="casAuthors">Lewis, Martin A.; Hunihan, Lisa; Watson, John; Gentles, Robert G.; Hu, Shuanghua; Huang, Yazhong; Bronson, Joanne; Macor, John E.; Beno, Brett R.; Ferrante, Meredith; Hendricson, Adam; Knox, Ronald J.; Molski, Thaddeus F.; Kong, Yan; Cvijic, Mary Ellen; Rockwell, Kristin L.; Weed, Michael R.; Cacace, Angela M.; Westphal, Ryan S.; Alt, Andrew; Brown, Jeffrey M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">354</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">340-349</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The present studies represent the first published report of a dopamine D1 pos. allosteric modulator (PAM).  D1 receptors have been proposed as a therapeutic target for the treatment of cognitive deficits assocd. with schizophrenia.  However, the clin. utility of orthosteric agonist compds. is limited by cardiovascular side effects, poor pharmacokinetics, lack of D1 selectivity, and an inverted dose response.  A no. of these challenges may be overcome by utilization of a selective D1 PAM.  The current studies describe two chem. distinct D1 PAMs: Compd. A [1-((rel-1S,3R,6R)-6-(benzo[d][1,3]dioxol-5-yl)bicyclo[4.1.0]heptan-3-yl)-4-(2-bromo-5-chlorobenzyl)piperazine] and Compd. B [rel-(9R,10R,12S)-N-(2,6-dichloro-3-methylphenyl)-12-methyl-9,10-dihydro-9,10-ethanoanthracene-12-carboxamide].  Compd. A shows pure PAM activity, with an EC50 of 230 nM and agonist activity at the D2 receptor in D2-expressing human embryonic kidney cells.  Compd. B shows superior potency (EC50 of 43 nM) and selectivity for D1 vs. D2 dopamine receptors.  Unlike Compd. A, Compd. B is selective for human and nonhuman primate D1 receptors, but lacks activity at the rodent (rat and mouse) D1 receptors.  Using mol. biol. techniques, a single amino acid was identified at position 130, which mediates the species selectivity of Compd. B.  These data represent the first described D1-selective PAMs and define crit. amino acids that regulate species selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDNdz5evIitLVg90H21EOLACvtfcHk0liJo2oWuetl7w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Ols7fJ&md5=65b8c08ed7f8af31822c15ce662e5724</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1124%2Fjpet.115.224071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.115.224071%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DM.%2BA.%26aulast%3DHunihan%26aufirst%3DL.%26aulast%3DWatson%26aufirst%3DJ.%26aulast%3DGentles%26aufirst%3DR.%2BG.%26aulast%3DHu%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DBronson%26aufirst%3DJ.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26aulast%3DBeno%26aufirst%3DB.%2BR.%26aulast%3DFerrante%26aufirst%3DM.%26aulast%3DHendricson%26aufirst%3DA.%26aulast%3DKnox%26aufirst%3DR.%2BJ.%26aulast%3DMolski%26aufirst%3DT.%2BF.%26aulast%3DKong%26aufirst%3DY.%26aulast%3DCvijic%26aufirst%3DM.%2BE.%26aulast%3DRockwell%26aufirst%3DK.%2BL.%26aulast%3DWeed%26aufirst%3DM.%2BR.%26aulast%3DCacace%26aufirst%3DA.%2BM.%26aulast%3DWestphal%26aufirst%3DR.%2BS.%26aulast%3DAlt%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DJ.%2BM.%26atitle%3DDiscovery%2520of%2520D1%2520dopamine%2520receptor%2520positive%2520allosteric%2520modulators%253A%2520characterization%2520of%2520pharmacology%2520and%2520identification%2520of%2520residues%2520that%2520regulate%2520species%2520selectivity%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D354%26issue%3D3%26spage%3D340%26epage%3D349%26doi%3D10.1124%2Fjpet.115.224071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Svensson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinz, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaus, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krushinski, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhard, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellman, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getman, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menezes, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maren, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falcone, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morin, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knopp, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogovoy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okun, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suter, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Statnick, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehlert, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucaites, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emkey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeLapp, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiernicki, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cramer, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruns, R. F.</span></span> <span> </span><span class="NLM_article-title">An allosteric potentiator of the dopamine D1 receptor increases locomotor activity in human D1 knock-in mice without causing stereotypy or tachyphylaxis</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>360</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">117</span>â <span class="NLM_lpage">128</span>, <span class="refDoi">Â DOI: 10.1124/jpet.116.236372</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1124%2Fjpet.116.236372" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=27811173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2sXptVOjsbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=360&publication_year=2017&pages=117-128&issue=1&author=K.+A.+Svenssonauthor=B.+A.+Heinzauthor=J.+M.+Schausauthor=J.+P.+Beckauthor=J.+Haoauthor=J.+H.+Krushinskiauthor=M.+R.+Reinhardauthor=M.+P.+Cohenauthor=S.+L.+Hellmanauthor=B.+G.+Getmanauthor=X.+Wangauthor=M.+M.+Menezesauthor=D.+L.+Marenauthor=J.+F.+Falconeauthor=W.+H.+Andersonauthor=R.+A.+Wrightauthor=S.+M.+Morinauthor=K.+L.+Knoppauthor=B.+L.+Adamsauthor=B.+Rogovoyauthor=I.+Okunauthor=T.+M.+Suterauthor=M.+A.+Statnickauthor=D.+R.+Gehlertauthor=D.+L.+Nelsonauthor=V.+L.+Lucaitesauthor=R.+Emkeyauthor=N.+W.+DeLappauthor=T.+R.+Wiernickiauthor=J.+W.+Cramerauthor=C.+R.+Yangauthor=R.+F.+Bruns&title=An+allosteric+potentiator+of+the+dopamine+D1+receptor+increases+locomotor+activity+in+human+D1+knock-in+mice+without+causing+stereotypy+or+tachyphylaxis&doi=10.1124%2Fjpet.116.236372"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">An allosteric potentiator of the dopamine D1 receptor increases locomotor activity in human D1 knock-in mice without causing stereotypy or tachyphylaxis</span></div><div class="casAuthors">Svensson, Kjell A.; Heinz, Beverly A.; Schaus, John M.; Beck, James P.; Hao, Junliang; Krushinski, Joseph H.; Reinhard, Matthew R.; Cohen, Michael P.; Hellman, Sarah L.; Getman, Brian G.; Wang, Xushan; Menezes, Michelle M.; Maren, Deanna L.; Falcone, Julie F.; Anderson, Wesley H.; Wright, Rebecca A.; Morin, S. Michelle; Knopp, Kelly L.; Adams, Benjamin L.; Rogovoy, Borys; Okun, Ilya; Suter, Todd M.; Statnick, Michael A.; Gehlert, Donald R.; Nelson, David L.; Lucaites, Virginia L.; Emkey, Renee; DeLapp, Neil W.; Wiernicki, Todd R.; Cramer, Jeffrey W.; Yang, Charles R.; Bruns, Robert F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">360</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">117-128</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Allosteric potentiators amplify the sensitivity of physiol. control circuits, a mode of action that could provide therapeutic advantages.  This hypothesis was tested with the dopamine D1 receptor potentiator DETQ [2-(2,6-dichlorophenyl)-1-((1S,3R)-3-(hydroxymethyl)-5-(2-hydroxypropan-2-yl)-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one].  In human embryonic kidney 293 (HEK293) cells expressing the human D1 receptor, DETQ induced a 21-fold leftward shift in the cAMP response to dopamine, with a Kb of 26 nM.  The max. response to DETQ alone was â¼12% of the max. response to dopamine, suggesting weak allosteric agonist activity.  DETQ was â¼30-fold less potent at rat and mouse D1 receptors and was inactive at the human D5 receptor.  To enable studies in rodents, an hD1 knock-in mouse was generated.  DETQ (3-20 mg/kg orally) caused a robust (â¼10-fold) increase in locomotor activity (LMA) in habituated hD1 mice but was inactive in wild-type mice.  The LMA response to DETQ was blocked by the D1 antagonist SCH39166 and was dependent on endogenous dopamine.  LMA reached a plateau at higher doses (30-240 mg/kg) even though free brain levels of DETQ continued to increase over the entire dose range.  In contrast, the D1 agonists SKF 82958, A-77636, and dihydrexidine showed bell-shaped dose-response curves with a profound redn. in LMA at higher doses; video-tracking confirmed that the redn. in LMA caused by SKF 82958 was due to competing stereotyped behaviors.  When dosed daily for 4 days, DETQ continued to elicit an increase in LMA, whereas the D1 agonist A-77636 showed complete tachyphylaxis by day 2.  These results confirm that allosteric potentiators may have advantages compared with direct-acting agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrslzO-nYslkLVg90H21EOLACvtfcHk0lgDG3HyV4HW7A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXptVOjsbg%253D&md5=3c9777e82d3ba85fa9f2ac40b8f4437b</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1124%2Fjpet.116.236372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.116.236372%26sid%3Dliteratum%253Aachs%26aulast%3DSvensson%26aufirst%3DK.%2BA.%26aulast%3DHeinz%26aufirst%3DB.%2BA.%26aulast%3DSchaus%26aufirst%3DJ.%2BM.%26aulast%3DBeck%26aufirst%3DJ.%2BP.%26aulast%3DHao%26aufirst%3DJ.%26aulast%3DKrushinski%26aufirst%3DJ.%2BH.%26aulast%3DReinhard%26aufirst%3DM.%2BR.%26aulast%3DCohen%26aufirst%3DM.%2BP.%26aulast%3DHellman%26aufirst%3DS.%2BL.%26aulast%3DGetman%26aufirst%3DB.%2BG.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DMenezes%26aufirst%3DM.%2BM.%26aulast%3DMaren%26aufirst%3DD.%2BL.%26aulast%3DFalcone%26aufirst%3DJ.%2BF.%26aulast%3DAnderson%26aufirst%3DW.%2BH.%26aulast%3DWright%26aufirst%3DR.%2BA.%26aulast%3DMorin%26aufirst%3DS.%2BM.%26aulast%3DKnopp%26aufirst%3DK.%2BL.%26aulast%3DAdams%26aufirst%3DB.%2BL.%26aulast%3DRogovoy%26aufirst%3DB.%26aulast%3DOkun%26aufirst%3DI.%26aulast%3DSuter%26aufirst%3DT.%2BM.%26aulast%3DStatnick%26aufirst%3DM.%2BA.%26aulast%3DGehlert%26aufirst%3DD.%2BR.%26aulast%3DNelson%26aufirst%3DD.%2BL.%26aulast%3DLucaites%26aufirst%3DV.%2BL.%26aulast%3DEmkey%26aufirst%3DR.%26aulast%3DDeLapp%26aufirst%3DN.%2BW.%26aulast%3DWiernicki%26aufirst%3DT.%2BR.%26aulast%3DCramer%26aufirst%3DJ.%2BW.%26aulast%3DYang%26aufirst%3DC.%2BR.%26aulast%3DBruns%26aufirst%3DR.%2BF.%26atitle%3DAn%2520allosteric%2520potentiator%2520of%2520the%2520dopamine%2520D1%2520receptor%2520increases%2520locomotor%2520activity%2520in%2520human%2520D1%2520knock-in%2520mice%2520without%2520causing%2520stereotypy%2520or%2520tachyphylaxis%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2017%26volume%3D360%26issue%3D1%26spage%3D117%26epage%3D128%26doi%3D10.1124%2Fjpet.116.236372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruns, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wafford, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanks, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâNeill, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastwood, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaus, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witkin, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chernet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katner, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryder, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masquelin, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Love, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maren, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falcone, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menezes, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svensson, K. A.</span></span> <span> </span><span class="NLM_article-title">Preclinical profile of a dopamine D1 potentiator suggests therapeutic utility in neurological and psychiatric disorders</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">351</span>â <span class="NLM_lpage">365</span>, <span class="refDoi">Â DOI: 10.1016/j.neuropharm.2017.10.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.neuropharm.2017.10.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=29102759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslygs7jN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2018&pages=351-365&author=R.+F.+Brunsauthor=S.+N.+Mitchellauthor=K.+A.+Waffordauthor=A.+J.+Harperauthor=E.+A.+Shanksauthor=G.+Carterauthor=M.+J.+O%E2%80%99Neillauthor=T.+K.+Murrayauthor=B.+J.+Eastwoodauthor=J.+M.+Schausauthor=J.+P.+Beckauthor=J.+Haoauthor=J.+M.+Witkinauthor=X.+Liauthor=E.+Chernetauthor=J.+S.+Katnerauthor=H.+Wangauthor=J.+W.+Ryderauthor=M.+E.+Masquelinauthor=L.+K.+Thompsonauthor=P.+L.+Loveauthor=D.+L.+Marenauthor=J.+F.+Falconeauthor=M.+M.+Menezesauthor=L.+Zhangauthor=C.+R.+Yangauthor=K.+A.+Svensson&title=Preclinical+profile+of+a+dopamine+D1+potentiator+suggests+therapeutic+utility+in+neurological+and+psychiatric+disorders&doi=10.1016%2Fj.neuropharm.2017.10.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical profile of a dopamine D1 potentiator suggests therapeutic utility in neurological and psychiatric disorders</span></div><div class="casAuthors">Bruns, Robert F.; Mitchell, Stephen N.; Wafford, Keith A.; Harper, Alex J.; Shanks, Elaine A.; Carter, Guy; O'Neill, Michael J.; Murray, Tracey K.; Eastwood, Brian J.; Schaus, John M.; Beck, James P.; Hao, Junliang; Witkin, Jeffrey M.; Li, Xia; Chernet, Eyassu; Katner, Jason S.; Wang, Hong; Ryder, John W.; Masquelin, Meghane E.; Thompson, Linda K.; Love, Patrick L.; Maren, Deanna L.; Falcone, Julie F.; Menezes, Michelle M.; Zhang, Linli; Yang, Charles R.; Svensson, Kjell A.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">351-365</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">DETQ, an allosteric potentiator of the dopamine D1 receptor, was tested in therapeutic models that were known to respond to D1 agonists.  Because of a species difference in affinity for DETQ, all rodent expts. used transgenic mice expressing the human D1 receptor (hD1 mice).  When given alone, DETQ reversed the locomotor depression caused by a low dose of reserpine.  DETQ also acted synergistically with L-DOPA to reverse the strong hypokinesia seen with a higher dose of reserpine.  These results indicate potential as both monotherapy and adjunct treatment in Parkinson's disease.  DETQ markedly increased release of both acetylcholine and histamine in the prefrontal cortex, and increased levels of histamine metabolites in the striatum.  In the hippocampus, the combination of DETQ and the cholinesterase inhibitor rivastigmine increased ACh to a greater degree than either agent alone.  DETQ also increased phosphorylation of the AMPA receptor (GluR1) and the transcription factor CREB in the striatum, consistent with enhanced synaptic plasticity.  In the Y-maze, DETQ increased arm entries but (unlike a D1 agonist) did not reduce spontaneous alternation between arms at high doses.  DETQ enhanced wakefulness in EEG studies in hD1 mice and decreased immobility in the forced-swim test, a model for antidepressant-like activity.  In rhesus monkeys, DETQ increased spontaneous eye-blink rate, a measure that is known to be depressed in Parkinson's disease.  Together, these results provide support for potential utility of D1 potentiators in the treatment of several neuropsychiatric disorders, including Parkinson's disease, Alzheimer's disease, cognitive impairment in schizophrenia, and major depressive disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbYbhSCBxGE7Vg90H21EOLACvtfcHk0lgDG3HyV4HW7A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslygs7jN&md5=4d7d7fb8c685b303b53ff90b7cd32b52</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2017.10.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2017.10.032%26sid%3Dliteratum%253Aachs%26aulast%3DBruns%26aufirst%3DR.%2BF.%26aulast%3DMitchell%26aufirst%3DS.%2BN.%26aulast%3DWafford%26aufirst%3DK.%2BA.%26aulast%3DHarper%26aufirst%3DA.%2BJ.%26aulast%3DShanks%26aufirst%3DE.%2BA.%26aulast%3DCarter%26aufirst%3DG.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DM.%2BJ.%26aulast%3DMurray%26aufirst%3DT.%2BK.%26aulast%3DEastwood%26aufirst%3DB.%2BJ.%26aulast%3DSchaus%26aufirst%3DJ.%2BM.%26aulast%3DBeck%26aufirst%3DJ.%2BP.%26aulast%3DHao%26aufirst%3DJ.%26aulast%3DWitkin%26aufirst%3DJ.%2BM.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DChernet%26aufirst%3DE.%26aulast%3DKatner%26aufirst%3DJ.%2BS.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DRyder%26aufirst%3DJ.%2BW.%26aulast%3DMasquelin%26aufirst%3DM.%2BE.%26aulast%3DThompson%26aufirst%3DL.%2BK.%26aulast%3DLove%26aufirst%3DP.%2BL.%26aulast%3DMaren%26aufirst%3DD.%2BL.%26aulast%3DFalcone%26aufirst%3DJ.%2BF.%26aulast%3DMenezes%26aufirst%3DM.%2BM.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DC.%2BR.%26aulast%3DSvensson%26aufirst%3DK.%2BA.%26atitle%3DPreclinical%2520profile%2520of%2520a%2520dopamine%2520D1%2520potentiator%2520suggests%2520therapeutic%2520utility%2520in%2520neurological%2520and%2520psychiatric%2520disorders%26jtitle%3DNeuropharmacology%26date%3D2018%26volume%3D128%26spage%3D351%26epage%3D365%26doi%3D10.1016%2Fj.neuropharm.2017.10.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huryn, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosford, N. D. P.</span></span> <span> </span><span class="NLM_article-title">The molecular libraries screening center network (MLSCN): identifying chemical probes of biological systems</span>. <i>Annu. Rep. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">401</span>â <span class="NLM_lpage">416</span>, <span class="refDoi">Â DOI: 10.1016/S0065-7743(07)42026-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2FS0065-7743%2807%2942026-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BD1cXksFOgsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2007&pages=401-416&author=D.+M.+Hurynauthor=N.+D.+P.+Cosford&title=The+molecular+libraries+screening+center+network+%28MLSCN%29%3A+identifying+chemical+probes+of+biological+systems&doi=10.1016%2FS0065-7743%2807%2942026-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">The molecular libraries screening center network (MLSCN): identifying chemical probes of biological systems</span></div><div class="casAuthors">Huryn, Donna M.; Cosford, Nicholas D. P.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Reports in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">401-416</span>CODEN:
                <span class="NLM_cas:coden">ARMCBI</span>;
        ISSN:<span class="NLM_cas:issn">0065-7743</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The NIH Mol. Libraries Screening Center Network (MLSCN) is a subset of the Mol. Libraries Initiative (MLI) component of the NIH Roadmap for Medical Research.  It consists of a consortium of 10 centers, each having expertise in assay development, high-throughput screening (HTS), chem. and informatics.  Using a centralized screening library of approx. 100,000 small mols. and assays from the research community, scientists at each center optimize assays, carry out high-throughput screens, and deposit the results into PubChem.  Based on the data from those assays, chemists at each center further optimize the initial hits in order to develop unique, small mol. probes of biol. systems.  Informaticists contribute to data handling and anal. throughout this process.  The chem. probes developed are available to researchers (both public and private sectors) via data deposition into PubChem, and in the future, via access to samples and synthetic protocols to prep. the probes.  These efforts support the ultimate goals of the MLSCN and the MLI, which is to "expand the availability, flexibility, and use of small-mol. chem. probes for basic research".  The completion of the human genome project, a coordinated effort between government, academia, and industry, has prompted a vast expanse of medical research focused on the understanding of the fundamental causes of human disease.  The Mol. Libraries and Imaging initiative is a natural extension of that ground-breaking effort.  By providing access to assays, HTS capabilities, small mol. libraries and chem. optimization expertise, novel chem. probes are being developed that will allow the study of gene function, biochem. pathways, and cellular biol.  It is also possible that through this initiative, starting points for new drugs, particularly of rare diseases, will be identified.  The data deposited into PubChem via this effort will also serve as an unprecedented source of information for scientists in all biomedical disciplines.  The availability of large datasets of biol. activity on a common set of compds. should serve to stimulate advances in computational and predictive models of biol. activities and chem. properties.  This dataset should also expedite biomedical research through its use to evaluate selectivity, toxicity, and off-target activities of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJo-AOD73gmLVg90H21EOLACvtfcHk0lgDG3HyV4HW7A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXksFOgsw%253D%253D&md5=8c3b1d51eb5b11b0cc8631dc23665d58</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2FS0065-7743%2807%2942026-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-7743%252807%252942026-7%26sid%3Dliteratum%253Aachs%26aulast%3DHuryn%26aufirst%3DD.%2BM.%26aulast%3DCosford%26aufirst%3DN.%2BD.%2BP.%26atitle%3DThe%2520molecular%2520libraries%2520screening%2520center%2520network%2520%2528MLSCN%2529%253A%2520identifying%2520chemical%2520probes%2520of%2520biological%2520systems%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2007%26volume%3D42%26spage%3D401%26epage%3D416%26doi%3D10.1016%2FS0065-7743%2807%2942026-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luderman, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conroy, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Free, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Southall, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Soto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moritz, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willette, B. K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fyfe, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Titus, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazelwood, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">AubÃ©, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frankowski, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span> <span> </span><span class="NLM_article-title">Identification of positive allosteric modulators of the D1 dopamine receptor that act at diverse binding sites</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>94</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1197</span>â <span class="NLM_lpage">1209</span>, <span class="refDoi">Â DOI: 10.1124/mol.118.113175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1124%2Fmol.118.113175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=30068735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVGgt7fM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2018&pages=1197-1209&issue=4&author=K.+D.+Ludermanauthor=J.+L.+Conroyauthor=R.+B.+Freeauthor=N.+Southallauthor=M.+Ferrerauthor=M.+Sanchez-Sotoauthor=A.+E.+Moritzauthor=B.+K.+A.+Willetteauthor=T.+J.+Fyfeauthor=P.+Jainauthor=S.+Titusauthor=L.+A.+Hazelwoodauthor=J.+Aub%C3%A9author=J.+R.+Laneauthor=K.+J.+Frankowskiauthor=D.+R.+Sibley&title=Identification+of+positive+allosteric+modulators+of+the+D1+dopamine+receptor+that+act+at+diverse+binding+sites&doi=10.1124%2Fmol.118.113175"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of positive allosteric modulators of the D1 dopamine receptor that act at diverse binding sites</span></div><div class="casAuthors">Luderman, Kathryn D.; Conroy, Jennie L.; Free, R. Benjamin; Southall, Noel; Ferrer, Marc; Sanchez-Soto, Marta; Moritz, Amy E.; Willette, Blair K. A.; Fyfe, Tim J.; Jain, Prashi; Titus, Steve; Hazelwood, Lisa A.; Aube, Jeffrey; Lane, J. Robert; Frankowski, Kevin J.; Sibley, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1197-1209</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The D1 dopamine receptor is linked to a variety of neuropsychiatric disorders and represents an attractive drug target for the enhancement of cognition in schizophrenia, Alzheimer disease, and other disorders.  Pos. allosteric modulators (PAMs), with their potential for greater selectivity and larger therapeutic windows, may represent a viable drug development strategy, as orthosteric D1 receptor agonists possess known clin. liabilities.  We discovered two structurally distinct D1 receptor PAMs, MLS6585 and MLS1082, via a high-throughput screen of the NIH Mol. Libraries program small-mol. library.  Both compds. potentiate dopamine-stimulated G protein- and Î²-arrestin-mediated signaling and increase the affinity of dopamine for the D1 receptor with low micromolar potencies.  Neither compd. displayed any intrinsic agonist activity.  Both compds. were also found to potentiate the efficacy of partial agonists.  We tested maximally effective concns. of each PAM in combination to det. if the compds. might act at sep. or similar sites.  In combination, MLS1082 + MLS6585 produced an additive potentiation of dopamine potency beyond that caused by either PAM alone for both Î²-arrestin recruitment and cAMP accumulation, suggesting diverse sites of action.  In addn., MLS6585, but not MLS1082, had additive activity with the previously described D1 receptor PAM "Compd. B," suggesting that MLS1082 and Compd. B may share a common binding site.  A point mutation (R130Q) in the D1 receptor was found to abrogate MLS1082 activity without affecting that of MLS6585, suggesting this residue may be involved in the binding/activity of MLS1082 but not that of MLS6585.  Together, MLS1082 and MLS6585 may serve as important tool compds. for the characterization of diverse allosteric sites on the D1 receptor as well as the development of optimized lead compds. for therapeutic use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFUUoar8r06LVg90H21EOLACvtfcHk0liT2-cG3coJ0A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVGgt7fM&md5=6d87d7a6fe63049c6fe61ff342f5c897</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1124%2Fmol.118.113175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.118.113175%26sid%3Dliteratum%253Aachs%26aulast%3DLuderman%26aufirst%3DK.%2BD.%26aulast%3DConroy%26aufirst%3DJ.%2BL.%26aulast%3DFree%26aufirst%3DR.%2BB.%26aulast%3DSouthall%26aufirst%3DN.%26aulast%3DFerrer%26aufirst%3DM.%26aulast%3DSanchez-Soto%26aufirst%3DM.%26aulast%3DMoritz%26aufirst%3DA.%2BE.%26aulast%3DWillette%26aufirst%3DB.%2BK.%2BA.%26aulast%3DFyfe%26aufirst%3DT.%2BJ.%26aulast%3DJain%26aufirst%3DP.%26aulast%3DTitus%26aufirst%3DS.%26aulast%3DHazelwood%26aufirst%3DL.%2BA.%26aulast%3DAub%25C3%25A9%26aufirst%3DJ.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26aulast%3DFrankowski%26aufirst%3DK.%2BJ.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26atitle%3DIdentification%2520of%2520positive%2520allosteric%2520modulators%2520of%2520the%2520D1%2520dopamine%2520receptor%2520that%2520act%2520at%2520diverse%2520binding%2520sites%26jtitle%3DMol.%2520Pharmacol.%26date%3D2018%26volume%3D94%26issue%3D4%26spage%3D1197%26epage%3D1209%26doi%3D10.1124%2Fmol.118.113175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burford, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livingston, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canals, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budenholzer, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâConnell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banks, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filizola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassoni, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehrman, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerritz, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alt, A.</span></span> <span> </span><span class="NLM_article-title">Discovery, synthesis, and molecular pharmacology of selective positive allosteric modulators of the Î´-opioid receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4220</span>â <span class="NLM_lpage">4229</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00007</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00007" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmvVyms70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4220-4229&issue=10&author=N.+T.+Burfordauthor=K.+E.+Livingstonauthor=M.+Canalsauthor=M.+R.+Ryanauthor=L.+M.+Budenholzerauthor=Y.+Hanauthor=Y.+Shangauthor=J.+J.+Herbstauthor=J.+O%E2%80%99Connellauthor=M.+Banksauthor=L.+Zhangauthor=M.+Filizolaauthor=D.+L.+Bassoniauthor=T.+S.+Wehrmanauthor=A.+Christopoulosauthor=J.+R.+Traynorauthor=S.+W.+Gerritzauthor=A.+Alt&title=Discovery%2C+synthesis%2C+and+molecular+pharmacology+of+selective+positive+allosteric+modulators+of+the+%CE%B4-opioid+receptor&doi=10.1021%2Facs.jmedchem.5b00007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery, Synthesis, and Molecular Pharmacology of Selective Positive Allosteric Modulators of the Î´-Opioid Receptor</span></div><div class="casAuthors">Burford, Neil T.; Livingston, Kathryn E.; Canals, Meritxell; Ryan, Molly R.; Budenholzer, Lauren M. L.; Han, Ying; Shang, Yi; Herbst, John J.; O'Connell, Jonathan; Banks, Martyn; Zhang, Litao; Filizola, Marta; Bassoni, Daniel L.; Wehrman, Tom S.; Christopoulos, Arthur; Traynor, John R.; Gerritz, Samuel W.; Alt, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4220-4229</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Allosteric modulators of G protein-coupled receptors (GPCRs) have a no. of potential advantages compared to agonists or antagonists that bind to the orthosteric site of the receptor.  These include the potential for receptor selectivity, maintenance of the temporal and spatial fidelity of signaling in vivo, the ceiling effect of the allosteric cooperativity which may prevent overdose issues, and engendering bias by differentially modulating distinct signaling pathways.  Here we describe the discovery, synthesis, and mol. pharmacol. of Î´-opioid receptor-selective pos. allosteric modulators (Î´ PAMs).  These Î´ PAMs increase the affinity and/or efficacy of the orthosteric agonists leu-enkephalin, SNC80 and TAN67, as measured by receptor binding, G protein activation, Î²-arrestin recruitment, adenylyl cyclase inhibition, and extracellular signal-regulated kinases (ERK) activation.  As such, these compds. are useful pharmacol. tools to probe the mol. pharmacol. of the Î´ receptor and to explore the therapeutic potential of Î´ PAMs in diseases such as chronic pain and depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqp9cc465_u0bVg90H21EOLACvtfcHk0liT2-cG3coJ0A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmvVyms70%253D&md5=3019381e050f2928f244954fa7d2bd46</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00007%26sid%3Dliteratum%253Aachs%26aulast%3DBurford%26aufirst%3DN.%2BT.%26aulast%3DLivingston%26aufirst%3DK.%2BE.%26aulast%3DCanals%26aufirst%3DM.%26aulast%3DRyan%26aufirst%3DM.%2BR.%26aulast%3DBudenholzer%26aufirst%3DL.%2BM.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DShang%26aufirst%3DY.%26aulast%3DHerbst%26aufirst%3DJ.%2BJ.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DJ.%26aulast%3DBanks%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DFilizola%26aufirst%3DM.%26aulast%3DBassoni%26aufirst%3DD.%2BL.%26aulast%3DWehrman%26aufirst%3DT.%2BS.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26aulast%3DGerritz%26aufirst%3DS.%2BW.%26aulast%3DAlt%26aufirst%3DA.%26atitle%3DDiscovery%252C%2520synthesis%252C%2520and%2520molecular%2520pharmacology%2520of%2520selective%2520positive%2520allosteric%2520modulators%2520of%2520the%2520%25CE%25B4-opioid%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D10%26spage%3D4220%26epage%3D4229%26doi%3D10.1021%2Facs.jmedchem.5b00007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ali, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurijssens, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostenfeld, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHugh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stylianou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott-Stevens, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosking, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewit, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic and pharmacodynamic profiling of a P2 Ã 7 receptor allosteric modulator GSK1482160 in healthy human subjects</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>75</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">197</span>â <span class="NLM_lpage">207</span>, <span class="refDoi">Â DOI: 10.1111/j.1365-2125.2012.04320.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1111%2Fj.1365-2125.2012.04320.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=22568863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVGmsbnF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2013&pages=197-207&issue=1&author=Z.+Aliauthor=B.+Laurijssensauthor=T.+Ostenfeldauthor=S.+McHughauthor=A.+Stylianouauthor=P.+Scott-Stevensauthor=L.+Hoskingauthor=O.+Dewitauthor=J.+C.+Richardsonauthor=C.+Chen&title=Pharmacokinetic+and+pharmacodynamic+profiling+of+a+P2+%C3%97+7+receptor+allosteric+modulator+GSK1482160+in+healthy+human+subjects&doi=10.1111%2Fj.1365-2125.2012.04320.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic and pharmacodynamic profiling of a P2X7 receptor allosteric modulator GSK1482160 in healthy human subjects</span></div><div class="casAuthors">Ali, Zahid; Laurijssens, Bart; Ostenfeld, Thor; McHugh, Simon; Stylianou, Anastasia; Scott-Stevens, Paul; Hosking, Louise; Dewit, Odile; Richardson, Jill C.; Chen, Chao</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">197-207</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT â¢ P2X7 receptors are involved in the prodn. of pro-inflammatory cytokines, such as Il-1Î², by central and peripheral immune cells.  Il-1Î² has been implicated as an important mediator of inflammation.  Therefore, the P2X7 receptor is an attractive therapeutic target for inflammatory diseases.  WHAT THIS STUDY ADDS â¢ Findings in pharmacokinetics, pharmacodynamics, safety and tolerability of a P2X7 receptor modulator, GSK1482160, from the first human study for the mol. are described.  A pharmacokinetic/pharmacodynamic model for LPS-stimulated ATP-induced Il-1Î² prodn. in blood allowed the integration of all relevant data and provided in vivo evidence of the nature of the drug-receptor interaction.  The model has the potential to be used to simulate future trials.  AIMS This paper describes findings from the first-in-human study for GSK1482160, an orally available allosteric P2X7 receptor modulator.  The study aimed to assess the pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of the compd. in healthy subjects.  METHODS Escalating single doses of up to 1 g were administered to healthy subjects in a single-blind and placebo-controlled fashion.  Safety, tolerability, blood drug concns. and ex vivo Il-1Î² prodn. in blood were evaluated.  RESULTS. Drug concn. peaked within 3.5 h of dosing under fasting conditions and declined thereafter with a relatively short half-life of less than 4.5 h.  Exposure was proportional to dose with between subject variability of less than 60%.  A PK/PD model quantified Il-1Î² as a function of drug exposure.  The model allowed simulation of in vivo pharmacol. for various untested dose levels and regimens.  Furthermore, the mechanistic model supported the hypothesis that the compd. reduces the efficacy of ATP at the P2X7 receptor without affecting its affinity.  No major safety or tolerability concerns were identified in this small study (n= 29), except for one case of asymptomatic accelerated idioventricular rhythm at the top dose.  CONCLUSION. The model-based approach maximized anal. power by integrating all biomarker data and revealed mechanistic insight into the pharmacol. of P2X7 modulation by GSK1482160.  Simulations by this model ultimately led to the discontinuation of the development of this compd.  The therapeutic relevance of the P2X7 receptor remains to be tested in patients.  The mechanistic-model-based approach can be applied widely to drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr41Bz54gV-qLVg90H21EOLACvtfcHk0lge7w-R-0HX1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVGmsbnF&md5=835023636e0c5b039245344c2a9a207a</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2012.04320.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2012.04320.x%26sid%3Dliteratum%253Aachs%26aulast%3DAli%26aufirst%3DZ.%26aulast%3DLaurijssens%26aufirst%3DB.%26aulast%3DOstenfeld%26aufirst%3DT.%26aulast%3DMcHugh%26aufirst%3DS.%26aulast%3DStylianou%26aufirst%3DA.%26aulast%3DScott-Stevens%26aufirst%3DP.%26aulast%3DHosking%26aufirst%3DL.%26aulast%3DDewit%26aufirst%3DO.%26aulast%3DRichardson%26aufirst%3DJ.%2BC.%26aulast%3DChen%26aufirst%3DC.%26atitle%3DPharmacokinetic%2520and%2520pharmacodynamic%2520profiling%2520of%2520a%2520P2%2520%25C3%2597%25207%2520receptor%2520allosteric%2520modulator%2520GSK1482160%2520in%2520healthy%2520human%2520subjects%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D75%26issue%3D1%26spage%3D197%26epage%3D207%26doi%3D10.1111%2Fj.1365-2125.2012.04320.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mistry, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valant, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuano, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scammells, P. J.</span></span> <span> </span><span class="NLM_article-title">Synthesis and pharmacological profiling of analogues of benzyl quinolone carboxylic acid (BQCA) as allosteric modulators of the M<sub>1</sub> muscarinic receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">5151</span>â <span class="NLM_lpage">5172</span>, <span class="refDoi">Â DOI: 10.1021/jm400540b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400540b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3sXosVaqtbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5151-5172&issue=12&author=S.+N.+Mistryauthor=C.+Valantauthor=P.+M.+Sextonauthor=B.+Capuanoauthor=A.+Christopoulosauthor=P.+J.+Scammells&title=Synthesis+and+pharmacological+profiling+of+analogues+of+benzyl+quinolone+carboxylic+acid+%28BQCA%29+as+allosteric+modulators+of+the+M1+muscarinic+receptor&doi=10.1021%2Fjm400540b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Pharmacological Profiling of Analogues of Benzyl Quinolone Carboxylic Acid (BQCA) as Allosteric Modulators of the M1 Muscarinic Receptor</span></div><div class="casAuthors">Mistry, Shailesh N.; Valant, Celine; Sexton, Patrick M.; Capuano, Ben; Christopoulos, Arthur; Scammells, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5151-5172</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Established therapy in Alzheimer's disease involves potentiation of the endogenous orthosteric ligand, acetylcholine, at the M1 muscarinic receptors found in higher concns. in the cortex and hippocampus.  Adverse effects, due to indiscriminate activation of other muscarinic receptor subtypes, are common.  M1 muscarinic pos. allosteric modulators/allosteric agonists such as BQCA [1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, I] offer an attractive soln., being exquisitely M1-selective over other muscarinic subtypes.  A common difficulty with allosteric ligands is interpreting SAR, based on composite potency values derived in the presence of fixed concn. of agonist.  In reality these values encompass multiple pharmacol. parameters, each potentially and differentially sensitive to structural modification of the ligand.  We report novel BQCA analogs which appear to augment ligand affinity for the receptor (pKB), intrinsic efficacy (ÏB), and both binding (Î±) and functional (Î²) cooperativity with acetylcholine.  Ultimately, development of such enriched SAR surrounding allosteric modulators will provide insight into their mode of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoigST7OJR7vbVg90H21EOLACvtfcHk0lge7w-R-0HX1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXosVaqtbs%253D&md5=ab134e0b5400aa825916695eaf1203b1</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm400540b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400540b%26sid%3Dliteratum%253Aachs%26aulast%3DMistry%26aufirst%3DS.%2BN.%26aulast%3DValant%26aufirst%3DC.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DCapuano%26aufirst%3DB.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26atitle%3DSynthesis%2520and%2520pharmacological%2520profiling%2520of%2520analogues%2520of%2520benzyl%2520quinolone%2520carboxylic%2520acid%2520%2528BQCA%2529%2520as%2520allosteric%2520modulators%2520of%2520the%2520M1%2520muscarinic%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D12%26spage%3D5151%26epage%3D5172%26doi%3D10.1021%2Fjm400540b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span> Value of Î± calculated assuming Î² = 1.<span class="NLM_contrib-group"><span class="NLM_string-name">Davoren, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnsey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettersen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodney, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edgerton, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortin, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimwood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkinson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenakin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazzaro, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotarski, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nottebaum, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâNeil, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popiolek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steyn, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorn, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, D.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of Î³- and Î´-Lactam M<sub>1</sub> positive allosteric modulators (PAMs): convulsion and cholinergic toxicity of an M1-selective PAM with weak agonist activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">6649</span>â <span class="NLM_lpage">6663</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b00597</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00597" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpslSktbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=6649-6663&issue=15&author=J.+E.+Davorenauthor=M.+Garnseyauthor=B.+Pettersenauthor=M.+A.+Brodneyauthor=J.+R.+Edgertonauthor=J.+P.+Fortinauthor=S.+Grimwoodauthor=A.+R.+Harrisauthor=S.+Jenkinsonauthor=T.+Kenakinauthor=J.+T.+Lazzaroauthor=C.+W.+Leeauthor=S.+M.+Lotarskiauthor=L.+Nottebaumauthor=S.+V.+O%E2%80%99Neilauthor=M.+Popiolekauthor=S.+Ramseyauthor=S.+J.+Steynauthor=C.+A.+Thornauthor=L.+Zhangauthor=D.+Webb&title=Design+and+synthesis+of+%CE%B3-+and+%CE%B4-Lactam+M1+positive+allosteric+modulators+%28PAMs%29%3A+convulsion+and+cholinergic+toxicity+of+an+M1-selective+PAM+with+weak+agonist+activity&doi=10.1021%2Facs.jmedchem.7b00597"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Î³- and Î´-Lactam M1 Positive Allosteric Modulators (PAMs): Convulsion and Cholinergic Toxicity of an M1-Selective PAM with Weak Agonist Activity</span></div><div class="casAuthors">Davoren, Jennifer E.; Garnsey, Michelle; Pettersen, Betty; Brodney, Michael A.; Edgerton, Jeremy R.; Fortin, Jean-Philippe; Grimwood, Sarah; Harris, Anthony R.; Jenkinson, Stephen; Kenakin, Terry; Lazzaro, John T.; Lee, Che-Wah; Lotarski, Susan M.; Nottebaum, Lisa; O'Neil, Steven V.; Popiolek, Michael; Ramsey, Simeon; Steyn, Stefanus J.; Thorn, Catherine A.; Zhang, Lei; Webb, Damien</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6649-6663</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recent data demonstrated that activation of the muscarinic M1 receptor by a subtype-selective pos. allosteric modulator (PAM) contributes to the gastrointestinal (GI) and cardiovascular (CV) cholinergic adverse events (AEs) previously attributed to M2 and M3 activation.  These studies were conducted using PAMs that also exhibited allosteric agonist activity, leaving open the possibility that direct activation by allosteric agonism, rather than allosteric modulation, could be responsible for the adverse effects.  This article describes the design and synthesis of lactam-derived M1 PAMs that address this hypothesis.  The lead mol. from this series, compd. I (PF-06827443), is a potent, low-clearance, orally bioavailable and CNS-penetrant M1-selective PAM with minimal agonist activity.  Compd. I was tested in dose escalation studies in rats and dogs and was found to induce cholinergic AEs and convulsion at therapeutic indexes similar to previous compds. with more agonist activity.  These findings provide preliminary evidence that pos. allosteric modulation of M1 is sufficient to elicit cholinergic AEs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsdLnKqXoZLrVg90H21EOLACvtfcHk0lge7w-R-0HX1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpslSktbg%253D&md5=abd7e12d7dc959269a0bae608467f827</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00597%26sid%3Dliteratum%253Aachs%26aulast%3DDavoren%26aufirst%3DJ.%2BE.%26aulast%3DGarnsey%26aufirst%3DM.%26aulast%3DPettersen%26aufirst%3DB.%26aulast%3DBrodney%26aufirst%3DM.%2BA.%26aulast%3DEdgerton%26aufirst%3DJ.%2BR.%26aulast%3DFortin%26aufirst%3DJ.%2BP.%26aulast%3DGrimwood%26aufirst%3DS.%26aulast%3DHarris%26aufirst%3DA.%2BR.%26aulast%3DJenkinson%26aufirst%3DS.%26aulast%3DKenakin%26aufirst%3DT.%26aulast%3DLazzaro%26aufirst%3DJ.%2BT.%26aulast%3DLee%26aufirst%3DC.%2BW.%26aulast%3DLotarski%26aufirst%3DS.%2BM.%26aulast%3DNottebaum%26aufirst%3DL.%26aulast%3DO%25E2%2580%2599Neil%26aufirst%3DS.%2BV.%26aulast%3DPopiolek%26aufirst%3DM.%26aulast%3DRamsey%26aufirst%3DS.%26aulast%3DSteyn%26aufirst%3DS.%2BJ.%26aulast%3DThorn%26aufirst%3DC.%2BA.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DWebb%26aufirst%3DD.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520%25CE%25B3-%2520and%2520%25CE%25B4-Lactam%2520M1%2520positive%2520allosteric%2520modulators%2520%2528PAMs%2529%253A%2520convulsion%2520and%2520cholinergic%2520toxicity%2520of%2520an%2520M1-selective%2520PAM%2520with%2520weak%2520agonist%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D15%26spage%3D6649%26epage%3D6663%26doi%3D10.1021%2Facs.jmedchem.7b00597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beshore, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMarco, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greshock, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seager, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeplinger, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuerst, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilodeau, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuduk, S. D.</span></span> <span> </span><span class="NLM_article-title">MK-7622: a first in class M<sub>1</sub> positive allosteric modulator development candidate</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">652</span>â <span class="NLM_lpage">656</span>, <span class="refDoi">Â DOI: 10.1021/acsmedchemlett.8b00095</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00095" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXos1Gmtbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=652-656&issue=7&author=D.+C.+Beshoreauthor=C.+N.+DiMarcoauthor=R.+K.+Changauthor=T.+J.+Greshockauthor=L.+Maauthor=M.+Wittmannauthor=M.+A.+Seagerauthor=K.+A.+Koeplingerauthor=C.+D.+Thompsonauthor=J.+Fuerstauthor=G.+D.+Hartmanauthor=M.+T.+Bilodeauauthor=W.+J.+Rayauthor=S.+D.+Kuduk&title=MK-7622%3A+a+first+in+class+M1+positive+allosteric+modulator+development+candidate&doi=10.1021%2Facsmedchemlett.8b00095"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">MK-7622: A First-in-Class M1 Positive Allosteric Modulator Development Candidate</span></div><div class="casAuthors">Beshore, Douglas C.; Di Marco, Christina N.; Chang, Ronald K.; Greshock, Thomas J.; Ma, Lei; Wittmann, Marion; Seager, Matthew A.; Koeplinger, Kenneth A.; Thompson, Charles D.; Fuerst, Joy; Hartman, George D.; Bilodeau, Mark T.; Ray, William J.; Kuduk, Scott D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">652-656</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Identification of ligands that selectively activate the M1 muscarinic signaling pathway was sought for decades to treat a range of neurol. and cognitive disorders.  Herein, we describe the optimization efforts focused on addressing key physicochem. and safety properties, ultimately leading to the clin. candidate MK-7622, a highly selective pos. allosteric modulator of the M1 muscarinic receptor that has entered Phase II studies in patients with Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO43jxaoq6QbVg90H21EOLACvtfcHk0liIU_kuomwdtQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXos1Gmtbg%253D&md5=892787348c2ceabab0536d05e0e6d9b5</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00095%26sid%3Dliteratum%253Aachs%26aulast%3DBeshore%26aufirst%3DD.%2BC.%26aulast%3DDiMarco%26aufirst%3DC.%2BN.%26aulast%3DChang%26aufirst%3DR.%2BK.%26aulast%3DGreshock%26aufirst%3DT.%2BJ.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DWittmann%26aufirst%3DM.%26aulast%3DSeager%26aufirst%3DM.%2BA.%26aulast%3DKoeplinger%26aufirst%3DK.%2BA.%26aulast%3DThompson%26aufirst%3DC.%2BD.%26aulast%3DFuerst%26aufirst%3DJ.%26aulast%3DHartman%26aufirst%3DG.%2BD.%26aulast%3DBilodeau%26aufirst%3DM.%2BT.%26aulast%3DRay%26aufirst%3DW.%2BJ.%26aulast%3DKuduk%26aufirst%3DS.%2BD.%26atitle%3DMK-7622%253A%2520a%2520first%2520in%2520class%2520M1%2520positive%2520allosteric%2520modulator%2520development%2520candidate%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26issue%3D7%26spage%3D652%26epage%3D656%26doi%3D10.1021%2Facsmedchemlett.8b00095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davoren, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâNeil, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodney, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chenard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dlugolenski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edgerton, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnsey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimwood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kauffman, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaChapelle, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazzaro, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotarski, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nason, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhart, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salomon-Ferrer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steyn, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span> <span> </span><span class="NLM_article-title">Design and optimization of selective azaindole amide M<sub>1</sub> positive allosteric modulators</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">650</span>â <span class="NLM_lpage">655</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2015.11.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.bmcl.2015.11.053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=26631313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFant73L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=650-655&issue=2&author=J.+E.+Davorenauthor=S.+V.+O%E2%80%99Neilauthor=D.+P.+Andersonauthor=M.+A.+Brodneyauthor=L.+Chenardauthor=K.+Dlugolenskiauthor=J.+R.+Edgertonauthor=M.+Greenauthor=M.+Garnseyauthor=S.+Grimwoodauthor=A.+R.+Harrisauthor=G.+W.+Kauffmanauthor=E.+LaChapelleauthor=J.+T.+Lazzaroauthor=C.+W.+Leeauthor=S.+M.+Lotarskiauthor=D.+M.+Nasonauthor=R.+S.+Obachauthor=V.+Reinhartauthor=R.+Salomon-Ferrerauthor=S.+J.+Steynauthor=D.+Webbauthor=J.+Yanauthor=L.+Zhang&title=Design+and+optimization+of+selective+azaindole+amide+M1+positive+allosteric+modulators&doi=10.1016%2Fj.bmcl.2015.11.053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Design and optimization of selective azaindole amide M1 positive allosteric modulators</span></div><div class="casAuthors">Davoren, Jennifer E.; O'Neil, Steven V.; Anderson, Dennis P.; Brodney, Michael A.; Chenard, Lois; Dlugolenski, Keith; Edgerton, Jeremy R.; Green, Michael; Garnsey, Michelle; Grimwood, Sarah; Harris, Anthony R.; Kauffman, Gregory W.; LaChapelle, Erik; Lazzaro, John T.; Lee, Che-Wah; Lotarski, Susan M.; Nason, Deane M.; Obach, R. Scott; Reinhart, Veronica; Salomon-Ferrer, Romelia; Steyn, Stefanus J.; Webb, Damien; Yan, Jiangli; Zhang, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">650-655</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Selective activation of the M1 receptor via a pos. allosteric modulator (PAM) is a new approach for the treatment of the cognitive impairments assocd. with schizophrenia and Alzheimer's disease.  A novel series of azaindole amides and their key pharmacophore elements are described.  The nitrogen of the azaindole core is a key design element as it forms an intramol. hydrogen bond with the amide N-H thus reinforcing the bioactive conformation predicted by published SAR and the authors' homol. model.  Representative compd. 25 is a potent and selective M1 PAM that has well aligned physicochem. properties, adequate brain penetration and pharmacokinetic (PK) properties, and is active in vivo.  These favorable properties indicate that this series possesses suitable qualities for further development and studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOEhH8MxkKIrVg90H21EOLACvtfcHk0liIU_kuomwdtQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFant73L&md5=5c227d1371fe4f0cc3348af8314dd370</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.11.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.11.053%26sid%3Dliteratum%253Aachs%26aulast%3DDavoren%26aufirst%3DJ.%2BE.%26aulast%3DO%25E2%2580%2599Neil%26aufirst%3DS.%2BV.%26aulast%3DAnderson%26aufirst%3DD.%2BP.%26aulast%3DBrodney%26aufirst%3DM.%2BA.%26aulast%3DChenard%26aufirst%3DL.%26aulast%3DDlugolenski%26aufirst%3DK.%26aulast%3DEdgerton%26aufirst%3DJ.%2BR.%26aulast%3DGreen%26aufirst%3DM.%26aulast%3DGarnsey%26aufirst%3DM.%26aulast%3DGrimwood%26aufirst%3DS.%26aulast%3DHarris%26aufirst%3DA.%2BR.%26aulast%3DKauffman%26aufirst%3DG.%2BW.%26aulast%3DLaChapelle%26aufirst%3DE.%26aulast%3DLazzaro%26aufirst%3DJ.%2BT.%26aulast%3DLee%26aufirst%3DC.%2BW.%26aulast%3DLotarski%26aufirst%3DS.%2BM.%26aulast%3DNason%26aufirst%3DD.%2BM.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DReinhart%26aufirst%3DV.%26aulast%3DSalomon-Ferrer%26aufirst%3DR.%26aulast%3DSteyn%26aufirst%3DS.%2BJ.%26aulast%3DWebb%26aufirst%3DD.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DDesign%2520and%2520optimization%2520of%2520selective%2520azaindole%2520amide%2520M1%2520positive%2520allosteric%2520modulators%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26issue%3D2%26spage%3D650%26epage%3D655%26doi%3D10.1016%2Fj.bmcl.2015.11.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flohr, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutter, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohnert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellisson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaffhauser, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of the first low-shift positive allosteric modulators for the muscarinic M<sub>1</sub> receptor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">5415</span>â <span class="NLM_lpage">5419</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2017.11.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.bmcl.2017.11.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=29146472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVWnurbN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=5415-5419&issue=24&author=A.+Flohrauthor=R.+Hutterauthor=B.+Muellerauthor=C.+Bohnertauthor=M.+Pellissonauthor=H.+Schaffhauser&title=Discovery+of+the+first+low-shift+positive+allosteric+modulators+for+the+muscarinic+M1+receptor&doi=10.1016%2Fj.bmcl.2017.11.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the first low-shift positive allosteric modulators for the muscarinic M1 receptor</span></div><div class="casAuthors">Flohr, Alexander; Hutter, Roman; Mueller, Barbara; Bohnert, Claudia; Pellisson, Melanie; Schaffhauser, Herve</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5415-5419</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Pos. modulation of the muscarinic M1-receptor has for a long time attracted scientists and drug developers for the potential treatment of Alzheimer's disease or Schizophrenia.  The precognitive potential of M1 activation has however not been clin. demonstrated as a result of side effects assocd. both with agonists and pos. allosteric modulators (PAM's) of the M1-receptor.  To avoid excessive activation of the M1-receptor the authors have designed a new screening format and developed the first low-shift pos. allosteric modulators for the M1 receptor.  Low-shift PAM's offer the potential of "use-dependent" attenuation of transmitter-signaling while avoiding pseudo-agonistic behavior in vivo as a common limitation of the so far described high-shift PAM's.  With these novel M1-PAM's, the M1 receptor is potentially the first GPCR for which both, high- and low shift PAM's have become available.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV5toqiOhU7LVg90H21EOLACvtfcHk0lhr54UyPDeXUA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVWnurbN&md5=285ddb376445245ba500498c008ae9d7</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.11.008%26sid%3Dliteratum%253Aachs%26aulast%3DFlohr%26aufirst%3DA.%26aulast%3DHutter%26aufirst%3DR.%26aulast%3DMueller%26aufirst%3DB.%26aulast%3DBohnert%26aufirst%3DC.%26aulast%3DPellisson%26aufirst%3DM.%26aulast%3DSchaffhauser%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520the%2520first%2520low-shift%2520positive%2520allosteric%2520modulators%2520for%2520the%2520muscarinic%2520M1%2520receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26issue%3D24%26spage%3D5415%26epage%3D5419%26doi%3D10.1016%2Fj.bmcl.2017.11.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahring, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">StrÃ¸bÃ¦k, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartiadi, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chebib, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Absalom, N.</span></span> <span> </span><span class="NLM_article-title">A pharmacological assessment of agonists and modulators at Î±4Î²2Î³2 and Î±4Î²2Î´ GABAA receptors: the challenge in comparing apples with oranges</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">563</span>â <span class="NLM_lpage">576</span>, <span class="refDoi">Â DOI: 10.1016/j.phrs.2016.05.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.phrs.2016.05.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=27178730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1yhu7fM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2016&pages=563-576&author=P.+K.+Ahringauthor=L.+H.+Bangauthor=M.+L.+Jensenauthor=D.+Str%C3%B8b%C3%A6kauthor=L.+Y.+Hartiadiauthor=M.+Chebibauthor=N.+Absalom&title=A+pharmacological+assessment+of+agonists+and+modulators+at+%CE%B14%CE%B22%CE%B32+and+%CE%B14%CE%B22%CE%B4+GABAA+receptors%3A+the+challenge+in+comparing+apples+with+oranges&doi=10.1016%2Fj.phrs.2016.05.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">A pharmacological assessment of agonists and modulators at Î±4Î²2Î³2 and Î±4Î²2Î´ GABAA receptors: The challenge in comparing apples with oranges</span></div><div class="casAuthors">Ahring, Philip K.; Bang, Line H.; Jensen, Marianne L.; Stroebaek, Dorte; Hartiadi, Leonny Y.; Chebib, Mary; Absalom, Nathan</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">563-576</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Extrasynaptically located Î³-aminobutyric acid (GABA) receptors type A are often characterized by the presence of a Î´ subunit in the receptor complex. Î´-Contg. receptors respond to low ambient concns. of GABA, or respond to spillover of GABA from the synapse, and give rise to tonic inhibitory currents.  In certain brain regions, e.g. thalamocortical neurons, tonic inhibition is estd. to represent the majority of total GABA-mediated inhibition, which has raised substantial interest in extrasynaptic receptors as potential drug targets.  Thalamocortical neurons typically express Î±4Î²2/3Î´ receptors, however, these have proven difficult to study in recombinant in vitro expression systems due to the inherently low current levels elicited in response to GABA.  In this study, we sought to characterize a range of agonists and pos. allosteric modulators at Î±4Î²2Î´ and Î±4Î²2Î³2 receptors.  All tested agonists (GABA, THIP, muscimol, and taurine) displayed between 8 and 22 fold increase in potency at the Î±4Î²2Î´ receptor.  In contrast, modulatory potencies of steroids (allopregnanolone, THDOC and alfaxalone), anesthetics (etomidate, pentobarbital) and Delta-Selective agents 1 and 2 (DS1 and DS2) were similar at Î±4Î²2Î´ and Î±4Î²2Î³2 receptors.  When evaluating modulatory efficacies, the neurosteroids and anesthetics displayed highest efficacy at Î±4Î²2Î³2 receptors whereas DS1 and in particular DS2 had highest efficacy at Î±4Î²2Î´ receptors.  Overall, several key messages emerged: (i) none of the tested compds. displayed significant selectivity and a great need for identifying new Î´-selective compds. remains; (ii) Î±4Î²2Î´ and Î±4Î²2Î³2 receptors have such divergent intrinsic activation properties that valid comparisons of modulator efficacies are at best challenging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZlw3cES06qrVg90H21EOLACvtfcHk0lhr54UyPDeXUA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1yhu7fM&md5=de88bf1f60cf6498d21b655efd4584b7</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2016.05.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2016.05.014%26sid%3Dliteratum%253Aachs%26aulast%3DAhring%26aufirst%3DP.%2BK.%26aulast%3DBang%26aufirst%3DL.%2BH.%26aulast%3DJensen%26aufirst%3DM.%2BL.%26aulast%3DStr%25C3%25B8b%25C3%25A6k%26aufirst%3DD.%26aulast%3DHartiadi%26aufirst%3DL.%2BY.%26aulast%3DChebib%26aufirst%3DM.%26aulast%3DAbsalom%26aufirst%3DN.%26atitle%3DA%2520pharmacological%2520assessment%2520of%2520agonists%2520and%2520modulators%2520at%2520%25CE%25B14%25CE%25B22%25CE%25B32%2520and%2520%25CE%25B14%25CE%25B22%25CE%25B4%2520GABAA%2520receptors%253A%2520the%2520challenge%2520in%2520comparing%2520apples%2520with%2520oranges%26jtitle%3DPharmacol.%2520Res.%26date%3D2016%26volume%3D111%26spage%3D563%26epage%3D576%26doi%3D10.1016%2Fj.phrs.2016.05.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Langmead, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span> <span> </span><span class="NLM_article-title">Supra-physiological efficacy at GPCRs: superstition or super agonists?</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>169</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">353</span>â <span class="NLM_lpage">356</span>, <span class="refDoi">Â DOI: 10.1111/bph.12142</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1111%2Fbph.12142" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=23441648" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvFSgt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2013&pages=353-356&issue=2&author=C.+J.+Langmeadauthor=A.+Christopoulos&title=Supra-physiological+efficacy+at+GPCRs%3A+superstition+or+super+agonists%3F&doi=10.1111%2Fbph.12142"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Supra-physiological efficacy at GPCRs: superstition or super agonists?</span></div><div class="casAuthors">Langmead, Christopher J.; Christopoulos, Arthur</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">353-356</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The concept of "super agonism" has been described since the discovery of peptide hormone analogs that yielded greater functional responses than the endogenous agonists, in the early 1980s.  It has remained an area of debate as to whether such compds. can really display greater efficacy than an endogenous agonist.  However, recent pharmacol. data, combined with crystal structures of different GPCR conformations and improved anal. methods for quantifying drug action, are starting to shed light on this phenomenon and indicate that super agonists may be more than superstition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrquBL04A_rILVg90H21EOLACvtfcHk0lhr54UyPDeXUA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmvFSgt7g%253D&md5=50b127c3cda2d82b859df07e556dc463</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1111%2Fbph.12142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12142%26sid%3Dliteratum%253Aachs%26aulast%3DLangmead%26aufirst%3DC.%2BJ.%26aulast%3DChristopoulos%26aufirst%3DA.%26atitle%3DSupra-physiological%2520efficacy%2520at%2520GPCRs%253A%2520superstition%2520or%2520super%2520agonists%253F%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D169%26issue%3D2%26spage%3D353%26epage%3D356%26doi%3D10.1111%2Fbph.12142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dale, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodbeck, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doller, D.</span></span> <span> </span><span class="NLM_article-title">Chemical biology of mGlu4 receptor activation: dogmas, challenges, strategies and opportunities</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">1755</span>â <span class="NLM_lpage">1770</span>, <span class="refDoi">Â DOI: 10.2174/1568026614666140902143830</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.2174%2F1568026614666140902143830" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=25183417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslGqur3P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=1755-1770&issue=15&author=X.+Huangauthor=E.+Daleauthor=R.+M.+Brodbeckauthor=D.+Doller&title=Chemical+biology+of+mGlu4+receptor+activation%3A+dogmas%2C+challenges%2C+strategies+and+opportunities&doi=10.2174%2F1568026614666140902143830"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical Biology of mGlu4 Receptor Activation: Dogmas, Challenges, Strategies and Opportunities</span></div><div class="casAuthors">Huang, Xinyan; Dale, Elena; Brodbeck, Robbin M.; Doller, Dario</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1755-1770</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Drug design necessitates a clear understanding of the phenotypic response to be elicited by a given ligand-target interaction.  This relationship is relatively well understood for classical biol. targets of drug action, but for some novel targets, notably those amenable to allosteric modulation, developing such understanding may represent a more challenging task.  In order to gain knowledge on the nature of the functional response derived from mGlu4 receptor activation, its mol. and cell biol. are reviewed, including signalling pathways involved, receptor localization in central nervous system and beyond, and potential genetic links to disease.  Broadly held views for both, orthosteric agonists as well as allosteric modulators, are compared with specific observations for the case of mGlu4 receptor activation via orthosteric and allosteric mechanisms.  First, sub-type selectivity and brain penetration of amino acid mGlu4 receptor agonists are discussed, followed by the quantification of functional allosteric effects, the potential role of heterodimers in the functional response, and the observation of supra-physiol. efficacy of mGlu4 receptor PAMs.  We show that, in our anal., these attributes differ from those that may be expected by extrapolating from broad knowledge.  In addn., recent progress with mGlu4 receptor radioligands and PET ligands is summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdK5_t0giBdbVg90H21EOLACvtfcHk0lgheCebE9eFgg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslGqur3P&md5=57caba4e324058a3d85f5abd11b39a69</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.2174%2F1568026614666140902143830&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026614666140902143830%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DDale%26aufirst%3DE.%26aulast%3DBrodbeck%26aufirst%3DR.%2BM.%26aulast%3DDoller%26aufirst%3DD.%26atitle%3DChemical%2520biology%2520of%2520mGlu4%2520receptor%2520activation%253A%2520dogmas%252C%2520challenges%252C%2520strategies%2520and%2520opportunities%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2014%26volume%3D14%26issue%3D15%26spage%3D1755%26epage%3D1770%26doi%3D10.2174%2F1568026614666140902143830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lavreysen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahnaou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drinkenburg, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langlois, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pype, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LÃ¼tjens, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Poul, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trabanco, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">NuÃ±ez, J. M.</span></span> <span> </span><span class="NLM_article-title">Pharmacological and pharmacokinetic properties of JNJ-40411813, a positive allosteric modulator of the mGlu2 receptor</span>. <i>Pharmacol. Res. Perspect.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">e00096</span>, <span class="refDoi">Â DOI: 10.1002/prp2.96</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1002%2Fprp2.96" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=25692015" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&pages=e00096&issue=1&author=H.+Lavreysenauthor=A.+Ahnaouauthor=W.+Drinkenburgauthor=X.+Langloisauthor=C.+Mackieauthor=S.+Pypeauthor=R.+L%C3%BCtjensauthor=E.+Le+Poulauthor=A.+A.+Trabancoauthor=J.+M.+Nu%C3%B1ez&title=Pharmacological+and+pharmacokinetic+properties+of+JNJ-40411813%2C+a+positive+allosteric+modulator+of+the+mGlu2+receptor&doi=10.1002%2Fprp2.96"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1002%2Fprp2.96&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprp2.96%26sid%3Dliteratum%253Aachs%26aulast%3DLavreysen%26aufirst%3DH.%26aulast%3DAhnaou%26aufirst%3DA.%26aulast%3DDrinkenburg%26aufirst%3DW.%26aulast%3DLanglois%26aufirst%3DX.%26aulast%3DMackie%26aufirst%3DC.%26aulast%3DPype%26aufirst%3DS.%26aulast%3DL%25C3%25BCtjens%26aufirst%3DR.%26aulast%3DLe%2BPoul%26aufirst%3DE.%26aulast%3DTrabanco%26aufirst%3DA.%2BA.%26aulast%3DNu%25C3%25B1ez%26aufirst%3DJ.%2BM.%26atitle%3DPharmacological%2520and%2520pharmacokinetic%2520properties%2520of%2520JNJ-40411813%252C%2520a%2520positive%2520allosteric%2520modulator%2520of%2520the%2520mGlu2%2520receptor%26jtitle%3DPharmacol.%2520Res.%2520Perspect.%26date%3D2015%26volume%3D3%26issue%3D1%26spage%3De00096%26doi%3D10.1002%2Fprp2.96" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Justinova, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panlilio, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Secci, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redhi, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mrzljak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medd, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaham, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, S. R.</span></span> <span> </span><span class="NLM_article-title">The novel metabotropic glutamate receptor 2 positive allosteric modulator, AZD8529, decreases nicotine self-administration and relapse in squirrel monkeys</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">452</span>â <span class="NLM_lpage">462</span>, <span class="refDoi">Â DOI: 10.1016/j.biopsych.2015.01.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.biopsych.2015.01.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=25802079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltFelurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2015&pages=452-462&issue=7&author=Z.+Justinovaauthor=L.+V.+Panlilioauthor=M.+E.+Secciauthor=G.+H.+Redhiauthor=C.+W.+Schindlerauthor=A.+J.+Crossauthor=L.+Mrzljakauthor=A.+Meddauthor=Y.+Shahamauthor=S.+R.+Goldberg&title=The+novel+metabotropic+glutamate+receptor+2+positive+allosteric+modulator%2C+AZD8529%2C+decreases+nicotine+self-administration+and+relapse+in+squirrel+monkeys&doi=10.1016%2Fj.biopsych.2015.01.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">The Novel Metabotropic Glutamate Receptor 2 Positive Allosteric Modulator, AZD8529, Decreases Nicotine Self-Administration and Relapse in Squirrel Monkeys</span></div><div class="casAuthors">Justinova, Zuzana; Panlilio, Leigh V.; Secci, Maria E.; Redhi, Godfrey H.; Schindler, Charles W.; Cross, Alan J.; Mrzljak, Ladislav; Medd, Amy; Shaham, Yavin; Goldberg, Steven R.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">452-462</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Based on rodent studies, group II metabotropic glutamate receptors (mGluR2 and mGluR3) were suggested as targets for addiction treatment.  However, LY379268 and other group II agonists do not discriminate between the mainly presynaptic inhibitory mGluR2 (the proposed treatment target) and mGluR3.  These agonists also produce tolerance over repeated administration and are no longer considered for addiction treatment.  Here, we detd. the effects of AZD8529, a selective pos. allosteric modulator of mGluR2, on abuse-related effects of nicotine in squirrel monkeys and rats.  We first assessed modulation of mGluR2 function by AZD8529 using functional in vitro assays in membranes prepd. from a cell line expressing human mGluR2 and in primate brain slices.  We then detd. AZD8529 (.03-10 mg/kg, i.m. injection) effects on i.v. nicotine self-administration and reinstatement of nicotine seeking induced by nicotine priming or nicotine-assocd. cues.  We also detd. AZD8529 effects on food self-administration in monkeys and nicotine-induced dopamine release in accumbens shell in rats.  AZD8529 potentiated agonist-induced activation of mGluR2 in the membrane-binding assay and in primate cortex, hippocampus, and striatum.  In monkeys, AZD8529 decreased nicotine self-administration at doses (.3-3 mg/kg) that did not affect food self-administration.  AZD8529 also reduced nicotine priming- and cue-induced reinstatement of nicotine seeking after extinction of the drug-reinforced responding.  In rats, AZD8529 decreased nicotine-induced accumbens dopamine release.  These results provide evidence for efficacy of pos. allosteric modulators of mGluR2 in nonhuman primate models of nicotine reinforcement and relapse.  This drug class should be considered for nicotine addiction treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiwrmhIL13xLVg90H21EOLACvtfcHk0lgheCebE9eFgg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltFelurg%253D&md5=3f9db3d76c99c14165eaa287a8032eae</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2015.01.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2015.01.014%26sid%3Dliteratum%253Aachs%26aulast%3DJustinova%26aufirst%3DZ.%26aulast%3DPanlilio%26aufirst%3DL.%2BV.%26aulast%3DSecci%26aufirst%3DM.%2BE.%26aulast%3DRedhi%26aufirst%3DG.%2BH.%26aulast%3DSchindler%26aufirst%3DC.%2BW.%26aulast%3DCross%26aufirst%3DA.%2BJ.%26aulast%3DMrzljak%26aufirst%3DL.%26aulast%3DMedd%26aufirst%3DA.%26aulast%3DShaham%26aufirst%3DY.%26aulast%3DGoldberg%26aufirst%3DS.%2BR.%26atitle%3DThe%2520novel%2520metabotropic%2520glutamate%2520receptor%25202%2520positive%2520allosteric%2520modulator%252C%2520AZD8529%252C%2520decreases%2520nicotine%2520self-administration%2520and%2520relapse%2520in%2520squirrel%2520monkeys%26jtitle%3DBiol.%2520Psychiatry%26date%3D2015%26volume%3D78%26issue%3D7%26spage%3D452%26epage%3D462%26doi%3D10.1016%2Fj.biopsych.2015.01.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doornbos, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">PÃ©rez-Benito, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tresadern, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulder-Krieger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biesmans, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trabanco, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cid, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavreysen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">IJzerman, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitman, L. H.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanism of positive allosteric modulation of the metabotropic glutamate receptor 2 by JNJ-46281222</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>173</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">588</span>â <span class="NLM_lpage">600</span>, <span class="refDoi">Â DOI: 10.1111/bph.13390</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1111%2Fbph.13390" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=26589404" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvVOlsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2016&pages=588-600&issue=3&author=M.+L.+Doornbosauthor=L.+P%C3%A9rez-Benitoauthor=G.+Tresadernauthor=T.+Mulder-Kriegerauthor=I.+Biesmansauthor=A.+A.+Trabancoauthor=J.+M.+Cidauthor=H.+Lavreysenauthor=A.+P.+IJzermanauthor=L.+H.+Heitman&title=Molecular+mechanism+of+positive+allosteric+modulation+of+the+metabotropic+glutamate+receptor+2+by+JNJ-46281222&doi=10.1111%2Fbph.13390"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanism of positive allosteric modulation of the metabotropic glutamate receptor 2 by JNJ-46281222</span></div><div class="casAuthors">Doornbos, Maarten L. J.; Perez-Benito, Laura; Tresadern, Gary; Mulder-Krieger, Thea; Biesmans, Ilse; Trabanco, Andres A.; Cid, Jose Maria; Lavreysen, Hilde; IJzerman, Adriaan P.; Heitman, Laura H.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">588-600</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : Allosteric modulation of the mGlu2 receptor is a potential strategy for treatment of various neurol. and psychiatric disorders.  Here, we describe the in vitro characterization of the mGlu2 pos. allosteric modulator (PAM) JNJ-46281222 and its radiolabeled counterpart [3H]-JNJ-46281222.  Using this novel tool, we also describe the allosteric effect of orthosteric glutamate binding and the presence of a bound G protein on PAM binding and use computational approaches to further investigate the binding mode.  Exptl. Approach : We have used radioligand binding studies, functional assays, site-directed mutagenesis, homol. modeling and mol. dynamics to study the binding of JNJ-46281222.  Key Results : JNJ-46281222 is an mGlu2-selective, highly potent PAM with nanomolar affinity (KD = 1.7 nM).  Binding of [3H]-JNJ-46281222 was increased by the presence of glutamate and greatly reduced by the presence of GTP, indicating the preference for a G protein bound state of the receptor for PAM binding.  Its allosteric binding site was visualized and analyzed by a computational docking and mol. dynamics study.  The simulations revealed amino acid movements in regions expected to be important for activation.  The binding mode was supported by [3H]-JNJ-46281222 binding expts. on mutant receptors.  Conclusion and Implications : Our results obtained with JNJ-46281222 in unlabeled and tritiated form further contribute to our understanding of mGlu2 allosteric modulation.  The computational simulations and mutagenesis provide a plausible binding mode with indications of how the ligand permits allosteric activation.  This study is therefore of interest for mGlu2 and class C receptor drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbLKlJtG-BPrVg90H21EOLACvtfcHk0lgheCebE9eFgg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvVOlsw%253D%253D&md5=fdbe099d035338dac3c036bd40d91f69</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1111%2Fbph.13390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13390%26sid%3Dliteratum%253Aachs%26aulast%3DDoornbos%26aufirst%3DM.%2BL.%26aulast%3DP%25C3%25A9rez-Benito%26aufirst%3DL.%26aulast%3DTresadern%26aufirst%3DG.%26aulast%3DMulder-Krieger%26aufirst%3DT.%26aulast%3DBiesmans%26aufirst%3DI.%26aulast%3DTrabanco%26aufirst%3DA.%2BA.%26aulast%3DCid%26aufirst%3DJ.%2BM.%26aulast%3DLavreysen%26aufirst%3DH.%26aulast%3DIJzerman%26aufirst%3DA.%2BP.%26aulast%3DHeitman%26aufirst%3DL.%2BH.%26atitle%3DMolecular%2520mechanism%2520of%2520positive%2520allosteric%2520modulation%2520of%2520the%2520metabotropic%2520glutamate%2520receptor%25202%2520by%2520JNJ-46281222%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2016%26volume%3D173%26issue%3D3%26spage%3D588%26epage%3D600%26doi%3D10.1111%2Fbph.13390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conde-Ceide, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MartÃ­nez-Viturro, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">AlcÃ¡zar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Barrantes, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavreysen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinson, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rook, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Megens, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langlois, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drinkenburg, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahnaou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niswender, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steckler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BartolomÃ©-Nebreda, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of VU0409551/JNJ-46778212: an mGlu5 positive allosteric modulator clinical candidate targeting schizophrenia</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">716</span>â <span class="NLM_lpage">720</span>, <span class="refDoi">Â DOI: 10.1021/acsmedchemlett.5b00181</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00181" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2MXovVSgu78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=716-720&issue=6&author=S.+Conde-Ceideauthor=C.+M.+Mart%C3%ADnez-Viturroauthor=J.+Alc%C3%A1zarauthor=P.+M.+Garcia-Barrantesauthor=H.+Lavreysenauthor=C.+Mackieauthor=P.+N.+Vinsonauthor=J.+M.+Rookauthor=T.+M.+Bridgesauthor=J.+S.+Danielsauthor=A.+Megensauthor=X.+Langloisauthor=W.+H.+Drinkenburgauthor=A.+Ahnaouauthor=C.+M.+Niswenderauthor=C.+K.+Jonesauthor=G.+J.+Macdonaldauthor=T.+Stecklerauthor=P.+J.+Connauthor=S.+R.+Staufferauthor=J.+M.+Bartolom%C3%A9-Nebredaauthor=C.+W.+Lindsley&title=Discovery+of+VU0409551%2FJNJ-46778212%3A+an+mGlu5+positive+allosteric+modulator+clinical+candidate+targeting+schizophrenia&doi=10.1021%2Facsmedchemlett.5b00181"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of VU0409551/JNJ-46778212: An mGlu5 Positive Allosteric Modulator Clinical Candidate Targeting Schizophrenia</span></div><div class="casAuthors">Conde-Ceide, Susana; Martinez-Viturro, Carlos M.; Alcazar, Jesus; Garcia-Barrantes, Pedro M.; Lavreysen, Hilde; Mackie, Claire; Vinson, Paige N.; Rook, Jerri M.; Bridges, Thomas M.; Daniels, J. Scott; Megens, Anton; Langlois, Xavier; Drinkenburg, Wilhelmus H.; Ahnaou, Abdellah; Niswender, Colleen M.; Jones, Carrie K.; Macdonald, Gregor J.; Steckler, Thomas; Conn, P. Jeffrey; Stauffer, Shaun R.; Bartolome-Nebreda, Jose Manuel; Lindsley, Craig W.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">716-720</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein, the authors report the structure-activity relationship of a novel series of potent, selective, and orally bioavailable metabotropic glutamate receptor subtype 5 (mGlu5) pos. allosteric modulators.  On the basis of its robust in vitro potency and in vivo efficacy in multiple preclin. models of multiple domains of schizophrenia, coupled with a good DMPK profile and an acceptable therapeutic window, I (VU0409551/JNJ-46778212) was selected as a candidate for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqz4F4S2MCNz7Vg90H21EOLACvtfcHk0liw9bMwOr1kvQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXovVSgu78%253D&md5=d92cd4c79b31d664deb53cafee809798</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00181%26sid%3Dliteratum%253Aachs%26aulast%3DConde-Ceide%26aufirst%3DS.%26aulast%3DMart%25C3%25ADnez-Viturro%26aufirst%3DC.%2BM.%26aulast%3DAlc%25C3%25A1zar%26aufirst%3DJ.%26aulast%3DGarcia-Barrantes%26aufirst%3DP.%2BM.%26aulast%3DLavreysen%26aufirst%3DH.%26aulast%3DMackie%26aufirst%3DC.%26aulast%3DVinson%26aufirst%3DP.%2BN.%26aulast%3DRook%26aufirst%3DJ.%2BM.%26aulast%3DBridges%26aufirst%3DT.%2BM.%26aulast%3DDaniels%26aufirst%3DJ.%2BS.%26aulast%3DMegens%26aufirst%3DA.%26aulast%3DLanglois%26aufirst%3DX.%26aulast%3DDrinkenburg%26aufirst%3DW.%2BH.%26aulast%3DAhnaou%26aufirst%3DA.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DJones%26aufirst%3DC.%2BK.%26aulast%3DMacdonald%26aufirst%3DG.%2BJ.%26aulast%3DSteckler%26aufirst%3DT.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DStauffer%26aufirst%3DS.%2BR.%26aulast%3DBartolom%25C3%25A9-Nebreda%26aufirst%3DJ.%2BM.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26atitle%3DDiscovery%2520of%2520VU0409551%252FJNJ-46778212%253A%2520an%2520mGlu5%2520positive%2520allosteric%2520modulator%2520clinical%2520candidate%2520targeting%2520schizophrenia%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26issue%3D6%26spage%3D716%26epage%3D720%26doi%3D10.1021%2Facsmedchemlett.5b00181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degnan, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balakrishnan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Easton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulianello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matchett, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santone, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senapati, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shields, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivarao, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westphal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiterock, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span> <span> </span><span class="NLM_article-title">Oxazolidinone-based allosteric modulators of mGluR5: defining molecular switches to create a pharmacological tool box</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">4165</span>â <span class="NLM_lpage">4169</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2016.07.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.bmcl.2016.07.065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=27496211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht12gu7bO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=4165-4169&issue=17&author=H.+Huangauthor=A.+P.+Degnanauthor=A.+Balakrishnanauthor=A.+Eastonauthor=M.+Gulianelloauthor=Y.+Huangauthor=M.+Matchettauthor=G.+Mattsonauthor=R.+Millerauthor=K.+S.+Santoneauthor=A.+Senapatiauthor=E.+E.+Shieldsauthor=D.+V.+Sivaraoauthor=L.+B.+Snyderauthor=R.+Westphalauthor=V.+J.+Whiterockauthor=F.+Yangauthor=J.+J.+Bronsonauthor=J.+E.+Macor&title=Oxazolidinone-based+allosteric+modulators+of+mGluR5%3A+defining+molecular+switches+to+create+a+pharmacological+tool+box&doi=10.1016%2Fj.bmcl.2016.07.065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Oxazolidinone-based allosteric modulators of mGluR5: Defining molecular switches to create a pharmacological tool box</span></div><div class="casAuthors">Huang, Hong; Degnan, Andrew P.; Balakrishnan, Anand; Easton, Amy; Gulianello, Michael; Huang, Yanling; Matchett, Michele; Mattson, Gail; Miller, Regina; Santone, Kenneth S.; Senapati, Arun; Shields, Eric E.; Sivarao, Digavalli V.; Snyder, Lawrence B.; Westphal, Ryan; Whiterock, Valerie J.; Yang, Fukang; Bronson, Joanne J.; Macor, John E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4165-4169</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Herein we describe the structure activity relationships uncovered in the pursuit of an mGluR5 pos. allosteric modulator (PAM) for the treatment of schizophrenia.  It was discovered that certain modifications of an oxazolidinone-based chemotype afforded predictable changes in the pharmacol. profile to give analogs with a wide range of functional activities.  The discovery of potent silent allosteric modulators (SAMs) allowed interrogation of the mechanism-based liabilities assocd. with mGluR5 activation and drove our medicinal chem. effort toward the discovery of low efficacy (fold shift) PAMs devoid of agonist activity.  This work resulted in the identification of dipyridyl 22 (BMS-952048), a compd. with a favorable free fraction, efficacy in a rodent-based cognition model, and low potential for convulsions in mouse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx6sChNZapurVg90H21EOLACvtfcHk0liw9bMwOr1kvQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht12gu7bO&md5=0b4e0da6c693d8e11e6237c77d679cca</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.07.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.07.065%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DDegnan%26aufirst%3DA.%2BP.%26aulast%3DBalakrishnan%26aufirst%3DA.%26aulast%3DEaston%26aufirst%3DA.%26aulast%3DGulianello%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DMatchett%26aufirst%3DM.%26aulast%3DMattson%26aufirst%3DG.%26aulast%3DMiller%26aufirst%3DR.%26aulast%3DSantone%26aufirst%3DK.%2BS.%26aulast%3DSenapati%26aufirst%3DA.%26aulast%3DShields%26aufirst%3DE.%2BE.%26aulast%3DSivarao%26aufirst%3DD.%2BV.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26aulast%3DWestphal%26aufirst%3DR.%26aulast%3DWhiterock%26aufirst%3DV.%2BJ.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DBronson%26aufirst%3DJ.%2BJ.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26atitle%3DOxazolidinone-based%2520allosteric%2520modulators%2520of%2520mGluR5%253A%2520defining%2520molecular%2520switches%2520to%2520create%2520a%2520pharmacological%2520tool%2520box%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26issue%3D17%26spage%3D4165%26epage%3D4169%26doi%3D10.1016%2Fj.bmcl.2016.07.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haas, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salazar, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herber, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degnan, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balakrishnan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albright, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strittmatter, S. M.</span></span> <span> </span><span class="NLM_article-title">Silent allosteric modulation of mGluR5 maintains glutamate signaling while rescuing Alzheimerâs mouse phenotypes</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">76</span>â <span class="NLM_lpage">88</span>, <span class="refDoi">Â DOI: 10.1016/j.celrep.2017.06.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.celrep.2017.06.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=28683325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFartbnN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2017&pages=76-88&issue=1&author=L.+T.+Haasauthor=S.+V.+Salazarauthor=L.+M.+Smithauthor=H.+R.+Zhaoauthor=T.+O.+Coxauthor=C.+S.+Herberauthor=A.+P.+Degnanauthor=A.+Balakrishnanauthor=J.+E.+Macorauthor=C.+F.+Albrightauthor=S.+M.+Strittmatter&title=Silent+allosteric+modulation+of+mGluR5+maintains+glutamate+signaling+while+rescuing+Alzheimer%E2%80%99s+mouse+phenotypes&doi=10.1016%2Fj.celrep.2017.06.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Silent Allosteric Modulation of mGluR5 Maintains Glutamate Signaling while Rescuing Alzheimer's Mouse Phenotypes</span></div><div class="casAuthors">Haas, Laura T.; Salazar, Santiago V.; Smith, Levi M.; Zhao, Helen R.; Cox, Timothy O.; Herber, Charlotte S.; Degnan, Andrew P.; Balakrishnan, Anand; Macor, John E.; Albright, Charles F.; Strittmatter, Stephen M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">76-88</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Metabotropic glutamate receptor 5 (mGluR5) has been implicated in Alzheimer's disease (AD) pathol.  We sought to understand whether mGluR5's role in AD requires glutamate signaling.  We used a potent mGluR5 silent allosteric modulator (SAM, BMS-984923) to sep. its well-known physiol. role in glutamate signaling from a pathol. role in mediating amyloid-Î² oligomer (AÎ²o) action.  Binding of the SAM to mGluR5 does not change glutamate signaling but strongly reduces mGluR5 interaction with cellular prion protein (PrPC) bound to AÎ²o.  The SAM compd. prevents AÎ²o-induced signal transduction in brain slices and in an AD transgenic mouse model, the APPswe/PS1ÎE9 strain.  Critically, 4 wk of SAM treatment rescues memory deficits and synaptic depletion in the APPswe/PS1ÎE9 transgenic mouse brain.  Our data show that mGluR5's role in AÎ²o-dependent AD phenotypes is sep. from its role in glutamate signaling and silent allosteric modulation of mGluR5 has promise as a disease-modifying AD intervention with a broad therapeutic window.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiq45bkzh9ebVg90H21EOLACvtfcHk0ljpWT0vzlpJ5A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFartbnN&md5=3e3e1a787fb58397ac649068f0ccd07e</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2017.06.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2017.06.023%26sid%3Dliteratum%253Aachs%26aulast%3DHaas%26aufirst%3DL.%2BT.%26aulast%3DSalazar%26aufirst%3DS.%2BV.%26aulast%3DSmith%26aufirst%3DL.%2BM.%26aulast%3DZhao%26aufirst%3DH.%2BR.%26aulast%3DCox%26aufirst%3DT.%2BO.%26aulast%3DHerber%26aufirst%3DC.%2BS.%26aulast%3DDegnan%26aufirst%3DA.%2BP.%26aulast%3DBalakrishnan%26aufirst%3DA.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26aulast%3DAlbright%26aufirst%3DC.%2BF.%26aulast%3DStrittmatter%26aufirst%3DS.%2BM.%26atitle%3DSilent%2520allosteric%2520modulation%2520of%2520mGluR5%2520maintains%2520glutamate%2520signaling%2520while%2520rescuing%2520Alzheimer%25E2%2580%2599s%2520mouse%2520phenotypes%26jtitle%3DCell%2520Rep.%26date%3D2017%26volume%3D20%26issue%3D1%26spage%3D76%26epage%3D88%26doi%3D10.1016%2Fj.celrep.2017.06.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turkmen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundgren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birzniece, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zingmark, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BÃ¤ckstrÃ¶m, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansson, I. M.</span></span> <span> </span><span class="NLM_article-title">3Î²,20Î²-dihydroxy-5Î±-pregnane (UC1011) antagonism of the GABA potentiation and the learning impairment induced in rats by allopregnanolone</span>. <i>Eur. J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1604</span>â <span class="NLM_lpage">1612</span>, <span class="refDoi">Â DOI: 10.1111/j.1460-9568.2004.03610.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1111%2Fj.1460-9568.2004.03610.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=15355327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A280%3ADC%252BD2cvksl2kuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2004&pages=1604-1612&issue=6&author=S.+Turkmenauthor=P.+Lundgrenauthor=V.+Birznieceauthor=E.+Zingmarkauthor=T.+B%C3%A4ckstr%C3%B6mauthor=I.+M.+Johansson&title=3%CE%B2%2C20%CE%B2-dihydroxy-5%CE%B1-pregnane+%28UC1011%29+antagonism+of+the+GABA+potentiation+and+the+learning+impairment+induced+in+rats+by+allopregnanolone&doi=10.1111%2Fj.1460-9568.2004.03610.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">3beta-20beta-dihydroxy-5alpha-pregnane (UC1011) antagonism of the GABA potentiation and the learning impairment induced in rats by allopregnanolone</span></div><div class="casAuthors">Turkmen Sahruh; Lundgren Per; Birzniece Vita; Zingmark Elisabeth; Backstrom Torbjorn; Johansson Inga-Maj</div><div class="citationInfo"><span class="NLM_cas:title">The European journal of neuroscience</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1604-12</span>
        ISSN:<span class="NLM_cas:issn">0953-816X</span>.
    </div><div class="casAbstract">Allopregnanolone is a progesterone metabolite and GABA-A receptor modulator with benzodiazepine like effects, including decreased learning and memory.  In vitro 3beta-hydroxypregnane steroids antagonize allopregnanolone-induced effects, but no antagonism has been shown in vivo.  Our purpose was to evaluate 3beta-20beta-dihydroxy-5alpha-pregnane (UC1011) as a blocker of allopregnanolone-induced effects in vivo and in vitro in rats.  We tested adult male Wistar rats in the Morris water maze 8 min after daily injections (i.v.) of allopregnanolone 2 mg/kg (n = 21); allopregnanolone : UC1011 2 : 6 (n = 7), 2 : 8 (n = 7), 2 : 20 (n = 14) mg/kg; UC1011 20 mg/kg (n = 14); or vehicle (10% 2-hydroxypropyl-beta-cyclodextrin, n = 4).  Studies of chloride ion uptake into cortical and hippocampal membrane preparations were performed.  The latency to find the hidden platform was still high in the allopregnanolone-injected group on day 6.  Day 3-6 rats injected with allopregnanolone and UC1011 (2 : 20 mg/kg) had lower latency (P < 0.05), compared to the allopregnanolone-injected group.  The group that only received UC1011 learned the location of the platform as fast as the controls.  There was no significant difference in swim speed between groups.  The time spent swimming close to the pool wall was in the allopregnanolone : UC1011 group (2 : 20 mg/kg) significantly decreased (P < 0.05, day 3-6), compared to the allopregnanolone-injected group.  The increased chloride ion uptake induced by increasing dosage of allopregnanolone in the presence of 10 micro m GABA was significantly decreased with UC1011 (P < 0.01), in both cortical and hippocampal homogenates.  In conclusion, UC1011 can via antagonism at the GABA-A receptor reduce the negative allopregnanolone effect on learning in the water maze.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSa5E42Hae79f6BottYdIAWfW6udTcc2eZTjmDmpwP3kbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2cvksl2kuw%253D%253D&md5=817bab3820053fa9be0175a3a3b313d8</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1111%2Fj.1460-9568.2004.03610.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1460-9568.2004.03610.x%26sid%3Dliteratum%253Aachs%26aulast%3DTurkmen%26aufirst%3DS.%26aulast%3DLundgren%26aufirst%3DP.%26aulast%3DBirzniece%26aufirst%3DV.%26aulast%3DZingmark%26aufirst%3DE.%26aulast%3DB%25C3%25A4ckstr%25C3%25B6m%26aufirst%3DT.%26aulast%3DJohansson%26aufirst%3DI.%2BM.%26atitle%3D3%25CE%25B2%252C20%25CE%25B2-dihydroxy-5%25CE%25B1-pregnane%2520%2528UC1011%2529%2520antagonism%2520of%2520the%2520GABA%2520potentiation%2520and%2520the%2520learning%2520impairment%2520induced%2520in%2520rats%2520by%2520allopregnanolone%26jtitle%3DEur.%2520J.%2520Neurosci.%26date%3D2004%26volume%3D20%26issue%3D6%26spage%3D1604%26epage%3D1612%26doi%3D10.1111%2Fj.1460-9568.2004.03610.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johansson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">StrÃ¶mberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragagnin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doverskog, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BÃ¤ckstrÃ¶m, T.</span></span> <span> </span><span class="NLM_article-title">GABAA receptor modulating steroid antagonists (GAMSA) are functional in vivo</span>. <i>J. Steroid Biochem. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>160</i></span>,  <span class="NLM_fpage">98</span>â <span class="NLM_lpage">105</span>, <span class="refDoi">Â DOI: 10.1016/j.jsbmb.2015.10.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.jsbmb.2015.10.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=26523675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsl2gsLrL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2016&pages=98-105&author=M.+Johanssonauthor=J.+Str%C3%B6mbergauthor=G.+Ragagninauthor=M.+Doverskogauthor=T.+B%C3%A4ckstr%C3%B6m&title=GABAA+receptor+modulating+steroid+antagonists+%28GAMSA%29+are+functional+in+vivo&doi=10.1016%2Fj.jsbmb.2015.10.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">GABAA receptor modulating steroid antagonists (GAMSA) are functional in vivo</span></div><div class="casAuthors">Johansson, Maja; Stroemberg, Jessica; Ragagnin, Gianna; Doverskog, Magnus; Baeckstroem, Torbjoern</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Steroid Biochemistry and Molecular Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">98-105</span>CODEN:
                <span class="NLM_cas:coden">JSBBEZ</span>;
        ISSN:<span class="NLM_cas:issn">0960-0760</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">GABAA receptor modulating steroid antagonists (GAMSA) selectively inhibit neurosteroid-mediated enhancement of GABA-evoked currents at the GABAA receptor.  3Î±-Hydroxy-neurosteroids, notably allopregnanolone and tetrahydrodeoxycorticosterone (THDOC), potentiate GABAA receptor-mediated currents.  On the contrary, various 3Î²-hydroxy-steroids antagonize this pos. neurosteroid-mediated modulation.  Importantly, GAMSAs are specific antagonists of the pos. neurosteroid-modulation of the receptor and do not inhibit GABA-evoked currents.  Allopregnanolone and THDOC have both neg. and pos. actions.  Allopregnanolone can impair encoding/consolidation and retrieval of memories.  Chronic administration of a physiol. allopregnanolone concn. reduces cognition in mice models of Alzheimer's disease.  In humans an allopregnanolone challenge impairs episodic memory and in hepatic encephalopathy cognitive deficits are accompanied by increased brain ammonia and allopregnanolone.  Hippocampal slices react in vitro to ammonia by allopregnanolone synthesis in CA1 neurons, which blocks long-term potentiation (LTP).  Thus, allopregnanolone may impair learning and memory by interfering with hippocampal LTP.  Contrary, pharmacol. treatment with allopregnanolone can promote neurogenesis and pos. influence learning and memory of trace eye-blink conditioning in mice.  In rat the GAMSA UC1011 inhibits an allopregnanolone-induced learning impairment and the GAMSA GR3027 restores learning and motor coordination in rats with hepatic encephalopathy.  In addn., the GAMSA isoallopregnanolone antagonizes allopregnanolone-induced anesthesia in rats, and in humans it antagonizes allopregnanolone-induced sedation and redns. in saccadic eye velocity.  17PA is also an effective GAMSA in vivo, as it antagonizes allopregnanolone-induced anesthesia and spinal analgesia in rats.  In vitro the allopregnanolone/THDOC-increased GABA-mediated GABAA receptor activity is antagonized by isoallopregnanolone, UC1011, GR3027 and 17PA, while the effect of GABA itself is not affected.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh3EEnyc79dbVg90H21EOLACvtfcHk0ljpWT0vzlpJ5A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsl2gsLrL&md5=8f75d41aeda34176dd8b8ca138d96c15</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fj.jsbmb.2015.10.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jsbmb.2015.10.019%26sid%3Dliteratum%253Aachs%26aulast%3DJohansson%26aufirst%3DM.%26aulast%3DStr%25C3%25B6mberg%26aufirst%3DJ.%26aulast%3DRagagnin%26aufirst%3DG.%26aulast%3DDoverskog%26aufirst%3DM.%26aulast%3DB%25C3%25A4ckstr%25C3%25B6m%26aufirst%3DT.%26atitle%3DGABAA%2520receptor%2520modulating%2520steroid%2520antagonists%2520%2528GAMSA%2529%2520are%2520functional%2520in%2520vivo%26jtitle%3DJ.%2520Steroid%2520Biochem.%2520Mol.%2520Biol.%26date%3D2016%26volume%3D160%26spage%3D98%26epage%3D105%26doi%3D10.1016%2Fj.jsbmb.2015.10.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blanco, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coughlin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salituro, F. G.</span></span> <span> </span><span class="NLM_article-title">Breakthroughs in neuroactive steroid drug discovery</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">61</span>â <span class="NLM_lpage">70</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2017.11.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.bmcl.2017.11.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=29223589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFejur3L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=61-70&issue=2&author=M.+J.+Blancoauthor=D.+Laauthor=Q.+Coughlinauthor=C.+Newmanauthor=A.+Griffinauthor=B.+L.+Harrisonauthor=F.+G.+Salituro&title=Breakthroughs+in+neuroactive+steroid+drug+discovery&doi=10.1016%2Fj.bmcl.2017.11.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Breakthroughs in neuroactive steroid drug discovery</span></div><div class="casAuthors">Blanco, Maria-Jesus; La, Daniel; Coughlin, Quinn; Newman, Caitlin A.; Griffin, Andrew M.; Harrison, Boyd L.; Salituro, Francesco G.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">61-70</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Endogenous and synthetic neuroactive steroids (NASs) or neurosteroids are effective modulators of multiple signaling pathways including receptors for the Î³-aminobutyric acid A (GABAA) and glutamate, in particular N-methyl-D-aspartate (NMDA).  These receptors are the major inhibitory and excitatory neurotransmitters in the central nervous system (CNS), and there is growing evidence suggesting that dysregulation of neurosteroid prodn. plays a role in numerous neurol. disorders.  The significant unmet medical need for treatment of CNS disorders has increased the interest for these types of compds.  In this review, we highlight recent progress in the clin. development of NAS drug candidates, in addn. to preclin. breakthroughs in the identification of novel NASs, mainly for GABAA and NMDA receptor modulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0S63TwFqhHbVg90H21EOLACvtfcHk0ljHHAJAk5kEsA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFejur3L&md5=321a2fbf7f8d5d4f90356633ab02f16e</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.11.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.11.043%26sid%3Dliteratum%253Aachs%26aulast%3DBlanco%26aufirst%3DM.%2BJ.%26aulast%3DLa%26aufirst%3DD.%26aulast%3DCoughlin%26aufirst%3DQ.%26aulast%3DNewman%26aufirst%3DC.%26aulast%3DGriffin%26aufirst%3DA.%26aulast%3DHarrison%26aufirst%3DB.%2BL.%26aulast%3DSalituro%26aufirst%3DF.%2BG.%26atitle%3DBreakthroughs%2520in%2520neuroactive%2520steroid%2520drug%2520discovery%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26issue%3D2%26spage%3D61%26epage%3D70%26doi%3D10.1016%2Fj.bmcl.2017.11.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span> <i>Marinus Pharmaceuticals</i>; <span class="NLM_publisher-name">Marinus
Pharmaceuticals</span>: <span class="NLM_publisher-loc">Radnor, PA</span>, <span class="NLM_year">2019</span>; <a href="http://www.marinuspharma.com/pipeline/" class="extLink">http://www.marinuspharma.com/pipeline/</a> (accessed on July 20,
2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Marinus+Pharmaceuticals%3B+Marinus%0APharmaceuticals%3A+Radnor%2C+PA%2C+2019%3B+http%3A%2F%2Fwww.marinuspharma.com%2Fpipeline%2F+%28accessed+on+July+20%2C%0A2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DMarinus%2520Pharmaceuticals%26pub%3DMarinus%250APharmaceuticals%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinez Botella, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salituro, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beresis, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanco, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belfort, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loya, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ackley, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Althaus, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossman, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robichaud, A. J.</span></span> <span> </span><span class="NLM_article-title">Neuroactive Steroids. 2. 3Î±-Hydroxy-3Î²-methyl-21-(4-cyano-1H-pyrazol-1â²-yl)-19-nor-5Î²-pregnan-20-one (SAGE-217): a clinical next generation neuroactive steroid positive allosteric modulator of the (Î³-aminobutyric acid)A receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">7810</span>â <span class="NLM_lpage">7819</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b00846</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00846" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A280%3ADC%252BC1cfitFSgsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7810-7819&issue=18&author=G.+Martinez+Botellaauthor=F.+G.+Salituroauthor=B.+L.+Harrisonauthor=R.+T.+Beresisauthor=Z.+Baiauthor=M.+J.+Blancoauthor=G.+M.+Belfortauthor=J.+Daiauthor=C.+M.+Loyaauthor=M.+A.+Ackleyauthor=A.+L.+Althausauthor=S.+J.+Grossmanauthor=E.+Hoffmannauthor=J.+J.+Dohertyauthor=A.+J.+Robichaud&title=Neuroactive+Steroids.+2.+3%CE%B1-Hydroxy-3%CE%B2-methyl-21-%284-cyano-1H-pyrazol-1%E2%80%B2-yl%29-19-nor-5%CE%B2-pregnan-20-one+%28SAGE-217%29%3A+a+clinical+next+generation+neuroactive+steroid+positive+allosteric+modulator+of+the+%28%CE%B3-aminobutyric+acid%29A+receptor&doi=10.1021%2Facs.jmedchem.7b00846"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroactive Steroids. 2. 3Î±-Hydroxy-3Î²-methyl-21-(4-cyano-1H-pyrazol-1'-yl)-19-nor-5Î²-pregnan-20-one (SAGE-217): A Clinical Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (Î³-Aminobutyric Acid)A Receptor</span></div><div class="casAuthors">Martinez Botella Gabriel; Salituro Francesco G; Harrison Boyd L; Blanco Maria-Jesus; Belfort Gabriel M; Dai Jing; Loya Carlos M; Ackley Michael A; Althaus Alison L; Grossman Scott J; Hoffmann Ethan; Doherty James J; Robichaud Albert J; Beresis Richard T; Bai Zhu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7810-7819</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Certain classes of neuroactive steroids (NASs) are positive allosteric modulators (PAM) of synaptic and extrasynaptic GABAA receptors.  Herein, we report new SAR insights in a series of 5Î²-nor-19-pregnan-20-one analogues bearing substituted pyrazoles and triazoles at C-21, culminating in the discovery of 3Î±-hydroxy-3Î²-methyl-21-(4-cyano-1H-pyrazol-1'-yl)-19-nor-5Î²-pregnan-20-one (SAGE-217, 3), a potent GABAA receptor modulator at both synaptic and extrasynaptic receptor subtypes, with excellent oral DMPK properties.  Compound 3 has completed a phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial and is currently being studied in parallel phase 2 clinical trials for the treatment of postpartum depression (PPD), major depressive disorder (MDD), and essential tremor (ET).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTiySZLUBmmmoUSrryheKE6fW6udTcc2eYEXeWhI0dLsrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cfitFSgsg%253D%253D&md5=d9cb22ed2087152aa0e67d0906faa583</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00846&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00846%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez%2BBotella%26aufirst%3DG.%26aulast%3DSalituro%26aufirst%3DF.%2BG.%26aulast%3DHarrison%26aufirst%3DB.%2BL.%26aulast%3DBeresis%26aufirst%3DR.%2BT.%26aulast%3DBai%26aufirst%3DZ.%26aulast%3DBlanco%26aufirst%3DM.%2BJ.%26aulast%3DBelfort%26aufirst%3DG.%2BM.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DLoya%26aufirst%3DC.%2BM.%26aulast%3DAckley%26aufirst%3DM.%2BA.%26aulast%3DAlthaus%26aufirst%3DA.%2BL.%26aulast%3DGrossman%26aufirst%3DS.%2BJ.%26aulast%3DHoffmann%26aufirst%3DE.%26aulast%3DDoherty%26aufirst%3DJ.%2BJ.%26aulast%3DRobichaud%26aufirst%3DA.%2BJ.%26atitle%3DNeuroactive%2520Steroids.%25202.%25203%25CE%25B1-Hydroxy-3%25CE%25B2-methyl-21-%25284-cyano-1H-pyrazol-1%25E2%2580%25B2-yl%2529-19-nor-5%25CE%25B2-pregnan-20-one%2520%2528SAGE-217%2529%253A%2520a%2520clinical%2520next%2520generation%2520neuroactive%2520steroid%2520positive%2520allosteric%2520modulator%2520of%2520the%2520%2528%25CE%25B3-aminobutyric%2520acid%2529A%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D18%26spage%3D7810%26epage%3D7819%26doi%3D10.1021%2Facs.jmedchem.7b00846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bixo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekberg, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poromaa, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirschberg, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonasson, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">AndrÃ©en, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timby, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wulff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrenborg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BÃ¤ckstrÃ¶m, T.</span></span> <span> </span><span class="NLM_article-title">Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC1010)-A randomized controlled trial</span>. <i>Psychoneuroendocrinology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">46</span>â <span class="NLM_lpage">55</span>, <span class="refDoi">Â DOI: 10.1016/j.psyneuen.2017.02.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.psyneuen.2017.02.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=28319848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2sXks1ShtLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2017&pages=46-55&author=M.+Bixoauthor=K.+Ekbergauthor=I.+S.+Poromaaauthor=A.+L.+Hirschbergauthor=A.+F.+Jonassonauthor=L.+Andr%C3%A9enauthor=E.+Timbyauthor=M.+Wulffauthor=A.+Ehrenborgauthor=T.+B%C3%A4ckstr%C3%B6m&title=Treatment+of+premenstrual+dysphoric+disorder+with+the+GABAA+receptor+modulating+steroid+antagonist+Sepranolone+%28UC1010%29-A+randomized+controlled+trial&doi=10.1016%2Fj.psyneuen.2017.02.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC1010)-A randomized controlled trial</span></div><div class="casAuthors">Bixo, Marie; Ekberg, Karin; Poromaa, Inger Sundstroem; Hirschberg, Angelica Linden; Jonasson, Aino Fianu; Andreen, Lotta; Timby, Erika; Wulff, Marianne; Ehrenborg, Agneta; Baeckstroem, Torbjoern</div><div class="citationInfo"><span class="NLM_cas:title">Psychoneuroendocrinology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">46-55</span>CODEN:
                <span class="NLM_cas:coden">PSYCDE</span>;
        ISSN:<span class="NLM_cas:issn">0306-4530</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Allopregnanolone is a metabolite from progesterone and a pos. modulator of the GABAA receptor.  This endogenous steroid may induce neg. mood in sensitive women when present in serum levels comparable to the premenstrual phase.  Its endogenous isomer, isoallopregnanolone, has been shown to antagonize allopregnanolone effects in exptl. animal and human models.  The objective was to test whether inhibition of allopregnanolone by treatment with the GABAA modulating steroid antagonist (GAMSA) Sepranolone (UC1010) during the premenstrual phase could reduce symptoms of the premenstrual dysphoric disorder (PMDD).  The pharmacokinetic parameters of UC1010 when given as a s.c. injection were measured in healthy women prior to the study in women with PMDD.  This was an explorative randomized, double-blind, placebo-controlled study.  Swedish multicentre study with 10 centers.  Participants were 26 healthy women in a pharmacokinetic phase I study part, and 126 women with PMDD in a phase II study part.  Diagnosis followed the criteria for PMDD in DSM-5 using Daily Record of Severity of Problems (DRSP) and Endicott's algorithm.  Subjects were randomized to treatment with UC1010 (10 or 16 mg) s.c. every second day during the luteal phase or placebo during one menstrual cycle.  The primary outcome measure was the sum of all 21 items in DRSP (Total DRSP score).  Secondary outcomes were Neg. mood score i.e. the ratings of the 4 key symptoms in PMDD (anger/irritability, depression, anxiety and lability) and impairment (impact on daily life).26 healthy women completed the pharmacokinetic phase I study and the dosing in the following trial was adjusted according to the results. 106 of the 126 women completed the phase II study.  Within this group, a significant treatment effect with UC1010 compared to placebo was obtained for the Total DRSP score (p = 0.041) and borderline significance (p = 0.051) for the sum of Neg. mood score.  Nineteen participants however showed symptoms during the follicular phase that might be signs of an underlying other conditions, and 27 participants had not received the medication as intended during the symptomatic phase.  Hence, to secure that the significant result described above was not due to chance, a post hoc sub-group anal. was performed, including only women with pure PMDD who completed the trial as intended (n = 60).  In this group UC1010 reduced Total DRSP scores by 75% compared with 47% following placebo; the effect size 0.7 (p = 0.006), and for sum of Neg. mood score (p = 0.003) and impairment (p = 0.010) with the effect size 0.6.  No severe adverse events were reported during the treatment and safety parameters (vital signs and blood chem.) remained normal during the study.  This explorative study indicates promising results for UC1010 as a potential treatment for PMDD.  The effect size was comparable to that of SSRIs and drospirenone contg. oral contraceptives.  UC1010 was well tolerated and deemed safe.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGog3DmRroK10bVg90H21EOLACvtfcHk0lhjNcI_V83JRQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXks1ShtLs%253D&md5=359aa13bf0094df0015523aadd1f6967</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.psyneuen.2017.02.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.psyneuen.2017.02.031%26sid%3Dliteratum%253Aachs%26aulast%3DBixo%26aufirst%3DM.%26aulast%3DEkberg%26aufirst%3DK.%26aulast%3DPoromaa%26aufirst%3DI.%2BS.%26aulast%3DHirschberg%26aufirst%3DA.%2BL.%26aulast%3DJonasson%26aufirst%3DA.%2BF.%26aulast%3DAndr%25C3%25A9en%26aufirst%3DL.%26aulast%3DTimby%26aufirst%3DE.%26aulast%3DWulff%26aufirst%3DM.%26aulast%3DEhrenborg%26aufirst%3DA.%26aulast%3DB%25C3%25A4ckstr%25C3%25B6m%26aufirst%3DT.%26atitle%3DTreatment%2520of%2520premenstrual%2520dysphoric%2520disorder%2520with%2520the%2520GABAA%2520receptor%2520modulating%2520steroid%2520antagonist%2520Sepranolone%2520%2528UC1010%2529-A%2520randomized%2520controlled%2520trial%26jtitle%3DPsychoneuroendocrinology%26date%3D2017%26volume%3D80%26spage%3D46%26epage%3D55%26doi%3D10.1016%2Fj.psyneuen.2017.02.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johansson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MÃ¥nsson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lins, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scharschmidt, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doverskog, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BÃ¤ckstrÃ¶m, T.</span></span> <span> </span><span class="NLM_article-title">GR3027 reversal of neurosteroid-induced, GABA-A receptor-mediated inhibition of human brain function: an allopregnanolone challenge study</span>. <i>Psychopharmacology (Berl)</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>235</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1533</span>â <span class="NLM_lpage">1543</span>, <span class="refDoi">Â DOI: 10.1007/s00213-018-4864-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1007%2Fs00213-018-4864-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=29492615" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A280%3ADC%252BC1MrmsFSrsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=235&publication_year=2018&pages=1533-1543&issue=5&author=M.+Johanssonauthor=M.+M%C3%A5nssonauthor=L.+E.+Linsauthor=B.+Scharschmidtauthor=M.+Doverskogauthor=T.+B%C3%A4ckstr%C3%B6m&title=GR3027+reversal+of+neurosteroid-induced%2C+GABA-A+receptor-mediated+inhibition+of+human+brain+function%3A+an+allopregnanolone+challenge+study&doi=10.1007%2Fs00213-018-4864-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">GR3027 reversal of neurosteroid-induced, GABA-A receptor-mediated inhibition of human brain function: an allopregnanolone challenge study</span></div><div class="casAuthors">Johansson Maja; Mansson Maria; Lins Lars-Eric; Scharschmidt Bruce; Doverskog Magnus; Backstrom Torbjorn; Johansson Maja; Backstrom Torbjorn</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">235</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1533-1543</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">RATIONALE:  GR3027 is a novel small molecule GABA-A receptor-modulating steroid antagonist, which in non-clinical studies has shown promise for treatment of human disorders due to allosteric over-activation of GABA-A receptors by neurosteroids, such as allopregnanolone.  We here studied its safety, pharmacokinetics, and ability to inhibit allopregnanolone effects in humans.  METHODS:  Safety and pharmacokinetics were studied in healthy adult males receiving ascending single or multiple oral GR3027 vs. placebo.  GR3027-mediated reversal of allopregnanolone effect on maximal saccadic eye velocity (SEV), and self-rated somnolence was studied in a double-blind, placebo-controlled, three-part cross-over study in which 3 or 30 mg oral GR3027 preceded 0.05 mg/kg of i.v. allopregnanolone.  RESULTS:  GR3027 was well tolerated, adverse events were generally mild and transient, and no dose-limiting toxicity or grade 3 adverse events were observed up to the highest single (200 mg) or multiple (100 mg every 12 h for 5 days) doses.  The maximum concentration (Cmax) and systemic exposure (area under the plasma concentration-time curve from dose extrapolated to infinity [AUC0-â] and/or AUC during the dosing interval [AUCÏ]) varied linearly with dose; with dose-dependent accumulation ratios of 1.3-1.6.  Allopregnanolone decreased SEV and induced somnolence in most, but not all subjects.  By predefined analyses, 30 mg GR3027 significantly inhibited allopregnanolone-induced decrease in SEV (p = 0.03); 3 and 30 mg GR3027 non-significantly inhibited allopregnanolone-induced sedation.  By post hoc analyses restricted to subjects with allopregnanolone-induced changes and the time period over which they occurred, GR3027 dose dependently inhibited allopregnanolone-induced decrease in SEV (p = 0.04 at 30 mg, non-significant at 3 mg) and allopregnanolone-induced sedation (p = 0.01/0.05 at 3/30 mg doses).  CONCLUSION:  Oral GR3027 mitigates inhibition of brain function induced by allopregnanolone at doses which are clinically well tolerated and associated with linear pharmacokinetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTDJhfcFAoVnBwLZxei1HN8fW6udTcc2eZ1PxUk8hAqxrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrmsFSrsQ%253D%253D&md5=9b89c9a17b9edd83f862badb682bb668</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1007%2Fs00213-018-4864-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-018-4864-1%26sid%3Dliteratum%253Aachs%26aulast%3DJohansson%26aufirst%3DM.%26aulast%3DM%25C3%25A5nsson%26aufirst%3DM.%26aulast%3DLins%26aufirst%3DL.%2BE.%26aulast%3DScharschmidt%26aufirst%3DB.%26aulast%3DDoverskog%26aufirst%3DM.%26aulast%3DB%25C3%25A4ckstr%25C3%25B6m%26aufirst%3DT.%26atitle%3DGR3027%2520reversal%2520of%2520neurosteroid-induced%252C%2520GABA-A%2520receptor-mediated%2520inhibition%2520of%2520human%2520brain%2520function%253A%2520an%2520allopregnanolone%2520challenge%2520study%26jtitle%3DPsychopharmacology%2520%2528Berl%2529%26date%3D2018%26volume%3D235%26issue%3D5%26spage%3D1533%26epage%3D1543%26doi%3D10.1007%2Fs00213-018-4864-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Linsenbardt, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emnett, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covey, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zorumski, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mennerick, S.</span></span> <span> </span><span class="NLM_article-title">Different oxysterols have opposing actions at <i>N</i>-methyl-D-aspartate receptors</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">232</span>â <span class="NLM_lpage">242</span>, <span class="refDoi">Â DOI: 10.1016/j.neuropharm.2014.05.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.neuropharm.2014.05.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=24878244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFyhtb7K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2014&pages=232-242&author=A.+J.+Linsenbardtauthor=A.+Taylorauthor=C.+M.+Emnettauthor=J.+J.+Dohertyauthor=K.+Krishnanauthor=D.+F.+Coveyauthor=S.+M.+Paulauthor=C.+F.+Zorumskiauthor=S.+Mennerick&title=Different+oxysterols+have+opposing+actions+at+N-methyl-D-aspartate+receptors&doi=10.1016%2Fj.neuropharm.2014.05.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Different oxysterols have opposing actions at N-methyl-D-aspartate receptors</span></div><div class="casAuthors">Linsenbardt, Andrew J.; Taylor, Amanda; Emnett, Christine M.; Doherty, James J.; Krishnan, Kathiresan; Covey, Douglas F.; Paul, Steven M.; Zorumski, Charles F.; Mennerick, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">232-242</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Oxysterols have emerged as important biomarkers in disease and as signaling mols.  We recently showed that the oxysterol 24(S)-hydroxycholesterol, the major brain cholesterol metabolite, potently and selectively enhances NMDA receptor function at a site distinct from other modulators.  Here we further characterize the pharmacol. mechanisms of 24(S)-hydroxycholesterol and its synthetic analog SGE201.  We describe an oxysterol antagonist of this pos. allosteric modulation, 25-hydroxycholesterol.  We found that 24(S)-hydroxycholesterol and SGE201 primarily increased the efficacy of NMDAR agonists but did not directly gate the channel or increase functional receptor no.  Rather than binding to a direct aq.-accessible site, oxysterols may partition into the plasma membrane to access the NMDAR, likely explaining slow onset and offset kinetics of modulation.  Interestingly, oxysterols were ineffective when applied to the cytosolic face of inside-out membrane patches or through a whole-cell pipet soln., suggesting a non-intracellular site.  We also found that another natural oxysterol, 25-hydroxycholesterol, although exhibiting slight potentiation on its own, non-competitively and enantioselectively antagonized the effects of 24(S)-hydroxycholesterol analogs.  In summary, we suggest two novel allosteric sites on NMDARs that sep. modulate channel gating, but together oppose each other.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMfECHj13EKLVg90H21EOLACvtfcHk0lhjNcI_V83JRQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFyhtb7K&md5=0fbd27a7cb8e4ac2db9fe70abe12466b</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2014.05.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2014.05.027%26sid%3Dliteratum%253Aachs%26aulast%3DLinsenbardt%26aufirst%3DA.%2BJ.%26aulast%3DTaylor%26aufirst%3DA.%26aulast%3DEmnett%26aufirst%3DC.%2BM.%26aulast%3DDoherty%26aufirst%3DJ.%2BJ.%26aulast%3DKrishnan%26aufirst%3DK.%26aulast%3DCovey%26aufirst%3DD.%2BF.%26aulast%3DPaul%26aufirst%3DS.%2BM.%26aulast%3DZorumski%26aufirst%3DC.%2BF.%26aulast%3DMennerick%26aufirst%3DS.%26atitle%3DDifferent%2520oxysterols%2520have%2520opposing%2520actions%2520at%2520N-methyl-D-aspartate%2520receptors%26jtitle%3DNeuropharmacology%26date%3D2014%26volume%3D85%26spage%3D232%26epage%3D242%26doi%3D10.1016%2Fj.neuropharm.2014.05.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paul, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robichaud, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belfort, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linsenbardt, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mennerick, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zorumski, C. F.</span></span> <span> </span><span class="NLM_article-title">The major brain cholesterol metabolite 24(<i>S</i>)-hydroxycholesterol is a potent allosteric modulator of <i>N</i>-methyl-D-aspartate receptors</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">44</span>),  <span class="NLM_fpage">17290</span>â <span class="NLM_lpage">17300</span>, <span class="refDoi">Â DOI: 10.1523/JNEUROSCI.2619-13.2013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1523%2FJNEUROSCI.2619-13.2013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=24174662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslCjtrbI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2013&pages=17290-17300&issue=44&author=S.+M.+Paulauthor=J.+J.+Dohertyauthor=A.+J.+Robichaudauthor=G.+M.+Belfortauthor=B.+Y.+Chowauthor=R.+S.+Hammondauthor=D.+C.+Crawfordauthor=A.+J.+Linsenbardtauthor=H.+J.+Shuauthor=Y.+Izumiauthor=S.+J.+Mennerickauthor=C.+F.+Zorumski&title=The+major+brain+cholesterol+metabolite+24%28S%29-hydroxycholesterol+is+a+potent+allosteric+modulator+of+N-methyl-D-aspartate+receptors&doi=10.1523%2FJNEUROSCI.2619-13.2013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">The major brain cholesterol metabolite 24(S)-hydroxycholesterol is a potent allosteric modulator of N-methyl-D-aspartate receptors</span></div><div class="casAuthors">Paul, Steven M.; Doherty, James J.; Robichaud, Albert J.; Belfort, Gabriel M.; Chow, Brian Y.; Hammond, Rebecca S.; Crawford, Devon C.; Linsenbardt, Andrew J.; Shu, Hong-Jin; Izumi, Yukitoshi; Mennerick, Steven J.; Zorumski, Charles F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">17290-17300</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">N-methyl-D-aspartate receptors (NMDARs) are glutamate-gated ion channels that are crit. to the regulation of excitatory synaptic function in the CNS.  NMDARs govern experience-dependent synaptic plasticity and have been implicated in the pathophysiol. of various neuropsychiatric disorders including the cognitive deficits of schizophrenia and certain forms of autism.  Certain neurosteroids modulate NMDARs exptl. but their low potency, poor selectivity, and very low brain concns. make them poor candidates as endogenous ligands or therapeutic agents.  Here we show that the major brain-derived cholesterol metabolite 24(S)-hydroxycholesterol (24(S)-HC) is a very potent, direct, and selective pos. allosteric modulator of NMDARs with a mechanism that does not overlap that of other allosteric modulators.  At submicromolar concns. 24(S)-HC potentiates NMDAR-mediated EPSCs in rat hippocampal neurons but fails to affect AMPAR or GABAA receptors (GABAARs)-mediated responses.  Cholesterol itself and other naturally occurring oxysterols present in brain do not modulate NMDARs at concns. â¤10 Î¼M.  In hippocampal slices, 24(S)-HC enhances the ability of subthreshold stimuli to induce long-term potentiation (LTP).  24(S)-HC also reverses hippocampal LTP deficits induced by the NMDAR channel blocker ketamine.  Finally, we show that synthetic drug-like derivs. of 24(S)-HC, which potently enhance NMDAR-mediated EPSCs and LTP, restore behavioral and cognitive deficits in rodents treated with NMDAR channel blockers.  Thus, 24(S)-HC may function as an endogenous modulator of NMDARs acting at a novel oxysterol modulatory site that also represents a target for therapeutic drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDNdn3JBVmtLVg90H21EOLACvtfcHk0lgP1Dy9e0xzDg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslCjtrbI&md5=35ab8bb8030a4ac752f224f8cd942fb4</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.2619-13.2013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.2619-13.2013%26sid%3Dliteratum%253Aachs%26aulast%3DPaul%26aufirst%3DS.%2BM.%26aulast%3DDoherty%26aufirst%3DJ.%2BJ.%26aulast%3DRobichaud%26aufirst%3DA.%2BJ.%26aulast%3DBelfort%26aufirst%3DG.%2BM.%26aulast%3DChow%26aufirst%3DB.%2BY.%26aulast%3DHammond%26aufirst%3DR.%2BS.%26aulast%3DCrawford%26aufirst%3DD.%2BC.%26aulast%3DLinsenbardt%26aufirst%3DA.%2BJ.%26aulast%3DShu%26aufirst%3DH.%2BJ.%26aulast%3DIzumi%26aufirst%3DY.%26aulast%3DMennerick%26aufirst%3DS.%2BJ.%26aulast%3DZorumski%26aufirst%3DC.%2BF.%26atitle%3DThe%2520major%2520brain%2520cholesterol%2520metabolite%252024%2528S%2529-hydroxycholesterol%2520is%2520a%2520potent%2520allosteric%2520modulator%2520of%2520N-methyl-D-aspartate%2520receptors%26jtitle%3DJ.%2520Neurosci.%26date%3D2013%26volume%3D33%26issue%3D44%26spage%3D17290%26epage%3D17300%26doi%3D10.1523%2FJNEUROSCI.2619-13.2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nickolls, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurrell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Amerongen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kammonen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stead, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mead, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fish, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitlock, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Gerven, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dua, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butt, R. P.</span></span> <span> </span><span class="NLM_article-title">Pharmacology in translation: the preclinical and early clinical profile of the novel Î±2/3 functionally selective GABA<sub>A</sub> receptor positive allosteric modulator PF-06372865</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>175</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">708</span>â <span class="NLM_lpage">725</span>, <span class="refDoi">Â DOI: 10.1111/bph.14119</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1111%2Fbph.14119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=29214652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFKrtrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2018&pages=708-725&issue=4&author=S.+A.+Nickollsauthor=R.+Gurrellauthor=G.+van+Amerongenauthor=J.+Kammonenauthor=L.+Caoauthor=A.+R.+Brownauthor=C.+Steadauthor=A.+Meadauthor=C.+Watsonauthor=C.+Hsuauthor=R.+M.+Owenauthor=A.+Pikeauthor=R.+L.+Fishauthor=L.+Chenauthor=R.+Qiuauthor=E.+D.+Morrisauthor=G.+Fengauthor=M.+Whitlockauthor=D.+Gormanauthor=J.+van+Gervenauthor=D.+S.+Reynoldsauthor=P.+Duaauthor=R.+P.+Butt&title=Pharmacology+in+translation%3A+the+preclinical+and+early+clinical+profile+of+the+novel+%CE%B12%2F3+functionally+selective+GABAA+receptor+positive+allosteric+modulator+PF-06372865&doi=10.1111%2Fbph.14119"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology in translation: the preclinical and early clinical profile of the novel Î±2/3 functionally selective GABAA receptor positive allosteric modulator PF-06372865</span></div><div class="casAuthors">Nickolls, Sarah A.; Gurrell, Rachel; van Amerongen, Guido; Kammonen, Juha; Cao, Lishuang; Brown, Adam R.; Stead, Clara; Mead, Andy; Watson, Christine; Hsu, Cathleen; Owen, Robert M.; Pike, Andy; Fish, Rebecca L.; Chen, Laigao; Qiu, Ruolun; Morris, Evan D.; Feng, Gang; Whitlock, Mark; Gorman, Donal; van Gerven, Joop; Reynolds, David S.; Dua, Pinky; Butt, Richard P.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">708-725</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose: Benzodiazepines, non-selective pos. allosteric modulators (PAMs) of GABAA receptors, have significant side effects that limit their clin. utility.  As many of these side effects are mediated by the Î±1 subunit, there has been a concerted effort to develop Î±2/3 subtype-selective PAMs.  Exptl. Approach: In vitro screening assays were used to identify mols. with functional selectivity for receptors contg. Î±2/3 subunits over those contg. Î±1 subunits.  In vivo receptor occupancy (RO) was conducted, prior to confirmation of in vivo Î±2/3 and Î±1 pharmacol. through quant. EEG (qEEG) beta frequency and zolpidem drug discrimination in rats resp.  PF-06372865 was then progressed to Phase 1 clin. trials.  Key Results: PF-06372865 exhibited functional selectivity for those receptors contg. Î±2/3/5 subunits, with significant pos. allosteric modulation (90-140%) but negligible activity (â¤20%) at GABAA receptors contg. Î±1 subunits.  PF-06372865 exhibited concn.-dependent occupancy of GABAA receptors in preclin. species.  There was an occupancy-dependent increase in qEEG beta frequency and no generalization to a GABAA Î±1 cue in the drug-discrimination assay, clearly demonstrating the lack of modulation at the GABAA receptors contg. an Î±1 subtype.  In a Phase 1 single ascending dose study in healthy volunteers, evaluation of the pharmacodynamics of PF-06372865 demonstrated a robust increase in saccadic peak velocity (a marker of Î±2/3 pharmacol.), increases in beta frequency qEEG and a slight satg. increase in body sway.  Conclusions and Implications: PF-06372865 has a unique clin. pharmacol. profile and a highly predictive translational data package from preclin. species to the clin. setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppCgUwgmVaq7Vg90H21EOLACvtfcHk0lgP1Dy9e0xzDg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFKrtrY%253D&md5=fea6d4ebedc564f92a73250d1dc8115d</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1111%2Fbph.14119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.14119%26sid%3Dliteratum%253Aachs%26aulast%3DNickolls%26aufirst%3DS.%2BA.%26aulast%3DGurrell%26aufirst%3DR.%26aulast%3Dvan%2BAmerongen%26aufirst%3DG.%26aulast%3DKammonen%26aufirst%3DJ.%26aulast%3DCao%26aufirst%3DL.%26aulast%3DBrown%26aufirst%3DA.%2BR.%26aulast%3DStead%26aufirst%3DC.%26aulast%3DMead%26aufirst%3DA.%26aulast%3DWatson%26aufirst%3DC.%26aulast%3DHsu%26aufirst%3DC.%26aulast%3DOwen%26aufirst%3DR.%2BM.%26aulast%3DPike%26aufirst%3DA.%26aulast%3DFish%26aufirst%3DR.%2BL.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DQiu%26aufirst%3DR.%26aulast%3DMorris%26aufirst%3DE.%2BD.%26aulast%3DFeng%26aufirst%3DG.%26aulast%3DWhitlock%26aufirst%3DM.%26aulast%3DGorman%26aufirst%3DD.%26aulast%3Dvan%2BGerven%26aufirst%3DJ.%26aulast%3DReynolds%26aufirst%3DD.%2BS.%26aulast%3DDua%26aufirst%3DP.%26aulast%3DButt%26aufirst%3DR.%2BP.%26atitle%3DPharmacology%2520in%2520translation%253A%2520the%2520preclinical%2520and%2520early%2520clinical%2520profile%2520of%2520the%2520novel%2520%25CE%25B12%252F3%2520functionally%2520selective%2520GABAA%2520receptor%2520positive%2520allosteric%2520modulator%2520PF-06372865%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2018%26volume%3D175%26issue%3D4%26spage%3D708%26epage%3D725%26doi%3D10.1111%2Fbph.14119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doller, D.</span></span> <span> </span><span class="NLM_article-title">Recent developments in group I metabotropic glutamate receptor allosteric modulators for the treatment of psychiatric and neurological disorders (2014-May 2015)</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">29</span>),  <span class="NLM_fpage">3470</span>â <span class="NLM_lpage">3526</span>, <span class="refDoi">Â DOI: 10.2174/1568026616666160405113536</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.2174%2F1568026616666160405113536" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=27048271" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslKksLzE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=3470-3526&issue=29&author=G.+Liauthor=M.+Jorgensenauthor=B.+M.+Campbellauthor=D.+Doller&title=Recent+developments+in+group+I+metabotropic+glutamate+receptor+allosteric+modulators+for+the+treatment+of+psychiatric+and+neurological+disorders+%282014-May+2015%29&doi=10.2174%2F1568026616666160405113536"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Developments in Group I Metabotropic Glutamate Receptor Allosteric Modulators for the Treatment of Psychiatric and Neurological Disorders (2014-May 2015)</span></div><div class="casAuthors">Li, Guiying; Jorgensen, Morten; Campbell, Brian M.; Doller, Dario</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">3470-3526</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">In the last â¼30 years, scientists have made great strides in understanding the biol. function of group I metabotropic glutamate receptors (mGlu) in health and disease, as well as developing a broad array of potent and selective agents able to activate or inhibit these receptors.  This article provides a comprehensive review of the most recent group I mGlu modulators published in patent and non-patent literatures from 2014 to May, 2015, including design, structure-activity relationship, in silico, in vitro and in vivo properties of key compds.  The current status of clin. mGlu5 neg. allosteric modulators (NAMs) and the development of mGlu1 and mGlu5 PET ligands are also highlighted.  While the therapeutic potential for group I mGlu modulating agents appears high, significant challenges remain.  Strategies to reduce clin. development risks and mitigate important side effects, including psychotomimetic events obsd. with several mGlu5 NAMs and cellular toxicity assocd. with mGlu5 pos. allosteric modulators (PAMs), while retaining therapeutic efficacy through approaches such as biased ligand signaling are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlCrD4Oz3xJLVg90H21EOLACvtfcHk0lg2oiE6SKOpkw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslKksLzE&md5=d931187d0a9c499c0fe875b823725ad3</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.2174%2F1568026616666160405113536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026616666160405113536%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DG.%26aulast%3DJorgensen%26aufirst%3DM.%26aulast%3DCampbell%26aufirst%3DB.%2BM.%26aulast%3DDoller%26aufirst%3DD.%26atitle%3DRecent%2520developments%2520in%2520group%2520I%2520metabotropic%2520glutamate%2520receptor%2520allosteric%2520modulators%2520for%2520the%2520treatment%2520of%2520psychiatric%2520and%2520neurological%2520disorders%2520%25282014-May%25202015%2529%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2016%26volume%3D16%26issue%3D29%26spage%3D3470%26epage%3D3526%26doi%3D10.2174%2F1568026616666160405113536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Youssef, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry-Kravis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czech, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagerman, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hessl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabbia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deptula, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinch, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewitt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindemann, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcinowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langland, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontoura, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santarelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quiroz, J. A.</span></span>; <span class="NLM_contrib-group">FragXis study group</span> <span> </span><span class="NLM_article-title">Effect of the mGluR5-NAM basimglurant on behavior in adolescents and adults with fragile X syndrome in a randomized, double-blind, placebo-controlled trial: FragXis phase 2 results</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">503</span>â <span class="NLM_lpage">512</span>, <span class="refDoi">Â DOI: 10.1038/npp.2017.177</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fnpp.2017.177" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=28816242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFantrbI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2018&pages=503-512&issue=3&author=E.+A.+Youssefauthor=E.+Berry-Kravisauthor=C.+Czechauthor=R.+J.+Hagermanauthor=D.+Hesslauthor=C.+Y.+Wongauthor=M.+Rabbiaauthor=D.+Deptulaauthor=A.+Johnauthor=R.+Kinchauthor=P.+Drewittauthor=L.+Lindemannauthor=M.+Marcinowskiauthor=R.+Langlandauthor=C.+Hornauthor=P.+Fontouraauthor=L.+Santarelliauthor=J.+A.+Quirozauthor=FragXis+study+group&title=Effect+of+the+mGluR5-NAM+basimglurant+on+behavior+in+adolescents+and+adults+with+fragile+X+syndrome+in+a+randomized%2C+double-blind%2C+placebo-controlled+trial%3A+FragXis+phase+2+results&doi=10.1038%2Fnpp.2017.177"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results</span></div><div class="casAuthors">Youssef, Eriene A.; Berry-Kravis, Elizabeth; Czech, Christian; Hagerman, Randi J.; Hessl, David; Wong, Chin Y.; Rabbia, Michael; Deptula, Dennis; John, Amy; Kinch, Russell; Drewitt, Philip; Lindemann, Lothar; Marcinowski, Moritz; Langland, Rachel; Horn, Carsten; Fontoura, Paulo; Santarelli, Luca; Quiroz, Jorge A.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">503-512</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Preclin. data suggest that inhibition of the metabotropic glutamate receptor 5 (mGluR5) receptor might hold therapeutic benefits in Fragile X syndrome (FXS).  Treatment of Fmr1 knockout mice with mGluR5-neg. allosteric modulators (NAMs) has been reported to correct a broad range of phenotypes related to FXS.  The early short-term clin. trials with mGluR5 NAMs, including basimglurant, assessing the effects in individuals with FXS, were supportive of further exploration in larger, well-controlled trials.  We evaluated basimglurant, a potent and selective mGluR5 NAM, in a 12-wk, double-blind, parallel-group study of 183 adults and adolescents (aged 14-50, mean 23.4 years) with FXS.  Individuals with an FMR1 full mutation were randomized to placebo or one of two doses of basimglurant.  The primary efficacy endpoint was the change from baseline in behavioral symptoms using the Anxiety Depression and Mood Scale (ADAMS) total score.  All treatment arms showed marked behavioral improvements from baseline to week 12 with less improvement in the basimglurant 1.5 mg arm than placebo; however, basimglurant 0.5 mg was inferior to placebo in the ADAMs total score.  Treatment with basimglurant was overall well-tolerated.  A higher incidence of adverse events classified as psychiatric disorders were reported in patients treated with basimglurant, including three patients with hallucinations or psychosis.  In this phase 2 clin. trial, basimglurant did not demonstrate improvement over placebo.  Evaluation of the overall risk-benefit in younger patient populations is an important consideration for the design of potential further investigations of efficacy with this class of medications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaxLdgyuHLnrVg90H21EOLACvtfcHk0lg2oiE6SKOpkw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFantrbI&md5=7759b9d123916553747889db318aa343</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2017.177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2017.177%26sid%3Dliteratum%253Aachs%26aulast%3DYoussef%26aufirst%3DE.%2BA.%26aulast%3DBerry-Kravis%26aufirst%3DE.%26aulast%3DCzech%26aufirst%3DC.%26aulast%3DHagerman%26aufirst%3DR.%2BJ.%26aulast%3DHessl%26aufirst%3DD.%26aulast%3DWong%26aufirst%3DC.%2BY.%26aulast%3DRabbia%26aufirst%3DM.%26aulast%3DDeptula%26aufirst%3DD.%26aulast%3DJohn%26aufirst%3DA.%26aulast%3DKinch%26aufirst%3DR.%26aulast%3DDrewitt%26aufirst%3DP.%26aulast%3DLindemann%26aufirst%3DL.%26aulast%3DMarcinowski%26aufirst%3DM.%26aulast%3DLangland%26aufirst%3DR.%26aulast%3DHorn%26aufirst%3DC.%26aulast%3DFontoura%26aufirst%3DP.%26aulast%3DSantarelli%26aufirst%3DL.%26aulast%3DQuiroz%26aufirst%3DJ.%2BA.%26aulast%3D%26atitle%3DEffect%2520of%2520the%2520mGluR5-NAM%2520basimglurant%2520on%2520behavior%2520in%2520adolescents%2520and%2520adults%2520with%2520fragile%2520X%2520syndrome%2520in%2520a%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520trial%253A%2520FragXis%2520phase%25202%2520results%26jtitle%3DNeuropsychopharmacology%26date%3D2018%26volume%3D43%26issue%3D3%26spage%3D503%26epage%3D512%26doi%3D10.1038%2Fnpp.2017.177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gould, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amato, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bubser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joffe, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nedelcovych, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickols, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuh, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felts, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byers, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rook, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niswender, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmitte, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. K.</span></span> <span> </span><span class="NLM_article-title">Partial mGlu<sub>5</sub> negative allosteric modulators attenuate cocaine-mediated behaviors and lack psychotomimetic-like effects</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>41</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1166</span>â <span class="NLM_lpage">1178</span>, <span class="refDoi">Â DOI: 10.1038/npp.2015.265</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fnpp.2015.265" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=26315507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2htrnE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2016&pages=1166-1178&issue=4&author=R.+W.+Gouldauthor=R.+J.+Amatoauthor=M.+Bubserauthor=M.+E.+Joffeauthor=M.+T.+Nedelcovychauthor=A.+D.+Thompsonauthor=H.+H.+Nickolsauthor=J.+P.+Yuhauthor=X.+Zhanauthor=A.+S.+Feltsauthor=A.+L.+Rodriguezauthor=R.+D.+Morrisonauthor=F.+W.+Byersauthor=J.+M.+Rookauthor=J.+S.+Danielsauthor=C.+M.+Niswenderauthor=P.+J.+Connauthor=K.+A.+Emmitteauthor=C.+W.+Lindsleyauthor=C.+K.+Jones&title=Partial+mGlu5+negative+allosteric+modulators+attenuate+cocaine-mediated+behaviors+and+lack+psychotomimetic-like+effects&doi=10.1038%2Fnpp.2015.265"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Partial mGlu5 Negative Allosteric Modulators Attenuate Cocaine-Mediated Behaviors and Lack Psychotomimetic-Like Effects</span></div><div class="casAuthors">Gould, Robert W.; Amato, Russell J.; Bubser, Michael; Joffe, Max E.; Nedelcovych, Michael T.; Thompson, Analisa D.; Nickols, Hilary H.; Yuh, Johannes P.; Zhan, Xiaoyan; Felts, Andrew S.; Rodriguez, Alice L.; Morrison, Ryan D.; Byers, Frank W.; Rook, Jerri M.; Daniels, John S.; Niswender, Colleen M.; Conn, P. Jeffrey; Emmitte, Kyle A.; Lindsley, Craig W.; Jones, Carrie K.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1166-1178</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cocaine abuse remains a public health concern for which pharmacotherapies are largely ineffective.  Comorbidities between cocaine abuse, depression, and anxiety support the development of novel treatments targeting multiple symptom clusters.  Selective neg. allosteric modulators (NAMs) targeting the metabotropic glutamate receptor 5 (mGlu5) subtype are currently in clin. trials for the treatment of multiple neuropsychiatric disorders and have shown promise in preclin. models of substance abuse.  However, complete blockade or inverse agonist activity by some full mGlu5 NAM chemotypes demonstrated adverse effects, including psychosis in humans and psychotomimetic-like effects in animals, suggesting a narrow therapeutic window.  Development of partial mGlu5 NAMs, characterized by their submaximal but saturable levels of blockade, may represent a novel approach to broaden the therapeutic window.  To understand potential therapeutic vs adverse effects in preclin. behavioral assays, we examd. the partial mGlu5 NAMs, M-5MPEP and Br-5MPEPy, in comparison with the full mGlu5 NAM MTEP across models of addiction and psychotomimetic-like activity.  M-5MPEP, Br-5MPEPy, and MTEP dose-dependently decreased cocaine self-administration and attenuated the discriminative stimulus effects of cocaine.  M-5MPEP and Br-5MPEPy also demonstrated antidepressant- and anxiolytic-like activity.  Dose-dependent effects of partial and full mGlu5 NAMs in these assays corresponded with increasing in vivo mGlu5 occupancy, demonstrating an orderly occupancy-to-efficacy relationship.  PCP-induced hyperlocomotion was potentiated by MTEP, but not by M-5MPEP and Br-5MPEPy.  Further, MTEP, but not M-5MPEP, potentiated the discriminative-stimulus effects of PCP.  The present data suggest that partial mGlu5 NAM activity is sufficient to produce therapeutic effects similar to full mGlu5 NAMs, but with a broader therapeutic index.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZe4O0o7NSy7Vg90H21EOLACvtfcHk0lg2oiE6SKOpkw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2htrnE&md5=5b6ebd4049872b33d32cfbadade1bdb3</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2015.265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2015.265%26sid%3Dliteratum%253Aachs%26aulast%3DGould%26aufirst%3DR.%2BW.%26aulast%3DAmato%26aufirst%3DR.%2BJ.%26aulast%3DBubser%26aufirst%3DM.%26aulast%3DJoffe%26aufirst%3DM.%2BE.%26aulast%3DNedelcovych%26aufirst%3DM.%2BT.%26aulast%3DThompson%26aufirst%3DA.%2BD.%26aulast%3DNickols%26aufirst%3DH.%2BH.%26aulast%3DYuh%26aufirst%3DJ.%2BP.%26aulast%3DZhan%26aufirst%3DX.%26aulast%3DFelts%26aufirst%3DA.%2BS.%26aulast%3DRodriguez%26aufirst%3DA.%2BL.%26aulast%3DMorrison%26aufirst%3DR.%2BD.%26aulast%3DByers%26aufirst%3DF.%2BW.%26aulast%3DRook%26aufirst%3DJ.%2BM.%26aulast%3DDaniels%26aufirst%3DJ.%2BS.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DEmmitte%26aufirst%3DK.%2BA.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DJones%26aufirst%3DC.%2BK.%26atitle%3DPartial%2520mGlu5%2520negative%2520allosteric%2520modulators%2520attenuate%2520cocaine-mediated%2520behaviors%2520and%2520lack%2520psychotomimetic-like%2520effects%26jtitle%3DNeuropsychopharmacology%26date%3D2016%26volume%3D41%26issue%3D4%26spage%3D1166%26epage%3D1178%26doi%3D10.1038%2Fnpp.2015.265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nickols, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuh, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmitte, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bubser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nedelcovych, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niswender, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span> <span> </span><span class="NLM_article-title">VU0477573: partial negative allosteric modulator of the subtype 5 metabotropic glutamate receptor with in vivo efficacy</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>356</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">123</span>â <span class="NLM_lpage">136</span>, <span class="refDoi">Â DOI: 10.1124/jpet.115.226597</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1124%2Fjpet.115.226597" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=26503377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhsleks78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2016&pages=123-136&issue=1&author=H.+H.+Nickolsauthor=J.+P.+Yuhauthor=K.+J.+Gregoryauthor=R.+D.+Morrisonauthor=B.+S.+Batesauthor=S.+R.+Staufferauthor=K.+A.+Emmitteauthor=M.+Bubserauthor=W.+Pengauthor=M.+T.+Nedelcovychauthor=A.+Thompsonauthor=X.+Lvauthor=Z.+Xiangauthor=J.+S.+Danielsauthor=C.+M.+Niswenderauthor=C.+W.+Lindsleyauthor=C.+K.+Jonesauthor=P.+J.+Conn&title=VU0477573%3A+partial+negative+allosteric+modulator+of+the+subtype+5+metabotropic+glutamate+receptor+with+in+vivo+efficacy&doi=10.1124%2Fjpet.115.226597"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">VU0477573: partial negative allosteric modulator of the subtype 5 metabotropic glutamate receptor with in vivo efficacy</span></div><div class="casAuthors">Nickols, Hilary Highfield; Yuh, Joannes P.; Gregory, Karen J.; Morrison, Ryan D.; Bates, Brittney S.; Stauffer, Shaun R.; Emmitte, Kyle A.; Bubser, Michael; Peng, Weimin; Nedelcovych, Michael T.; Thompson, Analisa; Lv, Xiaohui; Xiang, Zixiu; Daniels, J. Scott; Niswender, Colleen M.; Lindsley, Craig W.; Jones, Carrie K.; Conn, P. Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">123-136</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Neg. allosteric modulators (NAMs) of metabotropic glutamate receptor subtype 5 (mGlu5) have potential applications in the treatment of fragile X syndrome, levodopa-induced dyskinesia in Parkinson disease, Alzheimer disease, addiction, and anxiety; however, clin. and preclin. studies raise concerns that complete blockade of mGlu5 and inverse agonist activity of current mGlu5 NAMs contribute to adverse effects that limit the therapeutic use of these compds.  We report the discovery and characterization of a novel mGlu5 NAM, N,N-diethyl-5-((3-fluorophenyl)ethynyl)picolinamide (VU0477573) that binds to the same allosteric site as the prototypical mGlu5 NAM MPEP but displays weak neg. cooperativity.  Because of this weak cooperativity, VU0477573 acts as a "partial NAM" so that full occupancy of the MPEP site does not completely inhibit maximal effects of mGlu5 agonists on intracellular calcium mobilization, inositol phosphate (IP) accumulation, or inhibition of synaptic transmission at the hippocampal Schaffer collateral-CA1 synapse.  Unlike previous mGlu5 NAMs, VU0477573 displays no inverse agonist activity assessed using measures of effects on basal [3H]inositol phosphate (IP) accumulation.  VU0477573 acts as a full NAM when measuring effects on mGlu5-mediated extracellular signal-related kinases 1/2 phosphorylation, which may indicate functional bias.  VU0477573 exhibits an excellent pharmacokinetic profile and good brain penetration in rodents and provides dose-dependent full mGlu5 occupancy in the central nervous system (CNS) with systemic administration.  Interestingly, VU0477573 shows robust efficacy, comparable to the mGlu5 NAM MTEP, in models of anxiolytic activity at doses that provide full CNS occupancy of mGlu5 and demonstrate an excellent CNS occupancy-efficacy relationship.  VU0477573 provides an exciting new tool to investigate the efficacy of partial NAMs in animal models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopb5YLSgOc37Vg90H21EOLACvtfcHk0ljvu3P4Be6PDg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhsleks78%253D&md5=913f14cbfff58c61e1302fc2eeba52e2</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1124%2Fjpet.115.226597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.115.226597%26sid%3Dliteratum%253Aachs%26aulast%3DNickols%26aufirst%3DH.%2BH.%26aulast%3DYuh%26aufirst%3DJ.%2BP.%26aulast%3DGregory%26aufirst%3DK.%2BJ.%26aulast%3DMorrison%26aufirst%3DR.%2BD.%26aulast%3DBates%26aufirst%3DB.%2BS.%26aulast%3DStauffer%26aufirst%3DS.%2BR.%26aulast%3DEmmitte%26aufirst%3DK.%2BA.%26aulast%3DBubser%26aufirst%3DM.%26aulast%3DPeng%26aufirst%3DW.%26aulast%3DNedelcovych%26aufirst%3DM.%2BT.%26aulast%3DThompson%26aufirst%3DA.%26aulast%3DLv%26aufirst%3DX.%26aulast%3DXiang%26aufirst%3DZ.%26aulast%3DDaniels%26aufirst%3DJ.%2BS.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DJones%26aufirst%3DC.%2BK.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26atitle%3DVU0477573%253A%2520partial%2520negative%2520allosteric%2520modulator%2520of%2520the%2520subtype%25205%2520metabotropic%2520glutamate%2520receptor%2520with%2520in%2520vivo%2520efficacy%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2016%26volume%3D356%26issue%3D1%26spage%3D123%26epage%3D136%26doi%3D10.1124%2Fjpet.115.226597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keov, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span> <span> </span><span class="NLM_article-title">Allosteric modulation of G protein-coupled receptors: a pharmacological perspective</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">24</span>â <span class="NLM_lpage">35</span>, <span class="refDoi">Â DOI: 10.1016/j.neuropharm.2010.07.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.neuropharm.2010.07.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=20637785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVaitLzO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2011&pages=24-35&author=P.+Keovauthor=P.+M.+Sextonauthor=A.+Christopoulos&title=Allosteric+modulation+of+G+protein-coupled+receptors%3A+a+pharmacological+perspective&doi=10.1016%2Fj.neuropharm.2010.07.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric modulation of G protein-coupled receptors: A pharmacological perspective</span></div><div class="casAuthors">Keov, Peter; Sexton, Patrick M.; Christopoulos, Arthur</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">24-35</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  G protein-coupled receptor (GPCR)-based drug discovery has traditionally focused on targeting the orthosteric site for the endogenous agonist.  However, many GPCRs possess allosteric sites that offer enormous potential for greater selectivity in drug action.  The complex behaviors ascribed to allosteric ligands also present challenges to those interested in preclin. lead discovery.  These challenges include the need to detect and quantify various phenomena when screening for allosteric ligands, such as saturability of effect, probe dependence, differential effects on orthosteric ligand affinity vs. efficacy, system-dependent allosteric agonism, stimulus-bias (functional selectivity), and the potential existence of bitopic (hybrid orthosteric/allosteric) ligands.  These issues are also crit. when interpreting structure-function studies of allosteric GPCR modulators because mutations in receptor structure, either engineered or naturally occurring, can differentially affect not only modulator affinity, but also the nature, magnitude and direction of the allosteric effect on orthosteric ligand function.  The ever-expanding array of allosteric modulators arising from both academic and industrial research also highlights the need for the development of a uniform approach to nomenclature of such compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnUP5NIe912rVg90H21EOLACvtfcHk0ljvu3P4Be6PDg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVaitLzO&md5=42e41090cf9788ad016f02753f727432</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2010.07.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2010.07.010%26sid%3Dliteratum%253Aachs%26aulast%3DKeov%26aufirst%3DP.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DChristopoulos%26aufirst%3DA.%26atitle%3DAllosteric%2520modulation%2520of%2520G%2520protein-coupled%2520receptors%253A%2520a%2520pharmacological%2520perspective%26jtitle%3DNeuropharmacology%26date%3D2011%26volume%3D60%26spage%3D24%26epage%3D35%26doi%3D10.1016%2Fj.neuropharm.2010.07.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Im, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bundy, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VonVoigtlander, P. F.</span></span> <span> </span><span class="NLM_article-title">PNU-107484A with alpha isoform-dependent functional changes in alpha(x)beta2gamma2 subtypes of rat recombinant GABA(A) receptors</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>122</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">821</span>â <span class="NLM_lpage">824</span>, <span class="refDoi">Â DOI: 10.1038/sj.bjp.0701450</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fsj.bjp.0701450" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=9384496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADyaK2sXnt1Squ74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=1997&pages=821-824&issue=5&author=H.+K.+Imauthor=W.+B.+Imauthor=D.+B.+Carterauthor=T.+M.+Schwartzauthor=G.+L.+Bundyauthor=P.+F.+VonVoigtlander&title=PNU-107484A+with+alpha+isoform-dependent+functional+changes+in+alpha%28x%29beta2gamma2+subtypes+of+rat+recombinant+GABA%28A%29+receptors&doi=10.1038%2Fsj.bjp.0701450"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">PNU-107484A with Î± isoform-dependent functional changes in Î±xÎ²2Î³2 subtypes of rat recombinant GABAA receptors</span></div><div class="casAuthors">Im, Haesook K.; Im, Wha Bin; Carter, Donald B.; Schwartz, Theresa M.; Bundy, Gordon L.; VonVoigtlander, Philip F.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">821-824</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Stockton</span>)
        </div><div class="casAbstract">1. We discovered a novel Î³-aminobutyric acidA (GABAA) receptor ligand displaying seemingly opposite functionalities, depending on the Î± isoform of the Î±xÎ²2Î³2 subtypes.  PNU-107484A enhanced GABA-induced Cl- currents in the Î±1Î²2Î³2 subtype, but inhibited the currents in the Î±3Î²2Î³2 and Î±6Î²2Î³2 subtypes, and its half-maximal concns. in the subtypes were 3.1, 4.2, and 3.5 Î¼M, resp., without showing much dependency on Î± isoforms.  2. In the Î±1Î²2 subtype, the drug at concns. up to 40 Î¼M showed no effect on GABA-induced Cl- currents, suggesting the requirement of the Î³ subunit for its action.  3. PNU-107484A behaved like a pos. allosteric modulator of the Î±1Î²2Î³2 subtype with its binding site distinct from those for benzodiazepines, barbiturates and neurosteroids.  With the Î±3Î²2Î³2 subtype, the drug behaved like a non-competitive inhibitor of GABA, thus blocking Cl- currents by GABA alone or in the presence of pentobarbitone and neurosteroids.  4. It appears that PNU-107484A is a unique GABAA receptor ligand with Î± isoform-dependent functionalities, which may provide a basis for development of Î± isoform-selective ligands, and it could be useful as a probe to investigate the physiol. roles of the various Î± isoform subtypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhb9po8QvQorVg90H21EOLACvtfcHk0liP7oMuogh4BA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnt1Squ74%253D&md5=8a9e71ab228690dc5493eba4f53f6756</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0701450&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0701450%26sid%3Dliteratum%253Aachs%26aulast%3DIm%26aufirst%3DH.%2BK.%26aulast%3DIm%26aufirst%3DW.%2BB.%26aulast%3DCarter%26aufirst%3DD.%2BB.%26aulast%3DSchwartz%26aufirst%3DT.%2BM.%26aulast%3DBundy%26aufirst%3DG.%2BL.%26aulast%3DVonVoigtlander%26aufirst%3DP.%2BF.%26atitle%3DPNU-107484A%2520with%2520alpha%2520isoform-dependent%2520functional%2520changes%2520in%2520alpha%2528x%2529beta2gamma2%2520subtypes%2520of%2520rat%2520recombinant%2520GABA%2528A%2529%2520receptors%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1997%26volume%3D122%26issue%3D5%26spage%3D821%26epage%3D824%26doi%3D10.1038%2Fsj.bjp.0701450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kenakin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strachan, R. T.</span></span> <span> </span><span class="NLM_article-title">PAM-Antagonists: a better way to block pathological receptor signaling?</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">748</span>â <span class="NLM_lpage">765</span>, <span class="refDoi">Â DOI: 10.1016/j.tips.2018.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.tips.2018.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=29885909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVaisrnO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2018&pages=748-765&issue=8&author=T.+Kenakinauthor=R.+T.+Strachan&title=PAM-Antagonists%3A+a+better+way+to+block+pathological+receptor+signaling%3F&doi=10.1016%2Fj.tips.2018.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">PAM-Antagonists: A Better Way to Block Pathological Receptor Signaling?</span></div><div class="casAuthors">Kenakin, Terry; Strachan, Ryan T.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">748-765</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Seven transmembrane receptor (7TMR) responses are modulated by orthosteric and allosteric ligands to great therapeutic advantage.  Here we introduce a unique class of neg. allosteric modulator (NAM) - the pos. allosteric modulator (PAM)-antagonist - that increases the affinity of the receptor for the agonist but concomitantly decreases agonist efficacy when cobound.  Notably, the reciprocation of allosteric energy causes the orthosteric agonist to increase the affinity of the receptor for the PAM-antagonist; thus, this modulator seeks out and destroys agonist-bound receptor complexes.  When contrasted with std. orthosteric and allosteric antagonists it is clear that PAM-antagonists are uniquely well suited to reversing ongoing persistent agonism and provide favorable target coverage in vivo.  Specifically, the therapeutic application of PAM-antagonists to reverse pathol. overactivation (e.g., endothelin vasoconstriction) is emphasized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3htZbLIJO2LVg90H21EOLACvtfcHk0liP7oMuogh4BA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVaisrnO&md5=6a4b81c139f321490deb9e5b3bd8c3cb</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2018.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2018.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DKenakin%26aufirst%3DT.%26aulast%3DStrachan%26aufirst%3DR.%2BT.%26atitle%3DPAM-Antagonists%253A%2520a%2520better%2520way%2520to%2520block%2520pathological%2520receptor%2520signaling%253F%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2018%26volume%3D39%26issue%3D8%26spage%3D748%26epage%3D765%26doi%3D10.1016%2Fj.tips.2018.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kew, J. N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trube, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemp, J. A.</span></span> <span> </span><span class="NLM_article-title">A novel mechanism of activity-dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurons</span>. <i>J. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>497</i></span>,  <span class="NLM_fpage">761</span>â <span class="NLM_lpage">772</span>, <span class="refDoi">Â DOI: 10.1113/jphysiol.1996.sp021807</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1113%2Fjphysiol.1996.sp021807" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=9003561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADyaK2sXisVGltg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=497&publication_year=1996&pages=761-772&author=J.+N.+C.+Kewauthor=G.+Trubeauthor=J.+A.+Kemp&title=A+novel+mechanism+of+activity-dependent+NMDA+receptor+antagonism+describes+the+effect+of+ifenprodil+in+rat+cultured+cortical+neurons&doi=10.1113%2Fjphysiol.1996.sp021807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">A novel mechanism of activity-dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurons</span></div><div class="casAuthors">Kew, James N. C.; Trube, Gerhard; Kemp, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physiology (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">497</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">761-772</span>CODEN:
                <span class="NLM_cas:coden">JPHYA7</span>;
        ISSN:<span class="NLM_cas:issn">0022-3751</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">Ifenprodil is a selective, atypical non-competitive antagonist of NMDA receptors that contain the NR2B subunit with an undefined mechanism of action.  Ifenprodil is neuroprotective in in vivo models of cerebral ischemia but lacks many of the undesirable side-effects assocd. with NMDA antagonists.  Using whole-cell voltage-clamp recordings, the authors have studied the mechanism of inhibition of NMDA-evoked currents by ifenprodil in rat cultured cortical neurons in the presence of satg. concns. of glycine.  Ifenprodil antagonized NMDA receptors in an activity-dependent manner, while also increasing the receptor affinity for glutamate recognition-site agonists.  Ifenprodil inhibition curves against 10 and 100 Î¼M NMDA-evoked currents yielded IC50 values of 0.88 and 0.17 Î¼M, resp.  Thus, the apparent affinity of ifenprodil for the NMDA receptor is increased in an NMDA concn.-dependent manner.  Currents evoked by 0.3 and 1 Î¼M NMDA were potentiated to approx. 200% of control levels in the presence of 3 Î¼M ifenprodil.  Thus, with increasing concn. of NMDA the effect of ifenprodil on NMDA-evoked currents changed from one of potentiation to one of increasing inhibition.  These results are predicted by a reaction scheme in which ifenprodil exhibits a 39- and 50-fold higher affinity for the agonist-bound activated and desensitized states of the NMDA receptor, resp., relative to the resting, agonist-unbound state.  Furthermore, ifenprodil binding to the NMDA receptor results in a 6-fold higher affinity for glutamate site agonists.  This represents a novel mechanism of NMDA receptor antagonism that, together with the subunit selectivity, probably contributes to the attractive neuropharmacol. profile of this and related compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJg3J0KtQC3bVg90H21EOLACvtfcHk0liP7oMuogh4BA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXisVGltg%253D%253D&md5=d5b7b5abc0831974cab0cf7c312ab1a5</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1113%2Fjphysiol.1996.sp021807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1113%252Fjphysiol.1996.sp021807%26sid%3Dliteratum%253Aachs%26aulast%3DKew%26aufirst%3DJ.%2BN.%2BC.%26aulast%3DTrube%26aufirst%3DG.%26aulast%3DKemp%26aufirst%3DJ.%2BA.%26atitle%3DA%2520novel%2520mechanism%2520of%2520activity-dependent%2520NMDA%2520receptor%2520antagonism%2520describes%2520the%2520effect%2520of%2520ifenprodil%2520in%2520rat%2520cultured%2520cortical%2520neurons%26jtitle%3DJ.%2520Physiol.%26date%3D1996%26volume%3D497%26spage%3D761%26epage%3D772%26doi%3D10.1113%2Fjphysiol.1996.sp021807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fedele, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newcombe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topf, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smart, T. G.</span></span> <span> </span><span class="NLM_article-title">Disease-associated missense mutations in GluN2B subunit alter NMDA receptor ligand binding and ion channel properties</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">957</span>, <span class="refDoi">Â DOI: 10.1038/s41467-018-02927-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fs41467-018-02927-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=29511171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A280%3ADC%252BC1Mrotlekug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=957&issue=1&author=L.+Fedeleauthor=J.+Newcombeauthor=M.+Topfauthor=A.+Gibbauthor=R.+J.+Harveyauthor=T.+G.+Smart&title=Disease-associated+missense+mutations+in+GluN2B+subunit+alter+NMDA+receptor+ligand+binding+and+ion+channel+properties&doi=10.1038%2Fs41467-018-02927-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Disease-associated missense mutations in GluN2B subunit alter NMDA receptor ligand binding and ion channel properties</span></div><div class="casAuthors">Fedele Laura; Fedele Laura; Gibb Alasdair; Smart Trevor G; Newcombe Joseph; Topf Maya; Harvey Robert J; Harvey Robert J</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">957</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Genetic and bioinformatic analyses have identified missense mutations in GRIN2B encoding the NMDA receptor GluN2B subunit in autism, intellectual disability, Lennox Gastaut and West Syndromes.  Here, we investigated several such mutations using a near-complete, hybrid 3D model of the human NMDAR and studied their consequences with kinetic modelling and electrophysiology.  The mutants revealed reductions in glutamate potency; increased receptor desensitisation; and ablation of voltage-dependent Mg(2+) block.  In addition, we provide new views on Mg(2+) and NMDA channel blocker binding sites.  We demonstrate that these mutants have significant impact on excitatory transmission in developing neurons, revealing profound changes that could underlie their associated neurological disorders.  Of note, the NMDAR channel mutant GluN2B(V618G) unusually allowed Mg(2+) permeation, whereas nearby N615I reduced Ca(2+) permeability.  By identifying the binding site for an NMDAR antagonist that is used in the clinic to rescue gain-of-function phenotypes, we show that drug binding may be modified by some GluN2B disease-causing mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQwZXm-VCGgULrIbt-tGZmxfW6udTcc2eaZI_HVQk5kNrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mrotlekug%253D%253D&md5=3aa23d44fe8935cbdf496bcc077eb5e9</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-02927-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-02927-4%26sid%3Dliteratum%253Aachs%26aulast%3DFedele%26aufirst%3DL.%26aulast%3DNewcombe%26aufirst%3DJ.%26aulast%3DTopf%26aufirst%3DM.%26aulast%3DGibb%26aufirst%3DA.%26aulast%3DHarvey%26aufirst%3DR.%2BJ.%26aulast%3DSmart%26aufirst%3DT.%2BG.%26atitle%3DDisease-associated%2520missense%2520mutations%2520in%2520GluN2B%2520subunit%2520alter%2520NMDA%2520receptor%2520ligand%2520binding%2520and%2520ion%2520channel%2520properties%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26issue%3D1%26spage%3D957%26doi%3D10.1038%2Fs41467-018-02927-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mullier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sands, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghisdal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muglia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminski, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">AndrÃ©, V. M.</span></span> <span> </span><span class="NLM_article-title">GRIN2B gain of function mutations are sensitive to radiprodil, a negative allosteric modulator of GluN2B-containing NMDA receptors</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">322</span>â <span class="NLM_lpage">331</span>, <span class="refDoi">Â DOI: 10.1016/j.neuropharm.2017.05.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.neuropharm.2017.05.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=28533163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2sXosFWjtbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2017&pages=322-331&author=B.+Mullierauthor=C.+Wolffauthor=Z.+A.+Sandsauthor=P.+Ghisdalauthor=P.+Mugliaauthor=R.+M.+Kaminskiauthor=V.+M.+Andr%C3%A9&title=GRIN2B+gain+of+function+mutations+are+sensitive+to+radiprodil%2C+a+negative+allosteric+modulator+of+GluN2B-containing+NMDA+receptors&doi=10.1016%2Fj.neuropharm.2017.05.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">GRIN2B gain of function mutations are sensitive to radiprodil, a negative allosteric modulator of GluN2B-containing NMDA receptors</span></div><div class="casAuthors">Mullier, Brice; Wolff, Christian; Sands, Zara Amanda; Ghisdal, Philippe; Muglia, Pierandrea; Kaminski, Rafal Marian; Andre, Veronique Marie</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">322-331</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">De novo gain of function mutations in GRIN2B encoding the GluN2B subunit of the N-methyl-D-aspartate (NMDA) receptor have been linked with epileptic encephalopathies, including infantile spasms.  We investigated the effects of radiprodil, a selective GluN2B neg. allosteric modulator and other non-selective NMDA receptor inhibitors on glutamate currents mediated by NMDA receptors contg. mutated GluN2B subunits.  The expts. were performed in Xenopus oocytes co-injected with the following human mRNAs: GRIN1/GRIN2B, GRIN1/GRIN2B-R540H, GRIN1/GRIN2B-N615I and GRIN1/GRIN2B-V618G.  Glutamate displayed slightly increased potency in the R540H variant, but not in N615I and V618G variants.  However, the inhibition by Mg2+ was completely abolished in N615I and V618G variants.  In fact, Mg2+ enhanced glutamate responses in those variants.  The potency of radiprodil to block glutamate-evoked currents was not affected in any of the variants, while the effects by non-selective NMDA inhibitors were greatly reduced in some of the variants.  Addnl., in the Mg2+ insensitive variants, radiprodil blocked glutamate-activated currents with the same potency as in the absence of Mg2+.  The gain of function obsd. in the reported GRIN2B variants could be a key pathophysiol. factor leading to neuronal hyper-excitability in epileptic encephalopathies.  The GluN2B-selective inhibitor radiprodil fully retained its pharmacol. profile under these conditions, while other non-selective NMDA receptor antagonists lost their potency.  Consequently, our data suggest that radiprodil may be a valuable therapeutic option for treatment of pediatric epileptic encephalopathies assocd. with GRIN2B mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8FdYTEU85qrVg90H21EOLACvtfcHk0lgcPxm1aHiFDw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXosFWjtbg%253D&md5=0378c86d810af763ea1316a7133e4444</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2017.05.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2017.05.017%26sid%3Dliteratum%253Aachs%26aulast%3DMullier%26aufirst%3DB.%26aulast%3DWolff%26aufirst%3DC.%26aulast%3DSands%26aufirst%3DZ.%2BA.%26aulast%3DGhisdal%26aufirst%3DP.%26aulast%3DMuglia%26aufirst%3DP.%26aulast%3DKaminski%26aufirst%3DR.%2BM.%26aulast%3DAndr%25C3%25A9%26aufirst%3DV.%2BM.%26atitle%3DGRIN2B%2520gain%2520of%2520function%2520mutations%2520are%2520sensitive%2520to%2520radiprodil%252C%2520a%2520negative%2520allosteric%2520modulator%2520of%2520GluN2B-containing%2520NMDA%2520receptors%26jtitle%3DNeuropharmacology%26date%3D2017%26volume%3D123%26spage%3D322%26epage%3D331%26doi%3D10.1016%2Fj.neuropharm.2017.05.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leach, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conigrave, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span> <span> </span><span class="NLM_article-title">Impact of clinically relevant mutations on the pharmacoregulation and signaling bias of the calcium-sensing receptor by positive and negative allosteric modulators</span>. <i>Endocrinology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>154</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1105</span>â <span class="NLM_lpage">1116</span>, <span class="refDoi">Â DOI: 10.1210/en.2012-1887</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1210%2Fen.2012-1887" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=23372019" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsF2rsbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2013&pages=1105-1116&issue=3&author=K.+Leachauthor=A.+Wenauthor=A.+E.+Cookauthor=P.+M.+Sextonauthor=A.+D.+Conigraveauthor=A.+Christopoulos&title=Impact+of+clinically+relevant+mutations+on+the+pharmacoregulation+and+signaling+bias+of+the+calcium-sensing+receptor+by+positive+and+negative+allosteric+modulators&doi=10.1210%2Fen.2012-1887"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of clinically relevant mutations on the pharmacoregulation and signaling bias of the calcium-sensing receptor by positive and negative allosteric modulators</span></div><div class="casAuthors">Leach, Katie; Wen, Adriel; Cook, Anna E.; Sexton, Patrick M.; Conigrave, Arthur D.; Christopoulos, Arthur</div><div class="citationInfo"><span class="NLM_cas:title">Endocrinology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1105-1116</span>CODEN:
                <span class="NLM_cas:coden">ENDOAO</span>;
        ISSN:<span class="NLM_cas:issn">0013-7227</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Cinacalcet is predominantly used to treat secondary hyperparathyroidism due to end-stage renal failure, but, more recently, its potential clin. efficacy in treating patients with loss-of-function mutations in the calcium-sensing receptor (CaSR) has been recognized.  Many clin. relevant CaSR mutations are located in the heptahelical membrane spanning and extracellular loop regions of the receptor, where allosteric modulators are predicted to bind.  The aim of the present study was to investigate the impact of such mutations on the pharmacoregulation of the CaSR by the pos. and neg. allosteric modulators, cinacalcet and NPS-2143, resp.  Both cinacalcet and NPS-2143 effectively rescued mutants whose cell surface expression was substantially impaired, suggesting that both classes of drug can stabilize a receptor conformation that is trafficked more effectively to the cell surface.  In addn., functional impairments in almost all mutant CaSRs were rescued by either cinacalcet or NPS-2143 via restoration of intracellular signaling.  There was a significantly greater ability of both compds. to modulate agonist-stimulated intracellular Ca2+ mobilization than ERK1/2 phosphorylation, indicating that the allosteric modulators engender bias in agonist-stimulated CaSR signaling to different pathways.  Three mutations (G670R, P748R, and L773R) altered the binding affinity of allosteric modulators to the CaSR, and 3 mutations (V817I, L773R, and E767K) altered the cooperativity between the allosteric modulator and Ca2+o.  These findings have important implications for the treatment of diseases assocd. with CaSR mutations using allosteric CaSR modulators and for analyzing the effects of mutations on the function and pharmacoregulation of the CaSR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmgGmBvUfahrVg90H21EOLACvtfcHk0lgcPxm1aHiFDw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsF2rsbc%253D&md5=66939270cd67c0ed6f6f51ba536f86f7</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1210%2Fen.2012-1887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fen.2012-1887%26sid%3Dliteratum%253Aachs%26aulast%3DLeach%26aufirst%3DK.%26aulast%3DWen%26aufirst%3DA.%26aulast%3DCook%26aufirst%3DA.%2BE.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DConigrave%26aufirst%3DA.%2BD.%26aulast%3DChristopoulos%26aufirst%3DA.%26atitle%3DImpact%2520of%2520clinically%2520relevant%2520mutations%2520on%2520the%2520pharmacoregulation%2520and%2520signaling%2520bias%2520of%2520the%2520calcium-sensing%2520receptor%2520by%2520positive%2520and%2520negative%2520allosteric%2520modulators%26jtitle%3DEndocrinology%26date%3D2013%26volume%3D154%26issue%3D3%26spage%3D1105%26epage%3D1116%26doi%3D10.1210%2Fen.2012-1887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dalmau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graus, F.</span></span> <span> </span><span class="NLM_article-title">Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune diseases of the central nervous system</span>. <i>Physiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>97</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">839</span>â <span class="NLM_lpage">887</span>, <span class="refDoi">Â DOI: 10.1152/physrev.00010.2016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1152%2Fphysrev.00010.2016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=28298428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnsVOhurc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2017&pages=839-887&issue=2&author=J.+Dalmauauthor=C.+Geisauthor=F.+Graus&title=Autoantibodies+to+synaptic+receptors+and+neuronal+cell+surface+proteins+in+autoimmune+diseases+of+the+central+nervous+system&doi=10.1152%2Fphysrev.00010.2016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune diseases of the central nervous system</span></div><div class="casAuthors">Dalmau, Josep; Geis, Christian; Graus, Francesc</div><div class="citationInfo"><span class="NLM_cas:title">Physiological Reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">839-887</span>CODEN:
                <span class="NLM_cas:coden">PHREA7</span>;
        ISSN:<span class="NLM_cas:issn">0031-9333</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">Investigations in the last 10 years have revealed a new category of neurol. diseases mediated by antibodies against cell surface and synaptic proteins.  There are currently 16 such diseases all characterized by autoantibodies against neuronal proteins involved in synaptic signaling and plasticity.  In clin. practice these findings have changed the diagnostic and treatment approach to potentially lethal, but now treatable, neurol. and psychiatric syndromes previously considered idiopathic or not even suspected to be immune-mediated.  Studies show that patients' antibodies can impair the surface dynamics of the target receptors eliminating them from synapses (e.g., NMDA receptor), block the function of the antigens without changing their synaptic d. (e.g., GABAb receptor), interfere with synaptic protein-protein interactions (LGI1, Caspr2), alter synapse formation (e.g., neurexin-3Î±), or by unclear mechanisms assoc. to a new form of tauopathy (IgLON5).  Here we first trace the process of discovery of these diseases, describing the triggers and symptoms related to each autoantigen, and then review in detail the structural and functional alterations caused by the autoantibodies with special emphasis in those (NMDA receptor, amphiphysin) that have been modeled in animals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpD4Vp379HAhLVg90H21EOLACvtfcHk0lgcPxm1aHiFDw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnsVOhurc%253D&md5=e9be9781d75db66ebe7cdc81ec8ee8f6</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1152%2Fphysrev.00010.2016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fphysrev.00010.2016%26sid%3Dliteratum%253Aachs%26aulast%3DDalmau%26aufirst%3DJ.%26aulast%3DGeis%26aufirst%3DC.%26aulast%3DGraus%26aufirst%3DF.%26atitle%3DAutoantibodies%2520to%2520synaptic%2520receptors%2520and%2520neuronal%2520cell%2520surface%2520proteins%2520in%2520autoimmune%2520diseases%2520of%2520the%2520central%2520nervous%2520system%26jtitle%3DPhysiol.%2520Rev.%26date%3D2017%26volume%3D97%26issue%3D2%26spage%3D839%26epage%3D887%26doi%3D10.1152%2Fphysrev.00010.2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Warikoo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunwasser, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quirk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piccio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zorumski, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mennerick, S.</span></span> <span> </span><span class="NLM_article-title">Positive allosteric modulation as a potential therapeutic strategy in Anti-NMDA Receptor Encephalitis</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">3218</span>â <span class="NLM_lpage">3229</span>, <span class="refDoi">Â DOI: 10.1523/JNEUROSCI.3377-17.2018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1523%2FJNEUROSCI.3377-17.2018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=29476014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslartrbK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=3218-3229&issue=13&author=N.+Warikooauthor=S.+J.+Brunwasserauthor=A.+Benzauthor=H.+J.+Shuauthor=S.+M.+Paulauthor=M.+Lewisauthor=J.+Dohertyauthor=M.+Quirkauthor=L.+Piccioauthor=C.+F.+Zorumskiauthor=G.+S.+Dayauthor=S.+Mennerick&title=Positive+allosteric+modulation+as+a+potential+therapeutic+strategy+in+Anti-NMDA+Receptor+Encephalitis&doi=10.1523%2FJNEUROSCI.3377-17.2018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Positive allosteric modulation as a potential therapeutic strategy in anti-NMDA receptor encephalitis</span></div><div class="casAuthors">Warikoo, Natasha; Brunwasser, Samuel J.; Benz, Ann; Shu, Hong-Jin; Paul, Steven M.; Lewis, Michael; Doherty, James; Quirk, Michael; Piccio, Laura; Zorumski, Charles F.; Day, Gregory S.; Mennerick, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3218/1-3218/12</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">1529-2401</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">N-methyl-D-aspartate receptors (NMDARs) are ionotropic glutamate receptors important for synaptic plasticity, memory, and neuropsychiatric health.  NMDAR hypofunction contributes to multiple disorders, including anti-NMDAR encephalitis (NMDARE), an autoimmune disease of the CNS assocd. with GluN1 antibody-mediated NMDAR internalization.  Here we characterize the functional/pharmacol. consequences of exposure to CSF from female human NMDARE patients on NMDAR function, and we characterize the effects of intervention with recently described pos. allosteric modulators (PAMs) of NMDARs.  Incubation (48 h) of rat hippocampal neurons of both sexes in confirmed NMDARE patient CSF, but not control CSF, attenuated NMDA-induced current.  Residual NMDAR function was characterized by lack of change in channel open probability, indiscriminate loss of synaptic and extrasynaptic NMDARs, and indiscriminate loss of GluN2B-contg. and GluN2B-lacking NMDARs.  NMDARs tagged with N-terminal pHluorin fluorescence demonstrated loss of surface receptors.  Thus, function of residualNMDARsfollowing CSF exposure was indistinguishable from baseline, and deficits appear wholly accounted for by receptor loss.  Coapplication of CSF and PAMs of NMDARs (SGE-301 or SGE-550, oxysterolmimetic) for 24 h restored NMDAR function following 24 h incubation in patient CSF.  Curiously, restoration of NMDAR function was obsd. despite washout of PAMs before electrophysiol. recordings.  Subsequent expts. suggested that residual allosteric potentiation ofNMDARfunction explained the persistent rescue.  Further studies of the pathogenesis of NMDARE and intervention with PAMs may inform new treatments for NMDARE and other disorders assocd. with NMDAR hypofunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpA_rpJSpgz7bVg90H21EOLACvtfcHk0li7WN-vgK8Ocg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslartrbK&md5=4153aa478fbf9712c8925c927a82e53f</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.3377-17.2018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.3377-17.2018%26sid%3Dliteratum%253Aachs%26aulast%3DWarikoo%26aufirst%3DN.%26aulast%3DBrunwasser%26aufirst%3DS.%2BJ.%26aulast%3DBenz%26aufirst%3DA.%26aulast%3DShu%26aufirst%3DH.%2BJ.%26aulast%3DPaul%26aufirst%3DS.%2BM.%26aulast%3DLewis%26aufirst%3DM.%26aulast%3DDoherty%26aufirst%3DJ.%26aulast%3DQuirk%26aufirst%3DM.%26aulast%3DPiccio%26aufirst%3DL.%26aulast%3DZorumski%26aufirst%3DC.%2BF.%26aulast%3DDay%26aufirst%3DG.%2BS.%26aulast%3DMennerick%26aufirst%3DS.%26atitle%3DPositive%2520allosteric%2520modulation%2520as%2520a%2520potential%2520therapeutic%2520strategy%2520in%2520Anti-NMDA%2520Receptor%2520Encephalitis%26jtitle%3DJ.%2520Neurosci.%26date%3D2018%26volume%3D38%26issue%3D13%26spage%3D3218%26epage%3D3229%26doi%3D10.1523%2FJNEUROSCI.3377-17.2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petter, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitty, A.</span></span> <span> </span><span class="NLM_article-title">The resurgence of covalent drugs</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">307</span>, <span class="refDoi">Â DOI: 10.1038/nrd3410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fnrd3410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=21455239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=307&issue=4&author=J.+Singhauthor=R.+C.+Petterauthor=T.+A.+Baillieauthor=A.+Whitty&title=The+resurgence+of+covalent+drugs&doi=10.1038%2Fnrd3410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">The resurgence of covalent drugs</span></div><div class="casAuthors">Singh, Juswinder; Petter, Russell C.; Baillie, Thomas A.; Whitty, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-317</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Covalent drugs haveproved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project.  There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium.  This Review surveys the prevalence and pharmacol. advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreDCEmORV_NbVg90H21EOLACvtfcHk0li7WN-vgK8Ocg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D&md5=2190289081e151416c097be4a5b04460</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1038%2Fnrd3410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3410%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DWhitty%26aufirst%3DA.%26atitle%3DThe%2520resurgence%2520of%2520covalent%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26issue%3D4%26spage%3D307%26doi%3D10.1038%2Fnrd3410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span> <span> </span><span class="NLM_article-title">Designed covalent allosteric modulators: an emerging paradigm in drug discovery</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">447</span>â <span class="NLM_lpage">453</span>, <span class="refDoi">Â DOI: 10.1016/j.drudis.2016.11.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.drudis.2016.11.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=27888140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFOju7zJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=447-453&issue=2&author=S.+Luauthor=J.+Zhang&title=Designed+covalent+allosteric+modulators%3A+an+emerging+paradigm+in+drug+discovery&doi=10.1016%2Fj.drudis.2016.11.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Designed covalent allosteric modulators: an emerging paradigm in drug discovery</span></div><div class="casAuthors">Lu, Shaoyong; Zhang, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">447-453</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Covalent allosteric modulators possess the pharmacol. advantages (high potency, extended duration of action and low drug resistance) of covalent ligands and the addnl. benefit of the higher specificity and lower toxicity of allosteric modulators.  This approach is gaining increasing recognition as a valuable tool in drug discovery.  Here, we review the recent advances in the design of covalent allosteric modulators with an emphasis on successful examples.  A broad spectrum of protein targets capable of being modulated by them reflects the prevalence of this strategy.  We also discuss the challenges and future directions in the development of covalent allosteric modulators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnMtSOrLWxdrVg90H21EOLACvtfcHk0lj_kpNr-FB9fw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFOju7zJ&md5=bc656114f3f956ce44ba06c1a7669da4</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2016.11.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2016.11.013%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DDesigned%2520covalent%2520allosteric%2520modulators%253A%2520an%2520emerging%2520paradigm%2520in%2520drug%2520discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2017%26volume%3D22%26issue%3D2%26spage%3D447%26epage%3D453%26doi%3D10.1016%2Fj.drudis.2016.11.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nolte, W. M.</span>; <span class="NLM_string-name">Carpino, P. A.</span></span> <span> </span><span class="NLM_article-title">Positive Allosteric Modulators of G-Protein-Coupled Receptors that Act via Covalent Mechanisms of Action</span>. In  <i>Allosterism in Drug Discovery</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doller, D.</span></span>, Ed; <span class="NLM_publisher-name">Royal Society of Chemistry</span>: <span class="NLM_publisher-loc">Cambridge, UK</span>, <span class="NLM_year">2017</span>; pp  <span class="NLM_fpage">271</span>â <span class="NLM_lpage">280</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=271-280&author=W.+M.+Nolte&author=P.+A.+Carpinoauthor=D.+Doller&title=Allosterism+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DNolte%26aufirst%3DW.%2BM.%26atitle%3DPositive%2520Allosteric%2520Modulators%2520of%2520G-Protein-Coupled%2520Receptors%2520that%2520Act%2520via%2520Covalent%2520Mechanisms%2520of%2520Action%26btitle%3DAllosterism%2520in%2520Drug%2520Discovery%26aulast%3DDoller%26aufirst%3DD.%26pub%3DRoyal%2520Society%2520of%2520Chemistry%26date%3D2017%26spage%3D271%26epage%3D280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Samson, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garber, A.</span></span> <span> </span><span class="NLM_article-title">GLP-1R agonist therapy for diabetes: benefits and potential risks</span>. <i>Curr. Opin. Endocrinol., Diabetes Obes.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">87</span>â <span class="NLM_lpage">97</span>, <span class="refDoi">Â DOI: 10.1097/MED.0b013e32835edb32</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1097%2FMED.0b013e32835edb32" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=23403741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtF2ntrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=87-97&issue=2&author=S.+L.+Samsonauthor=A.+Garber&title=GLP-1R+agonist+therapy+for+diabetes%3A+benefits+and+potential+risks&doi=10.1097%2FMED.0b013e32835edb32"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">GLP-1R agonist therapy for diabetes: benefits and potential risks</span></div><div class="casAuthors">Samson, Susan L.; Garber, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Endocrinology, Diabetes and Obesity</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">87-97</span>CODEN:
                <span class="NLM_cas:coden">COEDFK</span>;
        ISSN:<span class="NLM_cas:issn">1752-296X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: Glucagon-like peptide 1 receptor (GLP-1R) agonists provide good glycemic control combined with low hypoglycemia risk and wt. loss.  Here, we summarize the recently published data for this therapy class, focusing on sustainability of action, use in combination with basal insulin, and the efficacy of longer acting agents currently in development.  The safety profile of GLP-1R agonists is also examd.  Recent findings: GLP-1R agonists provide sustained efficacy and their combination with basal insulin is well tolerated, providing addnl. glycemic control and wt. benefits compared with basal insulin alone.  Data suggest that the convenience of longer acting agents may be at the expense of efficacy.  Despite the initial concerns, most evidence indicates that GLP-1R agonists do not increase the risk of pancreatitis or thyroid cancer.  However, the extremely low incidence of these events means further investigations are required before a causal link can be eliminated.  Large-scale clin. trials investigating the long-term cardiovascular safety of this therapy class are ongoing and may also provide important insights into pancreatic and thyroid safety.  Summary: GLP-1R agonists offer sustained glycemic efficacy, wt. loss benefits, and a low risk of hypoglycemia.  The results of ongoing trials should help to clarify the safety of this therapy class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqk_39-CujErVg90H21EOLACvtfcHk0lj_kpNr-FB9fw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtF2ntrs%253D&md5=683f66371cb0cc77de01f9e90db77203</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1097%2FMED.0b013e32835edb32&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMED.0b013e32835edb32%26sid%3Dliteratum%253Aachs%26aulast%3DSamson%26aufirst%3DS.%2BL.%26aulast%3DGarber%26aufirst%3DA.%26atitle%3DGLP-1R%2520agonist%2520therapy%2520for%2520diabetes%253A%2520benefits%2520and%2520potential%2520risks%26jtitle%3DCurr.%2520Opin.%2520Endocrinol.%252C%2520Diabetes%2520Obes.%26date%3D2013%26volume%3D20%26issue%3D2%26spage%3D87%26epage%3D97%26doi%3D10.1097%2FMED.0b013e32835edb32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nolte, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortin, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aspnes, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoth, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathiowetz, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limberakis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hepworth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpino, P. A.</span></span> <span> </span><span class="NLM_article-title">A potentiator of orthosteric ligand activity at GLP-1R acts via covalent modification</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">629</span>, <span class="refDoi">Â DOI: 10.1038/nchembio.1581</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fnchembio.1581" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=24997604" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFSlsLrO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=629&issue=8&author=W.+M.+Nolteauthor=J.+P.+Fortinauthor=B.+D.+Stevensauthor=G.+E.+Aspnesauthor=D.+A.+Griffithauthor=L.+R.+Hothauthor=R.+B.+Ruggeriauthor=A.+M.+Mathiowetzauthor=C.+Limberakisauthor=D.+Hepworthauthor=P.+A.+Carpino&title=A+potentiator+of+orthosteric+ligand+activity+at+GLP-1R+acts+via+covalent+modification&doi=10.1038%2Fnchembio.1581"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">A potentiator of orthosteric ligand activity at GLP-1R acts via covalent modification</span></div><div class="casAuthors">Nolte, Whitney M.; Fortin, Jean-Philippe; Stevens, Benjamin D.; Aspnes, Gary E.; Griffith, David A.; Hoth, Lise R.; Ruggeri, Roger B.; Mathiowetz, Alan M.; Limberakis, Chris; Hepworth, David; Carpino, Philip A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">629-631</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We report that 4-(3-(benzyloxy)phenyl)-2-ethylsulfinyl-6-(trifluoromethyl)pyrimidine (BETP), which behaves as a pos. allosteric modulator at the glucagon-like peptide-1 receptor (GLP-1R), covalently modifies cysteines 347 and 438 in GLP-1R.  C347, located in intracellular loop 3 of GLP-1R, is crit. to the activity of BETP and a structurally distinct GLP-1R ago-allosteric modulator, N-(tert-butyl)-6,7-dichloro-3-(methylsulfonyl)quinoxalin-2-amine.  We further show that substitution of cysteine for phenylalanine 345 in the glucagon receptor is sufficient to confer sensitivity to BETP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRJ3ys4ywhgLVg90H21EOLACvtfcHk0lj_kpNr-FB9fw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFSlsLrO&md5=9b0d431ea2c96e8889f774c50fdf9452</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1581%26sid%3Dliteratum%253Aachs%26aulast%3DNolte%26aufirst%3DW.%2BM.%26aulast%3DFortin%26aufirst%3DJ.%2BP.%26aulast%3DStevens%26aufirst%3DB.%2BD.%26aulast%3DAspnes%26aufirst%3DG.%2BE.%26aulast%3DGriffith%26aufirst%3DD.%2BA.%26aulast%3DHoth%26aufirst%3DL.%2BR.%26aulast%3DRuggeri%26aufirst%3DR.%2BB.%26aulast%3DMathiowetz%26aufirst%3DA.%2BM.%26aulast%3DLimberakis%26aufirst%3DC.%26aulast%3DHepworth%26aufirst%3DD.%26aulast%3DCarpino%26aufirst%3DP.%2BA.%26atitle%3DA%2520potentiator%2520of%2520orthosteric%2520ligand%2520activity%2520at%2520GLP-1R%2520acts%2520via%2520covalent%2520modification%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D10%26issue%3D8%26spage%3D629%26doi%3D10.1038%2Fnchembio.1581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coopman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willars, G. B.</span></span> <span> </span><span class="NLM_article-title">Comparative effects of the endogenous agonist glucagon-like peptide-1 (GLP-1)-(7â36) amide and the small-molecule ago-allosteric agent âcompound 2â at the GLP-1 receptor</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>334</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">795</span>â <span class="NLM_lpage">808</span>, <span class="refDoi">Â DOI: 10.1124/jpet.110.166009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1124%2Fjpet.110.166009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=20507928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFyksL%252FJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=334&publication_year=2010&pages=795-808&issue=3&author=K.+Coopmanauthor=Y.+Huangauthor=N.+Johnstonauthor=S.+J.+Bradleyauthor=G.+F.+Wilkinsonauthor=G.+B.+Willars&title=Comparative+effects+of+the+endogenous+agonist+glucagon-like+peptide-1+%28GLP-1%29-%287%E2%80%9336%29+amide+and+the+small-molecule+ago-allosteric+agent+%E2%80%9Ccompound+2%E2%80%9D+at+the+GLP-1+receptor&doi=10.1124%2Fjpet.110.166009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative effects of the endogenous agonist glucagon-like peptide-1 (GLP-1)-(7-36) amide and the small-molecule agoallosteric agent compound 2 at the GLP-1 receptor</span></div><div class="casAuthors">Coopman, Karen; Huang, Yan; Johnston, Neil; Bradley, Sophie J.; Wilkinson, Graeme F.; Willars, Gary B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">334</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">795-808</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Glucagon-like peptide-1 (GLP-1) mediates antidiabetogenic effects through the GLP-1 receptor (GLP-1R), which is targeted for the treatment of type 2 diabetes.  Small-mol. GLP-1R agonists have been sought due to difficulties with peptide therapeutics.  Recently, 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline (compd. 2) has been described as a GLP-1R allosteric modulator and agonist.  Using human embryonic kidney-293 cells expressing human GLP-1Rs, we extended this work to consider the impact of compd. 2 on G protein activation, Ca2+ signaling and receptor internalization and particularly to compare compd. 2 and GLP-1 across a range of functional assays in intact cells.  GLP-1 and compd. 2 activated GÎ±s in cell membranes and increased cellular cAMP in intact cells, with compd. 2 being a partial and almost full agonist, resp.  GLP-1 increased intracellular [Ca2+] by release from intracellular stores, which was mimicked by compd. 2, with slower kinetics.  In either intact cells or membranes, the orthosteric antagonist exendin-(9-39), inhibited GLP-1 cAMP generation but increased the efficacy of compd. 2.  GLP-1 internalized enhanced green fluorescent protein-tagged GLP-1Rs, but the speed and magnitude evoked by compd. 2 were less.  Exendin-(9-39) inhibited internalization by GLP-1 and also surprisingly that by compd. 2.  Compd. 2 displays GLP-1R agonism consistent with action at an allosteric site, although an orthosteric antagonist increased its efficacy on cAMP and blocked compd. 2-mediated receptor internalization.  Full assessment of the properties of compd. 2 was potentially hampered by damaging effects that were particularly manifest in either longer term assays with intact cells or in acute assays with membranes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6y2rihMfShbVg90H21EOLACvtfcHk0lhtobSZqrGSgg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFyksL%252FJ&md5=0134b03ec49f7c33c30e809b438417af</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.166009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.166009%26sid%3Dliteratum%253Aachs%26aulast%3DCoopman%26aufirst%3DK.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DJohnston%26aufirst%3DN.%26aulast%3DBradley%26aufirst%3DS.%2BJ.%26aulast%3DWilkinson%26aufirst%3DG.%2BF.%26aulast%3DWillars%26aufirst%3DG.%2BB.%26atitle%3DComparative%2520effects%2520of%2520the%2520endogenous%2520agonist%2520glucagon-like%2520peptide-1%2520%2528GLP-1%2529-%25287%25E2%2580%259336%2529%2520amide%2520and%2520the%2520small-molecule%2520ago-allosteric%2520agent%2520%25E2%2580%259Ccompound%25202%25E2%2580%259D%2520at%2520the%2520GLP-1%2520receptor%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2010%26volume%3D334%26issue%3D3%26spage%3D795%26epage%3D808%26doi%3D10.1124%2Fjpet.110.166009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koole, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wootten, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simms, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valant, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodman, O. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summers, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span> <span> </span><span class="NLM_article-title">Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">456</span>â <span class="NLM_lpage">465</span>, <span class="refDoi">Â DOI: 10.1124/mol.110.065664</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1124%2Fmol.110.065664" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=20547734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFersbvE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2010&pages=456-465&issue=3&author=C.+Kooleauthor=D.+Woottenauthor=J.+Simmsauthor=C.+Valantauthor=R.+Sridharauthor=O.+L.+Woodmanauthor=L.+J.+Millerauthor=R.+J.+Summersauthor=A.+Christopoulosauthor=P.+M.+Sexton&title=Allosteric+ligands+of+the+glucagon-like+peptide+1+receptor+%28GLP-1R%29+differentially+modulate+endogenous+and+exogenous+peptide+responses+in+a+pathway-selective+manner%3A+implications+for+drug+screening&doi=10.1124%2Fmol.110.065664"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening</span></div><div class="casAuthors">Koole, Cassandra; Wootten, Denise; Simms, John; Valant, Celine; Sridhar, Rohan; Woodman, Owen L.; Miller, Laurence J.; Summers, Roger J.; Christopoulos, Arthur; Sexton, Patrick M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">456-465</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The glucagon-like peptide-1 (GLP-1) receptor is a key regulator of insulin secretion and a major therapeutic target for treatment of diabetes.  However, GLP-1 receptor function is complex, with multiple endogenous peptides that can interact with the receptor, including full-length (1-37) and truncated (7-37) forms of GLP-1 that can each exist in an amidated form and the related peptide oxyntomodulin.  We have investigated two GLP-1 receptor allosteric modulators, Novo Nordisk compd. 2 (6,7-dichloro2-methylsulfonyl-3-tert-butylaminoquinoxaline) and quercetin, and their ability to modify binding and signaling (cAMP formation, intracellular Ca2+ mobilization, and extracellular signal-regulated kinase 1/2 phosphorylation) of each of the naturally occurring endogenous peptide agonists, as well as the clin. used peptide mimetic exendin-4.  We identified and quantified stimulus bias across multiple endogenous peptides, with response profiles for truncated GLP-1 peptides distinct from those of either the full-length GLP-1 peptides or oxyntomodulin, the first demonstration of such behavior at the GLP-1 receptor.  Compd. 2 selectively augmented cAMP signaling but did so in a peptide-agonist dependent manner having greatest effect on oxyntomodulin, weaker effect on truncated GLP-1 peptides, and negligible effect on other peptide responses; these effects were principally driven by parallel changes in peptide agonist affinity.  In contrast, quercetin selectively modulated calcium signaling but with effects only on truncated GLP-1 peptides or exendin and not oxyntomodulin or full-length peptides.  These data have significant implications for how GLP-1 receptor targeted drugs are screened and developed, whereas the allosterically driven, agonist-selective, stimulus bias highlights the potential for distinct clin. efficacy depending on the properties of individual drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGourKpA5lnWprVg90H21EOLACvtfcHk0lhtobSZqrGSgg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFersbvE&md5=e88185a2ecad28e4b6b37fa773aa0b14</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1124%2Fmol.110.065664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.110.065664%26sid%3Dliteratum%253Aachs%26aulast%3DKoole%26aufirst%3DC.%26aulast%3DWootten%26aufirst%3DD.%26aulast%3DSimms%26aufirst%3DJ.%26aulast%3DValant%26aufirst%3DC.%26aulast%3DSridhar%26aufirst%3DR.%26aulast%3DWoodman%26aufirst%3DO.%2BL.%26aulast%3DMiller%26aufirst%3DL.%2BJ.%26aulast%3DSummers%26aufirst%3DR.%2BJ.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26atitle%3DAllosteric%2520ligands%2520of%2520the%2520glucagon-like%2520peptide%25201%2520receptor%2520%2528GLP-1R%2529%2520differentially%2520modulate%2520endogenous%2520and%2520exogenous%2520peptide%2520responses%2520in%2520a%2520pathway-selective%2520manner%253A%2520implications%2520for%2520drug%2520screening%26jtitle%3DMol.%2520Pharmacol.%26date%3D2010%26volume%3D78%26issue%3D3%26spage%3D456%26epage%3D465%26doi%3D10.1124%2Fmol.110.065664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morris, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nance, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gentry, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Days, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niswender, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locuson, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niswender, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of (<i>S</i>)-2-cyclopentyl-<i>N</i>-((1-isopropylpyrrolidin2-yl)-9-methyl-1-oxo-2,9-dihydro-1H-pyrrido[3,4-b]indole-4-carboxamide (VU0453379): a novel, CNS penetrant glucagon-like peptide 1 receptor (GLP-1R) positive allosteric modulator (PAM)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">10192</span>â <span class="NLM_lpage">10197</span>, <span class="refDoi">Â DOI: 10.1021/jm501375c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501375c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFOhtrbE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=10192-10197&issue=23&author=L.+C.+Morrisauthor=K.+D.+Nanceauthor=P.+R.+Gentryauthor=E.+L.+Daysauthor=C.+D.+Weaverauthor=C.+M.+Niswenderauthor=A.+D.+Thompsonauthor=C.+K.+Jonesauthor=C.+W.+Locusonauthor=R.+D.+Morrisonauthor=J.+S.+Danielsauthor=K.+D.+Niswenderauthor=C.+W.+Lindsley&title=Discovery+of+%28S%29-2-cyclopentyl-N-%28%281-isopropylpyrrolidin2-yl%29-9-methyl-1-oxo-2%2C9-dihydro-1H-pyrrido%5B3%2C4-b%5Dindole-4-carboxamide+%28VU0453379%29%3A+a+novel%2C+CNS+penetrant+glucagon-like+peptide+1+receptor+%28GLP-1R%29+positive+allosteric+modulator+%28PAM%29&doi=10.1021%2Fjm501375c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (S)-2-Cyclopentyl-N-((1-isopropylpyrrolidin-2-yl)-9-methyl-1-oxo-2,9-dihydro-1H-pyrido[3,4-b]indole-4-carboxamide (VU0453379): A Novel, CNS Penetrant Glucagon-Like Peptide 1 Receptor (GLP-1R) Positive Allosteric Modulator (PAM)</span></div><div class="casAuthors">Morris, Lindsey C.; Nance, Kellie D.; Gentry, Patrick R.; Days, Emily L.; Weaver, C. David; Niswender, Colleen M.; Thompson, Analisa D.; Jones, Carrie K.; Locuson, Chuck W.; Morrison, Ryan D.; Daniels, J. Scott; Niswender, Kevin D.; Lindsley, Craig W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10192-10197</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A duplexed, functional multiaddn. high throughput screening and subsequent iterative parallel synthesis effort identified the first highly selective and CNS penetrant glucagon-like peptide-1R (GLP-1R) pos. allosteric modulator (PAM).  PAM 1H-pyrido[3,4-b]indole-4-carboxamide deriv. I potentiated low-dose exenatide to augment insulin secretion in primary mouse pancreatic islets, and it alone was effective in potentiating endogenous GLP-1R to reverse haloperidol-induced catalepsy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHpe3U-qyvtbVg90H21EOLACvtfcHk0lhtobSZqrGSgg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFOhtrbE&md5=e2b51406183729a3429e9d666df12e7b</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1021%2Fjm501375c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501375c%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DL.%2BC.%26aulast%3DNance%26aufirst%3DK.%2BD.%26aulast%3DGentry%26aufirst%3DP.%2BR.%26aulast%3DDays%26aufirst%3DE.%2BL.%26aulast%3DWeaver%26aufirst%3DC.%2BD.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DThompson%26aufirst%3DA.%2BD.%26aulast%3DJones%26aufirst%3DC.%2BK.%26aulast%3DLocuson%26aufirst%3DC.%2BW.%26aulast%3DMorrison%26aufirst%3DR.%2BD.%26aulast%3DDaniels%26aufirst%3DJ.%2BS.%26aulast%3DNiswender%26aufirst%3DK.%2BD.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26atitle%3DDiscovery%2520of%2520%2528S%2529-2-cyclopentyl-N-%2528%25281-isopropylpyrrolidin2-yl%2529-9-methyl-1-oxo-2%252C9-dihydro-1H-pyrrido%255B3%252C4-b%255Dindole-4-carboxamide%2520%2528VU0453379%2529%253A%2520a%2520novel%252C%2520CNS%2520penetrant%2520glucagon-like%2520peptide%25201%2520receptor%2520%2528GLP-1R%2529%2520positive%2520allosteric%2520modulator%2520%2528PAM%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D23%26spage%3D10192%26epage%3D10197%26doi%3D10.1021%2Fjm501375c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Erve, J. C. L.</span></span> <span> </span><span class="NLM_article-title">Chemical toxicology: Reactive intermediates and their role in pharmacology and toxicology</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">923</span>â <span class="NLM_lpage">946</span>, <span class="refDoi">Â DOI: 10.1517/17425255.2.6.923</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1517%2F17425255.2.6.923" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=17125409" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1eks7nK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=923-946&issue=6&author=J.+C.+L.+Erve&title=Chemical+toxicology%3A+Reactive+intermediates+and+their+role+in+pharmacology+and+toxicology&doi=10.1517%2F17425255.2.6.923"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical toxicology: reactive intermediates and their role in pharmacology and toxicology</span></div><div class="casAuthors">Erve, John C. L.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">923-946</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Reactive intermediates formed during the metab. of drugs have been investigated extensively over the past decades.  Today, interest in reactive intermediates in drug discovery is focused on minimizing bioactivation in hopes of reducing the risk of causing so-called idiosyncratic toxicity.  These efforts are justified based on the hapten hypothesis', namely, that on binding to protein, reactive intermediates may elicit an immune response to the modified protein, leading to a cascade of events that ultimately manifests as a toxic outcome.  However, the pharmacol. action of certain drugs depends on reactive intermediates that modify crit. amino acid residues of proteins, typically enzymes, thereby altering their activity.  Thus, the notion that reactive intermediates are inherently dangerous is unjustified.  When a reactive intermediate is necessary for the desired pharmacol. effect of a drug, the selectivity it displays towards the target protein is crucial, as off-target binding may produce unwanted toxicities.  On the other hand, reactive intermediates may play no role in toxicity.  This review provides a balanced perspective, primarily focusing on the proposed role of reactive intermediates in drug toxicity, while also highlighting examples in which they are involved in causing the desired pharmacol.  It is hoped that this knowledge can help scientists involved in drug discovery and development in their challenging task of producing safe and effective drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBIFLSUGUWN7Vg90H21EOLACvtfcHk0lhLPumuQHl1Wg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1eks7nK&md5=320b9ade5e38e5d21b92a4e2781e9e62</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1517%2F17425255.2.6.923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.2.6.923%26sid%3Dliteratum%253Aachs%26aulast%3DErve%26aufirst%3DJ.%2BC.%2BL.%26atitle%3DChemical%2520toxicology%253A%2520Reactive%2520intermediates%2520and%2520their%2520role%2520in%2520pharmacology%2520and%2520toxicology%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2006%26volume%3D2%26issue%3D6%26spage%3D923%26epage%3D946%26doi%3D10.1517%2F17425255.2.6.923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borgan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veronese, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marques, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogdaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howes, O.</span></span> <span> </span><span class="NLM_article-title">F229. Cannabinoid 1 receptor and memory function in first episode psychosis: a multi-modal PET-fMRI study</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>83</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">S327</span>â <span class="NLM_lpage">328</span>, <span class="refDoi">Â DOI: 10.1016/j.biopsych.2018.02.843</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.biopsych.2018.02.843" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2018&pages=S327-328&issue=9&author=F.+Borganauthor=M.+Veroneseauthor=T.+Marquesauthor=M.+Rogdakiauthor=O.+Howes&title=F229.+Cannabinoid+1+receptor+and+memory+function+in+first+episode+psychosis%3A+a+multi-modal+PET-fMRI+study&doi=10.1016%2Fj.biopsych.2018.02.843"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2018.02.843&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2018.02.843%26sid%3Dliteratum%253Aachs%26aulast%3DBorgan%26aufirst%3DF.%26aulast%3DVeronese%26aufirst%3DM.%26aulast%3DMarques%26aufirst%3DT.%26aulast%3DRogdaki%26aufirst%3DM.%26aulast%3DHowes%26aufirst%3DO.%26atitle%3DF229.%2520Cannabinoid%25201%2520receptor%2520and%2520memory%2520function%2520in%2520first%2520episode%2520psychosis%253A%2520a%2520multi-modal%2520PET-fMRI%2520study%26jtitle%3DBiol.%2520Psychiatry%26date%3D2018%26volume%3D83%26issue%3D9%26spage%3DS327%26epage%3D328%26doi%3D10.1016%2Fj.biopsych.2018.02.843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span> <span> </span><span class="NLM_article-title">Endocannabinoid metabolism in neurodegenerative diseases</span>. <i>Neuroimmunol. Neuroinflamm.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">268</span>â <span class="NLM_lpage">270</span>, <span class="refDoi">Â DOI: 10.20517/2347-8659.2016.46</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.20517%2F2347-8659.2016.46" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=28638858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A280%3ADC%252BC1cjgs12rtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2016&pages=268-270&author=C.+Chen&title=Endocannabinoid+metabolism+in+neurodegenerative+diseases&doi=10.20517%2F2347-8659.2016.46"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Endocannabinoid metabolism in neurodegenerative diseases</span></div><div class="casAuthors">Chen Chu</div><div class="citationInfo"><span class="NLM_cas:title">Neuroimmunology and neuroinflammation</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">268-270</span>
        ISSN:<span class="NLM_cas:issn">2347-8659</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQb_ecrGl5b6UEgZCMqtRBifW6udTcc2eYBWWPEb_Fni7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjgs12rtQ%253D%253D&md5=c595b2231af027b7dcff65d4e694b91e</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.20517%2F2347-8659.2016.46&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.20517%252F2347-8659.2016.46%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%26atitle%3DEndocannabinoid%2520metabolism%2520in%2520neurodegenerative%2520diseases%26jtitle%3DNeuroimmunol.%2520Neuroinflamm.%26date%3D2016%26volume%3D3%26spage%3D268%26epage%3D270%26doi%3D10.20517%2F2347-8659.2016.46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alaverdashvili, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laprairie, R. B.</span></span> <span> </span><span class="NLM_article-title">The future of type 1 cannabinoid receptor allosteric ligands</span>. <i>Drug Metab. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">14</span>â <span class="NLM_lpage">25</span>, <span class="refDoi">Â DOI: 10.1080/03602532.2018.1428341</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1080%2F03602532.2018.1428341" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=29355038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2hsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2018&pages=14-25&issue=1&author=M.+Alaverdashviliauthor=R.+B.+Laprairie&title=The+future+of+type+1+cannabinoid+receptor+allosteric+ligands&doi=10.1080%2F03602532.2018.1428341"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">The future of type 1 cannabinoid receptor allosteric ligands</span></div><div class="casAuthors">Alaverdashvili, Mariam; Laprairie, Robert B.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">14-25</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Allosteric modulation of the type 1 cannabinoid receptor (CB1R) holds great therapeutic potential.  This is because allosteric modulators do not possess intrinsic efficacy, but instead augment (pos. allosteric modulation) or diminish (neg. allosteric modulation) the receptor's response to endogenous ligand.  Consequently, CB1R allosteric modulators have an effect ceiling which allows for the tempering of CB1R signaling without the desensitization, tolerance, dependence, and psychoactivity assocd. with orthosteric compds.  Pain, movement disorders, epilepsy, obesity are all potential therapeutic targets for CB1R allosteric modulation.  Several challenges exist for the development of CB1R allosteric modulators, such as receptor subtype specificity, translation to in vivo systems, and mixed allosteric/agonist/inverse agonist activity.  Despite these challenges, elucidation of crystal structures of CB1R and compd. design based on structure-activity relationships will advance the field.  In this review, we will cover recent progress for CB1R allosteric modulators and discuss the future promise of this research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZhuoErXo_VrVg90H21EOLACvtfcHk0lh70cWSlFBzRQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2hsr8%253D&md5=5acbaf05214d4ab5e34421b5201c469b</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1080%2F03602532.2018.1428341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F03602532.2018.1428341%26sid%3Dliteratum%253Aachs%26aulast%3DAlaverdashvili%26aufirst%3DM.%26aulast%3DLaprairie%26aufirst%3DR.%2BB.%26atitle%3DThe%2520future%2520of%2520type%25201%2520cannabinoid%2520receptor%2520allosteric%2520ligands%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D2018%26volume%3D50%26issue%3D1%26spage%3D14%26epage%3D25%26doi%3D10.1080%2F03602532.2018.1428341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahmoud, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shim, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kendall, D. A.</span></span> <span> </span><span class="NLM_article-title">Distinct roles of Î²-arrestin 1 and Î²-arrestin 2 in ORG27569-induced biased signaling and internalization of the cannabinoid receptor 1 (CB1)</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">9790</span>â <span class="NLM_lpage">9800</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M112.438804</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1074%2Fjbc.M112.438804" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=23449980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlsVCqurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=9790-9800&issue=14&author=K.+H.+Ahnauthor=M.+M.+Mahmoudauthor=J.+Y.+Shimauthor=D.+A.+Kendall&title=Distinct+roles+of+%CE%B2-arrestin+1+and+%CE%B2-arrestin+2+in+ORG27569-induced+biased+signaling+and+internalization+of+the+cannabinoid+receptor+1+%28CB1%29&doi=10.1074%2Fjbc.M112.438804"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Distinct Roles of Î²-Arrestin 1 and Î²-Arrestin 2 in ORG27569-induced Biased Signaling and Internalization of the Cannabinoid Receptor 1 (CB1)</span></div><div class="casAuthors">Ahn, Kwang H.; Mahmoud, Mariam M.; Shim, Joong-Youn; Kendall, Debra A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">9790-9800</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The cannabinoid receptor 1 (CB1) is a G protein-coupled receptor primarily expressed in brain tissue that has been implicated in several disease states.  CB1 allosteric compds., such as ORG27569, offer enormous potential as drugs over orthosteric ligands, but their mechanistic, structural, and downstream effects upon receptor binding have not been established.  Previously, we showed that ORG27569 enhances agonist binding affinity to CB1 but inhibits G protein-dependent agonist signaling efficacy in HEK293 cells and rat brain expressing the CB1 receptor.  Here, we identify the mediators of CB1 receptor internalization and ORG27569-induced G protein-independent signaling.  Using siRNA technol., we elucidate an ORG27569-induced signaling mechanism for CB1 wherein Î²-arrestin 1 mediates short term signaling to ERK1/2 with a peak at 5 min and other upstream kinase components including MEK1/2 and c-Src.  Consistent with these findings, we demonstrate co-localization of CB1-GFP with red fluorescent protein-Î²-arrestin 1 upon ORG27569 treatment using confocal microscopy.  In contrast, we show the crit. role of Î²-arrestin 2 in CB1 receptor internalization upon treatment with CP55940 (agonist) or treatment with ORG27569.  These results demonstrate for the first time the involvement of Î²-arrestin in CB1-biased signaling by a CB1 allosteric modulator and also define the differential role of the two Î²-arrestin isoforms in CB1 signaling and internalization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJX0Q8DB2Y97Vg90H21EOLACvtfcHk0lh70cWSlFBzRQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlsVCqurg%253D&md5=9bda79f796b19398ff444210a51526ac</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M112.438804&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M112.438804%26sid%3Dliteratum%253Aachs%26aulast%3DAhn%26aufirst%3DK.%2BH.%26aulast%3DMahmoud%26aufirst%3DM.%2BM.%26aulast%3DShim%26aufirst%3DJ.%2BY.%26aulast%3DKendall%26aufirst%3DD.%2BA.%26atitle%3DDistinct%2520roles%2520of%2520%25CE%25B2-arrestin%25201%2520and%2520%25CE%25B2-arrestin%25202%2520in%2520ORG27569-induced%2520biased%2520signaling%2520and%2520internalization%2520of%2520the%2520cannabinoid%2520receptor%25201%2520%2528CB1%2529%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26issue%3D14%26spage%3D9790%26epage%3D9800%26doi%3D10.1074%2Fjbc.M112.438804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tichkule, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laprairie, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denovan-Wright, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janero, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvonok, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makriyannis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascio, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertwee, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, G. A.</span></span> <span> </span><span class="NLM_article-title">Novel electrophilic and photoaffinity covalent probes for mapping the cannabinoid 1 receptor allosteric site(s)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">44</span>â <span class="NLM_lpage">60</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b01303</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01303" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslKlsbvN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=44-60&issue=1&author=P.+M.+Kulkarniauthor=A.+R.+Kulkarniauthor=A.+Kordeauthor=R.+B.+Tichkuleauthor=R.+B.+Laprairieauthor=E.+M.+Denovan-Wrightauthor=H.+Zhouauthor=D.+R.+Janeroauthor=N.+Zvonokauthor=A.+Makriyannisauthor=M.+G.+Cascioauthor=R.+G.+Pertweeauthor=G.+A.+Thakur&title=Novel+electrophilic+and+photoaffinity+covalent+probes+for+mapping+the+cannabinoid+1+receptor+allosteric+site%28s%29&doi=10.1021%2Facs.jmedchem.5b01303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Electrophilic and Photoaffinity Covalent Probes for Mapping the Cannabinoid 1 Receptor Allosteric Site(s)</span></div><div class="casAuthors">Kulkarni, Pushkar M.; Kulkarni, Abhijit R.; Korde, Anisha; Tichkule, Ritesh B.; Laprairie, Robert B.; Denovan-Wright, Eileen M.; Zhou, Han; Janero, David R.; Zvonok, Nikolai; Makriyannis, Alexandros; Cascio, Maria G.; Pertwee, Roger G.; Thakur, Ganesh A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">44-60</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Undesirable side effects assocd. with orthosteric agonists/antagonists of cannabinoid 1 receptor (CB1R), a tractable target for treating several pathologies affecting humans, have greatly limited their translational potential.  Recent discovery of CB1R neg. allosteric modulators (NAMs) has renewed interest in CB1R by offering a potentially safer therapeutic avenue.  To elucidate the CB1R allosteric binding motif and thereby facilitate rational drug discovery, we report the synthesis and biochem. characterization of first covalent ligands designed to bind irreversibly to the CB1R allosteric site.  Either an electrophilic or a photoactivatable group was introduced at key positions of two classical CB1R NAMs: Org27569 (1) and PSNCBAM-1 (2).  Among these, 20 (GAT100) emerged as the most potent NAM in functional assays, did not exhibit inverse agonism, and behaved as a robust pos. allosteric modulator of binding of orthosteric agonist CP55,940.  This novel covalent probe can serve as a useful tool for characterizing CB1R allosteric ligand-binding motifs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbbmPHS4hBwrVg90H21EOLACvtfcHk0lh70cWSlFBzRQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslKlsbvN&md5=bdd1f5e67ef28ecf57773817c7c2c00f</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01303%26sid%3Dliteratum%253Aachs%26aulast%3DKulkarni%26aufirst%3DP.%2BM.%26aulast%3DKulkarni%26aufirst%3DA.%2BR.%26aulast%3DKorde%26aufirst%3DA.%26aulast%3DTichkule%26aufirst%3DR.%2BB.%26aulast%3DLaprairie%26aufirst%3DR.%2BB.%26aulast%3DDenovan-Wright%26aufirst%3DE.%2BM.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DJanero%26aufirst%3DD.%2BR.%26aulast%3DZvonok%26aufirst%3DN.%26aulast%3DMakriyannis%26aufirst%3DA.%26aulast%3DCascio%26aufirst%3DM.%2BG.%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26aulast%3DThakur%26aufirst%3DG.%2BA.%26atitle%3DNovel%2520electrophilic%2520and%2520photoaffinity%2520covalent%2520probes%2520for%2520mapping%2520the%2520cannabinoid%25201%2520receptor%2520allosteric%2520site%2528s%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D1%26spage%3D44%26epage%3D60%26doi%3D10.1021%2Facs.jmedchem.5b01303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doornbos, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermond, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peeters, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">PÃ©rez-Benito, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trabanco, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavreysen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cid, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitman, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tresadern, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">IJzerman, A. P.</span></span> <span> </span><span class="NLM_article-title">Covalent allosteric probe for the metabotropic glutamate receptor 2: design, synthesis, and pharmacological characterization</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">223</span>â <span class="NLM_lpage">233</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b00051</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00051" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjs1Cgs78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=223-233&issue=1&author=M.+L.+Doornbosauthor=X.+Wangauthor=S.+C.+Vermondauthor=L.+Peetersauthor=L.+P%C3%A9rez-Benitoauthor=A.+A.+Trabancoauthor=H.+Lavreysenauthor=J.+M.+Cidauthor=L.+H.+Heitmanauthor=G.+Tresadernauthor=A.+P.+IJzerman&title=Covalent+allosteric+probe+for+the+metabotropic+glutamate+receptor+2%3A+design%2C+synthesis%2C+and+pharmacological+characterization&doi=10.1021%2Facs.jmedchem.8b00051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent Allosteric Probe for the Metabotropic Glutamate Receptor 2: Design, Synthesis, and Pharmacological Characterization</span></div><div class="casAuthors">Doornbos, Maarten L. J.; Wang, Xuesong; Vermond, Sophie C.; Peeters, Luc; Perez-Benito, Laura; Trabanco, Andres A.; Lavreysen, Hilde; Cid, Jose Maria; Heitman, Laura H.; Tresadern, Gary; IJzerman, Adriaan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">223-233</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Covalent labeling of G protein-coupled receptors (GPCRs) by small mols. is a powerful approach to understand binding modes, mechanism of action, pharmacol., and even facilitate structure elucidation.  We report the first covalent pos. allosteric modulator (PAM) for a class C GPCR, the mGlu2 receptor.  Three putatively covalent mGlu2 PAMs were designed and synthesized.  Pharmacol. characterization identified 2 to bind the receptor covalently.  Computational modeling combined with receptor mutagenesis revealed T7917.29Ã30 as the likely position of covalent interaction.  We show how this covalent ligand can be used to characterize the PAM binding mode and that it is a valuable tool compd. in studying receptor function and binding kinetics.  Our findings advance the understanding of the mGlu2 PAM interaction and suggest that 2 is a valuable probe for further structural and chem. biol. approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2VB7O45PSArVg90H21EOLACvtfcHk0lg-2WCPuRtS8A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjs1Cgs78%253D&md5=5d4cafa60439bbcdb81667789326099a</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00051%26sid%3Dliteratum%253Aachs%26aulast%3DDoornbos%26aufirst%3DM.%2BL.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DVermond%26aufirst%3DS.%2BC.%26aulast%3DPeeters%26aufirst%3DL.%26aulast%3DP%25C3%25A9rez-Benito%26aufirst%3DL.%26aulast%3DTrabanco%26aufirst%3DA.%2BA.%26aulast%3DLavreysen%26aufirst%3DH.%26aulast%3DCid%26aufirst%3DJ.%2BM.%26aulast%3DHeitman%26aufirst%3DL.%2BH.%26aulast%3DTresadern%26aufirst%3DG.%26aulast%3DIJzerman%26aufirst%3DA.%2BP.%26atitle%3DCovalent%2520allosteric%2520probe%2520for%2520the%2520metabotropic%2520glutamate%2520receptor%25202%253A%2520design%252C%2520synthesis%252C%2520and%2520pharmacological%2520characterization%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D1%26spage%3D223%26epage%3D233%26doi%3D10.1021%2Facs.jmedchem.8b00051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meiler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niswender, C. M.</span></span> <span> </span><span class="NLM_article-title">Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">692</span>, <span class="refDoi">Â DOI: 10.1038/nrd4308</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fnrd4308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=25176435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVCrtbzL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=692&issue=9&author=P.+J.+Connauthor=C.+W.+Lindsleyauthor=J.+Meilerauthor=C.+M.+Niswender&title=Opportunities+and+challenges+in+the+discovery+of+allosteric+modulators+of+GPCRs+for+treating+CNS+disorders&doi=10.1038%2Fnrd4308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders</span></div><div class="casAuthors">Conn, P. Jeffrey; Lindsley, Craig W.; Meiler, Jens; Niswender, Colleen M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">692-708</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Novel allosteric modulators of G protein-coupled receptors (GPCRs) are providing fundamental advances in the development of GPCR ligands with high subtype selectivity and novel modes of efficacy that have not been possible with traditional approaches.  As new allosteric modulators are advancing as drug candidates, we are developing an increased understanding of the major advantages and broad range of activities that can be achieved with these agents through selective modulation of specific signalling pathways, differential effects on GPCR homodimers vs. heterodimers, and other properties.  This understanding creates exciting opportunities, as well as unique challenges, in the optimization of novel therapeutic agents for disorders of the central nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS1YQIo2v0lLVg90H21EOLACvtfcHk0lg-2WCPuRtS8A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVCrtbzL&md5=07571da612fc9344e5d6af86aa3eaf83</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1038%2Fnrd4308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4308%26sid%3Dliteratum%253Aachs%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DMeiler%26aufirst%3DJ.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26atitle%3DOpportunities%2520and%2520challenges%2520in%2520the%2520discovery%2520of%2520allosteric%2520modulators%2520of%2520GPCRs%2520for%2520treating%2520CNS%2520disorders%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26issue%3D9%26spage%3D692%26doi%3D10.1038%2Fnrd4308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MÃ¸ller, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno-Delgado, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pin, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kniazeff, J.</span></span> <span> </span><span class="NLM_article-title">Class C G protein-coupled receptors: reviving old couples with new partners</span>. <i>Biophysics Reports</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">4â6</span>),  <span class="NLM_fpage">57</span>â <span class="NLM_lpage">63</span>, <span class="refDoi">Â DOI: 10.1007/s41048-017-0036-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1007%2Fs41048-017-0036-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=29238742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A280%3ADC%252BC1Mzht12isQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=57-63&issue=4%E2%80%936&author=T.+C.+M%C3%B8llerauthor=D.+Moreno-Delgadoauthor=J.+P.+Pinauthor=J.+Kniazeff&title=Class+C+G+protein-coupled+receptors%3A+reviving+old+couples+with+new+partners&doi=10.1007%2Fs41048-017-0036-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Class C G protein-coupled receptors: reviving old couples with new partners</span></div><div class="casAuthors">Moller Thor C; Moreno-Delgado David; Pin Jean-Philippe; Kniazeff Julie</div><div class="citationInfo"><span class="NLM_cas:title">Biophysics reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">57-63</span>
        ISSN:<span class="NLM_cas:issn">2364-3439</span>.
    </div><div class="casAbstract">G protein-coupled receptors (GPCRs) are key players in cell communication and are encoded by the largest family in our genome.  As such, GPCRs represent the main targets in drug development programs.  Sequence analysis revealed several classes of GPCRs: the class A rhodopsin-like receptors represent the majority, the class B includes the secretin-like and adhesion GPCRs, the class F includes the frizzled receptors, and the class C includes receptors for the main neurotransmitters, glutamate and GABA, and those for sweet and umami taste and calcium receptors.  Class C receptors are far more complex than other GPCRs, being mandatory dimers, with each subunit being composed of several domains.  In this review, we summarize our actual knowledge regarding the activation mechanism and subunit organization of class C GPCRs, and how this brings information for many other GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS1b0tR6zomhJ6KlWarZTAzfW6udTcc2eY4FxppdrgUYbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mzht12isQ%253D%253D&md5=d0576153a93c6e0991081468b0c94b4b</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1007%2Fs41048-017-0036-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs41048-017-0036-9%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25B8ller%26aufirst%3DT.%2BC.%26aulast%3DMoreno-Delgado%26aufirst%3DD.%26aulast%3DPin%26aufirst%3DJ.%2BP.%26aulast%3DKniazeff%26aufirst%3DJ.%26atitle%3DClass%2520C%2520G%2520protein-coupled%2520receptors%253A%2520reviving%2520old%2520couples%2520with%2520new%2520partners%26jtitle%3DBiophysics%2520Reports%26date%3D2017%26volume%3D3%26issue%3D4%25E2%2580%25936%26spage%3D57%26epage%3D63%26doi%3D10.1007%2Fs41048-017-0036-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xue, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rovira, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholler, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pin, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rondard, P.</span></span> <span> </span><span class="NLM_article-title">Major ligand-induced rearrangement of the heptahelical domain interface in a GPCR dimer</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">134</span>, <span class="refDoi">Â DOI: 10.1038/nchembio.1711</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fnchembio.1711" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=25503927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFKltL%252FI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=134&issue=2&author=L.+Xueauthor=X.+Roviraauthor=P.+Schollerauthor=H.+Zhaoauthor=J.+Liuauthor=J.+P.+Pinauthor=P.+Rondard&title=Major+ligand-induced+rearrangement+of+the+heptahelical+domain+interface+in+a+GPCR+dimer&doi=10.1038%2Fnchembio.1711"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Major ligand-induced rearrangement of the heptahelical domain interface in a GPCR dimer</span></div><div class="casAuthors">Xue, Li; Rovira, Xavier; Scholler, Pauline; Zhao, Han; Liu, Jianfeng; Pin, Jean-Philippe; Rondard, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">134-140</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">G protein-coupled receptors (GPCRs) are major players in cell communication.  Although they form functional monomers, increasing evidence indicates that GPCR dimerization has a crit. role in cooperative phenomena that are important for cell signal integration.  However, the structural bases of these phenomena remain elusive.  Here, using well-characterized receptor dimers, the metabotropic glutamate receptors (mGluRs), the authors show that structural changes at the dimer interface are linked to receptor activation.  The authors demonstrate that the main dimer interface is formed by transmembrane Î± helix 4 (TM4) and TM5 in the inactive state and by TM6 in the active state.  This major change in the dimer interface is required for receptor activity because locking the TM4-TM5 interface prevents activation by agonist, whereas locking the TM6 interface leads to a constitutively active receptor.  These data provide important information on the activation mechanism of mGluRs and improve the authors' understanding of the structural basis of the neg. cooperativity obsd. in these GPCR dimers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohcfUTDGoDNbVg90H21EOLACvtfcHk0lg8UL2bIsv5Ng"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFKltL%252FI&md5=0b9901b138949ad704a261bc435d0c9c</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1711&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1711%26sid%3Dliteratum%253Aachs%26aulast%3DXue%26aufirst%3DL.%26aulast%3DRovira%26aufirst%3DX.%26aulast%3DScholler%26aufirst%3DP.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DPin%26aufirst%3DJ.%2BP.%26aulast%3DRondard%26aufirst%3DP.%26atitle%3DMajor%2520ligand-induced%2520rearrangement%2520of%2520the%2520heptahelical%2520domain%2520interface%2520in%2520a%2520GPCR%2520dimer%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2015%26volume%3D11%26issue%3D2%26spage%3D134%26doi%3D10.1038%2Fnchembio.1711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christopher, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aves, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DorÃ©, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Errey, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jazayeri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okrasa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano-Vega, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tehan, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiggin, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span> <span> </span><span class="NLM_article-title">Fragment and structure-based drug discovery for a class C GPCR: discovery of the mGlu5 negative allosteric modulator HTL14242 (3-chloro-5-[6-(5-fluoropyridin-2-yl) pyrimidin-4-yl] benzonitrile)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">6653</span>â <span class="NLM_lpage">6664</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00892</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00892" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Gms7%252FP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6653-6664&issue=16&author=J.+A.+Christopherauthor=S.+J.+Avesauthor=K.+A.+Bennettauthor=A.+S.+Dor%C3%A9author=J.+C.+Erreyauthor=A.+Jazayeriauthor=F.+H.+Marshallauthor=K.+Okrasaauthor=M.+J.+Serrano-Vegaauthor=B.+G.+Tehanauthor=G.+R.+Wigginauthor=M.+Congreve&title=Fragment+and+structure-based+drug+discovery+for+a+class+C+GPCR%3A+discovery+of+the+mGlu5+negative+allosteric+modulator+HTL14242+%283-chloro-5-%5B6-%285-fluoropyridin-2-yl%29+pyrimidin-4-yl%5D+benzonitrile%29&doi=10.1021%2Facs.jmedchem.5b00892"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile)</span></div><div class="casAuthors">Christopher, John A.; Aves, Sarah J.; Bennett, Kirstie A.; Dore, Andrew S.; Errey, James C.; Jazayeri, Ali; Marshall, Fiona H.; Okrasa, Krzysztof; Serrano-Vega, Maria J.; Tehan, Benjamin G.; Wiggin, Giselle R.; Congreve, Miles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6653-6664</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Fragment screening of a thermostabilized mGlu5 receptor using a high-concn. radioligand binding assay enabled the identification of moderate affinity, high ligand efficiency (LE) pyrimidine hit.  Subsequent optimization using structure-based drug discovery methods led to the selection of I, HTL14242, as an advanced lead compd. for further development.  Structures of the stabilized mGlu5 receptor complexed with I and another mol. in the series, II, were detd. at resolns. of 2.6 and 3.1 Ã, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL70K7U4oxI7Vg90H21EOLACvtfcHk0lg8UL2bIsv5Ng"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Gms7%252FP&md5=7b5365ee069dc4c79e99f77fe68a781c</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00892&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00892%26sid%3Dliteratum%253Aachs%26aulast%3DChristopher%26aufirst%3DJ.%2BA.%26aulast%3DAves%26aufirst%3DS.%2BJ.%26aulast%3DBennett%26aufirst%3DK.%2BA.%26aulast%3DDor%25C3%25A9%26aufirst%3DA.%2BS.%26aulast%3DErrey%26aufirst%3DJ.%2BC.%26aulast%3DJazayeri%26aufirst%3DA.%26aulast%3DMarshall%26aufirst%3DF.%2BH.%26aulast%3DOkrasa%26aufirst%3DK.%26aulast%3DSerrano-Vega%26aufirst%3DM.%2BJ.%26aulast%3DTehan%26aufirst%3DB.%2BG.%26aulast%3DWiggin%26aufirst%3DG.%2BR.%26aulast%3DCongreve%26aufirst%3DM.%26atitle%3DFragment%2520and%2520structure-based%2520drug%2520discovery%2520for%2520a%2520class%2520C%2520GPCR%253A%2520discovery%2520of%2520the%2520mGlu5%2520negative%2520allosteric%2520modulator%2520HTL14242%2520%25283-chloro-5-%255B6-%25285-fluoropyridin-2-yl%2529%2520pyrimidin-4-yl%255D%2520benzonitrile%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D16%26spage%3D6653%26epage%3D6664%26doi%3D10.1021%2Facs.jmedchem.5b00892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L. H.</span></span> <span> </span><span class="NLM_article-title">Sulfonyl fluorides as privileged warheads in chemical biology</span>. <i>Chem, Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2650</span>â <span class="NLM_lpage">2659</span>, <span class="refDoi">Â DOI: 10.1039/C5SC00408J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1039%2FC5SC00408J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=28706662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksVamurc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=2650-2659&issue=5&author=A.+Narayananauthor=L.+H.+Jones&title=Sulfonyl+fluorides+as+privileged+warheads+in+chemical+biology&doi=10.1039%2FC5SC00408J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfonyl fluorides as privileged warheads in chemical biology</span></div><div class="casAuthors">Narayanan, Arjun; Jones, Lyn H.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2650-2659</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Sulfonyl fluoride electrophiles have found significant utility as reactive probes in chem. biol. and mol. pharmacol.  As warheads they possess the right balance of biocompatibility (including aq. stability) and protein reactivity.  Their functionality is privileged in this regard as they are known to modify not only reactive serines (resulting in their common use as protease inhibitors), but also context-specific threonine, lysine, tyrosine, cysteine and histidine residues.  This review describes the application of sulfonyl fluoride probes across various areas of research and explores new approaches that could further enhance the chem. biol. toolkit.  We believe that sulfonyl fluoride probes will find greater utility in areas such as covalent enzyme inhibition, target identification and validation, and the mapping of enzyme binding sites, substrates and protein-protein interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAuadIMxOl2bVg90H21EOLACvtfcHk0lg8UL2bIsv5Ng"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksVamurc%253D&md5=0009feb4068e912b4784fb8411cdb702</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1039%2FC5SC00408J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5SC00408J%26sid%3Dliteratum%253Aachs%26aulast%3DNarayanan%26aufirst%3DA.%26aulast%3DJones%26aufirst%3DL.%2BH.%26atitle%3DSulfonyl%2520fluorides%2520as%2520privileged%2520warheads%2520in%2520chemical%2520biology%26jtitle%3DChem%252C%2520Sci.%26date%3D2015%26volume%3D6%26issue%3D5%26spage%3D2650%26epage%3D2659%26doi%3D10.1039%2FC5SC00408J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wootten, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marti-Solano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of signalling and biased agonism in G protein-coupled receptors</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">638</span>â <span class="NLM_lpage">653</span>, <span class="refDoi">Â DOI: 10.1038/s41580-018-0049-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fs41580-018-0049-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=30104700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFSqtbzO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=638-653&issue=10&author=D.+Woottenauthor=A.+Christopoulosauthor=M.+Marti-Solanoauthor=M.+M.+Babuauthor=P.+M.+Sexton&title=Mechanisms+of+signalling+and+biased+agonism+in+G+protein-coupled+receptors&doi=10.1038%2Fs41580-018-0049-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of signalling and biased agonism in G protein-coupled receptors</span></div><div class="casAuthors">Wootten, Denise; Christopoulos, Arthur; Marti-Solano, Maria; Babu, M. Madan; Sexton, Patrick M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">638-653</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  G protein-coupled receptors (GPCRs) are the largest group of cell surface receptors in humans that signal in response to diverse inputs and regulate a plethora of cellular processes.  Hence, they constitute one of the primary drug target classes.  Progress in our understanding of GPCR dynamics, activation and signalling has opened new possibilities for selective drug development.  A key advancement has been provided by the concept of biased agonism, which describes the ability of ligands acting at the same GPCR to elicit distinct cellular signalling profiles by preferentially stabilizing different active conformational states of the receptor.  Application of this concept raises the prospect of 'designer' biased agonists as optimized therapeutics with improved efficacy and/or reduced side-effect profiles.  However, this application will require a detailed understanding of the spectrum of drug actions and a structural understanding of the drug-receptor interactions that drive distinct pharmacologies.  The recent revolution in GPCR structural biol. provides unprecedented insights into ligand binding, conformational dynamics and the control of signalling outcomes.  These insights, together with new approaches to multi-dimensional anal. of drug action, are allowing refined classification of drugs according to their pharmacodynamic profiles, which can be linked to receptor structure and predictions of preclin. drug efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHJ3GkBUq00rVg90H21EOLACvtfcHk0liSucFcrsmXgg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFSqtbzO&md5=61ffa3780b7da6df8a8ccee2365354ae</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1038%2Fs41580-018-0049-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41580-018-0049-3%26sid%3Dliteratum%253Aachs%26aulast%3DWootten%26aufirst%3DD.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DMarti-Solano%26aufirst%3DM.%26aulast%3DBabu%26aufirst%3DM.%2BM.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26atitle%3DMechanisms%2520of%2520signalling%2520and%2520biased%2520agonism%2520in%2520G%2520protein-coupled%2520receptors%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2018%26volume%3D19%26issue%3D10%26spage%3D638%26epage%3D653%26doi%3D10.1038%2Fs41580-018-0049-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coyle, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benneyworth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konopaske, G.</span></span> <span> </span><span class="NLM_article-title">Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications</span>. <i>Handb. Exp. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>213</i></span>,  <span class="NLM_fpage">267</span>â <span class="NLM_lpage">295</span>, <span class="refDoi">Â DOI: 10.1007/978-3-642-25758-2_10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1007%2F978-3-642-25758-2_10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=23027419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3sXns1Giu7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=213&publication_year=2012&pages=267-295&author=J.+T.+Coyleauthor=A.+Basuauthor=M.+Benneyworthauthor=D.+Baluauthor=G.+Konopaske&title=Glutamatergic+synaptic+dysregulation+in+schizophrenia%3A+therapeutic+implications&doi=10.1007%2F978-3-642-25758-2_10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications</span></div><div class="casAuthors">Coyle, Joseph T.; Basu, Alo; Benneyworth, Michael; Balu, Darrick; Konopaske, Glenn</div><div class="citationInfo"><span class="NLM_cas:title">Handbook of Experimental Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">213</span>
        (<span class="NLM_cas:issue">Novel Antischizophrenia Treatments</span>),
    <span class="NLM_cas:pages">267-295</span>CODEN:
                <span class="NLM_cas:coden">HEPHD2</span>;
        ISSN:<span class="NLM_cas:issn">0171-2004</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  Schizophrenia affects approx. 1% of the population and continues to be assocd. with poor outcome because of the limited efficacy of and noncompliance with existing antipsychotic medications.  An alternative hypothesis invoking the excitatory neurotransmitter, glutamate, arose out of clin. observations that NMDA receptor antagonists, the dissociative anesthetics like ketamine, can replicate in normal individuals the full range of symptoms of schizophrenia including psychosis, neg. symptoms, and cognitive impairments.  Low dose ketamine can also re-create a no. of physiol. abnormalities characteristic of schizophrenia.  Postmortem studies have revealed abnormalities in endogenous modulators of NMDA receptors in schizophrenia as well as components of a postsynaptic d. where NMDA receptors are localized.  Gene assocn. studies have revealed several genes that affect NMDA receptor function whose allelic variants are assocd. with increased risk for schizophrenia including genes encoding D-amino acid oxidase, its modulator G72, dysbindin, and neuregulin.  The parvalbumin-pos., fast-firing GABAergic interneurons that provide recurrent inhibition to cortical-limbic pyramidal neurons seem to be most sensitive to NMDA receptor hypofunction.  As a consequence, disinhibition of glutamatergic efferents disrupts cortical processing, causing cognitive impairments and neg. symptoms, and drives subcortical dopamine release, resulting in psychosis.  Drugs designed to correct the cortical-limbic dysregulated glutamatergic neurotransmission show promise for reducing neg. and cognitive symptoms of schizophrenia as well as its pos. symptoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCUOYchIYYK7Vg90H21EOLACvtfcHk0liSucFcrsmXgg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXns1Giu7w%253D&md5=1cda996ff05ed79c6ff89bc9cac0d050</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1007%2F978-3-642-25758-2_10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-642-25758-2_10%26sid%3Dliteratum%253Aachs%26aulast%3DCoyle%26aufirst%3DJ.%2BT.%26aulast%3DBasu%26aufirst%3DA.%26aulast%3DBenneyworth%26aufirst%3DM.%26aulast%3DBalu%26aufirst%3DD.%26aulast%3DKonopaske%26aufirst%3DG.%26atitle%3DGlutamatergic%2520synaptic%2520dysregulation%2520in%2520schizophrenia%253A%2520therapeutic%2520implications%26jtitle%3DHandb.%2520Exp.%2520Pharmacol.%26date%3D2012%26volume%3D213%26spage%3D267%26epage%3D295%26doi%3D10.1007%2F978-3-642-25758-2_10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Field, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span> <span> </span><span class="NLM_article-title">Targeting glutamate synapses in schizophrenia</span>. <i>Trends Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">689</span>â <span class="NLM_lpage">698</span>, <span class="refDoi">Â DOI: 10.1016/j.molmed.2011.08.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.molmed.2011.08.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=21955406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFGjtrvE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=689-698&author=J.+R.+Fieldauthor=A.+G.+Walkerauthor=P.+J.+Conn&title=Targeting+glutamate+synapses+in+schizophrenia&doi=10.1016%2Fj.molmed.2011.08.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting glutamate synapses in schizophrenia</span></div><div class="casAuthors">Field, Julie R.; Walker, Adam G.; Conn, P. Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Molecular Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">689-698</span>CODEN:
                <span class="NLM_cas:coden">TMMRCY</span>;
        ISSN:<span class="NLM_cas:issn">1471-4914</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Although early clin. observations implicated dopamine dysfunction in the neuropathol. of schizophrenia, accumulating evidence suggests that multiple neurotransmitter pathways are dysregulated.  The psychotomimetic actions of NMDA receptor antagonists point to an imbalance of glutamatergic signaling.  Encouragingly, numerous preclin. and clin. studies have elucidated several potential targets for increasing NMDA receptor function and equilibrating glutamatergic tone, including the metabotropic glutamate receptors 2, 3 and 5, the muscarinic acetylcholine receptors M1 and M4, and the glycine transporter GlyT1.  Highly specific allosteric and orthosteric ligands have been developed that modify the activity of these novel target proteins, and in this review we summarize both the glutamatergic mechanisms and the novel compds. that are increasing the promise for a multifaceted pharmacol. approach to treat schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR9OJUk-K7YbVg90H21EOLACvtfcHk0liSucFcrsmXgg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFGjtrvE&md5=f0704a3b57aaa67754cc6924a58f6793</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.molmed.2011.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmed.2011.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DField%26aufirst%3DJ.%2BR.%26aulast%3DWalker%26aufirst%3DA.%2BG.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26atitle%3DTargeting%2520glutamate%2520synapses%2520in%2520schizophrenia%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2011%26volume%3D17%26spage%3D689%26epage%3D698%26doi%3D10.1016%2Fj.molmed.2011.08.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Timms, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorschner, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wechsler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkwood, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girirajan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichler, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korvatska, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roche, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horwitz, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuang, D. W.</span></span> <span> </span><span class="NLM_article-title">Support for the <i>N</i>-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia from exome sequencing in multiplex families. <i>JAMA</i></span>. <i>Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">582</span>â <span class="NLM_lpage">590</span>, <span class="refDoi">Â DOI: 10.1001/jamapsychiatry.2013.1195</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1001%2Fjamapsychiatry.2013.1195" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpslClt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2013&pages=582-590&author=A.+E.+Timmsauthor=M.+O.+Dorschnerauthor=J.+Wechslerauthor=K.+Y.+Choiauthor=R.+Kirkwoodauthor=S.+Girirajanauthor=C.+Bakerauthor=E.+E.+Eichlerauthor=O.+Korvatskaauthor=K.+W.+Rocheauthor=M.+S.+Horwitzauthor=D.+W.+Tsuang&title=Support+for+the+N-methyl-D-aspartate+receptor+hypofunction+hypothesis+of+schizophrenia+from+exome+sequencing+in+multiplex+families.+JAMA&doi=10.1001%2Fjamapsychiatry.2013.1195"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Support for the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia from exome sequencing in multiplex families</span></div><div class="casAuthors">Timms, Andrew E.; Dorschner, Michael O.; Wechsler, Jeremy; Choi, Kyu Yeong; Kirkwood, Robert; Girirajan, Santhosh; Baker, Carl; Eichler, Evan E.; Korvatska, Olena; Roche, Katherine W.; Horwitz, Marshall S.; Tsuang, Debby W.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA Psychiatry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">582-590</span>CODEN:
                <span class="NLM_cas:coden">JPASDP</span>;
        ISSN:<span class="NLM_cas:issn">2168-622X</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Importance: Schizophrenia is a complex genetic disorder demonstrating considerable heritability.  Genetic studies have implicated many different genes and pathways, but much of the genetic liability remains unaccounted for.  Investigation of genetic forms of schizophrenia will lead to a better understanding of the underlying mol. pathways, which will then enable targeted approaches for disease prevention and treatment.  Objective: To identify new genetic factors strongly predisposing to schizophrenia in families with multiple affected individuals with schizophrenia.  Design: We performed genome-wide array comparative genomic hybridization, linkage anal., and exome sequencing in multiplex families with schizophrenia.  Setting: Probands and their family members were recruited from academic medical centers.  Participants: We intended to identify rare disease-causing mutations in 5 large families where schizophrenia transmission appears consistent with single-gene inheritance.  Intervention: Array comparative genomic hybridization was used to identify copy no. variants, while exome sequencing was used to identify variants shared in all affected individuals and linkage anal. was used to further filter shared variants of interest.  Anal. of select variants was performed in cultured cells to assess their functional consequences.  Main Outcome Measures: Rare inherited disease-related genetic mutations.  Results: No segregating rare copy no. variants were detected by array comparative genomic hybridization.  However, in all 5 families, exome sequencing detected rare protein-altering variants in 1 of 3 genes assocd. with the N-methyl-D-aspartate (NMDA) receptor.  One pedigree shared a missense and frameshift substitution of GRM5, encoding the metabotropic glutamate receptor subtype 5 (mGluR5), which is coupled to the NMDA receptor and potentiates its signaling; the frameshift disrupts binding to the scaffolding protein tamalin and increases mGluR5 internalization.  Another pedigree transmitted a missense substitution in PPEF2, encoding a calmodulin-binding protein phosphatase, which we show influences mGluR5 levels.  Three pedigrees demonstrated different missense substitutions within LRP1B, encoding a low-d. lipoprotein receptor-related protein tied to both the NMDA receptor and located in a chromosome 2q22 region previously strongly linked to schizophrenia.  Conclusions and Relevance: Exome sequencing of multiplex pedigrees uncovers new genes assocd. with risk for developing schizophrenia and suggests potential novel therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpi2DhCqTUgtLVg90H21EOLACvtfcHk0liSucFcrsmXgg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpslClt7g%253D&md5=8b2491ea10896299b3a5f1ab3de75e69</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1001%2Fjamapsychiatry.2013.1195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamapsychiatry.2013.1195%26sid%3Dliteratum%253Aachs%26aulast%3DTimms%26aufirst%3DA.%2BE.%26aulast%3DDorschner%26aufirst%3DM.%2BO.%26aulast%3DWechsler%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DK.%2BY.%26aulast%3DKirkwood%26aufirst%3DR.%26aulast%3DGirirajan%26aufirst%3DS.%26aulast%3DBaker%26aufirst%3DC.%26aulast%3DEichler%26aufirst%3DE.%2BE.%26aulast%3DKorvatska%26aufirst%3DO.%26aulast%3DRoche%26aufirst%3DK.%2BW.%26aulast%3DHorwitz%26aufirst%3DM.%2BS.%26aulast%3DTsuang%26aufirst%3DD.%2BW.%26atitle%3DSupport%2520for%2520the%2520N-methyl-D-aspartate%2520receptor%2520hypofunction%2520hypothesis%2520of%2520schizophrenia%2520from%2520exome%2520sequencing%2520in%2520multiplex%2520families.%2520JAMA%26jtitle%3DPsychiatry%26date%3D2013%26volume%3D70%26spage%3D582%26epage%3D590%26doi%3D10.1001%2Fjamapsychiatry.2013.1195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parmentier-Batteur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutson, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uslaner, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattson, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâBrien, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magliaro, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forest, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stump, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tynebor, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anthony, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huszar, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambeng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">FaurÃ©, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Poul, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosahl, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocher, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargreaves, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, T. M.</span></span> <span> </span><span class="NLM_article-title">Mechanism based neurotoxicity of mGlu5 positive allosteric modulatorsâdevelopment challenges for a promising novel antipsychotic target</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">161</span>â <span class="NLM_lpage">173</span>, <span class="refDoi">Â DOI: 10.1016/j.neuropharm.2012.12.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.neuropharm.2012.12.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=23291536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitlelsrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2014&pages=161-173&author=S.+Parmentier-Batteurauthor=P.+H.+Hutsonauthor=K.+Menzelauthor=J.+M.+Uslanerauthor=B.+A.+Mattsonauthor=J.+A.+O%E2%80%99Brienauthor=B.+C.+Magliaroauthor=T.+Forestauthor=C.+A.+Stumpauthor=R.+M.+Tyneborauthor=N.+J.+Anthonyauthor=T.+J.+Tuckerauthor=X.+F.+Zhangauthor=R.+Gomezauthor=S.+L.+Huszarauthor=N.+Lambengauthor=H.+Faur%C3%A9author=E.+Le+Poulauthor=S.+Poliauthor=T.+W.+Rosahlauthor=J.+P.+Rocherauthor=R.+Hargreavesauthor=T.+M.+Williams&title=Mechanism+based+neurotoxicity+of+mGlu5+positive+allosteric+modulators%E2%80%94development+challenges+for+a+promising+novel+antipsychotic+target&doi=10.1016%2Fj.neuropharm.2012.12.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism based neurotoxicity of mGlu5 positive allosteric modulators - Development challenges for a promising novel antipsychotic target</span></div><div class="casAuthors">Parmentier-Batteur, Sophie; Hutson, Peter H.; Menzel, Karsten; Uslaner, Jason M.; Mattson, Britta A.; O'Brien, Julie A.; Magliaro, Brian C.; Forest, Thomas; Stump, Craig A.; Tynebor, Robert M.; Anthony, Neville J.; Tucker, Thomas J.; Zhang, Xu-Fang; Gomez, Robert; Huszar, Sarah L.; Lambeng, Nathalie; Faure, H.; Le Poul, Emannuel; Poli, Sonia; Rosahl, Thomas W.; Rocher, Jean-Philippe; Hargreaves, Richard; Williams, Theresa M.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">161-173</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Previous work has suggested that activation of mGlu5 receptor augments NMDA receptor function and thereby may constitute a rational approach addressing glutamate hypofunction in schizophrenia and a target for novel antipsychotic drug development.  Here, we report the in vitro activity, in vivo efficacy and safety profile of 5PAM523 (4-Fluorophenyl){(2R,5S)-5-[5-(5-fluoropyridin-2-yl)-1,2,4-oxadiazol-3-yl]-2-methylpiperidin-1-yl}methanone, a structurally novel pos. allosteric modulator selective of mGlu5.  In cells expressing human mGlu5 receptor, 5PAM523 potentiated threshold responses to glutamate in fluorometric calcium assays, but does not have any intrinsic agonist activity. 5PAM523 acts as an allosteric modulator as suggested by the binding studies showing that 5PAM523 did not displace the binding of the orthosteric ligand quisqualic acid, but did partially compete with the neg. allosteric modulator, MPyEP.  In vivo, 5PAM523 reversed amphetamine-induced locomotor activity in rats.  Therefore, both the in vitro and in vivo data demonstrate that 5PAM523 acts as a selective mGlu5 PAM and exhibits anti-psychotic like activity.  To study the potential for adverse effects and particularly neurotoxicity, brain histopathol. exams were performed in rats treated for 4 days with 5PAM523 or vehicle.  The brain exam revealed moderate to severe neuronal necrosis in the rats treated with the doses of 30 and 50 mg/kg, particularly in the auditory cortex and hippocampus.  To investigate whether this neurotoxicity is mechanism specific to 5PAM523, similar safety studies were carried out with three other structurally distinct selective mGlu5 PAMs.  Results revealed a comparable pattern of neuronal cell death.  Finally, 5PAM523 was tested in mGlu5 knock-out (KO) and wild type (WT) mice. mGlu5 WT mice treated with 5PAM523 for 4 days at 100 mg/kg presented significant neuronal death in the auditory cortex and hippocampus.  Conversely, mGlu5 KO mice did not show any neuronal loss by histopathol., suggesting that enhancement of mGlu5 function is responsible for the toxicity of 5PAM523.  This study reveals for the first time that augmentation of mGlu5 function with selective allosteric modulators results in neurotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQKYyrycXxerVg90H21EOLACvtfcHk0lipxIOwvuVASg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitlelsrY%253D&md5=133389ccec73b22e9a6baa6518f987ab</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2012.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2012.12.003%26sid%3Dliteratum%253Aachs%26aulast%3DParmentier-Batteur%26aufirst%3DS.%26aulast%3DHutson%26aufirst%3DP.%2BH.%26aulast%3DMenzel%26aufirst%3DK.%26aulast%3DUslaner%26aufirst%3DJ.%2BM.%26aulast%3DMattson%26aufirst%3DB.%2BA.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DJ.%2BA.%26aulast%3DMagliaro%26aufirst%3DB.%2BC.%26aulast%3DForest%26aufirst%3DT.%26aulast%3DStump%26aufirst%3DC.%2BA.%26aulast%3DTynebor%26aufirst%3DR.%2BM.%26aulast%3DAnthony%26aufirst%3DN.%2BJ.%26aulast%3DTucker%26aufirst%3DT.%2BJ.%26aulast%3DZhang%26aufirst%3DX.%2BF.%26aulast%3DGomez%26aufirst%3DR.%26aulast%3DHuszar%26aufirst%3DS.%2BL.%26aulast%3DLambeng%26aufirst%3DN.%26aulast%3DFaur%25C3%25A9%26aufirst%3DH.%26aulast%3DLe%2BPoul%26aufirst%3DE.%26aulast%3DPoli%26aufirst%3DS.%26aulast%3DRosahl%26aufirst%3DT.%2BW.%26aulast%3DRocher%26aufirst%3DJ.%2BP.%26aulast%3DHargreaves%26aufirst%3DR.%26aulast%3DWilliams%26aufirst%3DT.%2BM.%26atitle%3DMechanism%2520based%2520neurotoxicity%2520of%2520mGlu5%2520positive%2520allosteric%2520modulators%25E2%2580%2594development%2520challenges%2520for%2520a%2520promising%2520novel%2520antipsychotic%2520target%26jtitle%3DNeuropharmacology%26date%3D2014%26volume%3D82%26spage%3D161%26epage%3D173%26doi%3D10.1016%2Fj.neuropharm.2012.12.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rook, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghoshal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickerson, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinson, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byun, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bubser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nedelcovych, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gould, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niswender, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavreysen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conde-Ceide, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcazar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BartolomÃ©-Nebreda, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talpos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steckler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span> <span> </span><span class="NLM_article-title">Biased mGlu5-positive allosteric modulators provide in vivo efficacy without potentiating mGlu5 modulation of NMDAR currents</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">1029</span>â <span class="NLM_lpage">1040</span>, <span class="refDoi">Â DOI: 10.1016/j.neuron.2015.03.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.neuron.2015.03.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=25937172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnslOisLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2015&pages=1029-1040&author=J.+M.+Rookauthor=Z.+Xiangauthor=X.+Lvauthor=A.+Ghoshalauthor=J.+W.+Dickersonauthor=T.+M.+Bridgesauthor=K.+A.+Johnsonauthor=D.+J.+Fosterauthor=K.+J.+Gregoryauthor=P.+N.+Vinsonauthor=A.+D.+Thompsonauthor=N.+Byunauthor=R.+L.+Collierauthor=M.+Bubserauthor=M.+T.+Nedelcovychauthor=R.+W.+Gouldauthor=S.+R.+Staufferauthor=J.+S.+Danielsauthor=C.+M.+Niswenderauthor=H.+Lavreysenauthor=C.+Mackieauthor=S.+Conde-Ceideauthor=J.+Alcazarauthor=J.+M.+Bartolom%C3%A9-Nebredaauthor=G.+J.+Macdonaldauthor=J.+C.+Talposauthor=T.+Stecklerauthor=C.+K.+Jonesauthor=C.+W.+Lindsleyauthor=P.+J.+Conn&title=Biased+mGlu5-positive+allosteric+modulators+provide+in+vivo+efficacy+without+potentiating+mGlu5+modulation+of+NMDAR+currents&doi=10.1016%2Fj.neuron.2015.03.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR Currents</span></div><div class="casAuthors">Rook, Jerri M.; Xiang, Zixiu; Lv, Xiaohui; Ghoshal, Ayan; Dickerson, Jonathan W.; Bridges, Thomas M.; Johnson, Kari A.; Foster, Daniel J.; Gregory, Karen J.; Vinson, Paige N.; Thompson, Analisa D.; Byun, Nellie; Collier, Rebekah L.; Bubser, Michael; Nedelcovych, Michael T.; Gould, Robert W.; Stauffer, Shaun R.; Daniels, J. Scott; Niswender, Colleen M.; Lavreysen, Hilde; Mackie, Claire; Conde-Ceide, Susana; Alcazar, Jesus; Bartolome-Nebreda, Jose M.; MacDonald, Gregor J.; Talpos, John C.; Steckler, Thomas; Jones, Carrie K.; Lindsley, Craig W.; Conn, P. Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1029-1040</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Schizophrenia is assocd. with disruptions in N-methyl-D-aspartate glutamate receptor subtype (NMDAR)-mediated excitatory synaptic signaling.  The metabotropic glutamate receptor subtype 5 (mGlu5) is a closely assocd. signaling partner with NMDARs and regulates NMDAR function in forebrain regions implicated in the pathol. of schizophrenia.  Efficacy of mGlu5 pos. allosteric modulators (PAMs) in animal models of psychosis and cognition was previously attributed to potentiation of NMDAR function.  To directly test this hypothesis, we identified VU0409551 as a novel mGlu5 PAM that exhibits distinct stimulus bias and selectively potentiates mGlu5 coupling to GÎ±q-mediated signaling but not mGlu5 modulation of NMDAR currents or NMDAR-dependent synaptic plasticity in the rat hippocampus.  Interestingly, VU0409551 produced robust antipsychotic-like and cognition-enhancing activity in animal models.  These data provide surprising new mechanistic insights into the actions of mGlu5 PAMs and suggest that modulation of NMDAR currents is not crit. for in vivo efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouKRBBcza96rVg90H21EOLACvtfcHk0lipxIOwvuVASg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnslOisLc%253D&md5=c5f0a8cf83e1b2d8e0d3541a39cd0529</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2Fj.neuron.2015.03.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuron.2015.03.063%26sid%3Dliteratum%253Aachs%26aulast%3DRook%26aufirst%3DJ.%2BM.%26aulast%3DXiang%26aufirst%3DZ.%26aulast%3DLv%26aufirst%3DX.%26aulast%3DGhoshal%26aufirst%3DA.%26aulast%3DDickerson%26aufirst%3DJ.%2BW.%26aulast%3DBridges%26aufirst%3DT.%2BM.%26aulast%3DJohnson%26aufirst%3DK.%2BA.%26aulast%3DFoster%26aufirst%3DD.%2BJ.%26aulast%3DGregory%26aufirst%3DK.%2BJ.%26aulast%3DVinson%26aufirst%3DP.%2BN.%26aulast%3DThompson%26aufirst%3DA.%2BD.%26aulast%3DByun%26aufirst%3DN.%26aulast%3DCollier%26aufirst%3DR.%2BL.%26aulast%3DBubser%26aufirst%3DM.%26aulast%3DNedelcovych%26aufirst%3DM.%2BT.%26aulast%3DGould%26aufirst%3DR.%2BW.%26aulast%3DStauffer%26aufirst%3DS.%2BR.%26aulast%3DDaniels%26aufirst%3DJ.%2BS.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DLavreysen%26aufirst%3DH.%26aulast%3DMackie%26aufirst%3DC.%26aulast%3DConde-Ceide%26aufirst%3DS.%26aulast%3DAlcazar%26aufirst%3DJ.%26aulast%3DBartolom%25C3%25A9-Nebreda%26aufirst%3DJ.%2BM.%26aulast%3DMacdonald%26aufirst%3DG.%2BJ.%26aulast%3DTalpos%26aufirst%3DJ.%2BC.%26aulast%3DSteckler%26aufirst%3DT.%26aulast%3DJones%26aufirst%3DC.%2BK.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26atitle%3DBiased%2520mGlu5-positive%2520allosteric%2520modulators%2520provide%2520in%2520vivo%2520efficacy%2520without%2520potentiating%2520mGlu5%2520modulation%2520of%2520NMDAR%2520currents%26jtitle%3DNeuron%26date%3D2015%26volume%3D86%26spage%3D1029%26epage%3D1040%26doi%3D10.1016%2Fj.neuron.2015.03.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balu, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takagi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Presti, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramikie, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rook, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolshakov, V. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coyle, J. T.</span></span> <span> </span><span class="NLM_article-title">An mGlu5-positive allosteric modulator rescues the neuroplasticity deficits in a genetic model of NMDA receptor hypofunction in schizophrenia</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">2052</span>â <span class="NLM_lpage">2061</span>, <span class="refDoi">Â DOI: 10.1038/npp.2016.2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fnpp.2016.2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=26741285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFyjsbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2016&pages=2052-2061&author=D.+T.+Baluauthor=Y.+Liauthor=S.+Takagiauthor=K.+T.+Prestiauthor=T.+S.+Ramikieauthor=J.+M.+Rookauthor=C.+K.+Jonesauthor=C.+W.+Lindsleyauthor=P.+J.+Connauthor=V.+Y.+Bolshakovauthor=J.+T.+Coyle&title=An+mGlu5-positive+allosteric+modulator+rescues+the+neuroplasticity+deficits+in+a+genetic+model+of+NMDA+receptor+hypofunction+in+schizophrenia&doi=10.1038%2Fnpp.2016.2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">An mGlu5-Positive Allosteric Modulator Rescues the Neuroplasticity Deficits in a Genetic Model of NMDA Receptor Hypofunction in Schizophrenia</span></div><div class="casAuthors">Balu, Darrick T.; Li, Yan; Takagi, Shunsuke; Presti, Kendall Taylor; Ramikie, Teniel S.; Rook, Jerri M.; Jones, Carrie K.; Lindsley, Craig W.; Conn, P. Jeffrey; Bolshakov, Vadim Y.; Coyle, Joseph T.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2052-2061</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">There is substantial evidence that NMDA receptor (NMDAR) hypofunction contributes to the pathophysiol. of schizophrenia (SCZ).  A recent large-scale genome-wide assocn. study identified serine racemase (SR), the enzyme that produces the NMDAR co-agonist D-serine, as a risk gene for SCZ.  Serine racemase knockout (SR-/-) mice, which lack D-serine, exhibit many of the neurochem. and behavioral abnormalities obsd. in SCZ.  Metabotropic glutamate receptor 5 (mGlu5)-pos. allosteric modulators (PAMs) are currently being developed to treat cognitive dysfunction.  We used in vitro electrophysiol. to det. whether the mGlu5 PAM VU0409551 directly enhances NMDAR function in hippocampal slices from adult male SR-/- mice.  We administered VU0409551 systemically for 5 days to adult male wild-type C57BL/6 animals to det. the optimal dose to test in SR-/- mice.  We used western blot analyses and trace-fear conditioning to det. whether 5 days of VU0409551 treatment could reverse the neuroplasticity and learning deficits, resp., in SR-/- mice.  We show that VU0409551 enhances NMDAR function and rescues long-term potentiation in hippocampal slices obtained from SR-/- mice.  Systemic treatment with VU0409551 (10 and 30 mg/kg) to wild-type mice causes a dose-dependent increase in the Akt/GS3KÎ±/Î² signaling pathway, which is reduced in SR-/- mice and in SCZ.  Furthermore, the administration of VU0409551 to SR-/- mice reverses their deficits in several neuroplasticity signaling pathways and improves their contextual fear memory.  These results support pos. allosteric modulation of mGlu5, particularly with VU0409551, as a viable mechanism to reverse the deficits in NMDAR function, synaptic plasticity, and memory that are known to be impaired in SCZ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVtWueFnsQx7Vg90H21EOLACvtfcHk0ljHNHF3xSb_DQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFyjsbg%253D&md5=0f86b437795d4fcfb53759e59a7bc110</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2016.2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2016.2%26sid%3Dliteratum%253Aachs%26aulast%3DBalu%26aufirst%3DD.%2BT.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DTakagi%26aufirst%3DS.%26aulast%3DPresti%26aufirst%3DK.%2BT.%26aulast%3DRamikie%26aufirst%3DT.%2BS.%26aulast%3DRook%26aufirst%3DJ.%2BM.%26aulast%3DJones%26aufirst%3DC.%2BK.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DBolshakov%26aufirst%3DV.%2BY.%26aulast%3DCoyle%26aufirst%3DJ.%2BT.%26atitle%3DAn%2520mGlu5-positive%2520allosteric%2520modulator%2520rescues%2520the%2520neuroplasticity%2520deficits%2520in%2520a%2520genetic%2520model%2520of%2520NMDA%2520receptor%2520hypofunction%2520in%2520schizophrenia%26jtitle%3DNeuropsychopharmacology%26date%3D2016%26volume%3D41%26spage%3D2052%26epage%3D2061%26doi%3D10.1038%2Fnpp.2016.2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, E. M.</span></span> <span> </span><span class="NLM_article-title">Role of the calcium-sensing receptor in extracellular calcium homeostasis</span>. <i>Best Pract. Res. Clin. Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">333</span>â <span class="NLM_lpage">343</span>, <span class="refDoi">Â DOI: 10.1016/j.beem.2013.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.beem.2013.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=23856263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktlCgtbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=333-343&author=E.+M.+Brown&title=Role+of+the+calcium-sensing+receptor+in+extracellular+calcium+homeostasis&doi=10.1016%2Fj.beem.2013.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the calcium-sensing receptor in extracellular calcium homeostasis</span></div><div class="casAuthors">Brown, Edward M.</div><div class="citationInfo"><span class="NLM_cas:title">Best Practice & Research, Clinical Endocrinology & Metabolism</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">333-343</span>CODEN:
                <span class="NLM_cas:coden">BPRCE9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Maintaining a const. level of blood Ca2+ is essential because of calcium's myriad intracellular and extracellular roles.  The CaSR plays key roles in maintaining \\Ca2+o\\ homeostasis by detecting small changes in blood Ca2+ and modulating the prodn./secretion of the Ca2+-regulating hormones, PTH, CT, FGF23 and 1,25(OH)2D3, so as to appropriately regulate Ca2+ transport into or out of blood via kidney, intestine, and/or bone.  When Ca2+ is high, the CaSR suppresses PTH synthesis and secretion, promotes its degrdn., and inhibits parathyroid cellular proliferation.  It has just the opposite effects on the C-cell, stimulating CT when \\Ca2+o\\ is high.  In bone, Ca2+, acting via the CaSR, stimulates recruitment and proliferation of preosteoblasts, their differentiation to mature osteoblasts, and synthesis and mineralization of bone proteins.  Conversely, \\Ca2+o\\ inhibits the formation and activity and promotes apoptosis of osteoclasts, likely via the CaSR.  These actions tend to mobilize skeletal Ca2+ during \\Ca2+o\\ deficiency and retain it when Ca2+ is plentiful.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKviIOVjKkTrVg90H21EOLACvtfcHk0ljHNHF3xSb_DQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktlCgtbg%253D&md5=67ff8283fc93be514d04588aca22becc</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.beem.2013.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.beem.2013.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DE.%2BM.%26atitle%3DRole%2520of%2520the%2520calcium-sensing%2520receptor%2520in%2520extracellular%2520calcium%2520homeostasis%26jtitle%3DBest%2520Pract.%2520Res.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2013%26volume%3D27%26spage%3D333%26epage%3D343%26doi%3D10.1016%2Fj.beem.2013.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alam, M. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirton, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towers, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouhi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vizard, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sage, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riccardi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canfield, A. E.</span></span> <span> </span><span class="NLM_article-title">Calcification is associated with loss of functional calcium-sensing receptor in vascular smooth muscle cells</span>. <i>Cardiovasc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">260</span>â <span class="NLM_lpage">268</span>, <span class="refDoi">Â DOI: 10.1093/cvr/cvn279</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1093%2Fcvr%2Fcvn279" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=18852253" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntVOhsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2009&pages=260-268&author=M.+U.+Alamauthor=J.+P.+Kirtonauthor=F.+L.+Wilkinsonauthor=E.+Towersauthor=S.+Sinhaauthor=M.+Rouhiauthor=T.+N.+Vizardauthor=A.+P.+Sageauthor=D.+Martinauthor=D.+T.+Wardauthor=M.+Y.+Alexanderauthor=D.+Riccardiauthor=A.+E.+Canfield&title=Calcification+is+associated+with+loss+of+functional+calcium-sensing+receptor+in+vascular+smooth+muscle+cells&doi=10.1093%2Fcvr%2Fcvn279"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Calcification is associated with loss of functional calcium-sensing receptor in vascular smooth muscle cells</span></div><div class="casAuthors">Alam, Masih-ul; Kirton, John Paul; Wilkinson, Fiona L.; Towers, Emily; Sinha, Smeeta; Rouhi, Mansour; Vizard, Thomas N.; Sage, Andrew P.; Martin, David; Ward, Donald T.; Alexander, Marie Yvonne; Riccardi, Daniela; Canfield, Ann E.</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">260-268</span>CODEN:
                <span class="NLM_cas:coden">CVREAU</span>;
        ISSN:<span class="NLM_cas:issn">0008-6363</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Vascular calcification (VC) is highly correlated with increased morbidity and mortality in advanced chronic kidney disease (CKD) patients.  Allosteric modulation of the calcium-sensing receptor (CaR) by calcimimetics inhibits VC in animal models of advanced CKD.  Here, we investigated the expression of the CaR in the vasculature and tested the ability of calcimimetics to prevent vascular smooth muscle cell (VSMC) calcification in vitro.  Immunohistochem. staining demonstrated that CaR protein is present in VSMC in normal, non-calcified human arteries.  In contrast, low levels of CaR immunoreactivity were detected in atherosclerotic, calcified arteries.  Immunfluorescence and immunoblotting revealed that CaR protein was also expressed by human and bovine VSMC in vitro.  Acute stimulation of VSMC with increased Ca2+ stimulated extracellular signal-regulated kinase (ERK1/2) phosphorylation, suggesting that the VSMC CaR is functional.  VSMC CaR expression decreased when these cells deposited a mineralized matrix or following 24 h incubation in mineralization medium with increased (i.e. 1.8 or 2.5 mM) Ca2+.  Culturing VSMC in mineralization medium contg. 1.8 and 2.5 mM Ca2+ or with the membrane-impermeant CaR agonist Gd3+ enhanced mineral deposition compared with that obsd. in 1.2 mM Ca2+.  Over-expression of dominant-neg. (R185Q) CaR enhanced, whereas the calcimimetic R-568 attenuated, VSMC mineral deposition.  These results demonstrate that: (i) VSMCs express a functional CaR; (ii) a redn. in CaR expression is assocd. with increased mineralization in vivo and in vitro; (iii) calcimimetics decrease mineral deposition by VSMC.  These data suggest that calcimimetics may inhibit the development of VC in CKD patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7MsBUaLuxeLVg90H21EOLACvtfcHk0ljHNHF3xSb_DQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntVOhsw%253D%253D&md5=94a8f26c71aebdf7619c68ec335e3a87</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1093%2Fcvr%2Fcvn279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcvr%252Fcvn279%26sid%3Dliteratum%253Aachs%26aulast%3DAlam%26aufirst%3DM.%2BU.%26aulast%3DKirton%26aufirst%3DJ.%2BP.%26aulast%3DWilkinson%26aufirst%3DF.%2BL.%26aulast%3DTowers%26aufirst%3DE.%26aulast%3DSinha%26aufirst%3DS.%26aulast%3DRouhi%26aufirst%3DM.%26aulast%3DVizard%26aufirst%3DT.%2BN.%26aulast%3DSage%26aufirst%3DA.%2BP.%26aulast%3DMartin%26aufirst%3DD.%26aulast%3DWard%26aufirst%3DD.%2BT.%26aulast%3DAlexander%26aufirst%3DM.%2BY.%26aulast%3DRiccardi%26aufirst%3DD.%26aulast%3DCanfield%26aufirst%3DA.%2BE.%26atitle%3DCalcification%2520is%2520associated%2520with%2520loss%2520of%2520functional%2520calcium-sensing%2520receptor%2520in%2520vascular%2520smooth%2520muscle%2520cells%26jtitle%3DCardiovasc.%2520Res.%26date%3D2009%26volume%3D81%26spage%3D260%26epage%3D268%26doi%3D10.1093%2Fcvr%2Fcvn279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coy, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollak, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wank, S. A.</span></span> <span> </span><span class="NLM_article-title">Calcium-sensing receptor is a physiologic multimodal chemosensor regulating gastric G-cell growth and gastrin secretion</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">17791</span>â <span class="NLM_lpage">17796</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1009078107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1073%2Fpnas.1009078107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=20876097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlalt7jN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=17791-17796&author=J.+Fengauthor=C.+D.+Petersenauthor=D.+H.+Coyauthor=J.+K.+Jiangauthor=C.+J.+Thomasauthor=M.+R.+Pollakauthor=S.+A.+Wank&title=Calcium-sensing+receptor+is+a+physiologic+multimodal+chemosensor+regulating+gastric+G-cell+growth+and+gastrin+secretion&doi=10.1073%2Fpnas.1009078107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Calcium-sensing receptor is a physiologic multimodal chemosensor regulating gastric G-cell growth and gastrin secretion</span></div><div class="casAuthors">Feng, Jianying; Petersen, Clark D.; Coy, David H.; Jiang, Jian-Kang; Thomas, Craig J.; Pollak, Martin R.; Wank, Stephen A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">17791-17796, S17791/1-S17791/4</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The calcium-sensing receptor (CaR) is the major sensor and regulator of extracellular Ca2+, whose activity is allosterically regulated by amino acids and pH.  Recently, CaR has been identified in the stomach and intestinal tract, where it has been proposed to function in a non-Ca2+ homeostatic capacity.  Luminal nutrients, such as Ca2+ and amino acids, have been recognized for decades as potent stimulants for gastrin and acid secretion, although the mol. basis for their recognition remains unknown.  The expression of CaR on gastrin-secreting G cells in the stomach and their shared activation by Ca2+, amino acids, and elevated pH suggest that CaR may function as the elusive physiol. sensor regulating gastrin and acid secretion.  The genetic and pharmacol. studies presented here comparing CaR-null mice and wild-type littermates support this hypothesis.  Gavage of Ca2+, peptone, phenylalanine, Hepes buffer (pH 7.4), and CaR-specific calcimimetic, cinacalcet, stimulated gastrin and acid secretion, whereas the calcilytic, NPS 2143, inhibited secretion only in the wild-type mouse.  Consistent with known growth and developmental functions of CaR, G-cell no. was progressively reduced between 30 and 90 d of age by more than 65% in CaR-null mice.  These studies of nutrient-regulated G-cell gastrin secretion and growth provide definitive evidence that CaR functions as a physiol. relevant multimodal sensor.  Medicinals targeting diseases of Ca2+ homeostasis should be reviewed for effects outside traditional Ca2+-regulating tissues in view of the broader distribution and function of CaR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-cdTzypSyDbVg90H21EOLACvtfcHk0lhSmruXcBhCAg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlalt7jN&md5=e195c80cef7f31a5bba25d12929f3f37</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1009078107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1009078107%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DPetersen%26aufirst%3DC.%2BD.%26aulast%3DCoy%26aufirst%3DD.%2BH.%26aulast%3DJiang%26aufirst%3DJ.%2BK.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26aulast%3DPollak%26aufirst%3DM.%2BR.%26aulast%3DWank%26aufirst%3DS.%2BA.%26atitle%3DCalcium-sensing%2520receptor%2520is%2520a%2520physiologic%2520multimodal%2520chemosensor%2520regulating%2520gastric%2520G-cell%2520growth%2520and%2520gastrin%2520secretion%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D17791%26epage%3D17796%26doi%3D10.1073%2Fpnas.1009078107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mace, O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span> <span> </span><span class="NLM_article-title">The regulation of K- and L-cell activity by GLUT2 and the calcium-sensing receptor CaS receptor in rat small intestine</span>. <i>J. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>590</i></span>,  <span class="NLM_fpage">2917</span>â <span class="NLM_lpage">2936</span>, <span class="refDoi">Â DOI: 10.1113/jphysiol.2011.223800</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1113%2Fjphysiol.2011.223800" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=22495587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFehtLjE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=590&publication_year=2012&pages=2917-2936&author=O.+J.+Maceauthor=M.+Schindlerauthor=S.+Patel&title=The+regulation+of+K-+and+L-cell+activity+by+GLUT2+and+the+calcium-sensing+receptor+CaS+receptor+in+rat+small+intestine&doi=10.1113%2Fjphysiol.2011.223800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">The regulation of K- and L-cell activity by GLUT2 and the calcium-sensing receptor CasR in rat small intestine</span></div><div class="casAuthors">Mace, Oliver J.; Schindler, Marcus; Patel, Sonal</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physiology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">590</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2917-2936</span>CODEN:
                <span class="NLM_cas:coden">JPHYA7</span>;
        ISSN:<span class="NLM_cas:issn">0022-3751</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Intestinal enteroendocrine cells (IECs) secrete gut peptides in response to both nutrients and non-nutrients.  Glucose and amino acids both stimulate gut peptide secretion.  Our hypothesis was that the facilitative glucose transporter, GLUT2, could act as a glucose sensor and the calcium-sensing receptor, CasR, could detect amino acids in the intestine to modify gut peptide secretion.  We used isolated loops of rat small intestine to study the secretion of gluco-insulinotropic peptide (GIP), glucagon-like peptide-1 (GLP-1) and peptide tyrosine tyrosine (PYY) secretion stimulated by luminal perfusion of nutrients or bile acid.  Inhibition of the sodium-dependent glucose cotransporter 1 (SGLT1) with phloridzin partially inhibited GIP, GLP-1 and PYY secretion by 45%, suggesting another glucose sensor might be involved in modulating peptide secretion.  The response was completely abolished in the presence of the GLUT2 inhibitors phloretin or cytochalasin B.  Given that GLUT2 modified gut peptide secretion stimulated by glucose, we investigated whether it was involved in the secretion of gut peptide by other gut peptide secretagogues.  Phloretin completely abolished gut peptide secretion stimulated by artificial sweetener (sucralose), dipeptide (glycylsarcosine), lipid (oleoylethanolamine), short chain fatty acid (propionate) and major rat bile acid (taurocholate) indicating a fundamental position for GLUT2 in the gut peptide secretory mechanism.  We investigated how GLUT2 was able to influence gut peptide secretion mediated by a diverse range of stimulators and discovered that GLUT2 affected membrane depolarization through the closure of K+ATP-sensitive channels.  In the absence of SGLT1 activity (or presence of phloridzin), the secretion of GIP, GLP-1 and PYY was sensitive to K+ATP-sensitive channel modulators tolbutamide and diazoxide.  L-Amino acids phenylalanine (Phe), tryptophan (Trp), asparagine (Asn), arginine (Arg) and glutamine (Gln) also stimulated GIP, GLP-1 and PYY secretion, which was completely abolished when extracellular Ca2+ was absent.  The gut peptide response stimulated by the amino acids was also blocked by the CasR inhibitor Calhex 231 and augmented by the CasR agonist NPS-R568.  GLUT2 and CasR regulate K- and L-cell activity in response to nutrient and non-nutrient stimuli.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT8oKxZEsLw7Vg90H21EOLACvtfcHk0lhSmruXcBhCAg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFehtLjE&md5=59b351a85cf9a0d7105e7788fec6a710</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1113%2Fjphysiol.2011.223800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1113%252Fjphysiol.2011.223800%26sid%3Dliteratum%253Aachs%26aulast%3DMace%26aufirst%3DO.%2BJ.%26aulast%3DSchindler%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DS.%26atitle%3DThe%2520regulation%2520of%2520K-%2520and%2520L-cell%2520activity%2520by%2520GLUT2%2520and%2520the%2520calcium-sensing%2520receptor%2520CaS%2520receptor%2520in%2520rat%2520small%2520intestine%26jtitle%3DJ.%2520Physiol.%26date%3D2012%26volume%3D590%26spage%3D2917%26epage%3D2936%26doi%3D10.1113%2Fjphysiol.2011.223800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chonchol, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locatelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abboud, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charytan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Francisco, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jolly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roger, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albizem, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mix, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Block, G. A.</span></span> <span> </span><span class="NLM_article-title">A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis</span>. <i>Am. J. Kidney Dis.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">197</span>â <span class="NLM_lpage">207</span>, <span class="refDoi">Â DOI: 10.1053/j.ajkd.2008.09.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1053%2Fj.ajkd.2008.09.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=19110359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVWgsb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2009&pages=197-207&author=M.+Choncholauthor=F.+Locatelliauthor=H.+E.+Abboudauthor=C.+Charytanauthor=A.+L.+de+Franciscoauthor=S.+Jollyauthor=M.+Kaplanauthor=S.+D.+Rogerauthor=S.+Sarkarauthor=M.+B.+Albizemauthor=T.+C.+Mixauthor=Y.+Kuboauthor=G.+A.+Block&title=A+randomized%2C+double-blind%2C+placebo-controlled+study+to+assess+the+efficacy+and+safety+of+cinacalcet+HCl+in+participants+with+CKD+not+receiving+dialysis&doi=10.1053%2Fj.ajkd.2008.09.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCI in participants with CKD not receiving dialysis</span></div><div class="casAuthors">Chonchol, Michel; Locatelli, Francesco; Abboud, Hanna E.; Charytan, Chaim; de Francisco, Angel L. M.; Jolly, Shivinder; Kaplan, Mark; Roger, Simon D.; Sarkar, Shyamal; Albizem, Moetaz B.; Mix, T. Christian H.; Kubo, Yumi; Block, Geoffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Kidney Diseases</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">197-207</span>CODEN:
                <span class="NLM_cas:coden">AJKDDP</span>;
        ISSN:<span class="NLM_cas:issn">0272-6386</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Secondary hyperparathyroidism is obsd. in patients with early chronic kidney disease (CKD).  This study investigated the safety and efficacy of cinacalcet for secondary hyperparathyroidism in participants with CKD not receiving dialysis.  Double-blind, randomized, 32-wk, phase 3 study.  Setting & Participants: 404 participants with stage 3 or 4 CKD from 73 centers in 9 countries.  Interventions: Cinacalcet:placebo (3:1 ratio).  Proportion of participants with a mean decrease of 30% or greater in intact parathyroid hormone (iPTH) level, proportion with iPTH level of 70 or less or 110 or less pg/mL (stage 3 and 4 CKD, resp.), and mean percentage of iPTH change from baseline, all during the efficacy-assessment phase.  A greater proportion of cinacalcet than placebo participants achieved a 30% or greater decrease in iPTH level (74% vs. 28%; P < 0.001), corresponding to a 43.1% decrease in iPTH level from baseline (cinacalcet) compared with a 1.1% increase (placebo).  At week 32, serum calcium levels were 8.9 Â± 0.8 mg/dL (-8.9%; cinacalcet) and 9.9 Â± 0.6 mg/dL (+0.8%; placebo), phosphorus levels were 4.5 Â± 1.0 mg/dL (+21.4%) and 4.0 Â± 0.7 mg/dL (+6.8%), and calcium-phosphorus product values were 40.1 Â± 8.3 mg2/dL2 (+18.9%) and 38.9 Â± 6.9 mg2/dL2 (+17.1%), resp.  During the study course, 62% (cinacalcet) and 1% (placebo) of participants experienced 2 consecutive serum calcium concns. less than 8.4 mg/dL.  They generally were asymptomatic and without significant clin. consequences.  Treatment generally was well tolerated, and most adverse events were mild to moderate in severity.  The study was not designed to assess the effects of cinacalcet on vascular calcification, bone histomorphometric parameters, or other clin. outcomes.  It is not known whether the obsd. differences in changes in iPTH levels are clin. more important than obsd. differences in changes in serum calcium or phosphorus levels or dosages of vitamin D sterols and phosphate binders.  These data show that cinacalcet treatment in patients with CKD not receiving dialysis can decrease plasma iPTH levels, but with frequent (albeit generally asymptomatic) serum calcium levels less than 8.4 mg/dL and increases in serum phosphorus levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodMRfeR8K80bVg90H21EOLACvtfcHk0lhDq6PG20ENqw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVWgsb4%253D&md5=98834ae0ddc6bfd428548434a3c5e20b</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1053%2Fj.ajkd.2008.09.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.ajkd.2008.09.021%26sid%3Dliteratum%253Aachs%26aulast%3DChonchol%26aufirst%3DM.%26aulast%3DLocatelli%26aufirst%3DF.%26aulast%3DAbboud%26aufirst%3DH.%2BE.%26aulast%3DCharytan%26aufirst%3DC.%26aulast%3Dde%2BFrancisco%26aufirst%3DA.%2BL.%26aulast%3DJolly%26aufirst%3DS.%26aulast%3DKaplan%26aufirst%3DM.%26aulast%3DRoger%26aufirst%3DS.%2BD.%26aulast%3DSarkar%26aufirst%3DS.%26aulast%3DAlbizem%26aufirst%3DM.%2BB.%26aulast%3DMix%26aufirst%3DT.%2BC.%26aulast%3DKubo%26aufirst%3DY.%26aulast%3DBlock%26aufirst%3DG.%2BA.%26atitle%3DA%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520study%2520to%2520assess%2520the%2520efficacy%2520and%2520safety%2520of%2520cinacalcet%2520HCl%2520in%2520participants%2520with%2520CKD%2520not%2520receiving%2520dialysis%26jtitle%3DAm.%2520J.%2520Kidney%2520Dis.%26date%3D2009%26volume%3D53%26spage%3D197%26epage%3D207%26doi%3D10.1053%2Fj.ajkd.2008.09.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arenas, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Fuente, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">RodrÃ­guez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">AlmadÃ©n, Y.</span></span> <span> </span><span class="NLM_article-title">Pharmacodynamics of cinacalcet over 48 h in patients with controlled secondary hyperparathyroidism: useful data in clinical practice</span>. <i>J. Clin. Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">1718</span>â <span class="NLM_lpage">1725</span>, <span class="refDoi">Â DOI: 10.1210/jc.2012-4003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1210%2Fjc.2012-4003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=23463658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtFehtb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2013&pages=1718-1725&author=M.+D.+Arenasauthor=V.+de+la+Fuenteauthor=P.+Delgadoauthor=M.+T.+Gilauthor=P.+Gutierrezauthor=J.+Riberoauthor=M.+Rodr%C3%ADguezauthor=Y.+Almad%C3%A9n&title=Pharmacodynamics+of+cinacalcet+over+48+h+in+patients+with+controlled+secondary+hyperparathyroidism%3A+useful+data+in+clinical+practice&doi=10.1210%2Fjc.2012-4003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacodynamics of cinacalcet over 48 hours in patients with controlled secondary hyperparathyroidism: useful data in clinical practice</span></div><div class="casAuthors">Arenas, M. Dolores; de la Fuente, Vanesa; Delgado, Pablo; Gil, Maria Teresa; Gutierrez, Patricia; Ribero, Jorge; Rodriguez, Mariano; Almaden, Yolanda</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1718-1725</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Cinacalcet induces immediate changes in serum PTH levels, but the pharmacodynamic effect throughout the daily dosing interval in controlled patients is unknown.  Also, in patients with reduced PTH, it is unknown what happens in the first 24 h after withdrawal.  Our aim was to describe the effect over 48 h of cinacalcet in hemodialysis patients with controlled secondary hyperparathyroidism.  This was a phase 4, open-label, single-arm, single-dose, single-center clin. trial.  The study was conducted at a public hospital (Hospital Perpetuo Socorro, Alicante, Spain).  We included 10 patients on cinacalcet for 6 mo or longer with intact PTH (iPTH) levels 100-400 pg/mL [8 men, mean age of 66 years (range 39-82 years)], chronically treated with 30 mg (n = 6), 60 mg (n = 3), or 90 mg (n = 1) of cinacalcet.  A single dose (30-90 mg) was administered at baseline.  IPTH (Duo Kit Scantibodies and Elecsys Roche), PTH 1-84, ionized calcium, phosphorus (P), and calcitonin were detd. at baseline and at 1, 3, 6, 12, 24, and 48 h.  There was a significant redn. in iPTH between 1 and 6 h, and values returned to baseline at 24 h [max. mean (95% confidence interval) percent change from baseline: -50%(-34; -66) at 3 h].  A transient increase in calcitonin and a decrease in P were also obsd., with no changes in calcium.  At 48 h, there was a significant increase in iPTH [+51% (26; 76)] and P.  Changes in PTH were similar with the 3 detn. methods.  In hemodialysis patients with secondary hyperparathyroidism controlled by cinacalcet, a transient (1-6 h) redn. in PTH and P and an increase in calcitonin are obsd. after each daily dose, with return to baseline at 24 h.  After calcimimetics discontinuation, PTH was significantly increased at 48 h.  The assay used to measure PTH does not influence relative changes induced by cinacalcet.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQLwgkc0KXFbVg90H21EOLACvtfcHk0lhDq6PG20ENqw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtFehtb8%253D&md5=880f7204fc37ae3f824f4bd5c6cf8e97</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1210%2Fjc.2012-4003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjc.2012-4003%26sid%3Dliteratum%253Aachs%26aulast%3DArenas%26aufirst%3DM.%2BD.%26aulast%3Dde%2Bla%2BFuente%26aufirst%3DV.%26aulast%3DDelgado%26aufirst%3DP.%26aulast%3DGil%26aufirst%3DM.%2BT.%26aulast%3DGutierrez%26aufirst%3DP.%26aulast%3DRibero%26aufirst%3DJ.%26aulast%3DRodr%25C3%25ADguez%26aufirst%3DM.%26aulast%3DAlmad%25C3%25A9n%26aufirst%3DY.%26atitle%3DPharmacodynamics%2520of%2520cinacalcet%2520over%252048%2520h%2520in%2520patients%2520with%2520controlled%2520secondary%2520hyperparathyroidism%253A%2520useful%2520data%2520in%2520clinical%2520practice%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2013%26volume%3D98%26spage%3D1718%26epage%3D1725%26doi%3D10.1210%2Fjc.2012-4003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Henley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morony, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shatzen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pretorius, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St. Jean, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fotsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reagan, J. D.</span></span> <span> </span><span class="NLM_article-title">Discovery of a calcimimetic with differential effects on parathyroid hormone and calcitonin secretion</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>337</i></span>,  <span class="NLM_fpage">681</span>â <span class="NLM_lpage">691</span>, <span class="refDoi">Â DOI: 10.1124/jpet.110.178681</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1124%2Fjpet.110.178681" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=21422163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvFeiurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=337&publication_year=2011&pages=681-691&author=C.+Henleyauthor=Y.+Yangauthor=J.+Davisauthor=J.+Y.+Luauthor=S.+Moronyauthor=W.+Fanauthor=M.+Florioauthor=B.+Sunauthor=E.+Shatzenauthor=J.+K.+Pretoriusauthor=W.+G.+Richardsauthor=D.+J.+St.+Jeanauthor=C.+Fotschauthor=J.+D.+Reagan&title=Discovery+of+a+calcimimetic+with+differential+effects+on+parathyroid+hormone+and+calcitonin+secretion&doi=10.1124%2Fjpet.110.178681"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a calcimimetic with differential effects on parathyroid hormone and calcitonin secretion</span></div><div class="casAuthors">Henley, Charles, III; Yang, Yuhua; Davis, James; Lu, Jenny Ying Lin; Morony, Sean; Fan, Wei; Florio, Monica; Sun, Banghua; Shatzen, Edward; Pretorius, James K.; Richards, William G.; St. Jean, David J., Jr.; Fotsch, Christopher; Reagan, Jeff D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">337</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">681-691</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Calcimimetics are pos. allosteric modulators to the calcium-sensing receptor (CaSR).  Activation of the CaSR inhibits the secretion of parathyroid hormone (PTH), stimulates the secretion of calcitonin, and decreases serum calcium (Ca2+).  Cinacalcet, a second-generation calcimimetic, is used therapeutically to control PTH in patients with chronic kidney disease who are on dialysis with secondary hyperparathyroidism.  A calcimimetic that displays increased sepn. of PTH vs. Ca2+ lowering in patients would potentially allow the use of calcimimetics to treat patients in earlier stages of renal disease because hypocalcemia can develop in this population.  Toward this end, we developed a third-generation calcimimetic, detd. the mol. pharmacol. properties of it using an operation model of allosteric modulation/agonism, and measured the compd. effects on PTH, serum ionized Ca2+, and calcitonin levels in 5/6 nephrectomized rats.  We found the new mol. effectively reduced PTH levels without promoting calcitonin secretion or hypocalcemia.  Furthermore, our third-generation mol. was less efficacious at promoting calcitonin secretion from human thyroid carcinoma cells compared with 3-(2-chlorophenyl)-N-((1R)-1-(3-methoxyphenyl)ethyl)-1-propanamine (R-568), a first-generation calcimimetic.  These data provide evidence that calcimimetics with increased potency can be used to lower PTH without prodn. of significant hypocalcemia because the threshold for inhibition of PTH secretion is much lower than the threshold for calcitonin secretion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaiYjVcexvsLVg90H21EOLACvtfcHk0lhDq6PG20ENqw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvFeiurw%253D&md5=0e303e288f29a0d80c375f0e4ce76dfb</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.178681&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.178681%26sid%3Dliteratum%253Aachs%26aulast%3DHenley%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DDavis%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DJ.%2BY.%26aulast%3DMorony%26aufirst%3DS.%26aulast%3DFan%26aufirst%3DW.%26aulast%3DFlorio%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DB.%26aulast%3DShatzen%26aufirst%3DE.%26aulast%3DPretorius%26aufirst%3DJ.%2BK.%26aulast%3DRichards%26aufirst%3DW.%2BG.%26aulast%3DSt.%2BJean%26aufirst%3DD.%2BJ.%26aulast%3DFotsch%26aufirst%3DC.%26aulast%3DReagan%26aufirst%3DJ.%2BD.%26atitle%3DDiscovery%2520of%2520a%2520calcimimetic%2520with%2520differential%2520effects%2520on%2520parathyroid%2520hormone%2520and%2520calcitonin%2520secretion%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D337%26spage%3D681%26epage%3D691%26doi%3D10.1124%2Fjpet.110.178681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafsson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabatabaei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmelzer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burstein, E. S.</span></span> <span> </span><span class="NLM_article-title">Characterization of highly efficacious allosteric agonists of the human calcium-sensing receptor</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>337</i></span>,  <span class="NLM_fpage">275</span>â <span class="NLM_lpage">284</span>, <span class="refDoi">Â DOI: 10.1124/jpet.110.178194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1124%2Fjpet.110.178194" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=21239511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGqu7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=337&publication_year=2011&pages=275-284&author=J.+N.+Maauthor=M.+Owensauthor=M.+Gustafssonauthor=J.+Jensenauthor=A.+Tabatabaeiauthor=K.+Schmelzerauthor=R.+Olssonauthor=E.+S.+Burstein&title=Characterization+of+highly+efficacious+allosteric+agonists+of+the+human+calcium-sensing+receptor&doi=10.1124%2Fjpet.110.178194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of highly efficacious allosteric agonists of the human calcium-sensing receptor</span></div><div class="casAuthors">Ma, Jian-Nong; Owens, Michelle; Gustafsson, Magnus; Jensen, Jacob; Tabatabaei, Ali; Schmelzer, Kara; Olsson, Roger; Burstein, Ethan S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">337</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">275-284</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We discovered structurally novel human calcium-sensing receptor (CaSR) allosteric agonists and compared their pharmacol. to phenylalkylamine calcimimetics.  1-Benzothiazol-2-yl-1-(2,4-dimethyl-phenyl)-ethanol (AC-265347) activated CaSR signaling in cellular proliferation and phosphatidylinositol (PI) hydrolysis assays with potencies of 30 and 10 nM, resp. (S)-1-Benzothiazol-2-yl-1-(2,4-dimethyl-phenyl)-ethanol [(S)-AC-265347], the S-enantiomer of AC-265347, was approx. 10- to 20-fold more potent than (R)-1-benzothiazol-2-yl-1-(2,4-dimethyl-phenyl)-ethanol [(R)-AC-265347].  The phenylalkylamines cinacalcet and calindol had activity similar to that of AC-265347 in cellular proliferation assays but less activity in PI assays.  All compds. had reduced activity when extracellular Ca2+ was removed, indicating that they cooperate with Ca2+ to activate CaSRs, and all activated CaSR isoforms with the N-terminal extracellular domain deleted, indicating that they interact with the transmembrane domains.  In both cases, AC-265347 and therefore (S)-AC-265347 were significantly more efficacious than the phenylalkylamines.  Mutations E837A7.39 and I841A7.43 strongly reduced phenylalkylamine-induced signaling, but not AC-265347- or (S)-AC-265347-induced signaling, suggesting different modes of binding.  AC-265347 and (S)-AC-265347 stimulated significantly greater responses than cinacalcet or calindol at each of 4 loss-of-function human polymorphic CaSR variants.  AC-265347 did not inhibit the CYP2D6 cytochrome P 450 isoenzyme, unlike cinacalcet, which is a potent CYP2D6 inhibitor.  In rats, AC-265347, (S)-AC-265347, and (R)-AC-265347 each reduced serum parathyroid hormone (PTH) with a rank order potency correlated with their in vitro potencies.  AC-265347 and (S)-AC-265347 also reduced plasma ionizable Ca ([Ca2+]o).  AC-265347 was orally active, and its plasma concns. correlated well with its effects on serum PTH.  Thus, these highly efficacious CaSR allosteric agonists represent leads for developing therapeutic agents with potential advantages over existing therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3kSepRESavLVg90H21EOLACvtfcHk0lh0aFrHLDvvEw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGqu7Y%253D&md5=797ba8b3059d82c04c4b9259149d9fe4</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.178194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.178194%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DJ.%2BN.%26aulast%3DOwens%26aufirst%3DM.%26aulast%3DGustafsson%26aufirst%3DM.%26aulast%3DJensen%26aufirst%3DJ.%26aulast%3DTabatabaei%26aufirst%3DA.%26aulast%3DSchmelzer%26aufirst%3DK.%26aulast%3DOlsson%26aufirst%3DR.%26aulast%3DBurstein%26aufirst%3DE.%2BS.%26atitle%3DCharacterization%2520of%2520highly%2520efficacious%2520allosteric%2520agonists%2520of%2520the%2520human%2520calcium-sensing%2520receptor%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D337%26spage%3D275%26epage%3D284%26doi%3D10.1124%2Fjpet.110.178194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roux, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BernÃ¨che, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egwolf, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lev, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noskov, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowley, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span> <span> </span><span class="NLM_article-title">Ion selectivity in channels and transporters</span>. <i>J. Gen. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>137</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">415</span>â <span class="NLM_lpage">426</span>, <span class="refDoi">Â DOI: 10.1085/jgp.201010577</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1085%2Fjgp.201010577" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=21518830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntlygsb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2011&pages=415-426&issue=5&author=B.+Rouxauthor=S.+Bern%C3%A8cheauthor=B.+Egwolfauthor=B.+Levauthor=S.+Y.+Noskovauthor=C.+N.+Rowleyauthor=H.+Yu&title=Ion+selectivity+in+channels+and+transporters&doi=10.1085%2Fjgp.201010577"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Ion selectivity in channels and transporters</span></div><div class="casAuthors">Roux, Benoit; Berneche, Simon; Egwolf, Bernhard; Lev, Bogdan; Noskov, Sergei Y.; Rowley, Christopher N.; Yu, Haibo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of General Physiology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">415-426</span>CODEN:
                <span class="NLM_cas:coden">JGPLAD</span>;
        ISSN:<span class="NLM_cas:issn">0022-1295</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">A review presents the understanding of ion selectivity as it has evolved over about 15 years from studies based on various specific structures: gramicidin A channels, the KcsA channel, the NaK channel, the LeuT transporter, and the Na/K pump.  It also discusses the insights that can be gained from simple models, which can be used to illustrate and clarify fundamental phys. principles governing ion selectivity in channels and transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPgn25Zh5M_rVg90H21EOLACvtfcHk0lh0aFrHLDvvEw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntlygsb8%253D&md5=8d79ac76351ae06dd9e85c4957b4509b</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1085%2Fjgp.201010577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1085%252Fjgp.201010577%26sid%3Dliteratum%253Aachs%26aulast%3DRoux%26aufirst%3DB.%26aulast%3DBern%25C3%25A8che%26aufirst%3DS.%26aulast%3DEgwolf%26aufirst%3DB.%26aulast%3DLev%26aufirst%3DB.%26aulast%3DNoskov%26aufirst%3DS.%2BY.%26aulast%3DRowley%26aufirst%3DC.%2BN.%26aulast%3DYu%26aufirst%3DH.%26atitle%3DIon%2520selectivity%2520in%2520channels%2520and%2520transporters%26jtitle%3DJ.%2520Gen.%2520Physiol.%26date%3D2011%26volume%3D137%26issue%3D5%26spage%3D415%26epage%3D426%26doi%3D10.1085%2Fjgp.201010577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noskov, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BernÃ¨che, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roux, B.</span></span> <span> </span><span class="NLM_article-title">Control of ion selectivity in potassium channels by electrostatic and dynamic properties of carbonyl ligands</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>431</i></span> (<span class="NLM_issue">7010</span>),  <span class="NLM_fpage">830</span>â <span class="NLM_lpage">834</span>, <span class="refDoi">Â DOI: 10.1038/nature02943</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fnature02943" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=15483608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotl2ktr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=431&publication_year=2004&pages=830-834&issue=7010&author=S.+Y.+Noskovauthor=S.+Bern%C3%A8cheauthor=B.+Roux&title=Control+of+ion+selectivity+in+potassium+channels+by+electrostatic+and+dynamic+properties+of+carbonyl+ligands&doi=10.1038%2Fnature02943"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Control of ion selectivity in potassium channels by electrostatic and dynamic properties of carbonyl ligands</span></div><div class="casAuthors">Noskov, Sergei Yu.; Berneche, Simon; Roux, Benoit</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">431</span>
        (<span class="NLM_cas:issue">7010</span>),
    <span class="NLM_cas:pages">830-834</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Potassium channels are essential for maintaining a normal ionic balance across cell membranes.  Central to this function is the ability of such channels to support transmembrane ion conduction at nearly diffusion-limited rates while discriminating for K+ over Na+ by more than a thousand-fold.  This selectivity arises because the transfer of the K+ ion into the channel pore is energetically favored, a feature commonly attributed to a structurally precise fit between the K+ ion and carbonyl groups lining the rigid and narrow pore.  But proteins are relatively flexible structures that undergo rapid thermal at. fluctuations larger than the small difference in ionic radius between K+ and Na+.  Here we present mol. dynamics simulations for the potassium channel KcsA, which show that the carbonyl groups coordinating the ion in the narrow pore are indeed very dynamic ('liq.-like') and that their intrinsic electrostatic properties control ion selectivity.  This finding highlights the importance of the classical concept of field strength.  Selectivity for K+ is seen to emerge as a robust feature of a flexible fluctuating pore lined by carbonyl groups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe-L8WaSy2VLVg90H21EOLACvtfcHk0lgIRWZmtcKthQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotl2ktr8%253D&md5=86396f17214821a6de671d059e134ab9</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1038%2Fnature02943&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature02943%26sid%3Dliteratum%253Aachs%26aulast%3DNoskov%26aufirst%3DS.%2BY.%26aulast%3DBern%25C3%25A8che%26aufirst%3DS.%26aulast%3DRoux%26aufirst%3DB.%26atitle%3DControl%2520of%2520ion%2520selectivity%2520in%2520potassium%2520channels%2520by%2520electrostatic%2520and%2520dynamic%2520properties%2520of%2520carbonyl%2520ligands%26jtitle%3DNature%26date%3D2004%26volume%3D431%26issue%3D7010%26spage%3D830%26epage%3D834%26doi%3D10.1038%2Fnature02943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noskov, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roux, B.</span></span> <span> </span><span class="NLM_article-title">Ion selectivity in potassium channels</span>. <i>Biophys. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>124</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">279</span>â <span class="NLM_lpage">291</span>, <span class="refDoi">Â DOI: 10.1016/j.bpc.2006.05.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.bpc.2006.05.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=16843584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Sgs7%252FL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2006&pages=279-291&issue=3&author=S.+Y.+Noskovauthor=B.+Roux&title=Ion+selectivity+in+potassium+channels&doi=10.1016%2Fj.bpc.2006.05.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Ion selectivity in potassium channels</span></div><div class="casAuthors">Noskov, Sergei Yu.; Roux, Benoit</div><div class="citationInfo"><span class="NLM_cas:title">Biophysical Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">279-291</span>CODEN:
                <span class="NLM_cas:coden">BICIAZ</span>;
        ISSN:<span class="NLM_cas:issn">0301-4622</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  K+ channels are tetrameric membrane-spanning proteins that provide a selective pore for the conduction of K+ across the cell membranes.  One of the main physiol. functions of potassium channels is efficient and very selective transport of K+ ions through the membrane to the cell.  Classical views of ion selectivity are summarized within a historical perspective, and contrasted with the mol. dynamics (MD) simulations free energy perturbation (FEP) performed on the basis of the crystallog. structure of the KcsA phospholipid membrane.  The results show that the KcsA channel does not select for K+ ions by providing a binding site of an appropriate (fixed) cavity size.  Rather, selectivity for K+ arises directly from the intrinsic local phys. properties of the ligands coordinating the cation in the binding site, and is a robust feature of a pore sym. lined by backbone carbonyl groups.  Further anal. reveals that it is the interplay between the attractive ion-ligand (favoring smaller cation) and repulsive ligand-ligand interactions (favoring larger cations) that is the basic element governing Na+/K+ selectivity in flexible protein binding sites.  Because the no. and the type of ligands coordinating an ion directly modulate such local interactions, this provides a potent mol. mechanism to achieve and maintain a high selectivity in protein binding sites despite a significant conformational flexibility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0eM2SobhOtbVg90H21EOLACvtfcHk0lgIRWZmtcKthQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Sgs7%252FL&md5=8c1bd8607651ede9375923bf3c1c95bb</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2Fj.bpc.2006.05.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bpc.2006.05.033%26sid%3Dliteratum%253Aachs%26aulast%3DNoskov%26aufirst%3DS.%2BY.%26aulast%3DRoux%26aufirst%3DB.%26atitle%3DIon%2520selectivity%2520in%2520potassium%2520channels%26jtitle%3DBiophys.%2520Chem.%26date%3D2006%26volume%3D124%26issue%3D3%26spage%3D279%26epage%3D291%26doi%3D10.1016%2Fj.bpc.2006.05.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chung, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GÃ¼ler, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caterina, M. J.</span></span> <span> </span><span class="NLM_article-title">TRPV1 shows dynamic ionic selectivity during agonist stimulation</span>. <i>Nat. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">555</span>â <span class="NLM_lpage">564</span>, <span class="refDoi">Â DOI: 10.1038/nn.2102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fnn.2102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=18391945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltFerur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2008&pages=555-564&issue=5&author=M.+K.+Chungauthor=A.+D.+G%C3%BClerauthor=M.+J.+Caterina&title=TRPV1+shows+dynamic+ionic+selectivity+during+agonist+stimulation&doi=10.1038%2Fnn.2102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">TRPV1 shows dynamic ionic selectivity during agonist stimulation</span></div><div class="casAuthors">Chung, Man-Kyo; Gueler, Ali D.; Caterina, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Neuroscience</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">555-564</span>CODEN:
                <span class="NLM_cas:coden">NANEFN</span>;
        ISSN:<span class="NLM_cas:issn">1097-6256</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Transient receptor potential vanilloid 1 (TRPV1) is an ion channel that is gated by noxious heat, capsaicin and other diverse stimuli.  It is a nonselective cation channel that prefers Ca2+ over Na+.  These permeability characteristics, as in most channels, are widely presumed to be static.  On the contrary, we found that activation of native or recombinant rat TRPV1 leads to time- and agonist concn.-dependent increases in relative permeability to large cations and changes in Ca2+ permeability.  Using the substituted cysteine accessibility method, we saw that these changes were attributable to alterations in the TRPV1 selectivity filter.  TRPV1 agonists showed different capabilities for evoking ionic selectivity changes.  Furthermore, protein kinase C-dependent phosphorylation of Ser-800 in the TRPV1 C terminus potentiated agonist-evoked ionic selectivity changes.  Thus, the qual. signaling properties of TRPV1 are dynamically modulated during channel activation, a process that probably shapes TRPV1 participation in pain, cytotoxicity and neurotransmitter release.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7FflcBBlyU7Vg90H21EOLACvtfcHk0lgIRWZmtcKthQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltFerur4%253D&md5=1fb8ab48220de8feb4f9925d2371a851</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1038%2Fnn.2102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnn.2102%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DM.%2BK.%26aulast%3DG%25C3%25BCler%26aufirst%3DA.%2BD.%26aulast%3DCaterina%26aufirst%3DM.%2BJ.%26atitle%3DTRPV1%2520shows%2520dynamic%2520ionic%2520selectivity%2520during%2520agonist%2520stimulation%26jtitle%3DNat.%2520Neurosci.%26date%3D2008%26volume%3D11%26issue%3D5%26spage%3D555%26epage%3D564%26doi%3D10.1038%2Fnn.2102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarov-Yarovoy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span> <span> </span><span class="NLM_article-title">The conformational wave in capsaicin activation of transient receptor potential vanilloid 1 ion channel</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2879</span>, <span class="refDoi">Â DOI: 10.1038/s41467-018-05339-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fs41467-018-05339-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=30038260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A280%3ADC%252BB3c7htFyntA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=2879&author=F.+Yangauthor=X.+Xiaoauthor=B.+H.+Leeauthor=S.+Vuauthor=W.+Yangauthor=V.+Yarov-Yarovoyauthor=J.+Zheng&title=The+conformational+wave+in+capsaicin+activation+of+transient+receptor+potential+vanilloid+1+ion+channel&doi=10.1038%2Fs41467-018-05339-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">The conformational wave in capsaicin activation of transient receptor potential vanilloid 1 ion channel</span></div><div class="casAuthors">Yang Fan; Yang Wei; Yang Fan; Xiao Xian; Lee Bo Hyun; Vu Simon; Yarov-Yarovoy Vladimir; Zheng Jie; Xiao Xian; Lee Bo Hyun</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2879</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The capsaicin receptor TRPV1 has been intensively studied by cryo-electron microscopy and functional tests.  However, though the apo and capsaicin-bound structural models are available, the dynamic process of capsaicin activation remains intangible, largely due to the lack of a capsaicin-induced open structural model and the low occupancy of the transition states.  Here we report that reducing temperature toward the freezing point substantially increased channel closure events even in the presence of saturating capsaicin.  We further used a combination of fluorescent unnatural amino acid (fUAA) incorporation, computational modeling, and rate-equilibrium linear free-energy relationships analysis (Î¦-analysis) to derive the fully open capsaicin-bound state model, and reveal how the channel transits from the apo to the open state.  We observed that capsaicin initiates a conformational wave that propagates through the S4-S5 linker towards the S6 bundle and finally reaching the selectivity filter.  Our study provides a temporal mechanism for capsaicin activation of TRPV1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSyt2qNcfvG-FMGsG_HTXYFfW6udTcc2eahKNQy0d7cabntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7htFyntA%253D%253D&md5=5fee8ae1beb7402e3eeb9e193042342f</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-05339-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-05339-6%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DF.%26aulast%3DXiao%26aufirst%3DX.%26aulast%3DLee%26aufirst%3DB.%2BH.%26aulast%3DVu%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DYarov-Yarovoy%26aufirst%3DV.%26aulast%3DZheng%26aufirst%3DJ.%26atitle%3DThe%2520conformational%2520wave%2520in%2520capsaicin%2520activation%2520of%2520transient%2520receptor%2520potential%2520vanilloid%25201%2520ion%2520channel%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D2879%26doi%3D10.1038%2Fs41467-018-05339-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peverini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beudez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunning, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chataigneau, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grutter, T.</span></span> <span> </span><span class="NLM_article-title">New insights into permeation of large cations through ATP-gated P2X receptors</span>. <i>Front. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">265</span>, <span class="refDoi">Â DOI: 10.3389/fnmol.2018.00265</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.3389%2Ffnmol.2018.00265" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=30108481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslahsLrL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=265&author=L.+Peveriniauthor=J.+Beudezauthor=K.+Dunningauthor=T.+Chataigneauauthor=T.+Grutter&title=New+insights+into+permeation+of+large+cations+through+ATP-gated+P2X+receptors&doi=10.3389%2Ffnmol.2018.00265"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">New insights into permeation of large cations through ATP-gated P2X receptors</span></div><div class="casAuthors">Peverini, Laurie; Beudez, Juline; Dunning, Kate; Chataigneau, Thierry; Grutter, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Molecular Neuroscience</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">265/1-265/12</span>CODEN:
                <span class="NLM_cas:coden">FMNRAJ</span>;
        ISSN:<span class="NLM_cas:issn">1662-5099</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">The permeability of large cations through the P2X pore has remained arguably the most controversial and complicated topic in P2X-related research, with the emergence of conflicting studies on the existence, mechanism and physiol. relevance of a so-called "dilated" state.  Due to the important role of several "dilating" P2X subtypes in numerous diseases, a clear and detailed understanding of this phenomenon represents a research priority.  Recent advances, however, have challenged the existence of a progressive, ATP-induced pore dilation, by demonstrating that this phenomenon is an artifact of the method employed.  Here, we discuss briefly the history of this controversial and enigmatic dilated state, from its initial discovery to its recent reconsideration.  We will discuss the literature in which mechanistic pathways to a large cation-permeable state are proposed, as well as important advances in the methodol. employed to study this elusive state.  Considering recent literature, we will also open the discussion as to whether an intrinsically dilating P2X pore exists, as well as the physiol. relevance of such a large cation-permeable pore and its potential use as therapeutic pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVAkXlj36-trVg90H21EOLACvtfcHk0lhIBiYIQZGH_w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslahsLrL&md5=e6076d32a9dff60af533193141e7d2f8</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2018.00265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2018.00265%26sid%3Dliteratum%253Aachs%26aulast%3DPeverini%26aufirst%3DL.%26aulast%3DBeudez%26aufirst%3DJ.%26aulast%3DDunning%26aufirst%3DK.%26aulast%3DChataigneau%26aufirst%3DT.%26aulast%3DGrutter%26aufirst%3DT.%26atitle%3DNew%2520insights%2520into%2520permeation%2520of%2520large%2520cations%2520through%2520ATP-gated%2520P2X%2520receptors%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2018%26volume%3D11%26spage%3D265%26doi%3D10.3389%2Ffnmol.2018.00265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khakh, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, X. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labarca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lester, H. A.</span></span> <span> </span><span class="NLM_article-title">Neuronal P2X transmitter-gated cation channels change their ion selectivity in seconds</span>. <i>Nat. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">322</span>â <span class="NLM_lpage">330</span>, <span class="refDoi">Â DOI: 10.1038/7233</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2F7233" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10204538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADyaK1MXitFGjs74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1999&pages=322-330&issue=4&author=B.+S.+Khakhauthor=X.+R.+Baoauthor=C.+Labarcaauthor=H.+A.+Lester&title=Neuronal+P2X+transmitter-gated+cation+channels+change+their+ion+selectivity+in+seconds&doi=10.1038%2F7233"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Neuronal P2X transmitter-gated cation channels change their ion selectivity in seconds</span></div><div class="casAuthors">Khakh, Baljit S.; Bao, Xiaoyan R.; Labarca, Cesar; Lester, Henry A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Neuroscience</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">322-330</span>CODEN:
                <span class="NLM_cas:coden">NANEFN</span>;
        ISSN:<span class="NLM_cas:issn">1097-6256</span>.
    
            (<span class="NLM_cas:orgname">Nature America</span>)
        </div><div class="casAbstract">Fast synaptic transmission depends on the selective ionic permeability of transmitter-gated ion channels.  Here we show changes in the ion selectivity of neuronal P2X transmitter-gated cation channels as a function of time (on the order of seconds) and previous ATP exposure.  Heterologously expressed P2X2, P2X2/P2X3 and P2X4 channels as well as native neuronal P2X channels possess various combinations of mono- or biphasic responses and permeability changes, measured by NMDG+ and fluorescent dye.  Furthermore, in P2X4 receptors, this ability to alter ion selectivity can be increased or decreased by altering an amino-acid residue thought to line the ion permeation pathway, identifying a region that governs this activity-dependent change.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKnoB1C_Kgg7Vg90H21EOLACvtfcHk0lhIBiYIQZGH_w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXitFGjs74%253D&md5=d215f0d6289154b43fd181a20bb9451d</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1038%2F7233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F7233%26sid%3Dliteratum%253Aachs%26aulast%3DKhakh%26aufirst%3DB.%2BS.%26aulast%3DBao%26aufirst%3DX.%2BR.%26aulast%3DLabarca%26aufirst%3DC.%26aulast%3DLester%26aufirst%3DH.%2BA.%26atitle%3DNeuronal%2520P2X%2520transmitter-gated%2520cation%2520channels%2520change%2520their%2520ion%2520selectivity%2520in%2520seconds%26jtitle%3DNat.%2520Neurosci.%26date%3D1999%26volume%3D2%26issue%3D4%26spage%3D322%26epage%3D330%26doi%3D10.1038%2F7233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herrington, J.</span>; <span class="NLM_string-name">Arey, B. J.</span></span> <span> </span><span class="NLM_article-title">Conformational Mechanisms of Signaling Bias of Ion Channels</span>. In  <i>Biased Signaling in Physiology, Pharmacology and Therapeutics</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arey, B.</span></span>, Ed.; <span class="NLM_publisher-name">Elsevier</span>: <span class="NLM_publisher-loc">Amsterdam</span>, <span class="NLM_year">2014</span>; Chapter 6, pp  <span class="NLM_fpage">173</span>â <span class="NLM_lpage">207</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2FB978-0-12-411460-9.00006-9" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&pages=173-207&author=J.+Herrington&author=B.+J.+Areyauthor=B.+Arey&title=Biased+Signaling+in+Physiology%2C+Pharmacology+and+Therapeutics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-411460-9.00006-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-12-411460-9.00006-9%26sid%3Dliteratum%253Aachs%26aulast%3DHerrington%26aufirst%3DJ.%26atitle%3DConformational%2520Mechanisms%2520of%2520Signaling%2520Bias%2520of%2520Ion%2520Channels%26btitle%3DBiased%2520Signaling%2520in%2520Physiology%252C%2520Pharmacology%2520and%2520Therapeutics%26aulast%3DArey%26aufirst%3DB.%26pub%3DElsevier%26date%3D2014%26spage%3D173%26epage%3D207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Halvard GrÃ¸nlien, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">HÃ¥kerud, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ween, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorin-Hagene, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briggs, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopalakrishnan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malysz, J.</span></span> <span> </span><span class="NLM_article-title">Distinct profiles of alpha7 nAChR positive allosteric modulation revealed by structurally diverse chemotypes</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">715</span>â <span class="NLM_lpage">724</span>, <span class="refDoi">Â DOI: 10.1124/mol.107.035410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1124%2Fmol.107.035410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=17565004" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2007&pages=715-724&author=J.+Halvard+Gr%C3%B8nlienauthor=M.+H%C3%A5kerudauthor=H.+Weenauthor=K.+Thorin-Hageneauthor=C.+A.+Briggsauthor=M.+Gopalakrishnanauthor=J.+Malysz&title=Distinct+profiles+of+alpha7+nAChR+positive+allosteric+modulation+revealed+by+structurally+diverse+chemotypes&doi=10.1124%2Fmol.107.035410"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1124%2Fmol.107.035410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.107.035410%26sid%3Dliteratum%253Aachs%26aulast%3DHalvard%2BGr%25C3%25B8nlien%26aufirst%3DJ.%26aulast%3DH%25C3%25A5kerud%26aufirst%3DM.%26aulast%3DWeen%26aufirst%3DH.%26aulast%3DThorin-Hagene%26aufirst%3DK.%26aulast%3DBriggs%26aufirst%3DC.%2BA.%26aulast%3DGopalakrishnan%26aufirst%3DM.%26aulast%3DMalysz%26aufirst%3DJ.%26atitle%3DDistinct%2520profiles%2520of%2520alpha7%2520nAChR%2520positive%2520allosteric%2520modulation%2520revealed%2520by%2520structurally%2520diverse%2520chemotypes%26jtitle%3DMol.%2520Pharmacol.%26date%3D2007%26volume%3D72%26spage%3D715%26epage%3D724%26doi%3D10.1124%2Fmol.107.035410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hackos, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, J. E.</span></span> <span> </span><span class="NLM_article-title">Diverse modes of NMDA receptor positive allosteric modulation: mechanisms and consequences</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">34</span>â <span class="NLM_lpage">45</span>, <span class="refDoi">Â DOI: 10.1016/j.neuropharm.2016.07.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.neuropharm.2016.07.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=27484578" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht12ksL%252FF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2017&pages=34-45&author=D.+H.+Hackosauthor=J.+E.+Hanson&title=Diverse+modes+of+NMDA+receptor+positive+allosteric+modulation%3A+mechanisms+and+consequences&doi=10.1016%2Fj.neuropharm.2016.07.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Diverse modes of NMDA receptor positive allosteric modulation: Mechanisms and consequences</span></div><div class="casAuthors">Hackos, David H.; Hanson, Jesse E.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">Part_A</span>),
    <span class="NLM_cas:pages">34-45</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">NMDA Receptors (NMDARs) play key roles in synaptic physiol. and NMDAR hypofunction has been implicated in various neurol. conditions.  In recent years an increasing no. of pos. allosteric modulators (PAMs) of NMDARs have been discovered and characterized.  These diverse PAM classes vary not only in their binding sites and GluN2 subunit selectivity profiles, but also in the nature of their impacts on channel function.  Major differences exist in the degree of slowing of channel deactivation and shifting of apparent agonist affinity between different classes of PAMs.  Here we review the diverse modes of potentiation by the currently known classes of NMDAR PAMs and discuss the potential consequences of different types of potentiation in terms of desirable and undesirable effects on brain function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_GGIqatskgrVg90H21EOLACvtfcHk0lgfJuYXYTnuWA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht12ksL%252FF&md5=ca79bbb01b992e8df19275399ad1fe12</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2016.07.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2016.07.037%26sid%3Dliteratum%253Aachs%26aulast%3DHackos%26aufirst%3DD.%2BH.%26aulast%3DHanson%26aufirst%3DJ.%2BE.%26atitle%3DDiverse%2520modes%2520of%2520NMDA%2520receptor%2520positive%2520allosteric%2520modulation%253A%2520mechanisms%2520and%2520consequences%26jtitle%3DNeuropharmacology%26date%3D2017%26volume%3D112%26spage%3D34%26epage%3D45%26doi%3D10.1016%2Fj.neuropharm.2016.07.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seljeset, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bright, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smart, T. G.</span></span> <span> </span><span class="NLM_article-title">Probing GABAA receptors with inhibitory neurosteroids</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">23</span>â <span class="NLM_lpage">36</span>, <span class="refDoi">Â DOI: 10.1016/j.neuropharm.2018.02.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.neuropharm.2018.02.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=29447845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtFOju7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2018&pages=23-36&author=S.+Seljesetauthor=D.+P.+Brightauthor=P.+Thomasauthor=T.+G.+Smart&title=Probing+GABAA+receptors+with+inhibitory+neurosteroids&doi=10.1016%2Fj.neuropharm.2018.02.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Probing GABAA receptors with inhibitory neurosteroids</span></div><div class="casAuthors">Seljeset, Sandra; Bright, Damian P.; Thomas, Philip; Smart, Trevor G.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">Part_A</span>),
    <span class="NLM_cas:pages">23-36</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Î³-aminobutyric acid type A receptors (GABAARs) are important components of the central nervous system and they are functionally tasked with controlling neuronal excitability.  These receptors are subject to post-translational modification and also to modulation by endogenous regulators, such as the neurosteroids.  These modulators can either potentiate or inhibit GABAAR function.  While the former class of neurosteroids are considered to bind to and act from the transmembrane domain of the receptor, the domains that are important for the inhibitory neurosteroids remain less clear.  In this study, we systematically compare a panel of recombinant synaptic-type and extrasynaptic-type GABAARs expressed in heterologous cell systems for their sensitivity to inhibition by the classic inhibitory neurosteroid, pregnenolone sulfate.  Generally, peak GABA current responses were inhibited less compared to steady-state currents, implicating the desensitized state in inhibition.  Moreover, pregnenolone sulfate inhibition increased with GABA concn., but showed minimal voltage dependence.  There was no strong dependence of inhibition on receptor subunit compn., the exception being the Ï1 receptor, which is markedly less sensitive.  By using competition expts. with pregnenolone sulfate and the GABA channel blocker picrotoxinin, discrete binding sites are proposed.  Furthermore, by assessing inhibition using site-directed mutagenesis and receptor chimeras comprising Î±, Î² or Î³ subunits with Ï1 subunits, the receptor transmembrane domains are strongly implicated in mediating inhibition and most likely the binding location for pregnenolone sulfate in GABAARs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe8Dgr53CyJbVg90H21EOLACvtfcHk0lgfJuYXYTnuWA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtFOju7k%253D&md5=d1af3467edd3408b40911bcf1a173480</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2018.02.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2018.02.008%26sid%3Dliteratum%253Aachs%26aulast%3DSeljeset%26aufirst%3DS.%26aulast%3DBright%26aufirst%3DD.%2BP.%26aulast%3DThomas%26aufirst%3DP.%26aulast%3DSmart%26aufirst%3DT.%2BG.%26atitle%3DProbing%2520GABAA%2520receptors%2520with%2520inhibitory%2520neurosteroids%26jtitle%3DNeuropharmacology%26date%3D2018%26volume%3D136%26spage%3D23%26epage%3D36%26doi%3D10.1016%2Fj.neuropharm.2018.02.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mennerick, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covey, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zorumski, C. F.</span></span> <span> </span><span class="NLM_article-title">Pregnenolone sulfate modulates inhibitory synaptic transmission by enhancing GABAA receptor desensitization</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">3571</span>â <span class="NLM_lpage">3579</span>, <span class="refDoi">Â DOI: 10.1523/JNEUROSCI.20-10-03571.2000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1523%2FJNEUROSCI.20-10-03571.2000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10804198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjtlKqs74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2000&pages=3571-3579&issue=10&author=W.+Shenauthor=S.+Mennerickauthor=D.+F.+Coveyauthor=C.+F.+Zorumski&title=Pregnenolone+sulfate+modulates+inhibitory+synaptic+transmission+by+enhancing+GABAA+receptor+desensitization&doi=10.1523%2FJNEUROSCI.20-10-03571.2000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Pregnenolone sulfate modulates inhibitory synaptic transmission by enhancing GABAA receptor desensitization</span></div><div class="casAuthors">Shen, Weixing; Mennerick, Steven; Covey, Douglas F.; Zorumski, Charles F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3571-3579</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">We examd. the effects of the neurosteroid pregnenolone sulfate (PS) on GABAA receptor-mediated synaptic currents and currents elicited by rapid applications of GABA onto nucleated outside-out patches in cultured postnatal rat hippocampal neurons.  At 10 Î¼M, PS significantly depressed peak responses and accelerated the decay of evoked inhibitory synaptic currents.  In nucleated outside-out patches, PS depressed peak currents and speeded deactivation after 5 ms applications of a satg. concn. of GABA.  PS also increased the rate and degree of macroscopic GABA receptor desensitization during prolonged GABA applications.  In a paired GABA application paradigm, PS slowed the rate of recovery from desensitization.  In contrast to its prominent effects on currents produced by satg. GABA concns., PS had only small effects on peak currents and failed to alter deactivation after brief applications of the weakly desensitizing GABAA receptor agonists taurine and Î²-alanine.  However, when Î²-alanine was applied for a sufficient duration to promote receptor desensitization, PS augmented macroscopic desensitization and slowed deactivation.  These results suggest that PS inhibits GABA-gated chloride currents by enhancing receptor desensitization and stabilizing desensitized states.  This contention is supported by kinetic modeling studies in which increases in the rate of entry into doubly liganded desensitized states mimic most effects of PS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFzC2r06wvdbVg90H21EOLACvtfcHk0lgfJuYXYTnuWA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjtlKqs74%253D&md5=f318b1ee38221e899fb970a971d92dc5</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.20-10-03571.2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.20-10-03571.2000%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DW.%26aulast%3DMennerick%26aufirst%3DS.%26aulast%3DCovey%26aufirst%3DD.%2BF.%26aulast%3DZorumski%26aufirst%3DC.%2BF.%26atitle%3DPregnenolone%2520sulfate%2520modulates%2520inhibitory%2520synaptic%2520transmission%2520by%2520enhancing%2520GABAA%2520receptor%2520desensitization%26jtitle%3DJ.%2520Neurosci.%26date%3D2000%26volume%3D20%26issue%3D10%26spage%3D3571%26epage%3D3579%26doi%3D10.1523%2FJNEUROSCI.20-10-03571.2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">PÃ¸hlsgaard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frydenvang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madsen, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastrup, J. S.</span></span> <span> </span><span class="NLM_article-title">Lessons from more than 80 structures of the GluA2 ligand-binding domain in complex with agonists, antagonists and allosteric modulators</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">135</span>â <span class="NLM_lpage">150</span>, <span class="refDoi">Â DOI: 10.1016/j.neuropharm.2010.08.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.neuropharm.2010.08.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=20713069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVaitL%252FK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2011&pages=135-150&issue=1&author=J.+P%C3%B8hlsgaardauthor=K.+Frydenvangauthor=U.+Madsenauthor=J.+S.+Kastrup&title=Lessons+from+more+than+80+structures+of+the+GluA2+ligand-binding+domain+in+complex+with+agonists%2C+antagonists+and+allosteric+modulators&doi=10.1016%2Fj.neuropharm.2010.08.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons from more than 80 structures of the GluA2 ligand-binding domain in complex with agonists, antagonists and allosteric modulators</span></div><div class="casAuthors">Pohlsgaard, Jacob; Frydenvang, Karla; Madsen, Ulf; Kastrup, Jette Sandholm</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">135-150</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Ionotropic glutamate receptors (iGluRs) constitute a family of ligand-gated ion channels that are essential for mediating fast synaptic transmission in the central nervous system.  These receptors play an important role for the development and function of the nervous system, and are essential in learning and memory.  However, iGluRs are also implicated in or have causal roles for several brain disorders, e.g. epilepsy, Alzheimer's disease, Parkinson's disease and schizophrenia.  Their involvement in neurol. diseases has stimulated widespread interest in their structure and function.  Since the first publication in 1998 of the structure of a recombinant sol. protein comprising the ligand-binding domain of GluA2 extensive studies have afforded numerous crystal structures of wildtype and mutant proteins including different ligands.  The structural information obtained combined with functional data have led to models for receptor activation and desensitization by agonists, inhibition by antagonists and block of desensitization by pos. allosteric modulators.  Furthermore, the structural and functional studies have formed a powerful platform for the design of new selective compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA5_dFKFmce7Vg90H21EOLACvtfcHk0ljSCwQTDp57Vg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVaitL%252FK&md5=cade4bfad431cb7da3f8620d56c9926b</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2010.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2010.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DP%25C3%25B8hlsgaard%26aufirst%3DJ.%26aulast%3DFrydenvang%26aufirst%3DK.%26aulast%3DMadsen%26aufirst%3DU.%26aulast%3DKastrup%26aufirst%3DJ.%2BS.%26atitle%3DLessons%2520from%2520more%2520than%252080%2520structures%2520of%2520the%2520GluA2%2520ligand-binding%2520domain%2520in%2520complex%2520with%2520agonists%252C%2520antagonists%2520and%2520allosteric%2520modulators%26jtitle%3DNeuropharmacology%26date%3D2011%26volume%3D60%26issue%3D1%26spage%3D135%26epage%3D150%26doi%3D10.1016%2Fj.neuropharm.2010.08.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krieger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greger, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahar, I.</span></span> <span> </span><span class="NLM_article-title">Activation and desensitization of ionotropic glutamate receptors by selectively triggering pre-existing motions</span>. <i>Neurosci. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>, <span class="refDoi">Â DOI: 10.1016/j.neulet.2018.02.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.neulet.2018.02.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=29481851" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=J.+Kriegerauthor=J.+Y.+Leeauthor=I.+H.+Gregerauthor=I.+Bahar&title=Activation+and+desensitization+of+ionotropic+glutamate+receptors+by+selectively+triggering+pre-existing+motions&doi=10.1016%2Fj.neulet.2018.02.050"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1016%2Fj.neulet.2018.02.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neulet.2018.02.050%26sid%3Dliteratum%253Aachs%26aulast%3DKrieger%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%2BY.%26aulast%3DGreger%26aufirst%3DI.%2BH.%26aulast%3DBahar%26aufirst%3DI.%26atitle%3DActivation%2520and%2520desensitization%2520of%2520ionotropic%2520glutamate%2520receptors%2520by%2520selectively%2520triggering%2520pre-existing%2520motions%26jtitle%3DNeurosci.%2520Lett.%26date%3D2018%26doi%3D10.1016%2Fj.neulet.2018.02.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleck, M. W.</span></span> <span> </span><span class="NLM_article-title">Targeting AMPA receptor gating processes with allosteric modulators and mutations</span>. <i>Biophys. J.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>92</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2392</span>â <span class="NLM_lpage">2402</span>, <span class="refDoi">Â DOI: 10.1529/biophysj.106.095091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1529%2Fbiophysj.106.095091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=17208968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjs1Kjsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2007&pages=2392-2402&issue=7&author=N.+A.+Mitchellauthor=M.+W.+Fleck&title=Targeting+AMPA+receptor+gating+processes+with+allosteric+modulators+and+mutations&doi=10.1529%2Fbiophysj.106.095091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting AMPA receptor gating processes with allosteric modulators and mutations</span></div><div class="casAuthors">Mitchell, Nicholas A.; Fleck, Mark W.</div><div class="citationInfo"><span class="NLM_cas:title">Biophysical Journal</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2392-2402</span>CODEN:
                <span class="NLM_cas:coden">BIOJAU</span>;
        ISSN:<span class="NLM_cas:issn">0006-3495</span>.
    
            (<span class="NLM_cas:orgname">Biophysical Society</span>)
        </div><div class="casAbstract">Allosteric modulators and mutations that slow AMPAR desensitization have addnl. effects on deactivation and agonist potency.  We investigated whether these are independent actions or the natural consequence of slowing desensitization.  Effects of cyclothiazide (CTZ), trichlormethiazide (TCM), and CX614 were compared at wild-type GluR1 and "nondesensitizing" GluR1-L497Y mutant receptors by patch-clamp recording with ultrafast perfusion.  CTZ, TCM, or L/Y mutation all essentially blocked GluR1 desensitization; however, the effects of L/Y mutation on deactivation and glutamate EC50 were three to five times greater than for modulators.  CTZ and TCM further slowed desensitization of L/Y mutant receptors but paradoxically accelerated deactivation and increased agonist EC50.  Results indicate that CTZ and TCM target deactivation and agonist potency independently of desensitization, most likely by modifying agonist dissocn. (koff).  Conversely, CX614 slowed desensitization and deactivation without affecting EC50 in both wild-type and L/Y receptors.  The S750Q or combined L497Y-S750Q mutations abolished all CTZ and TCM actions without disrupting CX614 activity.  Notably, the S/Q mutation also restored L/Y deactivation and EC50 to wild-type levels without restoring desensitization, further demonstrating that desensitization can be modulated independently of deactivation and EC50 by mutagenesis and possibly by allosteric modulators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpw2a6Bj1pqLVg90H21EOLACvtfcHk0ljSCwQTDp57Vg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjs1Kjsbs%253D&md5=6fa66738843990ce75a687118d101922</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1529%2Fbiophysj.106.095091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1529%252Fbiophysj.106.095091%26sid%3Dliteratum%253Aachs%26aulast%3DMitchell%26aufirst%3DN.%2BA.%26aulast%3DFleck%26aufirst%3DM.%2BW.%26atitle%3DTargeting%2520AMPA%2520receptor%2520gating%2520processes%2520with%2520allosteric%2520modulators%2520and%2520mutations%26jtitle%3DBiophys.%2520J.%26date%3D2007%26volume%3D92%26issue%3D7%26spage%3D2392%26epage%3D2402%26doi%3D10.1529%2Fbiophysj.106.095091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christiansen, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harbak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hede, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gouliaev, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frydenvang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egebjerg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastrup, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holm, M. M.</span></span> <span> </span><span class="NLM_article-title">A novel dualistic profile of an allosteric AMPA receptor modulator identified through studies on recombinant receptors, mouse hippocampal synapses and crystal structures</span>. <i>Neuroscience</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>310</i></span>,  <span class="NLM_fpage">709</span>â <span class="NLM_lpage">722</span>, <span class="refDoi">Â DOI: 10.1016/j.neuroscience.2015.09.073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.neuroscience.2015.09.073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=26450748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1ertLzL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=310&publication_year=2015&pages=709-722&author=G.+B.+Christiansenauthor=B.+Harbakauthor=S.+E.+Hedeauthor=A.+H.+Gouliaevauthor=L.+Olsenauthor=K.+Frydenvangauthor=J.+Egebjergauthor=J.+S.+Kastrupauthor=M.+M.+Holm&title=A+novel+dualistic+profile+of+an+allosteric+AMPA+receptor+modulator+identified+through+studies+on+recombinant+receptors%2C+mouse+hippocampal+synapses+and+crystal+structures&doi=10.1016%2Fj.neuroscience.2015.09.073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">A novel dualistic profile of an allosteric AMPA receptor modulator identified through studies on recombinant receptors, mouse hippocampal synapses and crystal structures</span></div><div class="casAuthors">Christiansen, G. B.; Harbak, B.; Hede, S. E.; Gouliaev, A. H.; Olsen, L.; Frydenvang, K.; Egebjerg, J.; Kastrup, J. S.; Holm, M. M.</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">310</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">709-722</span>CODEN:
                <span class="NLM_cas:coden">NRSCDN</span>;
        ISSN:<span class="NLM_cas:issn">0306-4522</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Pos. allosteric modulators (PAMs) of 2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid (AMPA) receptors receive increasing interest as therapeutic drugs and have long served as important exptl. tools in the study of the mol. mechanisms underlying glutamate-mediated neurotransmission.  The aim of this study was to investigate functional and structural aspects of a novel analog of the AMPA receptor PAM cyclothiazide (CTZ) on recombinant and native glutamate receptors.  We expressed rat GluA4flip and flop in Xenopus oocytes and characterized NS1376 and CTZ under two-electrode voltage-clamp.  The dose-response analyses revealed dual effects of NS1376.  The modulator induced 30-fold and 42-fold redns. in glutamate potency and increased the glutamate efficacy by 3.2-fold and 5.3-fold at GluA4flip and GluA4flop, resp.  Rapid application of glutamate to excised outside-out patches showed that NS1376 markedly attenuated desensitization, supporting the increased efficacy obsd. in the oocytes.  Furthermore, when applied to acutely isolated mouse brain slices, NS1376 reduced the field excitatory postsynaptic potentials (fEPSPs) in the hippocampus to 51.6 Â± 4.3% of baseline, likely as a consequence of reduced glutamate potency.  However, the modulator displayed no effects on a sub-maximal long-term potentiation (LTP) protocol.  We confirmed that CTZ increases presynaptic transmitter release, a property which was not shared by NS1376.  Finally, we obtained detailed mol. information through X-ray structures, docking and mol. dynamics, which revealed that NS1376 interacts at the dimer interface of the ligand-binding domain in a manner overall similar to CTZ.  NS1376 reveals that minor structural changes in CTZ can result in an altered modulatory profile, both enhancing agonist efficacy while markedly reducing agonist potency.  These unique properties add new aspects to the complexity of allosteric modulations in neuronal systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvn4gyfAbCo7Vg90H21EOLACvtfcHk0ljmLQLbsagM2w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1ertLzL&md5=b1816630204783cd7a56d3c7e978e267</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroscience.2015.09.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroscience.2015.09.073%26sid%3Dliteratum%253Aachs%26aulast%3DChristiansen%26aufirst%3DG.%2BB.%26aulast%3DHarbak%26aufirst%3DB.%26aulast%3DHede%26aufirst%3DS.%2BE.%26aulast%3DGouliaev%26aufirst%3DA.%2BH.%26aulast%3DOlsen%26aufirst%3DL.%26aulast%3DFrydenvang%26aufirst%3DK.%26aulast%3DEgebjerg%26aufirst%3DJ.%26aulast%3DKastrup%26aufirst%3DJ.%2BS.%26aulast%3DHolm%26aufirst%3DM.%2BM.%26atitle%3DA%2520novel%2520dualistic%2520profile%2520of%2520an%2520allosteric%2520AMPA%2520receptor%2520modulator%2520identified%2520through%2520studies%2520on%2520recombinant%2520receptors%252C%2520mouse%2520hippocampal%2520synapses%2520and%2520crystal%2520structures%26jtitle%3DNeuroscience%26date%3D2015%26volume%3D310%26spage%3D709%26epage%3D722%26doi%3D10.1016%2Fj.neuroscience.2015.09.073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weeks, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harms, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Partin, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benveniste, M.</span></span> <span> </span><span class="NLM_article-title">Functional insight into development of positive allosteric modulators of AMPA receptors</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">57</span>â <span class="NLM_lpage">66</span>, <span class="refDoi">Â DOI: 10.1016/j.neuropharm.2014.05.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.neuropharm.2014.05.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=24878241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFyhtLfJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2014&pages=57-66&author=A.+M.+Weeksauthor=J.+E.+Harmsauthor=K.+M.+Partinauthor=M.+Benveniste&title=Functional+insight+into+development+of+positive+allosteric+modulators+of+AMPA+receptors&doi=10.1016%2Fj.neuropharm.2014.05.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Functional insight into development of positive allosteric modulators of AMPA receptors</span></div><div class="casAuthors">Weeks, Autumn M.; Harms, Jonathan E.; Partin, Kathryn M.; Benveniste, Morris</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">57-66</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Pos. allosteric modulators of Î±-amino-3-hydroxy-5-methyl-isoxazole-propionic acid (AMPA) ionotropic glutamate receptors facilitate synaptic plasticity and contribute essentially to learning and memory, properties which make AMPA receptors targets for drug discovery and development.  One region at which several different classes of pos. allosteric modulators bind lies at the dimer interface between the ligand-binding core of the second, membrane-proximal, extracellular domain of AMPA receptors.  This solvent-accessible binding pocket has been the target of drug discovery efforts, leading to the recent delineation of five "subsites" which differentially allow access to modulator moieties, and for which distinct modulator affinities and apparent efficacies are attributed.  Here we use the voltage-clamp technique in conjunction with rapid drug application to study the effects of mutants lining subsites "A" and "B" of the allosteric modulator pocket to assess affinity and efficacy of allosteric modulation by cyclothiazide, CX614, CMPDA and CMPDB.  A novel anal. of the decay of current produced by the onset of desensitization has allowed us to est. both affinity and efficacy from single concns. of modulator.  Such an approach may be useful for effective high throughput screening of new target compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo04Hb_Ig1ZPrVg90H21EOLACvtfcHk0ljmLQLbsagM2w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFyhtLfJ&md5=419d67b3b2e882e24e723463f7b9149d</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2014.05.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2014.05.022%26sid%3Dliteratum%253Aachs%26aulast%3DWeeks%26aufirst%3DA.%2BM.%26aulast%3DHarms%26aufirst%3DJ.%2BE.%26aulast%3DPartin%26aufirst%3DK.%2BM.%26aulast%3DBenveniste%26aufirst%3DM.%26atitle%3DFunctional%2520insight%2520into%2520development%2520of%2520positive%2520allosteric%2520modulators%2520of%2520AMPA%2520receptors%26jtitle%3DNeuropharmacology%26date%3D2014%26volume%3D85%26spage%3D57%26epage%3D66%26doi%3D10.1016%2Fj.neuropharm.2014.05.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bretin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seguin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Challal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogez, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albinet, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iop, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villain, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krazem, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BÃ©rachochÃ©a, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billiald, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tordjman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lestage, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danober, L.</span></span> <span> </span><span class="NLM_article-title">Pharmacological characterisation of S 47445, a novel positive allosteric modulator of AMPA receptors</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">e0184429</span>, <span class="refDoi">Â DOI: 10.1371/journal.pone.0184429</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1371%2Fjournal.pone.0184429" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=28886144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXosVSitLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=e0184429&issue=9&author=S.+Bretinauthor=C.+Louisauthor=L.+Seguinauthor=S.+Wagnerauthor=J.+Y.+Thomasauthor=S.+Challalauthor=N.+Rogezauthor=K.+Albinetauthor=F.+Iopauthor=N.+Villainauthor=S.+Bertrandauthor=A.+Krazemauthor=D.+B%C3%A9rachoch%C3%A9aauthor=S.+Billialdauthor=C.+Tordjmanauthor=A.+Cordiauthor=D.+Bertrandauthor=P.+Lestageauthor=L.+Danober&title=Pharmacological+characterisation+of+S+47445%2C+a+novel+positive+allosteric+modulator+of+AMPA+receptors&doi=10.1371%2Fjournal.pone.0184429"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterisation of S 47445, a novel positive allosteric modulator of AMPA receptors</span></div><div class="casAuthors">Bretin, Sylvie; Louis, Caroline; Seguin, Laure; Wagner, Stephanie; Thomas, Jean-Yves; Challal, Sylvie; Rogez, Nathalie; Albinet, Karine; Iop, Fabrice; Villain, Nadege; Bertrand, Sonia; Krazem, Ali; Berachochea, Daniel; Billiald, Stephanie; Tordjman, Charles; Cordi, Alex; Bertrand, Daniel; Lestage, Pierre; Danober, Laurence</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e0184429/1-e0184429/28</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">S 47445 is a novel pos. allosteric modulator of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors (AMPA-PAM).  S 47445 enhanced glutamate's action at AMPA receptors on human and rat receptors and was inactive at NMDA and kainate receptors.  Potentiation did not differ among the different AMPA receptors subtypes (GluA1/2/4 flip and flop variants) (EC50 between 2.5-5.4 Î¼M), except a higher EC50 value for GluA4 flop (0.7 Î¼M) and a greater amt. of potentiation on GluA1 flop.  A low concn. of S 47445 (0.1 Î¼M) decreased receptor response decay time of GluA1flop/GluA2flip AMPA receptors and increased the sensitivity to glutamate.  Furthermore, S 47445 (0.1 and 0.3 Î¼M) in presence of repetitive glutamate pulses induced a progressive potentiation of the glutamate-evoked currents from the second pulse of glutamate confirming a rapid-enhancing effect of S 47445 at low concns.  The potentiating effect of S 47445 (1 Î¼M) was concn.-dependently reversed by the selective AMPA receptor antagonist GYKI52466 demonstrating the selective modulatory effect of S 47445 on AMPA receptors.  Using an AMPA-kainate chimera approach, it was confirmed that S 47445 binds to the common binding pocket of AMPA-PAMs.  S 47445 did not demonstrate neurotoxic effect against glutamate-mediated excitotoxicity in vitro, in contrast significantly protected rat cortical neurons at 10 Î¼M.  S 47445 was shown to improve both episodic and spatial working memory in adult rodents at 0.3 mg/kg, as measured in the natural forgetting condition of object recognition and T-maze tasks.  Finally, no deleterious effect on spontaneous locomotion and general behavior was obsd. up to 1000 mg/kg of S 47445 given acutely in rodents, neither occurrence of convulsion or tremors.  Collectively, these results indicate that S 47445 is a potent and selective AMPA-PAM presenting procognitive and potential neuroprotective properties.  This drug is currently evaluated in clin. phase 2 studies in Alzheimer's disease and in Major Depressive Disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJwB6oGr2kgLVg90H21EOLACvtfcHk0ljmLQLbsagM2w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXosVSitLc%253D&md5=bd7305e26b25e6721f0fe7e2d524262a</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0184429&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0184429%26sid%3Dliteratum%253Aachs%26aulast%3DBretin%26aufirst%3DS.%26aulast%3DLouis%26aufirst%3DC.%26aulast%3DSeguin%26aufirst%3DL.%26aulast%3DWagner%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DJ.%2BY.%26aulast%3DChallal%26aufirst%3DS.%26aulast%3DRogez%26aufirst%3DN.%26aulast%3DAlbinet%26aufirst%3DK.%26aulast%3DIop%26aufirst%3DF.%26aulast%3DVillain%26aufirst%3DN.%26aulast%3DBertrand%26aufirst%3DS.%26aulast%3DKrazem%26aufirst%3DA.%26aulast%3DB%25C3%25A9rachoch%25C3%25A9a%26aufirst%3DD.%26aulast%3DBilliald%26aufirst%3DS.%26aulast%3DTordjman%26aufirst%3DC.%26aulast%3DCordi%26aufirst%3DA.%26aulast%3DBertrand%26aufirst%3DD.%26aulast%3DLestage%26aufirst%3DP.%26aulast%3DDanober%26aufirst%3DL.%26atitle%3DPharmacological%2520characterisation%2520of%2520S%252047445%252C%2520a%2520novel%2520positive%2520allosteric%2520modulator%2520of%2520AMPA%2520receptors%26jtitle%3DPLoS%2520One%26date%3D2017%26volume%3D12%26issue%3D9%26spage%3De0184429%26doi%3D10.1371%2Fjournal.pone.0184429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rogawski, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanada, T.</span></span> <span> </span><span class="NLM_article-title">Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist</span>. <i>Acta Neurol. Scand.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">19</span>â <span class="NLM_lpage">24</span>, <span class="refDoi">Â DOI: 10.1111/ane.12100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1111%2Fane.12100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=22494246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsVCls70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2013&pages=19-24&author=M.+A.+Rogawskiauthor=T.+Hanada&title=Preclinical+pharmacology+of+perampanel%2C+a+selective+non-competitive+AMPA+receptor+antagonist&doi=10.1111%2Fane.12100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist</span></div><div class="casAuthors">Rogawski, M. A.; Hanada, T.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Neurologica Scandinavica</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">Suppl. 197</span>),
    <span class="NLM_cas:pages">19-24</span>CODEN:
                <span class="NLM_cas:coden">ANRSAS</span>;
        ISSN:<span class="NLM_cas:issn">1600-0404</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Perampanel [2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile; E2007] is a potent, selective, orally active non-competitive AMPA receptor antagonist developed for the treatment of epilepsy.  Perampanel has a 2,3'-bipyridin-6'-one core structure, distinguishing it chem. from other AMPA receptor antagonist classes.  Studies in various physiol. systems indicate that perampanel selectively inhibits AMPA receptor-mediated synaptic excitation without affecting NMDA receptor responses.  Blocking of AMPA receptors occurs at an allosteric site that is distinct from the glutamate recognition site.  Radioligand-binding studies suggest that the blocking site coincides with that of the non-competitive antagonist GYKI 52466, believed to be on linker peptide segments of AMPA receptor subunits that transduce agonist binding into channel opening.  As is typical for AMPA receptor antagonists, perampanel exhibits broad-spectrum antiseizure activity in diverse animal seizure models.  Perampanel has high oral bioavailability, dose-proportional kinetics, and undergoes oxidative metab., primarily via CYP3A4, followed by glucuronidation.  The terminal half-life (t1/2) in humans is 105 h; however, in the presence of a strong CYP3A4 inducer (such as carbamazepine), the t1/2 can be reduced.  In sum, perampanel is a selective, centrally acting, neg. allosteric modulator of AMPA receptors with good oral bioavailability and favorable pharmacokinetic properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpL0LRy4ANcZLVg90H21EOLACvtfcHk0liD5asrl9_MwQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsVCls70%253D&md5=7bd906fa7dc2767dc8c81fdc4ba9ff99</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1111%2Fane.12100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fane.12100%26sid%3Dliteratum%253Aachs%26aulast%3DRogawski%26aufirst%3DM.%2BA.%26aulast%3DHanada%26aufirst%3DT.%26atitle%3DPreclinical%2520pharmacology%2520of%2520perampanel%252C%2520a%2520selective%2520non-competitive%2520AMPA%2520receptor%2520antagonist%26jtitle%3DActa%2520Neurol.%2520Scand.%26date%3D2013%26volume%3D127%26spage%3D19%26epage%3D24%26doi%3D10.1111%2Fane.12100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hell, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogawski, M. A.</span></span> <span> </span><span class="NLM_article-title">Perampanel inhibition of AMPA receptor currents in cultured hippocampal neurons</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">e108021</span>, <span class="refDoi">Â DOI: 10.1371/journal.pone.0108021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1371%2Fjournal.pone.0108021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=25229608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslShtrzO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e108021&issue=9&author=C.+Y.+Chenauthor=L.+Mattauthor=J.+W.+Hellauthor=M.+A.+Rogawski&title=Perampanel+inhibition+of+AMPA+receptor+currents+in+cultured+hippocampal+neurons&doi=10.1371%2Fjournal.pone.0108021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Perampanel inhibition of AMPA receptor currents in cultured hippocampal neurons</span></div><div class="casAuthors">Chen, Chao-Yin; Matt, Lucas; Hell, Johannes Wilhelm; Rogawski, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e108021/1-e108021/7, 7 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Perampanel is an aryl substituted 2-pyridone AMPA receptor antagonist that was recently approved as a treatment for epilepsy.  The drug potently inhibits AMPA receptor responses but the mode of block has not been characterized.  Here the action of perampanel on AMPA receptors was investigated by whole-cell voltage-clamp recording in cultured rat hippocampal neurons.  Perampanel caused a slow (Ïâ¼1 s at 3 Î¼M), concn.-dependent inhibition of AMPA receptor currents evoked by AMPA and kainate.  The rates of block and unblock of AMPA receptor currents were 1.5 Ã 105 M-1 s-1 and 0.58 s-1, resp.  Perampanel did not affect NMDA receptor currents.  The extent of block of non-desensitizing kainate-evoked currents (IC50, 0.56 Î¼M) was similar at all kainate concns. (3-100 Î¼M), demonstrating a noncompetitive blocking action.  Parampanel did not alter the trajectory of AMPA evoked currents indicating that it does not influence AMPA receptor desensitization.  Perampanel is a selective neg. allosteric AMPA receptor antagonist of high-affinity and slow blocking kinetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrexa_W9wJuhrVg90H21EOLACvtfcHk0liD5asrl9_MwQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslShtrzO&md5=96e6d5c0631943ff7766830bd2db1d9d</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0108021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0108021%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%2BY.%26aulast%3DMatt%26aufirst%3DL.%26aulast%3DHell%26aufirst%3DJ.%2BW.%26aulast%3DRogawski%26aufirst%3DM.%2BA.%26atitle%3DPerampanel%2520inhibition%2520of%2520AMPA%2520receptor%2520currents%2520in%2520cultured%2520hippocampal%2520neurons%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26issue%3D9%26spage%3De108021%26doi%3D10.1371%2Fjournal.pone.0108021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stenum-Berg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abiega, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thisted, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kristensen, A. S.</span></span> <span> </span><span class="NLM_article-title">Identification and characterization of the binding pocket for negative allosteric modulators in AMPA receptors</span>. <i>Biophys. J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>112</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">418a</span>, <span class="refDoi">Â DOI: 10.1016/j.bpj.2016.11.2236</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.bpj.2016.11.2236" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2017&pages=418a&issue=3&author=C.+Stenum-Bergauthor=S.+C.+Abiegaauthor=C.+L.+Thistedauthor=A.+S.+Kristensen&title=Identification+and+characterization+of+the+binding+pocket+for+negative+allosteric+modulators+in+AMPA+receptors&doi=10.1016%2Fj.bpj.2016.11.2236"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1016%2Fj.bpj.2016.11.2236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bpj.2016.11.2236%26sid%3Dliteratum%253Aachs%26aulast%3DStenum-Berg%26aufirst%3DC.%26aulast%3DAbiega%26aufirst%3DS.%2BC.%26aulast%3DThisted%26aufirst%3DC.%2BL.%26aulast%3DKristensen%26aufirst%3DA.%2BS.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520the%2520binding%2520pocket%2520for%2520negative%2520allosteric%2520modulators%2520in%2520AMPA%2520receptors%26jtitle%3DBiophys.%2520J.%26date%3D2017%26volume%3D112%26issue%3D3%26spage%3D418a%26doi%3D10.1016%2Fj.bpj.2016.11.2236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MÃ¸llerud, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frydenvang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickering, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastrup, J. S.</span></span> <span> </span><span class="NLM_article-title">Lessons from crystal structures of kainate receptors</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">16</span>â <span class="NLM_lpage">28</span>, <span class="refDoi">Â DOI: 10.1016/j.neuropharm.2016.05.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.neuropharm.2016.05.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=27236079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252FksVWhsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2017&pages=16-28&author=S.+M%C3%B8llerudauthor=K.+Frydenvangauthor=D.+S.+Pickeringauthor=J.+S.+Kastrup&title=Lessons+from+crystal+structures+of+kainate+receptors&doi=10.1016%2Fj.neuropharm.2016.05.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons from crystal structures of kainate receptors</span></div><div class="casAuthors">Mollerud Stine; Frydenvang Karla; Pickering Darryl S; Kastrup Jette Sandholm</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">Pt A</span>),
    <span class="NLM_cas:pages">16-28</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Kainate receptors belong to the family of ionotropic glutamate receptors.  These receptors assemble from five subunits (GluK1-5) into tetrameric ion channels.  Kainate receptors are located at both pre- and postsynaptic membranes in the central nervous system where they contribute to excitatory synaptic transmission and modulate network excitability by regulating neurotransmitter release.  Dysfunction of kainate receptors has been implicated in several neurological disorders such as epilepsy, schizophrenia and depression.  Here we provide a review on the current understanding of kainate receptor structure and how they bind agonists, antagonists and ions.  The first structure of the ligand-binding domain of the GluK1 subunit was reported in 2005, seven years after publication of the crystal structure of a soluble construct of the ligand-binding domain of the AMPA-type subunit GluA2.  Today, a full-length structure has been determined of GluK2 by cryo electron microscopy to 7.6 ÃA resolution as well as 84 high-resolution crystal structures of N-terminal domains and ligand-binding domains, including agonist and antagonist bound structures, modulatory ions and mutations.  However, there are still many unanswered questions and challenges in front of us.  This article is part of the Special Issue entitled 'Ionotropic glutamate receptors'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSorFhi6dO1iNhSDZx9hyjKfW6udTcc2eZhF1jF_MD6ebntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252FksVWhsw%253D%253D&md5=7b98312e2ef8a69ecac23e2d2a045bb7</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2016.05.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2016.05.014%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25B8llerud%26aufirst%3DS.%26aulast%3DFrydenvang%26aufirst%3DK.%26aulast%3DPickering%26aufirst%3DD.%2BS.%26aulast%3DKastrup%26aufirst%3DJ.%2BS.%26atitle%3DLessons%2520from%2520crystal%2520structures%2520of%2520kainate%2520receptors%26jtitle%3DNeuropharmacology%26date%3D2017%26volume%3D112%26spage%3D16%26epage%3D28%26doi%3D10.1016%2Fj.neuropharm.2016.05.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">FiÃ¨vre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frydenvang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francotte, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirotte, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastrup, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulle, C.</span></span> <span> </span><span class="NLM_article-title">Identification and structure-function study of positive allosteric modulators of kainate receptors</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>91</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">576</span>â <span class="NLM_lpage">585</span>, <span class="refDoi">Â DOI: 10.1124/mol.116.107599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1124%2Fmol.116.107599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=28360094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Wlsrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2017&pages=576-585&issue=6&author=A.+P.+Larsenauthor=S.+Fi%C3%A8vreauthor=K.+Frydenvangauthor=P.+Francotteauthor=B.+Pirotteauthor=J.+S.+Kastrupauthor=C.+Mulle&title=Identification+and+structure-function+study+of+positive+allosteric+modulators+of+kainate+receptors&doi=10.1124%2Fmol.116.107599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and structure-function study of positive allosteric modulators of kainate receptors</span></div><div class="casAuthors">Larsen, Anja Probst; Fievre, Sabine; Frydenvang, Karla; Francotte, Pierre; Pirotte, Bernard; Kastrup, Jette Sandholm; Mulle, Christophe</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">576-585</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Kainate receptors (KARs) consist of a class of ionotropic glutamate receptors, which exert diverse pre- and postsynaptic functions through complex signaling regulating the activity of neural circuits.  Whereas numerous small-mol. pos. allosteric modulators of the ligand-binding domain of (S)-2- amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propanoic acid (AMPA) receptors have been reported, no such ligands are available for KARs.  In this study, we investigated the ability of three benzothiadiazine-based modulators to potentiate glutamate-evoked currents at recombinantly expressed KARs.  4-Cyclopropyl-7-fluoro-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide (BPAM344) potentiated glutamate-evoked currents of GluK2a 21-fold at the highest concn. tested (200 mM), with an EC50 of 79 mM.  BPAM344 markedly decreased desensitization kinetics (from 5.5 to 775 ms), whereas it only had a minor effect on deactivation kinetics.  4-Cyclopropyl-7-hydroxy-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide (BPAM521) potentiated the recorded peak current amplitude of GluK2a 12-fold at a concn. of 300 mM with an EC50 value of 159 mM, whereas no potentiation of the glutamate-evoked response was obsd. for 7-chloro-4-(2-fluoroethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine1,1-dioxide (BPAM121) at the highest concn. of modulator tested (300 mM).  BPAM344 (100 Î¼M) also potentiated the peak current amplitude of KAR subunits GluK3a (59-fold), GluK2a (15- fold), GluK1b (5-fold), as well as the AMPA receptor subunit GluA1i (5-fold).  X-ray structures of the three modulators in the GluK1 ligand-binding domain were detd., locating two modulator binding sites at the GluK1 dimer interface.  In conclusion, this study may enable the design of new pos. allosteric modulators selective for KARs, which will be of great interest for further investigation of the function of KARs in vivo and may prove useful for pharmacol. controlling the activity of neuronal networks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeApVTPg0Rt7Vg90H21EOLACvtfcHk0lhlua8pdxm6aw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Wlsrw%253D&md5=7df2c091dd2bc7f08ea441b166924ed3</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1124%2Fmol.116.107599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.116.107599%26sid%3Dliteratum%253Aachs%26aulast%3DLarsen%26aufirst%3DA.%2BP.%26aulast%3DFi%25C3%25A8vre%26aufirst%3DS.%26aulast%3DFrydenvang%26aufirst%3DK.%26aulast%3DFrancotte%26aufirst%3DP.%26aulast%3DPirotte%26aufirst%3DB.%26aulast%3DKastrup%26aufirst%3DJ.%2BS.%26aulast%3DMulle%26aufirst%3DC.%26atitle%3DIdentification%2520and%2520structure-function%2520study%2520of%2520positive%2520allosteric%2520modulators%2520of%2520kainate%2520receptors%26jtitle%3DMol.%2520Pharmacol.%26date%3D2017%26volume%3D91%26issue%3D6%26spage%3D576%26epage%3D585%26doi%3D10.1124%2Fmol.116.107599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutter, J.</span></span> <span> </span><span class="NLM_article-title">Whence cometh the allosterome?</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>103</i></span> (<span class="NLM_issue">28</span>),  <span class="NLM_fpage">10533</span>â <span class="NLM_lpage">10535</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0604452103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1073%2Fpnas.0604452103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=16818878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BD28XntFWnu7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=10533-10535&issue=28&author=J.+E.+Lindsleyauthor=J.+Rutter&title=Whence+cometh+the+allosterome%3F&doi=10.1073%2Fpnas.0604452103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Whence cometh the allosterome?</span></div><div class="casAuthors">Lindsley, Janet E.; Rutter, Jared</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">10533-10535</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">A review.  Regulation of cellular functions can be accomplished by many mechanisms, including transcriptional regulation, alternative splicing, translational regulation, phosphorylation and other posttranslational covalent modifications, degrdn., localization, protein-protein interactions, and small-mol. allosteric effectors.  Largely because of advances in the techniques of mol. biol. in the past few decades, our knowledge of regulation by most of these mechanisms has expanded enormously.  Regulation by small-mol., allosteric interactions is an exception.  Many of the best-known allosteric regulators were discovered decades ago, when we knew little about all of these other forms of regulation.  Allostery is the most direct, rapid, and efficient regulatory mechanism to sense changes in the concn. of small mols. and alter cellular responses to maintain homeostasis.  In this perspective, we present the argument that allosteric regulation is underappreciated in the systems biol. world and that many allosteric effectors remain to be discovered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkAICaQa4tBLVg90H21EOLACvtfcHk0lhlua8pdxm6aw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntFWnu7c%253D&md5=bc69a071dea38cc7d9ca74b0cfde472f</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0604452103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0604452103%26sid%3Dliteratum%253Aachs%26aulast%3DLindsley%26aufirst%3DJ.%2BE.%26aulast%3DRutter%26aufirst%3DJ.%26atitle%3DWhence%2520cometh%2520the%2520allosterome%253F%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26issue%3D28%26spage%3D10533%26epage%3D10535%26doi%3D10.1073%2Fpnas.0604452103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oswald, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, F. H.</span></span> <span> </span><span class="NLM_article-title">Applying structure-based drug design approaches to allosteric modulators of GPCRs</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">837</span>â <span class="NLM_lpage">847</span>, <span class="refDoi">Â DOI: 10.1016/j.tips.2017.05.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.tips.2017.05.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=28648526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVWrt7jE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2017&pages=837-847&issue=9&author=M.+Congreveauthor=C.+Oswaldauthor=F.+H.+Marshall&title=Applying+structure-based+drug+design+approaches+to+allosteric+modulators+of+GPCRs&doi=10.1016%2Fj.tips.2017.05.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Applying Structure-Based Drug Design Approaches to Allosteric Modulators of GPCRs</span></div><div class="casAuthors">Congreve, Miles; Oswald, Christine; Marshall, Fiona H.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">837-847</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Structural insights have been revealed from X-ray co-complexes of a range of G protein-coupled receptors (GPCRs) and their allosteric ligands.  The understanding of how small mols. can modulate the function of this important class of receptors by binding to a diverse range of pockets on and inside the proteins has had a profound impact on the structure-based drug design (SBDD) of new classes of therapeutic agents.  The types of allosteric pockets and the mode of modulation as well as the advantages and disadvantages of targeting allosteric pockets (as opposed to the natural orthosteric site) are considered in the context of these new structural findings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfYALhpSpc37Vg90H21EOLACvtfcHk0lhlua8pdxm6aw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVWrt7jE&md5=396af7b468f28376184c970ba72fe21f</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2017.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2017.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DOswald%26aufirst%3DC.%26aulast%3DMarshall%26aufirst%3DF.%2BH.%26atitle%3DApplying%2520structure-based%2520drug%2520design%2520approaches%2520to%2520allosteric%2520modulators%2520of%2520GPCRs%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2017%26volume%3D38%26issue%3D9%26spage%3D837%26epage%3D847%26doi%3D10.1016%2Fj.tips.2017.05.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moraes, I.</span></span> <span> </span><span class="NLM_article-title">Structural biology and structure-function relationships of membrane proteins</span>. <i>Biochem. Soc. Trans.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_fpage">BST20180269</span>, <span class="refDoi">Â DOI: 10.1042/BST20180269</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1042%2FBST20180269" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=30559269" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&pages=BST20180269&author=R.+Reisauthor=I.+Moraes&title=Structural+biology+and+structure-function+relationships+of+membrane+proteins&doi=10.1042%2FBST20180269"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1042%2FBST20180269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST20180269%26sid%3Dliteratum%253Aachs%26aulast%3DReis%26aufirst%3DR.%26aulast%3DMoraes%26aufirst%3DI.%26atitle%3DStructural%2520biology%2520and%2520structure-function%2520relationships%2520of%2520membrane%2520proteins%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2018%26spage%3DBST20180269%26doi%3D10.1042%2FBST20180269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baker, M.</span></span> <span> </span><span class="NLM_article-title">Making membrane proteins for structures: a trillion tiny tweaks</span>. <i>Nat. Methods</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">429</span>â <span class="NLM_lpage">434</span>, <span class="refDoi">Â DOI: 10.1038/nmeth0610-429</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fnmeth0610-429" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=20508636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmsF2it7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=429-434&issue=6&author=M.+Baker&title=Making+membrane+proteins+for+structures%3A+a+trillion+tiny+tweaks&doi=10.1038%2Fnmeth0610-429"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Making membrane proteins for structures: a trillion tiny tweaks</span></div><div class="casAuthors">Baker, Monya</div><div class="citationInfo"><span class="NLM_cas:title">Nature Methods</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">429-434</span>CODEN:
                <span class="NLM_cas:coden">NMAEA3</span>;
        ISSN:<span class="NLM_cas:issn">1548-7091</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review on multiple means to get high-quality membrane proteins for x-ray crystallog. and NMR spectroscopy studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU_8BLLqQ3SbVg90H21EOLACvtfcHk0lhwckxQlvrpdw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmsF2it7o%253D&md5=45cec959130da53eaf570f3767dd9087</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1038%2Fnmeth0610-429&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnmeth0610-429%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DM.%26atitle%3DMaking%2520membrane%2520proteins%2520for%2520structures%253A%2520a%2520trillion%2520tiny%2520tweaks%26jtitle%3DNat.%2520Methods%26date%3D2010%26volume%3D7%26issue%3D6%26spage%3D429%26epage%3D434%26doi%3D10.1038%2Fnmeth0610-429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bill, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunji, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neutze, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newstead, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poolman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tate, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, H.</span></span> <span> </span><span class="NLM_article-title">Overcoming barriers to membrane protein structure determination</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">335</span>â <span class="NLM_lpage">340</span>, <span class="refDoi">Â DOI: 10.1038/nbt.1833</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fnbt.1833" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=21478852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC3MXksVCkurY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=335-340&issue=4&author=R.+M.+Billauthor=P.+J.+Hendersonauthor=S.+Iwataauthor=E.+R.+Kunjiauthor=H.+Michelauthor=R.+Neutzeauthor=S.+Newsteadauthor=B.+Poolmanauthor=C.+G.+Tateauthor=H.+Vogel&title=Overcoming+barriers+to+membrane+protein+structure+determination&doi=10.1038%2Fnbt.1833"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming barriers to membrane protein structure determination</span></div><div class="casAuthors">Bill, Roslyn M.; Henderson, Peter J. F.; Iwata, So; Kunji, Edmund R. S.; Michel, Hartmut; Neutze, Richard; Newstead, Simon; Poolman, Bert; Tate, Christopher G.; Vogel, Horst</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">335-340</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  After decades of slow progress, the pace of research on membrane protein structures is beginning to quicken thanks to various improvements in technol., including protein engineering and microfocus X-ray diffraction.  Here we review these developments and, where possible, highlight generic new approaches to solving membrane protein structures based on recent technol. advances.  Rational approaches to overcoming the bottlenecks in the field are urgently required as membrane proteins, which typically comprise â¼30% of the proteomes of organisms, are dramatically under-represented in the structural database of the Protein Data Bank.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplLuk_M6X-RrVg90H21EOLACvtfcHk0lhwckxQlvrpdw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXksVCkurY%253D&md5=17cf34dfa2caeab434f940020f4c54e2</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1833&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1833%26sid%3Dliteratum%253Aachs%26aulast%3DBill%26aufirst%3DR.%2BM.%26aulast%3DHenderson%26aufirst%3DP.%2BJ.%26aulast%3DIwata%26aufirst%3DS.%26aulast%3DKunji%26aufirst%3DE.%2BR.%26aulast%3DMichel%26aufirst%3DH.%26aulast%3DNeutze%26aufirst%3DR.%26aulast%3DNewstead%26aufirst%3DS.%26aulast%3DPoolman%26aufirst%3DB.%26aulast%3DTate%26aufirst%3DC.%2BG.%26aulast%3DVogel%26aufirst%3DH.%26atitle%3DOvercoming%2520barriers%2520to%2520membrane%2520protein%2520structure%2520determination%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26issue%3D4%26spage%3D335%26epage%3D340%26doi%3D10.1038%2Fnbt.1833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bill, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jawhari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothnie, A. J.</span></span> <span> </span><span class="NLM_article-title">Overcoming bottlenecks in the membrane protein structural biology pipeline</span>. <i>Biochem. Soc. Trans.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">838</span>â <span class="NLM_lpage">844</span>, <span class="refDoi">Â DOI: 10.1042/BST20160049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1042%2FBST20160049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=27284049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC28Xps1Wmt7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=838-844&issue=3&author=D.+Hardyauthor=R.+M.+Billauthor=A.+Jawhariauthor=A.+J.+Rothnie&title=Overcoming+bottlenecks+in+the+membrane+protein+structural+biology+pipeline&doi=10.1042%2FBST20160049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming bottlenecks in the membrane protein structural biology pipeline</span></div><div class="casAuthors">Hardy, David; Bill, Roslyn M.; Jawhari, Anass; Rothnie, Alice J.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">838-844</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Membrane proteins account for a third of the eukaryotic proteome, but are greatly under-represented in the Protein Data Bank.  Unfortunately, recent technol. advances in X-ray crystallog. and EM cannot account for the poor soly. and stability of membrane protein samples.  A limitation of conventional detergent-based methods is that detergent mols. destabilize membrane proteins, leading to their aggregation.  The use of orthologues, mutants and fusion tags has helped improve protein stability, but at the expense of not working with the sequence of interest.  Novel detergents such as glucose neopentyl glycol (GNG), maltose neopentyl glycol (MNG) and calixarene-based detergents can improve protein stability without compromising their solubilizing properties.  Styrene maleic acid lipid particles (SMALPs) focus on retaining the native lipid bilayer of a membrane protein during purifn. and biophys. anal.  Overcoming bottlenecks in the membrane protein structural biol. pipeline, primarily by maintaining protein stability, will facilitate the elucidation of many more membrane protein structures in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqK0zW9Wt0KurVg90H21EOLACvtfcHk0lhwckxQlvrpdw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xps1Wmt7c%253D&md5=f10ec64f172fb2f9954c8476f5ef6473</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1042%2FBST20160049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST20160049%26sid%3Dliteratum%253Aachs%26aulast%3DHardy%26aufirst%3DD.%26aulast%3DBill%26aufirst%3DR.%2BM.%26aulast%3DJawhari%26aufirst%3DA.%26aulast%3DRothnie%26aufirst%3DA.%2BJ.%26atitle%3DOvercoming%2520bottlenecks%2520in%2520the%2520membrane%2520protein%2520structural%2520biology%2520pipeline%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2016%26volume%3D44%26issue%3D3%26spage%3D838%26epage%3D844%26doi%3D10.1042%2FBST20160049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. W.</span></span> <span> </span><span class="NLM_article-title">How cryo-electron microscopy and X-ray crystallography complement each other</span>. <i>Protein Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">32</span>â <span class="NLM_lpage">39</span>, <span class="refDoi">Â DOI: 10.1002/pro.3022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1002%2Fpro.3022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=27543495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOmur3P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2017&pages=32-39&issue=1&author=H.+W.+Wangauthor=J.+W.+Wang&title=How+cryo-electron+microscopy+and+X-ray+crystallography+complement+each+other&doi=10.1002%2Fpro.3022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">How Cryo-Electron Microscopy and X-ray Crystallography Complement Each Other</span></div><div class="casAuthors">Wang, Hong-Wei; Wang, Jia-Wei</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-39</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">1469-896X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">With the ability to resolve structures of macromols. at at. resoln., X-ray crystallog. has been the most powerful tool in modern structural biol.  At the same time, recent tech. improvements have triggered a resoln. revolution in the single particle cryo-EM method.  While the two methods are different in many respects, from sample prepn. to structure detn., they both have the power to solve macromol. structures at at. resoln.  It is important to understand the unique advantages and caveats of the two methods in solving structures and to appreciate the complementary nature of the two methods in structural biol.  In this review we provide some examples, and discuss how X-ray crystallog. and cryo-EM can be combined in deciphering structures of macromols. for our full understanding of their biol. mechanisms.  This article is protected by copyright.  All rights reserved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzL3Iy4EWUqbVg90H21EOLACvtfcHk0lj4kS0kgFHXAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOmur3P&md5=d67669a793d965772c2b657f56ab79a8</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1002%2Fpro.3022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpro.3022%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%2BW.%26aulast%3DWang%26aufirst%3DJ.%2BW.%26atitle%3DHow%2520cryo-electron%2520microscopy%2520and%2520X-ray%2520crystallography%2520complement%2520each%2520other%26jtitle%3DProtein%2520Sci.%26date%3D2017%26volume%3D26%26issue%3D1%26spage%3D32%26epage%3D39%26doi%3D10.1002%2Fpro.3022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masiulis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Colibus, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steyaert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aricescu, A. R.</span></span> <span> </span><span class="NLM_article-title">Structural basis for GABAA receptor potentiation by neurosteroids</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">986</span>â <span class="NLM_lpage">992</span>, <span class="refDoi">Â DOI: 10.1038/nsmb.3484</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fnsmb.3484" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=28991263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1aisrzM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=986-992&issue=11&author=P.+S.+Millerauthor=S.+Scottauthor=S.+Masiulisauthor=L.+De+Colibusauthor=E.+Pardonauthor=J.+Steyaertauthor=A.+R.+Aricescu&title=Structural+basis+for+GABAA+receptor+potentiation+by+neurosteroids&doi=10.1038%2Fnsmb.3484"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for GABAA receptor potentiation by neurosteroids</span></div><div class="casAuthors">Miller, Paul S.; Scott, Suzanne; Masiulis, Simonas; De Colibus, Luigi; Pardon, Els; Steyaert, Jan; Aricescu, A. Radu</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">986-992</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Type A Î³-aminobutyric acid receptors (GABAARs) are the principal mediators of inhibitory neurotransmission in the human brain.  Endogenous neurosteroids interact with GABAARs to regulate acute and chronic anxiety and are potent sedative, analgesic, anticonvulsant and anesthetic agents.  Their mode of binding and mechanism of receptor potentiation, however, remain unknown.  Here we report crystal structures of a chimeric GABAAR construct in apo and pregnanolone-bound states.  The neurosteroid-binding site is mech. coupled to the helixes lining the ion channel pore and modulates the desensitization-gate conformation.  We demonstrate that the equiv. site is responsible for physiol., heteromeric GABAAR potentiation and explain the contrasting modulatory properties of 3a vs. 3b neurosteroid epimers.  These results illustrate how peripheral lipid ligands can regulate the desensitization gate of GABAARs, a process of broad relevance to pentameric ligand-gated ion channels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_rFOSeRpWIrVg90H21EOLACvtfcHk0lj4kS0kgFHXAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1aisrzM&md5=8587877033cb81d7bc285fcdc5c62e86</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.3484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.3484%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DP.%2BS.%26aulast%3DScott%26aufirst%3DS.%26aulast%3DMasiulis%26aufirst%3DS.%26aulast%3DDe%2BColibus%26aufirst%3DL.%26aulast%3DPardon%26aufirst%3DE.%26aulast%3DSteyaert%26aufirst%3DJ.%26aulast%3DAricescu%26aufirst%3DA.%2BR.%26atitle%3DStructural%2520basis%2520for%2520GABAA%2520receptor%2520potentiation%2520by%2520neurosteroids%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2017%26volume%3D24%26issue%3D11%26spage%3D986%26epage%3D992%26doi%3D10.1038%2Fnsmb.3484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noviello, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, R. M.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hibbs, R. E.</span></span> <span> </span><span class="NLM_article-title">Structure of a human synaptic GABA<sub>A</sub> receptor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>559</i></span> (<span class="NLM_issue">7712</span>),  <span class="NLM_fpage">67</span>â <span class="NLM_lpage">72</span>, <span class="refDoi">Â DOI: 10.1038/s41586-018-0255-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fs41586-018-0255-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=29950725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1eisrzE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=559&publication_year=2018&pages=67-72&issue=7712&author=S.+Zhuauthor=C.+M.+Novielloauthor=J.+Tengauthor=R.+M.+Walshauthor=J.+J.+Kimauthor=R.+E.+Hibbs&title=Structure+of+a+human+synaptic+GABAA+receptor&doi=10.1038%2Fs41586-018-0255-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of a human synaptic GABAA receptor</span></div><div class="casAuthors">Zhu, Shaotong; Noviello, Colleen M.; Teng, Jinfeng; Walsh, Richard M., Jr.; Kim, Jeong Joo; Hibbs, Ryan E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">559</span>
        (<span class="NLM_cas:issue">7712</span>),
    <span class="NLM_cas:pages">67-72</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Fast inhibitory neurotransmission in the brain is principally mediated by the neurotransmitter GABA (Î³-aminobutyric acid) and its synaptic target, the type A GABA receptor (GABAA receptor).  Dysfunction of this receptor results in neurol. disorders and mental illnesses including epilepsy, anxiety and insomnia.  The GABAA receptor is also a prolific target for therapeutic, illicit and recreational drugs, including benzodiazepines, barbiturates, anesthetics and ethanol.  Here we present high-resoln. cryo-electron microscopy structures of the human Î±1Î²2Î³2 GABAA receptor, the predominant isoform in the adult brain, in complex with GABA and the benzodiazepine site antagonist flumazenil, the first-line clin. treatment for benzodiazepine overdose.  The receptor architecture reveals unique heteromeric interactions for this important class of inhibitory neurotransmitter receptor.  This work provides a template for understanding receptor modulation by GABA and benzodiazepines, and will assist rational approaches to therapeutic targeting of this receptor for neurol. disorders and mental illness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyjjS2mR9GnrVg90H21EOLACvtfcHk0lj4kS0kgFHXAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1eisrzE&md5=821bc718642c7b52811846149f696097</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1038%2Fs41586-018-0255-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-018-0255-3%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DS.%26aulast%3DNoviello%26aufirst%3DC.%2BM.%26aulast%3DTeng%26aufirst%3DJ.%26aulast%3DWalsh%26aufirst%3DR.%2BM.%26aulast%3DKim%26aufirst%3DJ.%2BJ.%26aulast%3DHibbs%26aufirst%3DR.%2BE.%26atitle%3DStructure%2520of%2520a%2520human%2520synaptic%2520GABAA%2520receptor%26jtitle%3DNature%26date%3D2018%26volume%3D559%26issue%3D7712%26spage%3D67%26epage%3D72%26doi%3D10.1038%2Fs41586-018-0255-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hackos, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupardus, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grand, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallweber, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volgraf, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paoletti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, J. E.</span></span> <span> </span><span class="NLM_article-title">Positive allosteric modulators of GluN2A-containing NMDARs with distinct modes of action and impacts on circuit function</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>89</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">983</span>â <span class="NLM_lpage">999</span>, <span class="refDoi">Â DOI: 10.1016/j.neuron.2016.01.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.neuron.2016.01.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=26875626" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC28XisFSrtbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2016&pages=983-999&issue=5&author=D.+H.+Hackosauthor=P.+J.+Lupardusauthor=T.+Grandauthor=Y.+Chenauthor=T.+M.+Wangauthor=P.+Reynenauthor=A.+Gustafsonauthor=H.+J.+Wallweberauthor=M.+Volgrafauthor=B.+D.+Sellersauthor=J.+B.+Schwarzauthor=P.+Paolettiauthor=M.+Shengauthor=Q.+Zhouauthor=J.+E.+Hanson&title=Positive+allosteric+modulators+of+GluN2A-containing+NMDARs+with+distinct+modes+of+action+and+impacts+on+circuit+function&doi=10.1016%2Fj.neuron.2016.01.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Positive Allosteric Modulators of GluN2A-Containing NMDARs with Distinct Modes of Action and Impacts on Circuit Function</span></div><div class="casAuthors">Hackos, David H.; Lupardus, Patrick J.; Grand, Teddy; Chen, Yelin; Wang, Tzu-Ming; Reynen, Paul; Gustafson, Amy; Wallweber, Heidi J. A.; Volgraf, Matthew; Sellers, Benjamin D.; Schwarz, Jacob B.; Paoletti, Pierre; Sheng, Morgan; Zhou, Qiang; Hanson, Jesse E.</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">983-999</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">To enhance physiol. function of NMDA receptors (NMDARs), we identified pos. allosteric modulators (PAMs) of NMDARs with selectivity for GluN2A subunit-contg. receptors.  X-ray crystallog. revealed a binding site at the GluN1-GluN2A dimer interface of the extracellular ligand-binding domains (LBDs).  Despite the similarity between the LBDs of NMDARs and AMPA receptors (AMPARs), GluN2A PAMs with good selectivity against AMPARs were identified.  Potentiation was obsd. with recombinant triheteromeric GluN1/GluN2A/GluN2B NMDARs and with synaptically activated NMDARs in brain slices from wild-type (WT), but not GluN2A knockout (KO), mice.  Individual GluN2A PAMs exhibited variable degrees of glutamate (Glu) dependence, impact on NMDAR Glu EC50, and slowing of channel deactivation.  These distinct PAMs also exhibited differential impacts during synaptic plasticity induction.  The identification of a new NMDAR modulatory site and characterization of GluN2A-selective PAMs provide powerful mol. tools to dissect NMDAR function and demonstrate the feasibility of a therapeutically desirable type of NMDAR enhancement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGros48fNAsozLVg90H21EOLACvtfcHk0lj4kS0kgFHXAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisFSrtbw%253D&md5=38661a9f898df39ba616e77f0bdf34e9</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1016%2Fj.neuron.2016.01.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuron.2016.01.016%26sid%3Dliteratum%253Aachs%26aulast%3DHackos%26aufirst%3DD.%2BH.%26aulast%3DLupardus%26aufirst%3DP.%2BJ.%26aulast%3DGrand%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DT.%2BM.%26aulast%3DReynen%26aufirst%3DP.%26aulast%3DGustafson%26aufirst%3DA.%26aulast%3DWallweber%26aufirst%3DH.%2BJ.%26aulast%3DVolgraf%26aufirst%3DM.%26aulast%3DSellers%26aufirst%3DB.%2BD.%26aulast%3DSchwarz%26aufirst%3DJ.%2BB.%26aulast%3DPaoletti%26aufirst%3DP.%26aulast%3DSheng%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DHanson%26aufirst%3DJ.%2BE.%26atitle%3DPositive%2520allosteric%2520modulators%2520of%2520GluN2A-containing%2520NMDARs%2520with%2520distinct%2520modes%2520of%2520action%2520and%2520impacts%2520on%2520circuit%2520function%26jtitle%3DNeuron%26date%3D2016%26volume%3D89%26issue%3D5%26spage%3D983%26epage%3D999%26doi%3D10.1016%2Fj.neuron.2016.01.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupardus, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallweber, H. J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volgraf, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackos, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, J. E.</span></span> <span> </span><span class="NLM_article-title">A novel NMDA receptor positive allosteric modulator that acts via the transmembrane domain</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">204</span>â <span class="NLM_lpage">218</span>, <span class="refDoi">Â DOI: 10.1016/j.neuropharm.2017.04.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.neuropharm.2017.04.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=28457974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnsFentLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2017&pages=204-218&author=T.+M.+Wangauthor=B.+M.+Brownauthor=L.+Dengauthor=B.+D.+Sellersauthor=P.+J.+Lupardusauthor=H.+J.+A.+Wallweberauthor=A.+Gustafsonauthor=E.+Wongauthor=M.+Volgrafauthor=J.+B.+Schwarzauthor=D.+H.+Hackosauthor=J.+E.+Hanson&title=A+novel+NMDA+receptor+positive+allosteric+modulator+that+acts+via+the+transmembrane+domain&doi=10.1016%2Fj.neuropharm.2017.04.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">A novel NMDA receptor positive allosteric modulator that acts via the transmembrane domain</span></div><div class="casAuthors">Wang, Tzu-Ming; Brown, Brandon M.; Deng, Lunbin; Sellers, Benjamin D.; Lupardus, Patrick J.; Wallweber, Heidi J. A.; Gustafson, Amy; Wong, Evera; Volgraf, Matthew; Schwarz, Jacob B.; Hackos, David H.; Hanson, Jesse E.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">204-218</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Ionotropic glutamate receptors (iGluRs) mediate fast excitatory neurotransmission and are key nervous system drug targets.  While diverse pharmacol. tools have yielded insight into iGluR extracellular domain function, less is known about mol. mechanisms underlying the ion conduction gating process within the transmembrane domain (TMD).  We have discovered a novel NMDAR pos. allosteric modulator (PAM), GNE-9278, with a unique binding site on the extracellular surface of the TMD.  Mutation of a single residue near the Lurcher motif on GluN1 M3 can convert GNE-9278 modulation from pos. to neg., and replacing three AMPAR pre-M1 residues with corresponding NMDAR residues can confer GNE-9278 sensitivity to AMPARs.  Modulation by GNE-9278 is state-dependent and significantly alters extracellular domain pharmacol.  The unique properties and structural determinants of GNE-9278 reveal new modulatory potential of the iGluR TMD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlpDlNo3PXSrVg90H21EOLACvtfcHk0lgojZK8qhRHFA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnsFentLk%253D&md5=e868c18884abbb5c63de5adb5873660c</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2017.04.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2017.04.041%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%2BM.%26aulast%3DBrown%26aufirst%3DB.%2BM.%26aulast%3DDeng%26aufirst%3DL.%26aulast%3DSellers%26aufirst%3DB.%2BD.%26aulast%3DLupardus%26aufirst%3DP.%2BJ.%26aulast%3DWallweber%26aufirst%3DH.%2BJ.%2BA.%26aulast%3DGustafson%26aufirst%3DA.%26aulast%3DWong%26aufirst%3DE.%26aulast%3DVolgraf%26aufirst%3DM.%26aulast%3DSchwarz%26aufirst%3DJ.%2BB.%26aulast%3DHackos%26aufirst%3DD.%2BH.%26aulast%3DHanson%26aufirst%3DJ.%2BE.%26atitle%3DA%2520novel%2520NMDA%2520receptor%2520positive%2520allosteric%2520modulator%2520that%2520acts%2520via%2520the%2520transmembrane%2520domain%26jtitle%3DNeuropharmacology%26date%3D2017%26volume%3D121%26spage%3D204%26epage%3D218%26doi%3D10.1016%2Fj.neuropharm.2017.04.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Volgraf, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ly, C. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villemure, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastor, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuen, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupardus, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallweber, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liederer, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plise, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrington, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dirksen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietz, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scearce-Levie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, J. B.</span></span> <span> </span><span class="NLM_article-title">Discovery of GluN2A-selective NMDA receptor positive allosteric modulators (PAMs): tuning deactivation kinetics via structure-based design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2760</span>â <span class="NLM_lpage">2779</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b02010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b02010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjt1ynt70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2760-2779&issue=6&author=M.+Volgrafauthor=B.+D.+Sellersauthor=Y.+Jiangauthor=G.+Wuauthor=C.+Q.+Lyauthor=E.+Villemureauthor=R.+M.+Pastorauthor=P.+W.+Yuenauthor=A.+Luauthor=X.+Luoauthor=M.+Liuauthor=S.+Zhangauthor=L.+Sunauthor=Y.+Fuauthor=P.+J.+Lupardusauthor=H.+J.+Wallweberauthor=B.+M.+Liedererauthor=G.+Deshmukhauthor=E.+Pliseauthor=S.+Tayauthor=P.+Reynenauthor=J.+Herringtonauthor=A.+Gustafsonauthor=Y.+Liuauthor=A.+Dirksenauthor=M.+G.+Dietzauthor=Y.+Liuauthor=T.+M.+Wangauthor=J.+E.+Hansonauthor=D.+Hackosauthor=K.+Scearce-Levieauthor=J.+B.+Schwarz&title=Discovery+of+GluN2A-selective+NMDA+receptor+positive+allosteric+modulators+%28PAMs%29%3A+tuning+deactivation+kinetics+via+structure-based+design&doi=10.1021%2Facs.jmedchem.5b02010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of GluN2A-Selective NMDA Receptor Positive Allosteric Modulators (PAMs): Tuning Deactivation Kinetics via Structure-Based Design</span></div><div class="casAuthors">Volgraf, Matthew; Sellers, Benjamin D.; Jiang, Yu; Wu, Guosheng; Ly, Cuong Q.; Villemure, Elisia; Pastor, Richard M.; Yuen, Po-wai; Lu, Aijun; Luo, Xifeng; Liu, Mingcui; Zhang, Shun; Sun, Liang; Fu, Yuhong; Lupardus, Patrick J.; Wallweber, Heidi J. A.; Liederer, Bianca M.; Deshmukh, Gauri; Plise, Emile; Tay, Suzanne; Reynen, Paul; Herrington, James; Gustafson, Amy; Liu, Yichin; Dirksen, Akim; Dietz, Matthias G. A.; Liu, Yanzhou; Wang, Tzu-Ming; Hanson, Jesse E.; Hackos, David; Scearce-Levie, Kimberly; Schwarz, Jacob B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2760-2779</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The N-methyl-D-aspartate receptor (NMDAR) is a Na+ and Ca2+ permeable ionotropic glutamate receptor that is activated by the coagonists glycine and glutamate.  NMDARs are crit. to synaptic signaling and plasticity, and their dysfunction has been implicated in a no. of neurol. disorders, including schizophrenia, depression, and Alzheimer's disease.  Herein we describe the discovery of potent GluN2A-selective NMDAR pos. allosteric modulators (PAMs) starting from a high-throughput screening hit.  Using structure-based design, we sought to increase potency at the GluN2A subtype, while improving selectivity against related Î±-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs).  The structure-activity relationship of channel deactivation kinetics was studied using a combination of electrophysiol. and protein crystallog.  Effective incorporation of these strategies resulted in the discovery of GNE-0723 (46), a highly potent and brain penetrant GluN2A-selective NMDAR PAM suitable for in vivo characterization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdza-qdjBnZbVg90H21EOLACvtfcHk0lgojZK8qhRHFA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjt1ynt70%253D&md5=2d9f7199cd3d9d9ac513006612e9bb01</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b02010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b02010%26sid%3Dliteratum%253Aachs%26aulast%3DVolgraf%26aufirst%3DM.%26aulast%3DSellers%26aufirst%3DB.%2BD.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DLy%26aufirst%3DC.%2BQ.%26aulast%3DVillemure%26aufirst%3DE.%26aulast%3DPastor%26aufirst%3DR.%2BM.%26aulast%3DYuen%26aufirst%3DP.%2BW.%26aulast%3DLu%26aufirst%3DA.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DFu%26aufirst%3DY.%26aulast%3DLupardus%26aufirst%3DP.%2BJ.%26aulast%3DWallweber%26aufirst%3DH.%2BJ.%26aulast%3DLiederer%26aufirst%3DB.%2BM.%26aulast%3DDeshmukh%26aufirst%3DG.%26aulast%3DPlise%26aufirst%3DE.%26aulast%3DTay%26aufirst%3DS.%26aulast%3DReynen%26aufirst%3DP.%26aulast%3DHerrington%26aufirst%3DJ.%26aulast%3DGustafson%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DDirksen%26aufirst%3DA.%26aulast%3DDietz%26aufirst%3DM.%2BG.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DT.%2BM.%26aulast%3DHanson%26aufirst%3DJ.%2BE.%26aulast%3DHackos%26aufirst%3DD.%26aulast%3DScearce-Levie%26aufirst%3DK.%26aulast%3DSchwarz%26aufirst%3DJ.%2BB.%26atitle%3DDiscovery%2520of%2520GluN2A-selective%2520NMDA%2520receptor%2520positive%2520allosteric%2520modulators%2520%2528PAMs%2529%253A%2520tuning%2520deactivation%2520kinetics%2520via%2520structure-based%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D6%26spage%3D2760%26epage%3D2779%26doi%3D10.1021%2Facs.jmedchem.5b02010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christopher, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OrgovÃ¡n, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DorÃ©, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Errey, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okrasa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rucktooa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano-Vega, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferenczy, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">KeserÅ±, G. M.</span></span> <span> </span><span class="NLM_article-title">Structure-based optimization strategies for G protein-coupled receptor (GPCR) allosteric modulators: a case study from analyses of new metabotropic glutamate receptor 5 (mGlu5) x-ray structures</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">207</span>â <span class="NLM_lpage">222</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b01722</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01722" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFCnt70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=207-222&issue=1&author=J.+A.+Christopherauthor=Z.+Orgov%C3%A1nauthor=M.+Congreveauthor=A.+S.+Dor%C3%A9author=J.+C.+Erreyauthor=F.+H.+Marshallauthor=J.+S.+Masonauthor=K.+Okrasaauthor=P.+Rucktooaauthor=M.+J.+Serrano-Vegaauthor=G.+G.+Ferenczyauthor=G.+M.+Keser%C5%B1&title=Structure-based+optimization+strategies+for+G+protein-coupled+receptor+%28GPCR%29+allosteric+modulators%3A+a+case+study+from+analyses+of+new+metabotropic+glutamate+receptor+5+%28mGlu5%29+x-ray+structures&doi=10.1021%2Facs.jmedchem.7b01722"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Optimization Strategies for G Protein-Coupled Receptor (GPCR) Allosteric Modulators: A Case Study from Analyses of New Metabotropic Glutamate Receptor 5 (mGlu5) X-ray Structures</span></div><div class="casAuthors">Christopher, John A.; Orgovan, Zoltan; Congreve, Miles; Dore, Andrew S.; Errey, James C.; Marshall, Fiona H.; Mason, Jonathan S.; Okrasa, Krzysztof; Rucktooa, Prakash; Serrano-Vega, Maria J.; Ferenczy, Gyorgy G.; Keseru, Gyorgy M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">207-222</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two interesting new X-ray structures of neg. allosteric modulator (NAM) ligands for the mGlu5 receptor, M-MPEP (3) and fenobam (4), are reported.  The new structures show how the binding of the ligands induces different receptor water channel conformations to previously published structures.  The structure of fenobam, where a urea replaces the acetylenic linker in M-MPEP and mavoglurant, reveals a binding mode where the ligand is rotated by 180Â° compared to a previously proposed docking model.  The need for multiple ligand structures for accurate GPCR structure-based drug design is demonstrated by the different growing vectors identified for the head groups of M-MPEP and mavoglurant and by the unexpected water-mediated receptor interactions of a new chemotype represented by fenobam.  The implications of the new structures for ligand design are discussed, with extensive anal. of the energetics of the water networks of both pseudoapo and bound structures providing a new design strategy for allosteric modulators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEggCq8N6KILVg90H21EOLACvtfcHk0ljcUj-Qq_r1fw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFCnt70%253D&md5=6ba235f3016b0637cd17dce6cffe0d14</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01722%26sid%3Dliteratum%253Aachs%26aulast%3DChristopher%26aufirst%3DJ.%2BA.%26aulast%3DOrgov%25C3%25A1n%26aufirst%3DZ.%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DDor%25C3%25A9%26aufirst%3DA.%2BS.%26aulast%3DErrey%26aufirst%3DJ.%2BC.%26aulast%3DMarshall%26aufirst%3DF.%2BH.%26aulast%3DMason%26aufirst%3DJ.%2BS.%26aulast%3DOkrasa%26aufirst%3DK.%26aulast%3DRucktooa%26aufirst%3DP.%26aulast%3DSerrano-Vega%26aufirst%3DM.%2BJ.%26aulast%3DFerenczy%26aufirst%3DG.%2BG.%26aulast%3DKeser%25C5%25B1%26aufirst%3DG.%2BM.%26atitle%3DStructure-based%2520optimization%2520strategies%2520for%2520G%2520protein-coupled%2520receptor%2520%2528GPCR%2529%2520allosteric%2520modulators%253A%2520a%2520case%2520study%2520from%2520analyses%2520of%2520new%2520metabotropic%2520glutamate%2520receptor%25205%2520%2528mGlu5%2529%2520x-ray%2520structures%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D1%26spage%3D207%26epage%3D222%26doi%3D10.1021%2Facs.jmedchem.7b01722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anighoro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graziani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettinelli, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cilia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Toma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longhi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangiarotti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menegon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirona, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poggesi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riva, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rastelli, G.</span></span> <span> </span><span class="NLM_article-title">Insights into the interaction of negative allosteric modulators with the metabotropic glutamate receptor 5: discovery and computational modeling of a new series of ligands with nanomolar affinity</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3040</span>â <span class="NLM_lpage">3058</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2015.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.bmc.2015.05.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=26014480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotlGrsbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=3040-3058&author=A.+Anighoroauthor=D.+Grazianiauthor=I.+Bettinelliauthor=A.+Ciliaauthor=C.+De+Tomaauthor=M.+Longhiauthor=F.+Mangiarottiauthor=S.+Menegonauthor=L.+Pironaauthor=E.+Poggesiauthor=C.+Rivaauthor=G.+Rastelli&title=Insights+into+the+interaction+of+negative+allosteric+modulators+with+the+metabotropic+glutamate+receptor+5%3A+discovery+and+computational+modeling+of+a+new+series+of+ligands+with+nanomolar+affinity&doi=10.1016%2Fj.bmc.2015.05.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into the interaction of negative allosteric modulators with the metabotropic glutamate receptor 5: Discovery and computational modeling of a new series of ligands with nanomolar affinity</span></div><div class="casAuthors">Anighoro, Andrew; Graziani, Davide; Bettinelli, Ilaria; Cilia, Antonio; De Toma, Carlo; Longhi, Matteo; Mangiarotti, Fabio; Menegon, Sergio; Pirona, Lorenza; Poggesi, Elena; Riva, Carlo; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3040-3058</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Metabotropic glutamate receptor 5 (mGlu5) is a biol. target implicated in major neurol. and psychiatric disorders.  In the present study, we have investigated structural determinants of the interaction of neg. allosteric modulators (NAMs) with the seven-transmembrane (7TM) domain of mGlu5.  A homol. model of the 7TM receptor domain built on the crystal structure of the mGlu1 template was obtained, and the binding modes of known NAMs, namely MPEP and fenobam, were investigated by docking and mol. dynamics simulations.  The results were validated by comparison with mutagenesis data available in the literature for these two ligands, and subsequently corroborated by the recently described mGlu5 crystal structure.  Moreover, a new series of NAMs was synthesized and tested, providing compds. with nanomolar affinity.  Several structural modifications were sequentially introduced with the aim of identifying structural features important for receptor binding.  The synthesized NAMs were docked in the validated homol. model and binding modes were used to interpret and discuss structure-activity relationships within this new series of compds.  Finally, the models of the interaction of NAMs with mGlu5 were extended to include important non-aryl alkyne mGlu5 NAMs taken from the literature.  Overall, the results provide useful insights into the mol. interaction of neg. allosteric modulators with mGlu5 and may facilitate the design of new modulators for this class of receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8hEyrYvgTFbVg90H21EOLACvtfcHk0ljcUj-Qq_r1fw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotlGrsbg%253D&md5=829cd7eced83a48dcd216a1afa490cc7</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DAnighoro%26aufirst%3DA.%26aulast%3DGraziani%26aufirst%3DD.%26aulast%3DBettinelli%26aufirst%3DI.%26aulast%3DCilia%26aufirst%3DA.%26aulast%3DDe%2BToma%26aufirst%3DC.%26aulast%3DLonghi%26aufirst%3DM.%26aulast%3DMangiarotti%26aufirst%3DF.%26aulast%3DMenegon%26aufirst%3DS.%26aulast%3DPirona%26aufirst%3DL.%26aulast%3DPoggesi%26aufirst%3DE.%26aulast%3DRiva%26aufirst%3DC.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DInsights%2520into%2520the%2520interaction%2520of%2520negative%2520allosteric%2520modulators%2520with%2520the%2520metabotropic%2520glutamate%2520receptor%25205%253A%2520discovery%2520and%2520computational%2520modeling%2520of%2520a%2520new%2520series%2520of%2520ligands%2520with%2520nanomolar%2520affinity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D3040%26epage%3D3058%26doi%3D10.1016%2Fj.bmc.2015.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dosa, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amin, E. A.</span></span> <span> </span><span class="NLM_article-title">Tactical approaches to interconverting GPCR agonists and antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">810</span>â <span class="NLM_lpage">840</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00982</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00982" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFamsr7P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=810-840&issue=3&author=P.+I.+Dosaauthor=E.+A.+Amin&title=Tactical+approaches+to+interconverting+GPCR+agonists+and+antagonists&doi=10.1021%2Facs.jmedchem.5b00982"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Tactical Approaches to Interconverting GPCR Agonists and Antagonists</span></div><div class="casAuthors">Dosa, Peter I.; Amin, Elizabeth Ambrose</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">810-840</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There are many reported examples of small structural modifications to GPCR-targeted ligands leading to major changes in their functional activity, converting agonists into antagonists or vice versa.  These shifts in functional activity are often accompanied by negligible changes in binding affinity.  The current perspective focuses on outlining and analyzing various approaches that have been used to interconvert GPCR agonists, partial agonists, and antagonists in order to achieve the intended functional activity at a GPCR of therapeutic interest.  An improved understanding of specific structural modifications that are likely to alter the functional activity of a GPCR ligand may be of use to researchers designing GPCR-targeted drugs and/or probe compds., specifically in cases where a particular ligand exhibits good potency but not the preferred functional activity at the GPCR of choice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohWg2-DQHq3LVg90H21EOLACvtfcHk0ljcUj-Qq_r1fw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFamsr7P&md5=99ffc0b892eb9c10aaf5d52a7d5dd8bc</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00982%26sid%3Dliteratum%253Aachs%26aulast%3DDosa%26aufirst%3DP.%2BI.%26aulast%3DAmin%26aufirst%3DE.%2BA.%26atitle%3DTactical%2520approaches%2520to%2520interconverting%2520GPCR%2520agonists%2520and%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D3%26spage%3D810%26epage%3D840%26doi%3D10.1021%2Facs.jmedchem.5b00982" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">PiÃ±eyro, G.</span></span> <span> </span><span class="NLM_article-title">Membrane signalling complexes: implications for development of functionally selective ligands modulating heptahelical receptor signalling</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">179</span>â <span class="NLM_lpage">185</span>, <span class="refDoi">Â DOI: 10.1016/j.cellsig.2008.08.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.cellsig.2008.08.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=18790047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFamtLfJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2009&pages=179-185&issue=2&author=G.+Pi%C3%B1eyro&title=Membrane+signalling+complexes%3A+implications+for+development+of+functionally+selective+ligands+modulating+heptahelical+receptor+signalling&doi=10.1016%2Fj.cellsig.2008.08.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Membrane signalling complexes: Implications for development of functionally selective ligands modulating heptahelical receptor signalling</span></div><div class="casAuthors">Pineyro, Graciela</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-185</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Technol. development has considerably changed the way in which we evaluate drug efficacy and has led to a conceptual revolution in pharmacol. theory.  In particular, mol. resoln. assays have revealed that heptahelical receptors may adopt multiple active conformations with unique signalling properties.  It is therefore becoming widely accepted that ligand ability to stabilize receptor conformations with distinct signalling profiles may allow to direct the stimulus generated by an activated receptor towards a specific signalling pathway.  This capacity to induce only a subset of the ensemble of responses regulated by a given receptor has been termed "functional selectivity" (or "stimulus trafficking"), and provides the bases for a highly specific regulation of receptor signalling.  Concomitant with these observations, heptahelical receptors have been shown to assoc. with G proteins and effectors to form multimeric arrays.  These complexes are constitutively formed during protein synthesis and are targeted to the cell surface as integral signalling units.  Herein we summarize evidence supporting the existence of such constitutive signalling arrays and analyze the possibility that they may constitute viable targets for developing ligands with "functional selectivity".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFyV0hMr8DT7Vg90H21EOLACvtfcHk0lg5GgU-0M2ZIQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFamtLfJ&md5=8e448db53eab5dd57c6e8c55f025bf54</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2008.08.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2008.08.013%26sid%3Dliteratum%253Aachs%26aulast%3DPi%25C3%25B1eyro%26aufirst%3DG.%26atitle%3DMembrane%2520signalling%2520complexes%253A%2520implications%2520for%2520development%2520of%2520functionally%2520selective%2520ligands%2520modulating%2520heptahelical%2520receptor%2520signalling%26jtitle%3DCell.%2520Signalling%26date%3D2009%26volume%3D21%26issue%3D2%26spage%3D179%26epage%3D185%26doi%3D10.1016%2Fj.cellsig.2008.08.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klein Herenbrink, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sykes, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donthamsetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canals, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coudrat, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shonberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scammells, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuano, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span> <span> </span><span class="NLM_article-title">The role of kinetic context in apparent biased agonism at GPCRs</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">10842</span>, <span class="refDoi">Â DOI: 10.1038/ncomms10842</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fncomms10842" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=26905976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjt1emtbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=10842&author=C.+Klein+Herenbrinkauthor=D.+A.+Sykesauthor=P.+Donthamsettiauthor=M.+Canalsauthor=T.+Coudratauthor=J.+Shonbergauthor=P.+J.+Scammellsauthor=B.+Capuanoauthor=P.+M.+Sextonauthor=S.+J.+Charltonauthor=J.+A.+Javitchauthor=A.+Christopoulosauthor=J.+R.+Lane&title=The+role+of+kinetic+context+in+apparent+biased+agonism+at+GPCRs&doi=10.1038%2Fncomms10842"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">The role of kinetic context in apparent biased agonism at GPCRs</span></div><div class="casAuthors">Klein Herenbrink, Carmen; Sykes, David A.; Donthamsetti, Prashant; Canals, Meritxell; Coudrat, Thomas; Shonberg, Jeremy; Scammells, Peter J.; Capuano, Ben; Sexton, Patrick M.; Charlton, Steven J.; Javitch, Jonathan A.; Christopoulos, Arthur; Lane, J. Robert</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10842</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Biased agonism describes the ability of ligands to stabilize different conformations of a GPCR linked to distinct functional outcomes and offers the prospect of designing pathway-specific drugs that avoid on-target side effects.  This mechanism is usually inferred from pharmacol. data with the assumption that the confounding influences of observational (i.e., assay dependent) and system (i.e., cell background dependent) bias are excluded by exptl. design and anal.  Here we reveal that 'kinetic context', as detd. by ligand-binding kinetics and the temporal pattern of receptor-signalling processes, can have a profound influence on the apparent bias of a series of agonists for the dopamine D2 receptor and can even lead to reversals in the direction of bias.  We propose that kinetic context must be acknowledged in the design and interpretation of studies of biased agonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoboe6-_23rF7Vg90H21EOLACvtfcHk0lg5GgU-0M2ZIQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjt1emtbk%253D&md5=3afdebd5ad1c8a8b1db93478e9b2c7d4</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1038%2Fncomms10842&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms10842%26sid%3Dliteratum%253Aachs%26aulast%3DKlein%2BHerenbrink%26aufirst%3DC.%26aulast%3DSykes%26aufirst%3DD.%2BA.%26aulast%3DDonthamsetti%26aufirst%3DP.%26aulast%3DCanals%26aufirst%3DM.%26aulast%3DCoudrat%26aufirst%3DT.%26aulast%3DShonberg%26aufirst%3DJ.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DCapuano%26aufirst%3DB.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520role%2520of%2520kinetic%2520context%2520in%2520apparent%2520biased%2520agonism%2520at%2520GPCRs%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D10842%26doi%3D10.1038%2Fncomms10842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, A. D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacCoss, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heer, J. P.</span></span> <span> </span><span class="NLM_article-title">Importance of rigidity in designing small molecule drugs to tackle proteinâprotein interactions (PPIs) through stabilization of desired conformers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4283</span>â <span class="NLM_lpage">4289</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b01120</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01120" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVWqtb7J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4283-4289&issue=10&author=A.+D.+G.+Lawsonauthor=M.+MacCossauthor=J.+P.+Heer&title=Importance+of+rigidity+in+designing+small+molecule+drugs+to+tackle+protein%E2%80%93protein+interactions+%28PPIs%29+through+stabilization+of+desired+conformers&doi=10.1021%2Facs.jmedchem.7b01120"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Importance of Rigidity in Designing Small Molecule Drugs To Tackle Protein-Protein Interactions (PPIs) through Stabilization of Desired Conformers</span></div><div class="casAuthors">Lawson, Alastair D. G.; MacCoss, Malcolm; Heer, Jag P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4283-4289</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tackling PPIs, particularly by stabilizing clin. favored conformations of target proteins, with orally available, bona fide small mols. remains a significant but immensely worthwhile challenge for the pharmaceutical industry.  Success may be more likely through the application of nature's learnings to build intrinsic rigidity into the design of clin. candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN_JJHmVzv_rVg90H21EOLACvtfcHk0lg5GgU-0M2ZIQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVWqtb7J&md5=665f95b08aeea2757f0a3b4dc4f813ed</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01120%26sid%3Dliteratum%253Aachs%26aulast%3DLawson%26aufirst%3DA.%2BD.%2BG.%26aulast%3DMacCoss%26aufirst%3DM.%26aulast%3DHeer%26aufirst%3DJ.%2BP.%26atitle%3DImportance%2520of%2520rigidity%2520in%2520designing%2520small%2520molecule%2520drugs%2520to%2520tackle%2520protein%25E2%2580%2593protein%2520interactions%2520%2528PPIs%2529%2520through%2520stabilization%2520of%2520desired%2520conformers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D10%26spage%3D4283%26epage%3D4289%26doi%3D10.1021%2Facs.jmedchem.7b01120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gautam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wess, J.</span></span> <span> </span><span class="NLM_article-title">Muscarinic acetylcholine receptors: novel opportunities for drug development</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">549</span>â <span class="NLM_lpage">560</span>, <span class="refDoi">Â DOI: 10.1038/nrd4295</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fnrd4295" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=24903776" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptlOitbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=549-560&issue=7&author=A.+C.+Kruseauthor=B.+K.+Kobilkaauthor=D.+Gautamauthor=P.+M.+Sextonauthor=A.+Christopoulosauthor=J.+Wess&title=Muscarinic+acetylcholine+receptors%3A+novel+opportunities+for+drug+development&doi=10.1038%2Fnrd4295"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Muscarinic acetylcholine receptors: novel opportunities for drug development</span></div><div class="casAuthors">Kruse, Andrew C.; Kobilka, Brian K.; Gautam, Dinesh; Sexton, Patrick M.; Christopoulos, Arthur; Wess, Jurgen</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">549-560</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The muscarinic acetylcholine receptors are a subfamily of G protein-coupled receptors that regulate numerous fundamental functions of the central and peripheral nervous system.  The past few years have witnessed unprecedented new insights into muscarinic receptor physiol., pharmacol. and structure.  These advances include the first structural views of muscarinic receptors in both inactive and active conformations, as well as a better understanding of the mol. underpinnings of muscarinic receptor regulation by allosteric modulators.  These recent findings should facilitate the development of new muscarinic receptor subtype-selective ligands that could prove to be useful for the treatment of many severe pathophysiol. conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnDtWGoryjILVg90H21EOLACvtfcHk0liUZFGrq4sbsQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptlOitbc%253D&md5=cc31a22098b5c613afac26df629d2a47</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1038%2Fnrd4295&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4295%26sid%3Dliteratum%253Aachs%26aulast%3DKruse%26aufirst%3DA.%2BC.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26aulast%3DGautam%26aufirst%3DD.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DWess%26aufirst%3DJ.%26atitle%3DMuscarinic%2520acetylcholine%2520receptors%253A%2520novel%2520opportunities%2520for%2520drug%2520development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26issue%3D7%26spage%3D549%26epage%3D560%26doi%3D10.1038%2Fnrd4295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span> <span> </span><span class="NLM_article-title">Subtype-Selective Allosteric modulators of muscarinic receptors for the treatment of CNS disorders</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">148</span>â <span class="NLM_lpage">155</span>, <span class="refDoi">Â DOI: 10.1016/j.tips.2008.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.tips.2008.12.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=19201489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVGguro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=148-155&issue=3&author=P.+J.+Connauthor=C.+K.+Jonesauthor=C.+W.+Lindsley&title=Subtype-Selective+Allosteric+modulators+of+muscarinic+receptors+for+the+treatment+of+CNS+disorders&doi=10.1016%2Fj.tips.2008.12.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders</span></div><div class="casAuthors">Conn, P. Jeffrey; Jones, Carrie K.; Lindsley, Craig W.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">148-155</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Muscarinic acetylcholine receptors (mAChRs) have long been viewed as viable targets for novel therapeutic agents for the treatment of Alzheimer's disease (AD) and other disorders involving impaired cognitive function.  More recent evidence indicates that mAChR activators might also have utility in treating psychosis and other symptoms assocd. with schizophrenia and other central nervous system (CNS) disorders.  Efforts to develop mAChR subtype-selective agonists have been hampered by difficulty in achieving high selectivity for individual mAChR subtypes important for CNS function (M1 and M4) and adverse effects due to activation of peripheral mAChRs (esp. M2 and M3).  Major advances have now been achieved in the discovery of allosteric agonists and pos. allosteric modulators of M1 and M4 that show greater selectivity for individual mAChR subtypes than do previous mAChR agonists.  Early studies indicate that these allosteric mAChR activators have properties needed for optimization as potential clin. candidates and have robust effects in animal models that predict efficacy in the treatment of AD, schizophrenia and related disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn8LX_geAENrVg90H21EOLACvtfcHk0liUZFGrq4sbsQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVGguro%253D&md5=65cf3e1dee603502b5eb72f60a98be98</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2008.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2008.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DJones%26aufirst%3DC.%2BK.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26atitle%3DSubtype-Selective%2520Allosteric%2520modulators%2520of%2520muscarinic%2520receptors%2520for%2520the%2520treatment%2520of%2520CNS%2520disorders%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2009%26volume%3D30%26issue%3D3%26spage%3D148%26epage%3D155%26doi%3D10.1016%2Fj.tips.2008.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ray, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seager, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getty, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marlatt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crouthamel, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sankaranarayananan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graufields, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bickel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posavec, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuduk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sur, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipe, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinney, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascarella, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seabrook, G.</span></span> <span> </span><span class="NLM_article-title">Allosteric potentiation of the M<sub>1</sub> muscarinic receptor provides unprecedented selectivity and a novel therapeutic strategy for the treatment of Alzheimerâs disease</span>. <i>Alzheimer's Dementia</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">T761</span>, <span class="refDoi">Â DOI: 10.1016/j.jalz.2008.05.2375</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.jalz.2008.05.2375" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=T761&issue=4&author=W.+J.+Rayauthor=M.+Seagerauthor=L.+Maauthor=M.+Wittmannauthor=K.+Gettyauthor=M.+Marlattauthor=M.-C.+Crouthamelauthor=G.+Wuauthor=S.+Sankaranarayanananauthor=A.+Simonauthor=M.+Burnoauthor=K.+Jonesauthor=V.+K.+Graufieldsauthor=D.+Bickelauthor=D.+Posavecauthor=J.+Cookauthor=L.+Vengauthor=S.+Kudukauthor=C.+Surauthor=W.+Shipeauthor=C.+Lindsleyauthor=G.+Kinneyauthor=D.+Pascarellaauthor=M.+Jacobsonauthor=G.+Seabrook&title=Allosteric+potentiation+of+the+M1+muscarinic+receptor+provides+unprecedented+selectivity+and+a+novel+therapeutic+strategy+for+the+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.jalz.2008.05.2375"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1016%2Fj.jalz.2008.05.2375&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jalz.2008.05.2375%26sid%3Dliteratum%253Aachs%26aulast%3DRay%26aufirst%3DW.%2BJ.%26aulast%3DSeager%26aufirst%3DM.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DWittmann%26aufirst%3DM.%26aulast%3DGetty%26aufirst%3DK.%26aulast%3DMarlatt%26aufirst%3DM.%26aulast%3DCrouthamel%26aufirst%3DM.-C.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DSankaranarayananan%26aufirst%3DS.%26aulast%3DSimon%26aufirst%3DA.%26aulast%3DBurno%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DK.%26aulast%3DGraufields%26aufirst%3DV.%2BK.%26aulast%3DBickel%26aufirst%3DD.%26aulast%3DPosavec%26aufirst%3DD.%26aulast%3DCook%26aufirst%3DJ.%26aulast%3DVeng%26aufirst%3DL.%26aulast%3DKuduk%26aufirst%3DS.%26aulast%3DSur%26aufirst%3DC.%26aulast%3DShipe%26aufirst%3DW.%26aulast%3DLindsley%26aufirst%3DC.%26aulast%3DKinney%26aufirst%3DG.%26aulast%3DPascarella%26aufirst%3DD.%26aulast%3DJacobson%26aufirst%3DM.%26aulast%3DSeabrook%26aufirst%3DG.%26atitle%3DAllosteric%2520potentiation%2520of%2520the%2520M1%2520muscarinic%2520receptor%2520provides%2520unprecedented%2520selectivity%2520and%2520a%2520novel%2520therapeutic%2520strategy%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DAlzheimer%2527s%2520Dementia%26date%3D2008%26volume%3D4%26issue%3D4%26spage%3DT761%26doi%3D10.1016%2Fj.jalz.2008.05.2375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seager, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bickel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graufelds, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCampbell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaspar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shughrue, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danziger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascarella, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreatsoulas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipe, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuduk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sur, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinney, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seabrook, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, W. J.</span></span> <span> </span><span class="NLM_article-title">Selective activation of the M<sub>1</sub> muscarinic acetylcholine receptor achieved by allosteric potentiation</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span> (<span class="NLM_issue">37</span>),  <span class="NLM_fpage">15950</span>â <span class="NLM_lpage">15955</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0900903106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1073%2Fpnas.0900903106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=19717450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFOqt7nL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=15950-15955&issue=37&author=L.+Maauthor=M.+A.+Seagerauthor=M.+Wittmannauthor=M.+Jacobsonauthor=D.+Bickelauthor=M.+Burnoauthor=K.+Jonesauthor=V.+K.+Graufeldsauthor=G.+Xuauthor=M.+Pearsonauthor=A.+McCampbellauthor=R.+Gasparauthor=P.+Shughrueauthor=A.+Danzigerauthor=C.+Reganauthor=R.+Flickauthor=D.+Pascarellaauthor=S.+Garsonauthor=S.+Doranauthor=C.+Kreatsoulasauthor=L.+Vengauthor=C.+W.+Lindsleyauthor=W.+Shipeauthor=S.+Kudukauthor=C.+Surauthor=G.+Kinneyauthor=G.+R.+Seabrookauthor=W.+J.+Ray&title=Selective+activation+of+the+M1+muscarinic+acetylcholine+receptor+achieved+by+allosteric+potentiation&doi=10.1073%2Fpnas.0900903106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation</span></div><div class="casAuthors">Ma, Lei; Seager, Matthew; Wittmann, Marion; Jacobson, Marlene; Bickel, Denise; Burno, Maryann; Jones, Keith; Graufelds, Valerie Kuzmick; Xu, Guangping; Pearson, Michelle; McCampbell, Alexander; Gaspar, Renee; Shughrue, Paul; Danziger, Andrew; Regan, Christopher; Flick, Rose; Pascarella, Danette; Garson, Susan; Doran, Scott; Kreatsoulas, Constantine; Veng, Lone; Lindsley, Craig W.; Shipe, William; Kuduk, Scott; Sur, Cyrille; Kinney, Gene; Seabrook, Guy R.; Ray, William J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">15950-15955, S15950/1-S15950/9</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The forebrain cholinergic system promotes higher brain function in part by signaling through the M, muscarinic acetylcholine receptor (mAChR).  During Alzheimer's disease (AD), these cholinergic neurons degenerate, therefore selectively activating M1 receptors could improve cognitive function in these patients while avoiding unwanted peripheral responses assocd. with non-selective muscarinic agonists.  We describe here benzyl quinolone carboxylic acid (BQCA), a highly selective allosteric potentiator of the M1 mAChR.  BQCA reduces the concn. of ACh required to activate M1 up to 129-fold with an inflection point value of 845 nM.  No potentiation, agonism, or antagonism activity on other mAChRs is obsd. up to 100 ArM.  Furthermore studies in M1-/- mice demonstrates that BQCA requires M1 to promote inositol phosphate turnover in primary neurons and to increase c-fos and arc RNA expression and ERK phosphorylation in the brain.  Radioligand-binding assays, mol. modeling, and site-directed mutagenesis expts. indicate that BQCA acts at an allosteric site involving residues Y179 and W400.  BQCA reverses scopolamine-induced memory deficits in contextual fear conditioning, increases blood flow to the cerebral cortex, and increases wakefulness while reducing delta sleep.  In contrast to M1 allosteric agonists, which do not improve memory in scopolamine-challenged mice in contextual fear conditioning, BQCA induces 13-arrestin recruitment to M1, suggesting a role for this signal transduction mechanism in the cholinergic modulation of memory.  In summary, BQCA exploits an allosteric potentiation mechanism to provide selectivity for the M1 receptor and represents a promising therapeutic strategy for cognitive disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0SGRL-coGErVg90H21EOLACvtfcHk0lglSrZvXTmjPQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFOqt7nL&md5=4470732fd762f761a18d2bc96220dcb1</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0900903106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0900903106%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DL.%26aulast%3DSeager%26aufirst%3DM.%2BA.%26aulast%3DWittmann%26aufirst%3DM.%26aulast%3DJacobson%26aufirst%3DM.%26aulast%3DBickel%26aufirst%3DD.%26aulast%3DBurno%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DK.%26aulast%3DGraufelds%26aufirst%3DV.%2BK.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DPearson%26aufirst%3DM.%26aulast%3DMcCampbell%26aufirst%3DA.%26aulast%3DGaspar%26aufirst%3DR.%26aulast%3DShughrue%26aufirst%3DP.%26aulast%3DDanziger%26aufirst%3DA.%26aulast%3DRegan%26aufirst%3DC.%26aulast%3DFlick%26aufirst%3DR.%26aulast%3DPascarella%26aufirst%3DD.%26aulast%3DGarson%26aufirst%3DS.%26aulast%3DDoran%26aufirst%3DS.%26aulast%3DKreatsoulas%26aufirst%3DC.%26aulast%3DVeng%26aufirst%3DL.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DShipe%26aufirst%3DW.%26aulast%3DKuduk%26aufirst%3DS.%26aulast%3DSur%26aufirst%3DC.%26aulast%3DKinney%26aufirst%3DG.%26aulast%3DSeabrook%26aufirst%3DG.%2BR.%26aulast%3DRay%26aufirst%3DW.%2BJ.%26atitle%3DSelective%2520activation%2520of%2520the%2520M1%2520muscarinic%2520acetylcholine%2520receptor%2520achieved%2520by%2520allosteric%2520potentiation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2009%26volume%3D106%26issue%3D37%26spage%3D15950%26epage%3D15955%26doi%3D10.1073%2Fpnas.0900903106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Canals, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scammells, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span> <span> </span><span class="NLM_article-title">A Monod-Wyman-Changeux mechanism can explain G protein-coupled receptor (GPCR) allosteric modulation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>287</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">650</span>â <span class="NLM_lpage">659</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M111.314278</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1074%2Fjbc.M111.314278" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=22086918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC38XotVGh" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2012&pages=650-659&issue=1&author=M.+Canalsauthor=J.+R.+Laneauthor=A.+Wenauthor=P.+J.+Scammellsauthor=P.+M.+Sextonauthor=A.+Christopoulos&title=A+Monod-Wyman-Changeux+mechanism+can+explain+G+protein-coupled+receptor+%28GPCR%29+allosteric+modulation&doi=10.1074%2Fjbc.M111.314278"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">A Monod-Wyman-Changeux Mechanism Can Explain G Protein-coupled Receptor (GPCR) Allosteric Modulation</span></div><div class="casAuthors">Canals, Meritxell; Lane, J. Robert; Wen, Adriel; Scammells, Peter J.; Sexton, Patrick M.; Christopoulos, Arthur</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">287</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">650-659</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The Monod-Wyman-Changeux (MWC) model was initially proposed to describe the allosteric properties of regulatory enzymes and subsequently extended to receptors.  Yet despite GPCRs representing the largest family of receptors and drug targets, no study has systematically evaluated the MWC mechanism as it applies to GPCR allosteric ligands.  We reveal how the recently described allosteric modulator, benzyl quinolone carboxylic acid (BQCA), behaves according to a strict, two-state MWC mechanism at the M1 muscarinic acetylcholine receptor (mAChR).  Despite having a low affinity for the M1 mAChR, BQCA demonstrated state dependence, exhibiting high pos. cooperativity with orthosteric agonists in a manner that correlated with efficacy but neg. cooperativity with inverse agonists.  The activity of BQCA was significantly increased at a constitutively active M1 mAChR but abolished at an inactive mutant.  Interestingly, BQCA possessed intrinsic signaling efficacy, ranging from near-quiescence to full agonism depending on the coupling efficiency of the chosen intracellular pathway.  This latter cellular property also detd. the difference in magnitude of pos. cooperativity between BQCA and the orthosteric agonist, carbachol, across pathways.  The lack of addnl., pathway-biased, allosteric modulation by BQCA was confirmed in genetically engineered yeast strains expressing different chimeras between the endogenous yeast Gpa1 protein and human GÎ± subunits.  These findings define a chem. biol. framework that can be applied to the study and classification of allosteric modulators across different GPCR families.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrrH0vtUu5lbVg90H21EOLACvtfcHk0lglSrZvXTmjPQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotVGh&md5=45d079afd141a137baf24fe171180124</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M111.314278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M111.314278%26sid%3Dliteratum%253Aachs%26aulast%3DCanals%26aufirst%3DM.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26aulast%3DWen%26aufirst%3DA.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DChristopoulos%26aufirst%3DA.%26atitle%3DA%2520Monod-Wyman-Changeux%2520mechanism%2520can%2520explain%2520G%2520protein-coupled%2520receptor%2520%2528GPCR%2529%2520allosteric%2520modulation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2012%26volume%3D287%26issue%3D1%26spage%3D650%26epage%3D659%26doi%3D10.1074%2Fjbc.M111.314278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marlo, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niswender, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Days, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirey, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brady, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nalywajko, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span> <span> </span><span class="NLM_article-title">Discovery and characterization of novel allosteric potentiators of m<sub>1</sub> muscarinic receptors reveals multiple modes of activity</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>75</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">577</span>â <span class="NLM_lpage">588</span>, <span class="refDoi">Â DOI: 10.1124/mol.108.052886</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1124%2Fmol.108.052886" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=19047481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BD1MXis1ajsr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2009&pages=577-588&issue=3&author=J.+E.+Marloauthor=C.+M.+Niswenderauthor=E.+L.+Daysauthor=T.+M.+Bridgesauthor=Y.+Xiangauthor=A.+L.+Rodriguezauthor=J.+K.+Shireyauthor=A.+E.+Bradyauthor=T.+Nalywajkoauthor=Q.+Luoauthor=C.+A.+Austinauthor=M.+B.+Williamsauthor=K.+Kimauthor=R.+Williamsauthor=D.+Ortonauthor=H.+A.+Brownauthor=C.+W.+Lindsleyauthor=C.+D.+Weaverauthor=P.+J.+Conn&title=Discovery+and+characterization+of+novel+allosteric+potentiators+of+m1+muscarinic+receptors+reveals+multiple+modes+of+activity&doi=10.1124%2Fmol.108.052886"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity</span></div><div class="casAuthors">Marlo, Joy E.; Niswender, Colleen M.; Days, Emily L.; Bridges, Thomas M.; Xiang, Yun; Rodriguez, Alice L.; Shirey, Jana K.; Brady, Ashley E.; Nalywajko, Tasha; Luo, Qingwei; Austin, Cheryl A.; Williams, Michael Baxter; Kim, Kwangho; Williams, Richard; Orton, Darren; Brown, H. Alex; Lindsley, Craig W.; Weaver, C. David; Conn, P. Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">577-588</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Activators of M1 muscarinic acetylcholine receptors (mAChRs) may provide novel treatments for schizophrenia and Alzheimer's disease.  Unfortunately, the development of M1-active compds. has resulted in nonselective activation of the highly related M2 to M5 mAChR subtypes, which results in dose-limiting side effects.  Using a functional screening approach, the authors identified several novel ligands that potentiated agonist activation of M1 with low micromolar potencies and induced 5-fold or greater leftward shifts of the acetylcholine (ACh) concn.-response curve.  These ligands did not compete for binding at the ACh binding site, indicating that they modulate receptor activity by binding to allosteric sites.  The two most selective compds., cyclopentyl 1,6-dimethyl-4-(6-nitrobenzo[d][1,3]dioxol-5-yl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (VU0090157) and (E)-2-(4-ethoxyphenylamino)-N'-((2-hydroxynaphthalen-1-yl)methylene)acetohydrazide (VU0029767), induced progressive shifts in ACh affinity at M1 that were consistent with their effects in a functional assay, suggesting that the mechanism for enhancement of M1 activity by these compds. is by increasing agonist affinity.  These compds. were strikingly different, however, in their ability to potentiate responses at a mutant M1 receptor with decreased affinity for ACh and in their ability to affect responses of the allosteric M1 agonist, 1-[1'-(2-tolyl)-1,4'-bipiperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one.  Furthermore, these two compds. were distinct in their abilities to potentiate M1-mediated activation of phosphoinositide hydrolysis and phospholipase D.  The discovery of multiple structurally distinct pos. allosteric modulators of M1 is an exciting advance in establishing the potential of allosteric modulators for selective activation of this receptor.  These data also suggest that structurally diverse M1 potentiators may act by distinct mechanisms and differentially regulate receptor coupling to downstream signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpVs4dgdrjCbVg90H21EOLACvtfcHk0lglSrZvXTmjPQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXis1ajsr0%253D&md5=deef44340efd29e5719692b255e50665</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1124%2Fmol.108.052886&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.108.052886%26sid%3Dliteratum%253Aachs%26aulast%3DMarlo%26aufirst%3DJ.%2BE.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DDays%26aufirst%3DE.%2BL.%26aulast%3DBridges%26aufirst%3DT.%2BM.%26aulast%3DXiang%26aufirst%3DY.%26aulast%3DRodriguez%26aufirst%3DA.%2BL.%26aulast%3DShirey%26aufirst%3DJ.%2BK.%26aulast%3DBrady%26aufirst%3DA.%2BE.%26aulast%3DNalywajko%26aufirst%3DT.%26aulast%3DLuo%26aufirst%3DQ.%26aulast%3DAustin%26aufirst%3DC.%2BA.%26aulast%3DWilliams%26aufirst%3DM.%2BB.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DWilliams%26aufirst%3DR.%26aulast%3DOrton%26aufirst%3DD.%26aulast%3DBrown%26aufirst%3DH.%2BA.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DWeaver%26aufirst%3DC.%2BD.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520novel%2520allosteric%2520potentiators%2520of%2520m1%2520muscarinic%2520receptors%2520reveals%2520multiple%2520modes%2520of%2520activity%26jtitle%3DMol.%2520Pharmacol.%26date%3D2009%26volume%3D75%26issue%3D3%26spage%3D577%26epage%3D588%26doi%3D10.1124%2Fmol.108.052886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span> </span><span class="NLM_article-title">Efficacy and safety of MK-7622 as adjunct
therapy in participants with Alzheimerâs disease (MK-7622â012)</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National
Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2018</span>; <a href="https://clinicaltrials.gov/ct2/show/NCT01852110" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01852110</a> (accessed Jun 27, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Efficacy+and+safety+of+MK-7622+as+adjunct%0Atherapy+in+participants+with+Alzheimer%E2%80%99s+disease+%28MK-7622%E2%80%93012%29.+ClinicalTrials.gov%3B+U.S.+National%0AInstitutes+of+Health%3A+Bethesda%2C+MD%2C+2018%3B+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01852110+%28accessed+Jun+27%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DEfficacy%2520and%2520safety%2520of%2520MK-7622%2520as%2520adjunct%250Atherapy%2520in%2520participants%2520with%2520Alzheimer%25E2%2580%2599s%2520disease%2520%2528MK-7622%25E2%2580%2593012%2529%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%250AInstitutes%2520of%2520Health%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moran, S.
P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickerson, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maksymetz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remke, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doyle, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajan, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niswender, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engers, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rook, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span> <span> </span><span class="NLM_article-title">M<sub>1</sub>-positive allosteric modulators lacking agonist activity provide the optimal profile for enhancing cognition</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1763</span>â <span class="NLM_lpage">1771</span>, <span class="refDoi">Â DOI: 10.1038/s41386-018-0033-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fs41386-018-0033-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=29581537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Cgt7%252FE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2018&pages=1763-1771&issue=8&author=S.%0AP.+Moranauthor=J.+W.+Dickersonauthor=H.+P.+Choauthor=Z.+Xiangauthor=J.+Maksymetzauthor=D.+H.+Remkeauthor=X.+Lvauthor=C.+A.+Doyleauthor=D.+H.+Rajanauthor=C.+M.+Niswenderauthor=D.+W.+Engersauthor=C.+W.+Lindsleyauthor=J.+M.+Rookauthor=P.+J.+Conn&title=M1-positive+allosteric+modulators+lacking+agonist+activity+provide+the+optimal+profile+for+enhancing+cognition&doi=10.1038%2Fs41386-018-0033-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">M1-positive allosteric modulators lacking agonist activity provide the optimal profile for enhancing cognition</span></div><div class="casAuthors">Moran, Sean P.; Dickerson, Jonathan W.; Cho, Hyekyung P.; Xiang, Zixiu; Maksymetz, James; Remke, Daniel H.; Lv, Xiaohui; Doyle, Catherine A.; Rajan, Deepa H.; Niswender, Colleen M.; Engers, Darren W.; Lindsley, Craig W.; Rook, Jerri M.; Conn, P. Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1763-1771</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Highly selective pos. allosteric modulators (PAMs) of the M1 subtype of muscarinic acetylcholine receptor have emerged as an exciting new approach for improving cognitive function in patients suffering from Alzheimer's disease and schizophrenia.  However, excessive activation of M1 is known to induce seizure activity and have actions in the prefrontal cortex (PFC) that could impair cognitive function.  We now report a series of pharmacol., electrophysiol., and behavioral studies in which we find that recently reported M1 PAMs, PF-06764427 and MK-7622, have robust agonist activity in cell lines and agonist effects in the mouse PFC, and have the potential to overactivate the M1 receptor and disrupt PFC function.  In contrast, structurally distinct M1 PAMs (VU0453595 and VU0550164) are devoid of agonist activity in cell lines and maintain activity dependence of M1 activation in the PFC.  Consistent with the previously reported effect of PF-06764427, the ago-PAM MK-7622 induces severe behavioral convulsions in mice.  In contrast, VU0453595 does not induce behavioral convulsions at doses well above those required for maximal efficacy in enhancing cognitive function.  Furthermore, in contrast to the robust efficacy of VU0453595, the ago-PAM MK-7622 failed to improve novel object recognition, a rodent assay of cognitive function.  These findings suggest that in vivo cognition-enhancing efficacy of M1 PAMs can be obsd. with PAMs lacking intrinsic agonist activity and that intrinsic agonist activity of M1 PAMs may contribute to adverse effects and reduced efficacy in improving cognitive function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoqZdwN9mb1LVg90H21EOLACvtfcHk0lhgXk3gs5mGuQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Cgt7%252FE&md5=1cdf212e1b161858689181afad6a1d61</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1038%2Fs41386-018-0033-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41386-018-0033-9%26sid%3Dliteratum%253Aachs%26aulast%3DMoran%26aufirst%3DS.%2BP.%26aulast%3DDickerson%26aufirst%3DJ.%2BW.%26aulast%3DCho%26aufirst%3DH.%2BP.%26aulast%3DXiang%26aufirst%3DZ.%26aulast%3DMaksymetz%26aufirst%3DJ.%26aulast%3DRemke%26aufirst%3DD.%2BH.%26aulast%3DLv%26aufirst%3DX.%26aulast%3DDoyle%26aufirst%3DC.%2BA.%26aulast%3DRajan%26aufirst%3DD.%2BH.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DEngers%26aufirst%3DD.%2BW.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DRook%26aufirst%3DJ.%2BM.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26atitle%3DM1-positive%2520allosteric%2520modulators%2520lacking%2520agonist%2520activity%2520provide%2520the%2520optimal%2520profile%2520for%2520enhancing%2520cognition%26jtitle%3DNeuropsychopharmacology%26date%3D2018%26volume%3D43%26issue%3D8%26spage%3D1763%26epage%3D1771%26doi%3D10.1038%2Fs41386-018-0033-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davoren, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâNeil, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodney, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chenard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dlugolenski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edgerton, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnsey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimwood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kauffman, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaChapelle, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazzaro, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotarski, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nason, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhart, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salomon-Ferrer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steyn, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span> <span> </span><span class="NLM_article-title">Design and optimization of selective azaindole amide M<sub>1</sub> positive allosteric modulators</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">650</span>â <span class="NLM_lpage">655</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2015.11.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1016%2Fj.bmcl.2015.11.053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=26631313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFant73L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=650-655&issue=2&author=J.+E.+Davorenauthor=S.+V.+O%E2%80%99Neilauthor=D.+P.+Andersonauthor=M.+A.+Brodneyauthor=L.+Chenardauthor=K.+Dlugolenskiauthor=J.+R.+Edgertonauthor=M.+Greenauthor=M.+Garnseyauthor=S.+Grimwoodauthor=A.+R.+Harrisauthor=G.+W.+Kauffmanauthor=E.+LaChapelleauthor=J.+T.+Lazzaroauthor=C.+W.+Leeauthor=S.+M.+Lotarskiauthor=D.+M.+Nasonauthor=R.+S.+Obachauthor=V.+Reinhartauthor=R.+Salomon-Ferrerauthor=S.+J.+Steynauthor=D.+Webbauthor=J.+Yanauthor=L.+Zhang&title=Design+and+optimization+of+selective+azaindole+amide+M1+positive+allosteric+modulators&doi=10.1016%2Fj.bmcl.2015.11.053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Design and optimization of selective azaindole amide M1 positive allosteric modulators</span></div><div class="casAuthors">Davoren, Jennifer E.; O'Neil, Steven V.; Anderson, Dennis P.; Brodney, Michael A.; Chenard, Lois; Dlugolenski, Keith; Edgerton, Jeremy R.; Green, Michael; Garnsey, Michelle; Grimwood, Sarah; Harris, Anthony R.; Kauffman, Gregory W.; LaChapelle, Erik; Lazzaro, John T.; Lee, Che-Wah; Lotarski, Susan M.; Nason, Deane M.; Obach, R. Scott; Reinhart, Veronica; Salomon-Ferrer, Romelia; Steyn, Stefanus J.; Webb, Damien; Yan, Jiangli; Zhang, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">650-655</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Selective activation of the M1 receptor via a pos. allosteric modulator (PAM) is a new approach for the treatment of the cognitive impairments assocd. with schizophrenia and Alzheimer's disease.  A novel series of azaindole amides and their key pharmacophore elements are described.  The nitrogen of the azaindole core is a key design element as it forms an intramol. hydrogen bond with the amide N-H thus reinforcing the bioactive conformation predicted by published SAR and the authors' homol. model.  Representative compd. 25 is a potent and selective M1 PAM that has well aligned physicochem. properties, adequate brain penetration and pharmacokinetic (PK) properties, and is active in vivo.  These favorable properties indicate that this series possesses suitable qualities for further development and studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOEhH8MxkKIrVg90H21EOLACvtfcHk0lhgXk3gs5mGuQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFant73L&md5=5c227d1371fe4f0cc3348af8314dd370</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.11.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.11.053%26sid%3Dliteratum%253Aachs%26aulast%3DDavoren%26aufirst%3DJ.%2BE.%26aulast%3DO%25E2%2580%2599Neil%26aufirst%3DS.%2BV.%26aulast%3DAnderson%26aufirst%3DD.%2BP.%26aulast%3DBrodney%26aufirst%3DM.%2BA.%26aulast%3DChenard%26aufirst%3DL.%26aulast%3DDlugolenski%26aufirst%3DK.%26aulast%3DEdgerton%26aufirst%3DJ.%2BR.%26aulast%3DGreen%26aufirst%3DM.%26aulast%3DGarnsey%26aufirst%3DM.%26aulast%3DGrimwood%26aufirst%3DS.%26aulast%3DHarris%26aufirst%3DA.%2BR.%26aulast%3DKauffman%26aufirst%3DG.%2BW.%26aulast%3DLaChapelle%26aufirst%3DE.%26aulast%3DLazzaro%26aufirst%3DJ.%2BT.%26aulast%3DLee%26aufirst%3DC.%2BW.%26aulast%3DLotarski%26aufirst%3DS.%2BM.%26aulast%3DNason%26aufirst%3DD.%2BM.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DReinhart%26aufirst%3DV.%26aulast%3DSalomon-Ferrer%26aufirst%3DR.%26aulast%3DSteyn%26aufirst%3DS.%2BJ.%26aulast%3DWebb%26aufirst%3DD.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DDesign%2520and%2520optimization%2520of%2520selective%2520azaindole%2520amide%2520M1%2520positive%2520allosteric%2520modulators%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26issue%3D2%26spage%3D650%26epage%3D655%26doi%3D10.1016%2Fj.bmcl.2015.11.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Popiolek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhart, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edgerton, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harms, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotarski, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steyn, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davoren, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimwood, S.</span></span> <span> </span><span class="NLM_article-title">Inositol phosphate accumulation in vivo provides a measure of muscarinic M<sub>1</sub> receptor activation</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">51</span>),  <span class="NLM_fpage">7073</span>â <span class="NLM_lpage">7085</span>, <span class="refDoi">Â DOI: 10.1021/acs.biochem.6b00688</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.6b00688" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCjt73K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=7073-7085&issue=51&author=M.+Popiolekauthor=D.+P.+Nguyenauthor=V.+Reinhartauthor=J.+R.+Edgertonauthor=J.+Harmsauthor=S.+M.+Lotarskiauthor=S.+J.+Steynauthor=J.+E.+Davorenauthor=S.+Grimwood&title=Inositol+phosphate+accumulation+in+vivo+provides+a+measure+of+muscarinic+M1+receptor+activation&doi=10.1021%2Facs.biochem.6b00688"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Inositol Phosphate Accumulation in Vivo Provides a Measure of Muscarinic M1 Receptor Activation</span></div><div class="casAuthors">Popiolek, Michael; Nguyen, David P.; Reinhart, Veronica; Edgerton, Jeremy R.; Harms, John; Lotarski, Susan M.; Steyn, Stefanus J.; Davoren, Jennifer E.; Grimwood, Sarah</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">7073-7085</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The rationale for using M1 selective muscarinic acetylcholine receptor activators for the treatment of cognitive impairment assocd. with psychiatric and neurodegenerative disease is well-established in the literature.  Here, we investigate measurement of inositol phosphate accumulation, an end point immediately downstream of the M1 muscarinic acetylcholine receptor signaling cascade, as an in vivo biochem. readout for M1 muscarinic acetylcholine receptor activation.  Five brain penetrant M1-subtype selective activators from three structurally distinct chem. series were pharmacol. profiled for functional activity in vitro using recombinant cell calcium mobilization and inositol phosphate assays, and a native tissue hippocampal slice electrophysiol. assay, to show that all five compds. presented a pos. allosteric modulator agonist profile, within a narrow range of potencies.  In vivo characterization using an amphetamine-stimulated locomotor activity behavioral assay and the inositol phosphate accumulation biochem. assay demonstrated that the latter has utility for assessing functional potency of M1 activators.  Efficacy measured by inositol phosphate accumulation in mouse striatum compared favorably to efficacy in reversing amphetamine-induced locomotor activity, suggesting that the inositol phosphate accumulation assay has utility for the evaluation of M1 muscarinic acetylcholine receptor activators in vivo.  The benefits of this in vivo biochem. approach include a wide response window, interrogation of specific brain circuit activation, an ability to model responses in the context of brain exposure, an ability to rank order compds. based on in vivo efficacy, and minimization of animal use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpubNvtFbullrVg90H21EOLACvtfcHk0lhzo6rP3ZBUTw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCjt73K&md5=ea1c7134941fe3e4d722e469f21385cb</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.6b00688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.6b00688%26sid%3Dliteratum%253Aachs%26aulast%3DPopiolek%26aufirst%3DM.%26aulast%3DNguyen%26aufirst%3DD.%2BP.%26aulast%3DReinhart%26aufirst%3DV.%26aulast%3DEdgerton%26aufirst%3DJ.%2BR.%26aulast%3DHarms%26aufirst%3DJ.%26aulast%3DLotarski%26aufirst%3DS.%2BM.%26aulast%3DSteyn%26aufirst%3DS.%2BJ.%26aulast%3DDavoren%26aufirst%3DJ.%2BE.%26aulast%3DGrimwood%26aufirst%3DS.%26atitle%3DInositol%2520phosphate%2520accumulation%2520in%2520vivo%2520provides%2520a%2520measure%2520of%2520muscarinic%2520M1%2520receptor%2520activation%26jtitle%3DBiochemistry%26date%3D2016%26volume%3D55%26issue%3D51%26spage%3D7073%26epage%3D7085%26doi%3D10.1021%2Facs.biochem.6b00688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rook, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nance, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luscombe, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickerson, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remke, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Barrantes, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engers, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engers, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blobaum, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niswender, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span> <span> </span><span class="NLM_article-title">Diverse effects on M<sub>1</sub> signaling and adverse effect liability within a series of M<sub>1</sub> ago-PAMs</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">866</span>â <span class="NLM_lpage">883</span>, <span class="refDoi">Â DOI: 10.1021/acschemneuro.6b00429</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.6b00429" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFaiurzK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=866-883&issue=4&author=J.+M.+Rookauthor=M.+Abeauthor=H.+P.+Choauthor=K.+D.+Nanceauthor=V.+B.+Luscombeauthor=J.+J.+Adamsauthor=J.+W.+Dickersonauthor=D.+H.+Remkeauthor=P.+M.+Garcia-Barrantesauthor=D.+W.+Engersauthor=J.+L.+Engersauthor=S.+Changauthor=J.+J.+Fosterauthor=A.+L.+Blobaumauthor=C.+M.+Niswenderauthor=C.+K.+Jonesauthor=P.+J.+Connauthor=C.+W.+Lindsley&title=Diverse+effects+on+M1+signaling+and+adverse+effect+liability+within+a+series+of+M1+ago-PAMs&doi=10.1021%2Facschemneuro.6b00429"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Diverse Effects on M1 Signaling and Adverse Effect Liability within a Series of M1 Ago-PAMs</span></div><div class="casAuthors">Rook, Jerri M.; Abe, Masahito; Cho, Hyekyung P.; Nance, Kellie D.; Luscombe, Vincent B.; Adams, Jeffrey J.; Dickerson, Jonathan W.; Remke, Daniel H.; Garcia-Barrantes, Pedro M.; Engers, Darren W.; Engers, Julie L.; Chang, Sichen; Foster, Jarrett J.; Blobaum, Anna L.; Niswender, Colleen M.; Jones, Carrie K.; Conn, P. Jeffrey; Lindsley, Craig W.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">866-883</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Both historical clin. and recent preclin. data suggest that the M1 muscarinic acetylcholine receptor is an exciting target for the treatment of Alzheimer's disease and the cognitive and neg. symptom clusters in schizophrenia; however, early drug discovery efforts targeting the orthosteric binding site have failed to afford selective M1 activation.  Efforts then shifted to focus on selective activation of M1 via either allosteric agonists or pos. allosteric modulators (PAMs).  While M1 PAMs have robust efficacy in rodent models, some chemotypes can induce cholinergic adverse effects (AEs) that could limit their clin. utility.  Here, the authors report studies aimed at understanding the subtle structural and pharmacol. nuances that differentiate efficacy from adverse effect liability within an indole-based series of M1 ago-PAMs.  The authors' data demonstrate that closely related M1 PAMs can display striking differences in their in vivo activities, and esp. their propensities to induce adverse effects.  The authors report the discovery of a novel PAM in this series that is devoid of observable adverse effect liability.  Interestingly, the mol. pharmacol. profile of this novel PAM is similar to that of a representative M1 PAM that induces severe AEs.  For instance, both compds. are potent ago-PAMs that demonstrate significant interaction with the orthosteric site (either bi-topic or neg. cooperativity).  However, there are subtle differences in efficacies of the compds. at potentiating M1 responses, agonist potencies, and abilities to induce receptor internalization.  While these differences may contribute to the differential in vivo profiles of these compds., the in vitro differences are relatively subtle and highlight the complexities of allosteric modulators and the need to focus on in vivo phenotypic screening to identify safe and effective M1 PAMs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTbiEiZmJq3bVg90H21EOLACvtfcHk0liqJa5Ktnn0jQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFaiurzK&md5=06d92ac4fccfaf7ea8ff3be807dacdc5</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.6b00429&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.6b00429%26sid%3Dliteratum%253Aachs%26aulast%3DRook%26aufirst%3DJ.%2BM.%26aulast%3DAbe%26aufirst%3DM.%26aulast%3DCho%26aufirst%3DH.%2BP.%26aulast%3DNance%26aufirst%3DK.%2BD.%26aulast%3DLuscombe%26aufirst%3DV.%2BB.%26aulast%3DAdams%26aufirst%3DJ.%2BJ.%26aulast%3DDickerson%26aufirst%3DJ.%2BW.%26aulast%3DRemke%26aufirst%3DD.%2BH.%26aulast%3DGarcia-Barrantes%26aufirst%3DP.%2BM.%26aulast%3DEngers%26aufirst%3DD.%2BW.%26aulast%3DEngers%26aufirst%3DJ.%2BL.%26aulast%3DChang%26aufirst%3DS.%26aulast%3DFoster%26aufirst%3DJ.%2BJ.%26aulast%3DBlobaum%26aufirst%3DA.%2BL.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DJones%26aufirst%3DC.%2BK.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26atitle%3DDiverse%2520effects%2520on%2520M1%2520signaling%2520and%2520adverse%2520effect%2520liability%2520within%2520a%2520series%2520of%2520M1%2520ago-PAMs%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2017%26volume%3D8%26issue%3D4%26spage%3D866%26epage%3D883%26doi%3D10.1021%2Facschemneuro.6b00429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span> </span><span class="NLM_article-title">Putative Cognitive Enhancer VU319</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National
Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2017</span>; <a href="https://www.clinicaltrials.gov/ct2/show/NCT03220295?term=nct03220295&amp;rank=1" class="extLink">https://www.clinicaltrials.gov/ct2/show/NCT03220295?term=nct03220295&rank=1</a> (accessed on July 5, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Putative+Cognitive+Enhancer+VU319.+ClinicalTrials.gov%3B+U.S.+National%0AInstitutes+of+Health%3A+Bethesda%2C+MD%2C+2017%3B+https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT03220295%3Fterm%3Dnct03220295%26rank%3D1+%28accessed+on+July+5%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DPutative%2520Cognitive%2520Enhancer%2520VU319%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%250AInstitutes%2520of%2520Health%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwaid, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornella-Taracido, I.</span></span> <span> </span><span class="NLM_article-title">Causes and significance of increased compound potency in cellular or physiological contexts</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1767</span>â <span class="NLM_lpage">1773</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b00762</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00762" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlCmsrvP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1767-1773&issue=5&author=A.+G.+Schwaidauthor=I.+Cornella-Taracido&title=Causes+and+significance+of+increased+compound+potency+in+cellular+or+physiological+contexts&doi=10.1021%2Facs.jmedchem.7b00762"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Causes and Significance of Increased Compound Potency in Cellular or Physiological Contexts</span></div><div class="casAuthors">Schwaid, Adam G.; Cornella-Taracido, Ivan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1767-1773</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Compd. potency is a key metric that is often used to drive medicinal chem. programs.  Compd. potency is also taken into account when identifying the mechanism of action of compds. whose pharmacol. target is unknown, particularly when these compds. are identified in phenotypic screens.  Often compd. potency is detd. from assays using recombinantly generated, purified protein.  It is well understood in the medicinal chem. community that potency measured with recombinant enzyme and potency measured in cell may not entirely coincide.  Decreases in cellular vs. recombinant potency are often anticipated or explainable.  What is less often realized is that compd. potency can increase in a cellular environment due to several factors including cellular metab. of compds., protein-protein interactions, post-translational modifications, and asym. intracellular localization of compd.  Here the authors discuss these factors and highlight examples where increases in cellular compd. potency were crit. to the development of probes or drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK01NxoWrY9rVg90H21EOLACvtfcHk0lhqndUR4An6BA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlCmsrvP&md5=faa234aab3bd4a9d9a11ab118128d4f4</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00762%26sid%3Dliteratum%253Aachs%26aulast%3DSchwaid%26aufirst%3DA.%2BG.%26aulast%3DCornella-Taracido%26aufirst%3DI.%26atitle%3DCauses%2520and%2520significance%2520of%2520increased%2520compound%2520potency%2520in%2520cellular%2520or%2520physiological%2520contexts%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D5%26spage%3D1767%26epage%3D1773%26doi%3D10.1021%2Facs.jmedchem.7b00762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bunnage, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hett, E. C.</span></span> <span> </span><span class="NLM_article-title">Know your target, know your molecule</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">368</span>â <span class="NLM_lpage">372</span>, <span class="refDoi">Â DOI: 10.1038/nchembio.1813</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1038%2Fnchembio.1813" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=25978985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFemtrvK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=368-372&issue=6&author=M.+E.+Bunnageauthor=A.+M.+Gilbertauthor=L.+H.+Jonesauthor=E.+C.+Hett&title=Know+your+target%2C+know+your+molecule&doi=10.1038%2Fnchembio.1813"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Know your target, know your molecule</span></div><div class="casAuthors">Bunnage, Mark E.; Gilbert, Adam M.; Jones, Lyn H.; Hett, Erik C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">368-372</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review. The pharmaceutical industry continues to experience significant attrition of drug candidates during phase 2 proof-of-concept clin. studies.  We describe some questions about the characteristics of protein targets and small-mol. drugs that may be important to consider in drug-discovery projects and could improve prospects for future clin. success.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRthCFSFvOXrVg90H21EOLACvtfcHk0lhqndUR4An6BA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFemtrvK&md5=f9606135ccea6af432040d8afb630ede</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1813&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1813%26sid%3Dliteratum%253Aachs%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DGilbert%26aufirst%3DA.%2BM.%26aulast%3DJones%26aufirst%3DL.%2BH.%26aulast%3DHett%26aufirst%3DE.%2BC.%26atitle%3DKnow%2520your%2520target%252C%2520know%2520your%2520molecule%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2015%26volume%3D11%26issue%3D6%26spage%3D368%26epage%3D372%26doi%3D10.1038%2Fnchembio.1813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Black, J. W.</span></span> <span> </span><span class="NLM_article-title">A personal view of pharmacology</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">33</span>, <span class="refDoi">Â DOI: 10.1146/annurev.pa.36.040196.000245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=10.1146%2Fannurev.pa.36.040196.000245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=8725380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;key=1%3ACAS%3A528%3ADyaK28Xis1ertLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1996&pages=1-33&author=J.+W.+Black&title=A+personal+view+of+pharmacology&doi=10.1146%2Fannurev.pa.36.040196.000245"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">A personal view of pharmacology</span></div><div class="casAuthors">Black, James</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-33</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">This essay is an account of the author's experience in trying to interpret the action of drugs as seen in in vitro bioassays.  The central theme is how the development of simple math. models has assisted in the interpretation of drug actions.  Starting from encounters with partial agonists, the essay described the development of an operational model of agonist activity, the significance of receptor distribution, the anal. of indirect competitive antagonism and various two-receptor systems, followed by examples of pharmacol. resultant activity.  Analyses of tissue and species variations are described.  The essay ends with an assessment of the future of bioassay in pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBZnHuCF9EXrVg90H21EOLACvtfcHk0lhqndUR4An6BA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xis1ertLo%253D&md5=fcf2be6ec8823486522e6adfff5aa6df</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pa.36.040196.000245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pa.36.040196.000245%26sid%3Dliteratum%253Aachs%26aulast%3DBlack%26aufirst%3DJ.%2BW.%26atitle%3DA%2520personal%2520view%2520of%2520pharmacology%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D1996%26volume%3D36%26spage%3D1%26epage%3D33%26doi%3D10.1146%2Fannurev.pa.36.040196.000245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Monod, J.</span></span> <i>Chance and Necessity: An Essay on the Natural Philosophy of Modern Biology</i>; <span class="NLM_publisher-name">Alfred A. Knopf</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">1971</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1971&author=J.+Monod&title=Chance+and+Necessity%3A+An+Essay+on+the+Natural+Philosophy+of+Modern+Biology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMonod%26aufirst%3DJ.%26btitle%3DChance%2520and%2520Necessity%253A%2520An%2520Essay%2520on%2520the%2520Natural%2520Philosophy%2520of%2520Modern%2520Biology%26pub%3DAlfred%2520A.%2520Knopf%26date%3D1971" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b01651&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-13%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b01651" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b01651" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799bfadecc824c7","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
